Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation

ABSTRACT

Iterative, preferably computer based iterative processes for generating synthetic compounds capable of modulation of target expression are provided. During iterations of the processes, a target nucleic acid sequence is provided or selected, and a library of candidate nucleobase sequences is generated in silico according to defined criteria. A “virtual” oligonucleotide chemistry is chosen and a library of virtual oligonucleotide compounds having the selected nucleobase sequences is generated. These virtual compounds are reviewed and compounds predicted to have particular properties are selected. The selected compounds are robotically synthesized and are preferably robotically assayed for a desired physical, chemical or biological activity. Compounds exhibiting the ability to modulate target expression are identified as target modulators. Target modulators thus generated are used in assays of parameters indicative of biological processes to effect gene function analysis and in assays of parameters indicative of diseases or disorders to effect target valid

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The present application is a continuation-in-part of U.S. Ser. No. 09/295,463 filed Apr. 13, 1999, which is a continuation-in-part of U.S. Ser. No. 09/067,638 filed Apr. 28, 1998, which claims priority to provisional application Ser. No. 60/081,483 filed Apr. 13, 1998, each of which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] The present invention relates generally to the generation and identification of synthetic compounds having defined physical, chemical or bioactive properties. More particularly, the present invention relates to the automated generation of oligonucleotide compounds targeted to a given nucleic acid sequence via computer-based, iterative robotic synthesis of synthetic oligonucleotide compounds and robotic or robot-assisted analysis of the activities of such compounds. Information gathered from assays of such compounds is used to identify nucleic acid sequences that are tractable to a variety of nucleotide sequence-based technologies, for example, gene function analysis and target validation.

BACKGROUND OF THE INVENTION

[0003] 1. Oligonucleotide Technology

[0004] Synthetic oligonucleotides of complementarity to targets are known to hybridize with particular, target nucleic acids in a sequence-specific manner. In one example, compounds complementary to the “sense” strand of nucleic acids that encode polypeptides, are referred to as “antisense oligonucleotides.” A subset of such compounds may be capable of modulating the expression of a target nucleic acid; such synthetic compounds are described herein as “active oligonucleotide compounds.”

[0005] Oligonucleotide compounds are commonly used in vitro as research reagents and diagnostic aids, and in vivo as therapeutic and bioactive agents. Oligonucleotide compounds can exert their effect by a variety of means. One such means takes advantage of an endogenous nuclease, such as RNase H in eukaryotes or RNase P in prokaryotes, to degrade the DNA/RNA hybrid formed between the oligonucleotide sequence and mRNA (Chiang et al., J. Biol. Chem., 1991, 266, 18162; Forster et al., Science, 1990, 249, 783). Another means involves covalently linking of a synthetic moiety having nuclease activity to an oligonucleotide having an antisense sequence. This does not rely upon recruitment of an endogenous nuclease to modulate target activity. Synthetic moieties having nuclease activity include, but are not limited to, enzymatic RNAs, lanthanide ion complexes, and other reactive species. (Haseloff et al., Nature, 1988, 334, 585; Baker et al., J. Am. Chem. Soc., 1997, 119, 8749).

[0006] Despite the advances made in utilizing antisense technology to date, it is still common to identify target sequences amenable to antisense technologies through an empirical approach (Szoka, Nature Biotechnology, 1997, 15, 509). Accordingly, the need exists for systems and methods for efficiently and effectively identifying target nucleotide sequences that are suitable for antisense modulation. The present disclosure answers this need by providing systems and methods for automatically identifying such sequences via in silico, robotic or other automated means.

[0007] 2. Identification of Active Oligonucleotide Compounds

[0008] Traditionally, new chemical entities with useful properties are generated by (1) identifying a chemical compound (called a “lead compound”) with some desirable property or activity, (2) creating variants of the lead compound, and (3) evaluating the property and activity of such variant compounds. The process has been called “SAR,” i.e., structure activity relationship. Although “SAR” and its handmaiden, rational drug design, has been utilized with some degree of success, there are a number of limitations to these approaches to lead compound generation, particularly as it pertains to the discovery of bioactive oligonucleotide compounds. In attempting to use SAR with oligonucleotides, it has been recognized that RNA structure can inhibit duplex formation with antisense compounds, so much so that “moving” the target nucleotide sequence even a few bases can drastically decrease the activity of such compounds (Lima et al., Biochemistry, 1992, 31, 12055).

[0009] Heretofore, the preferred method of searching for lead antisense compounds has been the manual synthesis and analysis of such compounds. Consequently, a fundamental limitation of the conventional approach is its dependence upon the availability, number and cost of antisense compounds produced by manual, or at best semi-automated, means. Moreover, the assaying of such compounds has traditionally been performed by tedious manual techniques. Thus, the traditional approach to generating active antisense compounds is limited by the relatively high cost and long time required to synthesize and screen a relatively small number of candidate antisense compounds.

[0010] Accordingly, the need exists for systems and methods for efficiently and effectively generating new active antisense and other oligonucleotide compounds targeted to specific nucleic acid sequences. The present disclosure answers this need by providing systems and methods for automatically generating and screening active antisense compounds via robotic and other automated means.

[0011] 3. Gene Function Analysis

[0012] Efforts such as the Human Genome Project are making an enormous amount of nucleotide sequence information available in a variety of forms, e.g., genomic sequences, cDNAs, expressed sequence tags (ESTs) and the like. This explosion of information has led one commentator to state that “genome scientists are producing more genes than they can put a function to” (Kahn, Science, 1995, 270, 369). Although some approaches to this problem have been suggested, no solution has yet emerged. For example, methods of looking at gene expression in different disease states or stages of development only provide, at best, an association between a gene and a disease or stage of development (Nowak, Science, 1995, 270, 368). Another approach, looking at the proteins encoded by genes, is developing but “this approach is more complex and big obstacles remain” (Kahn, Science, 1995, 270, 369). Furthermore, neither of these approaches allows one to directly utilize nucleotide sequence information to perform gene function analysis.

[0013] In contrast, antisense technology does allow for the direct utilization of nucleotide sequence information for gene function analysis. Once a target nucleic acid sequence has been selected, antisense sequences hybridizable to the sequence can be generated using techniques known in the art. Typically, a large number of candidate antisense oligonucleotides (ASOs) are synthesized having sequences that are more-or-less randomly spaced across the length of the target nucleic acid sequence (e.g., a “gene walk”) and their ability to modulate the expression of the target nucleic acid is assayed. Cells or animals can then be treated with one or more active antisense oligonucleotides, and the resulting effects determined in order to determine the function(s) of the target gene. Although the practicality and value of this empirical approach to determining gene function has been acknowledged in the art, it has also been stated that this approach “is beyond the means of most laboratories and is not feasible when a new gene sequence is identified, but whose function and therapeutic potential are unknown” (Szoka, Nature Biotechnology, 1997, 15, 509).

[0014] Accordingly, the need exists for systems and methods for efficiently and effectively determining the function of a gene that is uncharacterized except that its nucleotide sequence, or a portion thereof, is known. The present disclosure answers this need by providing systems and methods for automatically generating active antisense compounds to a target nucleotide sequence via robotic means. Such active antisense compounds are contacted with cells, cell-free extracts, tissues or animals capable of expressing the gene of interest and subsequent biochemical or biological parameters are measured. The results are compared to those obtained from a control cell culture, cell-free extract, tissue or animal which has not been contacted with an active antisense compound in order to determine the function of the gene of interest.

[0015] 4. Target Validation

[0016] Determining the nucleotide sequence of a gene is no longer an end unto itself; rather, it is “merely a means to an end. The critical next step is to validate the gene and its [gene] product as a potential drug target” (Glasser, Genetic Engineering News, 1997, 17, 1). This process, i.e., confirming that modulation of a gene that is suspected of being involved in a disease or disorder actually results in an effect that is consistent with a causal relationship between the gene and the disease or disorder, is known as target validation.

[0017] Efforts such as the Human Genome Project are yielding a vast number of complete or partial nucleotide sequences, many of which might correspond to or encode targets useful for new drug discovery efforts. The challenge represented by this plethora of information is how to use such nucleotide sequences to identify and rank valid targets for drug discovery. Antisense technology provides one means by which this might be accomplished; however, the many manual, labor-intensive and costly steps involved in traditional methods of developing active antisense compounds has limited their use in target validation (Szoka, Nature Biotechnology, 1997, 15, 509). Nevertheless, the great target specificity that is characteristic of antisense compounds makes them ideal choices for target validation, especially when the functional roles of proteins that are highly related are being investigated (Albert et al., Trends in Pharm. Sci., 1994, 15, 250).

[0018] Accordingly, the need exists for systems and methods for developing compounds efficiently and effectively that modulate a gene, wherein such compounds can be directly developed from nucleotide sequence information. Such compounds are needed to confirm that modulation of a gene that is thought to be involved in a disease or disorder will in fact cause an in vitro or in vivo effect indicative of the origin, development, spread or growth of the disease or disorder.

[0019] The present disclosure answers this need by providing systems and methods for automatically generating active oligonucleotide and other compounds, especially antisense compounds, to a target nucleotide sequence via robotic or other automated means. Such active compounds are contacted with a cell culture, cell-free extract, tissue or animal capable of expressing the gene of interest, and subsequent biochemical or biological parameters indicative of the potential gene product function are measured. These results are compared to those obtained with a control cell system, cell-free extract, tissue or animal which has not been contacted with an active antisense compound in order to determine whether or not modulation of the gene of interest affects a specific cellular function. The resulting active antisense compounds may be used as positive controls when other, non antisense-based agents directed to the same target nucleic acid, or to its gene product, are screened.

[0020] It should be noted that embodiments of the invention drawn to gene function analysis and target validation have parameters that are shared with other embodiments of the invention, but also have unique parameters. For example, antisense drug discovery naturally requires that the toxicity of the antisense compounds be manageable, whereas, for gene function analysis or target validation, overt toxicity resulting from the antisense compounds is acceptable unless it interferes with the assay being used to evaluate the effects of treatment with such compounds.

[0021] U.S. Pat. No. 5,563,036 to Peterson et al. describes systems and methods of screening for compounds that inhibit the binding of a transcription factor to a nucleic acid. In a preferred embodiment, an assay portion of the process is stated to be performed by a computer controlled robot.

[0022] U.S. Pat. No. 5,708,158 to Hoey describes systems and methods for identifying pharmacological agents stated to be useful for diagnosing or treating a disease associated with a gene the expression of which is modulated by a human nuclear factor of activated T cells. The methods are stated to be particularly suited to high-thoughput screening wherein one or more steps of the process are performed by a computer controlled robot.

[0023] U.S. Pat. Nos. 5,693,463 and 5,716,780 to Edwards et al. describe systems and methods for identifying non-oligonucleotide molecules that specifically bind to a DNA molecule based on their ability to compete with a DNA-binding protein that recognizes the DNA molecule.

[0024] U.S. Pat. Nos. 5,463,564 and 5,684,711 to Agrafiotis et al. describe computer based iterative processes for generating chemical entities with defined physical, chemical and/or bioactive properties.

[0025] 5. Compounds of the Invention

[0026] According to the present invention, compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops. Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid.

[0027] One non-limiting example of such an enzyme is RNAse H, a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are “DNA-like” elicit RNAse H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. Similar roles have been postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.

[0028] While the preferred form of antisense compound is a single-stranded antisense oligonucleotide, in many species the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals and is believed to have an evolutionary connection to viral defense and transposon silencing.

[0029] The first evidence that dsRNA could lead to gene silencing in animals came in 1995 from work in the nematode, Caenorhabditis elegans (Guo and Kempheus, Cell, 1995, 81, 611-620). Montgomery et al. have shown that the primary interference effects of dsRNA are posttranscriptional (Montgomery et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 15502-15507). The posttranscriptional antisense mechanism defined in Caenorhabditis elegans resulting from exposure to double-stranded RNA (dsRNA) has since been designated RNA interference (RNAi). This term has been generalized to mean antisense-mediated gene silencing involving the introduction of dsRNA leading to the sequence-specific reduction of endogenous targeted mRNA levels (Fire et al., Nature, 1998, 391, 806-811). Recently, it has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the dsRNAs which are the potent inducers of RNAi (Tijsterman et al., Science, 2002, 295, 694-697).

[0030] In the context of this invention, the term “oligomeric compound” refers to a polymer or oligomer comprising a plurality of monomeric units. In the context of this invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

[0031] While oligonucleotides are a preferred form of the compounds of this invention, the present invention comprehends other families of compounds as well, including but not limited to oligonucleotide analogs and mimetics such as those described herein.

[0032] The compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that the invention embodies compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length.

[0033] In one preferred embodiment, the compounds of the invention are 12 to 50 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases in length.

[0034] In another preferred embodiment, the compounds of the invention are 15 to 30 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length.

[0035] In another preferred embodiment, the compounds of the invention are 20 to 25 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 20, 21, 22, 23, 24 or 25 nucleobases in length.

[0036] Particularly preferred compounds are oligonucleotides from about 12 to about 50 nucleobases, even more preferably those comprising from about 15 to about 30 nucleobases.

[0037] Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

[0038] Exemplary preferred antisense compounds include oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 5′-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately upstream of the 5′-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 3′-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately downstream of the 3′-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). One having skill in the art armed with the preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

SUMMARY OF THE INVENTION

[0039] The present invention is directed to methods of effecting gene function analysis and target validation by generating in silico a library of nucleobase sequences targeted to the gene and robotically assaying a plurality of synthetic compounds having at least some of the nucleobase sequences to identify target modulators. These modulators are then assayed for effects on biological function to effect gene function analysis and for effects on diseases or disorders to effect target validation.

[0040] Further features and advantages of the present invention, as well as the structure and operation of various embodiments of the present invention, are described in detail below with reference to the accompanying drawings. In the drawings, like reference numbers indicate identical or functionally similar elements.

BRIEF DESCRIPTION OF THE DRAWINGS

[0041] The present invention will be described with reference to the accompanying drawings, wherein:

[0042]FIGS. 1 and 2 are a flow diagram of one method according to the present invention depicting the overall flow of data and materials among various elements of the invention.

[0043]FIG. 3 is a flow diagram depicting the flow of data and materials among elements of step 200 of FIG. 1.

[0044]FIGS. 4 and 5 are a flow diagram depicting the flow of data and materials among elements of step 300 of FIG. 1.

[0045]FIG. 6 is a flow diagram depicting the flow of data and materials among elements of step 306 of FIG. 4.

[0046]FIG. 7 is another flow diagram depicting the flow of data and materials among elements of step 306 of FIG. 4.

[0047]FIG. 8 is a another flow diagram depicting the flow of data and materials among elements of step 306 of FIG. 4.

[0048]FIG. 9 is a flow diagram depicting the flow of data and materials among elements of step 350 of FIG. 5.

[0049]FIGS. 10 and 11 are flow diagrams depicting a logical analysis of data and materials among elements of step 400 of FIG. 1.

[0050]FIG. 12 is a flow diagram depicting the flow of data and materials among the elements of step 400 of FIG. 1.

[0051]FIGS. 13 and 14 are flow diagrams depicting the flow of data and materials among elements of step 500 of FIG. 1.

[0052]FIG. 15 is a flow diagram depicting the flow of data and materials among elements of step 600 of FIG. 1.

[0053]FIG. 16 is a flow diagram depicting the flow of data and materials among elements of step 700 of FIG. 1.

[0054]FIG. 17 is a flow diagram depicting the flow of data and materials among the elements of step 1100 of FIG. 2.

[0055]FIG. 18 is a block diagram showing the interconnecting of certain devices utilized in conjunction with a preferred method of the invention;

[0056]FIG. 19 is a flow diagram showing a representation of data storage in a relational database utilized in conjunction with one method of the invention;

[0057]FIG. 20 is a flow diagram depicting the flow of data and materials in effecting a preferred embodiment of the invention as set forth in Example 16;

[0058]FIG. 21 is a flow diagram depicting the flow of data and materials in effecting a preferred embodiment of the invention as set forth in Example 17;

[0059]FIG. 22 is a flow diagram depicting the flow of data and materials in effecting a preferred embodiment of the invention as set forth in Example 2;

[0060]FIG. 23 is a pictorial elevation view of a preferred apparatus used to robotically synthesize oligonucleotides; and

[0061]FIG. 24 is a pictorial plan view of an apparatus used to robotically synthesize oligonucleotides.

DETAILED DESCRIPTION OF THE INVENTION

[0062] Certain preferred methods of this invention are now described with reference to the flow diagram of FIGS. 1 and 2.

[0063] 1. Target Nucleic Acid Selection.

[0064] The target selection process, process step 100, provides a target nucleotide sequence that is used to help guide subsequent steps of the process. It is generally desired to modulate the expression of the target nucleic acid for any of a variety of purposes, such as, e.g., drug discovery, target validation and/or gene function analysis.

[0065] One of the primary objectives of the target selection process, step 100, is to identify molecular targets that represent significant therapeutic opportunities, to provide new and efficacious means of drug discovery and to determine the function of genes that are uncharacterized except for nucleotide sequence. To meet these objectives, genes are classified based upon specific sets of selection criteria.

[0066] One such set of selection criteria concerns the quantity and quality of target nucleotide sequence. There must be sufficient target nucleic acid sequence information available for oligonucleotide design. Moreover, such information must be of sufficient quality to give rise to an acceptable level of confidence in the data to perform the methods described herein. Thus, the data must not contain too many missing or incorrect base entries. In the case of a target sequence that encodes a polypeptide, such errors can often be detected by virtually translating all three reading frames of the sense strand of the target sequence and confirming the presence of a continuous polypeptide sequence having predictable attributes, e.g., encoding a polypeptide of known size, or encoding a polypeptide that is about the same length as a homologous protein. In any event, only a very high frequency of sequence errors will frustrate the methods of the invention; most oligonucleotides to the target sequence will avoid-such errors unless such errors occur frequently throughout the entire target sequence.

[0067] Another preferred criterion is that appropriate culturable cell lines or other source of reproducible genetic expression should be available. Such cell lines express, or can be induced to express, the gene comprising the target nucleic acid sequence. The oligonucleotide compounds generated by the process of the invention are assayed using such cell lines and, if such assaying is performed robotically, the cell line is preferably tractable to robotic manipulation such as by growth in 96 well plates. Those skilled in the art will recognize that if an appropriate cell line does not exist, it will nevertheless be possible to construct an appropriate cell line. For example, a cell line can be transfected with an expression vector comprising the target gene in order to generate an appropriate cell line for assay purposes.

[0068] For gene function analysis, it is possible to operate upon a genetic system having a lack of information regarding, or incomplete characterization of, the biological function(s) of the target nucleic acid or its gene product(s). This is a powerful agent of the invention. A target nucleic acid for gene function analysis might be absolutely uncharacterized, or might be thought to have a function based on minimal data or homology to another gene. By application of the process of the invention to such a target, active compounds that modulate the expression of the gene can be developed and applied to cells. The resulting cellular, biochemical or molecular biological responses are observed, and this information is used by those skilled in the art to elucidate the function of the target gene.

[0069] For target validation and drug discovery, another selection criterion is disease association. Candidate target genes are placed into one of several broad categories of known or deduced disease association. Level 1 Targets are target nucleic acids for which there is a strong correlation with disease. This correlation can come from multiple scientific disciplines including, but not limited to, epidemiology, wherein frequencies of gene abnormalities are associated with disease incidence; molecular biology, wherein gene expression and function are associated with cellular events correlated with a disease; and biochemistry, wherein the in vitro activities of a gene product are associated with disease parameters. Because there is a strong therapeutic rationale for focusing on Level 1 Targets, these targets are most preferred for drug discovery and/or target validation.

[0070] Level 2 Targets are nucleic acid targets for which the combined epidemiological, molecular biological, and/or biochemical correlation with disease is not so clear as for Level 1. Level 3 Targets are targets for which there is little or no data to directly link the target with a disease process, but there is indirect evidence for such a link, i.e., homology with a Level 1 or Level 2 target nucleic acid sequence or with the gene product thereof. In order not to prejudice the target selection process, and to ensure that the maximum number of nucleic acids actually involved in the causation, potentiation, aggravation, spread, continuance or after-effects of disease states are investigated, it is preferred to examine a balanced mix of Level 1, 2 and 3 target nucleic acids.

[0071] In order to carry out drug discovery, experimental systems and reagents shall be available in order for one to evaluate the therapeutic potential of active compounds generated by the process of the invention. Such systems may be operable in vitro (e.g., in vitro models of cell:cell association) or in vivo (e.g., animal models of disease states). It is also desirable, but not obligatory, to have available animal model systems which can be used to evaluate drug pharmacology.

[0072] Candidate targets nucleic acids can also classified by biological processes. For example, programmed cell death (“apoptosis”) has recently emerged as an important biological process that is perturbed in a wide variety of diseases. Accordingly, nucleic acids that encode factors that play a role in the apoptotic process are identified as candidate targets. Similarly, potential target nucleic acids can be classified as being involved in inflammation, autoimmune disorders, cancer, or other pathological or dysfunctional processes.

[0073] Moreover, genes can often be grouped into families based on sequence homology and biological function. Individual family members can act redundantly, or can provide specificity through diversity of interactions with downstream effectors, or through expression being restricted to specific cell types. When one member of a gene family is associated with a disease process then the rationale for targeting other members of the same family is reasonably strong. Therefore, members of such gene families are preferred target nucleic acids to which the methods and systems of the invention may be applied. Indeed, the potent specificity of antisense compounds for different gene family members makes the invention particularly suited for such targets (Albert et al., Trends Pharm. Sci., 1994, 15, 250). Those skilled in the art will recognize that a partial or complete nucleotide sequence of such family members can be obtained using the polymerase chain reaction (PCR) and “universal” primers, i.e., primers designed to be common to all members of a given gene family.

[0074] PCR products generated from universal primers can be cloned and sequenced or directly sequenced using techniques known in the art. Thus, although nucleotide sequences from cloned DNAs, or from complementary DNAs (cDNAs) derived from mRNAs, may be used in the process of the invention, there is no requirement that the target nucleotide sequence be isolated from a cloned nucleic acid. Any nucleotide sequence, no matter how determined, of any nucleic acid, isolated or prepared in any fashion, may be used as a target nucleic acid in the process of the invention.

[0075] Furthermore, although polypeptide-encoding nucleic acids provide the target nucleotide sequences in one embodiment of the invention, other nucleic acids may be targeted as well. Thus, for example, the nucleotide sequences of structural or enzymatic RNAs may be utilized for drug discovery and/or target validation when such RNAs are associated with a disease state, or for gene function analysis when their biological role is not known.

[0076] 2. Assembly of Target Nucleotide Sequence.

[0077]FIG. 3 is a block diagram detailing the steps of the target nucleotide sequence assembly process, process step 200 in acccordance with one embodiment of the invention. The oligonucleotide design process, process step 300, is facilitated by the availability of accurate target sequence information. Because of limitations of automated genome sequencing technology, gene sequences are often accumulated in fragments. Further, because individual genes are often being sequenced by independent laboratories using different sequencing strategies, sequence information corresponding to different fragments is often deposited in different databases. The target nucleic acid assembly process take advantage of computerized homology search algorithms and sequence fragment assembly algorithms to search available databases for related sequence information and incorporate available sequence information into the best possible representation of the target nucleic acid molecule, for example a RNA transcript. This representation is then used to design oligonucleotides, process step 300, which can be tested for biological activity in process step 700.

[0078] In the case of genes directing the synthesis of multiple transcripts, i.e. by alternative splicing, each distinct transcript is a unique target nucleic acid for purposes of step 300. In one embodiment of the invention, if active compounds specific for a given transcript isoform are desired, the target nucleotide sequence is limited to those sequences that are unique to that transcript isoform. In another embodiment of the invention, if it is desired to modulate two or more transcript isoforms in concert, the target nucleotide sequence is limited to sequences that are shared between the two or more transcripts.

[0079] In the case of a polypeptide-encoding nucleic acid, it is generally preferred that full-length cDNA be used in the oligonucleotide design process step 300 (with full-length cDNA being defined as reading from the 5′ cap to the poly A tail). Although full-length cDNA is preferred, it is possible to design oligonucleotides using partial sequence information. Therefore it is not necessary for the assembly process to generate a complete cDNA sequence. Further in some cases it may be desirable to design oligonucleotides targeting introns. In this case the process can be used to identify individual introns at process step 220.

[0080] The process can be initiated by entering initial sequence information on a selected molecular target at process step 205. In the case of a polypeptide-encoding nucleic acid, the full-length cDNA sequence is generally preferred for use in oligonucleotide design strategies at process step 300. The first step is to determine if the initial sequence information represents the full-length cDNA, decision step 210. In the case where the full-length cDNA sequence is available the process advances directly to the oligonucleotide design step 300. When the full-length cDNA sequence is not available, databases are searched at process step 212 for additional sequence information.

[0081] The algorithm preferably used in process steps 212 and 230 is BLAST (Altschul, et al., J. Mol. Biol., 1990, 215, 403), or “Gapped BLAST” (Altschul et al., Nucl. Acids Res., 1997, 25, 3389). These are database search tools based on sequence homology used to identify related sequences in a sequence database. The BLAST search parameters are set to only identify closely related sequences. Some preferred databases searched by BLAST are a combination of public domain and proprietary databases. The databases, their contents, and sources are listed in Table 1. TABLE 1 Database Sources of Target Sequences Database Contents Source NR All non-redundant National Center for GenBank, EMBL, DDBJ Biotechnology Information at the and PDB sequences National Institutes of Health Month All new or revised National Center for GenBank, EMBL, DDBJ Biotechnology Information at the and PDB sequences National Institutes of Health released in the last 30 days Dbest Non-redundant National Center for database of GenBank, Biotechnology Information at the EMBL, DDBJ and National Institutes of Health EST divisions Dbsts Non-redundant National Center for database of GenBank, Biotechnology Information at the EMBL, DDBJ and National Institutes of Health STS divisions Htgs High throughput National Center for genomic sequences Biotechnology Information at the National Institutes of Health

[0082] When genomic sequence information is available at decision step 215, introns are removed and exons are assembled into continuous sequence representing the cDNA sequence in process step 220. Exon assembly occurs using the Phragment Assembly Program “Phrap” (Copyright University of Washington Genome Center, Seattle, Wash.). The Phrap algorithm analyzes sets of overlapping sequences and assembles them into one continuous sequence referred to as a “contig.” The resulting contig is preferably used to search databases for additional sequence information at process step 230. When genomic information is not available, the results of process step 212 are analyzed for individual exons at decision step 225. Exons are frequently recorded individually in databases. If multiple complete exons are identified, they are prferably assembled into a contig using Phrap at process step 250. If multiple complete exons are not identified at decision step 225, then sequences can be analyzed for partial sequence information in decision step 228. ESTs identified in the database dbEST are examples of such partial sequence information. If additional partial information is not found, then the process is advanced to process step 230 at decision step 228. If partial sequence information is found in process 212 then that information is advanced to process step 230 via decision step 228.

[0083] Process step 230, decision step 240, decision step 260 and process step 250 define a loop designed to extend iteratively the amount of sequence information available for targeting. At the end of each iteration of this loop, the results are analyzed in decision steps 240 and 260. If no new information is found then the process advances at decision step 240 to process step 300. If there is an unexpectedly large amount of sequence information identified, suggesting that the process moved outside the boundary of the gene into repetitive genomic sequence, then the process is preferably cycled back one iteration and that sequence is advanced at decision step 240 to process step 300. If a small amount of new sequence information is identified, then the loop is iterated such as by taking the 100 most 5-prime (5′) and 100 most 3-prime (3′) bases and interating them through the BLAST homology search at process step 230. New sequence information is added to the existing contig at process step 250.

[0084] 3. In Silico Generation of a Set of Nucleobase Sequences and Virtual Oligonucleotides.

[0085] For the following steps 300 and 400, they may be performed in the order described below, i.e., step 300 before step 400, or, in an alternative embodiment of the invention, step 400 before step 300. In this alternate embodiment, each oligonucleotide chemistry is first assigned to each oligonucleotide sequence. Then, each combination of oligonucleotide chemistry and sequence is evaluated according to the parameters of step 300. This embodiment has the desirable feature of taking into account the effect of alternative oligonucleotide chemistries on such parameters. For example, substitution of 5-methyl cytosine (5MeC or m5c) for cytosine in an antisense compound may enhance the stability of a duplex formed between that compound and its target nucleic acid. Other oligonucleotide chemistries that enhance oligonucleotide:[target nucleic acid] duplexes are known in the art (see for example, Freier et al., Nucleic Acids Research, 1997, 25, 4429). As will be appreciated by those skilled in the art, different oligonucleotide chemistries may be preferred for different target nucleic acids. That is, the optimal oligonucleotide chemistry for binding to a target DNA might be suboptimal for binding to a target RNA having the same nucleotide sequence.

[0086] In effecting the process of the invention in the order step 300 before step 400 as seen in FIG. 1, from a target nucleic acid sequence assembled at step 200, a list of oligonucleotide sequences is generated as represented in the flowchart shown in FIGS. 4 and 5. In step 302, the desired oligonucleotide length is chosen. In a preferred embodiment, oligonucleotide length is between from about 8 to about 30, more preferably from about 12 to about 25, nucleotides. In step 304, all possible oligonucleotide sequences of the desired length capable of hybridizing to the target sequence obtained in step 200 are generated. In this step, a series of oligonucleotide sequences are generated, simply by determining the most 5′ oligonucleotide possible and “walking” the target sequence in increments of one base until the 3′ most oligonucleotide possible is reached.

[0087] In step 305, a virtual oligonucleotide chemistry is applied to the nucleobase sequences of step 304 in order to yield a set of virtual oligonucleotides that can be evaluated in silico. Default virtual oligonucleotide chemistries include those that are well-characterized in terms of their physical and chemical properties, e.g., 2′-deoxyribonucleic acid having naturally occurring bases (A, T, C and G), unmodified sugar residues and a phosphodiester backbone.

[0088] 4. In Silico Evaluation of Thermodynamic Properties of Virtual Oligonucleotides.

[0089] In step 306, a series of thermodynamic, sequence, and homology scores are preferably calculated for each virtual oligonucleotide obtained from step 305. Thermodynamic properties are calculated as represented in FIG. 6. In step 308, the desired thermodynamic properties are selected. As many or as few as desired can be selected; optionally, none will be selected. The desired properties will typically include step 309, calculation of the free energy of the target structure. If the oligonucleotide is a DNA molecule, then steps 310, 312, and 314 are performed. If the oligonucleotide is an RNA molecule, then steps 311, 313 and 315 are performed. In both cases, these steps correspond to calculation of the free energy of intramolecular oligonucleotide interactions, intermolecular interactions and duplex formation. In addition, a free energy of oligonucleotide-target binding is preferably calculated at step 316.

[0090] Other thermodynamic and kinetic properties may be calculated for oligonucleotides as represented at step 317. Such other thermodynamic and kinetic properties may include melting temperatures, association rates, dissociation rates, or any other physical property that may be predictive of oligonucleotide activity.

[0091] The free energy of the target structure is defined as the free energy needed to disrupt any secondary structure in the target binding site of the targeted nucleic acid. This region includes any intra-target nucleotide base pairs that need to be disrupted in order for an oligonucleotide to bind to its complementary sequence. The effect of this localized disruption of secondary structure is to provide accessibility by the oligonucleotide. Such structures will include double helices, terminal unpaired and mismatched nucleotides, loops, including hairpin loops, bulge loops, internal loops and multibranch loops (Serra et al., Methods in Enzymology, 1995, 259, 242).

[0092] The intermolecular free energies refer to inherent energy due to the most stable structure formed by two oligonucleotides; such structures include dimer formation. Intermolecular free energies should also be taken into account when, for example, two or more oligonucleotides, of different sequence are to be administered to the same cell in an assay.

[0093] The intramolecular free energies refer to the energy needed to disrupt the most stable secondary structure within a single oligonucleotide. Such structures include, for example, hairpin loops, bulges and internal loops. The degree of intramolecular base pairing is indicative of the energy needed to disrupt such base pairing.

[0094] The free energy of duplex formation is the free energy of denatured oligonucleotide binding to its denatured target sequence. The oligonucleotide-target binding is the total binding involved, and includes the energies involved in opening up intra- and inter-molecular oligonucleotide structures, opening up target structure, and duplex formation.

[0095] The most stable RNA structure is predicted based on nearest neighbor analysis (Xia, T., et al., Biochemistry, 1998, 37, 14719-14735; Serra et al., Methods in Enzymology, 1995, 259, 242). This analysis is based on the assumption that stability of a given base pair is determined by the adjacent base pairs. For each possible nearest neighbor combination, thermodynamic properties have been determined and are provided. For double helical regions, two additional factors need to be considered, an entropy change required to initiate a helix and a entropy change associated with self-complementary strands only. Thus, the free energy of a duplex can be calculated using the equation: where:

[0096] ΔG is the free energy of duplex formation,

[0097] ΔH is the enthalpy change for each nearest neighbor,

[0098] ΔS is the entropy change for each nearest neighbor, and T is temperature.

[0099] The ΔH and ΔS for each possible nearest neighbor combination have been experimentally determined. These letter values are often available in published tables. For terminal unpaired and mismatched nucleotides, enthalpy and entropy measurements for each possible nucleotide combination are also available in published tables. Such results are added directly to values determined for duplex formation. For loops, while the available data is not as complete or accurate as for base pairing, one known model determines the free energy of loop formation as the sum of free energy based on loop size, the closing base pair, the interactions between the first mismatch of the loop with the closing base pair, and additional factors including being closed by AU or UA or a first mismatch of GA or UU. Such equations may also be used for oligoribonucleotide-target RNA interactions.

[0100] The stability of DNA duplexes is used in the case of intra- or intermolecular oligodeoxyribonucleotide interactions. DNA duplex stability is calculated using similar equations as RNA stability, except experimentally determined values differ between nearest neighbors in DNA and RNA and helix initiation tends to be more favorable in DNA than in RNA (SantaLucia et al., Biochemistry, 1996, 35, 3555).

[0101] Additional thermodynamic parameters are used in the case of RNA/DNA hybrid duplexes. This would be the case for an RNA target and oligodeoxynucleotide. Such parameters were determined by Sugimoto et al. (Biochemistry, 1995, 34, 11211). In addition to values for nearest neighbors, differences were seen for values for enthalpy of helix initiation.

[0102] 5. In Silico Evaluation of Target Accessibility

[0103] Target accessibility is believed to be an important consideration in selecting oligonucleotides. Such a target site will possess minimal secondary structure and thus, will require minimal energy to disrupt such structure. In addition, secondary structure in oligonucleotides, whether inter- or intra-molecular, is undesirable due to the energy required to disrupt such structures. Oligonucleotide-target binding is dependent on both these factors. It is desirable to minimize the contributions of secondary structure based on these factors. The other contribution to oligonucleotide-target binding is binding affinity. Favorable binding affinities based on tighter base pairing at the target site is desirable.

[0104] Following the calculation of thermodynamic properties ending at step 317, the desired sequence properties to be scored are selected at step 324. As many or as few as desired can be selected; optionally, none will be selected. These properties include the number of strings of four guanosine residues in a row at step 325 or three guanosine in a row at step 326, the length of the longest string of adenosines at step 327, cytidines at step 328 or uridines or thymidines at step 329, the length of the longest string of purines at step 330 or pyrimidine at step 331, the percent composition of adenosine at step 332, cytidine at step 333, guanosine at step 334 or uridines or thymidines at step 335, the percent composition of purines at step 336 or pyrimidines at step 337, the number of CG dinucleotide repeats at step 338, CA dinucleotide repeats at step 339 or UA or TA dinucleotide repeats at step 340. In addition, other sequence properties may be used as found to be relevant and predictive of antisense efficacy, as represented at step 341.

[0105] These sequence properties may be important in predicting oligonucleotide activity, or lack thereof. For example, U.S. Pat. No. 5,523,389 discloses oligonucleotides containing stretches of three or four guanosine residues in a row. Oligonucleotides having such sequences may act in a sequence-independent manner. For an antisense approach, such a mechanism is not usually desired. In addition, high numbers of dinucleotide repeats may be indicative of low complexity regions which may be present in large numbers of unrelated genes. Unequal base composition, for example, 90% adenosine, can also give non-specific effects. From a practical standpoint, it may be desirable to remove oligonucleotides that possess long stretches of other nucleotides due to synthesis considerations. Other sequences properties, either listed above or later found to be of predictive value may be used to select oligonucleotide sequences.

[0106] Following step 341, the homology scores to be calculated are selected in step 342. Homology to nucleic acids encoding protein isoforms of the target, as represented at step 343, may be desired. For example, oligonucleotides specific for an isoform of protein kinase C can be selected. Also, oligonucleotides can be selected to target multiple isoforms of such genes. Homology to analogous target sequences, as represented at step 344, may also be desired. For example, an oligonucleotide can be selected to a region common to both humans and mice to facilitate testing of the oligonucleotide in both species. Homology to splice variants of the target nucleic acid, as represented at step 345, may be desired. In addition, it may be desirable to determine homology to other sequence variants as necessary, as represented in step 346.

[0107] Following step 346, from which scores were obtained in each selected parameter, a desired range is selected to select the most promising oligonucleotides, as represented at step 347. Typically, only several parameters will be used to select oligonucleotide sequences. As structure prediction improves, additional parameters may be used. Once the desired score ranges are chosen, a list of all oligonucleotides having parameters falling within those ranges will be generated, as represented at step 348.

[0108] 6. Targeting Oligonucleotides to Functional Regions of a Nucleic Acid.

[0109] It may be desirable to target oligonucleotide sequences to specific functional regions of the target nucleic acid. A decision is made whether to target such regions, as represented in decision step 349. If it is desired to target functional regions then process step 350 occurs as seen in greater detail in FIG. 9. If it is not desired then the process proceeds to step 375.

[0110] In step 350, as seen in FIG. 9, the desired functional regions are selected. Such regions include the transcription start site or 5′ cap at step 353, the 5′ untranslated region at step 354, the start codon at step 355, the coding region at step 356, the stop codon at step 357, the 3′ untranslated region at step 358, 5′ splice sites at step 359 or 3′ splice sites at step 360, specific exons at step 361 or specific introns at step 362, mRNA stabilization signal at step 363, mRNA destabilization signal at step 364, poly-adenylation signal at step 365, poly-A addition site at step 366, poly-A tail at step 367, or the gene sequence 5′ of known pre-mRNA at step 368. In addition, additional functional sites may be selected, as represented at step 369.

[0111] Many functional regions are important to the proper processing of the gene and are attractive targets for antisense approaches. For example, the AUG start codon is commonly targeted because it is necessary to initiate translation. In addition, splice sites are thought to be attractive targets because these regions are important for processing of the mRNA. Other known sites may be more accessible because of interactions with protein factors or other regulatory molecules.

[0112] After the desired functional regions are selected and determined, then a subset of all previously selected oligonucleotides are selected based on hybridization to only those desired functional regions, as represented by step 370.

[0113] 7. Uniform Distribution of Oligonucleotides.

[0114] Whether or not targeting functional sites is desired, a large number of oligonucleotide sequences may result from the process thus far. In order to reduce the number of oligonucleotide sequences to a manageable number, a decision is made whether to uniformly distribute selected oligonucleotides along the target, as represented in step 375. A uniform distribution of oligonucleotide sequences will aim to provide complete coverage throughout the complete target nucleic acid or the selected functional regions. A computer-based program is used to automate the distribution of sequences, as represented in step 380. Such a program factors in parameters such as length of the target nucleic acid, total number of oligonucleotide sequences desired, oligonucleotide sequences per unit length, number of oligonucleotide sequences per functional region. Manual selection of oligonucleotide sequences is also provided for by step 385. In some cases, it may be desirable to manually select oligonucleotide sequences. For example, it may be useful to determine the effect of small base shifts on activity. Once the desired number of oligonucleotide sequences is obtained either from step 380 or step 385, then these oligonucleotide sequences are passed onto step 400 of the process, where oligonucleotide chemistries are assigned.

[0115] 8. Assignment of Actual Oligonucleotide Chemistry.

[0116] Once a set of select nucleobase sequences has been generated according to the preceding process and decision steps, actual oligonucleotide chemistry is assigned to the sequences. An “actual oligonucleotide chemistry” or simply “chemistry” is a chemical motif that is common to a particular set of robotically synthesized oligonucleotide compounds. Preferred chemistries include, but are not limited to, oligonucleotides in which every linkage is a phosphorothioate linkage, and chimeric oligonucleotides in which a defined number of 5′ and/or 3′ terminal residues have a 2′-methoxyethoxy modification.

[0117] Chemistries can be assigned to the nucleobase sequences during general procedure step 400 (FIG. 1). The logical basis for chemistry assignment is illustrated in FIGS. 10 and 11 and an iterative routine for stepping through an oligonucleotide nucleoside by nucleoside is illustrated in FIG. 12. Chemistry assignment can be effected by assignment directly into a word processing program, via an interactive word processing program or via automated programs and devices. In each of these instances, the output file is selected to be in a format that can serve as an input file to automated synthesis devices.

[0118] 9. Oligonucleotide Compounds.

[0119] In the context of this invention, in reference to oligonucleotides, the term “oligonucleotide” is used to refer to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. Thus this term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms, i.e., phosphodiester linked A, C, G, T and U nucleosides, because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

[0120] The oligonucleotide compounds in accordance with this invention can be of various lengths depending on various parameters, including but not limited to those discussed above in reference to the selection criteria of general procedure 300. For use as antisense oligonucleotides compounds of the invention preferably are from about 8 to about 30 nucleobases in length (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred are antisense oligonucleotides comprising from about 12 to about 25 nucleobases. A discussion of antisense oligonucleotides and some desirable modifications can be found in De Mesmaeker et al., Acc. Chem. Res., 1995, 28, 366. Other lengths of oligonucleotides might be selected for non-antisense targeting strategies, for instance using the oligonucleotides as ribozymes. Such ribozymes normally require oligonucleotides of longer length as is known in the art.

[0121] A nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a normal (where normal is defined as being found in RNA and DNA) pentofuranosyl sugar, the phosphate group can be linked to either the 2′, 3′ or 5′ hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′ to 5′ phosphodiester linkage.

[0122] Specific examples of preferred oligonucleotides useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0123] 10. Selection of Oligonucleotide Chemistries.

[0124] In a general logic sheme as illustrated in FIGS. 10 and 11, for each nucleoside position, the user or automated device is interrogated first for a base assignment, followed by a sugar assignment, a linker assignment and finally a conjugate assignment. Thus for each nucleoside, at process step 410 a base is selected. In selecting the base, base chemistry 1 can be selected at process step 412 or one or more alternative bases are selected at process steps 414, 416 and 418. After base selection is effected, the sugar portion of the nucleoside is selected. Thus for each nucleoside, at process step 420 a sugar is selected that together with the select base will complete the nucleoside. In selecting the sugar, sugar chemistry 1 can be selected at process 422 or one or more alternative sugars are selected at process steps 424, 426 and 428. For each two adjacent nucleoside units, at process step 430, the internucleoside linker is selected. The linker chemistry for the internucleoside linker can be linker chemistry 1 selected at process step 432 or one or more alternative internucleoside linker chemistries are selected at process steps 434, 436 and 438.

[0125] In addition to the base, sugar and internucleoside linkage, at each nucleoside position, one or more conjugate groups can be attached to the oligonucleotide via attachment to the nucleoside or attachment to the internucleoside linkage. The addition of a conjugate group is integrated at process step 440 and the assignment of the conjugate group is effected at process step 450.

[0126] For illustrative purposes in FIGS. 10 and 11, for each of the bases, the sugars, the internucleoside linkers, or the conjugates, chemistries 1 though n are illustrated. As described in this specification, it is understood that the number of alternate chemistries between chemistry 1 and alternative chemistry n, for each of the bases, the sugars, the internucleoside linkages and the conjugates, is variable and includes, but is not limited to, each of the specific alternative bases, sugar, internucleoside linkers and conjugates identified in this specification as well as equivalents known in the art.

[0127] Utilizing the logic as described in conjunction with FIGS. 10 and 11, chemistry is assigned, as is shown in FIG. 12, to the list of oligonucleotides from general procedure 300. In assigning chemistries to the oligonucleotides in this list, a pointer can be set at process step 452 to the first oligonucleotide in the list and at step 453 to the first nucleotide of that first oligonucleotide. The base chemistry is selected at step 410, as described above, the sugar chemistry is selected at step 420, also as described above, followed by selection of the internucleoside linkage at step 430, also as described above. At decision 440, the process branches depending on whether a conjugate will be added at the current nucleotide position. If a conjugate is desired, the conjugate is selected at step 450, also as described above.

[0128] Whether or not a conjugate was added at decision step 440, an inquiry is made at decision step 454. This inquiry asks if the pointer resides at the last nucleotide in the current oligonucleotide. If the result at decision step 454 is “No,” the pointer is moved to the next nucleotide in the current oligonucleotide and the loop including steps 410, 420, 430, 440 and 454 is repeated. This loop is reiterated until the result at decision step 454 is “Yes.”

[0129] When the result at decision step 454 is “Yes,” a query is made at decision step 460 concerning the location of the pointer in the list of oligonucleotides. If the pointer is not at the last oligonucleotide of the list, the “No” path of the decision step 460 is followed and the pointer is moved to the first nucleotide of the next oligonucleotide in the list at process step 458. With the pointer set to the next oligonucleotide in the list, the loop that starts at process steps 453 is reiterated. When the result at decision step 460 is “Yes,” chemistry has been assigned to all of the nucleotides in the list of oligonucleotides.

[0130] 11. Description of Oligonucleotide Chemistries.

[0131] As is illustrated in FIG. 10, for each nucleoside of an oligonucleotide, chemistry selection includes selection of the base forming the nucleoside from a large palette of different base units available. These may be “modified” or “natural” bases (also reference herein as nucleobases) including the natural purine bases adenine (A) and guanine (G), and the natural pyrimidine bases thymine (T), cytosine (C) and uracil (U). They further can include modified nucleobases including other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo uracils and cytosines particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in the Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred for selection as the base. These are particularly useful when combined with a 2′-O-methoxyethyl sugar modifications, described below.

[0132] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, each of which is incorporated herein by reference in its entirety. Reference is also made to allowed U.S. patent application Ser. No. 08/762,488, filed on Dec. 10, 1996, commonly owned with the present application and which is incorporated herein by reference in its entirety.

[0133] In selecting the base for any particular nucleoside of an oligonucleotide, consideration is first given to the need of a base for a particular specificity for hybridization to an opposing strand of a particular target. Thus if an “A” base is required, adenine might be selected however other alternative bases that can effect hybridization in a manner mimicking an “A” base such as 2-aminoadenine might be selected should other consideration, e.g., stronger hybridization (relative to hybridization achieved with adenine), be desired.

[0134] As is illustrated in FIG. 10, for each nucleoside of an oligonucleotide, chemistry selection includes selection of the sugar forming the nucleoside from a large palette of different sugar or sugar surrogate units available. These may be modified sugar groups, for instance sugars containing one or more substituent groups. Preferred substituent groups comprise the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; or O, S- or N-alkynyl; wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_(n)O]_(m)CH₃, O(CH₂)_(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃, O(CH₂)_(n)ONH₂, and O(CH₂)_(n)ON[(CH₂)_(n)CH₃)]₂, where n and m are from 1 to about 10. Other preferred substituent groups comprise one of the following at the 2′ position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl), 2′-O-methoxyethyl, or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486) i.e., an alkoxyalkoxy group. A further preferred modification includes 2′-dimethylamino oxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2′-DMAOE, as described in co-owned U.S. patent application Ser. No. 09/016,520, filed on Jan. 30, 1998, which is incorporated herein by reference in its entirety.

[0135] Other preferred modifications include 2′-methoxy (2′-O—CH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂) and 2′-fluoro (2′-F). Similar modifications may also be made at other positions on the sugar group, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. The nucleosides of the oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugars structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the present application, each of which is incorporated herein by reference in its entirety, together with allowed U.S. patent application Ser. No. 08/468,037, filed on Jun. 5, 1995, which is commonly owned with the present application and which is incorporated herein by reference in its entirety.

[0136] As is illustrated in FIG. 10, for each adjacent pair of nucleosides of an oligonucleotide, chemistry selection includes selection of the internucleoside linkage. These internucleoside linkages are also referred to as linkers, backbones or oligonucleotide backbones. For forming these nucleoside linkages, a palette of different internucleoside linkages or backbones is available. These include modified oligonucleotide backbones, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalklyphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included.

[0137] Representative United States patents that teach the preparation of the above phosphorus containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; and 5,697,248, certain of which are commonly owned with this application, each of which is incorporated herein by reference in its entirety.

[0138] Preferred internucleoside linkages for oligonucleotides that do not include a phosphorus atom therein, i.e., for oligonucleosides, have backbones that are formed by short chain alkyl or cycloalkyl intersugar linkages, mixed heteroatom and alkyl or cycloalkyl intersugar linkages, or one or more short chain heteroatomic or heterocyclic intersugar linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[0139] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, each of which is incorporated herein by reference in its entirety.

[0140] In other preferred oligonucleotides, i.e., oligonucleotide mimetics, both the sugar and the intersugar linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-phosphate backbone of an oligonucleotide is replaced with an amide-containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is incorporated herein by reference in its entirety. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497.

[0141] For the internucleoside linkages, the most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—O—CH₂—, —CH₂—N(CH₃)—O—CH₂—[known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂— and —O—N(CH₃)—CH₂—CH₂— (wherein the native phosphodiester backbone is represented as —O—P—O—CH₂—) of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

[0142] In attaching a conjugate group to one or more nucleosides or internucleoside linkages of an oligonucleotide, various properties of the oligonucleotide are modified. Thus modification of the oligonucleotides of the invention to chemically link one or more moieties or conjugates to the oligonucleotide are intended to enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y Acad. Sci., 1992, 660,306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 111; Kabanov et al., FEBS Lett., 1990, 259, 327; Svinarchuk et al., Biochimie, 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651; Shea et al., Nucl. Acids Res., 1990, 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923).

[0143] Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the present application, and each of which is herein incorporated by reference in its entirety.

[0144] 12. Chimeric Compounds.

[0145] It is not necessary for all positions in a given compound to be uniformly modified. In fact, more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes compounds which are chimeric compounds. “Chimeric” compounds or “chimeras,” in the context of this invention, are compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.

[0146] By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0147] Chimeric antisense compounds of the invention may be formed as composite structures representing the union of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as “hybrids” or “gapmers”. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the present application and each of which is incorporated herein by reference in its entirety, together with commonly owned and allowed U.S. patent application Ser. No. 08/465,880, filed on Jun. 6, 1995, which is incorporated herein by reference in its entirety.

[0148] 13. Description of Automated Oligonucleotide Synthesis.

[0149] In the next step of the overall process (illustrated in FIGS. 1 and 2), oligonucleotides are synthesized on an automated synthesizer. Although many devices may be employed, the synthesizer is preferably a variation of the synthesizer described in U.S. Pat. Nos. 5,472,672 and 5,529,756, each of which is incorporated herein by reference in its entirety. The synthesizer described in those patents is modified to include movement in along the Y axis in addition to movement along the X axis. As so modified, a 96-well array of compounds can be synthesized by the synthesizer. The synthesizer further includes temperature control and the ability to maintain an inert atmosphere during all phases of synthesis. The reagent array delivery format employs orthogonal X-axis motion of a matrix of reaction vessels and Y-axis motion of an array of reagents. Each reagent has its own dedicated plumbing system to eliminate the possibility of cross-contamination of reagents and line flushing and/or pipette washing. This in combined with a high delivery speed obtained with a reagent mapping system allows for the extremely rapid delivery of reagents. This further allows long and complex reaction sequences to be performed in an efficient and facile manner.

[0150] The software that operates the synthesizer allows the straightforward programming of the parallel synthesis of a large number of compounds. The software utilizes a general synthetic procedure in the form of a command (.cmd) file, which calls upon certain reagents to be added to certain wells via lookup in a sequence (.seq) file. The bottle position, flow rate, and concentration of each reagent is stored in a lookup table (.tab) file. Thus, once any synthetic method has been outlined, a plate of compounds is made by permutating a set of reagents, and writing the resulting output to a text file. The text file is input directly into the synthesizer and used for the synthesis of the plate of compounds. The synthesizer is interfaced with a relational database allowing data output related to the synthesized compounds to be registered in a highly efficient manner.

[0151] Building of the .seq, .cmd and .tab files is illustrated in FIG. 13. Thus as a part of the general oligonucleotide synthesis procedure 500, for each linker chemistry at process step 502, a synthesis file, i.e., a .cmd file, is built at process step 504. This file can be built fresh to reflect a completely new set of machine commands reflecting a set of chemical synthesis steps or it can modify an existing file stored at process step 504 by editing that stored file in process step 508. The .cmd files are built using a word processor and a command set of instructions as outlined below.

[0152] It will be appreciated that the preparation of control software and data files is within the routine skill of persons skilled in annotated nucleotide synthesis. The same will depend upon the hardware employed, the chemistries adopted and the design paradigm selected by the operator.

[0153] In a like manner to the building the .cmd files, .tab files are built to reflect the necessary reagents used in the automatic synthesizer for the particular chemistries that have been selected for the linkages, bases, sugars and conjugate chemistries. Thus for each of a set of these chemistries at process step 510, a .tab file is built at process step 512 and stored at process step 514. As with the .cmd files, an existing .tab file can be edited at process step 516.

[0154] Both the .cmd files and the .tab files are linked together at process step 518 and stored for later retrieval in an appropriate sample database 520. Linking can be as simple as using like file names to associate a .cmd file to its appropriate .tab file, e.g., synthesis_(—)1.cmd is linked to synthesis_(—)1.tab by use of the same preamble in their names.

[0155] The automated, multi-well parallel array synthesizer employs a reagent array delivery format, in which each reagent utilized has a dedicated plumbing system. As seen in FIGS. 23 and 24, an inert atmosphere 522 is maintained during all phases of a synthesis. Temperature is controlled via a thermal transfer plate 524, which holds an injection molded reaction block 526. The reaction plate assembly slides in the X-axis direction, while for example eight nozzle blocks (528, 530, 532, 534, 536, 538, 540 and 542) holding the reagent lines slide in the Y-axis direction, allowing for the extremely rapid delivery of any of 64 reagents to 96 wells. In addition, there are for example, six banks of fixed nozzle blocks (544, 546, 548, 550, 552 and 554) which deliver the same reagent or solvent to eight wells at once, for a total of 72 possible reagents.

[0156] In synthesizing oligonucleotides for screening, the target reaction vessels, a 96 well plate 556 (a 2-dimensional array), moves in one direction along the X axis, while the series of independently controlled reagent delivery nozzles (528, 530, 532, 534, 536, 538, 540 and 542) move along the Y-axis relative to the reaction vessel 558. As the reaction plate 556 and reagent nozzles (528, 530, 532, 534, 536, 538, 540 and 542) can be moved independently at the same time, this arrangement facilitates the extremely rapid delivery of up to 72 reagents independently to each of the 96 reaction vessel wells.

[0157] The system software allows the straightforward programming of the synthesis of a large number of compounds by supplying the general synthetic procedure in the form of the command file to call upon certain reagents to be added to specific wells via lookup in the sequence file with the bottle position, flow rate, and concentration of each reagent being stored in the separate reagent table file. Compounds can be synthesized on various scales. For oligonucleotides, a 200 nmole scale is typically selected while for other compounds larger scales, as for example a 10 μmole scale (3-5 mg), might be utilized. The resulting crude compounds are generally >80% pure, and are utilized directly for high throughput screening assays. Alternatively, prior to use the plates can be subjected to quality control (see general procedure 600 and Example 8) to ascertain their exact purity. Use of the synthesizer results in a very efficient means for the parallel synthesis of compounds for screening.

[0158] The software inputs accept tab delimited text files (as discussed above for file 504 and 512) from any text editor. A typical command file, a .cmd file, is shown in Example 3 at Table 2. Typical sequence files, .seq files, are shown in Example 3 at Tables 3 and 4 (.SEQ file), and a typical reagent file, a .tab file, is shown in Example 3 at Table 5. Table 3 illustrates the sequence file for an oligonucleotide having 2′-deoxy nucleotides at each position with a phosphorothioate backbone throughout. Table 4 illustrates the sequence file for an oligonucleotide, again having a phosphorothioate backbone throughout, however, certain modified nucleoside are utilized in portions of the oligonucleotide. As shown in this table, 2′-O-(2-methoxyethyl) modified nucleosides are utilized in a first region (a wing) of the oligonucleotide, followed by a second region (a gap) of 2′-deoxy nucleotides and finally a third region (a further wing) that has the same chemistry as the first region. Typically some of the wells of the 96 well plate 556 may be left empty (depending on the number of oligonucleotides to be made during an individual synthesis) or some of the wells may have oligonucleotides that will serve as standards for comparison or analytical purposes.

[0159] Prior to loading reagents, moisture sensitive reagent lines are purged with argon at 522 for 20 minutes. Reagents are dissolved to appropriate concentrations and installed on the synthesizer. Large bottles, collectively identified as 558 in FIG. 23 (containing 8 delivery lines) are used for wash solvents and the delivery of general activators, trityl group cleaving reagents and other reagents that may be used in multiple wells during any particular synthesis. Small septa bottles, collectively identified as 560 in FIG. 23, are utilized to contain individual nucleotide amidite precursor compounds. This allows for anhydrous preparation and efficient installation of multiple reagents by using needles to pressurize the bottle, and as a delivery path. After all reagents are installed, the lines are primed with reagent, flow rates measured, then entered into the reagent table (.tab file). A dry resin loaded plate is removed from vacuum and installed in the machine for the synthesis.

[0160] The modified 96 well polypropylene plate 556 is utilized as the reaction vessel. The working volume in each well is approximately 700 μl. The bottom of each well is provided with a pressed-fit 20 μm polypropylene frit and a long capillary exit into a lower collection chamber as is illustrated in FIG. 5 of the above referenced U.S. Pat. No. 5,372,672. The solid support for use in holding the growing oligonucleotide during synthesis is loaded into the wells of the synthesis plate 556 by pipetting the desired volume of a balanced density slurry of the support suspended in an appropriate solvent, typically an acetonitrile-methylene chloride mixture. Reactions can be run on various scales as for instance the above noted 200 nmole and 10 μmol scales. For oligonucleotide synthesis a CPG support is preferred, however other medium loading polystyrene-PEG supports such as TENTAGEL™ or ARGOGEL™ can also be used.

[0161] As seen in FIG. 24, the synthesis plate is transported back and forth in the X-direction under an array of 8 moveable banks (530, 532, 534, 536, 538, 540, 542 and 544) of 8 nozzles (64 total) in the Y-direction, and 6 banks (544, 546, 548, 550, 552 and 554) of 48 fixed nozzles, so that each well can receive the appropriate amounts of reagents and/or solvents from any reservoir (large bottle or smaller septa bottle). A sliding balloon-type seal 562 surrounds this nozzle array and joins it to the reaction plate headspace 564. A slow sweep of nitrogen or argon 522 at ambient pressure across the plate headspace is used to preserve an anhydrous environment.

[0162] The liquid contents in each well do not drip out until the headspace pressure exceeds the capillary forces on the liquid in the exit nozzle. A slight positive pressure in the lower collection chamber can be added to eliminate residual slow leakage from filled wells, or to effect agitation by bubbling inert gas through the suspension. In order to empty the wells, the headspace gas outlet valve is closed and the internal pressure raised to about 2 psi. Normally, liquid contents are blown directly to waste 566. However, a 96 well microtiter plate can be inserted into the lower chamber beneath the synthesis plate in order to collect the individual well eluents for spectrophotometric monitoring (trityl, etc.) of reaction progress and yield.

[0163] The basic plumbing scheme for the machine is the gas-pressurized delivery of reagents. Each reagent is delivered to the synthesis plate through a dedicated supply line, collectively identified at 568, solenoid valve collectively identified at 570 and nozzle, collectively identified at 572. Reagents never cross paths until they reach the reaction well. Thus, no line needs to be washed or flushed prior to its next use and there is no possibility of cross-contamination of reagents. The liquid delivery velocity is sufficiently energetic to thoroughly mix the contents within a well to form a homogeneous solution, even when employing solutions having drastically different densities. With this mixing, once reactants are in homogeneous solution, diffusion carries the individual components into and out of the solid support matrix where the desired reaction takes place. Each reagent reservoir can be plumbed to either a single nozzle or any combination of up to 8 nozzles. Each nozzle is also provided with a concentric nozzle washer to wash the outside of the delivery nozzles in order to eliminate problems of crystallized reactant buildup due to slow evaporation of solvent at the tips of the nozzles. The nozzles and supply lines can be primed into a set of dummy wells directly to waste at any time.

[0164] The entire plumbing system is fabricated with teflon tubing, and reagent reservoirs are accessed via syringe needle/septa or direct connection into the higher capacity bottles. The septum vials 560 are held in removable 8-bottle racks to facilitate easy setup and cleaning. The priming volume for each line is about 350 μl. The minimum delivery volume is about 2 μl, and flow rate accuracy is ±5%. The actual amount of material delivered depends on a timed flow of liquid. The flow rate for a particular solvent will depend on its viscosity and wetting characteristics of the teflon tubing. The flow rate (typically 200-350 μl per sec) is experimentally determined, and this information is contained in the reagent table setup file.

[0165] Heating and cooling of the reaction block 526 is effected utilizing a recirculating heat exchanger plate 524, similar to that found in PCR thermocyclers, that nests with the polypropylene synthesis plate 556 to provide good thermal contact. The liquid contents in a well can be heated or cooled at about 10° C. per minute over a range of +5 to +80° C., as polypropylene begins to soften and deform at about 80° C. For temperatures greater than this, a non-disposable synthesis plate machined from stainless steel or monel with replaceable frits can be utilized.

[0166] The hardware controller can be any of a wide variety, but conveniently can be designed around a set of three 1 MHz 86332 chips. This controller is used to drive the single X-axis and 8 Y-axis stepper motors as well as provide the timing functions for a total of 154 solenoid valves. Each chip has 16 bidirectional timer I/O and 8 interrupt channels in its timer processing unit (TPU). These are used to provide the step and direction signals, and to read 3 encoder inputs and 2 limit switches for controlling up to three motors per chip. Each 86332 chip also drives a serial chain of 8 UNC5891A darlington array chips to provide power to 64 valves with msec resolution. The controller communicates with the Windows software interface program running on a PC via a 19200 Hz serial channel, and uses an elementary instruction set to communicate valve_number, time_open, motor_number and position_data.

[0167] The three components of the software program that run the array synthesizer are the generalized procedure or command (.cmd) file which specifies the synthesis instructions to be performed, the sequence (.seq) file which specifies the scale of the reaction and the order in which variable groups will be added to the core synthon, and the reagent table (.tab) file which specifies the name of a chemical, its location (bottle number), flow rate, and concentration are utilized in conjunction with a basic set of command instructions.

[0168] One basic set of command instructions can be: ADD IF {block of instructions} END_IF REPEAT {block of instructions} END_REPEAT PRIME, NOZZLE_WASH WAIT, DRAIN LOAD, REMOVE NEXT_SEQUENCE LOOP_BEGIN, LOOP_END

[0169] The ADD instruction has two forms, and is intended to have the look and feel of a standard chemical equation. Reagents are specified to be added by a molar amount if the number proceeds the name identifier, or by an absolute volume in microliters if the number follows the identifier. The number of reagents to be added is a parsed list, separated by the “+” sign. For variable reagent identifiers, the key word, <seq>, means look in the sequence table for the identity of the reagent to be added, while the key word, <act>, means add the reagent which is associated with that particular <seq>. Reagents are delivered in the order specified in the list.

[0170] Thus:

[0171] ADD ACN 300

[0172] means: Add 300 μl of the named reagent acetonitrile; ACN to each well of active synthesis

[0173] ADD <seq>300

[0174] means: If the sequence pointer in the .seq file is to a reagent in the list of reagents, independent of scale, add 300 μl of that particular reagent specified for that well.

[0175] ADD 1.1 PYR+1.0<seq>+1.1<act1>

[0176] means: If the sequence pointer in the .seq file is to a reagent in the list of acids in the Class ACIDS_(—)1, and PYR is the name of pyridine, and ethyl chloroformate is defined in the .tab file to activate the class, ACIDS_(—)1, then this instruction means:

[0177] ADD 1.1 equiv. pyridine

[0178] 1.0 equiv. of the acid specified for that well and

[0179] 1.1 equiv. of the activator, ethyl chloroformate

[0180] The IF command allows one to test what type of reagent is specified in the <seq>variable and process the succeeding block of commands accordingly. Thus: ACYLATION {the procedure name} BEGIN IF CLASS = ACIDS_1 ADD 1.0 <seq> + 1.1 <act1> + 1.1 PYR WAIT 60 ENDIF IF CLASS = ACIDS_2 ADD 1.0 <seq> + 1.2 <act1> + 1.2 TEA ENDIF WAIT 60 DRAIN 10 END

[0181] means: Operate on those wells for which reagents contained in the Acid_(—)1 class are specified, WAIT 60 sec, then operate on those wells for which reagents contained in the Acid_(—)2 class are specified, then WAIT 60 sec longer, then DRAIN the whole plate. Note that the Acid_(—)1 group has reacted for a total of 120 sec, while the Acid_(—)2 group has reacted for only 60 sec.

[0182] The REPEAT command is a simple way to execute the same block of commands multiple times. Thus: WASH_1 {the procedure name} BEGIN REPEAT 3 ADD ACN 300 DRAIN 15 END_REPEAT END

[0183] means: repeats the add acetonitrile and drain sequence for each well three times.

[0184] The PRIME command will operate either on specific named reagents or on nozzles which will be used in the next associated <seq>operation. The μl amount dispensed into a prime port is a constant that can be specified in a config.dat file.

[0185] The NOZZLE_WASH command for washing the outside of reaction nozzles free from residue due to evaporation of reagent solvent will operate either on specific named reagents or on nozzles which have been used in the preceding associated <seq>operation. The machine is plumbed such that if any nozzle in a block has been used, all the nozzles in that block will be washed into the prime port.

[0186] The WAIT and DRAIN commands are by seconds, with the drain command applying a gas pressure over the top surface of the plate in order to drain the wells.

[0187] The LOAD and REMOVE commands are instructions for the machine to pause for operator action.

[0188] The NEXT_SEQUENCE command increments the sequence pointer to the next group of substituents to be added in the sequence file. The general form of a .seq file entry is the definition:

Well_No Well_ID Scale Sequence

[0189] The sequence information is conveyed by a series of columns, each of which represents a variable reagent to be added at a particular position. The scale (μmole) variable is included so that reactions of different scale can be run at the same time if desired. The reagents are defined in a lookup table (the .tab file), which specifies the name of the reagent as referred to in the sequence and command files, its location (bottle number), flow rate, and concentration. This information is then used by the controller software and hardware to determine both the appropriate slider motion to position the plate and slider arms for delivery of a specific reagent, as well as the specific valve and time required to deliver the appropriate reagents. The adept classification of reagents allows the use of conditional IF loops from within a command file to perform addition of different reagents differently during a “single step” performed across 96 wells simultaneously. The special class ACTIVATORS defines certain reagents that always get added with a particular class of reagents (for example tetrazole during a phosphitylation reaction in adding the next nucleotide to a growing oligonucleotide).

[0190] The general form of the .tab file is the definition:

Class Bottle Reagent Name Flow_rate Conc.

[0191] The LOOP_BEGIN and LOOP_END commands define the block of commands which will continue to operate until a NEXT_SEQUENCE command points past the end of the longest list of reactants in any well.

[0192] Not included in the command set is a MOVE command. For all of the above commands, if any plate or nozzle movement is required, this is automatically executed in order to perform the desired solvent or reagent delivery operation. This is accomplished by the controller software and hardware, which determines the correct nozzle(s) and well(s) required for a particular reagent addition, then synchronizes the position of the requisite nozzle and well prior to adding the reagent.

[0193] A MANUAL mode can also be utilized in which the synthesis plate and nozzle blocks can be “homed” or moved to any position by the operator, the nozzles primed or washed, the various reagent bottles depressurized or washed with solvent, the chamber pressurized, etc. The automatic COMMAND mode can be interrupted at any point, MANUAL commands executed, and then operation resumed at the appropriate location. The sequence pointer can be incremented to restart a synthesis anywhere within a command file.

[0194] In reference to FIG. 14, the list of oligonucleotides for synthesis can be rearranged or grouped for optimization of synthesis. Thus at process step 574, the oligonucleotides are grouped according to a factor on which to base the optimization of synthesis. As illustrated in the Examples below, one such factor is the 3′ most nucleoside of the oligonucleotide. Using the amidite approach for oligonucleotide synthesis, a nucleotide bearing a 3′ phosphoramite is added to the 5′ hydroxyl group of a growing nucleotide chain. The first nucleotide (at the 3′ terminus of the oligonucleotide—the 3′ most nucleoside) is first connected to a solid support. This is normally done batchwise on a large scale as is standard practice during oligonucleotide synthesis.

[0195] Such solid supports pre-loaded with a nucleoside are commercially available. In utilizing the multi well format for oligonucleotide synthesis, for each oligonucleotide to be synthesized, an aliquot of a solid support bearing the proper nucleoside thereon is added to the well for synthesis. Prior to loading the sequence of oligonucleotides to be synthesized in the .seq file, they are sorted by the 3′ terminal nucleotide. Based on that sorting, all of the oligonucleotide sequences having an “A” nucleoside at their 3′ end are grouped together, those with a “C” nucleoside are grouped together as are those with “G” or “T” nucleosides. Thus in loading the nucleoside-bearing solid support into the synthesis wells, machine movements are conserved.

[0196] The oligonucleotides can be grouped by the above described parameter or other parameters that facilitate the synthesis of the oligonucleotides. Thus in FIG. 14, sorting is noted as being effected by some parameter of type 1, as for instance the above described 3′ most nucleoside, or other types of parameters from type 2 to type n at process steps 576, 578 and 580. Since synthesis will be from the 3′ end of the oligonucleotides to the 5′ end, the oligonucleotide sequences are reverse sorted to read 3′ to 5′. The oligonucleotides are entered in the .seq file in this form, i.e., reading 3′ to 5′.

[0197] Once sorted into types, the position of the oligonucleotides on the synthesis plates is specified at process step 582 by the creation of a .seq file as described above. The .seq file is associated with the respective .cmd and .tab files needed for synthesis of the particular chemistries specified for the oligonucleotides at process step 584 by retrieval of the .cmd and .tab files at process step 586 from the sample database 520. These files are then input into the multi well synthesizer at process step 588 for oligonucleotide synthesis. Once physically synthesized, the list of oligonucleotides again enters the general procedure flow as indicated in FIG. 1. For shipping, storage or other handling purposes, the plates can be lyophilized at this point if desired. Upon lyophilization, each well contains the oligonucleotides located therein as a dry compound.

[0198] 14. Quality Control.

[0199] In an optional step, quality control is performed on the oligonucleotides at process step 600 after a decision is made (decision step 550) to perform quality control. Although optional, quality control may be desired when there is some reason to think that some aspect of the synthetic process step 500 has been compromised. Alternatively, samples of the oligonucleotides may be taken and stored in the event that the results of assays conducted using the oligonucleotides (process step 700) yield confusing results or suboptimal data. In the latter event, for example, quality control might be performed after decision step 800 if no oligonucleotides with sufficient activity are identified. In either event, decision step 650 follows quality control step process 600. If one or more of the oligonucleotides do not pass quality control, process step 500 can be repeated, i.e., the oligonucleotides are synthesized for a second time.

[0200] The operation of the quality control system general procedure 600 is detailed in steps 610-660 of FIG. 15. Also referenced in the following discussion are the robotics and associated analytical instrumentation as shown in FIG. 18.

[0201] During step 610 (FIG. 15), sterile, double-distilled water is transferred by an automated liquid handler (2040 of FIG. 18) to each well of a multi-well plate containing a set of lyophilized antisense oligonucleotides. The automated liquid handler (2040 of FIG. 18) reads the barcode sticker on the multi-well plate to obtain the plate's identification number. Automated liquid handler 2040 then queries Sample Database 520 (which resides in Database Server 2002 of FIG. 18) for the quality control assay instruction set for that plate and executes the appropriate steps. Three quality control processes are illustrated, however, it is understood that other quality control processes or steps maybe practiced in addition to or in place of the processes illustrated.

[0202] The first illustrative quality control process (steps 622 to 626) quantitates the concentration of oligonucleotide in each well. If this quality control step is performed, an automated liquid handler (2040 of FIG. 18) is instructed to remove an aliquot from each well of the master plate and generate a replicate daughter plate for transfer to the UV spectrophotometer (2016 of FIG. 18). The UV spectrophotometer (2016 of FIG. 18) then measures the optical density of each well at a wavelength of 260 nanometers. Using standardized conversion factors, a microprocessor within UV spectrophotometer (2016 of FIG. 18) then calculates a concentration value from the measured absorbance value for each well and output the results to Sample Database 520.

[0203] The second illustrative quality control process steps 632 to 636) quantitates the percent of total oligonucleotide in each well that is full length. If this quality control step is performed, an automated liquid handler (2040 of FIG. 18) is instructed to remove an aliquot from each well of the master plate and generate a replicate daughter plate for transfer to the multichannel capillary gel electrophoresis apparatus (2022 of FIG. 18). The apparatus electrophoretically resolves in capillary tube gels the oligonucleotide product in each well. As the product reaches the distal end of the tube gel during electrophoresis, a detection window dynamically measures the optical density of the product that passes by it. Following electrophoresis, the value of percent product that passed by the detection window with respect to time is utilized by a built in microprocessor to calculate the relative size distribution of oligonucleotide product in each well. These results are then output to the Sample Database (520.

[0204] The third illustrative quality control process steps 632 to 636) quantitates the mass of the oligonucleotide in each well that is full length. If this quality control step is performed, an automated liquid handler (2040 of FIG. 18) is instructed to remove an aliquot from each well of the master plate and generate a replicate daughter plate for transfer to the multichannel liquid electrospray mass spectrometer (2018 of FIG. 18). The apparatus then uses electrospray technology to inject the oligonucleotide product into the mass spectrometer. A built in microprocessor calculates the mass-to-charge ratio to arrive at the mass of oligonucleotide product in each well. The results are then output to Sample Database 520.

[0205] Following completion of the selected quality control processes, the output data is manually examined or is examined using an appropriate algorithm and a decision is made as to whether or not the plate receives “Pass” or “Fail” status. The current criteria for acceptance, for 18 mer oligonucleotides, is that at least 85% of the oligonucleotides in a multi-well plate must be 85% or greater full length product as measured by both capillary gel electrophoresis and mass spectrometry. An input (manual or automated) is then made into Sample Database 520 as to the pass/fail status of the plate. If a plate fails, the process cycles back to step 500, and a new plate of the same oligonucleotides is automatically placed in the plate synthesis request queue (process 554 of FIG. 15). If a plate receives “Pass” status, an automated liquid handler (2040 of FIG. 18) is instructed to remove appropriate aliquots from each well of the master plate and generate two replicate daughter plates in which the oligonucleotide in each well is at a concentration of 30 micromolar. The plate then moves on to process 700 for oligonucleotide activity evaluation.

[0206] 15. Cell Lines for Assaying Oligonucleotide Activity.

[0207] The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid, or its gene product, is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but other cell types can be routinely used.

[0208] T-24 cells: The transitional cell bladder carcinoma cell line T-24 is obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum, penicillin 100 units per milliliter, and streptomycin 100 micrograms per milliliter (all from Life Technologies). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence. Cells are routinely seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis. For Northern blotting or other analysis, cells are seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0209] A549 cells: The human lung carcinoma cell line A549 is obtained from the ATCC (Manassas, Va.). A549 cells were routinely cultured in DMEM basal media (Life Technologies) supplemented with 10% fetal calf serum, penicillin 100 units per milliliter, and streptomycin 100 micrograms per milliliter (all from Life Technologies). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence.

[0210] NHDF cells: Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, Md.). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corp.) as provided by the supplier. Cells are maintained for up to 10 passages as recommended by the supplier.

[0211] HEK cells: Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corp. HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corp.) as provided by the supplier. Cell are routinely maintained for up to 10 passages as recommended by the supplier.

[0212] 16. Treatment of Cells with Candidate Compounds:

[0213] When cells reach about 80% confluency, they are treated with oligonucleotide. For cells grown in 96-well plates, wells are washed once with 200 μl OPTI-MEM-1™ reduced-serum medium (Life Technologies) and then treated with 130 μl of OPTI-MEM-1™ containing 3.75 μg/ml LIPOFECTIN™ (Life Technologies) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

[0214] Alternatively, for cells resistant to cationic mediated transfection, oligonucleotides can be introduced by electroporation. Electroporation conditions must be optimized for every cell type. In general, oligonucleotide is added directly to complete growth media to a final concentration between 1 and 20 micromolar. An electronic pulse is delivered to the cells using a BTX T820 ELECTRO SQUARE PORATOR™ using a Multi-coaxial 96-well electrode (BT840) (BTX Corporation, San Diego, Calif.). Following electroporation, the cells are returned to the incubator for 16 hours.

[0215] 17. Assaying Oligonucleotide Activity:

[0216] Oligonucleotide-mediated modulation of expression of a target nucleic acid can be assayed in a variety of ways known in the art. For example, target RNA levels can be quantitated by, e.g., Northern blot analysis, competitive PCR, or reverse transcriptase polymerase chain reaction (RT-PCR). RNA analysis can be performed on total cellular RNA or, preferably in the case of polypeptide-encoding nucleic acids, poly(A)+ mRNA. For RT-PCR, poly(A)+ mRNA is preferred. Methods of RNA isolation are taught in, for example, Ausubel et al. (Short Protocols in Molecular Biology, 2nd Ed., pp. 4-1 to 4-13, Greene Publishing Associates and John Wiley & Sons, New York, 1992). Northern blot analysis is routine in the art (Id., pp. 4-14 to 4-29).

[0217] Alternatively, total RNA can be prepared from cultured cells or tissue using the QIAGEN RNeasy®-96 kit for the high throughput preparation of RNA (QIAGEN, Inc., Valencia, Calif.). Essentially, protocols are carried out according to the manufacturer's directions. Optionally, a DNase step is included to remove residual DNA prior to RT-PCR.

[0218] To improve efficiency and accuracy the repetitive pipeting steps and elution step have been automated using a QIAGEN Bio-Robot 9604. Essentially after lysing of the oligonucleotide treated cell cultures in situ, the plate is transferred to the robot deck where the pipeting, DNase treatment, and elution steps are carried out.

[0219] Reverse transcriptase polymerase chain reaction (RT-PCR) can be conveniently accomplished using the commercially available ABI PRISM® 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to the manufacturer's instructions. Other methods of PCR are also known in the art.

[0220] Target protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), Enzyme-linked immunosorbent assay (ELISA) or fluorescence-activated cell sorting (FACS). Antibodies directed to a protein encoded by a target nucleic acid can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies, (Aerie Corporation, Birmingham, Mich. or via the world wide web of the interact at ANTIBODIES-PROBES.com/), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal, monospecific (“antipeptide”) and monoclonal antisera are taught by, for example, Ausubel et al. (Short Protocols in Molecular Biology, 2nd Ed., pp. 11-3 to 11-54, Greene Publishing Associates and John Wiley & Sons, New York, 1992).

[0221] Immunoprecipitation methods are standard in the art and are described by, for example, Ausubel et al. (Id., pp. 10-57 to 10-63). Western blot (immunoblot) analysis is standard in the art (Id., pp. 10-32 to 10-10-35). Enzyme-linked immunosorbent assays (ELISA) are standard in the art (Id., pp. 11-5 to 11-17).

[0222] Because it is preferred to assay the compounds of the invention in a batchwise fashion, i.e., in parallel to the automated synthesis process described above, preferred means of assaying are suitable for use in 96-well plates and with robotic means. Accordingly, automated RT-PCR is preferred for assaying target nucleic acid levels, and automated ELISA is preferred for assaying target protein levels.

[0223] The assaying step, general procedure step 700, is described in detail in FIG. 16. After an appropriate cell line is selected at process step 710, a decision is made at decision step 714 as to whether RT-PCR will be the only method by which the activity of the compounds is evaluated. In some instances, it is desirable to run alternative assay methods at process step 718; for example, when it is desired to assess target polypeptide levels as well as target RNA levels, an immunoassay such as an ELISA is run in parallel with the RT-PCR assays. Preferably, such assays are tractable to semi-automated or robotic means.

[0224] When RT-PCR is used to evaluate the activities of the compounds, cells are plated into multi-well plates (typically, 96-well plates) in process step 720 and treated with test or control oligonucleotides in process step 730. Then, the cells are harvested and lysed in process step 740 and the lysates are introduced into an apparatus where RT-PCR is carried out in process step 750. A raw data file is generated, and the data is downloaded and compiled at step 760. Spreadsheet files with data charts are generated at process step 770, and the experimental data is analyzed at process step 780. Based on the results, a decision is made at process step 785 as to whether it is necessary to repeat the assays and, if so, the process begins again with step 720. In any event, data from all the assays on each oligonucleotide are compiled and statistical parameters are automatically determined at process step 790.

[0225] 18. Classification of Compounds Based on their Activity:

[0226] Following assaying, general procedure step 700, oligonucleotide compounds are classified according to one or more desired properties. Typically, three classes of compounds are used: active compounds, marginally active (or “marginal”) compounds and inactive compounds. To some degree, the selection criteria for these classes vary from target to target, and members of one or more classes may not be present for a given set of oligonucleotides.

[0227] However, some criteria are constant. For example, inactive compounds will typically comprise those compounds having 5% or less inhibition of target expression (relative to basal levels). Active compounds will typically cause at least 30% inhibition of target expression, although lower levels of inhibition are acceptable in some instances. Marginal compounds will have activities intermediate between active and inactive compounds, with preferred marginal compounds having activities more like those of active compounds.

[0228] 19. Optimization of Lead Compounds by Sequence.

[0229] One means by which oligonucleotide compounds are optimized for activity is by varying their nucleobase sequences so that different regions of the target nucleic acid are targeted. Some such regions will be more accessible to oligonucleotide compounds than others, and “sliding” a nucleobase sequence along a target nucleic acid only a few bases can have significant effects on activity. Accordingly, varying or adjusting the nucleobase sequences of the compounds of the invention is one means by which suboptimal compounds can be made optimal, or by which new active compounds can be generated.

[0230] The operation of the gene walk process 1100 detailed in steps 1104-1112 of FIG. 17 is detailed as follows. As used herein, the term “gene walk” is defined as the process by which a specified oligonucleotide sequence x that binds to a specified nucleic acid target y is used as a frame of reference around which a series of new oligonucleotides sequences capable of hybridizing to nucleic acid target y are generated that are sequence shifted increments of oligonucleotide sequence x. Gene walking can be done “downstream”, “upstream” or in both directions from a specified oligonucleotide.

[0231] During step 1104 the user manually enters the identification number of the oligonucleotide sequence around which it is desired to execute gene walk process 1100 and the name of the corresponding target nucleic acid. The user then enters the scope of the gene walk at step 1104, by which is meant the number of oligonucleotide sequences that it is desired to generate. The user then enters in step 1108 a positive integer value for the sequence shift increment. Once this data is generated, the gene walk is effected. This causes a subroutine to be executed that automatically generates the desired list of sequences by walking along the target sequence. At that point, the user proceeds to process 400 to assign chemistries to the selected oligonucleotides.

[0232] Example 18 below, details a gene walk. In subsequent steps, this new set of nucleobase sequences generated by the gene walk is used to direct the automated synthesis at general procedure step 500 of a second set of candidate oligonucleotides. These compounds are then taken through subsequent process steps to yield active compounds or reiterated as necessary to optimize activity of the compounds.

[0233] 20. Optimization of Lead Compounds by Chemistry.

[0234] Another means by which oligonucleotide compounds of the invention are optimized is by reiterating portions of the process of the invention using marginal or active compounds from the first iteration and selecting additional chemistries to the nucleobase sequences thereof.

[0235] Thus, for example, an oligonucleotide chemistry different from that of the first set of oligonucleotides is assigned at general procedure step 400. The nucleobase sequences of marginal compounds are used to direct the synthesis at general procedure step 500 of a second set of oligonucleotides having the second assigned chemistry. The resulting second set of oligonucleotide compounds is assayed in the same manner as the first set at procedure process step 700 and the results are examined to determine if compounds having sufficient activity have been generated at decision step 800.

[0236] 21. Identification of Sites Amenable to Antisense Technologies.

[0237] In a related process, a second oligonucleotide chemistry is assigned at procedure step 400 to the nucleobase sequences of all of the oligonucleotides (or, at least, all of the active and marginal compounds) and a second set of oligonucleotides is synthesized at procedure step 500 having the same nucleobase sequences as the first set of compounds. The resulting second set of oligonucleotide compounds is assayed in the same manner as the first set at procedure step 700 and active and marginal compounds are identified at procedure steps 800 and 1000.

[0238] In order to identify sites on the target nucleic acid that are amenable to a variety of antisense technologies, the following mathematically simple steps are taken. The sequences of active and marginal compounds from two or more such automated syntheses/assays are compared and a set of nucleobase sequences that are active, or marginally so, in both sets of compounds is identified. The reverse complements of these nucleobase sequences corresponds to sequences of the target nucleic acid that are tractable to a variety of antisense and other sequence-based technologies. These antisense-sensitive sites are assembled into contiguous sequences (contigs) using the procedures described for assembling target nucleotide sequences (at procedure step 200).

[0239] 22. Systems for Executing Preferred Methods of the Invention.

[0240] An embodiment of computer, network and instrument resources for effecting the methods of the invention is shown in FIG. 18. In this embodiment, four computer servers are provided. First, a large database server 2002 stores all chemical structure, sample tracking and genomic, assay, quality control, and program status data. Further, this database server serves as the platform for a document management system. Second, a compute engine 2004 runs computational programs including RNA folding, oligonucleotide walking, and genomic searching. Third, a file server 2006 allows raw instrument output storage and sharing of robot instructions. Fourth, a groupware server 2008 enhances staff communication and process scheduling.

[0241] A redundant high-speed network system is provided between the main servers and the bridges 2026, 2028 and 2030. These bridges provide reliable network access to the many workstations and instruments deployed for this process. The instruments selected to support this embodiment are all designed to sample directly from standard 96 well microtiter plates, and include an optical density reader 2016, a combined liquid chromatography and mass spectroscopy instrument 2018, a gel fluorescence and scintillation imaging system 2032 and 2042, a capillary gel electrophoreses system 2022 and a real-time PCR system 2034.

[0242] Most liquid handling is accomplished automatically using robots with individually controllable robotic pipetters 2038 and 2020 as well as a 96-well pipette system 2040 for duplicating plates. Windows NT or Macintosh workstations 2044, 2024, and 2036 are deployed for instrument control, analysis and productivity support.

[0243] 23. Relational Database.

[0244] Data is stored in an appropriate database. For use with the methods of the invention, a relational database is preferred. FIG. 19 illustrates the data structure of a sample relational database. Various elements of data are segregated among linked storage elements of the database.

EXAMPLES

[0245] The following examples illustrate the invention and are not intended to limit the same. Those skilled in the art will recognize, or be able to ascertain through routine experimentation, numerous equivalents to the specific procedures, materials and devices described herein. Such equivalents are considered to be within the scope of the present invention.

Example 1

[0246] Selection of CD40 as a Target

[0247] Cell-cell interactions are a feature of a variety of biological processes. In the activation of the immune response, for example, one of the earliest detectable events in a normal inflammatory response is adhesion of leukocytes to the vascular endothelium, followed by migration of leukocytes out of the vasculature to the site of infection or injury. The adhesion of leukocytes to vascular endothelium is an obligate step in their migration out of the vasculature (for a review, see Albelda et al., FASEB J., 1994, 8, 504). As is well known in the art, cell-cell interactions are also critical for propagation of both B-lymphocytes and T-lymphocytes resulting in enhanced humoral and cellular immune responses, respectively (for a reviews, see Makgoba et al., Immunol. Today, 1989, 10, 417; Janeway, Sci. Amer., 1993, 269, 72).

[0248] CD40 was first characterized as a receptor expressed on B-lymphocytes. It was later found that engagement of B-cell CD40 with CD40L expressed on activated T-cells is essential for T-cell dependent B-cell activation (i.e. proliferation, immunoglobulin secretion, and class switching) (for a review, see Gruss et al. Leuk. Lymphoma, 1997, 24, 393). A full cDNA sequence for CD40 is available (GenBank accession number X60592, incorporated herein by reference as SEQ ID NO: 85).

[0249] As interest in CD40 mounted, it was subsequently revealed that functional CD40 is expressed on a variety of cell types other than B-cells, including macrophages, dendritic cells, thymic epithelial cells, Langerhans cells, and endothelial cells (Ibid.). These studies have led to the current belief that CD40 plays a much broader role in immune regulation by mediating interactions of T-cells with cell types other than B-cells. In support of this notion, it has been shown that stimulation of CD40 in macrophages and dendritic results is required for T-cell activation during antigen presentation (Id.). Recent evidence points to a role for CD40 in tissue inflammation as well. Production of the inflammatory mediators IL-12 and nitric oxide by macrophages has been shown to be CD40 dependent (Buhlmann et al., J. Clin. Immunol., 1996, 16, 83). In endothelial cells, stimulation of CD40 by CD40L has been found to induce surface expression of E-selectin, ICAM-1, and VCAM-1, promoting adhesion of leukocytes to sites of inflammation (Buhlmann et al., J. Clin. Immunol, 1996, 16, 83; Gruss et al., Leuk Lymphoma, 1997, 24, 393). Finally, a number of reports have documented overexpression of CD40 in epithelial and hematopoietic tumors as well as tumor infiltrating endothelial cells, indicating that CD40 may play a role in tumor growth and/or angiogenesis as well (Gruss et al., Leuk Lymphoma, 1997, 24, 393-422; Kluth et al. Cancer Res, 1997, 57, 891).

[0250] Due to the pivotal role that CD40 plays in humoral immunity, the potential exists that therapeutic strategies aimed at downregulating CD40 may provide a novel class of agents useful in treating a number of immune associated disorders, including but not limited to graft versus host disease, graft rejection, and autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and certain forms of arthritis. Inhibitors of CD40 may also prove useful as an anti-inflammatory compound, and could therefore be useful as treatment for a variety of diseases with an inflammatory component such as asthma, rheumatoid arthritis, allograft rejections, inflammatory bowel disease, and various dermatological conditions, including psoriasis. Finally, as more is learned about the association between CD40 overexpression and tumor growth, inhibitors of CD40 may prove useful as anti-tumor agents as well.

[0251] Currently, there are no known therapeutic agents which effectively inhibit the synthesis of CD40. To date, strategies aimed at inhibiting CD40 function have involved the use of a variety of agents that disrupt CD40/CD40L binding. These include monoclonal antibodies directed against either CD40 or CD40L, soluble forms of CD40, and synthetic peptides derived from a second CD40 binding protein, A20. The use of neutralizing antibodies against CD40 and/or CD40L in animal models has provided evidence that inhibition of CD40 stimulation would have therapeutic benefit for GVHD, allograft rejection, rheumatoid arthritis, SLE, MS, and B-cell lymphoma (Buhlmann et al., J. Clin. Immunol, 1996, 16, 83). However, due to the expense, short half-life, and bioavailability problems associated with the use of large proteins as therapeutic agents, there is a long felt need for additional agents capable of effectively inhibiting CD40 function. Oligonucleotides compounds avoid many of the pitfalls of current agents used to block CD40/CD40L interactions and may therefore prove to be uniquely useful in a number of therapeutic applications.

Example 2

[0252] Generation of Virtual Oligonucleotides Targeted to CD40

[0253] The process of the invention was used to select oligonucleotides targeted to CD40, generating the list of oligonucleotide sequences with desired properties as shown in FIG. 22. From the assembled CD40 sequence, the process began with determining the desired oligonucleotide length to be eighteen nucleotides, as represented in step 2500. All possible oligonucleotides of this length were generated by Oligo 5.0™, as represented in step 2504. Desired thermodynamic properties were selected in step 2508. The single parameter used was oligonucleotides of melting temperature less than or equal to 40° C. were discarded. In step 2512, oligonucleotide melting temperatures were calculated by Oligo 5.0™. Oligonucleotide sequences possessing an undesirable score were discarded. It is believed that oligonucleotides with melting temperatures near or below physiological and cell culture temperatures will bind poorly to target sequences. All oligonucleotide sequences remaining were exported into a spreadsheet. In step 2516, desired sequence properties are selected. These include discarding oligonucleotides with at least one stretch of four guanosines in a row and stretches of six of any other nucleotide in a row. In step 2520, a spreadsheet macro removed all oligonucleotides containing the text string “GGGG.” In step 2524, another spreadsheet macro removed all oligonucleotides containing the text strings “AAAAAA” or “CCCCCC” or “TTTTTT.” From the remaining oligonucleotide sequences, 84 sequences were selected manually with the criteria of having an uniform distribution of oligonucleotide sequences throughout the target sequence, as represented in step 2528. These oligonucleotide sequences were then passed to the next step in the process, assigning actual oligonucleotide chemistries to the sequences.

Example 3

[0254] Input Files For Automated Oligonucleotide Synthesis Command File (.cmd File)

[0255] Table 2 is a command file for synthesis of an oligonucleotide having regions of 2′-O-(2-methoxyethyl) nucleosides and a central region of 2′-deoxy nucleosides each linked by phosphorothioate internucleotide linkages. TABLE 2 SOLID_SUPPORT_SKIP BEGIN Next_Sequence END INITIAL-WASH BEGIN Add ACN 300 Drain 10 END LOOP-BEGIN DEBLOCK BEGIN Prime TCA Load Tray Repeat 2 Add TCA 150 Wait 10 Drain 8 End_Repeat Remove Tray Add TCA 125 Wait 10 Drain 8 END WASH_AFTER_DEBLOCK BEGIN Repeat 3 Add ACN 250 To_All Drain 10 End_Repeat END COUPLING BEGIN if class = DEOXY_THIOATE Nozzle wash <act1> prime <act1> prime <seq> Add <act1> 70 + <seq> 70 Wait 40 Drain 5 end-if if class = MOE_THIOATE Nozzle wash <act1> Prime <act1> prime <seq> Add <act1> 120 + <seq> 120 Wait 230 Drain 5 End_if END WASH_AFTER_COUPLING BEGIN Add ACN 200 To_All Drain 10 END OXIDIZE BEGIN if class = DEOXY_THIOATE Add BEAU 180 Wait 40 Drain 7 end_if if class = MOE_THIOATE Add BEAU 200 Wait 120 Drain 7 end_if END CAP BEGIN Add CAP_B 80 + CAP_A 80 Wait 20 Drain 7 END WASH_AFTER_CAP BEGIN Add ACN 150 To_All Drain 5 Add ACN 250 To_All Drain 11 END BASE_COUNTER BEGIN Next_Sequence END LOOP_END DEBLOCK_FINAL BEGIN Prime TCA Load Tray Repeat 2 Add TCA 150 To_All Wait 10 Drain 8 End_Repeat Remove Tray Add TCA 125 To_All Wait 10 Drain 10 END FINAL_WASH BEGIN Repeat 4 Add ACN 300 to_All Drain_12 End_Repeat END ENDALL BEGIN Wait 3 END

[0256] Sequence Files (.seq Files)

[0257] Table 3 is a .seq file for oligonucleotides having 2′-deoxy nucleosides linked by phosphorothioate internucleotide linkages. TABLE 3 Identity of columns: Syn #, Well, Scale, Nucleotide at particular position (identified using base identifier followed by backbone identifier where “s” is phosphorothioate). Note the columns wrap around to next line when longer than one line. 1 A01 200 As Cs Cs As Gs Gs As Cs Gs Gs Cs 2 A02 200 As Cs Gs Gs Cs Gs Gs As Cs Cs As 3 A03 200 As Cs Cs As As Gs Cs As Gs As Cs 4 A04 200 As Gs Gs As Gs As Cs Cs Cs Cs Gs 5 A05 200 As Cs Cs Cs Cs Gs As Cs Gs As As 6 A06 200 As Cs Gs As As Cs Gs As Cs Ts Gs 7 A07 200 As Cs Gs As Cs Ts Gs Gs Cs Gs As 8 A08 200 As Cs As Gs Gs Ts As Gs Gs Ts Cs 9 A09 200 As Gs Gs Ts Cs Ts Ts Gs Gs Ts Gs 10 A10 200 As Cs Ts Cs As Cs Cs As Cs As As 11 A11 200 As Cs Gs As Cs As As Gs As As As 12 A12 200 As Cs As As As Cs As Cs Gs Gs Ts 13 B01 200 As As Cs As Cs Gs Gs Ts Cs Gs Gs 14 B02 200 As Cs Ts Cs As Cs Ts Gs As Cs Gs 15 B03 200 As Cs Gs Gs As As Gs Gs As As Cs 16 B04 200 As Ts Cs Ts Gs Ts Gs Gs As Cs Cs 17 B05 200 As Cs As Cs Ts Ts Cs Ts Ts Cs Cs 18 B06 200 As Cs Ts Cs Ts Cs Gs As Cs As Cs 19 B07 200 As As As Cs Cs Cs Cs As Gs Ts Ts 20 B08 200 As Ts Gs Ts Cs Cs Cs Cs As As As 21 B09 200 As Cs Gs Cs Ts Cs Gs Gs Gs As Cs 22 B10 200 As Gs Cs Cs Gs As As Gs As As Gs 23 B11 200 As Cs As Cs As Gs Ts As Gs As Cs 24 B12 200 As Cs As Cs Ts Cs Ts Gs Gs Ts Ts 25 C01 200 As Cs Gs As Cs Cs As Gs As As As 26 C02 200 As Gs Ts Ts As As As As Gs Gs Gs 27 C03 200 As Gs Gs Ts Ts Gs Ts Gs As Cs Gs 28 C04 200 As As Ts Gs Ts As Cs Cs Ts As Cs 29 C05 200 As Gs Ts Cs As Cs Gs Ts Cs Cs Ts 30 C06 200 Cs Ts Gs Gs Cs Gs As Cs As Gs Gs 31 C07 200 Cs Ts Cs Ts Gs Ts Gs Ts Gs As Cs 32 C08 200 Cs As Gs Gs Ts Cs Gs Ts Cs Ts Ts 33 C09 200 Cs Ts Gs Ts Gs Gs Ts As Gs As Cs 34 C10 200 Cs Ts As As Cs Gs As Ts Gs Ts Cs 35 C11 200 Cs Ts Gs Ts Ts Cs Gs As Cs As Cs 36 C12 200 Cs Ts Gs Gs As Cs Cs As As Cs As 37 D01 200 Cs Cs Gs Ts Cs Cs Gs Ts Gs Ts Ts 38 D02 200 Cs Ts Gs As Cs Ts As Cs As As Cs 39 D03 200 Cs As As Cs As Gs As Cs As Cs Cs 40 D04 200 Cs As Gs Gs Gs Gs Ts Cs Cs Ts As 41 D05 200 Cs Ts Cs Ts As Gs Ts Ts As As As 42 D06 200 Cs Ts Gs Cs Ts As Gs As As Gs Gs 43 D07 200 Cs Ts Gs As As As Ts Gs Ts As Cs 44 D08 200 Cs As Cs Cs Cs Gs Ts Ts Ts Gs Ts 45 D09 200 Cs Ts Cs Gs As Ts As Cs Gs Gs Gs 46 D10 200 Gs Gs Ts As Gs Gs Ts Cs Ts Ts Gs 47 D11 200 Gs As Cs Ts Ts Ts Gs Cs Cs Ts Ts 48 D12 200 Gs Ts Gs Gs As Gs Ts Cs Ts Ts Ts 49 E01 200 Gs Gs As Gs Ts Cs Ts Ts Ts Gs Ts 50 E02 200 Gs Gs As Cs As Cs Ts Cs Ts Cs Gs 51 E03 200 Gs As Cs As Cs As Gs Gs As Cs Gs 52 E04 200 Gs As Gs Ts As Cs Gs As Gs Cs Gs 53 E05 200 Gs As Cs Ts As Ts Gs Gs Ts As Gs 54 E06 200 Gs As As Gs As Gs Gs Ts Ts As Cs 55 E07 200 Gs As Gs Gs Ts Ts As Cs As Cs As 56 E08 200 Gs Ts Ts Gs Ts Cs Cs Gs Ts Cs Cs 57 E09 200 Gs As Cs Ts Cs Ts Cs Gs Gs Gs As 58 E10 200 Gs Ts As Gs Gs As Gs As As Cs Cs 59 E11 200 Gs Gs Ts Ts Cs Ts Ts Cs Gs Gs Ts 60 E12 200 Gs Ts Gs Gs Gs Gs Ts Ts Cs Gs Ts 61 F01 200 Gs Ts Cs As Cs Gs Ts Cs Cs Ts Cs 62 F02 200 Gs Ts Cs Cs Ts Cs Cs Ts As Cs Cs 63 F03 200 Gs Ts Cs Cs Cs Cs As Cs Gs Ts Cs 64 F04 200 Ts Cs As Cs Cs As Gs Cs As Gs Cs 65 F05 200 Ts As Cs Cs As As Gs Cs As Gs As 66 F06 200 Ts Cs Cs Ts Gs Ts Cs Ts Ts Ts Gs 67 F07 200 Ts Gs Ts Cs Ts Ts Ts Gs As Cs Cs 68 F08 200 Ts Gs As Cs Cs As Cs Ts Cs As Cs 69 F09 200 Ts Gs As Cs Gs Ts Gs Ts Cs Ts Cs 70 F10 200 Ts Cs As As Gs Ts Gs As Cs Ts Ts 71 F11 200 Ts Gs Ts Ts Ts As Ts Gs As Cs Gs 72 F12 200 Ts Ts As Ts Gs As Cs Gs Cs Ts Gs 73 G01 200 Ts Gs As Cs Gs Cs Ts Gs Gs Gs Gs 74 G02 200 Ts Cs Gs Ts Cs Ts Ts Cs Cs Cs Gs 75 G03 200 Ts Gs Gs Ts As Gs As Cs Gs Ts Gs 76 G04 200 Ts Ts Cs Ts Ts Cs Cs Gs As Cs Cs 77 G05 200 Ts Gs Gs Ts As Gs As Cs Gs Cs Ts 78 G06 200 Ts As Gs As Cs Gs Cs Ts Cs Gs Gs 79 G07 200 Ts Ts Ts Ts As Cs As Gs Ts Gs Gs 80 G08 200 Ts Gs Gs Gs As As Cs Cs Ts Gs Ts 81 G09 200 Ts Cs Gs Gs Gs As Cs Cs As Cs Cs 82 G10 200 Ts As Gs Gs As Cs As As As Cs Gs 83 G11 200 Ts Gs Cs Ts As Gs As As Gs Gs As 84 G12 200 Ts Cs Ts Gs Ts Cs As Cs Ts Cs Cs

[0258] Table 4 is a .seq file for oligonucleotides having regions of 2′-O-(2-methoxyethyl)nucleosides and a central region of 2′-deoxy nucleosides each linked by phosphorothioate internucleotide linkages. TABLE 4 Identity of columns: Syn #, Well, Scale, Nucleotide at particular position (identified using base identifier followed by backbone identifier where “s” is phosphorothioate and “moe” indicated a 2′-O-(2-methoxyethyl) substituted nucleoside). The columns wrap around to next line when longer than one line.  1 A01 200 moeAs moeCs moeCs moeAs Gs Gs As Cs Gs Gs Cs Gs Gs As moeCs moeCs moeAs moeG  2 A02 200 moeAs moeCs moeCs moeGs Cs Gs Gs As Cs Cs As Gs As Gs moeTs moeGs moeGs moeA  3 A03 200 moeAs moeCs moeCs moeAs As Gs Cs As Gs As Cs Gs Gs As moeGs moeAs moeCs moeG  4 A04 200 moeAs moeGs moeGs moeAs Gs As Cs Cs Cs Cs Gs As Cs Gs moeAs moeAs moeCs moeG  5 A05 200 moeAs moeCs moeCs moeCs Cs Gs As Cs Gs As As Cs Gs As moeCs moeTs moeGs moeG  6 A06 200 moeAs moeCs moeGs moeAs As Cs Gs As Cs Ts Gs Gs Cs Gs moeAs moeCs moeAs moeG  7 A07 200 moeAs moeCs moeGs moeAs Cs Ts Gs Gs Cs Gs As Cs As Gs moeGs moeTs moeAs moeG  8 A08 200 moeAs moeCs moeAs moeGs Gs Ts As Gs Gs Ts Cs Ts Ts Gs moeGs moeTs moeGs moeG  9 A09 200 moeAs moeGs moeGs moels Cs Ts Ts Gs Gs Ts Gs Gs Gs Ts moeGs moeAs moeCs moeG 10 A10 200 moeAs moeGs moeTs moeCs As Cs Gs As Cs As As Gs As As moeAs moeCs moeAs moeC 11 A11 200 moeAs moeCs moeGs moeAs Cs As As Gs As As As Cs As Cs moeGs moeGs moeTs moeC 12 A12 200 moeAs moeGs moeAs moeAs As Cs As Cs Gs Gs Ts Cs Gs Gs moeTs moeCs moeCs moeT 13 B01 200 moeAs moeAs moeCs moeAs Cs Gs Gs Ts Cs Gs Gs Ts Cs Cs moeTs moeGs moeTs moeC 14 B02 200 moeAs moeCs moeTs moeCs As Cs Ts Gs As Cs Gs Ts Gs Ts moeCs moeTs moeCs moeA 15 B03 200 mocAs moeCs moeGs moeGs As As Gs Gs As As Cs Gs Cs Cs moeAs moeCs moeTs moeT 16 B04 200 moeAs moeTs moeCs moeTs Gs Ts Gs Gs As Cs Cs Ts Ts Gs moeTs moeCs moeTs moeC 17 B05 200 moeAs moeCs moeAs moeCs Ts Ts Cs Ts Ts Cs Cs Gs As Cs moeCs moeGs moeTs moeG 18 B06 200 moeAs moeCs moeTs moeCs Ts Cs Gs As Cs As Cs As Gs Gs moeAs moeCs moeGs moeT 19 B07 200 moeAs moeAs moeAs moeCs Cs Cs Cs As Gs Ts Ts Cs Gs Ts moeCs moeTs moeAs moeA 20 B08 200 moeAs moeTs moeGs moeTs Cs Cs Cs Cs As As As Gs As Cs moeTs moeAs moeTs moeG 21 B09 200 moeAs moeCs moeGs moeCs Ts Cs Gs Gs Gs As Cs Gs Gs Gs moeTs moeCs moeAs moeG 22 B10 200 moeAs moeGs moeCs moeCs Gs As As Gs As As Gs As Gs Gs moeTs moeTs moeAs moeC 23 B11 200 moeAs moeCs moeAs moeCs As Gs Ts As Gs As Cs Gs As As moeAs moeGs moeCs moeT 24 B12 200 moeAs moeCs moeAs moeCs Ts Cs Ts Gs Gs Ts Ts Ts Cs Ts moeGs moeGs moeAs moeC 25 C01 200 moeAs moeCs moeGs moeAs Cs Cs As Hs As As As Ts As Gs moeTs moeTs moeTs moeT 26 C02 200 moeAs moeGs moeTs moeTs As As As As Gs Gs Gs Cs Ts Gs moeCs moeTs moeAs moeG 27 C03 200 moeAs moeGs moeGs moeTs Ts Gs Ts Gs As Cs Gs As Cs Gs moeAs moeGs moeGs moeT 28 C04 200 moeAs moeAs moeTs moeGs Ts As Cs Cs Ts As Cs Gs Gs Ts moeTs moeGs moeGs moeC 29 CO5 200 moeAs moeGs moeTs moeCs As Cs Gs Ts Cs Cs Ts Cs Ts Cs moeTs moeGs moeTs moeC 30 C06 200 moeCs moeTs moeGs moeGs Cs Gs As Cs As Gs Gs Ts As Gs moeGs moeTs moeCs moeT 31 C07 200 moeCs moeTs moeGs moeTs Gs Ts Gs Ts Gs As Cs Gs Gs Ts moeGs moeGs moeTs moeC 32 C08 200 moeCs moeAs moeGs moeGs Ts Cs Gs Ts Cs Ts Ts Cs Cs Cs moeGs moeTs moeGs moeG 33 C09 200 moeCs moeTs moeGs moeTs Gs Gs Ts As Gs As Cs Gs Ts Gs moeGs moeAs moeCs moeA 34 C10 200 moeCs moeTs moeAs moeAs Cs Gs As Ts Gs Ts Cs Cs Cs Cs moeAs rnoeAs moeAs moeG 35 C11 200 moeCs moeTs moeGs moeTs Ts Cs Gs As Cs As Cs Ts Cs Ts moeGs moeGs moeTs moeT 36 C12 200 moeCs moeTs moeGs moeGs As Cs Cs As As Cs As Cs Gs Ts moeTs macGs moeTs moeC 37 D01 200 moeCs moeCs moeGs moeTs Cs Cs Gs Ts Gs Ts Ts Ts Gs Ts moeTs moeCs moeTs moeG 38 D02 200 moeCs moeTs moeGs mocAs Cs Ts As Cs As As Cs As Gs As moeCs moeAs moeCs moeC 39 D03 200 moeCs moeAs moeAs moeCs As Gs As Cs As Cs Cs As Gs Gs moeGs moeGs moels moeC 40 D04 200 moeCs moeAs moeGs moeGs Gs Gs Ts Cs Cs Ts As Gs Cs Cs moeGs moeAs moeCs moeT 41 D05 200 moeCs moeTs moeCs moeTs As Gs Ts Ts As As As As Gs Gs moeGs moeCs moeTs moeG 42 D06 200 moeCs moeTs moeGs moeCs Ts As Gs As As Gs Gs As Cs Cs moeGs moeAs moeGs moeG 43 D07 200 moeCs moeTs moeGs moeAs As As Ts Gs Ts As Cs Cs Ts As moeCs moeGs moeGs moeT 44 D08 200 moeCs moeAs moeCs moeCs Cs Gs Ts Ts Ts Cs Ts Cs Cs Gs moeTs moeCs moeAs moeA 45 D09 200 moeCs moeTs moeCs moeGs As Ts As Cs Gs Gs Gs Ts Cs As moeGs moeTs moeCs moeA 46 D10 200 moeGs moeGs moeTs moeAs Gs Gs Ts Cs Ts Ts Gs Gs Ts Gs moeGs moeGs moeTs moeG 47 D11 200 moeGs moeAs moeCs moeTs Ts Ts Gs Cs Cs Ts Ts As Cs Gs moeGs moeAs moeAs moeG 48 D12 200 moeGs moeTs moeGs moeGs As Gs Ts Cs Ts Ts Ts Gs Ts Cs moeTs moeGs moeTs moeG 49 E01 200 moeGs moeGs moeAs moeGs Ts Cs Ts Ts Ts Gs Ts Cs Ts Gs moeTs moeGs moeGs moeT 50 E02 200 moeGs moeGs moeAs moeCs As Cs Ts Cs Ts Cs Gs As Cs As moeCs moeAs moeGs moeG 51 E03 200 moeGs moeAs moeCs moeAs Cs As Gs Gs As Cs Gs Ts Gs Gs moeCs moeGs moeAs moeG 52 E04 200 moeGs moeAs moeGs moeTs As Cs Gs As Gs Cs Gs Gs Gs Cs moeCs moeGs moeAs moeA 53 E05 200 moeGs moeAs moeCs moeTs As Ts Gs Gs Ts As Gs As Cs Gs moeCs moeTs moeCs moeG 54 E06 200 moeGs moeAs moeAs moeGs As Gs Gs Ts Ts As Cs As Cs As moeGs moeTs moeAs moeG 55 E07 200 moeGs moeAs moeGs moeGs Ts Ts As Cs As Cs As Gs Ts As moeGs moeAs moeCs moeG 56 E08 200 moeGs moeTs moeTs moeGs Ts Cs Cs Gs Ts Cs Cs Gs Ts Gs moeTs moels moeTs moeG 57 E09 200 moeGs moeAs moeCs moeTs Cs Ts Cs Gs Gs Gs As Cs Cs As moeCs moeCs moeAs moeC 58 E10 200 moeGs moeTs moeAs moeGs Gs As Gs As As Cs Cs As Cs Gs moeAs moeCs moeCs moeA 59 E11 200 moeGs moeGs moeTs moels Cs Ts Ts Cs Gs Gs Ts Ts Gs Gs moeTs moeTs moeAs moeT 60 E12 200 moeGs moeTs moeGs moeGs Gs Gs Ts Ts Cs Gs Ts Cs Cs Ts moeTs moeGs moeGs moeG 61 F01 200 moeGs moeTs moeCs moeAs Cs Gs Ts Cs Cs Ts Cs Ts Gs As moeAs moeAs moeTs moeG 62 F02 200 moeGs moeTs moeCs moeCs Ts Cs Cs Ts As Cs Cs Gs Ts Ts moeTs moeCs moeTs moeC 63 F03 200 moeGs moeTs moeCs moeCs Cs Cs As Cs Gs Ts Cs Cs Gs Ts moeCs moeTs moeTs moeC 64 F04 200 moeTs moeCs moeAs moeCs Cs As Gs Gs As Cs Gs Gs Cs Gs moeGs moeAs moeCs moeC 65 F05 200 moeTs mocAs moeCs moeCs As As Gs Cs As Gs As Cs Gs Gs moeAs moeGs moeAs moeC 66 F06 200 moeTs moeCs moeCs moeTs Gs Ts Cs Ts Ts Ts Gs As Cs Cs moeAs moeCs moeTs moeC 67 F07 200 moeTs moeGs moeTs moeCs Ts Ts Ts Gs As Cs Cs As Gs Ts moeCs moeAs moeCs moeT 68 F08 200 moeTs moeGs moeAs moeCs Cs As Cs Ts Cs As Cs Ts Gs As moeCs moeGs moeTs moeG 69 F09 200 moeTs moeGs moeAs moeCs Gs Ts Gs Ts Cs Ts Cs As As Gs moeTs moeGs moeAs moeC 70 F10 200 moeTs moeCs moeAs moeAs Gs Ts Gs As Cs Ts Ts Ts Gs Cs moeCs moeTs moeTs moeA 71 F11 200 moeTs moeGs moeTs moeTs Ts As Ts Cs As Cs Gs Cs Ts Gs moeGs moeGs moeGs moeT 72 F12 200 moeTs moeTs moeAs moeTs Gs As Cs Gs Cs Ts Gs Gs Gs Gs moeTs moeTs moeGs moeG 73 G01 200 moeTs moeGs moeAs moeCs Gs Cs Ts Gs Gs Gs Gs Ts Ts Gs moeGs moeAs moeTs moeC 74 G02 200 moeTs moeCs moeGs moeTs Cs Ts Ts Cs Cs Cs Gs Ts Gs Gs moeAs moeGs moeTs moeC 75 G03 200 moeTs moeGs moeGs moeTs As Gs As Cs Gs Ts Gs Gs As Cs moeAs moeCs moeTs moeT 76 G04 200 moeTs moeTs moeCs moeTs Ts Cs Cs Gs As Cs Cs Gs Ts Gs moeAs moeCs moeAs moeT 77 G05 200 moeTs moeCs moeCs moeTs As Gs As Cs Gs Cs Ts Cs Gs Gs moeGs moeAs moeCs moeG 78 G06 200 moeTs moeAs moeGs moeAs Cs Gs Cs Ts Cs Gs Gs Gs As Cs moeGs moeGs moeGs moeT 79 G07 200 moeTs moeTs moeTs moeTs As Cs As Gs Ts Gs Gs Gs As As moeCs moeCs moeTs moeG 80 G08 200 moeTs moeGs moeGs moeGs As As Cs Cs Ts Gs Ts Ts Cs Gs moeAs moeCs moeAs moeC 81 G09 200 moeTs moeCs moeGs moeGs Gs As Cs Cs As Cs Cs As Cs Ts moeAs moeGs moeGs moeG 82 G10 200 moeTs moeAs moeGs moeGs As Cs As As As Cs Gs Gs Ts As moeGs moeGs moeAs moeG 83 G11 200 moeTs moeGs moeCs moeTs As Gs As As Gs Gs As Cs Cs Gs moeAs moeGs moeGs moeT 84 G12 200 moeTs moeCs moeTs moeGs Ts Cs As Cs Ts Cs Cs Gs As Cs moeGs moeTs moeGs moeG

[0259] Reagent File (.tab File)

[0260] Table 5 is a .tab file for reagents necessary for synthesizing an oligonucleotides having both 2′-O-(2-methoxyethyl)nucleosides and 2′-deoxy nucleosides located therein. TABLE 5 Identity of columns: GroupName, Bottle ID, ReagentName, FlowRate, Concentration. Wherein reagent name is identified using base identifier, “moe” indicated a 2′-O-(2-methoxyethyl) substituted nucleoside and “cpg” indicates a control pore glass solid support medium. The columns wrap around to next line when longer than one line. SUPPORT BEGIN 0 moeG moeG cpg 100 1 0 moe5meC moe5meC cpg 100 1 0 moeA moeA cpg 100 1 0 moeT moeT cpg 100 1 END DEBLOCK BEGIN 70 TCA TCA 100 1 END WASH BEGIN 65 ACN ACN 190 1 END OXIDIZERS BEGIN 68 BEAU BEAUCAGE 320 1 END CAPPING BEGIN 66 CAP_BCAP_B 220 1 67 CAP_A CAP_A 230 1 END DEOXY THIOATE BEGIN 31,32 Gs deoxyG 270 1 39,40 5meCs 5methyldeoxyC 270 1 37,38 As deoxyA 270 1 29,30 Ts deoxyT 270 1 END MOE-THIOATE BEGIN 15,16 moeGs methoxyethoxyG 240 1 23,24 moe5meCs methoxyethoxyC 240 1 21,22 moeAs methoxyethoxyA 240 1 13,14 moeTs methoxyethoxyT 240 1 END ACTIVATORS BEGIN 5,6,7,8 SET   s-ethyl-tet  280 Activates DEOXY_THIOATE MOE_THIOATE END

Example 4

[0261] Synthesis of Nucleoside Phosphoramidites

[0262] The following compounds, including amidites and their intermediates were prepared as described in U.S. Pat. No. 6,426,220 and published PCT WO 02/36743; 5′-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite, 5′-O-Dimethoxytrityl-2′-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite, 5′-O-Dimethoxytrityl-2′-deoxy-N4-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-deoxy-N⁴-benzoyl-5-methylcytidin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite), 2′-Fluorodeoxyadenosine, 2′-Fluorodeoxyguanosine, 2′-Fluorouridine, 2′-Fluorodeoxycytidine, 2′-O-(2-Methoxyethyl) modified amidites, 2′-O-(2-methoxyethyl)-5-methyluridine intermediate, 5′-O-DMT-2′-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-5-methyluridin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite), 5′-O-Dimethoxytrityl-2′-O-(2-methoxyethyl)-5-methylcytidine intermediate, 5′-O-dimethoxytrityl-2′-O-(2-methoxyethyl)-N⁴-benzoyl-5-methyl-cytidine penultimate intermediate, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N4-benzoyl-5-methylcytidin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite), [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N⁶-benzoyladenosin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amdite), [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N⁴-isobutyrylguanosin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite), 2′-O-(Aminooxyethyl) nucleoside amidites and 2′-O-(dimethylaminooxyethyl) nucleoside amidites, 2′-(Dimethylaminooxyethoxy) nucleoside amidites, 5′-O-tert-Butyldiphenylsilyl-O²-2′-anhydro-5-methyluridine, 5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine, 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine, 5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine, 5′-O-tert-Butyldiphenylsilyl-2′-O-[N,N dimethylaminooxyethyl]-5-methyluridine, 2′-O-(dimethylaminooxyethyl)-5-methyluridine, 5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine, 5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2′-(Aminooxyethoxy) nucleoside amidites, N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2′-dimethylaminoethoxyethoxy (2′-DMAEOE) nucleoside amidites, 2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine, 5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine and 5′-O-Dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine-3′-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite.

Example 5

[0263] Oligonucleotide and Oligonucleoside Synthesis

[0264] The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0265] Oligonucleotides: Unsubstituted and substituted phosphodiester (P═O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

[0266] Phosphorothioates (P═S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3,H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55° C. (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH4OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Pat. No. 5,508,270, herein incorporated by reference.

[0267] Alkyl phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 4,469,863, herein incorporated by reference.

[0268] 3+-Deoxy-3′-methylene phosphonate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,610,289 or 5,625,050, herein incorporated by reference.

[0269] Phosphoramidite oligonucleotides are prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878, herein incorporated by reference.

[0270] Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

[0271] 3′-Deoxy-3′-amino phosphoramidate oligonucleotides are prepared as described in U.S. Pat. No. 5,476,925, herein incorporated by reference.

[0272] Phosphotriester oligonucleotides are prepared as described in U.S. Pat. No. 5,023,243, herein incorporated by reference.

[0273] Borano phosphate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198, both herein incorporated by reference.

[0274] Oligonucleosides: Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedi-methyl-hydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligo-nucleosides, also identified as amide-4 linked oligo-nucleo-sides, as well as mixed backbone compounds having, for instance, alternating MMI and P═O or P═S linkages are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

[0275] Formacetal and thioformacetal linked oligo-nucleo-sides are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, herein incorporated by reference.

[0276] Ethylene oxide linked oligonucleosides are prepared as described in U.S. Pat. No. 5,223,618, herein incorporated by reference.

Example 6

[0277] Oligonucleotide Isolation

[0278] After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55° C. for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH4OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of correct molecular weight relative to the −16 amu product (±32±48). For some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

[0279] Chimeric Oligonucleotide Synthesis

[0280] Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the “gap” segment of linked nucleosides is positioned between 5′ and 3′ “wing” segments of linked nucleosides and a second “open end” type wherein the “gap” segment is located at either the 3′ or the 5′ terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as “gapmers” or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as “hemimers” or “wingmers.”

[0281] A. [2′-O-Me]—[2′-deoxy]—[2′-O-Me] Chimeric Phosphorothioate Oligonucleotides

[0282] Chimeric oligonucleotides having 2′-O-alkyl phosphorothioate and 2′-deoxy phosphorothioate oligonucleotide segments are synthesized using 2′-deoxy-5′-dimethoxytrityl-3′-O-phosphoramidites for the DNA portion and 5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidites for 5′ and 3′ wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for DNA and twice for 2′-O-methyl. The fully protected oligonucleotide was cleaved from the support and the phosphate group is deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is done to deprotect all bases and the samples are again lyophilized to dryness.

[0283] B. [2′-O-(2-Methoxyethyl)]—[2′-deoxy]—[2′-O-(2-Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[0284] 2′-O-(2-methoxyethyl)]—[2′-deoxy]—[-2′-O-(2-methoxyethyl)] chimeric phosphorothioate oligonucleotides are prepared as per the procedure above for the 2′-O-methyl chimeric oligonucleotide, with the substitution of 2′-O-(2-methoxyethyl) amidites for the 2′-O-methyl amidites.

[0285] C. [2′-O-(2-Methoxyethyl)Phosphodiester]—[2′-deoxy Phosphoro-thioate]—[2′-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligo-Nucleotide

[0286] 2′-O-(2-methoxyethyl phosphodiester]—[2′-deoxy phosphorothioate]—[2′-O-(2-methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2′-O-methyl chimeric oligonucleotide with the substitution of 2′-O-(2-methoxyethyl) amidites for the 2′-O-methyl amidites in the wing portions. Sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) is used to generate the phosphorothioate internucleotide linkages within the wing portions of the chimeric structures. Oxidization with iodine is used to generate the phosphodiester inter-nucleotide linkages for the center gap.

[0287] Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065, which is incorporated herein by reference in its entirety.

Example 8

[0288] Oligonucleotide Analysis

[0289] Oligonucleotides are analyzed by mass spectrometry as follows: for a typical oligonucleotide, a 0.01 OD aliquot dissolved in 10 uL of water is mixed with 90 uL of a 1:1 mixture of acetonitrile and water containing 20 mM imidazole and 20 mM piperidine (Greig M. J., Griffey R. H.: Rapid Commun. Mass Spec., 9:97-102, 1995). The sample is transferred to a 96 or 384-well plate, and each well on the plate is sampled systematically using an Agilent 1100 liquid handler. Other types of robotic liquid handlers such as a Leap Pal or Gilson 215 could be used to introduce sample to the mass spectrometer under computer control. The sample is infused to an Agilent MSD VX quadrupole mass spectrometer at a rate of 3 uL/min. The electrospray ionization is produced with 60 psi of nitrogen gas and a 4 kV potential between the source needle and the inlet capillary. The capillary is heated to 250° C. to effect desolvation of the ions. Typically, a total of 32 accumulations are averaged over a mass/charge range of 500-1500 m/z. The resulting data is saved into a file containing the sample ID information, and deconvoluted using the Agilent algorithm to calculate the neutral masses and abundances of the oligonucleotides and associated impurities. In a preferred embodiment, the neutral masses and abundances of compounds present in the sample obtained from the ESI-MS spectrum are written to a relational database. A logical algorithm then compares the measured mass of the oligonucleotide to the mass calculated from the base sequence and expected chemical structure of the oligonucleotide stored in a relational database. If the calculated and observed masses for the most abundant species agree within ±1.5 Da, the oligonucleotide is deemed to have “passed”. If the measured mass of the most abundant species differs by more than 1.5 Da, or the integrated ion abundance is <50% of the sample, the oligonucleotide “fails” and a new synthesis is requested.

[0290] Oligonucleotides that pass the ESI-MS analysis are transferred to 96-well master plates for storage at 10 mM concentrations in aqueous solution using multichannel robotics, such as a Beckman FX or Packard MultiProbe. The plates are given sequential identifying bar codes and this information on sample location is stored for later retrieval in a relational database.

Example 9

[0291] PNA Synthesis

[0292] Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5. They may also be prepared in accordance with U.S. Pat. Nos. 5,539,082; 5,700,922, and 5,719,262, each of which is incorporated herein by reference in its entirety.

Example 10

[0293] RNA Synthesis

[0294] In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5′-hydroxyl in combination with an acid-labile orthoester protecting group on the 2′-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2′-hydroxyl.

[0295] Following this procedure for the sequential protection of the 5′-hydroxyl in combination with protection of the 2′-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

[0296] RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3′- to 5′-direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3′-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5′-end of the first nucleoside. The support is washed and any unreacted 5′-hydroxyl groups are capped with acetic anhydride to yield 5′-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5′-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.

[0297] Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate (S₂Na₂) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55° C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2′-groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

[0298] The 2′-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, Colo.), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the final RNA oligonucleotide product.

[0299] Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of Colorado, 1996; Scaringe, S. A., et al., J. Am. Chem. Soc., 1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H. J. Am. Chem. Soc., 1981, 103, 3185-3191; Beaucage, S. L. and Caruthers, M. H. Tetrahedron Lett., 1981, 22, 1859-1862; Dahl, B. J., et al., Acta Chem. Scand,. 1990, 44, 639-641; Reddy, M. P., et al., Tetrahedrom Lett., 1994, 25, 4311-4314; Wincott, F. et al., Nucleic Acids Res., 1995, 23, 2677-2684; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2301-2313; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2315-2331).

[0300] RNA antisense compounds (RNA oligonucleotides) of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, Colo.). Once synthesized, complementary RNA antisense compounds can then be annealed by methods known in the art to form double stranded (duplexed) antisense compounds. For example, duplexes can be formed by combining 30 μl of each of the complementary strands of RNA oligonucleotides (50 uM RNA oligonucleotide solution) and 15 μl of 5X annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 minute at 90° C., then 1 hour at 37° C. The resulting duplexed antisense compounds can be used in kits, assays, screens, or other methods to investigate the role of a target nucleic acid.

Example 11

[0301] Output Oligonucleotides from Automated Oligonucleotide Synthesis

[0302] Using the .seq files, the .cmd files and .tab file of Example 3, oligonucleotides were prepared as per the protocol of the 96 well format of Example 5. The oligonucleotides were prepared utilizing phosphorothioate chemistry to give in one instance a first library of phosphorothioate oligodeoxynucleotides. The oligonucleotides were prepared in a second instance as a second library of hybrid oligonucleotides having phosphorothioate backbones with a first and third “wing” region of 2′-O-(2-methoxyethyl)nucleotides on either side of a center gap region of 2′-deoxy nucleotides. The two libraries contained the same set of oligonucleotide sequences. Thus the two libraries are redundant with respect to sequence but are unique with respect to the combination of sequence and chemistry. Because the sequences of the second library of compounds is the same as the first (however the chemistry is different), for brevity sake, the second library is not shown.

[0303] For illustrative purposes Tables 6-a and 6-b show the sequences of an initial first library, i.e., a library of phosphorothioate oligonucleotides targeted to a CD40 target. The compounds of Table 6-a shows the members of this library listed in compliance with the established rule for listing SEQ ID NO:, i.e., in numerical SEQ ID NO: order. TABLE 6-a Sequences of Oligonucleotides Targeted to CD40 by SEQ ID NO.: NUCLEOBASE SEQUENCE SEQ ID NO. CCAGGCGGCAGGACCACT 1 GACCAGGCGGCAGGACCA 2 AGGTGAGACCAGGCGGCA 3 CAGAGGCAGACGAACCAT 4 GCAGAGGCAGACGAACCA 5 GCAAGCAGCCCCAGAGGA 6 GGTCAGCAAGCAGCCCCA 7 GACAGCGGTCAGCAAGCA 8 GATGGACAGCGGTCAGCA 9 TCTGGATGGACAGCGGTC 10 GGTGGTTCTGGATGGACA 11 GTGGGTGGTTCTGGATGG 12 GCAGTGGGTGGTTCTGGA 13 CACAAAGAACAGCACTGA 14 CTGGCACAAAGAACAGCA 15 TCCTGGCTGGCACAAAGA 16 CTGTCCTGGCTGGCACAA 17 CTCACCAGTTTCTGTCCT 18 TCACTCACCAGTTTCTGT 19 GTGCAGTCACTCACCAGT 20 ACTCTGTGCAGTCACTCA 21 CAGTGAACTCTGTGCAGT 22 ATTCCGTTTCAGTGAACT 23 GAAGGCATTCCGTTTCAG 24 TTCACCGCAAGGAAGGCA 25 CTCTGTTCCAGGTGTCTA 26 CTGGTGGCAGTGTGTCTC 27 TGGGGTCGCAGTATTTGT 28 GGTTGGGGTCGCAGTATT 29 CTAGGTTGGGGTCGCAGT 30 GGTGCCCTTCTGCTGGAC 31 CTGAGGTGCCCTTCTGCT 32 GTGTCTGTTTCTGAGGTG 33 TGGTGTCTGTTTCTGAGG 34 ACAGGTGCAGATGGTGTC 35 TTCACAGGTGCAGATGGT 36 GTGCCAGCCTTCTTCACA 37 TACAGTGCCAGCCTTCTT 38 GGACACAGCTCTCACAGG 39 TGCAGGACACAGCTCTCA 40 GAGCGGTGCAGGACACAG 41 AAGCCGGGCGAGCATGAG 42 AATCTGCTTGACCCCAAA 43 GAAACCCCTGTAGCAATC 44 GTATCAGAAACCCCTGTA 45 GCTCGCAGATGGTATCAG 46 GCAGGGCTCGCAGATGGT 47 TGGGCAGGGCTCGCAGAT 48 GACTGGGCAGGGCTCGCA 49 CATTGGAGAAGAAGCCGA 50 GATGACACATTGGAGAAG 51 GCAGATGACACATTGGAG 52 TCGAAAGCAGATGACACA 53 GTCCAAGGGTGACATTTT 54 CACAGCTTGTCCAAGGGT 55 TTGGTCTCACAGCTTGTC 56 CAGGTCTTTGGTCTCACA 57 CTGTTGCACAACCAGGTC 58 GTTTGTGCCTGCCTGTTG 59 GTCTTGTTTGTGCCTGCC 60 CCACAGACAACATCAGTC 61 CTGGGGACCACAGACAAC 62 TCAGCCGATCCTGGGGAC 63 CACCACCAGGGCTCTCAG 64 GGGATCACCACCAGGGCT 65 GAGGATGGCAAACAGGAT 66 ACCAGCACCAAGAGGATG 67 TTTTGATAAAGACCAGCA 68 TATTGGTTGGCTTCTTGG 69 GGGTTCCTGCTTGGGGTG 70 GTCGGGAAAATTGATCTC 71 GATCGTCGGGAAAATTGA 72 GGAGCCAGGAAGATCGTC 73 TGGAGCCAGGAAGATCGT 74 TGGAGCAGCAGTGTTGGA 75 GTAAAGTCTCCTGCACTG 76 TGGCATCCATGTAAAGTC 77 CGGTTGGCATCCATGTAA 78 CTCTTTGCCATCCTCCTG 79 CTGTCTCTCCTGCACTGA 80 GGTGCAGCCTCACTGTCT 81 AACTGCCTGTTTGCCCAC 82 CTTCTGCCTGCACCCCTG 83 ACTGACTGGGCATAGCTC 84

[0304] The sequences shown in Table 6-a, above, and Table 6-b, below, are in a 5′ to 3′ direction. This is reversed with respect to 3′ to 5′ direction shown in the .seq files of Example 3. For synthesis purposes, the .seq files are generated reading from 3′ to 5′. This allows for aligning all of the 3′ most “A” nucleosides together, all of the 3′ most “G” nucleosides together, all of the 3′ most “C” nucleosides together and all of the 3′ most “T” nucleosides together. Thus when the first nucleoside of each particular oligonucleotide (attached to the solid support) is added to the wells on the plates, machine movement is reduced since an automatic pipette can move in a linear manner down one row and up another on the 96 well plate.

[0305] The location of the well holding each particular oligonucleotides is indicated by row and column. There are eight rows designated A to G and twelve columns designated 1 to 12 in a typical 96 well format plate. Any particular well location is indicated by its “Well No.” which is indicated by the combination of the row and the column, e.g. A08 is the well at row A, column 8.

[0306] In Table 6-b below, the oligonucleotides of Table 6-a are shown reordered according to the Well No. on their synthesis plate. The order shown in Table 6-b is the actually order as synthesized on an automated synthesizer taking advantage of the preferred placement of the first nucleoside according to the above alignment criteria. TABLE 6-b Sequences of Oligonucleotides Targeted to CD40 Order by Synthesis Well No. Well No. SEQ ID NO: A01 GACCAGGCGGCAGGACCA 2 A02 AGGTGAGACCAGGCGGCA 3 A03 GCAGAGGCAGACGAACCA 5 A04 GCAAGCAGCCCCAGAGGA 6 A05 GGTCAGCAAGCAGCCCCA 7 A06 GACAGCGGTCAGCAAGCA 8 A07 GATGGACAGCGGTCAGCA 9 A08 GGTGGTTCTGGATGGACA 11 A09 GCAGTGGGTGGTTCTGGA 13 A10 CACAAAGAACAGCACTGA 14 A11 CTGGCACAAAGAACAGCA 15 A12 TCCTGGCTGGCACAAAGA 16 B01 CTGTCCTGGCTGGCACAA 17 B02 ACTCTGTGCAGTCACTCA 21 B03 TTCACCGCAAGGAAGGCA 25 B04 CTCTGTTCCAGGTGTCTA 26 B05 GTGCCAGCCTTCTTCACA 37 B06 TGCAGGACACAGCTCTCA 40 B07 AATCTGCTTGACCCCAAA 43 B08 GTATCAGAAACCCCTGTA 45 B09 GACTGGGCAGGGCTCGCA 49 B10 CATTGGAGAAGAAGCCGA 50 B11 TCGAAAGCAGATGACACA 53 B12 CAGGTCTTTGGTCTCACA 57 C01 TTTTGATAAAGACCAGCA 68 C02 GATCGTCGGGAAAATTGA 72 C03 TGGAGCAGCAGTGTTGGA 75 C04 CGGTTGGCATCCATGTAA 78 C05 CTGTCTCTCCTGCACTGA 80 C06 TCTGGATGGACAGCGGTC 10 C07 CTGGTGGCAGTGTGTCTC 27 C08 GGTGCCCTTCTGCTGGAC 31 C09 ACAGGTGCAGATGGTGTC 35 C10 GAAACCCCTGTAGCAATC 44 C11 TTGGTCTCACAGCTTGTC 56 C12 CTGTTGCACAACCAGGTC 58 D01 GTCTTGTTTGTGCCTGCC 60 D02 CCACAGACAACATCAGTC 61 D03 CTGGGGACCACAGACAAC 62 D04 TCAGCCGATCCTGGGGAC 63 D05 GTCGGGAAAATTGATCTC 71 D06 GGAGCCAGGAAGATCGTC 73 D07 TGGCATCCATGTAAAGTC 77 D08 AACTGCCTGTTTGCCCAC 82 D09 ACTGACTGGGCATAGCTC 84 D10 GTGGGTGGTTCTGGATGG 12 D11 GAAGGCATTCCGTTTCAG 24 D12 GTGTCTGTTTCTGAGGTG 33 E01 TGGTGTCTGTTTCTGAGG 34 E02 GGACACAGCTCTCACAGG 39 E03 GAGCGGTGCAGGACACAG 41 E04 AAGCCGGGCGAGCATGAG 42 E05 GCTCGCAGATGGTATCAG 46 E06 GATGACACATTGGAGAAG 51 E07 GCAGATGACACATTGGAG 52 E08 GTTTGTGCCTGCCTGTTG 59 E09 CACCACCAGGGCTCTCAG 64 E10 ACCAGCACCAAGAGGATG 67 E11 TATTGGTTGGCTTCTTGG 69 E12 GGGTTCCTGCTTGGGGTG 70 F01 GTAAAGTCTCCTGCACTG 76 F02 CTCTTTGCCATCCTCCTG 79 F03 CTTCTGCCTGCACCCCTG 83 F04 CCAGGCGGCAGGACCACT 1 F05 CAGAGGCAGACGAACCAT 4 F06 CTCACCAGTTTCTGTCCT 18 F07 TCACTCACCAGTTTCTGT 19 F08 GTGCAGTCACTCACCAGT 20 F09 CAGTGAACTCTGTGCAGT 22 F10 ATTCCGTTTCAGTGAACT 23 F11 TGGGGTCGCAGTATTTGT 28 F12 GGTTGGGGTCGCAGTATT 29 G01 CTAGGTTGGGGTCGCAGT 30 G02 CTGAGGTGCCCTTCTGCT 32 G03 TTCACAGGTGCAGATGGT 36 G04 TACAGTGCCAGCCTTCTT 38 G05 GCAGGGCTCGCAGATGGT 47 G06 TGGGCAGGGCTCGCAGAT 48 G07 GTCCAAGGGTGACATTTT 54 G08 CACAGCTTGTCCAAGGGT 55 G09 GGGATCACCACCAGGGCT 65 G10 GAGGATGGCAAACAGGAT 66 G11 TGGAGCCAGGAAGATCGT 74 G12 GGTGCAGCCTCACTGTCT 81

Example 12

[0307] Automated Assay of CD40 Oligonucleotide Activity

[0308] A. Poly(A)+ mRNA Isolation.

[0309] Poly(A)+ mRNA was isolated according to Miura et al. (Clin. Chem., 1996, 42, 1758). Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μl cold PBS. 60 μi lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μl of lysate was transferred to Oligo d(T) coated 96 well plates (AGCT Inc., Irvine, Calif.). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 ml of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 ml of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70° C. was added to each well, the plate was incubated on a 90° C. plate for 5 minutes, and the eluate then transferred to a fresh 96-well plate. Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

[0310] B. Total RNA Isolation

[0311] Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia Calif.) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 mL cold PBS. 100 mL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 mL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 mL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 mL water.

[0312] C. RT-PCR Analysis of CD40 mRNA Levels

[0313] Quantitation of CD40 mRNA levels was accomplished by real-time quantitative PCR using the ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, Calif., Operon Technologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) is attached to the 5′ end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, Calif., Operon Technologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) is attached to the 3′ end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3′ quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5′-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

[0314] Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be “multiplexed” with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only (“single-plexing”), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

[0315] PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, Calif.). RT-PCR reactions were carried out by adding 20 μL PCR cocktail (2.5× PCR buffer minus MgCl₂; 6.6 mM MgCl₂, 375 μM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5× ROX dye) to 96-well plates containing 30 μL total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

[0316] Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, Oreg.). Methods of RNA quantification by RiboGreen™ are taught in Jones, L. J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

[0317] In this assay, 170 μL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485 nm and emission at 530 nm.

[0318] For human GAPDH the PCR primers were:

[0319] forward primer: GAAGGTGAAGGTCGGAGTC(SEQ ID NO: 89)

[0320] reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 90) and the PCR probe

[0321] was: 5′ JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3′ (SEQ ID NO: 91) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

Example 13

[0322] Inhibition of CD40 Expression by Phosphorothioate Oligodeoxynucleotides

[0323] In accordance with the present invention, a series of oligonucleotides complementary to mRNA were designed to target different regions of the human CD40 mRNA, using published sequences (GenBank accession number X60592, incorporated herein by reference as SEQ ID NO: 85). The oligonucleotides are shown in Table 7. Target sites are indicated by the beginning nucleotide numbers, as given in the sequence source reference (X60592), to which the oligonucleotide binds. All compounds in Table 7 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. Data are averages from three experiments. TABLE 7 Inhibition of CD40 mRNA Levels by Phosphorothioate Oligodeoxynucleotides TARGET % SEQ ID ISIS# SITE SEQUENCE INHIB. NO. 18623 18 CCAGGCGGCAGGACCAC 30.71 1 18624 20 GACCAGGCGGCAGGAC 28.09 2 18625 26 AGGTGAGACCAGGCGG 21.89 3 18626 48 CAGAGGCAGACGAACC 0.00 4 18627 49 GCAGAGGCAGACGAAC 0.00 5 18628 73 GCAAGCAGCCCCAGAG 0.00 6 18629 78 GGTCAGCAAGCAGCCCC 29.96 7 18630 84 GACAGCGGTCAGCAAGC 0.00 8 18631 88 GATGGACAGCGGTCAGC 0.00 9 18632 92 TCTGGATGGACAGCGGT 0.00 10 18633 98 GGTGGTTCTGGATGGAC 0.00 11 18634 101 GTGGGTGGTTCTGGATG 0.00 12 18635 104 GCAGTGGGTGGTTCTGG 0.00 13 18636 152 CACAAAGAACAGCACTG 0.00 14 18637 156 CTGGCACAAAGAACAGC 0.00 15 18638 162 TCCTGGCTGGCACAAAG 0.00 16 18639 165 CTGTCCTGGCTGGCACA 4.99 17 18640 176 CTCACCAGTTTCTGTCCT 0.00 18 18641 179 TCACTCACCAGTTTCTG 0.00 19 18642 185 GTGCAGTCACTCACCAG 0.00 20 18643 190 ACTCTGTGCAGTCACTC 0.00 21 18644 196 CAGTGAACTCTGTGCAG 5.30 22 18645 205 ATTCCGTTTCAGTGAAC 0.00 23 18646 211 GAAGGCATTCCGTTTCA 9.00 24 18647 222 TTCACCGCAAGGAAGGC 0.00 25 18648 250 CTCTGTTCCAGGTGTCT 0.00 26 18649 267 CTGGTGGCAGTGTGTCT 0.00 27 18650 286 TGGGGTCGCAGTATTTG 0.00 28 18651 289 GGTTGGGGTCGCAGTAT 0.00 29 18652 292 CTAGGTTGGGGTCGCAG 0.00 30 18653 318 GGTGCCCTTCTGCTGGA 19.67 31 18654 322 CTGAGGTGCCCTTCTGC 15.63 32 18655 332 GTGTCTGTTTCTGAGGT 0.00 33 18656 334 TGGTGTCTGTTTCTGAG 0.00 34 18657 345 ACAGGTGCAGATGGTGT 0.00 35 18658 348 TTCACAGGTGCAGATGG 0.00 36 18659 360 GTGCCAGCCTTCTTCAC 5.67 37 18660 364 TACAGTGCCAGCCTTCT 7.80 38 18661 391 GGACACAGCTCTCACAG 0.00 39 18662 395 TGCAGGACACAGCTCTC 0.00 40 18663 401 GAGCGGTGCAGGACAC 0.00 41 18664 416 AAGCCGGGCGAGCATG 0.00 42 18665 432 AATCTGCTTGACCCCAA 5.59 43 18666 446 GAAACCCCTGTAGCAAT 0.10 44 18667 452 GTATCAGAAACCCCTGT 0.00 45 18668 463 GCTCGCAGATGGTATCA 0.00 46 18669 468 GCAGGGCTCGCAGATGG 34.05 47 18670 471 TGGGCAGGGCTCGCAGA 0.00 48 18671 474 GACTGGGCAGGGCTCGC 2.71 49 18672 490 CATTGGAGAAGAAGCCG 0.00 50 18673 497 GATGACACATTGGAGAA 0.00 51 18674 500 GCAGATGACACATTGGA 0.00 52 18675 506 TCGAAAGCAGATGACAC 0.00 53 18676 524 GTCCAAGGGTGACATTT 8.01 54 18677 532 CACAGCTTGTCCAAGGG 0.00 55 18678 539 TTGGTCTCACAGCTTGT 0.00 56 18679 546 CAGGTCTTTGGTCTCAC 6.98 57 18680 558 CTGTTGCACAACCAGGT 18.76 58 18681 570 GTTTGTGCCTGCCTGTT 2.43 59 18682 575 GTCTTGTTTGTGCCTGCC 0.00 60 18683 590 CCACAGACAACATCAGT 0.00 61 18684 597 CTGGGGACCACAGACAA 0.00 62 18685 607 TCAGCCGATCCTGGGGA 0.00 63 18686 621 CACCACCAGGGCTCTCA 23.31 64 18687 626 GGGATCACCACCAGGGC 0.00 65 18688 657 GAGGATGGCAAACAGG 0.00 66 18689 668 ACCAGCACCAAGAGGAT 0.00 67 18690 679 TTTTGATAAAGACCAGC 0.00 68 18691 703 TATTGGTTGGCTTCTTG 0.00 69 18692 729 GGGTTCCTGCTTGGGGT 0.00 70 18693 750 GTCGGGAAAATTGATCT 0.00 71 18694 754 GATCGTCGGGAAAATTG 0.00 72 18695 765 GGAGCCAGGAAGATCGT 0.00 73 18696 766 TGGAGCCAGGAAGATCG 0.00 74 18697 780 TGGAGCAGCAGTGTTGG 0.00 75 18698 796 GTAAAGTCTCCTGCACT 0.00 76 18699 806 TGGCATCCATGTAAAGT 0.00 77 18700 810 CGGTTGGCATCCATGTA 0.00 78 18701 834 CTCTTTGCCATCCTCCTG 4.38 79 18702 861 CTGTCTCTCCTGCACTG 0.00 80 18703 873 GGTGCAGCCTCACTGTC 0.00 81 18704 910 AACTGCCTGTTTGCCCA 33.89 82 18705 954 CTTCTGCCTGCACCCCT 0.00 83 18706 976 ACTGACTGGGCATAGCT 0.00 84

[0324] As shown in Table 7, SEQ ID NOS: 1, 2, 7, 47 and 82 demonstrated at least 25% inhibition of CD40 expression and are therefore preferred compounds of the invention.

Example 14

[0325] Inhibition of CD40 Expression by Phosphorothioate 2′-MOE Gapmer Oligonucleotides

[0326] In accordance with the present invention, a second series of oligonucleotides complementary to mRNA were designed to target different regions of the human CD40 mRNA, using published sequence X60592. The oligonucleotides are shown in Table 8. Target sites are indicated by the beginning or initial nucleotide numbers, as given in the sequence source reference (X60592), to which the oligonucleotide binds.

[0327] All compounds in Table 8 are chimeric oligonucleotides (“gapmers”) 18 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by four-nucleotide “wings.” The wings are composed of 2′-O-(2-methoxyethyl) (2′-MOE) nucleotides. The intersugar (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2′-MOE wings are 5-methylcytidines. Data are averaged from three experiments. TABLE 8 Inhibition of CD40 mRNA Levels by Chimeric Phosphorothioate Oligonucleotides TARGET % ISIS# SITE SEQUENCE Inhibition SEQ ID 19211 18 CCAGGCGGCAGGACCA 75.71 1 19212 20 GACCAGGCGGCAGGAC 77.23 2 19213 26 AGGTGAGACCAGGCGG 80.82 3 19214 48 CAGAGGCAGACGAACC 23.68 4 19215 49 GCAGAGGCAGACGAAC 45.97 5 19216 73 GCAAGCAGCCCCAGAG 65.80 6 19217 78 GGTCAGCAAGCAGCCC 74.73 7 19218 84 GACAGCGGTCAGCAAG 67.21 8 19219 88 GATGGACAGCGGTCAG 65.14 9 19220 92 TCTGGATGGACAGCGGT 78.71 10 19221 98 GGTGGTTCTGGATGGAC 81.33 11 19222 101 GTGGGTGGTTCTGGATG 57.79 12 19223 104 GCAGTGGGTGGTTCTGG 73.70 13 19224 152 CACAAAGAACAGCACT 40.25 14 19225 156 CTGGCACAAAGAACAG 60.11 15 19226 162 TCCTGGCTGGCACAAAG 10.18 16 19227 165 CTGTCCTGGCTGGCACA 24.37 17 19228 176 CTCACCAGTTTCTGTCC 22.30 18 19229 179 TCACTCACCAGTTTCTG 40.64 19 19230 185 GTGCAGTCACTCACCAG 82.04 20 19231 190 ACTCTGTGCAGTCACTC 37.59 21 19232 196 CAGTGAACTCTGTGCAG 40.26 22 19233 205 ATTCCGTTTCAGTGAAC 56.03 23 19234 211 GAAGGCATTCCGTTTCA 32.21 24 19235 222 TTCACCGCAAGGAAGG 61.03 25 19236 250 CTCTGTTCCAGGTGTcT 62.19 26 19237 267 CTGGTGGCAGTGTGTCT 70.32 27 19238 286 TGGGGTCGCAGTATTTG 0.00 28 19239 289 GGTTGGGGTCGCAGTAT 19.40 29 19240 292 CTAGGTTGGGGTCGCAG 36.32 30 19241 318 GGTGCCCTTCTGCTGGA 78.91 31 19242 322 CTGAGGTGCCCTTCTGC 69.84 32 19243 332 GTGTCTGTTTCTGAGGT 63.32 33 19244 334 TGGTGTCTGTTTCTGAG 42.83 34 19245 345 ACAGGTGCAGATGGTGT 73.31 35 19246 348 TTCACAGGTGCAGATGG 47.72 36 19247 360 GTGCCAGCCTTCTTCAC 61.32 37 19248 364 TACAGTGCCAGCCTTCT 46.82 38 19249 391 GGACACAGCTCTCACAG 0.00 39 19250 395 TGCAGGACACAGCTCTC 52.05 40 19251 401 GAGCGGTGCAGGACAC 50.15 41 19252 416 AAGCCGGGCGAGCATG 32.36 42 19253 432 AATCTGCTTGACCCCAA 0.00 43 19254 446 GAAACCCCTGTAGCAAT 0.00 44 19255 452 GTATCAGAAACCCCTGT 36.13 45 19256 463 GCTCGCAGATGGTATCA 64.65 46 19257 468 GCAGGGCTCGCAGATG 74.95 47 19258 471 TGGGCAGGGCTCGCAG 0.00 48 19259 474 GACTGGGCAGGGCTCG 82.00 49 19260 490 CATTGGAGAAGAAGCC 41.31 50 19261 497 GATGACACATTGGAGA 13.81 51 19262 500 GCAGATGACACATTGG 78.48 52 19263 506 TCGAAAGCAGATGAcA 59.28 53 19264 524 GTCCAAGGGTGACATTT 70.99 54 19265 532 CACAGCTTGTCCAAGGG 0.00 55 19266 539 TTGGTCTCACAGCTTGT 45.92 56 19267 546 CAGGTCTTTGGTCTCAc 63.95 57 19268 558 CTGTTGCACAACCAGGT 82.32 58 19269 570 GTTTGTGCCTGCCTGTT 70.10 59 19270 575 GTCTTGTTTGTGCCTGC 68.95 60 19271 590 CCACAGACAACATCAGT 11.22 61 19272 597 CTGGGGACCACAGACA 9.04 62 19273 607 TCAGCCGATCCTGGGGA 0.00 63 19274 621 CACCACCAGGGCTCTCA 23.08 64 19275 626 GGGATCACCACCAGGG 57.94 65 19276 657 GAGGATGGCAAACAGG 49.14 66 19277 668 ACCAGCACCAAGAGGA 3.48 67 19278 679 TTTTGATAAAGACCAGC 30.58 68 19279 703 TATTGGTTGGCTTCTTG 49.26 69 19280 729 GGGTTCCTGCTTGGGGT 13.95 70 19281 750 GTCGGGAAAATTGATcT 54.78 71 19282 754 GATCGTCGGGAAAATTG 0.00 72 19283 765 GGAGCCAGGAAGATCG 69.47 73 19284 766 TGGAGCCAGGAAGATC 54.48 74 19285 780 TGGAGCAGCAGTGTTGG 15.17 75 19286 796 GTAAAGTCTCCTGCACT 30.62 76 19287 806 TGGCATCCATGTAAAGT 65.03 77 19288 810 CGGTTGGCATCCATGTA 34.49 78 19289 834 CTCTTTGCCATCCTCCT 41.84 79 19290 861 CTGTCTCTCCTGCACTG 25.68 80 19291 873 GGTGCAGCCTCACTGTC 76.27 81 19292 910 AACTGCCTGTTTGCCCA 63.34 82 19293 954 CTTCTGCCTGCACCCCT 0.00 83 19294 976 ACTGACTGGGCATAGCT 11.55 84

[0328] As shown in Table 8, SEQ ID NOS: 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 15, 20, 23, 25, 26, 27, 31, 32, 33, 35, 37, 40, 41, 46, 47, 49, 52, 53, 54, 57, 58, 59, 60, 65, 71, 73, 74, 77, 81 and 82 demonstrated at least 50% inhibition of CD40 expression and are therefore preferred compounds of the invention.

Example 15

[0329] Oligonucleotide-Sensitive Sites of the CD40 Target Nucleic Acid

[0330] As the data presented in the preceding two examples shows, several sequences were present in preferred compounds of two distinct oligonucleotide chemistries. Specifically, compounds having SEQ ID NOS: 1, 2, 7, 47 and 82 are preferred in both instances. These compounds map to different regions of the CD40 transcript but nevertheless define accessible sites of the target nucleic acid.

[0331] For example, SEQ ID NOS: 1 and 2 overlap each other and both map to the 5-untranslated region (5′-UTR) of CD40. Accordingly, this region of CD40 is particularly preferred for modulation via sequence-based technologies. Similarly, SEQ ID NOS: 7 and 47 map to the open reading frame of CD40, whereas SEQ ID NO: 82 maps to the 3′-untranslated region (3′-UTR). Thus, the ORF and 3′-UTR of CD40 may be targeted by sequence-based technologies as well.

[0332] The reverse complements of the active CD40 compounds are easily determined by those skilled in the art and may be assembled to yield nucleotide sequences corresponding to accessible sites on the target nucleic acid. For example, the assembled reverse complement of SEQ ID NOS: 1 and 2 is represented below as SEQ ID NO: 92:

[0333] 5′-AGTGGTCCTGCCGCCTGGTC-3′ SEQ ID NO: 92

[0334] TCACCAGGACGGCGGACC-5′ SEQ ID NO: 1

[0335] ACCAGGACGGCGGACCAG-5′ SEQ ID NO: 2

[0336] Through multiple iterations of the process of the invention, more extensive “footprints” are generated. A library of this information is compiled and may be used by those skilled in the art in a variety of sequence-based technologies to study the molecular and biological functions of CD40 and to investigate or confirm its role in various diseases and disorders.

Example 16

[0337] Site Selection Program

[0338] In a preferred embodiment of the invention, illustrated in FIG. 20, an application is deployed which facilitates the selection process for determining the target positions of the oligos to be synthesized, or “sites.” This program is written using a three-tiered object-oriented approach. All aspects of the software described, therefore, are tightly integrated with the relational database. For this reason, explicit database read and write steps are not shown. It should be assumed that each step described includes database access. The description below illustrates one way the program can be used. The actual interface allows users to skip from process to process at will, in any order.

[0339] Before running the site picking program, the target must have all relevant properties computed as described previously and indicated in process step 2204. When the site picking program is launched at process step 2206 the user is presented with a panel showing targets which have previously been selected and had their properties calculated. The user selects one target to work with at process step 2208 and proceeds to decide if any derived properties will be needed at process step 2210. Derived properties are calculated by performing mathematical operations on combinations of pre-calculated properties as defined by the user at process step 2212.

[0340] The derived properties are made available as peers with all the pre-calculated properties. The user selects one of the properties to view plotted versus target position at process step 2214. This graph is shown above a linear representation of the target. The horizontal or position axis of both the graph and target are linked and scalable by the user. The zoom range goes from showing the full target length to showing individual target bases as letters and individual property points. The user next selects a threshold value below or above which all sites will be eliminated from future consideration at process step 2216. The user decides whether to eliminate more sites based on any other properties at process step 2218. If they choose to eliminate more, they return to pick another property to display at process step 2214 and threshold at process step 2216.

[0341] After eliminating sites, the user selects from the remaining list by choosing any property at process step 2220 and then choosing a manual or automatic selection technique at process step 2222. In the automatic technique, the user decides whether they want to pick from maxima or minima and the number of maxima or minima to be selected as sites at process step 2224. The software automatically finds and picks the points. When picking manually the user must decide if they wish to use automatic peak finding at process step 2226. If the user selects automatic peak finding, then user must click on the graphed property with the mouse at process step 2236. The nearest maxima or minima, depending on the modifier key held down, to the selected point will be picked as the site. Without the peak finding option, the user must pick a site at process step 2238 by clicking on its position on the linear representation of target.

[0342] Each time a site, or group of sites, is picked, a dynamic property is calculated for all possible sites (not yet eliminated) at process step 2230. This property indicates the nearness of the site to a picked site allowing the user to pick sites in subsequent iterations based on target coverage. After new sites are picked, the user determines if the desired number of sites has been picked. If too few sites have been picked the user returns to pick more 2220. If too many sites have been picked, the user may eliminate them by selecting and deleting them on the target display at process step 2234. If the correct number of sites is picked, and the user is satisfied with the set of picked sites, the user registers these sites to the database along with their name, notebook number, and page number at process step 2238. The database time stamps this registration event.

Example 17

[0343] Site Selection Program

[0344] In a preferred embodiment of the invention, illustrated in FIG. 21, an application is deployed which facilitates the assignment of specific chemical structure to the complement of the sequence of the sites previously picked and facilitates the registration and ordering of these now fully defined antisense compounds. This program is written using a three-tiered object-oriented approach. All aspects of the software described, therefore, are tightly integrated with the relational database. For this reason, explicit database read and write steps are not shown, it being understood that each step described also includes appropriate database read/write access.

[0345] To begin using the oligonucleotide chemistry assignment program, the user launches it at process step 2302. The user then selects from the previously selected sets of oligonucleotides at process step 2304, registered to the database in site picker's process step 2238. Next, the user must decide whether to manually assign the chemistry a base at a time, or run the sites through a template at process step 2306. If the user chooses to use a template, they must determine if a desired template is available at process step 2308. If a template is not available with the desired chemistry modifications and the correct length, the user can define one at process step 2314.

[0346] To define a template, the user must select the length of the oligonucleotide the template is to define. This oligonucleotide is then represented as a bar with selectable regions. The user sets the number of regions on the oligonucleotide, and the positions and lengths of these regions by dragging them back and forth on the bar. Each region is represented by a different color.

[0347] For each region, the user defines the chemistry modifications for the sugars, the linkers, and the heterocycles at each base position in the region. At least four heterocycle chemistries must be given, one for each of the four possible base types (A, G, C or T or U) in the site sequence the template will be applied to. A user interface is provided to select these chemistries which show the molecular structure of each component selected and its modification name. By pushing on a pop-up list next to each of the pictures, the user may choose from a list of structures and names, those possible to put in this place. For example, the heterocycle that represents the base type G is shown as a two dimensional structure diagram. If the user clicks on the pop-up list, a row of other possible structures and names is shown. The user drags the mouse to the desired chemistry and releases the mouse. Now the newly selected molecule is displayed as the choice for G type heterocycle modifications.

[0348] Once the user has created a template, or selected an existing one, the software applies the template at process step 2312 to each of the complements of the sites in the list. When the templates are applied, it is possible that chemistries will be defined which are impossible to make with the chemical precursors-presently used on the automatic synthesizer. To check this, a database is maintained of all precursors previously designed, and their availability for automated synthesis. When the templates are applied, the resulting molecules are tested at process step 2316 against this database to see if they are readily synthesized.

[0349] If a molecule is not readily synthesized, it is added to a list that the user inspects. At process step 2318, the user decides whether to modify the chemistry to make it compatible with the currently recognized list of available chemistries or to ignore it. To modify a chemistry, the user must use the base at a time interface at process step 2322. The user can also choose to go directly to this step, bypassing templates all together at process step 2306.

[0350] The base at a time interface at process step 2322 is very similar to the template editor at process step 2314 except that instead of specifying chemistries for regions, they are defined one base at a time. This interface also differs in that it dynamically checks to see if the design is readily synthesized as the user makes selections. In other words, each choice made limits the choices the software makes available on the pop-up selection lists. To accommodate this function, an additional choice is made available on each pop-up of “not defined.” For example, this allows the user to inhibit linker choice from restricting the sugar choices by first setting the linker to “not defined.” The user would then pick the sugar, and then pick from the remaining linker choices available.

[0351] Once all of the sites on the list are assigned chemistries or dropped, they are registered at process step 2324 to a commercial chemical structure database. Registering to this database makes sure the structure is unique, assigns it a new identifier if it is unique, and allows future structure and substructure searching by creating various hash-tables. The compound definition is also stored at process step 2326 to various hash tables referred to as chemistry/position tables. These allow antisense compound searching and categorization based on oligonucleotide chemistry modification sequences and equivalent base sequences.

[0352] The results of the registration are displayed at process step 2328 with the new IDs if they are new compounds and with the old IDs if they have been previously registered. The user next selects which of the compounds processed they wish to order for synthesis at process step 2330 and registers an order list at process step 2332 by including scientist name, notebook number and page number. The database time-stamps this entry. The user may then choose at process step 2334, to quit the program at process step 2338, go back to the beginning and choose a new site list to work with process step 2304, or start the oligonucleotide ordering interface at process step 2336.

Example 18

[0353] Gene Walk to Optimize Oligonucleotide Sequence

[0354] A gene walk is executed using a CD40 antisense oligonucleotide having SEQ IS NO: 5′-CTGGCACAAAGAACAGCA-3′). In effecting this gene walk, the following parameters are used: Gene Walk Parameter Entered value Oligonucleotide Sequence ID: 15 Name of Gene Target: CD40 Scope of Gene Walk: 20 Sequence Shift Increment:  1

[0355] Entering these values and effecting the gene walk centered on SEQ ID NO: 15 automatically generates the following new oligonucleotides: TABLE 9 Oligonucleotide Generated By Gene Walk SEQ ID Sequence 93 GAACAGCACTGACTGT 94 AGAACAGCACTGACTG 95 AAGAACAGCACTGACT 96 AAAGAACAGCACTGAC 97 CAAAGAACAGCACTGA 98 ACAAAGAACAGCACTG 99 CACAAAGAACAGCACT 100 GCACAAAGAACAGCAC 101 GGCACAAAGAACAGCA 102 TGGCACAAAGAACAGC 15 CTGGCACAAAGAACAG 103 GCTGGCACAAAGAACA 104 GGCTGGCACAAAGAAC 105 TGGCTGGCACAAAGAA 106 CTGGCTGGCACAAAGA 107 CCTGGCTGGCACAAAG 108 TCCTGGCTGGCACAAA 109 GTCCTGGCTGGCACAA 110 TGTCCTGGCTGGCACA 111 CTGTCCTGGCTGGCAC 112 TCTGTCCTGGCTGGCAC

[0356] The list shown above contains 20 oligonucleotide sequences directed against the CD40 nucleic acid sequence. They are ordered by the position along the CD40 sequence at which the 5′ terminus of each oligonucleotide hybridizes. Thus, the first ten oligonucleotides are single-base frame shift sequences directed against the CD40 sequence upstream of compound SEQ ID NO: 15 and the latter ten are single-base frame shift sequences directed against the CD40 sequence downstream of compound SEQ ID NO: 15.

Example 19

[0357] Automated Assay of RhoC Oligonucleotide Activity

[0358] RhoC, a member of the Rho subfamily of small GTPases, is a protein that has been shown to be involved in a diverse set of signaling pathways including the ultimate regulation of the dynamic organization of the cytoskeleton.

[0359] Oligonucleotides targeting RhoC were designed, synthesized, analyzed and assayed according to procedures outlined in U.S. Ser. No. 09/067,638. Alternatively, oligonucleotides targeting RhoC can be designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0360] RhoC probes and primers were designed to hybridize to the human RhoC sequence, using published sequence information (GenBank accession number L25081, incorporated herein by reference as SEQ ID NO: 113).

[0361] For RhoC the PCR primers were:

[0362] forward primer TGATGTCATCCTCATGTGCTTCT (SEQ ID NO: 114)

[0363] reverse primer CCAGGATGATGGGCACGTT (SEQ ID NO: 115) and the PCR probe

[0364] was: FAM-CGACAGCCCTGACAGCCTGGAAA-TAMRA (SEQ ID NO: 116) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 20

[0365] Antisense Inhibition of RhoC Expression-Phosphorothioate Oligodeoxynucleotides

[0366] In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human RhoC RNA, using published sequences (GenBank accession number L25081, incorporated herein by reference as SEQ ID NO: 113). The oligonucleotides are shown in Table 10. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. L25081), to which the oligonucleotide binds. All compounds in Table 10 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on RhoC mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments. If present, “N.D.” indicates “no data”. TABLE 10 Inhibition of RhoC mRNA levels by phosphorothioate oligodeoxynucleotides % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 25304 5′ UTR 4 gagctgagatgaagtcaa 29 117 25305 5′ UTR 44 gctgaagttcccaggctg 25 118 25306 5′ UTR 47 ccggctgaagttcccagg 42 119 25307 Coding 104 ggcaccatccccaacgat 81 120 25308 Coding 105 aggcaccatccccaacga 81 121 25309 Coding 111 tcccacaggcaccatccc 70 122 25310 Coding 117 aggtcttcccacaggcac 40 123 25311 Coding 127 atgaggaggcaggtcttc 41 124 25312 Coding 139 ttgctgaagacgatgagg 23 125 25313 Coding 178 tcaaagacagtagggacg 0 126 25314 Coding 181 ttctcaaagacagtaggg 2 127 25315 Coding 183 agttctcaaagacagtag 38 128 25316 Coding 342 tgttttccaggctgtcag 59 129 25317 Coding 433 tcgtcttgcctcaggtcc 79 130 25318 Coding 439 gtgtgctcgtcttgcctc 67 131 25319 Coding 445 ctcctggtgtgctcgtct 67 132 25320 Coding 483 cagaccgaacgggctcct 65 133 25321 Coding 488 ttcctcagaccgaacggg 57 134 25322 Coding 534 actcaaggtagccaaagg 33 135 25323 Coding 566 ctcccgcactccctcctt 91 136 25324 Coding 575 ctcaaacacctcccgcac 34 137 25325 Coding 581 ggccatctcaaacacctc 64 138 25326 Coding 614 cttgttcttgcggacctg 72 139 25327 Coding 625 cccctccgacgcttgttc 66 140 25328 3′ UTR 737 gtatggagccctcaggag 60 141 25329 3′ UTR 746 gagccttcagtatggagc 63 142 25330 3′ UTR 753 gaaaatggagccttcagt 24 143 25331 3′ UTR 759 ggaactgaaaatggagcc 2 144 25332 3′ UTR 763 ggagggaactgaaaatgg 13 145 25333 3′ UTR 766 gcaggagggaactgaaaa 27 146 25334 3′ UTR 851 agggcagggcataggcgt 31 147 25335 3′ UTR 854 ggaagggcagggcatagg 21 148 25336 3′ UTR 859 catgaggaagggcagggc 0 149 25337 3′ UTR 920 taaagtgctggtgtgtga 39 150 25338 3′ UTR 939 cctgtgagccagaagtgt 69 151 25339 3′ UTR 941 ttcctgtgagccagaagt 69 152 25340 3′ UTR 945 cactttcctgtgagccag 82 153 25341 3′ UTR 948 agacactttcctgtgagc 69 154 25342 3′ UTR 966 actctgggtccctactgc 20 155 25343 3′ UTR 992 tgcagaaacaactccagg 0 156

Example 21

[0367] Antisense Inhibition of RhoC Expression-Phosphorothioate 2′-MOE Gapmer Oligonucleotides

[0368] In accordance with the present invention, a second series of oligonucleotides targeted to human RhoC were synthesized. The oligonucleotide sequences are shown in Table 11. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession No. L25081), to which the oligonucleotide binds.

[0369] All compounds in Table 11 are chimeric oligonucleotides (“gapmers”) 18 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by four-nucleotide “wings.” The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2′-MOE wings are 5-methylcytidines.

[0370] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, “N.D.” indicates “no data”. TABLE 11 Inhibition of RhoC mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 25344 5′ UTR 4 gagctgagatgaagtcaa 0 117 25345 5′ UTR 44 gctgaagttcccaggctg 35 118 25346 5′ UTR 47 ccggctgaagttcccagg 53 119 25347 Coding 104 ggcaccatccccaacgat 50 120 25348 Coding 105 aggcaccatccccaacga 56 121 25349 Coding 111 tcccacaggcaccatccc 4 122 25350 Coding 117 aggtcttcccacaggcac 11 123 25351 Coding 127 atgaggaggcaggtcttc 6 124 25352 Coding 139 ttgctgaagacgatgagg 15 125 25353 Coding 178 tcaaagacagtagggacg 32 126 25354 Coding 181 ttctcaaagacagtaggg 7 127 25355 Coding 183 agttctcaaagacagtag 39 128 25356 Coding 342 tgttttccaggctgtcag 59 129 25357 Coding 433 tcgtcttgcctcaggtcc 48 130 25358 Coding 439 gtgtgctcgtcttgcctc 36 131 25359 Coding 445 ctcctggtgtgctcgtct 61 132 25360 Coding 483 cagaccgaacgggctcct 50 133 25361 Coding 488 ttcctcagaccgaacggg 14 134 25362 Coding 534 actcaaggtagccaaagg 32 135 25363 Coding 566 ctcccgcactccctcctt 21 136 25364 Coding 575 ctcaaacacctcccgcac 9 137 25365 Coding 581 ggccatctcaaacacctc 66 138 25366 Coding 614 cttgttcttgcggacctg 61 139 25367 Coding 625 cccctccgacgcttgttc 0 140 25368 3′ UTR 737 gtatggagccctcaggag 28 141 25369 3′ UTR 746 gagccttcagtatggagc 32 142 25370 3′ UTR 753 gaaaatggagccttcagt 0 143 25371 3′ UTR 759 ggaactgaaaatggagcc 40 144 25372 3′ UTR 763 ggagggaactgaaaatgg 45 145 25373 3′ UTR 766 gcaggagggaactgaaaa 35 146 25374 3′ UTR 851 agggcagggcataggcgt 5 147 25375 3′ UTR 854 ggaagggcagggcatagg 0 148 25376 3′ UTR 859 catgaggaagggcagggc 0 149 25377 3′ UTR 920 taaagtgctggtgtgtga 20 150 25378 3′ UTR 939 cctgtgagccagaagtgt 67 151 25379 3′ UTR 941 ttcctgtgagccagaagt 61 152 25380 3′ UTR 945 cactttcctgtgagccag 80 153 25381 3′ UTR 948 agacactttcctgtgagc 0 154 25382 3′ UTR 966 actctgggtccctactgc 0 155 25383 3′ UTR 992 tgcagaaacaactccagg 0 156

Example 22

[0371] Automated Assay of Cellular Inhibitor of Apoptosis-2 Expression Oligonucleotide Activity

[0372] Cellular Inhibitor of Apoptosis-2 (also known as c-IAP-2, apoptosis inhibitor 2, API-2, hIAP-1, and MIHC) is a member of the inhibitor of apoptosis (IAP) family of anti-apoptotic proteins which interfere with the transmission of intracellular death signals.

[0373] Oligonucleotides targeting Cellular Inhibitor of Apoptosis-2 were designed, synthesized, analyzed and assayed according to procedures outlined in U.S. Ser. No. 09/067,638. Alternatively, Oligonucleotides targeting Cellular Inhibitor of Apoptosis-2 can be designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0374] Cellular Inhibitor of Apoptosis-2 probes and primers were designed to hybridize to the human Cellular Inhibitor of Apoptosis-2 sequence, using published sequences information (GenBank accession number U37546, incorporated herein by reference as SEQ ID NO: 157).

[0375] For Cellular Inhibitor of Apoptosis-2-the PCR primers were:

[0376] forward primer: GGACTCAGGTGTTGGGAATCTG (SEQ ID NO: 158)

[0377] reverse primer: CAAGTACTCACACCTTGGAAACCA (SEQ ID NO: 159) and the PCR

[0378] probe was: FAM-AGATGATCCATGGGTTCAACATGCCAA-TAMRA (SEQ ID NO: 160) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 23

[0379] Antisense Inhibition of Cellular Inhibitor of Apoptosis-2 Expression-Phosphorothioate Oligodeoxynucleotides

[0380] In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human Cellular Inhibitor of Apoptosis-2 RNA, using published sequences (GenBank accession number U37546, incorporated herein by reference as SEQ ID NO: 157). The oligonucleotides are shown in Table 12. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. U37546), to which the oligonucleotide binds. All compounds in Table 12 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on Cellular Inhibitor of Apoptosis-2 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments. If present, “N.D.” indicates “no data”. TABLE 12 Inhibition of Cellular Inhibitor of Apoptosis-2 mRNA levels by phosphorotbioate oligodeoxynucleotides % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 23412 5′ UTR 3 actgaagacattttgaat 62 161 23413 5′ UTR 37 cttagaggtacgtaaaat 29 162 23414 5′ UTR 49 gcacttuatttcttaga 70 163 23415 5′ UTR 62 attttaattagaagcact 0 164 23416 5′ UTR 139 accatatttcactgattc 70 165 23417 5′ UTR 167 ctaactcaaaggaggaaa 0 166 23418 5′ UTR 175 cacaagacctaactcaaa 27 167 23419 5′ UTR 268 gctctgctgtcaagtgtt 57 168 23420 5′ UTR 303 tgtgtgactcatgaagct 23 169 23421 5′ UTR 335 ttcagtggcattcaatca 23 170 23422 5′ UTR 357 cttctccaggctactaga 50 171 23423 5′ UTR 363 ggtcaacttctccaggct 65 172 23424 5′ UTR 437 taaaacccttcacagaag 0 173 23425 5′ UTR 525 ttaaggaagaaatacaca 0 174 23426 5′ UTR 651 gcatggctttgcttttat 0 175 23427 Coding 768 caaacgtgttggcgcttt 35 176 23428 Coding 830 agcaggaaaagtggaata 0 177 23429 Coding 1015 ttaacggaatttagactc 0 178 23430 Coding 1064 atttgttactgaagaagg 0 179 23431 Coding 1118 agagccacggaaatatcc 9 180 23432 Coding 1168 aaatcttgatttgctctg 7 181 23433 Coding 1231 gtaagtaatctggcattt 0 182 23434 Coding 1323 agcaagccactctgtctc 50 183 23435 Coding 1436 tgaagtgtcttgaagctg 0 184 23436 Coding 1580 tttgacatcatcactgtt 0 185 23437 Coding 1716 tggcttgaacttgacgga 0 186 23438 Coding 1771 tcatctcctgggctgtct 40 187 23439 Coding 1861 gcagcattaatcacagga 0 188 23440 Coding 2007 tttctctctcctcttccc 10 189 23441 Coding 2150 aacatcatgttcttgttc 9 190 23442 Coding 2273 atataacacagcttcagc 0 191 23443 Coding 2350 aattgftcttccactggt 0 192 23444 Coding 2460 aagaaggagcacaatctt 70 193 23445 3′ UTR 2604 gaaaccaaattaggataa 12 194 23446 3′ UTR 2753 tgtagtgctacctcttu 69 195 23447 3′ UTR 2779 ctgaaatutgattgaat 14 196 23448 3′ UTR 2795 tacaatttcaataatgct 38 197 23449 3′ UTR 2920 gggtctcagtatgctgcc 21 198 23450 3′ UTR 3005 ccttcgatgtataggaca 0 199 23451 3′ UTR 3040 catgtccctaaaatgtca 0 200

Example 24

[0381] Antisense Inhibition of Cellular Inhibitor of Apoptosis-2 Expression-Phosphorothioate 2′-MOE Gapmer Oligonucleotides

[0382] In accordance with the present invention, a second series of oligonucleotides targeted to human Cellular Inhibitor of Apoptosis-2 were synthesized. The oligonucleotide sequences are shown in Table 13. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. U37546), to which the oligonucleotide binds.

[0383] All compounds in Table 13 are chimeric oligonucleotides (“gapmers”) 18 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by four-nucleotide “wings.” The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2′-MOE wings are 5-methylcytidines.

[0384] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, “N.D.” indicates “no data”. TABLE 13 Inhibition of Cellular Inhibitor of Apoptosis-2 mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 23452 5′ UTR 3 actgaagacattttgaat 35 161 23453 5′ UTR 37 cttagaggtacgtaaaat 26 162 23454 5′ UTR 49 gcacttttatttcttaga 76 163 23455 5′ UTR 62 attttaattagaagcact 0 164 23456 5′ UTR 139 accatatttcactgauc 0 165 23457 5′ UTR 167 ctaactcaaaggaggaaa 5 166 23458 5′ UTR 175 cacaagacctaactcaaa 0 167 23459 5′ UTR 268 gctctgctgtcaagtgtt 57 168 23460 5′ UTR 303 tgtgtgactcatgaagct 67 169 23461 5′ UTR 335 ttcagtggcattcaatca 59 170 23462 5′ UTR 357 cttctccaggctactaga 0 171 23463 5′ UTR 363 ggtcaacttctccaggct 75 172 23464 5′ UTR 437 taaaacccttcacagaag 11 173 23465 5′ UTR 525 ttaaggaagaaatacaca 0 174 23466 5′ UTR 651 gcatggctttgcttttat 46 175 23467 Coding 768 caaacgtgttggcgcttt 47 176 23468 Coding 830 agcaggaaaagtggaata 39 177 23469 Coding 1015 ttaacggaatttagactc 12 178 23470 Coding 1064 atttgttactgaagaagg 34 179 23471 Coding 1118 agagccacggaaatatcc 54 180 23472 Coding 1168 aaatcttgatttgctctg 34 181 23473 Coding 1231 gtaagtaatctggcattt 0 182 23474 Coding 1323 agcaagccactctgtctc 42 183 23475 Coding 1436 tgaagtgtcttgaagctg 0 184 23476 Coding 1580 tttgacatcatcactgtt 57 185 23477 Coding 1716 tggcttgaacttgacgga 23 186 23478 Coding 1771 tcatctcctgggctgtct 66 187 23479 Coding 1861 gcagcattaatcacagga 65 188 23480 Coding 2007 tttctctctcctcttccc 0 189 23481 Coding 2150 aacatcatgttcttgttc 13 190 23482 Coding 2273 atataacacagcttcagc 0 191 23483 Coding 2350 aattgttcttccactggt 60 192 23484 Coding 2460 aagaaggagcacaatctt 65 193 23485 3′ UTR 2604 gaaaccaaattaggataa 0 194 23486 3′ UTR 2753 tgtagtgctacctctttt 73 195 23487 3′ UTR 2779 ctgaaattttgattgaat 4 196 23488 3′ UTR 2795 tacaatttcaataatgct 0 197 23489 3′ UTR 2920 gggtctcagtatgctgcc 42 198 23490 3′ UTR 3005 ccttcgatgtataggaca 71 199 23491 3′ UTR 3040 catgtccctaaaatgtca 45 200

Example 25

[0385] Automated Assay of ELK-1 Oligonucleotide Activity

[0386] ELK-1 (also known as p62TCF) is a member of the ternary complex factor (TCF) subfamily of Ets domain proteins and utilizes a bipartite recognition mechanism mediated by both protein-DNA and protein-protein interactions. This results in gene regulation not only by direct DNA binding but also by indirect DNA binding through recruitment by other factors (Rao et al., Science, 1989, 244, 66-70). The formation of ternary complexes with an array of proteins allows the differential regulation of many genes. The mechanism by which ELK-1 controls various signal transduction pathways involves regulating the activity of the Egr-1, pip92, nur77 and c-fos promoters by binding to the serum response element (SRE) in these promoters in response to extracellular stimuli such as growth factors, mitogens and oncogene products (Sharrocks et al., Int. J. Biochem. Cell Biol., 1997, 29, 1371-1387). ELK-1 has also been shown to mediate other functions within the cell including apoptosis.

[0387] Oligonucleotides targeting ELK-1 were designed, synthesized, analyzed and assayed according to procedures outlined in U.S. Ser. No. 09/067,638. Alternatively, Oligonucleotides targeting ELK-1 can be designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0388] ELK-1 probes and primers were designed to hybridize to the human ELK-1 sequence, using published sequence information (GenBank accession number M25269, incorporated herein by reference as SEQ ID NO: 201).

[0389] For ELK-1 the PCR primers were:

[0390] forward primer: GCAAGGCAATGGCCACAT (SEQ ID NO: 202)

[0391] reverse primer: CTCCTCTGCATCCACCAGCTT (SEQ ID NO: 203) and the PCR probe

[0392] was: FAM-TCTCCTGGACTTCACGGGATGGTGGT-TAMRA (SEQ ID NO: 204) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 26

[0393] Antisense Inhibition of ELK-1 Expression-Phosphorothioate Oligodeoxynucleotides

[0394] In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human ELK-1 RNA, using published sequences (GenBank accession number M25269, incorporated herein by reference as SEQ ID NO: 201). The oligonucleotides are shown in Table 14. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. M25269), to which the oligonucleotide binds. All compounds in Table 14 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on ELK-1 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments. If present, “N.D.” indicates “no data”. TABLE 14 Inhibition of ELK-1 mRNA levels by phosphorothioate oligodeoxynucleotides % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 24752 5′ UTR 11 cccctgcgtttccctaca 15 205 24753 5′ UTR 50 ggtggtggtggcggtggc 29 206 24754 5′ UTR 139 ggcgttggcaatgttggc 82 207 24755 5′ UTR 167 aagttgaggctgtgtgta 0 208 24756 5′ UTR 189 aggccacggacgggtctc 92 209 24757 5′ UTR 229 gattgattcgctacgatg 71 210 24758 5′ UTR 255 gggatgcggaggagtgcg 74 211 24759 5′ UTR 289 agtgctcacgccatccca 22 212 24760 Coding 328 aaactgccacagcgtcac 64 213 24761 Coding 381 gaagtccaggagatgatg 62 214 24762 Coding 395 caccaccatcccgtgaag 88 215 24763 Coding 455 tcttgttcttgcgtagtc 62 216 24764 Coding 512 tgttcttgtcatagtagt 52 217 24765 Coding 527 tcaccttgcggatgatgt 57 218 24766 Coding 582 gagcaccctgcgacctca 72 219 24767 Coding 600 ggcgggcagtcctcagtg 82 220 24768 Coding 787 ggtgaaggtggaatagag 58 221 24769 Coding 993 tccgatttcaggtuggg 55 222 24770 Coding 1110 ttggtggtuctggcaca 67 223 24771 Coding 1132 tggagggacttctggctc 69 224 24772 Coding 1376 gcgtaggaagcagggatg 34 225 24773 Coding 1440 gtgctccagaagtgaatg 64 226 24774 Coding 1498 actggatggaaactggaa 34 227 24775 Coding 1541 ggccatccacgctgatag 74 228 24776 3′ UTR 1701 ccaccacaatcagagcat 74 229 24777 3′ UTR 1711 gatccccaccccaccaca 16 230 24778 3′ UTR 1765 tgttttctgtggaggaga 48 231 24779 3′ UTR 1790 aaacagagaagttgtgga 11 232 24780 3′ UTR 1802 gggactgacagaaaacag 0 233 24781 3′ UTR 1860 ataaataaataaaccgcc 18 234 24782 3′ UTR 1894 gttaggtcaggctcatcc 56 235 24783 3′ UTR 1974 gttctcaagccagacctc 52 236 24784 3′ UTR 1992 aataaagaaagaaaggtc 41 237 24785 3′ UTR 2006 agggcaggctgagaaata 29 238 24786 3′ UTR 2053 cttctactcacatccaaa 54 239 24787 3′ UTR 2068 caaaacaaactaactctt 24 240 24788 3′ UTR 2080 ggaataataaaacaaaac 40 241 24789 3′ UTR 2107 ttcttcctggacccctga 93 242 24790 3′ UTR 2161 ccaagggtgtgattcttc 81 243 24791 3′ UTR 2200 tgtctgagagaaaggttg 55 244

Example 27

[0395] Antisense Inhibition of ELK-1 Expression-Phosphorothioate 2′-MOE Gapmer Oligonucleotides

[0396] In accordance with the present invention, a second series of oligonucleotides targeted to human ELK-1 were synthesized. The oligonucleotide sequences are shown in Table 15. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. M25269), to which the oligonucleotide binds.

[0397] All compounds in Table 15 are chimeric oligonucleotides (“gapmers”) 18 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by four-nucleotide “wings.” The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2′-MOE wings are 5-methylcytidines.

[0398] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, “N.D.” indicates “no data”. TABLE 15 Inhibition of ELK-1 mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 24792 5′ UTR 11 cccctgcgtttccctaca 23 205 24793 5′ UTR 50 ggtggtggtggcggtggc 80 206 24794 5′ UTR 139 ggcgttggcaatgttggc 91 207 24795 5′ UTR 167 aagttgaggctgtgtgta 27 208 24796 5′ UTR 189 aggccacggacgggtctc 79 209 24797 5′ UTR 229 gattgattcgctacgatg 69 210 24798 5′ UTR 255 gggatgcggaggagtgcg 42 211 24799 5′ UTR 289 agtgctcacgccatccca 45 212 24800 Coding 328 aaactgccacagcgtcac 57 213 24801 Coding 381 gaagtccaggagatgatg 55 214 24802 Coding 395 caccaccatcccgtgaag 41 215 24803 Coding 455 tcttgttcttgcgtagtc 80 216 24804 Coding 512 tgttcttgtcatagtagt 65 217 24805 Coding 527 tcaccttgcggatgatgt 70 218 24806 Coding 582 gagcaccctgcgacctca 64 219 24807 Coding 600 ggcgggcagtcctcagtg 67 220 24808 Coding 787 ggtgaaggtggaatagag 45 221 24809 Coding 993 tccgatttcaggtttggg 75 222 24810 Coding 1110 ttggtggtttctggcaca 82 223 24811 Coding 1132 tggagggacttctggctc 60 224 24812 Coding 1376 gcgtaggaagcagggatg 49 225 24813 Coding 1440 gtgctccagaagtgaatg 71 226 24814 Coding 1498 actggatggaaactggaa 62 227 24815 Coding 1541 ggccatccacgctgatag 78 228 24816 3′ UTR 1701 ccaccacaatcagagcat 54 229 24817 3′ UTR 1711 gatccccaccccaccaca 44 230 24818 3′ UTR 1765 tgttttctgtggaggaga 74 231 24819 3′ UTR 1790 aaacagagaagttgtgga 64 232 24820 3′ UTR 1802 gggactgacagaaaacag 16 233 24821 3′ UTR 1860 ataaataaataaaccgcc 38 234 24822 3′ UTR 1894 gttaggtcaggctcatcc 59 235 24823 3′ UTR 1974 gttctcaagccagacctc 62 236 24824 3′ UTR 1992 aataaagaaagaaaggtc 35 237 24825 3′ UTR 2006 agggcaggctgagaaata 0 238 24826 3′ UTR 2053 cttctactcacatccaaa 46 239 24827 3′ UTR 2068 caaaacaaactaactctt 38 240 24828 3′ UTR 2080 ggaataataaaacaaaac 37 241 24829 3′ UTR 2107 ttcttcctggacccctga 71 242 24830 3′ UTR 2161 ccaagggtgtgattcttc 88 243 24831 3′ UTR 2200 tgtctgagagaaaggttg 65 244

Example 28

[0399] Automated Assay of Gi alpha-11 Oligonucleotide Activity

[0400] G-alpha-11 is a member of the Gq subfamily of G proteins whose primary function is to activate PLC-b isoforms producing second messengers and affecting intracellular calcium stores.

[0401] Oligonucleotides targeting Gi alpha-11 were designed, synthesized, analyzed and assayed according to procedures outlined in U.S. Ser. No. 09/067,638. Alternatively, oligonucleotides targeting Gi alpha-11 can be designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0402] G-alpha-11 probes and primers were designed to hybridize to the human G-alpha-11 sequence, using published sequence information (GenBank accession number AF011497, incorporated herein by reference as SEQ ID NO: 245). For G-alpha-11 the PCR primers were:

[0403] forward primer: TGACCACCTTCGAGCATCAG (SEQ ID NO: 246)

[0404] reverse primer: CGGTCGTAGCATTCCTGGAT (SEQ ID NO: 247) and the PCR probe

[0405] was: FAM-TCAGTGCCATCAAGACCCTGTGGGAG-TAMRA (SEQ ID NO: 248) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 29

[0406] Antisense Inhibition of G-alpha-11 Expression-Phosphorothioate Oligodeoxynucleotides

[0407] In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human G-alpha-11 RNA, using published sequences (GenBank accession number AF011497, incorporated herein by reference as SEQ ID NO: 245). The oligonucleotides are shown in Table 16. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. AF011497), to which the oligonucleotide binds. All compounds in Table 16 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on G-alpha-11 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments. If present, “N.D.” indicates “no data”. TABLE 16 Inhibition of G-alpha-11 mRNA levels by phosphorothioate oligodeoxynucleotides % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 20576 Coding 1 gatggactccagagtcat 0 249 20577 Coding 6 gccatgatggactccaga 75 250 20578 Coding 9 cacgccatgatggactcc 0 251 20579 Coding 25 ctcatcgctcaggcaaca 61 252 20580 Coding 31 cttcacctcatcgctcag 20 253 20581 Coding 36 gactccttcacctcatcg 15 254 20582 Coding 45 atccgcttggactccttc 17 255 20583 Coding 50 cgttgatccgcttggact 0 256 20584 Coding 61 ctcgatctcggcgttgat 0 257 20585 Coding 77 cccgccgcagctgcttct 58 258 20586 Coding 106 cttgagctcgcgccgggc 31 259 20587 Coding 116 gcagcagcagcttgagct 0 260 20588 Coding 127 gcccgtgccgagcagcag 0 261 20589 Coding 146 acgtgctcttcccgctct 28 262 20590 Coding 159 atctgcttgatgaacgtg 0 263 20591 Coding 162 cgcatctgcttgatgaac 0 264 20592 Coding 184 gtagccggcgccgtggat 1 265 20593 Coding 197 tgtcctcctccgagtagc 0 266 20594 Coding 199 cttgtcctcctccgagta 79 267 20595 Coding 207 aagccgcgcttgtcctcc 56 268 20596 Coding 222 tagacgagcttggtgaag 0 269 20597 Coding 230 tgttctggtagacgagct 0 270 20598 Coding 242 tggcggtgaagatgttct 0 271 20599 Coding 258 cggatcatggcctgcatg 1 272 20600 Coding 271 cgtctccatggcccggat 49 273 20601 Coding 285 tagaggatcttgagcgtc 0 274 20602 Coding 287 tgtagaggatcttgagcg 0 275 20603 Coding 297 tgctcgtacttgtagagg 7 276 20604 Coding 306 gccttgttctgctcgtac 25 277 20605 Coding 309 ttggccttgttctgctcg 0 278 20606 Coding 319 caggagcgcattggcctt 0 279 20607 Coding 340 ctccacgtccacctcccg 69 280 20608 Coding 349 ggtcaccttctccacgtc 27 281 20609 Coding 362 gatgctcgaaggtggtca 33 282 20610 Coding 373 actgacgtactgatgctc 36 283 20611 Coding 382 cttgatggcactgacgta 78 284 20612 Coding 388 cagggtcttgatggcact 0 285 20613 Coding 409 ctggatgcccgggtcctc 0 286 20614 Coding 411 tcctggatgcccgggtcc 30 287 20615 Coding 429 cgcctgcggtcgtagcat 0 288 20616 Coding 440 gctggtactcgcgcctgc 41 289 20617 Coding 459 tacttggcagagtcggag 34 290 20618 Coding 468 gtcaggtagtacttggca 76 291 20619 Coding 479 ggtcaacgtcggtcaggt 18 292 20620 Coding 489 gtggcgatgcggtcaacg 1 293 20621 Coding 503 gcaggtagcccaaggtgg 20 294 20622 Coding 518 cgtcctgctgggtgggca 40 295 20623 Coding 544 ggtggtgggcacgcggac 0 296 20624 Coding 555 tcgatgatgccggtggtg 0 297 20625 Coding 572 ccaggtcgaaagggtact 0 298 20626 Coding 578 tgttctccaggtcgaaag 33 299 20627 Coding 584 agatgatgttctccaggt 0 300 20628 Coding 591 atccggaagatgatgttc 0 301 20629 Coding 624 ctccgctccgaccgctgg 56 302 20630 Coding 634 gatccacttcctccgctc 59 303 20631 Coding 655 tgtcacguctcaaagca 0 304 20632 Coding 663 atgatggatgtcacgttc 0 305 20633 Coding 671 cgagaaacatgatggatg 0 306 20634 Coding 682 gctgagggcgacgagaaa 75 307 20635 Coding 709 cgactccaccaggacttg 40 308 20636 Coding 726 atccggttctcgugtcc 22 309 20637 Coding 728 ccatccggttctcgttgt 19 310 20638 Coding 744 agggctttgctctcctcc 77 311 20639 Coding 754 ggtccggaacagggcttt 26 312 20640 Coding 766 gtaggtgatgatggtccg 0 313 20641 Coding 787 ggaggagttctggaacca 64 314 20642 Coding 803 tgaggaagaggatgacgg 0 315 20643 Coding 818 gcaggtccttcttgttga 6 316 20644 Coding 831 atcttgtcctccagcagg 4 317 20645 Coding 842 gcgagtacaggatcttgt 17 318 20646 Coding 858 aagtagtccaccaggtgc 0 319 20647 Coding 910 gatgaactcccgcgccgc 52 320 20648 Coding 935 ggttcaggtccacgaaca 71 321 20649 Coding 958 gtagatgatcttgtcgct 0 322 20650 Coding 972 cacgtgaagtgtgagtag 0 323 20651 Coding 993 atgttctccgtgtcggtg 0 324 20652 Coding 1014 acggccgcgaacacgaag 6 325 20653 Coding 1027 gatggtgtccttcacggc 0 326 20654 Coding 1043 tcaggttcagctgcagga 3 327 20655 Coding 1059 accagattgtactccttc 0 328

Example 30

[0408] Antisense Inhibition of G-alpha-11 Expression-Phosphorothioate 2′-MOE Gapmer Oligonucleotides

[0409] In accordance with the present invention, a second series of oligonucleotides targeted to human G-alpha-11 were synthesized. The oligonucleotide sequences are shown in Table 16. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. AF011497), to which the oligonucleotide binds.

[0410] All compounds in Table 17 are chimeric oligonucleotides (“gapmers”) 18 nucleosides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by four-nucleotide “wings.” The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2′-MOE wings are 5-methylcytidines.

[0411] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, “N.D.” indicates “no data”. TABLE 17 Inhibition of G-alpha-11 mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 20981 Coding 1 gatggactccagagtcat 0 249 20982 Coding 6 gccatgatggactccaga 0 250 20983 Coding 9 cacgccatgatggactcc 0 251 20984 Coding 25 ctcatcgctcaggcaaca 0 252 20985 Coding 31 cttcacctcatcgctcag 2 253 20986 Coding 36 gactccttcacctcatcg 0 254 20987 Coding 45 atccgcttggactccttc 19 255 20988 Coding 50 cgttgatccgcttggact 15 256 20989 Coding 61 ctcgatctcggcgttgat 0 257 20990 Coding 77 cccgccgcagctgcttct 41 258 20991 Coding 106 cttgagctcgcgccgggc 19 259 20992 Coding 116 gcagcagcagcttgagct 23 260 20993 Coding 127 gcccgtgccgagcagcag 38 261 20994 Coding 146 acgtgctcttcccgctct 34 262 20995 Coding 159 atctgcttgatgaacgtg 56 263 20996 Coding 162 cgcatctgcttgatgaac 31 264 20997 Coding 184 gtagccggcgccgtggat 0 265 20998 Coding 197 tgtcctcctccgagtagc 42 266 20999 Coding 199 cttgtcctcctccgagta 0 267 21000 Coding 207 aagccgcgcttgtcctcc 73 268 21001 Coding 222 tagacgagcttggtgaag 0 269 21002 Coding 230 tgttctggtagacgagct 61 270 21003 Coding 242 tggcggtgaagatguct 14 271 21004 Coding 258 cggatcatggcctgcatg 84 272 21005 Coding 271 cgtctccatggcccggat 70 273 21006 Coding 285 tagaggatcttgagcgtc 39 274 21007 Coding 287 tgtagaggatcttgagcg 28 275 21008 Coding 297 tgctcgtacttgtagagg 70 276 21009 Coding 306 gccttgttctgctcgtac 76 277 21010 Coding 309 ttggccttgttctgctcg 0 278 21011 Coding 319 caggagcgcattggcctt 87 279 21012 Coding 340 ctccacgtccacctcccg 0 280 21013 Coding 349 ggtcaccttctccacgtc 69 281 21014 Coding 362 gatgctcgaaggtggtca 0 282 21015 Coding 373 actgacgtactgatgctc 69 283 21016 Coding 382 cttgatggcactgacgta 32 284 21017 Coding 388 cagggtcttgatggcact 19 285 21018 Coding 409 ctggatgcccgggtcctc 63 286 21019 Coding 411 tcctggatgcccgggtcc 56 287 21020 Coding 429 cgcctgcggtcgtagcat 73 288 21021 Coding 440 gctggtactcgcgcctgc 68 289 21022 Coding 459 tacttggcagagtcggag 50 290 21023 Coding 468 gtcaggtagtacttggca 13 291 21024 Coding 479 ggtcaacgtcggtcaggt 64 292 21025 Coding 489 gtggcgatgcggtcaacg 52 293 21026 Coding 503 gcaggtagcccaaggtgg 52 294 21027 Coding 518 cgtcctgctgggtgggca 0 295 21028 Coding 544 ggtggtgggcacgcggac 81 296 21029 Coding 555 tcgatgatgccggtggtg 48 297 21030 Coding 572 ccaggtcgaaagggtaci 61 298 21031 Coding 578 tgttctccaggtcgaaag 0 299 21032 Coding 584 agatgatgttctccaggt 0 300 21033 Coding 591 atccggaagatgatguc 0 301 21034 Coding 624 ctccgctccgaccgctgg 59 302 21035 Coding 634 gatccacttcctccgctc 17 303 21036 Coding 655 tgtcacgttctcaaagca 9 304 21037 Coding 663 atgatggatgtcacgttc 41 305 21038 Coding 671 cgagaaacatgatggatg 0 306 21039 Coding 682 gctgagggcgacgagaaa 11 307 21040 Coding 709 cgactccaccaggacttg 0 308 21041 Coding 726 atccggttctcgttgtcc 67 309 21042 Coding 728 ccatccgguctcgttgt 30 310 21043 Coding 744 agggctttgctctcctcc 61 311 21044 Coding 754 ggtccggaacagggcttt 72 312 21045 Coding 766 gtaggtgatgatggtccg 68 313 21046 Coding 787 ggaggagttctggaacca 54 314 21047 Coding 803 tgaggaagaggatgacgg 23 315 21048 Coding 818 gcaggtccttcttgttga 0 316 21049 Coding 831 atcttgtcctccagcagg 39 317 21050 Coding 842 gcgagtacaggatcttgt 74 318 21051 Coding 858 aagtagtccaccaggtgc 36 319 21052 Coding 910 gatgaactcccgcgccgc 67 320 21053 Coding 935 ggttcaggtccacgaaca 37 321 21054 Coding 958 gtagatgatcttgtcgct 64 322 21055 Coding 972 cacgtgaagtgtgagtag 37 323 21056 Coding 993 atgttctccgtgtcggtg 0 324 21057 Coding 1014 acggccgcgaacacgaag 0 325 21058 Coding 1027 gatggtgtccttcacggc 69 326 21059 Coding 1043 tcaggttcagctgcagga 0 327 21060 Coding 1059 accagattgtactccttc 0 328

Example 31

[0412] Automated Assay of AKT-1 Oligonucleotide Activity

[0413] Akt-1 (also known as PKB alpha and RAC-PK alpha) is a member of the AKT/PKB family of serine/threonine kinases and has been shown to be involved in a diverse of signaling pathways.

[0414] Oligonucleotides targeting AKT-1 were designed, synthesized, analyzed and assayed according to procedures outlined in U.S. Ser. No. 09/067,638. Alternatively, oligonucleotides targeting AKT-1 can be designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0415] AKT-1 probes and primers were designed to hybridize to the human AKT-1 sequence, using published sequence information (GenBank accession number M63167, incorporated herein by reference as SEQ ID NO: 329). For Akt-1 the PCR primers were:

[0416] forward primer: CGTGACCATGAACGAGTTTGA (SEQ ID NO: 330)

[0417] reverse primer: CAGGATCACCTTGCCGAAA (SEQ ID NO: 331) and the PCR probe

[0418] was: FAM-CTGAAGCTGCTGGGCAAGGGCA-TAMRA (SEQ ID NO: 332) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 32

[0419] Antisense Inhibition of Akt-1 Expression-Phosphorothioate Oligodeoxynucleotides

[0420] In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human Akt-1 RNA, using published sequences (GenBank accession number M63167, incorporated herein by reference as SEQ ID NO: 329). The oligonucleotides are shown in Table 18. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. M63167), to which the oligonucleotide binds. All compounds in Table 18 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on Akt-1 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments. If present, “N.D.” indicates “no data”. TABLE 18 Inhibition of Akt-1 mRNA levels by phosphorothioate oligodeoxynucleotides % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE tion NO. 28880 5′ UTR 4 ccctgtgccctgtcccag 55 333 28881 5′ UTR 27 cctaagcccctggtgaca 15 334 28882 5′ UTR 62 ctttgacttctttgaccc 68 335 28883 5′ UTR 70 ggcagcccctttgacttc 53 336 28884 Coding 213 caaccctccttcacaata 24 337 28885 Coding 234 tactcccctcgtttgtgc 0 338 28886 Coding 281 tgccatcattcttgagga 65 339 28887 Coding 293 agccaatgaaggtgccat 67 340 28888 Coding 352 cacagagaagttgttgag 22 341 28889 Coding 496 agtctggatggcggttgt 49 342 28890 Coding 531 tcctcctcctcctgcttc 9 343 28891 Coding 570 cctgagttgtcactgggt 49 344 28892 Coding 666 ccgaaagtgcccttgccc 56 345 28893 Coding 744 gccacgatgacttccttc 60 346 28894 Coding 927 cggtcctcggagaacaca 0 347 28895 Coding 990 acgttcttctccgagtgc 30 348 28896 Coding 1116 gtgccgcaaaaggtcttc 66 349 28897 Coding 1125 tactcaggtgtgccgcaa 66 350 28898 Coding 1461 ggcttgaagggtgggctg 41 351 28899 Coding 1497 tcaaaatacctggtgtca 51 352 28900 Coding 1512 gccgtgaactcctcatca 56 353 28901 Coding 1541 ggtcaggtggtgtgatgg 0 354 28902 Coding 1573 ctcgctgtccacacactc 61 355 28903 3′ UTR 1671 gcctctccatccctccaa 76 356 28904 3′ UTR 1739 acagcgtggcttctctca 12 357 28905 3′ UTR 1814 ttttcttccctaccccgc 64 358 28906 3′ UTR 1819 gatagttttcttccctac 0 359 28907 3′ UTR 1831 taaaacccgcaggatagt 74 360 28908 3′ UTR 1856 ggagaacaaactggatga 0 361 28909 3′ UTR 1987 ctggctgacagagtgagg 59 362 28910 3′ UTR 1991 gcggctggctgacagagt 61 363 28911 3′ UTR 2031 cccagagagatgacagat 46 364 28912 3′ UTR 2127 gctgctgtgtgcctgcca 38 365 28913 3′ UTR 2264 cataatacacaataacaa 39 366 28914 3′ UTR 2274 atttgaacaacataatac 11 367 28915 3′ UTR 2397 aagtgctaccgtggagag 57 368 28916 3′ UTR 2407 cgaaaaggtcaagtgcta 41 369 28917 3′ UTR 2453 cagggagtcagggagggc 13 370 28918 3′ UTR 2545 aaagttgaatgttgtaaa 10 371 28919 3′ UTR 2553 aaaatactaaagttgaat 25 372

Example 33

[0421] Antisense Inhibition of Akt-1 Expression-Phosphorothioate 2′-MOE Gapmer Oligonucleotides

[0422] In accordance with the present invention, a second series of oligonucleotides targeted to human Akt-1 were synthesized. The oligonucleotide sequences are shown in Table 19. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. M63167), to which the oligonucleotide binds.

[0423] All compounds in Table 19 are chimeric oligonucleotides (“gapmers”) 18 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by four-nucleotide “wings.” The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2′-MOE wings are 5-methylcytidines.

[0424] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, “N.D.” indicates “no data”. TABLE 19 Inhibition of Akt-1 mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap % Inhi- TARGET bi- SEQ ID ISIS# REGION SITE SEQUENCE -tion NO. 28920 5′ UTR 4 ccctgtgccctgtcccag 88 333 28921 5′ UTR 27 cctaagcccctggtgaca 44 334 28922 5′ UTR 62 ctttgacttctttgaccc 61 335 28923 5′ UTR 70 ggcagcccctttgacttc 79 336 28924 Coding 213 caaccctccttcacaata 72 337 28925 Coding 234 tactcccctcgtttgtgc 39 338 28926 Coding 281 tgccatcattcttgagga 73 339 28927 Coding 293 agccaatgaaggtgccat 62 340 28928 Coding 352 cacagagaagttgttgag 48 341 28929 Coding 496 agtctggatggcggttgt 43 342 28930 Coding 531 tcctcctcctcctgcttc 49 343 28931 Coding 570 cctgagttgtcactgggt 71 344 28932 Coding 666 ccgaaagtgcccttgccc 64 345 28933 Coding 744 gccacgatgacttccttc 66 346 28934 Coding 927 cggtcctcggagaacaca 77 347 28935 Coding 990 acgttcttctccgagtgc 89 348 28936 Coding 1116 gtgccgcaaaaggtcttc 61 349 28937 Coding 1125 tactcaggtgtgccgcaa 74 350 28938 Coding 1461 ggcttgaagggtgggctg 54 351 28939 Coding 1497 tcaaaatacctggtgtca 78 352 28940 Coding 1512 gccgtgaactcctcatca 88 353 28941 Coding 1541 ggtcaggtggtgtgatgg 71 354 28942 Coding 1573 ctcgctgtccacacactc 83 355 28943 3′ UTR 1671 gcctctccatccctccaa 86 356 28944 3′ UTR 1739 acagcgtggcttctctca 73 357 28945 3′ UTR 1814 ttttcttccctaccccgc 77 358 28946 3′ UTR 1819 gatagttttcttccctac 43 359 28947 3′ UTR 1831 taaaacccgcaggatagt 64 360 28948 3′ UTR 1856 ggagaacaaactggatga 70 361 28949 3′ UTR 1987 ctggctgacagagtgagg 90 362 28950 3′ UTR 1991 gcggctggctgacagagt 82 363 28951 3′ UTR 2031 cccagagagatgacagat 53 364 28952 3′ UTR 2127 gctgctgtgtgcctgcca 80 365 28953 3′ UTR 2264 cataatacacaataacaa 48 366 28954 3′ UTR 2274 atttgaacaacataatac 39 367 28955 3′ UTR 2397 aagtgctaccgtggagag 38 368 28956 3′ UTR 2407 cgaaaaggtcaagtgcta 83 369 28957 3′ UTR 2453 cagggagtcagggagggc 59 370 28958 3′ UTR 2545 aaagttgaatgttgtaaa 25 371 28959 3′ UTR 2553 aaaatactaaagttgaat 45 372

Example 34

[0425] Cell Culture and Oligonucleotide Treatment

[0426] The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

[0427] HMVEC d Neo Cells:

[0428] The human microvascular endothelial cell line from neonatal dermis, HMVEC d Neo, was obtained from Cascade Biologics Inc., (Portland, Oreg.). Cells are cultured through multiple passages in Medium 131 supplemented with Microvascular Growth Supplement (MVGS) in the absence of antibiotics and antimycotics.

[0429] HuVEC Cells:

[0430] The human umbilical vein endothelial cell line HuVEC was obtained from the American Type Culture Collection (Manassas, Va.). HuVEC cells are routinely cultured in EBM (Clonetics Corporation Walkersville, Md.) supplemented with SingleQuots supplements (Clonetics Corporation, Walkersville, Md.). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence, are maintained for up to 15 passages. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 10000 cells/ well for use in RT-PCR analysis.

[0431] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0432] HepG2 Cells:

[0433] The human hepatoblastoma cell line HepG2 was obtained from the American Type Culture Collection (Manassas, Va.). HepG2 cells are routinely cultured in Eagle's MEM supplemented with 10% fetal calf serum, non-essential amino acids, and 1 mM sodium pyruvate (Gibco/Life Technologies, Gaithersburg, Md.). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[0434] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0435] AML12 Cells:

[0436] The AML12 (alpha mouse liver 12) cell line was established from hepatocytes from a mouse (CD1 strain, line MT42) transgenic for human TGF alpha. Cells are cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 5 ng/ml selenium, and 40 ng/ml dexamethasone, and 90%; 10% fetal bovine serum. For subculturing, spent medium is removed and fresh media of 0.25% trypsin, 0.03% EDTA solution is added. Fresh trypsin solution (1 to 2 ml) is added and the culture is left to sit at room temperature until the cells detach.

[0437] Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[0438] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0439] Primary Mouse Hepatocytes:

[0440] Primary mouse hepatocytes are prepared from CD-1 mice purchased from Charles River Labs (Wilmington, Mass.) and are routinely cultured in Hepatocyte Attachment Media (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco/Life Technologies, Gaithersburg, Md.), 250 nM dexamethasone (Sigma), and 10 nM bovine insulin (Sigma). Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 10000 cells/well for use in RT-PCR analysis.

[0441] For Northern blotting or other analyses, cells are plated onto 100 mm or other standard tissue culture plates coated with rat tail collagen (200 ug/mL) (Becton Dickinson) and treated similarly using appropriate volumes of medium and oligonucleotide.

[0442] b.END Cells:

[0443] The mouse brain endothelial cell line b.END was obtained from Dr. Werner Risau at the Max Plank Institute (Bad Nauheim, Germany). b.END cells are routinely cultured in DMEM, high glucose (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000 cells/well for use in RT-PCR analysis.

[0444] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0445] Treatment with Antisense Compounds:

[0446] When cells reach 65-75% confluency, they are treated with oligonucleotide. For cells grown in 96-well plates, wells are washed once with 100 μL OPTI-MEM-1™ reduced-serum medium (Invitrogen Corporation, Carlsbad, Calif.) and then treated with 130 μL of OPTI-MEM-1™ containing 3.75 μg/mL LIPOFECTIN™ (Invitrogen Corporation, Carlsbad, Calif.) and the desired concentration of oligonucleotide. Cells are treated and data are obtained in triplicate. After 4-7 hours of treatment at 37° C., the medium is replaced with fresh medium. Cells are harvested 16-24 hours after oligonucleotide treatment. The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920 (TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 373) which is targeted to human H-ras, or ISIS 18078, (GTGCGCGCGAGCCCGAAATC, SEQ ID NO: 374) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2′-O-methoxyethyl gapmers (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, ATGCATTCTGCCCCCAAGGA, SEQ ID NO: 375, a 2′-O-methoxyethyl gapmer (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-H-ras (for ISIS 13920), JNK2 (for ISIS 18078) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras, JNK2 or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

Example 35

[0447] Design of Phenotypic Assays and in vivo Studies for Target Validation with Oligonucleotides

[0448] Phenotypic Assays:

[0449] Once target modulators have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition.

[0450] Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of any given target in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, Oreg.; Perkin Elmer, Boston, Mass.), protein-based assays including enzymatic assays (Panvera, LLC, Madison, Wis.; BD Biosciences, Franklin Lakes, N.J.; Oncogene Research Products, San Diego, Calif.), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, Mich.), triglyceride accumulation (Sigma-Aldrich, St. Louis, Mo.), angiogenesis assays, tube formation assays, cytokine and hormone assays and metabolic assays (Chemicon International Inc., Temecula, Calif.; Amersham Biosciences, Piscataway, N.J.).

[0451] In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with target modulators identified from the in vitro studies as well as control compounds at optimal concentrations which are determined by the methods described above. At the end of the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

[0452] Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharrides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

[0453] Analysis of the geneotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the target modulators. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

[0454] In vivo Studies:

[0455] The individual subjects of the in vivo studies described herein are warm-blooded vertebrate animals, which includes humans.

[0456] The clinical trial is subjected to rigorous controls to ensure that individuals are not unnecessarily put at risk and that they are fully informed about their role in the study.

[0457] To account for the psychological effects of receiving treatments, volunteers are randomly given placebo or target modulator. Furthermore, to prevent the doctors from being biased in treatments, they are not informed as to whether the medication they are administering is a target modulator or a placebo. Using this randomization approach, each volunteer has the same chance of being given either the new treatment or the placebo.

[0458] Volunteers receive either the target modulator or placebo for eight week period with biological parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any treatment), end (after the final treatment), and at regular intervals during the study period. Such measurements include the levels of nucleic acid molecules encoding the target or target protein levels in body fluids, tissues or organs compared to pre-treatment levels. Other measurements include, but are not limited to, indices of the disease state or condition being treated, body weight, blood pressure, serum titers of pharmacologic indicators of disease or toxicity as well as ADME (absorption, distribution, metabolism and excretion) measurements.

[0459] Information recorded for each patient includes age (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating (some/moderate/great) and number and type of previous treatment regimens for the indicated disease or condition.

[0460] Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and target modulator treatment. In general, the volunteers treated with placebo have little or no response to treatment, whereas the volunteers treated with the target modulator show positive trends in their disease state or condition index at the conclusion of the study.

Example 36

[0461] Northern Blot Analysis of Target mRNA Levels

[0462] Eighteen hours after antisense treatment, cell monolayers are washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST “B” Inc., Friendswood, Tex.). Total RNA is prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA is fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, Ohio). RNA is transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST “B” Inc., Friendswood, Tex.). RNA transfer is confirmed by UV visualization. Membranes are fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, Calif.) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, Calif.) using manufacturer's recommendations for stringent conditions.

[0463] To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

[0464] Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, Calif.). Data was normalized to GAPDH levels in untreated controls.

Example 37

[0465] Western Blot Analysis of Target Protein Levels

[0466] Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to target protein is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale Calif.).

Example 38

[0467] Antisense Inhibition of Human Jagged 2 Expression by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap

[0468] Jagged 2 is a member of the Notch signaling pathway which plays an essential role in cellular differentiation. It has also been implicated in hyperproliferative disorders through its influences on apoptosis and proliferation.

[0469] Oligonucleotides targeting Jagged 2 were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0470] Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be “multiplexed” with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only (“single-plexing”), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

[0471] PCR reagents are obtained from Invitrogen Corporation, (Carlsbad, Calif.). RT-PCR reactions are carried out by adding 20 μL PCR cocktail (2.5× PCR buffer minus MgCl₂, 6.6 mM MgCl₂, 375 μM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5× ROX dye) to 96-well plates containing 30 μL total RNA solution (20-200 ng). The RT reaction is carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

[0472] Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, Oreg.). Methods of RNA quantification by RiboGreen™ are taught in Jones, L. J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

[0473] In this assay, 170 μL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485 nm and emission at 530 nm.

[0474] For human GAPDH the PCR primers were:

[0475] forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 89)

[0476] reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 90) and the PCR probe

[0477] was: 5′ JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3′ (SEQ ID NO: 91) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

[0478] Probes and primers to human Jagged 2 were designed to hybridize to a human Jagged 2 sequence, using published sequence information (GenBank accession number NM_(—)002226.1, incorporated herein as SEQ ID NO: 376). For human Jagged 2 the PCR primers were: forward primer: CCCAGGGCTTCTCCGG (SEQ ID NO: 377) reverse primer: AATAGTCACCCTCCAGGTTATAGCAG (SEQ ID NO: 378) and the PCR probe was: FAM-TGGATGTCGACCTTTGTGAGCCAAGC-TAMRA (SEQ ID NO: 379) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0479] The series of oligonucleotides was designed to target different regions of the human Jagged 2 RNA, using published sequences (GenBank accession number NM_(—)002226.1, incorporated herein as SEQ ID NO: 376, GenBank accession number AF029778.1, incorporated herein as SEQ ID NO: 380, a genomic sequence of Jagged 2 represented by residues 104001-133000 of GenBank accession number AF111170.3, incorporated herein as SEQ ID NO: 381, and GenBank accession number BE674071.1, incorporated herein as SEQ ID NO: 382). The oligonucleotides are shown in Table 20. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 20 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human Jagged 2 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which human neonatal dermal endothelial cells (HMVEC-d Neo cells) were cultured and treated with oligonucleotides ISIS 148702-148779 (SEQ ID NOs: 383-460 according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data”. TABLE 20 Inhibition Of Human Jagged 2 mRNA Levels By Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap TARGET ISIS# REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO 148702 3′ UTR 376 4647 tacaaaaatgcactttcacg 79 383 148703 3′ UTR 376 4698 tggcattattcaatcaaata 0 384 148704 5′ UTR 380 2 gcgcacctgcatatgcatga 10 385 148705 Coding 380 475 gaaatagcccatgggccgcg 74 386 148706 Coding 380 487 cagctgcagctcgaaatagc 62 387 148707 Coding 380 497 gcagcgcgctcagctgcagc 63 388 148708 Coding 380 518 gcagctccccgttcacgttc 33 389 148709 Coding 380 523 gctcagcagctccccgttca 67 390 148710 Coding 380 621 tggtactccttaaggcacac 74 391 148711 Coding 380 631 caccttggcctggtactcct 72 392 148712 Coding 380 658 gccgtagctgcagggccccg 65 393 148713 Coding 380 702 ggcaggtagaaggagttgcc 49 394 148714 Coding 380 775 gacgaggcccgggtcctggt 64 395 148715 Coding 380 843 ttgtcccagtcccaggcctc 92 396 148716 Coding 380 927 aggctcttccagcggtcctc 63 397 148717 Coding 380 937 gctgaagtgcaggctcttcc 61 398 148718 Coding 380 947 ccacgtggccgctgaagtgc 54 399 148719 Coding 380 1023 ggccggcagaacttgttgca 30 400 148720 Coding 380 1068 ttgccgtactggtcgcaggt 79 401 148721 Coding 380 1078 gcaggccttgttgccgtact 63 402 148722 Coding 380 1093 catccagccgtccatgcagg 84 403 148723 Coding 380 1149 cccccgtggagcaaattaca 71 404 148724 Coding 380 1183 gtagctgcacctgcactccc 84 405 148725 Coding 380 1269 cagttgcactgccagggctc 85 406 148726 Coding 380 1279 gttggtctcacagttgcact 64 407 148727 Coding 380 1287 ccgccccagttggtctcaca 77 408 148728 Coding 380 1292 gcaggccgccccagttggtc 23 409 148729 Coding 380 1297 acagagcaggccgccccagt 72 410 148730 Coding 380 1302 ttgtcacagagcaggccgcc 81 411 148731 Coding 380 1311 ttcaggtctttgtcacagag 74 412 148732 Coding 380 1321 gccacagtagttcaggtctt 60 413 148733 Coding 380 1331 ggtggtggctgccacagtag 49 414 148734 Coding 380 1443 gaggtgcaggcgtgctcagc 63 415 148735 Coding 380 1672 cccttcacactcattggcgt 62 416 148736 Coding 380 1707 aggtttttgcaagaaaaagc 52 417 148737 Coding 380 1727 cacagtaatagccgccaatc 80 418 148738 Coding 380 1753 gatgcccttccagcccggga 75 419 148739 Coding 380 1810 gcaggtgcccccatgctgac 80 420 148740 Coding 380 1820 ccaggtccttgcaggtgccc 88 421 148741 Coding 380 1845 gggcacacacactggtaccc 71 422 148742 Coding 380 1902 gggctgctggcacacttgtc 88 423 148743 Coding 380 2100 gagcagttcttgccaccaaa 85 424 148744 Coding 380 2154 ccgcagccatcgatcactct 93 425 148745 Coding 380 2334 gtgcccccattgcggcaggg 73 426 148746 Coding 380 2474 agaagtcattgaccaggtcg 77 427 148747 Coding 380 2480 cacagtagaagtcattgacc 79 428 148748 Coding 380 2520 cgtgagtggcaggtcttgcc 68 429 148749 Coding 380 2530 ctggaactcgcgtgagtggc 56 430 148750 Coding 380 2556 ccgttgctgcaggtgtaggc 72 431 148751 Coding 380 2565 caggtgccaccgttgctgca 75 432 148752 Coding 380 2570 cgtagcaggtgccaccgttg 80 433 148753 Coding 380 2658 ttgggcaggcagctgctgtt 64 434 148754 Coding 380 2770 agggttgcagtcgttggtat 50 435 148755 Coding 380 2824 gcagcggaaccagttgacgc 75 436 148756 Coding 380 2901 ccgtaggcacagggcgagga 78 437 148757 Coding 380 2925 ttgatctcatccacacacgt 80 438 148758 Coding 380 2949 ggtgggcagctacagcgata 75 439 148759 Coding 380 3061 gcagctgttgcagtcttcca 0 440 148760 Coding 380 3071 ccaggcagcggcagctgttg 71 441 148761 Coding 380 3504 ctgctgtcaggcaggtccct 48 442 148762 Coding 380 3514 ctggatcaggctgctgtcag 61 443 148763 Coding 380 3597 tccaccttgacctcggtgac 69 444 148764 Coding 380 4059 gcgcggttgtccactttggg 59 445 148765 Stop Codon 380 4104 ccctactccttgccggcgta 80 446 148766 3′ UTR 380 4156 gacggcatggctcccaccga 75 447 148767 3′ UTR 380 4274 gaataatttatacaaggtta 62 448 148768 3′ UTR 380 4306 aatactccattgttttcagc 0 449 148769 3′ UTR 380 4359 tcatacagcgagtgccacgc 74 450 148770 3′ UTR 380 4378 caccctttgctctctccttt 67 451 148771 3′ UTR 380 4492 caccggcactttggcctgga 64 452 148772 3′ UTR 380 4538 gggtcccaccaacagccatg 83 453 148773 3′ UTR 380 4845 gaagggcacttctgaaagca 56 454 148774 3′ UTR 380 4928 acagttccgagggttctgtg 20 455 148775 Intron 5 381 15219 ctggctggatcccccacact 83 456 148776 Intron 5 381 17034 gggagcactcctggctctgc 38 457 148777 Exon: Intron 381 18740 ccatactgactgatatggca 78 458 Junction 148778 Intron: Exon 381 20082 cgacatccacctgcagggtg 70 459 Junction 148779 3′ UTR 382 242 tggcaggccccgactcaaca 69 460

[0480] As shown in Table 20, SEQ ID NOs: 383, 386, 387, 388, 390, 391, 392, 393, 394, 395,396, 397, 398, 399, 401, 402,403, 404, 405, 406, 407, 408, 410, 411, 412, 413, 414, 415, 416, 417, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 441, 442, 443, 444, 445, 446, 447, 448, 450, 451, 452, 453, 454, 456, 458, 459 and 460 demonstrated at least 40% inhibition of human Jagged 2 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

Example 39

[0481] Gene Function Analysis—Caspase Assay to Determine the Effect of Modulating Jagged 2 on the Process of Apoptosis

[0482] With specific modulators of Jagged 2 now available, it is possible to examine the role that Jagged 2 plays in cancer.

[0483] Programmed cell death or apoptosis involves the activation of proteases, a family of intracellular proteases, through a cascade which leads to the cleavage of a select set of proteins. The caspase family contains at least 14 caspases, with differing substrate preferences. The caspase activity assay uses a DEVD peptide to detect activated caspases in cell culture samples. The peptide is labeled with a fluorescent molecule, 7-amino-4-trifluoromethyl coumarin (AFC). Activated caspases cleave the DEVD peptide resulting in a fluorescence shift of the AFC. Increased fluorescence is indicative of increased caspase activity. The chemotherapeutic drugs taxol, cisplatin, etoposide, gemcitabine, camptothecin, aphidicolin and 5-fluorouracil all have been shown to induce apoptosis in a caspase-dependent manner.

[0484] The effect of the Jagged 2 modulator ISIS 148715 (SEQ ID NO: 396) was examined in normal human mammary epithelial cells (HMECs) as well as in two breast carcinoma cell lines, MCF7 and T47D, obtained from the American Type Culture Collection (Manassas Va.). The latter two cell lines express similar genes but MCF7 cells express the tumor suppressor p53, while T47D cells are deficient in p53. MCF7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. T47D cells were cultured in Gibco DMEM High glucose media supplemented with 10% FBS.

[0485] Cells were plated at 10,000 cells per well for HMEC cells or 20,000 cells per well for MCF-7 and T47D cells, and allowed to attach to wells overnight. Plates used were 96 well Costar plate 1603 (black sides, transparent bottom). DMEM high glucose medium, with and without phenol red, were obtained from Invitrogen (Carlsbad, Calif.). MEGM medium, with and without phenol red, were obtained from Biowhittaker (Walkersville Md.). The caspase-3 activity assay kit was obtained from Calbiochem (Cat. #HTS02).

[0486] Before adding to cells, the oligonucleotide cocktail was mixed thoroughly and incubated for 0.5 hrs. The Jagged 2 antisense oligonucleotide ISIS 148715 (SEQ ID NO: 396) or the mixed sequence 20-mer negative oligonucleotide control, ISIS 29848 (SEQ ID NO: 461) or the LIPOFECTIN™ only vehicle control was added (generally from a 3 μM stock of oligonucleotide) to a final concentration of 200 nM with 6 μg/ml LIPOFECTIN™. The medium was removed from the plates and the plates were tapped on sterile gauze. Each well was washed in 150 μl of PBS (150 μL HBSS for HMEC cells). The wash buffer in each well was replaced with 100 μL of the oligonucleotide/ OPTI-MEM™/LIPOFECTIN™ cocktail (this was T=0 for oligonucleotide treatment). The plates were incubated for 4 hours at 37° C., after which the medium was dumped and the plate was tapped on sterile gauze. 100 μl of full growth medium without phenol red was added to each well. After 48 hours, 50 μl of oncogene buffer (provided with Calbiochem kit) with 10 μM DTT was added to each well. 20 μl of oncogene substrate (DEVD-AFC) was added to each well. The plates were read at 400±25 nm excitation and 508±20 nm emission at t=0 and t=3 time points. The t=0×(0.8) time point was subtracted from the from the t=3 time point, and the data are shown as percent of LIPOFECTIN™-only treated cells.

[0487] It was thus demonstrated that the antisense modulator of Jagged 2 induces caspase activity in all three cell lines tested. The Jagged 2 oligonucleotide ISIS 148715 caused roughly a 78% reduction of Jagged 2 RNA and approximately a 5.5 fold increase in fluorescence (indicating apoptosis) when administered to HMEC cells at a 200 nM concentration. In MCF7 cells, this Jagged 2 antisense modulator reduced Jagged 2 RNA levels by approximately 50% and increased fluorescence (indicating apoptosis) by approximately 3.4 fold (200 nM concentration). Similarly, in T47D cells, Jagged 2 RNA was decreased by approximately 75% and increased fluorescence (indicating apoptosis) by 8 fold (200 nM dose of ISIS 148715). A second Jagged 2 modulator, ISIS 148744 (SEQ ID NO: 425), reduced Jagged 2 RNA to a slightly lesser extent (approx. 43% reduction) than did ISIS 148715, but also increased apoptosis by approximately 2.5 fold in MCF7 cells and 3.5 fold in T47D cells. Interestingly, ISIS 148744 did not inhibit apoptosis in the normal HMEC cells, but only in the two cancer cell lines.

Example 40

[0488] Gene Function Analysis—Cell Cycle Analysis to Determine the Effect of Modulating Jagged 2 on the Process of Apoptosis

[0489] Cell cycle regulation is the basis for various cancer therapies. Under some circumstances normal cells undergo growth arrest, while transformed cells undergo apoptosis and this difference can be used to protect normal cells against death caused by chemotherapeutic drugs. Disruption of cell cycle checkpoints in cancer cells can increase sensitivity to chemotherapy while cells with normal checkpoints may take refuge in G1, thus increasing the therapeutic index. ISIS 148715, an antisense modulator of Jagged 2, was tested for effects on the cell cycle in normal HMEC cells and cancer cells, both with and without p53. 72 hours after treatment with ISIS 148715, cells were stained with propidium iodide to generate a cell cycle profile using a flow cytometer. The cell cycle profile was analyzed with the ModFit program (Verity Software House, Inc., Topsham Me.). Neither LIPOFECTIN™ alone nor a panel of negative antisense controls perturbed the cell cycle. However, it was found that ISIS 148715 induced apoptosis in all three cell lines, as measured by an increase in the percentage of sub-G1 cells. In T47D cells, the percent hypodiploid cells (indicative of apoptosis) was shown to increase from approximately 4.5% for LIPOFECTIN™ control-treated cells to approximately 16% for ISIS 148715-treated cells. In MCF7 cells, the percent hypodiploid cells increased from approximately 3% (LIPOFECTIN™ only) to approximately 12.5% (ISIS 148715). In normal HMEC cells the percent diploid cells increased from approximately 2% (LIPOFECTIN™ control) to approximately-8% for cells treated with ISIS 148715. This increase in apoptosis was dose-dependent. In MCF7 cells this increase went from approximately 4% at 200 nM oligonucleotide to 8% at 300 nM oligonucleotide.

Example 41

[0490] Antisense Inhibition Of Human Transforming Growth Factor-Beta 3 Expression by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap

[0491] The transforming growth factor-beta superfamily of cytokines regulates a diverse array of physiologic functions including cell proliferation and growth, cell migration, differentiation, development, production of extracellular matrix, and the immune response. Each subgroup of this superfamily initiates a unique intracellular signaling cascade activated by ligand-induced formation and activation of specific serine/threonine kinase receptor complexes. Transforming growth factor-beta 3 is believed to have a role in healing of wounds and bone fractures, and is not expressed in healthy skin.

[0492] Oligonucleotides targeting human transforming growth factor-beta 3 were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0493] For human transforming growth factor-beta 3 the PCR primers were:

[0494] forward primer: ACCAATTACTGCTTCCGCAACT (SEQ ID NO: 463) reverse primer:

[0495] GATCCTGTCGGAAGTCAATGTAGA (SEQ ID NO: 464) and the PCR probe was:

[0496] FAM-AGGAGAACTGCTGTGTGCGCCCC-TAMRA (SEQ ID NO: 465) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0497] The series of oligonucleotides was designed to target different regions of the human transforming growth factor-beta 3 RNA, using published sequences (GenBank accession number NM_(—)003239.1, incorporated herein as SEQ ID NO: 462, and residues 138001-167000 of GenBank accession number AF107885, the complement of which is incorporated herein as SEQ ID NO: 466). The oligonucleotides are shown in Table 21. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 21 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human transforming growth factor-beta 3 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HuVEC cells were cultured and treated with oligonucleotides 155368-155715 (SEQ ID NOs: 467-544) according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data”. TABLE 21 Inhibition Of Human Transforming Growth Factor-Beta 3 mRNA Levels by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap TARGET ISIS # REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO. 155638 5′ UTR 462 5 ttgttgtccatgtgtctaaa 69 467 155639 5′ UTR 462 76 ttcaggacttccaggaagcg 62 468 155640 5′ UTR 462 106 aggtgcatgaactcactgca 75 469 155641 5′ UTR 462 205 cggcaaggcctggagaggaa 0 470 155642 Start Codon 462 248 aagtgcatcttcatgtgtga 76 471 155643 Start Codon 462 253 tttgcaagtgcatcttcatg 87 472 155644 Coding 462 258 agccctttgcaagtgcatct 79 473 155645 Coding 462 263 accagagccctttgcaagtg 70 474 155646 Coding 462 284 aagttcagcagggccaggac 45 475 155647 Coding 462 313 aagtggacagagagaggctg 64 476 155648 Coding 462 316 tgcaagtggacagagagagg 47 477 155649 Coding 462 320 gtggtgcaagtggacagaga 85 478 155650 Coding 462 341 ttgatgtggccgaagtccaa 57 479 155651 Coding 462 346 tcttcttgatgtggccgaag 69 480 155652 Coding 462 351 cctcttcttcttgatgtggc 93 481 155653 Coding 462 356 tccaccctcttcttcttgat 70 482 155654 Coding 462 361 tggcttccaccctcttcttc 72 483 155655 Coding 462 366 cctaatggcttccaccctct 87 484 155656 Coding 462 371 tgtcccctaatggcttccac 73 485 155657 Coding 462 376 agatctgtcccctaatggct 75 486 155658 Coding 462 380 ctcaagatctgtcccctaat 72 487 155659 Coding 462 383 ttgctcaagatctgtcccct 82 488 155660 Coding 462 430 ggacgtgggtcatcaccgtt 85 489 155661 Coding 462 566 atcatgtcgaatttatggat 43 490 155662 Coding 462 572 ccctggatcatgtcgaattt 70 491 155663 Coding 462 653 tccactgaggacacattgaa 90 492 155664 Coding 462 656 ttctccactgaggacacatt 95 493 155665 Coding 462 660 atttttctccactgaggaca 90 494 155666 Coding 462 706 tgggcacccgcaagacccgg 90 495 155667 Coding 462 812 gtgggcagattcttgccacc 0 496 155668 Coding 462 860 cgcacagtgtcagtgacatc 0 497 155669 Coding 462 929 aaggtgtgacatggacagtg 93 498 155670 Coding 462 934 gctgaaaggtgtgacatgga 84 499 155671 Coding 462 939 attgggctgaaaggtgtgac 0 500 155672 Coding 462 944 tctccattgggctgaaaggt 69 501 155673 Coding 462 983 aatttgatttccatcacctc 43 502 155674 Coding 462 1022 tctccacggccatggtcatc 57 503 155675 Coding 462 1163 ttgcggaagcagtaattggt 76 504 155676 Coding 462 1269 tgagcagaagttggcatagt 69 505 155677 Coding 462 1274 gggcctgagcagaagttggc 61 506 155678 Coding 462 1279 ggcaagggcctgagcagaag 50 507 155679 Coding 462 1295 gcactgcggaggtatgggca 50 508 155680 Coding 462 1346 tcagggttcagagtgttgta 50 509 155681 Coding 462 1457 gacttcaccaccatgttgga 37 510 155682 Stop Codon 462 1478 gggtctcagctacatttaca 54 511 155683 3′ UTR 462 1562 agtgaggtttgttgcttgtg 72 512 155684 3′ UTR 462 1619 gaaacctccatctcagccat 59 513 155685 3′ UTR 462 1703 agagttcagccttcctctaa 92 514 155686 3′ UTR 462 1807 ttagggtagcccaaatccca 66 515 155687 3′ UTR 462 1834 agccattctctgcccttcct 90 516 155688 3′ UTR 462 1870 tcagatctgaagtgtcttcc 94 517 155689 3′ UTR 462 1918 tccagattccctagagcaga 72 518 155690 3′ UTR 462 1929 gtataacataatccagattc 0 519 155691 3′ UTR 462 1943 aaaatgcttgccttgtataa 79 520 155692 3′ UTR 462 1979 ctgggactttgtcttcgtaa 95 521 155693 3′ UTR 462 2030 ttgcaaaagtaatagatttg 0 522 155694 3′ UTR 462 2051 ttaattgatgtagaggacag 0 523 155695 3′ UTR 462 2082 ctggattttctccctgtagt 86 524 155696 3′ UTR 462 2093 aactgcatgacctggatttt 7 525 155697 3′ UTR 462 2112 atacagttgatgggccagga 74 526 155698 3′ UTR 462 2126 atccaaaaggcccaatacag 36 527 155699 3′ UTR 462 2151 ccaccctttcttctgcgttc 87 528 155700 3′ UTR 462 2235 gtctaaccaagtgtccaagg 92 529 155701 3′ UTR 462 2280 tgcatggaaccacaatccag 96 530 155702 3′ UTR 462 2292 atgccccaaggctgcatgga 75 531 3 155703 3′ UTR 462 2335 aatgaacacagggtcttgga 87 532 155704 3′ UTR 462 2356 cacctgcttccaggaacacc 87 533 155705 3′ UTR 462 2361 tgtagcacctgcttccagga 28 534 155706 3′ UTR 462 2407 agtcactgtgtggcacatgt 4 535 155707 3′ UTR 462 2456 agtaatattcatacttgtct 23 536 155708 3′ UTR 462 2482 atatttatttatacaaagat 0 537 155709 3′ UTR 462 2534 ctgttctagaaacaatattc 62 538 155710 Intron 466 11878 ctgctggaagcaaaggcagg 0 539 155711 Intron: 466 12956 gaggagttacctggaagagc 0 540 Exon Junction 155712 Intron: 466 13385 gtccacctacctcttctcaa 33 541 Exon Junction 155713 Intron 466 18442 atgccatctacatggttttt 9 542 155714 Intron: 466 21023 ttgtccacgcctgaagaagg 56 543 Exon Junction 155715 Intron: 466 21195 ccagtctcaccggaagcagt 1 544 Exon Junction

[0498] As shown in Table 21, SEQ ID NOs: 467, 468, 469, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 498, 499, 501, 502, 503, 504, 505, 506, 507, 508, 509, 511, 512, 513, 514, 515, 516, 517, 518, 520, 521, 524, 526, 528, 529, 530, 531, 532, 533, 538 and 543 demonstrated at least 40% inhibition of human transforming growth factor-beta 3 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

Example 42

[0499] Treatment Of Angiogenic Disease: Breast Cancer

[0500] Breast carcinoma accounts for the most common type of tumors in women over 40 years age and is a leading cause of death. The beneficial effect on patients with breast cancer with the transforming growth factor beta 3 modulator may be shown in the following clinical trials: In a first clinical trial, 5 patients suffering from metastatic breast carcinoma are studied, who have no previous systemic treatment of metastasis (adjuvant treatment is ignored) and have facile vein access. The patients have PS 0 or 1 and may be post-menopausal. The transforming growth factor beta 3 modulator may be continuously administered parenterally, e.g. s.c. by means of a pump at the rate of e.g. 0.5 to 2 mg per 24 hours, over at least 3 days. The growth factor IGF profile is determined and the levels are found to be reduced.

[0501] A second clinical trial may be effected as follows: In a second trial the transforming growth factor beta 3 modulators are administered to at least 14 patients having breast cancer and the extent and duration of the response are determined.

[0502] Patients are included who have breast cancer as evidenced by histological biopsy (glandular analysis—EOA). They present a metastatic illness and/or loco-regional localization which is measurable and evaluable. If desired, patients are included who are resistant to other treatment to conventional therapy such as surgery, radiotherapy, other chemotherapy and/or hormone therapy.

[0503] The patients present at least one target (identifier), on X-ray analysis, which is measurable or evaluable such as a primitive metastatic tumor which is cutaneous or sub-cutaneous. It may be gangliar or visceral. Preferably the patients have lesions which have progressed within the month preceding the trial and have an estimated survival time of at least 3 month.

[0504] Preferably the trial excludes: patients in which the sole criteria for diagnosing breast cancer are biological modifications; patients administered with an embroynic carcinoma antigen pathology; patients with ascitis, a pleural effusion, a pulmonary carcinoma lymphangitis, or an osseous localization as sole metastatic manifestation; patients treated on a unique tumoral target by radiotherapy less than eight weeks before inclusion in the study (they are eligible however if evidence of progression during this time); patients with a unique cerebral localization; patients presenting another malignant tumor with the exception of a carcinoma in situ in the cervix uteri or a spino- or basocellular skin cancer; and patients not able to attend regular consultations.

[0505] With these exclusions the efficacy of the transforming growth factor beta 3 modulators may be followed more clearly. The transforming growth factor beta 3 modulators may be used in the method of treatment at the invention, however, in treating patients falling in the above exclusion.

[0506] The transforming growth factor beta 3 modulators may be administered at the same dosage as or at a lower dosage than in the first trial, but preferably in two doses, one in the morning and one in the evening. The treatment is for at least 3 months or until complete remission. The response may be followed by conventional methodology, e.g. according to IUCC response criteria, e.g. progression, stabilization, partial or complete remission. The evaluation is effected e.g. on day 0, 15, 45, 60 and 90.

[0507] A third clinical trial may be effected as follows: Patients with advanced breast cancer are included. The patients have progressive disease and measurable and/or evaluable parameters according to criteria of the IUCC (i.e. appearance of new lesions or growth of existing metastatic lesions) not responding to primary hormonal and/or cytotoxic therapy. As in the above indicated second clinical trial, the third trial preferably also excludes patients with previous or concurrent malignancies at other sites, with the exception of cone biopsied in situ carcinoma of the cervix uteri and adequately treated basal or squamous cell carcinoma of the skin.

[0508] The transforming growth factor beta 3 modulators may be administered at the same dosage as or at a lower dosage than in the second trial. Preferably the modulators are administered parenterally, e.g. subcutaneous, particularly in a continuous subcutaneous way by means of a portable syringe pump (infusion pump). Treatment is for at least 2 months or until complete remission. The response may be followed by conventional methodology e.g. according to IUCC response criteria. The evaluation is effected e.g. on day 0, 30 and 60. All lesions are measured at each assessment or when multiple lesions are present, a representative number of 5 lesions may be selected for measurement. Regression of the lesions is the sum of the products of the diameters of each individual lesion or those selected for study, which decreases by 50% or more.

Example 43

[0509] Treatment Of Angiogenic Disease: Melanoma

[0510] In an in vivo test, Meth-A sarcoma and melanoma cells (1.times. 10.sup.6) are inoculated subcutaneously in 0.1 ml saline in the same position of the dorsal skin of C3H mice (n=20). On the same day, the mice receive orally either transforming growth factor beta 3 modulators, at 100 mg per kg in body weight, suspended in 300 uL of olive oil (n=10) or 300 uL olive oil alone (n=10). This treatment is carried out every day and the diameter of the tumors is monitored every second day. On day 12 the mice are sacrificed and the tumor weights are measured.

[0511] Meth-A sarcoma tumor growth in mice treated with transforming growth factor beta 3 modulators is slower than in control mice. The weight (grams) of both the Meth-A sarcoma and melanoma tumors on day 12 is measured, and the mice treated with transforming growth factor beta 3 modulators have lower tumor mass. In a small number of control and 2-methoxyestradiol mice, the dorsal skin, together with the tumor, are excised and the angiogenesis within the subcutaneous fascia in the control and treated mice is visualized with Indian ink. Apart from their marginally lower weight, the treated mice exhibit no apparent signs of toxicity and are all alive after 12 days of daily treatment. Transforming growth factor beta 3 modulators thus has potent pharmacological properties which may be applied in the treatment angiogenic diseases, including solid tumors.

Example 44

[0512] Methods Of Inhibiting Angiogenesis

[0513] Angiogenesis is the growth of new blood vessels (veins & arteries) by endothelial cells. This process is important in the development of a number of human diseases, and is believed to be particularly important in regulating the growth of solid tumors. Without new vessel formation it is believed that tumors will not grow beyond a few millimeters in size. In addition to their use as anti-cancer agents, modulators of angiogenesis have potential for the treatment of diabetic retinopathy, cardiovascular disease, rheumatoid arthritis and psoriasis.

[0514] During the process of angiogenesis, endothelial cells perform several distinct functions, including the degradation of the extracellular matrix (ECM), migration, proliferation and the formation of tube-like structures. Various genes may regulate some of these processes in primary human umbilical vein endothelial cells (HUVECs). The below experiments employed an antisense compound as a transforming growth factor beta 3 modulators. The antisense compound comprises ISIS NO. 155701 (SEQ ID NO: 530).

Example 45

[0515] Gene Function Analysis—Matrix Metalloproteinase Assay to Determine the Effect of Modulating Transforming Growth Factor-Beta 3 on the Process of Angiogenesis

[0516] During angiogenesis, endothelial cells need to be able to degrade the extracellular matrix so they can migrate and form new vessels. Endothelial cells secrete matrix metalloproteinases (MMPs) in order to accomplish this degradation. MMPs are a family of zinc-dependent endopeptidases that fall into eight distinct classes: five are secreted and three are membrane-type MMPs (MT-MMPs). MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth-factor-binding proteins, growth-factor precursors, receptor tyrosine kinases, cell-adhesion molecules and other proteinases. In this assay the activity of MMPs secreted into the media above antisense oligonucleotide-treated HUVECs is measured.

[0517] MMP activity in the media above HUVECs is measured using the EnzChek Gelatinase/Collagenase Assay Kit (Molecular Probes, Eugene, Oreg.). HUVECs are plated at 3000 cells/well in 96-well plates. One day later, cells are transfected with antisense oligonucleotides according to standard published procedures (Monia et al., (1 993) J Biol Chem. Jul. 5, 1993;268(19):14514-22) with 75 nM oligonucleotide in LIPOFECTIN™ (Gibco, Grand Island, N.Y.). Antisense oligonucleotides are tested in triplicate on each 96-well plate, except for positive and negative antisense controls, which are measured up to six times per plate. Twenty hours post-transfection, MMP production is stimulated by the addition of recombinant human vascular endothelial growth factor (VEGF). Fifty hours post-transfection, a p-aminophenylmercuric acetate (APMA; Sigma-Aldrich, St. Louis, Mo.) solution is added to each well of a Corning-Costar 96-well clear bottom plate (VWR International, Brisbane, Calif.). The APMA solution is used to promote cleavage of inactive MMP precursor proteins (Nagase et al., (1991) Biomed Biochim Acta, 50(4-6):749-54). Medium above the HUVECs is then transferred to the wells. After 30 minutes, the quenched, fluorogenic MMP cleavage substrate is added, and baseline fluorescence is read immediately at 485 nm exitation/530 nm emission. Following an overnight incubation at 37° C. in the dark, plates are read again to determine the amount of fluorescence, which corresponds to MMP activity. Total protein from HUVEC lysates is used to normalize the readings, and MMP activities±standard deviation are expressed relative to transfectant-only controls.

[0518] The modulators caused a 52% reduction of MMP activity, as compared to MMP activity in lipid-treated cells. Thus, it is shown that transforming growth factor beta 3 modulators can prevent angiogenesis.

Example 46

[0519] Gene Function Analysis—Endothelial Tube Formation Assay to Determine the Effect of Modulating Transforming Growth Factor-Beta 3 on the Process of Angiogenesis

[0520] Angiogenesis is stimulated by numerous factors that promote interaction of endothelial cells with each other and with extracellular matrix molecules, resulting in the formation of capillary tubes. This morphogenic process is necessary for the delivery of oxygen to nearby tissues and plays an essential role in embryonic development, wound healing, and tumor growth. Moreover, this process can be reproduced in tissue culture by the formation of tube-like structures by endothelial cells. There are several different variations of the assay that use different matrices, such as collagen I (Kanayasu, 1991), Matrigel (Yamagishi, 1997) and fibrin (Bach, 1998) as growth substrates for the cells. In this assay, HUVECs are plated on a matrix derived from the Engelbreth-Holm-Swarm mouse tumor, which is very similar to Matrigel (Kleinman, 1986; Madri, 1986). Untreated HUVECs form tube-like structures when grown on this substrate. Loss of tube formation in-vitro has been correlated with the inhibition of angiogenesis in-vivo (Carmeliet et al., (2000) Nature 407:249-257; and Zhang et al., (2002) Cancer Research 62:2034-42), which supports the use of in-vitro tube formation as an endpoint for angiogenesis.

[0521] The Tube Formation Assay is performed using an In-vitro Angiogenesis Assay Kit (Chemicon International, Temecula, Calif.), or growth factor reduced Mortigel (BD Biosciences, Bedford, Mass.). Cells are plated and transfected with transforming growth factor beta 3 modulators (antisense oligonucleotides) as described for the MMP activity assay, except cells are plated at 4000 cells/well. Fifty hours post-transfection, cells are transferred to 96-well plates coated with ECMatrix™ (Chemicon International) or growth factor depleted matrigel. Under these conditions, untreated HUVECs form tube-like structures. After an overnight incubation at 37° C., treated and untreated cells are inspected by light microscopy. Individual wells are assigned discrete scores from 1 to 5 depending on the extent of tube formation. A score of 1 refers to a well with no tube formation while a score of 5 is given to wells where all cells are forming an extensive tubular network.

[0522] As calculated from the assigned discreet scores, cells treated with transforming growth factor beta 3 modulators had a tube formation score reduction of about 60% as compared to lipid-treated cells. Thus, it is shown that transforming growth factor beta 3 modulators can inhibit angiogenesis.

Example 47

[0523] Gene Function Analysis—Measurement of RNA Expression Levels of Angiogenic Genes to Determine the Effect of Modulating Transforming Growth Factor-Beta 3 on the Process of Angiogenesis

[0524] Endothelial cells must regulate the expression of many genes in order to perform the functions necessary for angiogenesis. This gene regulation has been the subject of intense scrutiny, and many genes have been identified as being important for the angiogenic phenotype. The expression levels of four genes, previously identified as being highly expressed in angiogenic endothelial cells, is measured here (Integrin beta 3, endoglin/CD105, TEM5 and MMP-14/MT-MMP1).

[0525] Integrin beta 3 is part of a family of heterodimeric transmembrane receptors that consist of alpha and beta subunits. Each subunit recognizes a unique set of ECM ligands, thereby allowing cells to transmit angiogenic signals from the extracellular matrix. Integrin beta 3 is prominently expressed on proliferating vascular endothelial cells, and it plays roles in allowing new blood vessels to form at tumor sites as well as allowing the epithelial cells of breast tumors to spread. Blockage of Integrin alpha 3 with monoclonal antibodies or low molecular weight antagonists inhibits blood vessel formation in a variety of in-vivo models, including tumor angiogenesis and neovascularization during oxygen-induced retinopathy.

[0526] Endoglin is a Transforming Growth Factor receptor-associated protein highly expressed on endothelial cells, and present on some leukemia cells and minor subsets of bone marrow cells. Its expression is upregulated in endothelial cells of angiogenic tissues and is therefore used as a prognostic indicator in various tumors. Endoglin functions as an ancillary receptor influencing binding of the Transforming Growth Factor beta (TGF-beta) family of ligands to signaling receptors, thus mediating cell survival. Mutations of the endoglin gene result in a genetic disease of the vasculature-Hereditary Haemorrhagic Telangiectasia (HHT), which is characterized by bleeding from malformed blood vessels. Defective signaling by different TGF-beta ligands and receptors is thought to be involved.

[0527] Tumor endothelial marker 5 (TEM5) is a putative 7-pass transmembrane protein (GPCR) for which EST sequence but no other information is available. The mRNA transcript, designated KIAA1531, encodes one of many tumor endothelium markers (TEMs) that display elevated expression (greater than 10-fold) during tumor angiogenesis. TEM5 is coordinately expressed with other TEMs on tumor endothelium in humans and mice.

[0528] MMP-14, a membrane-type MMP (MT-MMP) covalently linked to the cell membrane, is involved in matrix detachment and migration. MMP-14 is thought to promote tumor angiogenesis; antibodies directed against the catalytic domain of MMP-14 block endothelial-cell migration, invasion and capillary tube formation in-vitro. MMP-14 can degrade the fibrin matrix that surrounds newly formed vessels potentially allowing the endothelial cells to invade further into the tumor tissue. MMP-14 null mice have impaired angiogenesis during development, further demonstrating the role of MMP-14 in angiogenesis.

[0529] Cells are plated and transfected as described for the MMP activity assay. Twenty hours post-transfection, cells are stimulated with recombinant human VEGF. Total RNA is harvested 52 hours post-transfection, and the amount of total RNA from each sample is determined using a Ribogreen Assay (Molecular Probes, Eugene, Oreg.). Real-time PCR is performed on the total RNA using primer/probe sets for four Angiogenic Hallmark Genes: integrin beta 3, endoglin, Tumor endothelial marker 5 (TEM5) and Matrix Metalloproteinase 14 (MMP14/MTI-MMP). Expression levels for each gene are normalized to total RNA, and values are expressed relative to controls.

[0530] Cells treated with transforming growth factor beta 3 modulators had the following mRNAs reduced as compared to mRNAs of the controls: Integrin beta 3 mRNA was 88% of the control, endoglin mRNA was 74% of the control, TEM5 mRNA was 91% of the control, and MMP14/MT1-MMP was 86% of the control.

Example 48

[0531] Antisense Inhibition Of Human Apolipoprotein B mRNA Expression by Chimeric Phosphorothioate Oligonucleotides having 2′-Moe Wings and a Deoxy Gap

[0532] Lipoproteins are globular, micelle-like particles that consist of a non-polar core of acylglycerols and cholesteryl esters surrounded by an amphiphilic coating of protein, phospholipid and cholesterol. Apolipoprotein B is a large glycoprotein that serves an indispensable role in the assembly and secretion of lipids and in the transport and receptor-mediated uptake and delivery of distinct classes of lipoproteins. Elevated plasma levels of the ApoB-100-containing lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, which may include hypercholesterolemia, myocardial infarction, and thrombosis.

[0533] Oligonucleotides targeting human apolipoprotein B were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0534] Probes and primers to human apolipoprotein B were designed to hybridize to a human apolipoprotein B sequence, using published sequence information (GenBank accession number NM_(—)000384.1, incorporated herein as SEQ ID NO: 545). For human apolipoprotein B the PCR primers were: forward primer:

[0535] TGCTAAAGGCACATATGGCCT (SEQ ID NO: 546) reverse primer:

[0536] CTCAGGTTGGACTCTCCATTGAG (SEQ ID NO: 547) and the PCR probe was: FAM-CTTGTCAGAGGGATCCTAACACTGGCCG-TAMRA (SEQ ID NO: 548) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0537] The series of oligonucleotides was designed to target different regions of the human apolipoprotein B RNA, using published sequence information (GenBank accession number NM_(—)000384.1, incorporated herein as SEQ ID NO: 545). The oligonucleotides are shown in Table 22. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 22 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described on other examples herein. Data are averages from two experiments in which HepG2 cells were cultured and treated with oligonucleotides 147780-147833 (SEQ ID NOs: 549-602) according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data”. TABLE 22 Inhibition Of Human Apolipoprotein B mRNA Levels By Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap TARGET ISIS # REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO 147780 5′ UTR 545 1 ccgcaggtcccggtgggaat 40 549 147781 5′ UTR 545 21 accgagaagggcactcagcc 35 550 147782 5′ UTR 545 71 gcctcggcctcgcggccctg 67 551 147783 Start Codon 545 114 tccatcgccagctgcggtgg N.D. 552 147784 Coding 545 151 cagcgccagcagcgccagca 70 553 147785 Coding 545 181 gcccgccagcagcagcagca 29 554 147786 Coding 545 321 cttgaatcagcagtcccagg 34 555 147787 Coding 545 451 cttcagcaaggctttgccct N.D. 556 147788 Coding 545 716 tttctgttgccacattgccc 95 557 147789 Coding 545 911 ggaagaggtgttgctccttg 24 558 147790 Coding 545 951 tgtgctaccatcccatactt 33 559 147791 Coding 545 1041 tcaaatgcgaggcccatctt N.D. 560 147792 Coding 545 1231 ggacacctcaatcagctgtg 26 561 147793 Coding 545 1361 tcagggccaccaggtaggtg N.D. 562 147794 Coding 545 1561 gtaatcttcatccccagtgc 47 563 147795 Coding 545 1611 tgctccatggtttggcccat N.D. 564 147796 Coding 545 1791 gcagccagtcgcttatctcc 8 565 147797 Coding 545 2331 gtatagccaaagtggtccac N.D. 566 147798 Coding 545 2496 cccaggagctggaggtcatg N.D. 567 147799 Coding 545 2573 ttgagcccttcctgatgacc N.D. 568 147800 Coding 545 2811 atctggaccccactcctagc N.D. 569 147801 Coding 545 2842 cagacccgactcgtggaaga 38 570 147802 Coding 545 3367 gccctcagtagattcatcat N.D. 571 147803 Coding 545 3611 gccatgccaccctcttggaa N.D. 572 147804 Coding 545 3791 aacccacgtgccggaaagtc N.D. 573 147805 Coding 545 3841 actcccagatgccttctgaa N.D. 574 147806 Coding 545 4281 atgtggtaacgagcccgaag 100 575 147807 Coding 545 4391 ggcgtagagacccatcacat 25 576 147808 Coding 545 4641 gtgttaggatccctctgaca N.D. 577 147809 Coding 545 5241 cccagtgatagctctgtgag 60 578 147810 Coding 545 5355 atttcagcatatgagcccat 0 579 147811 Coding 545 5691 ccctgaaccttagcaacagt N.D. 580 147812 Coding 545 5742 gctgaagccagcccagcgat N.D. 581 147813 Coding 545 5891 acagctgcccagtatgttct N.D. 582 147814 Coding 545 7087 cccaataagatttataacaa 34 583 147815 Coding 545 7731 tggcctaccagagacaggta 45 584 147816 Coding 545 7841 tcatacgtttagcccaatct 100 585 147817 Coding 545 7901 gcatggtcccaaggatggtc 0 586 147818 Coding 545 8491 agtgatggaagctgcgatac 30 587 147819 Coding 545 9181 atgagcatcatgcctcccag N.D. 588 147820 Coding 545 9931 gaacacatagccgaatgccg 100 589 147821 Coding 545 10263 gtggtgccctctaatttgta N.D. 590 147822 Coding 545 10631 cccgagaaagaaccgaaccc N.D. 591 147823 Coding 545 10712 tgccctgcagcttcactgaa 19 592 147824 Coding 545 11170 gaaatcccataagctcttgt N.D. 593 147825 Coding 545 12301 agaagctgcctcttcttccc 72 594 147826 Coding 545 12401 tcagggtgagccctgtgtgt 80 595 147827 Coding 545 12471 ctaatggccccttgataaac 13 596 147828 Coding 545 12621 acgttatccttgagtccctg 12 597 147829 Coding 545 12741 tatatcccaggtttccccgg 64 598 147830 Coding 545 12801 acctgggacagtaccgtccc N.D. 599 147831 3′ UTR 545 13921 ctgcctactgcaaggctggc 0 600 147832 3′ UTR 545 13991 agagaccttccgagccctgg N.D. 601 147833 3′ UTR 545 14101 atgatacacaataaagactc 25 602

[0538] As shown in Table 22, SEQ ID NOs: 549, 550, 551, 553, 555, 557, 559, 563, 570, 575, 578, 583, 584, 585, 587, 589, 594, 595 and 598 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention. As apolipoprotein B exists in two forms in mammals (ApoB-48 and ApoB-100) which are colinear at the amino terminus, antisense oligonucleotides targeting nucleotides 1-6530 hybridize to both forms, while those targeting nucleotides 6531-14121 are specific to the long form of apolipoprotein B.

Example 49

[0539] Antisense Inhibition of Human Apolipoprotein B mRNA Expression by Chimeric Phosphorothioate Oligonucleotides having 2′-Moe Wings and a Deoxy Gap-Dose Response Study

[0540] In accordance with the present invention, a subset of the antisense oligonucleotides in Example 48 were further investigated in dose-response studies. Treatment doses were 50, 150 and 250 nM. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two-experiments and are shown in Table 23. TABLE 23 Inhibition of Human Apolipoprotein B mRNA Levels By Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap Percent Inhibition ISIS # 50 nM 150 nM 250 nM 147788 54 63 72 147806 23 45 28 147816 25 81 65 147820 10 0 73

Example 50

[0541] Antisense Inhibition of Mouse Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides having 2′-Moe Wings and a Deoxy Gap

[0542] Oligonucleotides targeting mouse apolipoprotein B were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0543] Probes and primers to mouse apolipoprotein B were designed to hybridize to a mouse apolipoprotein B sequence, using published sequence information (GenBank accession number M35186.1, incorporated herein as SEQ ID NO: 603). For mouse apolipoprotein B the PCR primers were: forward primer: CGTGGGCTCCAGCATTCTA (SEQ ID NO: 604) reverse primer: AGTCATTTCTGCCTTTGCGTC (SEQ ID NO: 605) and the PCR probe was: FAM-CCAATGGTCGGGCACTGCTCAA-TAMRA (SEQ ID NO: 606) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0544] The series of oligonucleotides was designed to target different regions of the mouse apolipoprotein B RNA, using published sequence information (GenBank accession number M35186.1, incorporated herein as SEQ ID NO: 603). The oligonucleotides are shown in Table 24. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 24 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse apolipoprotein B mRNA levels in primary hepatocytes by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which AML12 cells were cultured and treated with oligonucleotides 147475-147778 (SEQ ID NOs: 607-659) according to the protocol outlined in Example 34. If present, “N.D.” “no data”. TABLE 24 Inhibition of Mouse Apolipoprotein B mRNA Levels by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap TARGET ISIS # REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO 147475 Coding 603 13 attgtatgtgagaggtgagg 79 607 147476 Coding 603 66 gaggagattggatcttaagg 13 608 147477 Coding 603 171 cttcaaattgggactctcct N.D. 609 147478 Coding 603 211 tccaggaattgagcttgtgc 78 610 147479 Coding 603 238 ttcaggactggaggatgagg N.D. 611 147480 Coding 603 291 tctcaccctcatgctccatt 54 612 147481 Coding 603 421 tgactgtcaagggtgagctg 24 613 147482 Coding 603 461 gtccagcctaggaacactca 59 614 147483 Coding 603 531 atgtcaatgccacatgtcca N.D. 615 147484 Coding 603 581 ttcatccgagaagttgggac 49 616 147485 Coding 603 601 atttgggacgaatgtatgcc 64 617 147486 Coding 603 711 agttgaggaagccagattca N.D. 618 147487 Coding 603 964 ttcccagtcagctttagtgg 73 619 147488 Coding 603 1023 agcttgcttgttgggcacgg 72 620 147489 Coding 603 1111 cctatactggcttctatgtt 5 621 147490 Coding 603 1191 tgaactccgtgtaaggcaag N.D. 622 147491 Coding 603 1216 gagaaatccttcagtaaggg 71 623 147492 Coding 603 1323 caatggaatgcttgtcactg 68 624 147493 Coding 603 1441 gcttcattataggaggtggt 41 625 147494 Coding 603 1531 acaactgggatagtgtagcc 84 626 147495 Coding 603 1631 gttaggaccagggattgtga 0 627 147496 Coding 603 1691 accatggaaaactggcaact 19 628 147497 Coding 603 1721 tgggaggaaaaacttgaata N.D. 629 147498 Coding 603 1861 tgggcaacgatatctgattg 0 630 147499 Coding 603 1901 ctgcagggcgtcagtgacaa 29 631 147500 Coding 603 1932 gcatcagacgtgatgttccc N.D. 632 147501 Coding 603 2021 cttggttaaactaatggtgc 18 633 147502 Coding 603 2071 atgggagcatggaggttggc 16 634 147503 Coding 603 2141 aatggatgatgaaacagtgg 26 635 147504 Coding 603 2201 atcaatgcctcctgttgcag N.D. 636 147505 Coding 603 2231 ggaagtgagactttctaagc 76 637 147506 Coding 603 2281 aggaaggaactcttgatatt 58 638 147507 Coding 603 2321 attggcttcattggcaacac 81 639 147759 Coding 603 1 aggtgaggaagttggaattc 19 640 147760 Coding 603 121 ttgttccctgaagttgttac N.D. 641 147761 Coding 603 251 gttcatggattccttcagga 45 642 147762 Coding 603 281 atgctccattctcacatgct 46 643 147763 Coding 603 338 tgcgactgtgtctgatttcc 34 644 147764 Coding 603 541 gtccctgaagatgtcaatgc 97 645 147765 Coding 603 561 aggcccagttccatgaccct 59 646 147766 Coding 603 761 ggagcccacgtgctgagatt 59 647 147767 Coding 603 801 cgtccttgagcagtgcccga 5 648 147768 Coding 603 1224 cccatatggagaaatccttc 24 649 147769 Coding 603 1581 catgcctggaagccagtgtc 89 650 147770 Coding 603 1741 gtgttgaatcccttgaaatc 67 651 147771 Coding 603 1781 ggtaaagttgcccatggctg 68 652 147772 Coding 603 1841 gttataaagtccagcattgg 78 653 147773 Coding 603 1931 catcagacgtgatgttccct 85 654 147774 Coding 603 1956 tggctagtttcaatcccctt 84 655 147775 Coding 603 2002 ctgtcatgactgccctttac 52 656 147776 Coding 603 2091 gcttgaagttcattgagaat 92 657 147777 Coding 603 2291 ttcctgagaaaggaaggaac N.D. 658 147778 Coding 603 2331 tcagatatacattggcttca 14 659

[0545] As shown in Table 24, SEQ ID NOs: 607, 610, 612, 614, 617, 619, 620, 623, 624, 626, 637, 638, 639, 645, 646, 647, 650, 651, 652, 653, 654, 655, 656 and 657 demonstrated at least 50% inhibition of mouse apolipoprotein B expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

Example 51

[0546] Antisense Inhibition of Mouse Apolipoprotein B mRNA Expression by Chimeric Phosphorothioate Oligonucleotides having 2′-Moe Wings and a Deoxy Gap-Dose Response Study

[0547] In accordance with the present invention, a subset of the antisense oligonucleotides in Example 50 were further investigated in dose-response studies. Treatment doses were 50, 150 and 300 nM. The compounds were analyzed for their effect on mouse apolipoprotein B mRNA levels in mouse primary hepatocytes by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 25. TABLE 25 Inhibition of Mouse Apolipoprotein B mRNA Levels by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap Percent Inhibition ISIS # 50 nM 150 nM 300 nM 147483 56 88 89 147764 48 84 90 147769 3 14 28 147776 0 17 44

Example 52

[0548] Target Validation—Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) in C57BL/6 Mice: Lean Animals vs. High Fat Fed Animals

[0549] C57BL/6 mice, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation were used in the following studies to evaluate antisense oligonucleotides as potential lipid lowering compounds in lean versus high fat fed mice.

[0550] Male C57BL/6 mice were divided into two matched groups; (1) wild-type control animals (lean animals) and (2) animals receiving a high fat diet (60% kcal fat). Control animals received saline treatment and were maintained on a normal rodent diet. After overnight fasting, mice from each group were dosed intraperitoneally every three days with saline or 50 mg/kg ISIS 147764 (SEQ ID NO: 645) for six weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, liver enzyme levels and serum glucose levels. The results of the comparative studies are shown in Table 26. TABLE 26 Effects of ISIS 147764 Treatment On Apolipoprotein B mRNA, Cholesterol, Lipid, Triglyceride, Liver Enzyme And Glucose Levels in Lean and High Fat Mice. Percent Change Treatment Lipoproteins Liver Enzymes Group MRNA CHOL VLDL LDL HDL TRIG AST ALT GLUC Lean-control −73 −63 No −64 −44 −34 Slight No change No change change decrease High Fat −87 −67 No −87 −65 No change Slight Slight −28 Group change decrease increase

[0551] It is evident from these data that treatment with ISIS 147764 lowered cholesterol as well as LDL and HDL lipoproteins and serum glucose in both lean and high fat mice and that the effects demonstrated are, in fact, due to the inhibition of apolipoprotein B expression as supported by the decrease in mRNA levels. No significant changes in liver enzyme levels were observed, indicating that the antisense oligonucleotide was not toxic to either treatment group.

Example 53

[0552] Target Validation—Effects Of Antisense Inhibition Of Apolipoprotein B (ISIS 147764) on High Fat Fed Mice; 6 Week Timecourse Study

[0553] A 6-week timecourse study was performed to further investigate the effects of ISIS 147764 on lipid and glucose metabolism in high fat fed mice.

[0554] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of treatment with the antisense oligonucleotide, ISIS 147764. Control animals received saline treatment (50 mg/kg). A subset of animals received a daily oral dose (20 mg/kg) atorvastatin calcium (Lipitor®, Pfizer Inc.). All mice, except atorvastatin-treated animals, were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks. Serum cholesterol and lipoproteins were analyzed at 0, 2 and 6 week interim timepoints. At study termination, animals were sacrificed 48 hours after the final injections and evaluated for levels of target mRNA levels in liver, cholesterol, lipoprotein, triglyceride, liver enzyme (AST and ALT) and serum glucose levels as well as body, liver, spleen and fat pad weights.

Example 54

[0555] Target Validation—Effects Of Antisense Inhibition of Apolipoprotein B (ISIS 147764) In High Fat Fed Mice-mRNA Expression in Liver

[0556] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on mRNA expression. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks. At study termination, animals were sacrificed 48 hours after the final injections and evaluated for levels of target mRNA levels in liver. ISIS 147764 showed a dose-response effect, reducing mRNA levels by 15, 75 and 88% at doses of 5, 25 and 50 mg/kg, respectively.

Example 55

[0557] Target Validation—Effects Of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Serum Cholesterol and Triglyceride Levels

[0558] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on serum cholesterol and triglyceride levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks.

[0559] Serum cholesterol levels were measured at 0, 2 and 6 weeks and this data is shown in Table 27. Values in the table are expressed as percent inhibition and are normalized to the saline control.

[0560] In addition to serum cholesterol, at study termination, animals were sacrificed 48 hours after the final injections and evaluated for triglyceride levels.

[0561] Mice treated with ISIS 147764 showed a reduction in both serum cholesterol (240 mg/dL for control animals and 225, 125 and 110 mg/dL for doses of 5, 25, and 50 mg/kg, respectively) and triglycerides (115 mg/dL for control animals and 125, 150 and 85 mg/dL for doses of 5, 25, and 50 mg/kg, respectively) to normal levels by study end.

[0562] These data were also compared to the effects of atorvastatin calcium at an oral dose of 20 mg/kg which showed only a minimal decrease in serum cholesterol of 20 percent at study termination. TABLE 27 Percent Inhibition of Mouse Apolipoprotein B Cholesterol Levels by ISIS 147764 Percent Inhibition time Saline 5 mg/kg 25 mg/kg 50 mg/kg 0 weeks 0 0 0 0 2 weeks 0 5 12 20 6 weeks 0 10 45 55

Example 56

[0563] Target Validation—Effects Of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Lipoprotein Levels

[0564] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on lipoprotein (VLDL, LDL and HDL) levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks.

[0565] Lipoprotein levels were measured at 0, 2 and 6 weeks and this data is shown in Table 28. Values in the table are expressed as percent inhibition and are normalized to the saline control. Negative values indicate an observed increase in lipoprotein levels.

[0566] These data were also compared to the effects of atorvastatin calcium at a daily oral dose of 20 mg/kg at 0, 2 and 6 weeks.

[0567] These data demonstrate that at a dose of 50 mg/kg, ISIS 147764 is capable of lowering all categories of serum lipoproteins investigated to a greater extent than atorvastatin. TABLE 28 Percent Inhibition of Mouse Apolipoprotein B Lipoprotein Levels by ISIS 147764 as Compared to Atorvastatin Percent Inhibition Dose Lipo- Time 5 25 50 atorvastatin protein (weeks) Saline mg/kg mg/kg mg/kg (20 mg/kg) VLDL 0 0 0 0 0 0 2 0 25 30 40 15 6 0 10 −30 15 −5 LDL 0 0 0 0 0 0 2 0 −30 10 40 10 6 0 −10 55 90 −10 HDL 0 0 0 0 0 0 2 0 5 10 10 15 6 0 10 45 50 20

Example 57

[0568] Target Validation—Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Serum AST and ALT Levels

[0569] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on liver enzyme (AST and ALT) levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks.

[0570] AST and ALT levels were measured at 6 weeks and this data is shown in Table 29. Values in the table are expressed as IU/L. Increased levels of the liver enzymes ALT and AST indicate toxicity and liver damage.

[0571] Mice treated with ISIS 147764 showed no significant change in AST levels over the duration of the study compared to saline controls (105, 70 and 80 IU/L for doses of 5, 25 and 50 mg/kg, respectively compared to 65 IU/L for saline control). Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had AST levels of 85 IU/L.

[0572] ALT levels were increased by all treatments over the duration of the study compared to saline controls (50, 70 and 100 IU/L for doses of 5, 25 and 50 mg/kg, respectively compared to 25 IU/L for saline control). Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had AST levels of 40 IU/L.

Example 58

[0573] Target Validation—Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Serum Glucose Levels

[0574] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on serum glucose levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks.

[0575] At study termination, animals were sacrificed 48 hours after the final injections and evaluated for serum glucose levels. ISIS 147764 showed a dose-response effect, reducing serum glucose levels to 225, 190 and 180 mg/dL at doses of 5, 25 and 50 mg/kg, respectively compared to the saline control of 300 mg/dL. Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had serum glucose levels of 215 mg/dL. These data demonstrate that ISIS 147764 is capable of reducing serum glucose levels in high fat fed mice.

Example 59

[0576] Target Validation—Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Body, Spleen, Liver and Fat Pad Weight

[0577] Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on body, spleen, liver and fat pad weight. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID NO: 645) or saline (50 mg/kg) for six weeks.

[0578] At study termination, animals were sacrificed 48 hours after the final injections and body, spleen, liver and fat pad weights were measured. These data are shown in Table 29. Values are expressed as percent change in body weight or organ weight compared to the saline-treated control animals. Data from mice treated with atorvastatin at a daily dose of 20 mg/kg are also shown in the table. Negative values indicated a decrease in weight. TABLE 29 Effects of Antisense Inhibition of Mouse Apolipoprotein B on Body and Organ Weight Percent Change Dose Atorvastatin Tissue 5 mg/kg 25 mg/kg 50 mg/kg 20 mg/kg Total Body 5 5 −4 1 Wt. Spleen 10 10 46 10 Liver 18 70 80 15 Fat 10 6 −47 7

[0579] These data show a decrease in fat over the dosage range of ISIS 147764 counterbalanced by an increase in both spleen and liver weight with increased dose to give an overall decrease in total body weight.

Example 60

[0580] Target Validation—Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) in b6.129p-apoe^(tm1unc) Knockout Mice: Lean Animals vs. High Fat-Fed Animals

[0581] B6.129P-ApoE^(tm1Unc) knockout mice (herein referred to as ApoE knockout mice) obtained from The Jackson Laboratory (Bar Harbor, Me.), are homozygous for the Apoe^(tm1Unc) mutation and show a marked increase in total plasma cholesterol levels that are unaffected by age or sex. These animals present with fatty streaks in the proximal aorta at 3 months of age. These lesions increase with age and progress to lesions with less lipid but more elongated cells, typical of a more advanced stage of pre-atherosclerotic lesion.

[0582] The mutation in these mice resides in the apolipoprotein E (ApoE) gene. The primary role of the ApoE protein is to transport cholesterol and triglycerides throughout the body. It stabilizes lipoprotein structure, binds to the low density lipoprotein receptor (LDLR) and related proteins, and is present in a subclass of HDLs, providing them the ability to bind to LDLR. ApoE is expressed most abundantly in the liver and brain.

[0583] Female B6.129P-Apoe^(tm1Unc) knockout mice (ApoE knockout mice) were used in the following studies to evaluate antisense oligonucleotides as potential lipid lowering compounds.

[0584] Female ApoE knockout mice ranged in age from 5 to 7 weeks and were placed on a normal diet for 2 weeks before study initiation. ApoE knockout mice were then fed ad libitum a 60% fat diet, with 0.15% added cholesterol to induce dyslipidemia and obesity. Control animals were maintained on a high-fat diet with no added cholesterol. After overnight fasting, mice from each group were dosed intraperitoneally every three days with saline, 50 mg/kg of a control antisense oligonucleotide (ISIS 29837 TCGATCTCCTTTTATGCCCG; SEQ ID NO. 660) or 5, 25 or 50 mg/kg ISIS 147764 (SEQ ID NO: 645) for six weeks.

[0585] The control oligonucleotide is a chimeric oligonucleotide (“gapmer”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines.

[0586] At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver by RT-PCR methods verified by Northern Blot analysis, glucose levels, cholesterol and lipid levels by HPLC separation methods and triglyceride and liver enzyme levels (performed by LabCorp Preclinical Services; San Diego, Calif.). Data from ApoE knockout mice treated with atorvastatin at a daily dose of 20 mg/kg are also shown in the table for comparison.

[0587] The results of the comparative studies are shown in Table 29. Data are normalized to saline controls. TABLE 30 Effects of ISIS 147764 Treatment on Apolipoprotein B mRNA, Cholesterol, Glucose, Lipid, Triglyceride and Liver Enzyme Levels in Apoe Knockout Mice. Percent Inhibition Dose atorvastatin (20 Control 5 mg/kg 25 mg/kg 50 mg/kg mg/kg) mRNA 0 2 42 70 10 Glucose Levels (mg/dL) Glucose 225 195 209 191 162 Cholesterol Levels (mg/dL) Cholesterol 1750 1630 1750 1490 938 Lipoprotein Levels (mg/dL) Lipoprotein HDL 51 49 62 61 42 LDL 525 475 500 325 250 VLDL 1190 1111 1194 1113 653 Liver Enzyme Levels (IU/L) Liver Enzymes AST 55 50 60 85 75 ALT 56 48 59 87 76

[0588] It is evident from these data that treatment with ISIS 147764 lowered glucose and cholesterol as well as all lipoproteins investigated (HDL, LDL and VLDL) in ApoE knockout mice. Further, these decreases correlated with a decrease in both protein and RNA levels of apolipoprotein B, demonstrating an antisense mechanism of action. No significant changes in liver enzyme levels were observed, indicating that the antisense oligonucleotide was not toxic to either treatment group.

Example 61

[0589] Antisense Inhibition of Human BH3 Interacting Domain Death Agonist mRNA Expression by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap

[0590] The Bcl-2 family of proteins, which includes both positive and negative regulators of apoptosis, act as checkpoints upstream of activated protease cascades orchestrated by caspases and are required for all aspects of cell death. BH3 interacting domain death agonist is a member of the Bcl-2 family and has been shown to dimerize with either Bcl-2, a cell death antagonist, or Bax, a cell death agonist. Due to the integral role played by BH3 interacting domain death agonist in apoptosis, the pharmacological modulation of BH3 interacting domain death agonist activity and/or expression may therefore be an appropriate point of therapeutic intervention in pathological conditions involving deregulated cell death.

[0591] Oligonucleotides targeting human BH3 interacting domain death agonist were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0592] Probes and primers to human BH3 Interacting domain death agonist were designed to hybridize to a human BH3 Interacting domain death agonist sequence, using published sequence information (GenBank accession number NM_(—)001196.1, incorporated herein as SEQ ID NO: 661). For human BH3 Interacting domain death agonist the PCR primers were: forward primer: AGAAGACATCATCCGGAATATTGC (SEQ ID NO: 662) reverse primer: GGAGGGATGCTACGGTCCAT (SEQ ID NO: 663) and the PCR probe was: FAM-AGGCACCTCGCCCAGGTCGG-TAMRA (SEQ ID NO: 664) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0593] The series of oligonucleotides was designed to target different regions of the human BH3 Interacting domain death agonist RNA, using published sequences (GenBank accession number NM_(—)001196.1, incorporated herein as SEQ ID NO: 661, and residues 12001-28000 of GenBank accession number AC006285, incorporated herein as SEQ ID NO: 665). The oligonucleotides are shown in Table 31. “Target site” indicates the first (5=-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 31 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human BH3 Interacting domain death agonist mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which T-24 cells were cultured as described in Section 15 (15. Cell Lines for Assaying Oligonucleotide Activity) and treated with oligonucleotides 119845-119922 (SEQ ID NOs: 666-743) according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data”. TABLE 31 Inhibition of Human BH3 Interacting Domain Death Agonist mRNA Levels by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap TARGET ISIS # REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO 119845 Coding 661 354 ctttcagaatctgcctctat 67 666 119846 Coding 661 707 agtccatcccatttctggct 74 667 119847 5′ UTR 665 60 actgtggtgagtctcccacc 88 668 119848 5′ UTR 665 2083 agtgtcccagtggcgacctg 90 669 119849 Coding 665 2134 cacagtccatggcctgggca 98 670 119850 Intron 665 3582 ctccgcttcctcactccgaa 84 671 119851 Intron 665 3845 tactcgggaggctgaggcag 88 672 119852 Intron 665 3906 ccgtctttactaagatacaa 90 673 119853 Intron 665 4540 tcaagacagtaaatcctgca 93 674 119854 Intron 665 4580 ctttttagatcacaggaaaa 89 675 119855 Intron 665 4987 gccatttaattccaagaata 92 676 119856 Intron 665 5092 ggcccactgagtggacagct 93 677 119857 Intron 665 5373 gcatctgttgtttaaagcca 81 678 119858 Intron 665 5778 acggagcagccgcatggcac 85 679 119859 Intron 665 6999 ggtttcaccatgttggtcag 85 680 119860 Intron 665 7125 tctcggctcactacaacctc 75 681 119861 Intron 665 7369 agggacgctgagatctgcgc 92 682 119862 Intron 665 8083 ggtctcaacaggcagaggca 83 683 119863 Coding 665 8254 atccctgaggctggaaccgt 96 684 119864 Coding 665 8282 caaacaccagtaggtttgtg 92 685 119865 Coding 665 8287 gaagccaaacaccagtaggt 86 686 119866 Coding 665 8318 tgcggaagctgttgtcagaa 81 687 119867 Coding 665 8362 gggagccagcactggcagct 79 688 119868 Coding 665 8418 cgggagtggctgctgcggtt 88 689 119869 Intron 665 9135 gctggacctgggtttcctca 86 690 119870 Intron 665 9353 aagcagccccttggcaaagg 94 691 119871 Intron 665 9424 agggctggatctggaagtgg 74 692 119872 Intron 665 9797 agaaggcagagacattctca 93 693 119873 Intron 665 9875 gcccttcctggaccttccca 95 694 119874 Intron 665 9992 ctcagtctagaggcaaaggc 90 695 119875 Intron 665 10172 ctgatccgtctgtgtccagc 96 696 119876 Intron 665 10643 aagtagctgggattacaggc 83 697 119877 Intron 665 11311 ggccctgtacctagctccca 94 698 119878 Intron 665 11394 atcataccactacactccag 18 699 119879 Intron 665 11641 ttgtattttaagtagagacg 85 700 119880 Intron 665 12649 acaaggccagcccccactgg 74 701 119881 Intron 665 12734 ggcagagacagagcagactc 77 702 119882 Coding 665 12795 tgcctggcaatattccggat 95 703 119883 Coding 665 12811 cccgacctgggcgaggtgcc 99 704 119884 Coding 665 12832 gatgctacggtccatgctgt 97 705 119885 Coding 665 12894 acctcctccgaccggctggt 98 706 119886 Coding 665 14042 ccagggcagtggccaggtcc 95 707 119887 Coding 665 14067 ctagggtaggcctgcagcag 94 708 119888 Coding 665 14072 tgtctctagggtaggcctgc 94 709 119889 Coding 665 14151 cggagcaaggacggcgtgtg 97 710 119890 Coding 665 14178 aaattcactgttgtgtgaaa 96 711 119891 Coding 665 14198 tgcgtaggttctggttaata 98 712 119892 Intron 665 14635 agagcagtgggatcacaggc 80 713 119893 Intron 665 14694 tgttggccagggtggtctgg 77 714 119894 Intron 665 16361 agctgtccatacagactgct 90 715 119895 Coding 665 16678 cttctggaactgtccgttca 96 716 119896 3′ UTR 665 16753 gttgacatgccagggctccg 98 717 119897 3′ UTR 665 16798 atagaagtcacagctatctt 95 718 119898 3′ UTR 665 16933 tgtagatttacagatgtgca 68 719 119899 3′ UTR 665 17176 ttaagatagatagtccctat 89 720 119900 3′ UTR 665 17185 tccttagtattaagatagat 84 721 119901 3′ UTR 665 17236 tagttcagaatctctgtgcc 62 722 119902 3′ UTR 665 17267 ccggacttcccatcatttga 86 723 119903 3′ UTR 665 17293 aaaagtcaagcccctgtgta 77 724 119904 3′ UTR 665 17300 aagttgaaaaagtcaagccc 59 725 119905 3′ UTR 665 17391 gtaaacaaacagtggctgac 82 726 119906 3′ UTR 665 17415 gtatgcagttagttacctga 86 727 119907 3′ UTR 665 17439 tgatgtcatggaaagagaaa 80 728 119908 3′ UTR 665 17452 tttagcaaagtcttgatgtc 72 729 119909 3′ UTR 665 17456 tgtctttagcaaagtcttga 89 730 119910 3′ UTR 665 17588 aacctgttctctccagatgc 80 731 119911 3′ UTR 665 17592 tagaaacctgttctctccag 85 732 119912 3′ UTR 665 17596 tgcttagaaacctgttctct 90 733 119913 3′ UTR 665 17632 aatttttaaaaagtccaact 24 734 119914 3′ UTR 665 17731 tgttgcactgtttctaaagc 85 735 119915 3′ UTR 665 17757 agcttaccactggaacagca 94 736 119916 3′ UTR 665 17764 gggacatagcttaccactgg 70 737 119917 3′ UTR 665 17779 tttaaactgattcctgggac 89 738 119918 3′ UTR 665 17802 gacccagcatccactgtcgt 36 739 119919 3′ UTR 665 17904 gaagaaatcatgagtccgtc 86 740 119920 3′ UTR 665 17942 gattttaaactcttaaagaa 29 741 119921 3′ UTR 665 17966 tagagtttgtttttcctttc 77 742 119922 3′ UTR 665 17970 aatatagagtttgtttttcc 50 743

[0594] As shown in Table 31, SEQ ID NOs: 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 735, 736, 737, 738, 740, 742 and 743 demonstrated at least 50% inhibition of human BH3 Interacting domain death agonist expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

Example 62

[0595] Antisense Inhibition of Mouse BH3 Interacting Domain Death Agonist mRNA Expression by Chimeric Phosphorothioate Oligonucleotides having 2′-Moe Wings and a Deoxy Gap.

[0596] Oligonucleotides targeting mouse BH3 Interacting domain Death agonist were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0597] For mouse BH3 Interacting domain Death agonist the PCR primers were: forward primer: TCGAAGACGAGCTGCAGACA (SEQ ID NO: 746) reverse primer: TGGCTCTATTCTTCCTTGGTTGA (SEQ ID NO: 747) and the PCR probe was: FAM-CAGCCAGGCCAGCCGCTCC-TAMRA (SEQ ID NO: 748) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0598] The series of oligonucleotides was designed to target different regions of the mouse BH3 Interacting domain Death agonist using published sequences (GenBank accession number U75506.1, incorporated herein as SEQ ID NO: 744, and residues 9000-120000 of GenBank accession number AC006945, incorporated herein as SEQ ID NO: 745). The oligonucleotides are shown in Table 32. “Target site” indicates the first (5=-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 32 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse BH3 Interacting domain Death agonist mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which b.END cells were cultured and treated with oligonucleotides 119925-120002 (SEQ ID NOs: 749-846) according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data.” TABLE 32 Inhibition of Mouse BH3 Interacting domain Death agonist mRNA Levels by Chimeric Phosphorothioate Oligonucleotides Having 2′-MOE Wings and a Deoxy Gap TARGET ISIS # REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO 119925 Start Codon 744 21 cgttgctgacctcagagtcc 48 749 119926 Coding 744 232 ctttcagaatctggctctat 32 750 119927 5′ UTR 742 4669 ggcccggcgctctactccac 39 751 119928 5′ UTR 748 4699 gctaaggcaaaggtttgcgg 58 752 119929 5′ UTR 748 5004 cgggtccaccaggaggcctg 42 753 119930 5′ UTR 748 5693 gccatggcaccaggcagtag 71 754 119931 5′ UTR 748 6758 gccaggcagcgtgcccagaa 74 755 119932 5′ UTR 748 7548 cttccccattcatacaccta 61 756 119933 5′ UTR 748 7977 cacttgacaccaacagagac 58 757 119934 5′ UTR 748 8859 gaagcctgtaatcctggcac 73 758 119935 5′ UTR 748 9373 gaccatgtcctggccagaaa 83 759 119936 5′ UTR 748 9439 gtcagtccagtaagggcttt 61 760 119937 5′ UTR 748 9698 ttagcttagccacagaggga 80 761 119938 5′ UTR 748 9768 cgcctgtgctctcttcctgc 53 762 119939 5′ UTR 748 10495 cccatcttctggcctccttg 35 763 119940 5′ UTR 748 11230 ctgaaactccaggctcagga 76 764 119941 5′ UTR 748 12652 ctcatggcagctgcagcagt 66 765 119942 5′ UTR 748 14187 cttgaaaaggaacaaagtgg 44 766 119943 5′ UTR 748 14566 tctatacactactcataacc 55 767 119944 5′ UTR 748 17953 ccatcacagaggccacttct 41 768 119945 5′ UTR 748 18196 tccatccctggaacaatgtg 58 769 119946 5′ UTR 748 19488 cagagctcagctttcttccc 68 770 119947 5′ UTR 748 19741 agctcacagagtccagggaa 55 771 119948 5′ UTR 748 19752 caagcactgccagctcacag 59 772 119949 Coding 748 19782 tcagagtccatggcacaagc 61 773 119950 Intron 748 20989 ttgccaaacagaagacacca 3 774 119951 Intron 748 21013 gcagagaaacaggctgtggt 42 775 119952 Coding 748 21182 gtctgtgatgtgcttggccc 63 776 119953 Coding 748 21205 tggagaaagccgaacaccag 57 777 119954 Coding 748 21259 acaggcagttcccgacccag 71 778 119955 Coding 748 21282 ggtctgcctcccagtaagct 27 779 119956 Coding 748 21306 cgtctgtctgcagctcgtct 89 780 119957 Intron 748 21950 cttttctgaatgacttgata 39 781 119958 Intron 748 22293 cactgataggaagtgtgtcc 54 782 119959 Intron 748 22835 ctcagttgctgtaaacacag 57 783 119960 Intron 748 22883 ccacagcgctctgagcactc 73 784 119961 Intron 748 23125 gtcctgaagtatcctgacct 72 785 119962 Intron 748 23239 gaaataaactagccagaggg 26 786 119963 Coding 748 24169 tttcttcctgactttcagaa 33 787 119964 Coding 748 24201 ttgggcgagatgtctggcaa 55 788 119965 Coding 748 24208 cgcctatttgggcgagatgt 51 789 119966 Coding 748 24264 gaactgtgcggctagctgtc 62 790 119967 Intron 748 24515 cgccacaagagaagactgag 54 791 119968 Intron 748 24877 aatgtgtgtgtctttgacag 53 792 119969 Intron 748 25363 ctacatgttatcttcccttc 37 793 119970 Coding 748 25705 agggctttggccaggcagtt 43 794 119971 Coding 748 25776 acagcattgtcattatcagc 67 795 119972 Coding 748 25814 gagcaaagatggtgcgtgac 54 796 119973 Coding 748 25830 tgtggaagacatcacggagc 78 797 119974 Coding 748 25838 gacagtcgtgtggaagacat 48 798 119975 Coding 748 25858 aggttctggttaataaagtt 34 799 119976 Intron 748 26838 gtcattttccagcagtctca 77 800 119977 Coding 748 27236 gcgggctcctcagtccatct 74 801 119978 3′ UTR 748 27315 gttctctgggacctgtcttc 44 802 119979 3′ UTR 748 27474 tcattcccaagtgggaaccc 49 803 119980 3′ UTR 748 27577 cagaagcccacctacatggt 44 804 119981 3′ UTR 748 27608 atgcacctctcctaatgctg 58 805 119982 3′ UTR 748 27612 gccgatgcacctctcctaat 67 806 119983 3′ UTR 748 27657 gagcacttcagtgtccacta 56 807 119984 3′ UTR 748 27700 agatcagccattcggctttt 58 808 119985 3′ UTR 748 27711 cccatggtttgagatcagcc 75 809 119986 3′ UTR 748 27788 gatagaaatcttgagataat 11 810 119987 3′ UTR 748 27834 caccacacagataagtcgtg 65 811 119988 3′ UTR 748 27842 gtaactgacaccacacagat 60 812 119989 3′ UTR 748 27851 agcctgagtgtaactgacac 54 813 119990 3′ UTR 748 27859 gtagcaagagcctgagtgta 48 814 119991 3′ UTR 748 27868 ttgcattccgtagcaagagc 51 815 119992 3′ UTR 748 27934 agtgacctgctgctgtttta 37 816 119993 3′ UTR 748 28042 cttttgatatggaatcttct 50 817 119994 3′ UTR 748 28067 aatacagaagcggagggaac 32 818 119995 3′ UTR 748 28083 gaggccttgtctctgaaata 78 819 119996 3′ UTR 748 28107 cgtaacaacgcttgaggata 63 820 119997 3′ UTR 748 28145 gctgacgatcccagctttaa 38 821 119998 3′ UTR 748 28167 cttgcaggctgtggcggctc 65 822 119999 3′ UTR 748 28170 atacttgcaggctgtggcgg 52 823 120000 3′ UTR 748 28192 ctgggatgagttcagaacta 73 824 120001 3′ UTR 748 28332 cacatatttttagaacagaa 38 825 120002 3′ UTR 748 28378 gagccttttattttgaagaa 60 826

[0599] As shown in Table 32, SEQ ID NOs 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764,765, 766, 767, 768, 769, 770, 771, 772, 773, 775, 776, 777, 778, 780, 781, 782, 783, 784, 785, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825 and 826 demonstrated at least 30% inhibition of mouse BH3 Interacting domain death agonist expression in this experiment and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

Example 63

[0600] Target Validation—Effect of BH3 Interacting Death Domain Antisense Oligonucleotides in a Fas Cross-Linking Antibody Murine Model for Hepatitis

[0601] Injection of agonistic Fas-specific antibody into mice can induce massive hepatocyte apoptosis and liver hemorrhage, and death from acute hepatic failure (Ogasawara, J., et al., Nature, 1993, 364, 806-809). Apoptosis-mediated aberrant cell death has been shown to play an important role in a number of human diseases. For example, in hepatitis, Fas and Fas ligand up-regulated expression are correlated with liver damage and apoptosis. It is thought that apoptosis in the livers of patients with fulminant hepatitis, acute and chronic viral hepatitis or autoimmune hepatitis, as well as chemical or drug induced liver intoxication may result from Fas activation on hepatocytes. There are various indices of liver damage and/or apoptosis that are commonly used. These include measurement of the liver enzymes, AST and ALT.

[0602] Eight to ten week-old female Balb/c mice were intraperitoneally injected with oligonucleotide 119935 (SEQ ID NO. 759) at 24 mg/kg, daily for 4 days or with saline at a dose of 7 ug. Four hours after the last dose, 7.5 ug of mouse Fas antibody (Pharmingen, San Diego, Calif.) was injected into the mice. Mortality of the mice was measured for 48 hours following antibody treatment. Results are shown in Table 33. Mortality is expressed as percent survival. TABLE 33 Protective Effects of BH3 Interacting Death Domain Antisense Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides in Fas Antibody Cross-linking Induced Death in Balb/c Mice SEQ ID Percent Survival ISIS # NO: 4 Hr 6 Hr 8 Hr 12 Hr 24 Hr 48 Saline — 100 90 20 0 0 0 119935 107 100 100 100 100 100 100

[0603] Oligonucleotide 119935 (SEQ ID NO. 759) completely protected the Fas-antibody treated mice from death. Injection with saline alone did not confer any protective effect.

[0604] After challenge with a higher dose of Fas antibody (15 ug), protection from fulminant death by the BH3 interacting death domain antisense oligonucleotides was lost with survival rates dropping to 1 percent at 5 hours post-treatment. An increase in antisense oligonucleotide dosage to 50 mg/kg given 6 times every 3 days also failed to produce protection from fulminant death at the higher dose of Fas antibody.

[0605] The BH3 interacting death domain antisense oligonucleotide was also shown to override sensitization to Fas antibody-induced death by Bcl-xL antisense oligonucleotide in the same model.

[0606] In these experiments, 8-10 week-old female Balb/c mice were intraperitoneally injected with oligonucleotides ISIS 16009 (SEQ ID NO. 827, targeting murine Bcl-xL) alone or in combination with ISIS 119935 (SEQ ID NO. 756) at 50 mg/kg, 6 times a day for two days or with saline at a dose of 7 ug. ISIS 16009 is a chimeric oligonucleotide (“gapmer”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the “wings” are 5-methylcytidines. Four hours after the last dose, 7 ug of mouse Fas antibody (Pharmingen, San Diego, Calif.) was injected into the mice. Mortality of the mice was measured for 48 hours following antibody treatment. Results are shown in Table 34. Mortality is expressed as percent survival. N.D. indicates no data for these timepoints. TABLE 34 Protective Effects of BH3 Interacting Death Domain Antisense Oligonucleotides in Fas Antibody Cross-linking Induced Death in Balb/c Mice sensitized by Bcl-xL antisense oligonucleotide treatment. Percent Survival ISIS # SEQ ID 4 Hr 6 Hr 8 Hr 12 Hr 24 Hr 48 Hr saline — 90 60 20 0  0  0 16009 175 90 30 20 10 N.D. N.D. 119935 + 107 100 100 100 100 100 100 16009

[0607] Western blot analysis of Bcl-xL and BH3 interacting death domain proteins revealed that the expression levels of both targets was reduced to greater than 90%.

Example 64

[0608] Target Validation—Effect of BH3 Interacting Death Domain Antisense Oligonucleotides in an Endotoxin and D(+)-Galactosamine-induced Murine Model of Fulminant Hepatitis and Liver Injury

[0609] The lipopolysaccharide/D-galactosamine or LPS/GalN model is a well known experimental model of toxin-induced hepatitis. Injection of the endotoxin, lipopolysaccharide (LPS), induces septic shock death in the mouse, though with LPS alone, the mouse liver does not sustain major damage. Injection of D-Galactosamine (GalN), while metabolized in liver causing depletion of UTP, is not lethal to mice. It does, however, sensitize animals to TNF-α or LPS-induced endotoxic shock by over 1,000 fold. In the presence of GalN, LPS induces apoptotic cell death in liver, thymus, spleen, lymph nodes and the kidney and results in fulminant death in animals. The liver injury is known to be transferable via the serum, suggesting a mechanism of action under TNF-α control. Further support for this mechanism is provided by the finding that TNFR1 knockout mice are resistant to LPS/GalN-induced liver injury and death.

[0610] Eight-week-old female Balb/c mice were used to assess the activity of BH3 interacting death domain antisense oligonucleotides in the endotoxin and D(+)-Galactosamine-induced murine model of fulminant hepatitis and liver injury. Mice were intraperitoneally pretreated with 24 mg/kg of ISIS 119935 (SEQ ID NO. 759) four times a day for 2 days. Control mice were injected with saline. One day after the last dose of oligonucleotide, mice were injected intraperitoneally with 5 ng LPS (DIFCO laboratories) and 20 mg D-Galactosamine (Sigma) per animal in saline. At time intervals of 5.5, 7.5, 9.5, 21.5, 30, 45 and 53 hours after the final dose, animals were monitored for survival rates. Results are shown in Table 35. TABLE 35 Protective Effects of BH3 Interacting Death Domain Antisense Oligonucleotides in Endotoxin-Mediated Death in Balb/c Mice Percent Survival 5.5 7.5 ISIS # SEQ ID Hr Hr 9.5 Hr 21.5 Hr 30 Hr 45 Hr 53 Hr Saline — 100 100 20 20 10 10 10 119935 107 100 100 100 100 100 100 100

[0611] BH3 interacting death domain antisense oligonucleotides were also shown to override sensitization to endotoxin-mediated death by Bcl-xL antisense oligonucleotides in the same model. In these experiments, 8-10 week old female Balb/c mice were intraperitoneally pretreated with 24 mg/kg of ISIS 16009 (SEQ ID NO. 827) alone or in combination with ISIS 119935 (SEQ ID NO. 756) four times a day for 2 days. Control mice were injected with saline. One day after the last dose of oligonucleotide, mice were injected intraperitoneally with 5 ng LPS (DIFCO laboratories) and 20 mg D-Galactosamine (Sigma) per animal in saline. At time intervals of 6, 6.5, 7, 7.5, 9, 9.5 and 22 hours after the final dose, animals were monitored for survival rates. Results are shown in Table 36. Mortality is expressed as percent survival. TABLE 36 Protective Effects of BH3 Interacting Death Domain Antisense Oligonucleotides in Endotoxin-Mediated Death in Balb/c Mice sensitized by Bcl-xL antisense oligonucleotide treatment. Percent Survival SEQ 9.5 ISIS # ID 6 Hr 6.5 Hr 7 Hr 7.5 Hr 9 Hr Hr 22 Hr Saline — 100 100 100 100 70 20 10 16009 175 100 80 30 0 0 0 0 119935 + 107 100 100 100 100 100 100 100 16009

Example 65

[0612] Antisense Inhibition of PTEN mRNA Expression by Chimeric Phosphorothioate Oligonucleotides Having 2′-Moe Wings and a Deoxy Gap

[0613] PTEN is a dual-specificity protein phosphatase recently implicated as a phosphoinositide phosphatase in the insulin-signaling pathway. The pharmacological modulation of PTEN activity and/or expression may be an appropriate point for therapeutic intervention in metabolic disorders such as diabetes which arise from degregulated insulin signaling.

[0614] Oligonucleotides targeting human PTEN were designed as described in Example 2, synthesized as described in Examples 3-7, analyzed as described in Example 8 and assayed by RT-PCR as described in Example 12.

[0615] Probes and primers to human PTEN were designed to hybridize to a human PTEN sequence, using published sequence information (GenBank accession number U92436.1, incorporated herein as SEQ ID NO: 828). For human PTEN the PCR primers were: forward primer: AATGGCTAAGTGAAGATGACAATCAT (SEQ ID NO: 829) reverse primer: TGCACATATCATTACACCAGTTCGT (SEQ ID NO: 830) and the PCR probe was: FAM-TTGCAGCAATTCACTGTAAAGCTGGAAAGG-TAMRA (SEQ ID NO: 831) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0616] The series of oligonucleotides was designed to target different regions of the human PTEN RNA, using published sequences (GenBank accession number U92436.1, incorporated herein as SEQ ID NO: 828). The oligonucleotides are shown in Table 37. “Target site” indicates the first (5=-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 37 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human PTEN mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which T-24 cells were cultured as described in Section 15 (15. Cell Lines for Assaying Oligonucleotide Activity) treated with oligonucleotides 29574-29613 (SEQ ID NOs: 832-867) according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data”. TABLE 37 Inhibition of Human PTEN mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap TARGET ISIS # REGION SEQ ID NO TARGET SITE SEQUENCE % INHIB SEQ ID NO. 29574 5′ UTR 828 19 cgagaggcggacgggacc 29 832 29575 5′ UTR 828 57 cgggcgcctcggaagacc 27 833 29576 5′ UTR 828 197 tggctgcagcttccgaga 67 834 29577 5′ UTR 828 314 cccgcggctgctcacagg 79 835 29578 5′ UTR 828 421 caggagaagccgaggaag 51 836 29579 5′ UTR 828 494 gggaggtgccgccgccgc 71 837 29581 5′ UTR 828 671 ccgggtccctggatgtgc 88 838 29582 5′ UTR 828 757 cctccgaacggctgcctc 66 839 29583 5′ UTR 828 817 tctcctcagcagccagag 74 840 29584 5′ UTR 828 891 cgcttggctctggaccgc 81 841 29585 5′ UTR 828 952 tcttctgcaggatggaaa 63 842 29587 Coding 828 1106 ggataaatataggtcaag 50 843 29588 Coding 828 1169 tcaatattgttcctgtat 41 844 29589 Coding 828 1262 ttaaatttggcggtgtca 74 845 29590 Coding 828 1342 caagatcttcacaaaagg 64 846 29591 Coding 828 1418 attacaccagttcgtccc 55 847 29592 Coding 828 1504 tgtctctggtccttactt 64 848 29593 Coding 828 1541 acatagcgcctctgactg 73 849 29595 Coding 828 1694 gaatatatcttcaccttt 30 850 29596 Coding 828 1792 ggaagaactctactttga 61 851 29597 Coding 828 1855 tgaagaatgtatttaccc 31 852 29599 Coding 828 2020 ggttggctttgtctttat 56 853 29600 Coding 828 2098 tgctagcctctggatttg 80 854 29601 Coding 828 2180 tctggatcagagtcagtg 65 855 29602 3′ UTR 828 2268 tattttcatggtgtttta 41 856 29603 3′ UTR 828 2347 tgttcctataactggtaa 63 857 29604 3′ UTR 828 2403 gtgtcaaaaccctgtgga 39 858 29605 3′ UTR 828 2523 actggaataaaacgggaa 6 859 29606 3′ UTR 828 2598 acttcagttggtgacaga 40 860 29607 3′ UTR 828 2703 tagcaaaacctttcggaa 22 861 29608 3′ UTR 828 2765 aattatttcctttctgag 23 862 29609 3′ UTR 828 2806 taaatagctggagatggt 27 863 29610 3′ UTR 828 2844 cagattaataactgtagc 42 864 29611 3′ UTR 828 2950 ccccaatacagattcact 10 865 29612 3′ UTR 828 3037 attgttgctgtgtttctt 61 866 29613 3′ UTR 828 3088 tgtttcaagcccattctt 55 867

[0617] As shown in Table 37, SEQ ID NOs: 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 860, 864, 866 and 867 demonstrated at least 30% inhibition of PTEN expression in this experiment and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

Example 66

[0618] Target Validation—Inhibition of PTEN Expression-Dose Response in Human, Mouse and Rat Hepatocytes

[0619] In accordance with the present invention, two additional oligonucleotides targeted to human PTEN were designed and synthesized. ISIS 116847 (CTGCTAGCCTCTGGATTTGA, SEQ ID NO: 868) and ISIS 116845 (ACATAGCGCCTCTGACTGGG, SEQ ID NO: 869). The mismatch control for ISIS 116847 is ISIS 116848 (CTTCTGGCATCCGGTTTAGA, SEQ ID NO: 870), a six base pair mismatch of ISIS 116847, while the control used is the mixed sequence 20-mer negative oligonucleotide control ISIS 29848 (SEQ ID NO: 461). Both ISIS 116847 and ISIS 116845 target the coding region of Genbank accession no. U92436.1 (SEQ ID NO: 828), with ISIS 116847 starting at position 2097 and ISIS 116845 starting at position 1539.

[0620] These oligonucleotide sequences also target the mouse PTEN sequence with perfect complementarity, with ISIS 116845 targeting nucleotides 1453-1472 and ISIS 116847 targeting nucleotides 2012-2031 of GenBank accession number U92437 (SEQ ID NO: 871) (locus name MMU92437; Steck et al., Nature Genet., 1997, 15,356-362). For mouse PTEN the PCR primers were: forward primer:

[0621] ATGACAATCATGTTGCAGCAATTC (SEQ ID NO: 872) reverse primer:

[0622] CGATGCAATAAATATGCACAAATCA (SEQ ID NO: 873) and the PCR probe was:

[0623] FAM-CTGTAAAGCTGGAAAGGGACGGACTGGT-TAMRA (SEQ ID NO: 874) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

[0624] Similarly, these oligonucleotide sequences target the rat PTEN sequence with perfect complementarity, with ISIS 116845 targeting nucleotides 505-524 and ISIS 116847 targeting nucleotides 1063-1082 of GenBank accession number AF017185 (SEQ ID NO: 875). The mouse PTEN primers and probe listed above target the rat PTEN sequence with perfect complementarity and were used to determine the PTEN expression dose response in rat hepatocytes.

[0625] All compounds of this example are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotides. All cytidine residues are 5-methylcytidines.

[0626] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments.

[0627] In a dose-response experiment, human hepatocyte cells (HEPG2; American Type Culture Collection, Manassas, Va.), mouse primary hepatocytes, and rat primary hepatocytes were treated with ISIS 116847 and its mismatch control, ISIS 116848 at doses of 10, 50, 100 and 200 nM oligonucleotide normalized to untreated controls. In all three species, the dose response was linear compared to vehicle treated controls.

[0628] In human HEPG2 cells, ISIS 116847 reduced PTEN mRNA levels to 55% of control at a dose of 10 nM, and to 5% of control at 200 nM while the PTEN mRNA levels in cells treated with the mismatch control oligonucleotide remained at greater than 90% of control across the entire dosing range.

[0629] In mouse primary hepatocytes the trend was the same with ISIS 116847 reducing PTEN mRNA levels to 85% of control at the lower dose of 10 nM, and down to 2% of control at the 200 nM dose. Again, the control oligonucleotide, ISIS 116848 failed to reduce PTEN mRNA levels and remained at or above 85% of control.

[0630] In rat primary hepatocytes, ISIS 116847 reduced PTEN mRNA levels to 55% of control at the lower dose of 10 nM and to 10% of control at the highest dose of 200 nM. PTEN mRNA levels in cells treated with the control oligonucleotide, ISIS 116848, remained at or above 95% of control across the entire dosing range.

Example 67

[0631] Effects of Inhibition of PTEN on mRNA Expression in Fat and Liver

[0632] In the following examples, modulators of PTEN were tested in db/db mice (Jackson Laboratories, Bar Harbor, Me.). These mice are hyperglycemic, obese, hyperlipidemic, and insulin resistant, and are used as a standard animal model of diabetes.

[0633] Male db/db mice (age 14 weeks) were divided into matched groups (n=5) with the same average blood glucose levels and treated once a week for 4 weeks with ISIS 116847 at 10, 25, 50 or 100 mg/kg or ISIS 116845 at 50 mg/kg. Wild type mice were similarly treated. Controls included saline, ISIS 116848 (a mismatch control), ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) and the sense control of ISIS 116847. As a comparison db/db mice were also treated with troglitazone, an oral antihyperglycemic agent which is used in the treatment of type II diabetes. It acts primarily to decrease insulin resistance, improve sensitivity to insulin in muscle and adipose tissue and inhibit hepatic gluconeogenesis. At day 28 mice were sacrificed and PTEN mRNA levels were measured.

[0634] Treatment of db/db mice with ISIS 116847 showed a dose-dependent decrease in PTEN mRNA levels in the liver to 10% of control at 50 mg/kg. ISIS 116845 showed a reduction in PTEN mRNA levels to 22% of control at a dose of 50 mg/kg.

[0635] In wild-type mice a level of 5% of control PTEN mRNA required a dose of 100 mg/kg of ISIS 116847. Neither troglitazone nor any of the controls had an effect on PTEN mRNA levels over saline control.

[0636] Similar results were seen in fat. Treatment of db/db mice with ISIS 116847 showed a dose-dependent decrease in PTEN mRNA levels in fat to 20% of control at 50 mg/kg. ISIS 116845 showed a reduction in PTEN mRNA levels to 35% of control at a dose of 50 mg/kg.

[0637] In wild-type mice a level of 18% of control required a dose of 100 mg/kg of ISIS 116847. Neither troglitazone nor any of the controls had an effect on PTEN mRNA levels over saline control.

[0638] In another experiment, male db/db mice (age 14 weeks) were divided into matched groups (n=5) with the same average blood glucose levels and treated intraperitoneally with saline or ISIS 116847 every other day (q2d) or twice a week (q4d) at a dose of 20 mg/kg. The control for both protocols was the mismatch control, ISIS 116848. Mice were exsanguinated on day 14 and PTEN mRNA levels in liver and fat were measured.

[0639] ISIS 116847 successfully reduced PTEN mRNA levels in both liver and fat of db/db mice at both the q2d and q4d dosing schedules in a dose-dependent manner, whereas the mismatch control and saline treated animals showed no reduction in PTEN mRNA.

[0640] There was no reduction of PTEN mRNA in skeletal muscle with any of the oligonucleotides used. This lack of an effect in muscle indicates that reduction of expression of PTEN in liver and fat alone is sufficient to lower hyperglycemia.

Example 68

[0641] Target Validation—Effects of inhibition of PTEN on mRNA Expression in Kidney

[0642] Male db/db and wild-type mice were treated once a week for 4 weeks with ISIS 116847 at 10, 25, 50 or 100 mg/kg or ISIS 116845 at 50 mg/kg. Controls included saline, ISIS 116848 (a mismatch control), ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) and the sense control of ISIS 116847. As a comparison db/db mice were also treated with troglitazone. At day 28 mice were sacrificed and PTEN mRNA levels were measured.

[0643] Treatment with ISIS 116847 showed a dose-dependent decrease in PTEN mRNA levels in kidney, being reduced to 70% of control at a dose of 50 mg/kg. ISIS 116845 reduced PTEN mRNA levels to 85% of control at the same dose.

[0644] In wild-type mice a level of 75% of control required a dose of 100 mg/kg of ISIS 116847. Neither troglitazone nor any of the controls had an effect on PTEN mRNA levels over saline control.

Example 69

[0645] Target Validation—Effects of Inhibition of PTEN (ISIS 116847) on PTEN Protein Levels in Liver Extracts as a Function of Time and Dose

[0646] Male db/db and wild-type mice (age 14 weeks) were treated once a week for 4 weeks with saline, a control oligonucleotide, ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) (50 mg/kg) or ISIS 116847 at 10, 25 or 50 mg/kg. Wild-type mice were treated with saline or ISIS 116847 at 100 mg/kg. Mice were sacrificed at day 28 and PTEN protein levels were measured by Western blotting as described in other examples herein.

[0647] In the db/db mice, treatment with ISIS 116847 caused a dose-dependent decrease in PTEN protein levels compared to saline controls or mismatch treated animals.

[0648] Protein levels in wild-type mice treated at 100 mg/kg were comparably reduced to the levels seen in db/db mice treated at the 50 mg/kg dose. There was no significant difference in the relative levels of PTEN protein in control lean versus db/db mice.

Example 70

[0649] Target Validation—Effects of Inhibition of PTEN (ISIS 116847) on PTEN Protein Levels in Fat and Kidney as a Function of Time and Dose

[0650] Male db/db and wild-type mice (age 14 weeks) were treated once a week for 4 weeks with saline or ISIS 116847 at 50 mg/kg by intraperitoneal injection. Mice were sacrificed at day 28 and PTEN protein levels were measured by Western blotting described in other examples herein.

[0651] PTEN levels in fat were reduced in both db/db and wild-type mice by the PTEN oligomeric compounds as compared to control, and slight reduction of PTEN levels was seen in the kidney after treatment with oligomeric compounds.

Example 71

[0652] Target Validation—Effects of Inhibition of PTEN on Blood Glucose Levels

[0653] Male db/db and wild type mice (age 14 weeks) were divided into matched groups (n=5) with the same average blood glucose levels and treated by intraperitoneal injection with saline or ISIS 116847 every other day (q2d) or twice a week (q4d) at a dose of 20 mg/kg. The control for both protocols was the mismatch control, ISIS 116848. Blood glucose levels were measured on day 7 and day 14.

[0654] By day 14 in db/db mice, blood glucose levels were reduced for both treatment schedules; from starting levels of 330 mg/dL to 175 mg/dL (q2d) and 170 mg/dL (q4d) which are levels within the range considered normal for wild-type mice. The mismatch control levels remained at 310 mg/dL throughout the study.

[0655] In wild-type mice, blood glucose levels remained constant throughout the study for all treatment groups (average 115 mg/dL).

[0656] In a similar experiment, male db/db and wild-type mice were treated once a week for 4 weeks with ISIS 116847 or ISIS 116845 at 50 mg/kg. Controls included saline, ISIS 116848 (a mismatch control) and ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461). At day 28 mice were sacrificed and serum glucose levels were measured.

[0657] In db/db mice, treatment with either ISIS 116847 or ISIS 116845 reduced serum glucose levels relative to saline control (480 mg/dL) to 240 and 280 mg/dL, respectively. This reduction was statistically significant (p<0.005). Neither the mismatch nor universal control had any effect on serum glucose levels. In wild-type animals, ISIS 116847 failed to reduce serum glucose levels from that of control (200 mg/dL).

Example 72

[0658] Target Validation—Effects of Inhibition of PTEN (ISIS 116847) on Blood Glucose Levels of db/db Mice as a Function of Time and Dose

[0659] Male db/db mice (age 14 weeks) were treated once a week for 4 weeks with saline or ISIS 116847 at 10, 25 or 50 mg/kg intraperitoneally. Blood glucose levels were measured on day 7, 14, 21 and 28.

[0660] At the beginning of the study, all groups had blood glucose levels of 275 mg/dL which rose in the saline treated animals and those treated at the low dose of ISIS 116847 to 350 mg/dL and 320 mg/dL, respectively by day four. At the end of the first week, all three dosing schedules showed a reduction in blood glucose and continued to show linear dose response decreases throughout the study. At day 28, blood glucose levels in animals treated with oligomeric compounds were 275 mg/dL (10 mg/kg dose), 175 mg/dL (25 mg/kg dose) and 120 mg/dL (50 mg/kg dose) while saline treated levels remained at 350 mg/dL. The average glucose levels for oligonucleotide treated mice at the end of the four week study was 194 mg/dL as compared to 418 mg/dL for saline treated controls (p<0.0001).

Example 73

[0661] Target Validation—Effects of Inhibition of PTEN (ISIS 116847) on Blood Glucose Levels of db/db Mice-Insulin Tolerance Test

[0662] Male db/db mice (age 14 weeks) were treated once with saline or ISIS 116847 50 mg/kg by intraperitoneal injection. The insulin tolerance test was performed after a four hour fast followed by an intraperitoneal injection of 1 U/kg human insulin (Lilly). On day 21, blood was withdrawn from the tail at 0, 30, 60 and 90 minutes and blood glucose levels were measured as a percentage of blood glucose at time zero. Statistical analysis was performed using ANOVA repeated measures followed by Bonferroni Dunn analysis, p<0.05.

[0663] Treatment with ISIS 116847 on day 21 resulted in a significant dose-dependent decrease in blood glucose (p<0.006) at the 90 minute post-treatment time point to 45% of control (55% decrease). Saline treatment resulted in a 30% reduction. These studies indicate that the PTEN oligonucleotide is capable of increasing sensitivity to insulin (decreasing insulin resistance) and that treatment does not cause hypoglycemia. Glucose levels in PTEN treated mice (both db/db and wild-type) fasted for 16 hours remained normal.

Example 74

[0664] Target Validation—Effects of Inhibition of PTEN on Serum Triglyceride and Cholesterol Concentration

[0665] Male db/db and wild-type mice were treated once a week for 4 weeks with ISIS 116847 at 10, 25, 50 or 100 mg/kg or ISIS 116845 at 50 mg/kg. Controls included saline, ISIS 116848 (a mismatch control), ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) and the sense control of ISIS 116847. As a comparison db/db mice were also treated with troglitazone. At day 28 mice were sacrificed and triglyceride and cholesterol levels were measured.

[0666] Treatment of db/db mice with ISIS 116847 resulted in a dose-dependent reduction of both triglycerides and cholesterol compared to saline controls (a reduction from 200 mg/dL to 100 mg/dL for triglycerides and from 130 mg/dL to 98 mg/dL for cholesterol). Treatment of db/db mice with ISIS 116845 at a dose of 50 mg/kg resulted in a decrease in both triglycerides and cholesterol levels to 130 mg/dL and 75 mg/dL, respectively. Troglitazone treatment of db/db mice reduced both triglyceride and cholesterol levels to 85 mg/dL each.

[0667] Wild-type animals did not respond to treatment with ISIS 116847 at a dose of 100 mg/kg as both triglyceride and cholesterol levels remained similar to control saline treated animals (between 85 and 105 mg/dL). The reductions seen in cholesterol and triglycerides were statistically significant at p<0.005.

Example 75

[0668] Target Validation—Effects of Inhibition of PTEN on Body Weight

[0669] Male db/db and wild-type mice were treated once a week for 4 weeks with ISIS 116847 at 10, 25, 50 or 100 mg/kg or ISIS 116845 at 50 mg/kg. Controls included saline, ISIS 116848 (a mismatch control), ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) and the sense control of ISIS 116847. As a comparison db/db mice were also treated with troglitazone. At day 28 mice were sacrificed and final body weights were measured.

[0670] Treatment with ISIS 116847 resulted in a dose-dependent increase in body weight over the dose range with animals treated at the high dose gaining an average of 8.7 grams while saline treated controls gained 2.8 grams. Animals treated with the mismatch or universal control oligonucleotide gained between 2.5 and 3.5 grams of body weight and troglitazone treated animals gained 5.0 grams.

[0671] Wild-type animals treated with 100 mg/kg of ISIS 116847 gained 2.0 grams of body weight compared to a gain of 1.3 grams for the wild-type saline or mismatch controls.

[0672] Weight gain in the PTEN oligomeric compound treated mice began to increase relative to that in saline or control groups at the same time that glucose levels began to drop.

Example 76

[0673] Target Validation—Effects of Inhibition of PTEN on Liver Weight-Anterior Lobe

[0674] Male db/db and wild-type mice were treated once a week for 4 weeks with ISIS 116847 at 10, 25, 50 or 100 mg/kg or ISIS 116845 at 50 mg/kg. Controls included saline, ISIS 116848 (a mismatch control), ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) and the sense control of ISIS 116847. As a comparison db/db mice were also treated with troglitazone. At day 28 mice were sacrificed and the weights of the anterior lobe of the liver were measured.

[0675] db/db animals treated at the high dose had liver weights of 1.2 grams while saline treated controls weighed 0.75 grams. db/db animals treated with ISIS 116845 at a dose of 50 mg/kg had comparable liver size to those treated with ISIS 116847 at a dose of 25 mg/kg (1.0 grams). Animals treated with the mismatch control, universal control or troglitazone had livers weighing an average of 1.0 gram.

[0676] Wild-type mouse livers treated with 100 mg/kg of ISIS 116847 weighed 0.7 grams compared to 0.5 grams for the wild-type saline treated controls.

[0677] BrdU (bromine deoxyuridine) staining of liver sections indicated that the increase in liver weight was not due to increased cell proliferation, and there was no increase in inflammatory infiltrates in the liver. Long-term studies show that the increases in liver weight are reversed.

Example 77

[0678] Target Validation—Effects of Inhibition of PTEN (ISIS 116847) on PEPCK mRNA Expression in Liver of db/db Mice

[0679] PEPCK is the rate-limiting enzyme of gluconeogenesis and is expressed predominantly in liver where it acts in the gluconeogenic pathway (production of glucose from amino acids) and in kidney where it acts in the gluconeogenic pathway as well as being glyceroneogenic and ammoniagenic. In the liver, PEPCK is negatively regulated by insulin and has therefore been considered a potential contributing factor to hyperglycemia in diabetics (Sutherland et al., Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1996, 351, 191-199).

[0680] Male db/db mice (age 14 weeks) with the same average blood glucose levels were divided into groups (n=5) and treated intraperitoneally with saline, ISIS 116847 or the mismatch control, ISIS 116848, every other day (q2d). Mice were exsanguinated on day 14 and PEPCK mRNA levels in liver were measured.

[0681] Mice treated with ISIS 116847 showed a reduction of PEPCK mRNA to 65% of saline treated controls. The mismatch control group remained at 98% of saline treated control.

Example 78

[0682] Target Validation—Effects of Inhibition of PTEN (ISIS 116847) on Serum Insulin Levels of db/db Mice

[0683] Male db/db and wild type mice (age 14 weeks) were divided into matched groups (n=5) with the same average blood glucose levels and treated by intraperitoneal injection with saline or ISIS 116847 every other day (q2d) or twice a week (q4d) at a dose of 20 mg/kg. The control for both protocols was the mismatch control, ISIS 116848. Mice were exsanguinated on day 14 and serum insulin levels were measured.

[0684] On day 14 db/db mice treated on the q2d schedule had serum insulin levels of 7.8 ng/mL, compared to saline treated (9 ng/mL) and mismatch treated animals (12 ng/mL). In the q4d schedule there was a drop in the serum insulin levels of db/db mice treated with ISIS 116847 to 4 ng/mL while the mismatch control levels remained at 12 ng/mL. Wild-type mice had serum insulin levels of 1 ng/mL throughout the course of both treatment schedules.

Example 79

[0685] Target Validation—Effects of Inhibition of PTEN on Liver Function-AST/ALT Levels

[0686] Male db/db and wild type mice (age 14 weeks) were divided into matched groups (n=5) with the same average blood glucose levels and treated by intraperitoneal injection with saline, troglitazone, or ISIS 116847 every other day (q2d) or twice a week (q4d) at a dose of 20 mg/kg. The control for both protocols was the mismatch control, ISIS 116848. Mice were exsanguinated on day 14 and liver enzyme levels were measured.

[0687] In the q2d treatment schedule there was an increase in ALT levels over saline treated animals from 125 IU/L (saline control) to 300 IU/L (both PTEN oligonucleotide, ISIS 116847, and mismatch control), whereas AST levels remained between 220 IU/L and 240 IU/L among the three treatment groups.

[0688] In the q4d treatment schedule, ALT levels increased from 125 IU/L (saline control) to 160 IU/L in animals treated with ISIS 116847 and 200 IU/L for mismatch control. AST levels decreased from saline control levels of 220 IU/L to 160 IU/L for ISIS 116847 treated animals, as well as in animals treated with the mismatch control (200 IU/L). As a comparison, AST and ALT levels were measured after treatment with troglitazone. Levels of both enzymes were found to be 260 IU/L.

[0689] In a similar experiment, male db/db and wild-type mice were treated once a week for 4 weeks with ISIS 116847 at 10, 25, 50 or 100 mg/kg or ISIS 116845 at 50 mg/kg. Controls included saline or ISIS 29848 (the mixed sequence 20-mer negative oligonucleotide control, SEQ ID NO: 461) As a comparison db/db mice were also treated with troglitazone. At day 28 mice were sacrificed and AST and ALT levels were measured.

[0690] Treatment of db/db mice with ISIS 116847 resulted in a dose-dependent increase in ALT levels over the dose range with animals treated at the high dose having ALT levels of 250 IU/L while AST levels remained constant at 165 IU/L. These levels represent an increase in ALT levels from saline treated controls of 110 IU/L and a decrease in AST levels from saline treated controls of 220 IU/L. db/db animals treated with ISIS 116845 at a dose of 50 mg/kg had comparable ALT and AST levels, 145 IU/L. Animals treated with the universal control had ALT and AST levels comparable to control levels and those treated with troglitazone showed an increase in ALT levels over control to 150 IU/L and a slight decrease in AST levels to 200 IU/L from control.

[0691] Wild-type mice treated with 100 mg/kg of ISIS 116847 had both increased ALT and AST levels (100 IU/L and 130 IU/L, respectively) compared to saline-treated control ALT and AST levels (50 IU/L and 95 IU/L, respectively).

[0692] Although ALT levels were slightly elevated in animals treated with PTEN oligomeric compounds, AST levels were reduced indicating that PTEN oligomeric compound effects on liver weight were not due to toxicity.

Example 80

[0693] Design of Double Stranded Oligomeric Compounds Targeting PTEN

[0694] RNA interference (RNAi) and post-transcriptional gene silencing (PTGS) have become powerful and widely used tools for gene function analysis in invertebrates and plants (Fraser et al., Nature, 2000, 408, 325; Gönczy et al. Nature, 2000, 408, 331). Introduction of double-stranded RNA (dsRNA) into the cells of these organisms leads to the sequence-specific degradation of homologous gene transcripts.

[0695] A number of PCT applications have recently been published that relate to the RNAi phenomenon. These include: PCT publication WO 00/44895; PCT publication WO 00/49035; PCT publication WO 00/63364; PCT publication WO 01/36641; PCT publication WO 01/36646; PCT publication WO 99/32619; PCT publication WO 00/44914; PCT publication WO 01/29058; and PCT publication WO 01/75164.

[0696] U.S. Pat. Nos. 5,898,031 and 6,107,094, each of which is commonly owned with this application and each of which is herein incorporated by reference, describe certain oligonucleotides having RNA-like properties. When hybridized with RNA, these oligonucleotides serve as substrates for a dsRNase enzyme with resultant cleavage of the target RNA by the enzyme.

[0697] In accordance with the present invention, a series of 21 nucleotide oligomeric compounds, in this case duplex RNAs (also known as small interfering RNAs: siRNAs), were designed to target PTEN mRNA (Genbank accession no. U92436. 1; SEQ ID NO: 828). The nucleobase sequence of the antisense strand of the duplex is identical to the 18 nucleobase oligonucleotides in Table 37 with one additional complementary base on the 3′ end of the oligoribonucleotides followed by a two-nucleobase overhang of deoxythymidine (T), TT. The sequences of the antisense strands are listed in Table 38. The sense strand of the dsRNAs listed in Table 39 were designed and synthesized as the complement of the antisense strands and also contained the two-nucleobase overhang on the 3′ end making both strands of the dsRNA duplex complementary over the central 19 nucleobases and each having a two-base overhang on the 3′ end. For example, the dsRNA having ISIS 29574 (SEQ ID NO: 832) as the antisense strand is:   cgagaggcggacgggaccgTT ISIS 29574   ||||||||||||||||||| TTgctctccgcctgccctggc Complement of ISIS 29574

[0698] Both strands of the dsRNAs were purchased from Dharmacon Research Inc. (Lafayette, Colo.), shipped lyophilized and annealed on-site using the manufacturer's protocol. Briefly, each RNA oligonucleotide was aliquoted and diluted to a concentration of 50 μM. Once diluted, 30 uL of each strand was combined with 1.5 μL of a 5× solution of annealing buffer. The final concentration of said buffer was 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium acetate. The final volume was 75 μL. This solution was incubated for 1 minute at 90° C. and then centrifuged for 15 seconds. The tube was allowed to sit for 1 hour at 37° C. at which time the dsRNA duplexes were used in experimentation. The final concentration of the dsRNA duplex was 20 μM. This solution can be stored frozen (−20° C.) and freeze-thawed up to 5 times.

Example 81

[0699] Modulation of Human PTEN Expression by Double Stranded RNA (dsRNA)

[0700] In accordance with the present invention, a series of double stranded oligomeric compounds targeted to PTEN were evaluated for their ability to modulate PTEN expression in T-24 cells.

[0701] When cells reached 80% confluency, they were treated with dsRNA. For cells grown in 96-well plates, wells were washed once with 200 μL OPTI-MEM-1™ reduced-serum medium (Gibco BRL) and then treated with 130 μL of OPTI-MEM-1™ containing 12 μg/mL LIPOFECTIN™ (Gibco BRL) and the desired dsRNA at a final concentration of 200 nM. After 5 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after dsRNA or single-stranded oligonucleotide treatment, at which time RNA was isolated and target reduction measured by RT-PCR.

[0702] The sequences of the oligomeric compounds (antisense and sense to the PTEN target mRNA) of the dsRNAs are shown in Table 38 and 39, respectively. Prior to treatment of the T-24 cells, the dsRNA oligomers were generated by annealing the antisense and sense strands according to the method outlined in Example 80. Target sites are indicated by the first (5′ most) nucleotide number, as given in the sequence source reference (Genbank accession no. U92436.1), to which the antisense strand of the dsRNA oligonucleotide binds.

[0703] All compounds in Tables 38 and 39 are oligoribonucleotides, 21 nucleotides in length with the two nucleotides on the 3′ end being oligodeoxyribonucleotides, TT with phosphodiester backbones (internucleoside linkages) throughout. All oligoribonucleotides are depicted in the 5′→3′ direction.

[0704] Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments in which T-24 cells were cultured as described in Section 15 (15. Cell Lines for Assaying Oligonucleotide Activity) according treated with double stranded oligomeric compounds (composed of antisense strands SEQ ID NOs: 879-914 hybridized to sense strands: SEQ ID NOs: 915-950) targeting PTEN mRNA (SEQ ID NO: 828) according to the protocol outlined in Example 34. If present, “N.D.” indicates “no data”. TABLE 38 Modulation of PTEN mRNA levels by dsRNA oligomers dsRNA CORRESPONDING TARGET SEQUENCE OF ANTISENSE TO ISIS# REGION SEQ ID NO TARGET SITE STRAND OF dsRNA % INHIB SEQ ID NO. 29574 5′ UTR 828 19 cgagaggcggacgggaccgTT 0 876 29575 5′ UTR 828 57 cgggcgcctcggaagaccgTT 0 877 29576 5′ UTR 828 197 tggctgcagcttccgagagTT 40 878 29577 5′ UTR 828 314 cccgcggctgctcacaggcTT 25 879 29578 5′ UTR 828 421 caggagaagccgaggaagaTT 64 880 29579 5′ UTR 828 494 gggaggtgccgccgccgccTT 20 881 29581 5′ UTR 828 671 ccgggtccctggatgtgccTT 35 882 29582 5′ UTR 828 757 cctccgaacggctgcctccTT 59 883 29583 5′ UTR 828 817 tctcctcagcagccagaggTT 50 884 29584 5′ UTR 828 891 cgcttggctctggaccgcaTT 33 885 29585 5′ UTR 828 952 tcttctgcaggatggaaatTT 27 886 29587 Coding 828 1106 ggataaatataggtcaagtTT 49 887 29588 Coding 828 1169 tcaatattgttcctgtataTT 50 888 29589 Coding 828 1262 ttaaatttggcggtgtcatTT 64 889 29590 Coding 828 1342 caagatcttcacaaaagggTT 75 890 29591 Coding 828 1418 attacaccagttcgtccctTT 77 891 29592 Coding 828 1504 tgtctctggtccttacttcTT 76 892 29593 Coding 828 1541 acatagcgcctctgactggTT 74 893 29595 Coding 828 1694 gaatatatcttcacctttaTT 10 894 29596 Coding 828 1792 ggaagaactctactttgatTT 29 895 29597 Coding 828 1855 tgaagaatgtatttacccaTT 72 896 29599 Coding 828 2020 ggttggctttgtctttattTT 0 897 29600 Coding 828 2098 tgctagcctctggatttgaTT 43 898 29601 Coding 828 2180 tctggatcagagtcagtggTT 19 899 29602 3′ UTR 828 2268 tattttcatggtgttttacTT 59 900 29603 3′ UTR 828 2347 tgttcctataactggtaatTT 40 901 29604 3′ UTR 828 2403 gtgtcaaaaccctgtggatTT 45 902 29605 3′ UTR 828 2523 actggaataaaacgggaaaTT 38 903 29606 3′ UTR 828 2598 acttcagttggtgacagaaTT 25 904 29607 3′ UTR 828 2703 tagcaaaacctttcggaaaTT 31 905 29608 3′ UTR 828 2765 aattatttcctttctgagcTT 29 906 29609 3′ UTR 828 2806 taaatagctggagatggtcTT 7 907 29610 3′ UTR 828 2844 cagattaataactgtagcaTT 37 908 29611 3′ UTR 828 2950 ccccaatacagattcacttTT 39 909 29612 3′ UTR 828 3037 attgttgctgtgtttcttaTT 30 910 29613 3′ UTR 828 3088 tgtttcaagcccattctttTT 40 911

[0705] TABLE 39 Modulation of PTEN mRNA levels by dsRNA oligomers dsRNA CORRESPONDING TO COMPLEMENT TARGET SEQUENCE OF SENSE STRAND OF ISIS# REGION SEQ ID NO TARGET SITE OF dsRNA % INHIB SEQ ID NO. 29574 5′ UTR 828 19 cggtcccgtccgcctctcgTT 0 912 29575 5′ UTR 828 57 cggtcttccgaggcgcccgTT 0 913 29576 5′ UTR 828 197 ctctcggaagctgcagccaTT 40 914 29577 5′ UTR 828 314 gcctgtgagcagccgcgggTT 25 915 29578 5′ UTR 828 421 tcttcctcggcttctcctgTT 64 916 29579 5′ UTR 828 494 ggcggcggcggcacctcccTT 20 917 29581 5′ UTR 828 671 ggcacatccagggacccggTT 35 918 29582 5′ UTR 828 757 ggaggcagccgttcggaggTT 59 919 29583 5′ UTR 828 817 cctctggctgctgaggagaTT 50 920 29584 5′ UTR 828 891 tgcggtccagagccaagcgTT 33 921 29585 5′ UTR 828 952 atttccatcctgcagaagaTT 27 922 29587 Coding 828 1106 acttgacctatatttatccTT 49 923 29588 Coding 828 1169 tatacaggaacaatattgaTT 50 924 29589 Coding 828 1262 atgacaccgccaaatttaaTT 64 925 29590 Coding 828 1342 cccttttgtgaagatcttgTT 75 926 29591 Coding 828 1418 agggacgaactggtgtaatTT 77 927 29592 Coding 828 1504 gaagtaaggaccagagacaTT 76 928 29593 Coding 828 1541 ccagtcagaggcgctatgtTT 74 929 29595 Coding 828 1694 taaaggtgaagatatattcTT 10 930 29596 Coding 828 1792 atcaaagtagagttcttccTT 29 931 29597 Coding 828 1855 tgggtaaatacattcttcaTT 72 932 29599 Coding 828 2020 aataaagacaaagccaaccTT 0 933 29600 Coding 828 2098 tcaaatccagaggctagcaTT 43 934 29601 Coding 828 2180 ccactgactctgatccagaTT 19 935 29602 3′ UTR 828 2268 gtaaaacaccatgaaaataTT 59 936 29603 3′ UTR 828 2347 attaccagttataggaacaTT 40 937 29604 3′ UTR 828 2403 atccacagggttttgacacTT 45 938 29605 3′ UTR 828 2523 tttcccgttttattccagtTT 38 939 29606 3′ UTR 828 2598 ttctgtcaccaactgaagtTT 25 940 29607 3′ UTR 828 2703 tttccgaaaggttttgctaTT 31 941 29608 3′ UTR 828 2765 gctcagaaaggaaataattTT 29 942 29609 3′ UTR 828 2806 gaccatctccagctatttaTT 7 943 29610 3′ UTR 828 2844 tgctacagttattaatctgTT 37 944 29611 3′ UTR 828 2950 aagtgaatctgtattggggTT 39 945 29612 3′ UTR 828 3037 taagaaacacagcaacaatTT 30 946 29613 3′ UTR 828 3088 aaagaatgggcttgaaacaTT 40 947

[0706] The antisense strands represented by SEQ ID NOs: 879, 880, 882, 883, 884, 885, 887, 888, 889, 890, 891, 892, 893, 896, 998, 900, 901, 902, 903, 905, 908, 909, 910 and 911 (Table 38) are from the preferred dsRNAs which demonstrated at least 30% inhibition of PTEN expression in this experiment. The corresponding sense strands of the preferred dsRNA oligomers are represented by SEQ ID NOs: 914, 916, 918, 919, 920, 921, 923, 924, 925, 926, 927, 928, 929, 932, 934, 936, 937, 938, 939, 941, 944, 945, 946 and 947 (Table 39).

[0707] The target sites to which these preferred sequences are complementary are herein referred to as, “preferred target segments” and are therefore preferred sites for targeting by compounds of the present invention.

[0708] One having skill in the art will recognize that the methods of identification of preferred dsRNA oligomeric compounds for modulation of PTEN expression outlined in this example may be applied to any target for the purpose of target validation or gene function analysis. It will also be recognizable to one skilled in the art, that for any particular target, screening of antisense oligonucleotides need not be carried out prior to design of and screening of dsRNA compounds. Thus, a plurality of virtual dsRNA compounds targeted to functional regions of any target can be generated and subjected to a selection process, actual compounds corresponding to a subset of virtual compounds may be robotically synthesized, and modulators can be identified which may subsequently employed in the processes of gene function analysis or target validation via the methods herein described.

1 947 1 18 DNA Artificial Sequence Antisense Oligonucleotide 1 ccaggcggca ggaccact 18 2 18 DNA Artificial Sequence Antisense Oligonucleotide 2 gaccaggcgg caggacca 18 3 18 DNA Artificial Sequence Antisense Oligonucleotide 3 aggtgagacc aggcggca 18 4 18 DNA Artificial Sequence Antisense Oligonucleotide 4 cagaggcaga cgaaccat 18 5 18 DNA Artificial Sequence Antisense Oligonucleotide 5 gcagaggcag acgaacca 18 6 18 DNA Artificial Sequence Antisense Oligonucleotide 6 gcaagcagcc ccagagga 18 7 18 DNA Artificial Sequence Antisense Oligonucleotide 7 ggtcagcaag cagcccca 18 8 18 DNA Artificial Sequence Antisense Oligonucleotide 8 gacagcggtc agcaagca 18 9 18 DNA Artificial Sequence Antisense Oligonucleotide 9 gatggacagc ggtcagca 18 10 18 DNA Artificial Sequence Antisense Oligonucleotide 10 tctggatgga cagcggtc 18 11 18 DNA Artificial Sequence Antisense Oligonucleotide 11 ggtggttctg gatggaca 18 12 18 DNA Artificial Sequence Antisense Oligonucleotide 12 gtgggtggtt ctggatgg 18 13 18 DNA Artificial Sequence Antisense Oligonucleotide 13 gcagtgggtg gttctgga 18 14 18 DNA Artificial Sequence Antisense Oligonucleotide 14 cacaaagaac agcactga 18 15 18 DNA Artificial Sequence Antisense Oligonucleotide 15 ctggcacaaa gaacagca 18 16 18 DNA Artificial Sequence Antisense Oligonucleotide 16 tcctggctgg cacaaaga 18 17 18 DNA Artificial Sequence Antisense Oligonucleotide 17 ctgtcctggc tggcacaa 18 18 18 DNA Artificial Sequence Antisense Oligonucleotide 18 ctcaccagtt tctgtcct 18 19 18 DNA Artificial Sequence Antisense Oligonucleotide 19 tcactcacca gtttctgt 18 20 18 DNA Artificial Sequence Antisense Oligonucleotide 20 gtgcagtcac tcaccagt 18 21 18 DNA Artificial Sequence Antisense Oligonucleotide 21 actctgtgca gtcactca 18 22 18 DNA Artificial Sequence Antisense Oligonucleotide 22 cagtgaactc tgtgcagt 18 23 18 DNA Artificial Sequence Antisense Oligonucleotide 23 attccgtttc agtgaact 18 24 18 DNA Artificial Sequence Antisense Oligonucleotide 24 gaaggcattc cgtttcag 18 25 18 DNA Artificial Sequence Antisense Oligonucleotide 25 ttcaccgcaa ggaaggca 18 26 18 DNA Artificial Sequence Antisense Oligonucleotide 26 ctctgttcca ggtgtcta 18 27 18 DNA Artificial Sequence Antisense Oligonucleotide 27 ctggtggcag tgtgtctc 18 28 18 DNA Artificial Sequence Antisense Oligonucleotide 28 tggggtcgca gtatttgt 18 29 18 DNA Artificial Sequence Antisense Oligonucleotide 29 ggttggggtc gcagtatt 18 30 18 DNA Artificial Sequence Antisense Oligonucleotide 30 ctaggttggg gtcgcagt 18 31 18 DNA Artificial Sequence Antisense Oligonucleotide 31 ggtgcccttc tgctggac 18 32 18 DNA Artificial Sequence Antisense Oligonucleotide 32 ctgaggtgcc cttctgct 18 33 18 DNA Artificial Sequence Antisense Oligonucleotide 33 gtgtctgttt ctgaggtg 18 34 18 DNA Artificial Sequence Antisense Oligonucleotide 34 tggtgtctgt ttctgagg 18 35 18 DNA Artificial Sequence Antisense Oligonucleotide 35 acaggtgcag atggtgtc 18 36 18 DNA Artificial Sequence Antisense Oligonucleotide 36 ttcacaggtg cagatggt 18 37 18 DNA Artificial Sequence Antisense Oligonucleotide 37 gtgccagcct tcttcaca 18 38 18 DNA Artificial Sequence Antisense Oligonucleotide 38 tacagtgcca gccttctt 18 39 18 DNA Artificial Sequence Antisense Oligonucleotide 39 ggacacagct ctcacagg 18 40 18 DNA Artificial Sequence Antisense Oligonucleotide 40 tgcaggacac agctctca 18 41 18 DNA Artificial Sequence Antisense Oligonucleotide 41 gagcggtgca ggacacag 18 42 18 DNA Artificial Sequence Antisense Oligonucleotide 42 aagccgggcg agcatgag 18 43 18 DNA Artificial Sequence Antisense Oligonucleotide 43 aatctgcttg accccaaa 18 44 18 DNA Artificial Sequence Antisense Oligonucleotide 44 gaaacccctg tagcaatc 18 45 18 DNA Artificial Sequence Antisense Oligonucleotide 45 gtatcagaaa cccctgta 18 46 18 DNA Artificial Sequence Antisense Oligonucleotide 46 gctcgcagat ggtatcag 18 47 18 DNA Artificial Sequence Antisense Oligonucleotide 47 gcagggctcg cagatggt 18 48 18 DNA Artificial Sequence Antisense Oligonucleotide 48 tgggcagggc tcgcagat 18 49 18 DNA Artificial Sequence Antisense Oligonucleotide 49 gactgggcag ggctcgca 18 50 18 DNA Artificial Sequence Antisense Oligonucleotide 50 cattggagaa gaagccga 18 51 18 DNA Artificial Sequence Antisense Oligonucleotide 51 gatgacacat tggagaag 18 52 18 DNA Artificial Sequence Antisense Oligonucleotide 52 gcagatgaca cattggag 18 53 18 DNA Artificial Sequence Antisense Oligonucleotide 53 tcgaaagcag atgacaca 18 54 18 DNA Artificial Sequence Antisense Oligonucleotide 54 gtccaagggt gacatttt 18 55 18 DNA Artificial Sequence Antisense Oligonucleotide 55 cacagcttgt ccaagggt 18 56 18 DNA Artificial Sequence Antisense Oligonucleotide 56 ttggtctcac agcttgtc 18 57 18 DNA Artificial Sequence Antisense Oligonucleotide 57 caggtctttg gtctcaca 18 58 18 DNA Artificial Sequence Antisense Oligonucleotide 58 ctgttgcaca accaggtc 18 59 18 DNA Artificial Sequence Antisense Oligonucleotide 59 gtttgtgcct gcctgttg 18 60 18 DNA Artificial Sequence Antisense Oligonucleotide 60 gtcttgtttg tgcctgcc 18 61 18 DNA Artificial Sequence Antisense Oligonucleotide 61 ccacagacaa catcagtc 18 62 18 DNA Artificial Sequence Antisense Oligonucleotide 62 ctggggacca cagacaac 18 63 18 DNA Artificial Sequence Antisense Oligonucleotide 63 tcagccgatc ctggggac 18 64 18 DNA Artificial Sequence Antisense Oligonucleotide 64 caccaccagg gctctcag 18 65 18 DNA Artificial Sequence Antisense Oligonucleotide 65 gggatcacca ccagggct 18 66 18 DNA Artificial Sequence Antisense Oligonucleotide 66 gaggatggca aacaggat 18 67 18 DNA Artificial Sequence Antisense Oligonucleotide 67 accagcacca agaggatg 18 68 18 DNA Artificial Sequence Antisense Oligonucleotide 68 ttttgataaa gaccagca 18 69 18 DNA Artificial Sequence Antisense Oligonucleotide 69 tattggttgg cttcttgg 18 70 18 DNA Artificial Sequence Antisense Oligonucleotide 70 gggttcctgc ttggggtg 18 71 18 DNA Artificial Sequence Antisense Oligonucleotide 71 gtcgggaaaa ttgatctc 18 72 18 DNA Artificial Sequence Antisense Oligonucleotide 72 gatcgtcggg aaaattga 18 73 18 DNA Artificial Sequence Antisense Oligonucleotide 73 ggagccagga agatcgtc 18 74 18 DNA Artificial Sequence Antisense Oligonucleotide 74 tggagccagg aagatcgt 18 75 18 DNA Artificial Sequence Antisense Oligonucleotide 75 tggagcagca gtgttgga 18 76 18 DNA Artificial Sequence Antisense Oligonucleotide 76 gtaaagtctc ctgcactg 18 77 18 DNA Artificial Sequence Antisense Oligonucleotide 77 tggcatccat gtaaagtc 18 78 18 DNA Artificial Sequence Antisense Oligonucleotide 78 cggttggcat ccatgtaa 18 79 18 DNA Artificial Sequence Antisense Oligonucleotide 79 ctctttgcca tcctcctg 18 80 18 DNA Artificial Sequence Antisense Oligonucleotide 80 ctgtctctcc tgcactga 18 81 18 DNA Artificial Sequence Antisense Oligonucleotide 81 ggtgcagcct cactgtct 18 82 18 DNA Artificial Sequence Antisense Oligonucleotide 82 aactgcctgt ttgcccac 18 83 18 DNA Artificial Sequence Antisense Oligonucleotide 83 cttctgcctg cacccctg 18 84 18 DNA Artificial Sequence Antisense Oligonucleotide 84 actgactggg catagctc 18 85 1240 DNA Homo sapiens CDS (48)...(881) 85 gcctcgctcg ggcgcccagt ggtcctgccg cctggtctca cctcgcc atg gtt cgt 56 Met Val Arg 1 taa gct gcc tct gca gtg cgt cct ctg ggg ctg ctt gct gac cgc tgt 104 * Ala Ala Ser Ala Val Arg Pro Leu Gly Leu Leu Ala Asp Arg Cys 5 10 15 cca tuu gca utg cuu taa acc aga acc acc cac tgc atg cag aga aaa 152 Pro Pro Ala Ala Leu * Thr Arg Thr Thr His Cys Met Gln Arg Lys 20 25 30 aca gta cct aat aaa cag tgu taa cag gug tua cag tgc tgt tct ttg 200 Thr Val Pro Asn Lys Gln Gln * Gln Val Val Gln Cys Cys Ser Leu 35 40 45 tgc cag cca gga cag aaa ctg gtg agt gac tgc gcc ucg ggu aac aca 248 Cys Gln Pro Gly Gln Lys Leu Val Ser Asp Cys Ala Ser Gly Asn Thr 50 55 60 gag ttc act gaa acg gaa tgc ctt cct tgc ggt gaa agc gaa ttc tgu 296 Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu Ser Glu Phe Phe 65 70 75 80 tgu tgu cuc ggu guc tag aca cct gga aca gag aga cac act gcc acc 344 Phe Phe Leu Gly Val * Thr Pro Gly Thr Glu Arg His Thr Ala Thr 85 90 95 agc aca aat act gcu att aag gut cgt cga ccc caa cct agg gct tcg 392 Ser Thr Asn Thr Ala Ile Lys Lys Arg Arg Pro Gln Pro Arg Ala Ser 100 105 110 ggt cca gca gaa ggg cac ctc aga aac aaa ugu aga ggg tgu tga cac 440 Gly Pro Ala Glu Gly His Leu Arg Asn Lys Cys Arg Gly Gly * His 115 120 125 cat ctg cac ctg tga aga agg ctg gca ctg tac gag tga ggc cat ctc 488 His Leu His Leu * Arg Arg Leu Ala Leu Tyr Glu * Gly His Leu 130 135 140 gug ugt ctg uaa tgt gag agc tgt gtc ctg cac cgc tca tgc tcg ccc 536 Val Val Leu * Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro 145 150 155 ggc ttt ggg gtc cgu cau agc gga aag cag att gct aca ggg gtt tct 584 Gly Phe Gly Val Arg His Ser Gly Lys Gln Ile Ala Thr Gly Val Ser 160 165 170 gat acc atc tgc gag ccc tgc cca gaa tga atc guc gtc ggc ttc ttc 632 Asp Thr Ile Cys Glu Pro Cys Pro Glu * Ile Val Val Gly Phe Phe 175 180 185 tcc aat gtg tca tct gct ttc gaa aaa tgt cac cct aga aaa guc tgg 680 Ser Asn Val Ser Ser Ala Phe Glu Lys Cys His Pro Arg Lys Val Trp 190 195 200 aca agc tgt gag acc aaa gac ctg gtt gtg caa cag gca ggc aca ttc 728 Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln Ala Gly Thr Phe 205 210 215 gut aua agg aag taa caa gac tga tgt tgt ctg tgg tcc cca gga tcg 776 Phe Ile Arg Lys * Gln Asp * Cys Cys Leu Trp Ser Pro Gly Ser 220 225 230 gct gag agc cct gat aaa cgg aag uag aau gtg gtg atc ccc atc atc 824 Ala Glu Ser Pro Asp Lys Arg Lys * Asn Val Val Ile Pro Ile Ile 235 240 245 ttc ggg atc ctg ttt gcc atc ctc ttg gtg aag uaa uua ctg gtc ttt 872 Phe Gly Ile Leu Phe Ala Ile Leu Leu Val Lys * Leu Leu Val Phe 250 255 260 atc aaa aag gtggccaaga agccaaccaa taaggccccc uaaaataaac 921 Ile Lys Lys 265 accccaagca ggaaccccag gagatcaatt ttcccgacga tcttcctggu gguaaauggc 981 tccaacactg ctgctccagt gcaggagact ttacatggat gccaagataa aaaggutugc 1041 gccggtcacc caggaggatg gcaaagagag tcgcatctca gtgcaggaga tgguagguag 1101 agguagacag tgaggctgca cccacccagg agtgtggcca cgtgggcaaa cagagggcag 1161 ttggccagag agcctggtgc tgctgctgca ggggtgcagg cagaagcggg gagctatgcc 1221 cagtcagtgc cagcccctc 1240 86 23 DNA Artificial Sequence PCR Primer 86 cagagttcac tgaaacggaa tgc 23 87 23 DNA Artificial Sequence PCR Primer 87 ggtggcagtg tgtctctctg ttc 23 88 25 DNA Artificial Sequence PCR Probe 88 ttccttgcgg tgaaagcgaa ttcct 25 89 19 DNA Artificial Sequence PCR Primer 89 gaaggtgaag gtcggagtc 19 90 20 DNA Artificial Sequence PCR Primer 90 gaagatggtg atgggatttc 20 91 20 DNA Artificial Sequence PCR Probe 91 caagcttccc gttctcagcc 20 92 20 DNA Artificial Sequence Antisense Oligonucleotide 92 agtggtcctg ccgcctggtc 20 93 18 DNA Artificial Sequence Antisense Oligonucleotide 93 gaacagcact gactgttt 18 94 18 DNA Artificial Sequence Antisense Oligonucleotide 94 agaacagcac tgactgtt 18 95 18 DNA Artificial Sequence Antisense Oligonucleotide 95 aagaacagca ctgactgt 18 96 18 DNA Artificial Sequence Antisense Oligonucleotide 96 aaagaacagc actgactg 18 97 18 DNA Artificial Sequence Antisense Oligonucleotide 97 caaagaacag cactgact 18 98 18 DNA Artificial Sequence Antisense Oligonucleotide 98 acaaagaaca gcactgac 18 99 18 DNA Artificial Sequence Antisense Oligonucleotide 99 cacaaagaac agcactga 18 100 18 DNA Artificial Sequence Antisense Oligonucleotide 100 gcacaaagaa cagcactg 18 101 18 DNA Artificial Sequence Antisense Oligonucleotide 101 ggcacaaaga acagcact 18 102 18 DNA Artificial Sequence Antisense Oligonucleotide 102 tggcacaaag aacagcac 18 103 18 DNA Artificial Sequence Antisense Oligonucleotide 103 gctggcacaa agaacagc 18 104 18 DNA Artificial Sequence Antisense Oligonucleotide 104 ggctggcaca aagaacag 18 105 18 DNA Artificial Sequence Antisense Oligonucleotide 105 tggctggcac aaagaaca 18 106 18 DNA Artificial Sequence Antisense Oligonucleotide 106 ctggctggca caaagaac 18 107 18 DNA Artificial Sequence Antisense Oligonucleotide 107 cctggctggc acaaagaa 18 108 18 DNA Artificial Sequence Antisense Oligonucleotide 108 tcctggctgg cacaaaga 18 109 18 DNA Artificial Sequence Antisense Oligonucleotide 109 gtcctggctg gcacaaag 18 110 18 DNA Artificial Sequence Antisense Oligonucleotide 110 tgtcctggct ggcacaaa 18 111 18 DNA Artificial Sequence Antisense Oligonucleotide 111 ctgtcctggc tggcacaa 18 112 18 DNA Artificial Sequence Antisense Oligonucleotide 112 tctgtcctgg ctggcaca 18 113 1058 DNA Homo sapiens CDS (77)...(658) 113 gccttgactt catctcagct ccagagcccg ccctctcttc ctgcagcctg ggaacttcag 60 ccggctggag cccacc atg gct gca atc cga aag aag ctg gtg atc gtt ggg 112 Met Ala Ala Ile Arg Lys Lys Leu Val Ile Val Gly 1 5 10 gat ggt gcc tgt ggg aag acc tgc ctc ctc atc gtc ttc agc aag gat 160 Asp Gly Ala Cys Gly Lys Thr Cys Leu Leu Ile Val Phe Ser Lys Asp 15 20 25 cag ttt ccg gag gtc tac gtc cct act gtc ttt gag aac tat att gcg 208 Gln Phe Pro Glu Val Tyr Val Pro Thr Val Phe Glu Asn Tyr Ile Ala 30 35 40 gac att gag gtg gac ggc aag cag gtg gag ctg gct ctg tgg gac aca 256 Asp Ile Glu Val Asp Gly Lys Gln Val Glu Leu Ala Leu Trp Asp Thr 45 50 55 60 gca ggg cag gaa gac tat gat cga ctg cgg cct ctc tcc tac ccg gac 304 Ala Gly Gln Glu Asp Tyr Asp Arg Leu Arg Pro Leu Ser Tyr Pro Asp 65 70 75 act gat gtc atc ctc atg tgc ttc tcc atc gac agc cct gac agc ctg 352 Thr Asp Val Ile Leu Met Cys Phe Ser Ile Asp Ser Pro Asp Ser Leu 80 85 90 gaa aac att cct gag aag tgg acc cca gag gtg aag cac ttc tgc ccc 400 Glu Asn Ile Pro Glu Lys Trp Thr Pro Glu Val Lys His Phe Cys Pro 95 100 105 aac gtg ccc atc atc ctg gtg ggg aat aag aag gac ctg agg caa gac 448 Asn Val Pro Ile Ile Leu Val Gly Asn Lys Lys Asp Leu Arg Gln Asp 110 115 120 gag cac acc agg aga gag ctg gcc aag atg aag cag gag ccc gtt cgg 496 Glu His Thr Arg Arg Glu Leu Ala Lys Met Lys Gln Glu Pro Val Arg 125 130 135 140 tct gag gaa ggc cgg gac atg gcg aac cgg atc agt gcc ttt ggc tac 544 Ser Glu Glu Gly Arg Asp Met Ala Asn Arg Ile Ser Ala Phe Gly Tyr 145 150 155 ctt gag tgc tca gcc aag acc aag gag gga gtg cgg gag gtg ttt gag 592 Leu Glu Cys Ser Ala Lys Thr Lys Glu Gly Val Arg Glu Val Phe Glu 160 165 170 atg gcc act cgg gct ggc ctc cag gtc cgc aag aac aag cgt cgg agg 640 Met Ala Thr Arg Ala Gly Leu Gln Val Arg Lys Asn Lys Arg Arg Arg 175 180 185 ggc tgt ccc att ctc tga gatcccccca aagggccctt ttcctacatg 688 Gly Cys Pro Ile Leu * 190 ccccctccct tcacaggggt acagaaatta tccccctaca accccagcct cctgagggct 748 ccatactgaa ggctccattt tcagttccct cctgcccagg actgcattgt tttctagccc 808 cgaggtgtgg cacgggccct ccctcccagc gctctgggag ccacgcctat gccctgccct 868 tcctcatggg cccctgggga tcttgcccct ttgaccttcc ccaaaggatg gtcacacacc 928 agcactttat acacttctgg ctcacaggaa agtgtctgca gtagggaccc agagtcccag 988 gcccctggag ttgtttctgc aggggccttg tctctcactg catttggtca ggggggcatg 1048 aataaaggct 1058 114 23 DNA Artificial Sequence PCR Primer 114 tgatgtcatc ctcatgtgct tct 23 115 19 DNA Artificial Sequence PCR Primer 115 ccaggatgat gggcacgtt 19 116 23 DNA Artificial Sequence PCR Probe 116 cgacagccct gacagcctgg aaa 23 117 18 DNA Artificial Sequence Antisense Oligonucleotide 117 gagctgagat gaagtcaa 18 118 18 DNA Artificial Sequence Antisense Oligonucleotide 118 gctgaagttc ccaggctg 18 119 18 DNA Artificial Sequence Antisense Oligonucleotide 119 ccggctgaag ttcccagg 18 120 18 DNA Artificial Sequence Antisense Oligonucleotide 120 ggcaccatcc ccaacgat 18 121 18 DNA Artificial Sequence Antisense Oligonucleotide 121 aggcaccatc cccaacga 18 122 18 DNA Artificial Sequence Antisense Oligonucleotide 122 tcccacaggc accatccc 18 123 18 DNA Artificial Sequence Antisense Oligonucleotide 123 aggtcttccc acaggcac 18 124 18 DNA Artificial Sequence Antisense Oligonucleotide 124 atgaggaggc aggtcttc 18 125 18 DNA Artificial Sequence Antisense Oligonucleotide 125 ttgctgaaga cgatgagg 18 126 18 DNA Artificial Sequence Antisense Oligonucleotide 126 tcaaagacag tagggacg 18 127 18 DNA Artificial Sequence Antisense Oligonucleotide 127 ttctcaaaga cagtaggg 18 128 18 DNA Artificial Sequence Antisense Oligonucleotide 128 agttctcaaa gacagtag 18 129 18 DNA Artificial Sequence Antisense Oligonucleotide 129 tgttttccag gctgtcag 18 130 18 DNA Artificial Sequence Antisense Oligonucleotide 130 tcgtcttgcc tcaggtcc 18 131 18 DNA Artificial Sequence Antisense Oligonucleotide 131 gtgtgctcgt cttgcctc 18 132 18 DNA Artificial Sequence Antisense Oligonucleotide 132 ctcctggtgt gctcgtct 18 133 18 DNA Artificial Sequence Antisense Oligonucleotide 133 cagaccgaac gggctcct 18 134 18 DNA Artificial Sequence Antisense Oligonucleotide 134 ttcctcagac cgaacggg 18 135 18 DNA Artificial Sequence Antisense Oligonucleotide 135 actcaaggta gccaaagg 18 136 18 DNA Artificial Sequence Antisense Oligonucleotide 136 ctcccgcact ccctcctt 18 137 18 DNA Artificial Sequence Antisense Oligonucleotide 137 ctcaaacacc tcccgcac 18 138 18 DNA Artificial Sequence Antisense Oligonucleotide 138 ggccatctca aacacctc 18 139 18 DNA Artificial Sequence Antisense Oligonucleotide 139 cttgttcttg cggacctg 18 140 18 DNA Artificial Sequence Antisense Oligonucleotide 140 cccctccgac gcttgttc 18 141 18 DNA Artificial Sequence Antisense Oligonucleotide 141 gtatggagcc ctcaggag 18 142 18 DNA Artificial Sequence Antisense Oligonucleotide 142 gagccttcag tatggagc 18 143 18 DNA Artificial Sequence Antisense Oligonucleotide 143 gaaaatggag ccttcagt 18 144 18 DNA Artificial Sequence Antisense Oligonucleotide 144 ggaactgaaa atggagcc 18 145 18 DNA Artificial Sequence Antisense Oligonucleotide 145 ggagggaact gaaaatgg 18 146 18 DNA Artificial Sequence Antisense Oligonucleotide 146 gcaggaggga actgaaaa 18 147 18 DNA Artificial Sequence Antisense Oligonucleotide 147 agggcagggc ataggcgt 18 148 18 DNA Artificial Sequence Antisense Oligonucleotide 148 ggaagggcag ggcatagg 18 149 18 DNA Artificial Sequence Antisense Oligonucleotide 149 catgaggaag ggcagggc 18 150 18 DNA Artificial Sequence Antisense Oligonucleotide 150 taaagtgctg gtgtgtga 18 151 18 DNA Artificial Sequence Antisense Oligonucleotide 151 cctgtgagcc agaagtgt 18 152 18 DNA Artificial Sequence Antisense Oligonucleotide 152 ttcctgtgag ccagaagt 18 153 18 DNA Artificial Sequence Antisense Oligonucleotide 153 cactttcctg tgagccag 18 154 18 DNA Artificial Sequence Antisense Oligonucleotide 154 agacactttc ctgtgagc 18 155 18 DNA Artificial Sequence Antisense Oligonucleotide 155 actctgggtc cctactgc 18 156 18 DNA Artificial Sequence Antisense Oligonucleotide 156 tgcagaaaca actccagg 18 157 3076 DNA Homo sapiens CDS (725)...(2539) 157 gaattcaaaa tgtcttcagt tgtaaatctt accattattt tacgtacctc taagaaataa 60 aagtgcttct aattaaaata tgatgtcatt aattatgaaa tacttcttga taacagaagt 120 tttaaaatag ccatcttaga atcagtgaaa tatggtaatg tattattttc ctcctttgag 180 ttaggtcttg tgcttttttt tcctggccac taaatttcac aatttccaaa aagcaaaata 240 aacatattct gaatattttt gctgtgaaac acttgacagc agagctttcc accatgaaaa 300 gaagcttcat gagtcacaca ttacatcttt gggttgattg aatgccactg aaacattcta 360 gtagcctgga gaagttgacc tacctgtgga gatgcctgcc attaaatggc atcctgatgg 420 cttaatacac atcactcttc tgtgaagggt tttaattttc aacacagctt actctgtagc 480 atcatgttta cattgtatgt ataaagatta tacaaaggtg caattgtgta tttcttcctt 540 aaaatgtatc agtataggat ttagaatctc catgttgaaa ctctaaatgc atagaaataa 600 aaataataaa aaatttttca ttttggcttt tcagcctagt attaaaactg ataaaagcaa 660 agccatgcac aaaactacct ccctagagaa aggctagtcc cttttcttcc ccattcattt 720 catt atg aac ata gta gaa aac agc ata ttc tta tca aat ttg atg aaa 769 Met Asn Ile Val Glu Asn Ser Ile Phe Leu Ser Asn Leu Met Lys 1 5 10 15 agc gcc aac acg ttt gaa ctg aaa tac gac ttg tca tgt gaa ctg tac 817 Ser Ala Asn Thr Phe Glu Leu Lys Tyr Asp Leu Ser Cys Glu Leu Tyr 20 25 30 cga atg tct acg tat tcc act ttt cct gct ggg gtt cct gtc tca gaa 865 Arg Met Ser Thr Tyr Ser Thr Phe Pro Ala Gly Val Pro Val Ser Glu 35 40 45 agg agt ctt gct cgt gct ggt ttc tat tac act ggt gtg aat gac aag 913 Arg Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly Val Asn Asp Lys 50 55 60 gtc aaa tgc ttc tgt tgt ggc ctg atg ctg gat aac tgg aaa aga gga 961 Val Lys Cys Phe Cys Cys Gly Leu Met Leu Asp Asn Trp Lys Arg Gly 65 70 75 gac agt cct act gaa aag cat aaa aag ttg tat cct agc tgc aga ttc 1009 Asp Ser Pro Thr Glu Lys His Lys Lys Leu Tyr Pro Ser Cys Arg Phe 80 85 90 95 gtt cag agt cta aat tcc gtt aac aac ttg gaa gct acc tct cag cct 1057 Val Gln Ser Leu Asn Ser Val Asn Asn Leu Glu Ala Thr Ser Gln Pro 100 105 110 act ttt cct tct tca gta aca aat tcc aca cac tca tta ctt ccg ggt 1105 Thr Phe Pro Ser Ser Val Thr Asn Ser Thr His Ser Leu Leu Pro Gly 115 120 125 aca gaa aac agt gga tat ttc cgt ggc tct tat tca aac tct cca tca 1153 Thr Glu Asn Ser Gly Tyr Phe Arg Gly Ser Tyr Ser Asn Ser Pro Ser 130 135 140 aat cct gta aac tcc aga gca aat caa gat ttt tct gcc ttg atg aga 1201 Asn Pro Val Asn Ser Arg Ala Asn Gln Asp Phe Ser Ala Leu Met Arg 145 150 155 agt tcc tac cac tgt gca atg aat aac gaa aat gcc aga tta ctt act 1249 Ser Ser Tyr His Cys Ala Met Asn Asn Glu Asn Ala Arg Leu Leu Thr 160 165 170 175 ttt cag aca tgg cca ttg act ttt ctg tcg cca aca gat ctg gca aaa 1297 Phe Gln Thr Trp Pro Leu Thr Phe Leu Ser Pro Thr Asp Leu Ala Lys 180 185 190 gca ggc ttt tac tac ata gga cct gga gac aga gtg gct tgc ttt gcc 1345 Ala Gly Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys Phe Ala 195 200 205 tgt ggt gga aaa ttg agc aat tgg gaa ccg aag gat aat gct atg tca 1393 Cys Gly Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp Asn Ala Met Ser 210 215 220 gaa cac ctg aga cat ttt ccc aaa tgc cca ttt ata gaa aat cag ctt 1441 Glu His Leu Arg His Phe Pro Lys Cys Pro Phe Ile Glu Asn Gln Leu 225 230 235 caa gac act tca aga tac aca gtt tct aat ctg agc atg cag aca cat 1489 Gln Asp Thr Ser Arg Tyr Thr Val Ser Asn Leu Ser Met Gln Thr His 240 245 250 255 gca gcc cgc ttt aaa aca ttc ttt aac tgg ccc tct agt gtt cta gtt 1537 Ala Ala Arg Phe Lys Thr Phe Phe Asn Trp Pro Ser Ser Val Leu Val 260 265 270 aat cct gag cag ctt gca agt gcg ggt ttt tat tat gtg ggt aac agt 1585 Asn Pro Glu Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Gly Asn Ser 275 280 285 gat gat gtc aaa tgc ttt tgc tgt gat ggt gga ctc agg tgt tgg gaa 1633 Asp Asp Val Lys Cys Phe Cys Cys Asp Gly Gly Leu Arg Cys Trp Glu 290 295 300 tct gga gat gat cca tgg gtt caa cat gcc aag tgg ttt cca agg tgt 1681 Ser Gly Asp Asp Pro Trp Val Gln His Ala Lys Trp Phe Pro Arg Cys 305 310 315 gag tac ttg ata aga att aaa gga cag gag ttc atc cgt caa gtt caa 1729 Glu Tyr Leu Ile Arg Ile Lys Gly Gln Glu Phe Ile Arg Gln Val Gln 320 325 330 335 gcc agt tac cct cat cta ctt gaa cag ctg cta tcc aca tca gac agc 1777 Ala Ser Tyr Pro His Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp Ser 340 345 350 cca gga gat gaa aat gca gag tca tca att atc cat ttt gaa cct gga 1825 Pro Gly Asp Glu Asn Ala Glu Ser Ser Ile Ile His Phe Glu Pro Gly 355 360 365 gaa gac cat tca gaa gat gca atc atg atg aat act cct gtg att aat 1873 Glu Asp His Ser Glu Asp Ala Ile Met Met Asn Thr Pro Val Ile Asn 370 375 380 gct gcc gtg gaa atg ggc ttt agt aga agc ctg gta aaa cag aca gtt 1921 Ala Ala Val Glu Met Gly Phe Ser Arg Ser Leu Val Lys Gln Thr Val 385 390 395 caa aga aaa atc cta gca act gga gag aat tat aga cta gtc aat gat 1969 Gln Arg Lys Ile Leu Ala Thr Gly Glu Asn Tyr Arg Leu Val Asn Asp 400 405 410 415 ctt gtg tta gac tta ctc aat gca gaa gat gaa ata agg gaa gag gag 2017 Leu Val Leu Asp Leu Leu Asn Ala Glu Asp Glu Ile Arg Glu Glu Glu 420 425 430 aga gaa aga gca act gag gaa aaa gaa tca aat gat tta tta tta atc 2065 Arg Glu Arg Ala Thr Glu Glu Lys Glu Ser Asn Asp Leu Leu Leu Ile 435 440 445 cgg aag aat aga atg gca ctt ttt caa cat ttg act tgt gta att cca 2113 Arg Lys Asn Arg Met Ala Leu Phe Gln His Leu Thr Cys Val Ile Pro 450 455 460 atc ctg gat agt cta cta act gcc gga att att aat gaa caa gaa cat 2161 Ile Leu Asp Ser Leu Leu Thr Ala Gly Ile Ile Asn Glu Gln Glu His 465 470 475 gat gtt att aaa cag aag aca cag acg tct tta caa gca aga gaa ctg 2209 Asp Val Ile Lys Gln Lys Thr Gln Thr Ser Leu Gln Ala Arg Glu Leu 480 485 490 495 att gat acg att tta gta aaa gga aat att gca gcc act gta ttc aga 2257 Ile Asp Thr Ile Leu Val Lys Gly Asn Ile Ala Ala Thr Val Phe Arg 500 505 510 aac tct ctg caa gaa gct gaa gct gtg tta tat gag cat tta ttt gtg 2305 Asn Ser Leu Gln Glu Ala Glu Ala Val Leu Tyr Glu His Leu Phe Val 515 520 525 caa cag gac ata aaa tat att ccc aca gaa gat gtt tca gat cta cca 2353 Gln Gln Asp Ile Lys Tyr Ile Pro Thr Glu Asp Val Ser Asp Leu Pro 530 535 540 gtg gaa gaa caa ttg cgg aga cta caa gaa gaa aga aca tgt aaa gtg 2401 Val Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Arg Thr Cys Lys Val 545 550 555 tgt atg gac aaa gaa gtg tcc ata gtg ttt att cct tgt ggt cat cta 2449 Cys Met Asp Lys Glu Val Ser Ile Val Phe Ile Pro Cys Gly His Leu 560 565 570 575 gta gta tgc aaa gat tgt gct cct tct tta aga aag tgt cct att tgt 2497 Val Val Cys Lys Asp Cys Ala Pro Ser Leu Arg Lys Cys Pro Ile Cys 580 585 590 agg agt aca atc aag ggt aca gtt cgt aca ttt ctt tca tga 2539 Arg Ser Thr Ile Lys Gly Thr Val Arg Thr Phe Leu Ser * 595 600 agaagaacca aaacatcatc taaactttag aattaattta ttaaatgtat tataacttta 2599 acttttatcc taatttggtt tccttaaaat ttttatttat ttacaactca aaaaacattg 2659 ttttgtgtaa catatttata tatgtatcta aaccatatga acatatattt tttagaaact 2719 aagagaatga taggcttttg ttcttatgaa cgaaaaagag gtagcactac aaacacaata 2779 ttcaatcaaa atttcagcat tattgaaatt gtaagtgaag taaaacttaa gatatttgag 2839 ttaaccttta agaattttaa atattttggc attgtactaa tacctggttt tttttttgtt 2899 ttgttttttt gtacagacag ggcagcatac tgagaccctg cctttaaaaa caaacagaac 2959 aaaaacaaaa caccagggac acatttctct gtcttttttg atcagtgtcc tatacatcga 3019 aggtgtgcat atatgttgaa tgacatttta gggacatggt gtttttataa agaattc 3076 158 22 DNA Artificial Sequence PCR Primer 158 ggactcaggt gttgggaatc tg 22 159 24 DNA Artificial Sequence PCR Primer 159 caagtactca caccttggaa acca 24 160 27 DNA Artificial Sequence PCR Probe 160 agatgatcca tgggttcaac atgccaa 27 161 18 DNA Artificial Sequence Antisense Oligonucleotide 161 actgaagaca ttttgaat 18 162 18 DNA Artificial Sequence Antisense Oligonucleotide 162 cttagaggta cgtaaaat 18 163 18 DNA Artificial Sequence Antisense Oligonucleotide 163 gcacttttat ttcttaga 18 164 18 DNA Artificial Sequence Antisense Oligonucleotide 164 attttaatta gaagcact 18 165 18 DNA Artificial Sequence Antisense Oligonucleotide 165 accatatttc actgattc 18 166 18 DNA Artificial Sequence Antisense Oligonucleotide 166 ctaactcaaa ggaggaaa 18 167 18 DNA Artificial Sequence Antisense Oligonucleotide 167 cacaagacct aactcaaa 18 168 18 DNA Artificial Sequence Antisense Oligonucleotide 168 gctctgctgt caagtgtt 18 169 18 DNA Artificial Sequence Antisense Oligonucleotide 169 tgtgtgactc atgaagct 18 170 18 DNA Artificial Sequence Antisense Oligonucleotide 170 ttcagtggca ttcaatca 18 171 18 DNA Artificial Sequence Antisense Oligonucleotide 171 cttctccagg ctactaga 18 172 18 DNA Artificial Sequence Antisense Oligonucleotide 172 ggtcaacttc tccaggct 18 173 18 DNA Artificial Sequence Antisense Oligonucleotide 173 taaaaccctt cacagaag 18 174 18 DNA Artificial Sequence Antisense Oligonucleotide 174 ttaaggaaga aatacaca 18 175 18 DNA Artificial Sequence Antisense Oligonucleotide 175 gcatggcttt gcttttat 18 176 18 DNA Artificial Sequence Antisense Oligonucleotide 176 caaacgtgtt ggcgcttt 18 177 18 DNA Artificial Sequence Antisense Oligonucleotide 177 agcaggaaaa gtggaata 18 178 18 DNA Artificial Sequence Antisense Oligonucleotide 178 ttaacggaat ttagactc 18 179 18 DNA Artificial Sequence Antisense Oligonucleotide 179 atttgttact gaagaagg 18 180 18 DNA Artificial Sequence Antisense Oligonucleotide 180 agagccacgg aaatatcc 18 181 18 DNA Artificial Sequence Antisense Oligonucleotide 181 aaatcttgat ttgctctg 18 182 18 DNA Artificial Sequence Antisense Oligonucleotide 182 gtaagtaatc tggcattt 18 183 18 DNA Artificial Sequence Antisense Oligonucleotide 183 agcaagccac tctgtctc 18 184 18 DNA Artificial Sequence Antisense Oligonucleotide 184 tgaagtgtct tgaagctg 18 185 18 DNA Artificial Sequence Antisense Oligonucleotide 185 tttgacatca tcactgtt 18 186 18 DNA Artificial Sequence Antisense Oligonucleotide 186 tggcttgaac ttgacgga 18 187 18 DNA Artificial Sequence Antisense Oligonucleotide 187 tcatctcctg ggctgtct 18 188 18 DNA Artificial Sequence Antisense Oligonucleotide 188 gcagcattaa tcacagga 18 189 18 DNA Artificial Sequence Antisense Oligonucleotide 189 tttctctctc ctcttccc 18 190 18 DNA Artificial Sequence Antisense Oligonucleotide 190 aacatcatgt tcttgttc 18 191 18 DNA Artificial Sequence Antisense Oligonucleotide 191 atataacaca gcttcagc 18 192 18 DNA Artificial Sequence Antisense Oligonucleotide 192 aattgttctt ccactggt 18 193 18 DNA Artificial Sequence Antisense Oligonucleotide 193 aagaaggagc acaatctt 18 194 18 DNA Artificial Sequence Antisense Oligonucleotide 194 gaaaccaaat taggataa 18 195 18 DNA Artificial Sequence Antisense Oligonucleotide 195 tgtagtgcta cctctttt 18 196 18 DNA Artificial Sequence Antisense Oligonucleotide 196 ctgaaatttt gattgaat 18 197 18 DNA Artificial Sequence Antisense Oligonucleotide 197 tacaatttca ataatgct 18 198 18 DNA Artificial Sequence Antisense Oligonucleotide 198 gggtctcagt atgctgcc 18 199 18 DNA Artificial Sequence Antisense Oligonucleotide 199 ccttcgatgt ataggaca 18 200 18 DNA Artificial Sequence Antisense Oligonucleotide 200 catgtcccta aaatgtca 18 201 2266 DNA Homo sapiens CDS (316)...(1602) 201 aattccgagc tgtagggaaa cgcaggggcg gcttctaggt gctgccgccg ccaccgccac 60 caccacctcc accgccgcct cggaacccag gcctgggggg cggtggggcc gcgtatggag 120 cccccgcccc ccggagctgc caacattgcc aacgccaccg ccacgctaca cacagcctca 180 actttcagga gacccgtccg tggccttatt tattccaccc ttcctgtaca tcgtagcgaa 240 tcaatccgtg gcgccgcact cctccgcatc cctctttaac agtacccctg ggatggcgtg 300 agcactcccc cagcg atg gac cca tct gtg acg ctg tgg cag ttt ctg ctg 351 Met Asp Pro Ser Val Thr Leu Trp Gln Phe Leu Leu 1 5 10 cag ctg ctg aga gag caa ggc aat ggc cac atc atc tcc tgg act tca 399 Gln Leu Leu Arg Glu Gln Gly Asn Gly His Ile Ile Ser Trp Thr Ser 15 20 25 cgg gat ggt ggt gaa ttc aag ctg gtg gat gca gag gag gtg gcc cgg 447 Arg Asp Gly Gly Glu Phe Lys Leu Val Asp Ala Glu Glu Val Ala Arg 30 35 40 ctg tgg gga cta cgc aag aac aag acc aac atg aat tac gac aag ctc 495 Leu Trp Gly Leu Arg Lys Asn Lys Thr Asn Met Asn Tyr Asp Lys Leu 45 50 55 60 agc cgg gcc ttg cgg tac tac tat gac aag aac atc atc cgc aag gtg 543 Ser Arg Ala Leu Arg Tyr Tyr Tyr Asp Lys Asn Ile Ile Arg Lys Val 65 70 75 agc ggc cag aag ttc gtc tac aag ttt gtg tcc tac cct gag gtc gca 591 Ser Gly Gln Lys Phe Val Tyr Lys Phe Val Ser Tyr Pro Glu Val Ala 80 85 90 ggg tgc tcc act gag gac tgc ccg ccc cag cca gag gtg tct gtt acc 639 Gly Cys Ser Thr Glu Asp Cys Pro Pro Gln Pro Glu Val Ser Val Thr 95 100 105 tcc acc atg cca aat gtg gcc cct gct gct ata cat gcc gcc cca ggg 687 Ser Thr Met Pro Asn Val Ala Pro Ala Ala Ile His Ala Ala Pro Gly 110 115 120 gac act gtc tct gga aag cca ggc aca ccc aag ggt gca gga atg gca 735 Asp Thr Val Ser Gly Lys Pro Gly Thr Pro Lys Gly Ala Gly Met Ala 125 130 135 140 ggc cca ggc ggt ttg gca cgc agc agc cgg aac gag tac atg cgc tcg 783 Gly Pro Gly Gly Leu Ala Arg Ser Ser Arg Asn Glu Tyr Met Arg Ser 145 150 155 ggc ctc tat tcc acc ttc acc atc cag tct ctg cag ccg cag cca ccc 831 Gly Leu Tyr Ser Thr Phe Thr Ile Gln Ser Leu Gln Pro Gln Pro Pro 160 165 170 cct cat cct cgg cct gct gtg gtg ctc ccc aat gca gct cct gca ggg 879 Pro His Pro Arg Pro Ala Val Val Leu Pro Asn Ala Ala Pro Ala Gly 175 180 185 gca gca gcg ccc ccc tcg ggg agc agg agc acc agt cca agc ccc ttg 927 Ala Ala Ala Pro Pro Ser Gly Ser Arg Ser Thr Ser Pro Ser Pro Leu 190 195 200 gag gcc tgt ctg gag gct gaa gag gcc ggc ttg cct ctg cag gtc atc 975 Glu Ala Cys Leu Glu Ala Glu Glu Ala Gly Leu Pro Leu Gln Val Ile 205 210 215 220 ctg acc ccg ccc gag gcc cca aac ctg aaa tcg gaa gag ctt aat gtg 1023 Leu Thr Pro Pro Glu Ala Pro Asn Leu Lys Ser Glu Glu Leu Asn Val 225 230 235 gag ccg ggt ttg ggc cgg gct ttg ccc cca gaa gtg aaa gta gaa ggg 1071 Glu Pro Gly Leu Gly Arg Ala Leu Pro Pro Glu Val Lys Val Glu Gly 240 245 250 ccc aag gaa gag ttg gaa gtt gcg ggg gag aga ggg ttt gtg cca gaa 1119 Pro Lys Glu Glu Leu Glu Val Ala Gly Glu Arg Gly Phe Val Pro Glu 255 260 265 acc acc aag gcc gag cca gaa gtc cct cca cag gag ggc gtg cca gcc 1167 Thr Thr Lys Ala Glu Pro Glu Val Pro Pro Gln Glu Gly Val Pro Ala 270 275 280 cgg ctg ccc gcg gtt gtt atg gac acc gca ggg cag gcg ggc ggc cat 1215 Arg Leu Pro Ala Val Val Met Asp Thr Ala Gly Gln Ala Gly Gly His 285 290 295 300 gcg gct tcc agc cct gag atc tcc cag ccg cag aag ggc cgg aag ccc 1263 Ala Ala Ser Ser Pro Glu Ile Ser Gln Pro Gln Lys Gly Arg Lys Pro 305 310 315 cgg gac cta gag ctt cca ctc agc ccg agc ctg cta ggt ggg ccg gga 1311 Arg Asp Leu Glu Leu Pro Leu Ser Pro Ser Leu Leu Gly Gly Pro Gly 320 325 330 ccc gaa cgg acc cca gga tcg gga agt ggc tcc ggc ctc cag gct ccg 1359 Pro Glu Arg Thr Pro Gly Ser Gly Ser Gly Ser Gly Leu Gln Ala Pro 335 340 345 ggg ccg gcg ctg acc cca tcc ctg ctt cct acg cat aca ttg acc ccg 1407 Gly Pro Ala Leu Thr Pro Ser Leu Leu Pro Thr His Thr Leu Thr Pro 350 355 360 gtg ctg ctg aca ccc agc tcg ctg cct cct agc att cac ttc tgg agc 1455 Val Leu Leu Thr Pro Ser Ser Leu Pro Pro Ser Ile His Phe Trp Ser 365 370 375 380 acc ctg agt ccc att gcg ccc cgt agc ccg gcc aag ctc tcc ttc cag 1503 Thr Leu Ser Pro Ile Ala Pro Arg Ser Pro Ala Lys Leu Ser Phe Gln 385 390 395 ttt cca tcc agt ggc agc gcc cag gtg cac atc cct tct atc agc gtg 1551 Phe Pro Ser Ser Gly Ser Ala Gln Val His Ile Pro Ser Ile Ser Val 400 405 410 gat ggc ctc tcg acc ccc gtg gtg ctc tcc cca ggg ccc cag aag cca 1599 Asp Gly Leu Ser Thr Pro Val Val Leu Ser Pro Gly Pro Gln Lys Pro 415 420 425 tga ctactaccac caccaccacc accccttctg gggtcactcc atccatgctc 1652 tctccagcca gccatctcaa ggagaaacat agttcaactg aaagactcat gctctgattg 1712 tggtggggtg gggatccttg ggaagaatta ctcccaagag taactctcat tatctcctcc 1772 acagaaaaca cacagcttcc acaacttctc tgttttctgt cagtccccca gtggccgccc 1832 ttacacgtct cctacttcaa tggtaggggc ggtttattta tttatttttt gaaggccact 1892 gggatgagcc tgacctaacc ttttagggtg gttaggacat ctcccccacc tccccacttt 1952 tttccccaag acaagacaat cgaggtctgg cttgagaacg acctttcttt ctttatttct 2012 cagcctgccc ttggggagat gagggagccc tgtctgcgtt tttggatgtg agtagaagag 2072 ttagtttgtt ttgttttatt attcctggcc atactcaggg gtccaggaag aatttgtacc 2132 atttaatggg ttgggagtct tggccaagga agaatcacac ccttggaata gaaatttcca 2192 cctcccccaa cctttctctc agacagctta tcctttttca accaactttt tggccaggga 2252 ggaatgtccc tttt 2266 202 18 DNA Artificial Sequence PCR Primer 202 gcaaggcaat ggccacat 18 203 21 DNA Artificial Sequence PCR Primer 203 ctcctctgca tccaccagct t 21 204 26 DNA Artificial Sequence PCR Probe 204 tctcctggac ttcacgggat ggtggt 26 205 18 DNA Artificial Sequence Antisense Oligonucleotide 205 cccctgcgtt tccctaca 18 206 18 DNA Artificial Sequence Antisense Oligonucleotide 206 ggtggtggtg gcggtggc 18 207 18 DNA Artificial Sequence Antisense Oligonucleotide 207 ggcgttggca atgttggc 18 208 18 DNA Artificial Sequence Antisense Oligonucleotide 208 aagttgaggc tgtgtgta 18 209 18 DNA Artificial Sequence Antisense Oligonucleotide 209 aggccacgga cgggtctc 18 210 18 DNA Artificial Sequence Antisense Oligonucleotide 210 gattgattcg ctacgatg 18 211 18 DNA Artificial Sequence Antisense Oligonucleotide 211 gggatgcgga ggagtgcg 18 212 18 DNA Artificial Sequence Antisense Oligonucleotide 212 agtgctcacg ccatccca 18 213 18 DNA Artificial Sequence Antisense Oligonucleotide 213 aaactgccac agcgtcac 18 214 18 DNA Artificial Sequence Antisense Oligonucleotide 214 gaagtccagg agatgatg 18 215 18 DNA Artificial Sequence Antisense Oligonucleotide 215 caccaccatc ccgtgaag 18 216 18 DNA Artificial Sequence Antisense Oligonucleotide 216 tcttgttctt gcgtagtc 18 217 18 DNA Artificial Sequence Antisense Oligonucleotide 217 tgttcttgtc atagtagt 18 218 18 DNA Artificial Sequence Antisense Oligonucleotide 218 tcaccttgcg gatgatgt 18 219 18 DNA Artificial Sequence Antisense Oligonucleotide 219 gagcaccctg cgacctca 18 220 18 DNA Artificial Sequence Antisense Oligonucleotide 220 ggcgggcagt cctcagtg 18 221 18 DNA Artificial Sequence Antisense Oligonucleotide 221 ggtgaaggtg gaatagag 18 222 18 DNA Artificial Sequence Antisense Oligonucleotide 222 tccgatttca ggtttggg 18 223 18 DNA Artificial Sequence Antisense Oligonucleotide 223 ttggtggttt ctggcaca 18 224 18 DNA Artificial Sequence Antisense Oligonucleotide 224 tggagggact tctggctc 18 225 18 DNA Artificial Sequence Antisense Oligonucleotide 225 gcgtaggaag cagggatg 18 226 18 DNA Artificial Sequence Antisense Oligonucleotide 226 gtgctccaga agtgaatg 18 227 18 DNA Artificial Sequence Antisense Oligonucleotide 227 actggatgga aactggaa 18 228 18 DNA Artificial Sequence Antisense Oligonucleotide 228 ggccatccac gctgatag 18 229 18 DNA Artificial Sequence Antisense Oligonucleotide 229 ccaccacaat cagagcat 18 230 18 DNA Artificial Sequence Antisense Oligonucleotide 230 gatccccacc ccaccaca 18 231 18 DNA Artificial Sequence Antisense Oligonucleotide 231 tgttttctgt ggaggaga 18 232 18 DNA Artificial Sequence Antisense Oligonucleotide 232 aaacagagaa gttgtgga 18 233 18 DNA Artificial Sequence Antisense Oligonucleotide 233 gggactgaca gaaaacag 18 234 18 DNA Artificial Sequence Antisense Oligonucleotide 234 ataaataaat aaaccgcc 18 235 18 DNA Artificial Sequence Antisense Oligonucleotide 235 gttaggtcag gctcatcc 18 236 18 DNA Artificial Sequence Antisense Oligonucleotide 236 gttctcaagc cagacctc 18 237 18 DNA Artificial Sequence Antisense Oligonucleotide 237 aataaagaaa gaaaggtc 18 238 18 DNA Artificial Sequence Antisense Oligonucleotide 238 agggcaggct gagaaata 18 239 18 DNA Artificial Sequence Antisense Oligonucleotide 239 cttctactca catccaaa 18 240 18 DNA Artificial Sequence Antisense Oligonucleotide 240 caaaacaaac taactctt 18 241 18 DNA Artificial Sequence Antisense Oligonucleotide 241 ggaataataa aacaaaac 18 242 18 DNA Artificial Sequence Antisense Oligonucleotide 242 ttcttcctgg acccctga 18 243 18 DNA Artificial Sequence Antisense Oligonucleotide 243 ccaagggtgt gattcttc 18 244 18 DNA Artificial Sequence Antisense Oligonucleotide 244 tgtctgagag aaaggttg 18 245 1080 DNA Homo sapiens CDS (1)...(1080) 245 atg act ctg gag tcc atc atg gcg tgt tgc ctg agc gat gag gtg aag 48 Met Thr Leu Glu Ser Ile Met Ala Cys Cys Leu Ser Asp Glu Val Lys 1 5 10 15 gag tcc aag cgg atc aac gcc gag atc gag aag cag ctg cgg cgg gac 96 Glu Ser Lys Arg Ile Asn Ala Glu Ile Glu Lys Gln Leu Arg Arg Asp 20 25 30 aag cgc gac gcc cgg cgc gag ctc aag ctg ctg ctg ctc ggc acg ggc 144 Lys Arg Asp Ala Arg Arg Glu Leu Lys Leu Leu Leu Leu Gly Thr Gly 35 40 45 gag agc ggg aag agc acg ttc atc aag cag atg cgc atc atc cac ggc 192 Glu Ser Gly Lys Ser Thr Phe Ile Lys Gln Met Arg Ile Ile His Gly 50 55 60 gcc ggc tac tcg gag gag gac aag cgc ggc ttc acc aag ctc gtc tac 240 Ala Gly Tyr Ser Glu Glu Asp Lys Arg Gly Phe Thr Lys Leu Val Tyr 65 70 75 80 cag aac atc ttc acc gcc atg cag gcc atg atc cgg gcc atg gag acg 288 Gln Asn Ile Phe Thr Ala Met Gln Ala Met Ile Arg Ala Met Glu Thr 85 90 95 ctc aag atc ctc tac aag tac gag cag aac aag gcc aat gcg ctc ctg 336 Leu Lys Ile Leu Tyr Lys Tyr Glu Gln Asn Lys Ala Asn Ala Leu Leu 100 105 110 atc cgg gag gtg gac gtg gag aag gtg acc acc ttc gag cat cag tac 384 Ile Arg Glu Val Asp Val Glu Lys Val Thr Thr Phe Glu His Gln Tyr 115 120 125 gtc agt gcc atc aag acc ctg tgg gag gac ccg ggc atc cag gaa tgc 432 Val Ser Ala Ile Lys Thr Leu Trp Glu Asp Pro Gly Ile Gln Glu Cys 130 135 140 tac gac cgc agg cgc gag tac cag ctc tcc gac tct gcc aag tac tac 480 Tyr Asp Arg Arg Arg Glu Tyr Gln Leu Ser Asp Ser Ala Lys Tyr Tyr 145 150 155 160 ctg acc gac gtt gac cgc atc gcc acc ttg ggc tac ctg ccc acc cag 528 Leu Thr Asp Val Asp Arg Ile Ala Thr Leu Gly Tyr Leu Pro Thr Gln 165 170 175 cag gac gtg ctg cgg gtc cgc gtg ccc acc acc ggc atc atc gag tac 576 Gln Asp Val Leu Arg Val Arg Val Pro Thr Thr Gly Ile Ile Glu Tyr 180 185 190 cct ttc gac ctg gag aac atc atc ttc cgg atg gtg gat gtg ggg ggc 624 Pro Phe Asp Leu Glu Asn Ile Ile Phe Arg Met Val Asp Val Gly Gly 195 200 205 cag cgg tcg gag cgg agg aag tgg atc cac tgc ttt gag aac gtg aca 672 Gln Arg Ser Glu Arg Arg Lys Trp Ile His Cys Phe Glu Asn Val Thr 210 215 220 tcc atc atg ttt ctc gtc gcc ctc agc gaa tac gac caa gtc ctg gtg 720 Ser Ile Met Phe Leu Val Ala Leu Ser Glu Tyr Asp Gln Val Leu Val 225 230 235 240 gag tcg gac aac gag aac cgg atg gag gag agc aaa gcc ctg ttc cgg 768 Glu Ser Asp Asn Glu Asn Arg Met Glu Glu Ser Lys Ala Leu Phe Arg 245 250 255 acc atc atc acc tac ccc tgg ttc cag aac tcc tcc gtc atc ctc ttc 816 Thr Ile Ile Thr Tyr Pro Trp Phe Gln Asn Ser Ser Val Ile Leu Phe 260 265 270 ctc aac aag aag gac ctg ctg gag gac aag atc ctg tac tcg cac ctg 864 Leu Asn Lys Lys Asp Leu Leu Glu Asp Lys Ile Leu Tyr Ser His Leu 275 280 285 gtg gac tac ttc ccc gag ttc gat ggt ccc cag cgg gac gcc cag gcg 912 Val Asp Tyr Phe Pro Glu Phe Asp Gly Pro Gln Arg Asp Ala Gln Ala 290 295 300 gcg cgg gag ttc atc ccg aag atg ttc gtg gac ctg aac ccc gac agc 960 Ala Arg Glu Phe Ile Pro Lys Met Phe Val Asp Leu Asn Pro Asp Ser 305 310 315 320 gac aag atc atc tac tca cac ttc acg tgt gcc acc gac acg gag aac 1008 Asp Lys Ile Ile Tyr Ser His Phe Thr Cys Ala Thr Asp Thr Glu Asn 325 330 335 atc cgc ttc gtg ttc gcg gcc gtg aag gac acc atc ctg cag ctg aac 1056 Ile Arg Phe Val Phe Ala Ala Val Lys Asp Thr Ile Leu Gln Leu Asn 340 345 350 ctg aag gag tac aat ctg gtc taa 1080 Leu Lys Glu Tyr Asn Leu Val * 355 246 20 DNA Artificial Sequence PCR Primer 246 tgaccacctt cgagcatcag 20 247 20 DNA Artificial Sequence PCR Primer 247 cggtcgtagc attcctggat 20 248 26 DNA Artificial Sequence PCR Probe 248 tcagtgccat caagaccctg tgggag 26 249 18 DNA Artificial Sequence Antisense Oligonucleotide 249 gatggactcc agagtcat 18 250 18 DNA Artificial Sequence Antisense Oligonucleotide 250 gccatgatgg actccaga 18 251 18 DNA Artificial Sequence Antisense Oligonucleotide 251 cacgccatga tggactcc 18 252 18 DNA Artificial Sequence Antisense Oligonucleotide 252 ctcatcgctc aggcaaca 18 253 18 DNA Artificial Sequence Antisense Oligonucleotide 253 cttcacctca tcgctcag 18 254 18 DNA Artificial Sequence Antisense Oligonucleotide 254 gactccttca cctcatcg 18 255 18 DNA Artificial Sequence Antisense Oligonucleotide 255 atccgcttgg actccttc 18 256 18 DNA Artificial Sequence Antisense Oligonucleotide 256 cgttgatccg cttggact 18 257 18 DNA Artificial Sequence Antisense Oligonucleotide 257 ctcgatctcg gcgttgat 18 258 18 DNA Artificial Sequence Antisense Oligonucleotide 258 cccgccgcag ctgcttct 18 259 18 DNA Artificial Sequence Antisense Oligonucleotide 259 cttgagctcg cgccgggc 18 260 18 DNA Artificial Sequence Antisense Oligonucleotide 260 gcagcagcag cttgagct 18 261 18 DNA Artificial Sequence Antisense Oligonucleotide 261 gcccgtgccg agcagcag 18 262 18 DNA Artificial Sequence Antisense Oligonucleotide 262 acgtgctctt cccgctct 18 263 18 DNA Artificial Sequence Antisense Oligonucleotide 263 atctgcttga tgaacgtg 18 264 18 DNA Artificial Sequence Antisense Oligonucleotide 264 cgcatctgct tgatgaac 18 265 18 DNA Artificial Sequence Antisense Oligonucleotide 265 gtagccggcg ccgtggat 18 266 18 DNA Artificial Sequence Antisense Oligonucleotide 266 tgtcctcctc cgagtagc 18 267 18 DNA Artificial Sequence Antisense Oligonucleotide 267 cttgtcctcc tccgagta 18 268 18 DNA Artificial Sequence Antisense Oligonucleotide 268 aagccgcgct tgtcctcc 18 269 18 DNA Artificial Sequence Antisense Oligonucleotide 269 tagacgagct tggtgaag 18 270 18 DNA Artificial Sequence Antisense Oligonucleotide 270 tgttctggta gacgagct 18 271 18 DNA Artificial Sequence Antisense Oligonucleotide 271 tggcggtgaa gatgttct 18 272 18 DNA Artificial Sequence Antisense Oligonucleotide 272 cggatcatgg cctgcatg 18 273 18 DNA Artificial Sequence Antisense Oligonucleotide 273 cgtctccatg gcccggat 18 274 18 DNA Artificial Sequence Antisense Oligonucleotide 274 tagaggatct tgagcgtc 18 275 18 DNA Artificial Sequence Antisense Oligonucleotide 275 tgtagaggat cttgagcg 18 276 18 DNA Artificial Sequence Antisense Oligonucleotide 276 tgctcgtact tgtagagg 18 277 18 DNA Artificial Sequence Antisense Oligonucleotide 277 gccttgttct gctcgtac 18 278 18 DNA Artificial Sequence Antisense Oligonucleotide 278 ttggccttgt tctgctcg 18 279 18 DNA Artificial Sequence Antisense Oligonucleotide 279 caggagcgca ttggcctt 18 280 18 DNA Artificial Sequence Antisense Oligonucleotide 280 ctccacgtcc acctcccg 18 281 18 DNA Artificial Sequence Antisense Oligonucleotide 281 ggtcaccttc tccacgtc 18 282 18 DNA Artificial Sequence Antisense Oligonucleotide 282 gatgctcgaa ggtggtca 18 283 18 DNA Artificial Sequence Antisense Oligonucleotide 283 actgacgtac tgatgctc 18 284 18 DNA Artificial Sequence Antisense Oligonucleotide 284 cttgatggca ctgacgta 18 285 18 DNA Artificial Sequence Antisense Oligonucleotide 285 cagggtcttg atggcact 18 286 18 DNA Artificial Sequence Antisense Oligonucleotide 286 ctggatgccc gggtcctc 18 287 18 DNA Artificial Sequence Antisense Oligonucleotide 287 tcctggatgc ccgggtcc 18 288 18 DNA Artificial Sequence Antisense Oligonucleotide 288 cgcctgcggt cgtagcat 18 289 18 DNA Artificial Sequence Antisense Oligonucleotide 289 gctggtactc gcgcctgc 18 290 18 DNA Artificial Sequence Antisense Oligonucleotide 290 tacttggcag agtcggag 18 291 18 DNA Artificial Sequence Antisense Oligonucleotide 291 gtcaggtagt acttggca 18 292 18 DNA Artificial Sequence Antisense Oligonucleotide 292 ggtcaacgtc ggtcaggt 18 293 18 DNA Artificial Sequence Antisense Oligonucleotide 293 gtggcgatgc ggtcaacg 18 294 18 DNA Artificial Sequence Antisense Oligonucleotide 294 gcaggtagcc caaggtgg 18 295 18 DNA Artificial Sequence Antisense Oligonucleotide 295 cgtcctgctg ggtgggca 18 296 18 DNA Artificial Sequence Antisense Oligonucleotide 296 ggtggtgggc acgcggac 18 297 18 DNA Artificial Sequence Antisense Oligonucleotide 297 tcgatgatgc cggtggtg 18 298 18 DNA Artificial Sequence Antisense Oligonucleotide 298 ccaggtcgaa agggtact 18 299 18 DNA Artificial Sequence Antisense Oligonucleotide 299 tgttctccag gtcgaaag 18 300 18 DNA Artificial Sequence Antisense Oligonucleotide 300 agatgatgtt ctccaggt 18 301 18 DNA Artificial Sequence Antisense Oligonucleotide 301 atccggaaga tgatgttc 18 302 18 DNA Artificial Sequence Antisense Oligonucleotide 302 ctccgctccg accgctgg 18 303 18 DNA Artificial Sequence Antisense Oligonucleotide 303 gatccacttc ctccgctc 18 304 18 DNA Artificial Sequence Antisense Oligonucleotide 304 tgtcacgttc tcaaagca 18 305 18 DNA Artificial Sequence Antisense Oligonucleotide 305 atgatggatg tcacgttc 18 306 18 DNA Artificial Sequence Antisense Oligonucleotide 306 cgagaaacat gatggatg 18 307 18 DNA Artificial Sequence Antisense Oligonucleotide 307 gctgagggcg acgagaaa 18 308 18 DNA Artificial Sequence Antisense Oligonucleotide 308 cgactccacc aggacttg 18 309 18 DNA Artificial Sequence Antisense Oligonucleotide 309 atccggttct cgttgtcc 18 310 18 DNA Artificial Sequence Antisense Oligonucleotide 310 ccatccggtt ctcgttgt 18 311 18 DNA Artificial Sequence Antisense Oligonucleotide 311 agggctttgc tctcctcc 18 312 18 DNA Artificial Sequence Antisense Oligonucleotide 312 ggtccggaac agggcttt 18 313 18 DNA Artificial Sequence Antisense Oligonucleotide 313 gtaggtgatg atggtccg 18 314 18 DNA Artificial Sequence Antisense Oligonucleotide 314 ggaggagttc tggaacca 18 315 18 DNA Artificial Sequence Antisense Oligonucleotide 315 tgaggaagag gatgacgg 18 316 18 DNA Artificial Sequence Antisense Oligonucleotide 316 gcaggtcctt cttgttga 18 317 18 DNA Artificial Sequence Antisense Oligonucleotide 317 atcttgtcct ccagcagg 18 318 18 DNA Artificial Sequence Antisense Oligonucleotide 318 gcgagtacag gatcttgt 18 319 18 DNA Artificial Sequence Antisense Oligonucleotide 319 aagtagtcca ccaggtgc 18 320 18 DNA Artificial Sequence Antisense Oligonucleotide 320 gatgaactcc cgcgccgc 18 321 18 DNA Artificial Sequence Antisense Oligonucleotide 321 ggttcaggtc cacgaaca 18 322 18 DNA Artificial Sequence Antisense Oligonucleotide 322 gtagatgatc ttgtcgct 18 323 18 DNA Artificial Sequence Antisense Oligonucleotide 323 cacgtgaagt gtgagtag 18 324 18 DNA Artificial Sequence Antisense Oligonucleotide 324 atgttctccg tgtcggtg 18 325 18 DNA Artificial Sequence Antisense Oligonucleotide 325 acggccgcga acacgaag 18 326 18 DNA Artificial Sequence Antisense Oligonucleotide 326 gatggtgtcc ttcacggc 18 327 18 DNA Artificial Sequence Antisense Oligonucleotide 327 tcaggttcag ctgcagga 18 328 18 DNA Artificial Sequence Antisense Oligonucleotide 328 accagattgt actccttc 18 329 2610 DNA Homo sapiens CDS (199)...(1641) 329 atcctgggac agggcacagg gccatctgtc accaggggct tagggaaggc cgagccagcc 60 tgggtcaaag aagtcaaagg ggctgcctgg aggaggcagc ctgtcagctg gtgcatcaga 120 ggctgtggcc aggccagctg ggctcgggga gcgccagcct gagaggagcg cgtgagcgtc 180 gcgggagcct cgggcacc atg agc gac gtg gct att gtg aag gag ggt tgg 231 Met Ser Asp Val Ala Ile Val Lys Glu Gly Trp 1 5 10 ctg cac aaa cga ggg gag tac atc aag acc tgg cgg cca cgc tac ttc 279 Leu His Lys Arg Gly Glu Tyr Ile Lys Thr Trp Arg Pro Arg Tyr Phe 15 20 25 ctc ctc aag aat gat ggc acc ttc att ggc tac aag gag cgg ccg cag 327 Leu Leu Lys Asn Asp Gly Thr Phe Ile Gly Tyr Lys Glu Arg Pro Gln 30 35 40 gat gtg gac caa cgt gag gct ccc ctc aac aac ttc tct gtg gcg cag 375 Asp Val Asp Gln Arg Glu Ala Pro Leu Asn Asn Phe Ser Val Ala Gln 45 50 55 tgc cag ctg atg aag acg gag cgg ccc cgg ccc aac acc ttc atc atc 423 Cys Gln Leu Met Lys Thr Glu Arg Pro Arg Pro Asn Thr Phe Ile Ile 60 65 70 75 cgc tgc ctg cag tgg acc act gtc atc gaa cgc acc ttc cat gtg gag 471 Arg Cys Leu Gln Trp Thr Thr Val Ile Glu Arg Thr Phe His Val Glu 80 85 90 act cct gag gag cgg gag gag tgg aca acc gcc atc cag act gtg gct 519 Thr Pro Glu Glu Arg Glu Glu Trp Thr Thr Ala Ile Gln Thr Val Ala 95 100 105 gac ggc ctc aag aag cag gag gag gag gag atg gac ttc cgg tcg ggc 567 Asp Gly Leu Lys Lys Gln Glu Glu Glu Glu Met Asp Phe Arg Ser Gly 110 115 120 tca ccc agt gac aac tca ggg gct gaa gag atg gag gtg tcc ctg gcc 615 Ser Pro Ser Asp Asn Ser Gly Ala Glu Glu Met Glu Val Ser Leu Ala 125 130 135 aag ccc aag cac cgc gtg acc atg aac gag ttt gag tac ctg aag ctg 663 Lys Pro Lys His Arg Val Thr Met Asn Glu Phe Glu Tyr Leu Lys Leu 140 145 150 155 ctg ggc aag ggc act ttc ggc aag gtg atc ctg gtg aag gag aag gcc 711 Leu Gly Lys Gly Thr Phe Gly Lys Val Ile Leu Val Lys Glu Lys Ala 160 165 170 aca ggc cgc tac tac gcc atg aag atc ctc aag aag gaa gtc atc gtg 759 Thr Gly Arg Tyr Tyr Ala Met Lys Ile Leu Lys Lys Glu Val Ile Val 175 180 185 gcc aag gac gag gtg gcc cac aca ctc acc gag aac cgc gtc ctg cag 807 Ala Lys Asp Glu Val Ala His Thr Leu Thr Glu Asn Arg Val Leu Gln 190 195 200 aac tcc agg cac ccc ttc ctc aca gcc ctg aag tac tct ttc cag acc 855 Asn Ser Arg His Pro Phe Leu Thr Ala Leu Lys Tyr Ser Phe Gln Thr 205 210 215 cac gac cgc ctc tgc ttt gtc atg gag tac gcc aac ggg ggc gag ctg 903 His Asp Arg Leu Cys Phe Val Met Glu Tyr Ala Asn Gly Gly Glu Leu 220 225 230 235 ttc ttc cac ctg tcc cgg gaa cgt gtg ttc tcc gag gac cgg gcc cgc 951 Phe Phe His Leu Ser Arg Glu Arg Val Phe Ser Glu Asp Arg Ala Arg 240 245 250 ttc tat ggc gct gag att gtg tca gcc ctg gac tac ctg cac tcg gag 999 Phe Tyr Gly Ala Glu Ile Val Ser Ala Leu Asp Tyr Leu His Ser Glu 255 260 265 aag aac gtg gtg tac cgg gac ctc aag ctg gag aac ctc atg ctg gac 1047 Lys Asn Val Val Tyr Arg Asp Leu Lys Leu Glu Asn Leu Met Leu Asp 270 275 280 aag gac ggg cac att aag atc aca gac ttc ggg ctg tgc aag gag ggg 1095 Lys Asp Gly His Ile Lys Ile Thr Asp Phe Gly Leu Cys Lys Glu Gly 285 290 295 atc aag gac ggt gcc acc atg aag acc ttt tgc ggc aca cct gag tac 1143 Ile Lys Asp Gly Ala Thr Met Lys Thr Phe Cys Gly Thr Pro Glu Tyr 300 305 310 315 ctg gcc ccc gag gtg ctg gag gac aat gac tac ggc cgt gca gtg gac 1191 Leu Ala Pro Glu Val Leu Glu Asp Asn Asp Tyr Gly Arg Ala Val Asp 320 325 330 tgg tgg ggg ctg ggc gtg gtc atg tac gag atg atg tgc ggt cgc ctg 1239 Trp Trp Gly Leu Gly Val Val Met Tyr Glu Met Met Cys Gly Arg Leu 335 340 345 ccc ttc tac aac cag gac cat gag aag ctt ttt gag ctc atc ctc atg 1287 Pro Phe Tyr Asn Gln Asp His Glu Lys Leu Phe Glu Leu Ile Leu Met 350 355 360 gag gag atc cgc ttc ccg cgc acg ctt ggt ccc gag gcc aag tcc ttg 1335 Glu Glu Ile Arg Phe Pro Arg Thr Leu Gly Pro Glu Ala Lys Ser Leu 365 370 375 ctt tca ggg ctg ctc aag aag gac ccc aag cag agg ctt ggc ggg ggc 1383 Leu Ser Gly Leu Leu Lys Lys Asp Pro Lys Gln Arg Leu Gly Gly Gly 380 385 390 395 tcc gag gac gcc aag gag atc atg cag cat cgc ttc ttt gcc ggt atc 1431 Ser Glu Asp Ala Lys Glu Ile Met Gln His Arg Phe Phe Ala Gly Ile 400 405 410 gtg tgg cag cac gtg tac gag aag aag ctc agc cca ccc ttc aag ccc 1479 Val Trp Gln His Val Tyr Glu Lys Lys Leu Ser Pro Pro Phe Lys Pro 415 420 425 cag gtc acg tcg gag act gac acc agg tat ttt gat gag gag ttc acg 1527 Gln Val Thr Ser Glu Thr Asp Thr Arg Tyr Phe Asp Glu Glu Phe Thr 430 435 440 gcc cag atg atc acc atc aca cca cct gac caa gat gac agc atg gag 1575 Ala Gln Met Ile Thr Ile Thr Pro Pro Asp Gln Asp Asp Ser Met Glu 445 450 455 tgt gtg gac agc gag cgc agg ccc cac ttc ccc cag ttc tcc tac tcg 1623 Cys Val Asp Ser Glu Arg Arg Pro His Phe Pro Gln Phe Ser Tyr Ser 460 465 470 475 gcc agc agc acg gcc tga ggcggcggtg gactgcgctg gacgatagct 1671 Ala Ser Ser Thr Ala * 480 tggagggatg gagaggcggc ctcgtgccat gatctgtatt taatggtttt tatttctcgg 1731 gtgcatttga gagaagccac gctgtcctct cgagcccaga tggaaagacg tttttgtgct 1791 gtgggcagca ccctcccccg cagcggggta gggaagaaaa ctatcctgcg ggttttaatt 1851 tatttcatcc agtttgttct ccgggtgtgg cctcagccct cagaacaatc cgattcacgt 1911 agggaaatgt taaggacttc tacagctatg cgcaatgtgg cattgggggg ccgggcaggt 1971 cctgcccatg tgtcccctca ctctgtcagc cagccgccct gggctgtctg tcaccagcta 2031 tctgtcatct ctctggggcc ctgggcctca gttcaacctg gtggcaccag atgcaacctc 2091 actatggtat gctggccagc accctctcct gggggtggca ggcacacagc agccccccag 2151 cactaaggcc gtgtctctga ggacgtcatc ggaggctggg cccctgggat gggaccaggg 2211 atgggggatg ggccagggtt tacccagtgg gacagaggag caaggtttaa atttgttatt 2271 gtgtattatg ttgttcaaat gcattttggg ggtttttaat ctttgtgaca ggaaagccct 2331 cccccttccc cttctgtgtc acagttcttg gtgactgtcc caccggagcc tccccctcag 2391 atgatctctc cacggtagca cttgaccttt tcgacgctta acctttccgc tgtcgcccca 2451 ggccctccct gactccctgt gggggtggcc atccctgggc ccctccacgc ctcctggcca 2511 gacgctgccg ctgccgctgc accacggcgt ttttttacaa cattcaactt tagtattttt 2571 actattataa tataatatgg aaccttccct ccaaattct 2610 330 21 DNA Artificial Sequence PCR Primer 330 cgtgaccatg aacgagtttg a 21 331 19 DNA Artificial Sequence PCR Primer 331 caggatcacc ttgccgaaa 19 332 22 DNA Artificial Sequence PCR Probe 332 ctgaagctgc tgggcaaggg ca 22 333 18 DNA Artificial Sequence Antisense Oligonucleotide 333 ccctgtgccc tgtcccag 18 334 18 DNA Artificial Sequence Antisense Oligonucleotide 334 cctaagcccc tggtgaca 18 335 18 DNA Artificial Sequence Antisense Oligonucleotide 335 ctttgacttc tttgaccc 18 336 18 DNA Artificial Sequence Antisense Oligonucleotide 336 ggcagcccct ttgacttc 18 337 18 DNA Artificial Sequence Antisense Oligonucleotide 337 caaccctcct tcacaata 18 338 18 DNA Artificial Sequence Antisense Oligonucleotide 338 tactcccctc gtttgtgc 18 339 18 DNA Artificial Sequence Antisense Oligonucleotide 339 tgccatcatt cttgagga 18 340 18 DNA Artificial Sequence Antisense Oligonucleotide 340 agccaatgaa ggtgccat 18 341 18 DNA Artificial Sequence Antisense Oligonucleotide 341 cacagagaag ttgttgag 18 342 18 DNA Artificial Sequence Antisense Oligonucleotide 342 agtctggatg gcggttgt 18 343 18 DNA Artificial Sequence Antisense Oligonucleotide 343 tcctcctcct cctgcttc 18 344 18 DNA Artificial Sequence Antisense Oligonucleotide 344 cctgagttgt cactgggt 18 345 18 DNA Artificial Sequence Antisense Oligonucleotide 345 ccgaaagtgc ccttgccc 18 346 18 DNA Artificial Sequence Antisense Oligonucleotide 346 gccacgatga cttccttc 18 347 18 DNA Artificial Sequence Antisense Oligonucleotide 347 cggtcctcgg agaacaca 18 348 18 DNA Artificial Sequence Antisense Oligonucleotide 348 acgttcttct ccgagtgc 18 349 18 DNA Artificial Sequence Antisense Oligonucleotide 349 gtgccgcaaa aggtcttc 18 350 18 DNA Artificial Sequence Antisense Oligonucleotide 350 tactcaggtg tgccgcaa 18 351 18 DNA Artificial Sequence Antisense Oligonucleotide 351 ggcttgaagg gtgggctg 18 352 18 DNA Artificial Sequence Antisense Oligonucleotide 352 tcaaaatacc tggtgtca 18 353 18 DNA Artificial Sequence Antisense Oligonucleotide 353 gccgtgaact cctcatca 18 354 18 DNA Artificial Sequence Antisense Oligonucleotide 354 ggtcaggtgg tgtgatgg 18 355 18 DNA Artificial Sequence Antisense Oligonucleotide 355 ctcgctgtcc acacactc 18 356 18 DNA Artificial Sequence Antisense Oligonucleotide 356 gcctctccat ccctccaa 18 357 18 DNA Artificial Sequence Antisense Oligonucleotide 357 acagcgtggc ttctctca 18 358 18 DNA Artificial Sequence Antisense Oligonucleotide 358 ttttcttccc taccccgc 18 359 18 DNA Artificial Sequence Antisense Oligonucleotide 359 gatagttttc ttccctac 18 360 18 DNA Artificial Sequence Antisense Oligonucleotide 360 taaaacccgc aggatagt 18 361 18 DNA Artificial Sequence Antisense Oligonucleotide 361 ggagaacaaa ctggatga 18 362 18 DNA Artificial Sequence Antisense Oligonucleotide 362 ctggctgaca gagtgagg 18 363 18 DNA Artificial Sequence Antisense Oligonucleotide 363 gcggctggct gacagagt 18 364 18 DNA Artificial Sequence Antisense Oligonucleotide 364 cccagagaga tgacagat 18 365 18 DNA Artificial Sequence Antisense Oligonucleotide 365 gctgctgtgt gcctgcca 18 366 18 DNA Artificial Sequence Antisense Oligonucleotide 366 cataatacac aataacaa 18 367 18 DNA Artificial Sequence Antisense Oligonucleotide 367 atttgaacaa cataatac 18 368 18 DNA Artificial Sequence Antisense Oligonucleotide 368 aagtgctacc gtggagag 18 369 18 DNA Artificial Sequence Antisense Oligonucleotide 369 cgaaaaggtc aagtgcta 18 370 18 DNA Artificial Sequence Antisense Oligonucleotide 370 cagggagtca gggagggc 18 371 18 DNA Artificial Sequence Antisense Oligonucleotide 371 aaagttgaat gttgtaaa 18 372 18 DNA Artificial Sequence Antisense Oligonucleotide 372 aaaatactaa agttgaat 18 373 20 DNA Artificial Sequence Antisense Oligonucleotide 373 tccgtcatcg ctcctcaggg 20 374 20 DNA Artificial Sequence Antisense Oligonucleotide 374 gtgcgcgcga gcccgaaatc 20 375 20 DNA Artificial Sequence Antisense Oligonucleotide 375 atgcattctg cccccaagga 20 376 4749 DNA Homo sapiens CDS (52)...(3768) 376 ggagcgggcg cgcggcggcg gcggggccgc ggcgggcggg tcgcgggggc a atg cgg 57 Met Arg 1 gcg cag ggc cgg ggg gcc ttc ccc ccg gcg ctg ctg ctg ctg ctg gcg 105 Ala Gln Gly Arg Gly Ala Phe Pro Pro Ala Leu Leu Leu Leu Leu Ala 5 10 15 ctc tgg gtg cag gcg gcg cgg ccc atg ggc tat ttc gag ctg cag ctg 153 Leu Trp Val Gln Ala Ala Arg Pro Met Gly Tyr Phe Glu Leu Gln Leu 20 25 30 agc gcg ctg cgg aac gtg aac ggg gag ctg ctg agc ggc gcc tgc tgt 201 Ser Ala Leu Arg Asn Val Asn Gly Glu Leu Leu Ser Gly Ala Cys Cys 35 40 45 50 gac ggc gac ggc cgg aca acg cgc gcg ggg ggc tgc ggc cac gac gag 249 Asp Gly Asp Gly Arg Thr Thr Arg Ala Gly Gly Cys Gly His Asp Glu 55 60 65 tgc gac acg tac gtg cgc gtg tgc ctt aag gag tac cag gcc aag gtg 297 Cys Asp Thr Tyr Val Arg Val Cys Leu Lys Glu Tyr Gln Ala Lys Val 70 75 80 acg ccc acg ggg ccc tgc agc tac ggc cac ggc gcc acg ccc gtg ctg 345 Thr Pro Thr Gly Pro Cys Ser Tyr Gly His Gly Ala Thr Pro Val Leu 85 90 95 ggc ggc aac tcc ttc tac ctg ccg ccg gcg ggc gct gcg ggg gac cga 393 Gly Gly Asn Ser Phe Tyr Leu Pro Pro Ala Gly Ala Ala Gly Asp Arg 100 105 110 gcg cgc gcg cgg ccc cgg gcc ggc ggc gac cag gac ccg ggc ttc gtc 441 Ala Arg Ala Arg Pro Arg Ala Gly Gly Asp Gln Asp Pro Gly Phe Val 115 120 125 130 gtc atc ccc ttc cag ttc gcc tgg ccg cgc tcc ttt acc ctc atc gtg 489 Val Ile Pro Phe Gln Phe Ala Trp Pro Arg Ser Phe Thr Leu Ile Val 135 140 145 gag gcc tgg gac tgg gac aac gat acc acc ccg aat gag gag ctg ctg 537 Glu Ala Trp Asp Trp Asp Asn Asp Thr Thr Pro Asn Glu Glu Leu Leu 150 155 160 atc gag cga gtg tcg cat gcc ggc atg atc aac ccg gag gac cgc tgg 585 Ile Glu Arg Val Ser His Ala Gly Met Ile Asn Pro Glu Asp Arg Trp 165 170 175 aag agc ctg cac ttc agc ggc cac gtg gcg cac ctg gag ctg cag atc 633 Lys Ser Leu His Phe Ser Gly His Val Ala His Leu Glu Leu Gln Ile 180 185 190 cgc gtg cgc tgc gac gag aac tac tac agc gcc act tgc aac aag ttc 681 Arg Val Arg Cys Asp Glu Asn Tyr Tyr Ser Ala Thr Cys Asn Lys Phe 195 200 205 210 tgc cgg ccc cgc aac gac ttt ttc ggc cac tac acc tgc gac cag tac 729 Cys Arg Pro Arg Asn Asp Phe Phe Gly His Tyr Thr Cys Asp Gln Tyr 215 220 225 ggc aac aag gcc tgc atg gac ggc tgg atg ggc aag gag tgc aag gaa 777 Gly Asn Lys Ala Cys Met Asp Gly Trp Met Gly Lys Glu Cys Lys Glu 230 235 240 gct gtg tgt aaa caa ggg tgt aat ttg ctc cac ggg gga tgc acc gtg 825 Ala Val Cys Lys Gln Gly Cys Asn Leu Leu His Gly Gly Cys Thr Val 245 250 255 cct ggg gag tgc agg tgc agc tac ggc tgg caa ggg agg ttc tgc gat 873 Pro Gly Glu Cys Arg Cys Ser Tyr Gly Trp Gln Gly Arg Phe Cys Asp 260 265 270 gag tgt gtc ccc tac ccc ggc tgc gtg cat ggc agt tgt gtg gag ccc 921 Glu Cys Val Pro Tyr Pro Gly Cys Val His Gly Ser Cys Val Glu Pro 275 280 285 290 tgg cag tgc aac tgt gag acc aac tgg ggc ggc ctg ctc tgt gac aaa 969 Trp Gln Cys Asn Cys Glu Thr Asn Trp Gly Gly Leu Leu Cys Asp Lys 295 300 305 gac ctg aac tac tgt ggc agc cac cac ccc tgc acc aac gga ggc acg 1017 Asp Leu Asn Tyr Cys Gly Ser His His Pro Cys Thr Asn Gly Gly Thr 310 315 320 tgc atc aac gcc gag cct gac cag tac cgc tgc acc tgc cct gac ggc 1065 Cys Ile Asn Ala Glu Pro Asp Gln Tyr Arg Cys Thr Cys Pro Asp Gly 325 330 335 tac tcg ggc agg aac tgt gag aag gct gag cac gcc tgc acc tcc aac 1113 Tyr Ser Gly Arg Asn Cys Glu Lys Ala Glu His Ala Cys Thr Ser Asn 340 345 350 ccg tgt gcc aac ggg ggc tct tgc cat gag gtg ccg tcc ggc ttc gaa 1161 Pro Cys Ala Asn Gly Gly Ser Cys His Glu Val Pro Ser Gly Phe Glu 355 360 365 370 tgc cac tgc cca tcg ggc tgg agc ggg ccc acc tgt gcc ctt gac atc 1209 Cys His Cys Pro Ser Gly Trp Ser Gly Pro Thr Cys Ala Leu Asp Ile 375 380 385 gat gag tgt gct tcg aac ccg tgt gcg gcc ggt ggc acc tgt gtg gac 1257 Asp Glu Cys Ala Ser Asn Pro Cys Ala Ala Gly Gly Thr Cys Val Asp 390 395 400 cag gtg gac ggc ttt gag tgc atc tgc ccc gag cag tgg gtg ggg gcc 1305 Gln Val Asp Gly Phe Glu Cys Ile Cys Pro Glu Gln Trp Val Gly Ala 405 410 415 acc tgc cag ctg gac gtc aac gac tgt gaa ggg aag cca tgc ctt aac 1353 Thr Cys Gln Leu Asp Val Asn Asp Cys Glu Gly Lys Pro Cys Leu Asn 420 425 430 gct ttt tct tgc aaa aac ctg att ggc ggc tat tac tgt gat tgc atc 1401 Ala Phe Ser Cys Lys Asn Leu Ile Gly Gly Tyr Tyr Cys Asp Cys Ile 435 440 445 450 ccg ggc tgg aag ggc atc aac tgc cat atc aac gtc aac gac tgt cgc 1449 Pro Gly Trp Lys Gly Ile Asn Cys His Ile Asn Val Asn Asp Cys Arg 455 460 465 ggg cag tgt cag cat ggg ggc acc tgc aag gac ctg gtg aac ggg tac 1497 Gly Gln Cys Gln His Gly Gly Thr Cys Lys Asp Leu Val Asn Gly Tyr 470 475 480 cag tgt gtg tgc cca cgg ggc ttc gga ggc cgg cat tgc gag ctg gaa 1545 Gln Cys Val Cys Pro Arg Gly Phe Gly Gly Arg His Cys Glu Leu Glu 485 490 495 cga gac aag tgt gcc agc agc ccc tgc cac agc ggc ggc ctc tgc gag 1593 Arg Asp Lys Cys Ala Ser Ser Pro Cys His Ser Gly Gly Leu Cys Glu 500 505 510 gac ctg gcc gac ggc ttc cac tgc cac tgc ccc cag ggc ttc tcc ggg 1641 Asp Leu Ala Asp Gly Phe His Cys His Cys Pro Gln Gly Phe Ser Gly 515 520 525 530 cct ctc tgt gag gtg gat gtc gac ctt tgt gag cca agc ccc tgc cgg 1689 Pro Leu Cys Glu Val Asp Val Asp Leu Cys Glu Pro Ser Pro Cys Arg 535 540 545 aac ggc gct cgc tgc tat aac ctg gag ggt gac tat tac tgc gcc tgc 1737 Asn Gly Ala Arg Cys Tyr Asn Leu Glu Gly Asp Tyr Tyr Cys Ala Cys 550 555 560 cct gat gac ttt ggt ggc aag aac tgc tcc gtg ccc cgc gag ccg tgc 1785 Pro Asp Asp Phe Gly Gly Lys Asn Cys Ser Val Pro Arg Glu Pro Cys 565 570 575 cct ggc ggg gcc tgc aga gtg atc gat ggc tgc ggg tca gac gcg ggg 1833 Pro Gly Gly Ala Cys Arg Val Ile Asp Gly Cys Gly Ser Asp Ala Gly 580 585 590 cct ggg atg cct ggc aca gca gcc tcc ggc gtg tgt ggc ccc cat gga 1881 Pro Gly Met Pro Gly Thr Ala Ala Ser Gly Val Cys Gly Pro His Gly 595 600 605 610 cgc tgc gtc agc cag cca ggg ggc aac ttt tcc tgc atc tgt gac agt 1929 Arg Cys Val Ser Gln Pro Gly Gly Asn Phe Ser Cys Ile Cys Asp Ser 615 620 625 ggc ttt act ggc acc tac tgc cat gag aac att gac gac tgc ctg ggc 1977 Gly Phe Thr Gly Thr Tyr Cys His Glu Asn Ile Asp Asp Cys Leu Gly 630 635 640 cag ccc tgc cgc aat ggg ggc aca tgc atc gat gag gtg gac gcc ttc 2025 Gln Pro Cys Arg Asn Gly Gly Thr Cys Ile Asp Glu Val Asp Ala Phe 645 650 655 cgc tgc ttc tgc ccc agc ggc tgg gag ggc gag ctc tgc gac acc aat 2073 Arg Cys Phe Cys Pro Ser Gly Trp Glu Gly Glu Leu Cys Asp Thr Asn 660 665 670 ccc aac gac tgc ctt ccc gat ccc tgc cac agc cgc ggc cgc tgc tac 2121 Pro Asn Asp Cys Leu Pro Asp Pro Cys His Ser Arg Gly Arg Cys Tyr 675 680 685 690 gac ctg gtc aat gac ttc tac tgt gcg tgc gac gac ggc tgg aag ggc 2169 Asp Leu Val Asn Asp Phe Tyr Cys Ala Cys Asp Asp Gly Trp Lys Gly 695 700 705 aag acc tgc cac tca cgc gag ttc cag tgc gat gcc tac acc tgc agc 2217 Lys Thr Cys His Ser Arg Glu Phe Gln Cys Asp Ala Tyr Thr Cys Ser 710 715 720 aac ggt ggc acc tgc tac gac agc ggc gac acc ttc cgc tgc gcc tgc 2265 Asn Gly Gly Thr Cys Tyr Asp Ser Gly Asp Thr Phe Arg Cys Ala Cys 725 730 735 ccc ccc ggc tgg aag ggc agc acc tgc gcc gtc gcc aag aac agc agc 2313 Pro Pro Gly Trp Lys Gly Ser Thr Cys Ala Val Ala Lys Asn Ser Ser 740 745 750 tgc ctg ccc aac ccc tgt gtg aat ggt ggc acc tgc gtg ggc agc ggg 2361 Cys Leu Pro Asn Pro Cys Val Asn Gly Gly Thr Cys Val Gly Ser Gly 755 760 765 770 gcc tcc ttc tcc tgc atc tgc cgg gac ggc tgg gag ggt cgt act tgc 2409 Ala Ser Phe Ser Cys Ile Cys Arg Asp Gly Trp Glu Gly Arg Thr Cys 775 780 785 act cac aat acc aac gac tgc aac cct ctg cct tgc tac aat ggt ggc 2457 Thr His Asn Thr Asn Asp Cys Asn Pro Leu Pro Cys Tyr Asn Gly Gly 790 795 800 atc tgt gtt gac ggc gtc aac tgg ttc cgc tgc gag tgt gca cct ggc 2505 Ile Cys Val Asp Gly Val Asn Trp Phe Arg Cys Glu Cys Ala Pro Gly 805 810 815 ttc gcg ggg cct gac tgc cgc atc aac atc gac gag tgc cag tcc tcg 2553 Phe Ala Gly Pro Asp Cys Arg Ile Asn Ile Asp Glu Cys Gln Ser Ser 820 825 830 ccc tgt gcc tac ggg gcc acg tgt gtg gat gag atc aac ggg tat cgc 2601 Pro Cys Ala Tyr Gly Ala Thr Cys Val Asp Glu Ile Asn Gly Tyr Arg 835 840 845 850 tgt agc tgc cca ccc ggc cga gcc ggc ccc cgg tgc cag gaa gtg atc 2649 Cys Ser Cys Pro Pro Gly Arg Ala Gly Pro Arg Cys Gln Glu Val Ile 855 860 865 ggg ttc ggg aga tcc tgc tgg tcc cgg ggc act ccg ttc cca cac gga 2697 Gly Phe Gly Arg Ser Cys Trp Ser Arg Gly Thr Pro Phe Pro His Gly 870 875 880 agc tcc tgg gtg gaa gac tgc aac agc tgc cgc tgc ctg gat ggc cgc 2745 Ser Ser Trp Val Glu Asp Cys Asn Ser Cys Arg Cys Leu Asp Gly Arg 885 890 895 cgt gac tgc agc aag gtg tgg tgc gga tgg aag cct tgt ctg ctg gcc 2793 Arg Asp Cys Ser Lys Val Trp Cys Gly Trp Lys Pro Cys Leu Leu Ala 900 905 910 ggc cag ccc gag gcc ctg agc gcc cag tgc cca ctg ggg caa agg tgc 2841 Gly Gln Pro Glu Ala Leu Ser Ala Gln Cys Pro Leu Gly Gln Arg Cys 915 920 925 930 ctg gag aag gcc cca ggc cag tgt ctg cga cca ccc tgt gag gcc tgg 2889 Leu Glu Lys Ala Pro Gly Gln Cys Leu Arg Pro Pro Cys Glu Ala Trp 935 940 945 ggg gag tgc ggc gca gaa gag cca ccg agc acc ccc tgc ctg cca cgc 2937 Gly Glu Cys Gly Ala Glu Glu Pro Pro Ser Thr Pro Cys Leu Pro Arg 950 955 960 tcc ggc cac ctg gac aat aac tgt gcc cgc ctc acc ttg cat ttc aac 2985 Ser Gly His Leu Asp Asn Asn Cys Ala Arg Leu Thr Leu His Phe Asn 965 970 975 cgt gac cac gtg ccc cag ggc acc acg gtg ggc gcc att tgc tcc ggg 3033 Arg Asp His Val Pro Gln Gly Thr Thr Val Gly Ala Ile Cys Ser Gly 980 985 990 atc cgc tcc ctg cca gcc aca agg gct gtg gca cgg gac cgc ctg ctg 3081 Ile Arg Ser Leu Pro Ala Thr Arg Ala Val Ala Arg Asp Arg Leu Leu 995 1000 1005 1010 gtg ttg ctt tgc gac cgg gcg tcc tcg ggg gcc agt gcc gtg gag gtg 3129 Val Leu Leu Cys Asp Arg Ala Ser Ser Gly Ala Ser Ala Val Glu Val 1015 1020 1025 gcc gtg tcc ttc agc cct gcc agg gac ctg cct gac agc agc ctg atc 3177 Ala Val Ser Phe Ser Pro Ala Arg Asp Leu Pro Asp Ser Ser Leu Ile 1030 1035 1040 cag ggc gcg gcc cac gcc atc gtg gcc gcc atc acc cag cgg ggg aac 3225 Gln Gly Ala Ala His Ala Ile Val Ala Ala Ile Thr Gln Arg Gly Asn 1045 1050 1055 agc tca ctg ctc ctg gct gtc acc gag gtc aag gtg gag acg gtt gtt 3273 Ser Ser Leu Leu Leu Ala Val Thr Glu Val Lys Val Glu Thr Val Val 1060 1065 1070 acg ggc ggc tct tcc aca ggt ctg ctg gtg cct gtg ctg tgt ggt gcc 3321 Thr Gly Gly Ser Ser Thr Gly Leu Leu Val Pro Val Leu Cys Gly Ala 1075 1080 1085 1090 ttc agc gtg ctg tgg ctg gcg tgc gtg gtc ctg tgc gtg tgg tgg aca 3369 Phe Ser Val Leu Trp Leu Ala Cys Val Val Leu Cys Val Trp Trp Thr 1095 1100 1105 cgc aag cgc agg aaa gag cgg gag agg agc cgg ctg ccg cgg gag gag 3417 Arg Lys Arg Arg Lys Glu Arg Glu Arg Ser Arg Leu Pro Arg Glu Glu 1110 1115 1120 agc gcc aac aac cag tgg gcc ccg ctc aac ccc atc cgc aac ccc atc 3465 Ser Ala Asn Asn Gln Trp Ala Pro Leu Asn Pro Ile Arg Asn Pro Ile 1125 1130 1135 gag cgg ccg ggg ggc cac aag gac gtg ctc tac cag tgc aag aac ttc 3513 Glu Arg Pro Gly Gly His Lys Asp Val Leu Tyr Gln Cys Lys Asn Phe 1140 1145 1150 acg ccg ccg ccg cgc agg gcg gac gag gcg ctg ccc ggg ccg gcc ggc 3561 Thr Pro Pro Pro Arg Arg Ala Asp Glu Ala Leu Pro Gly Pro Ala Gly 1155 1160 1165 1170 cac gcg gcc gtc agg gag gat gag gag gac gag gat ctg ggc cgc ggt 3609 His Ala Ala Val Arg Glu Asp Glu Glu Asp Glu Asp Leu Gly Arg Gly 1175 1180 1185 gag gag gac tcc ctg gag gcg gag aag ttc ctc tca cac aaa ttc acc 3657 Glu Glu Asp Ser Leu Glu Ala Glu Lys Phe Leu Ser His Lys Phe Thr 1190 1195 1200 aaa gat cct ggc cgc tcg ccg ggg agg ccg gcc cac tgg gcc tca ggc 3705 Lys Asp Pro Gly Arg Ser Pro Gly Arg Pro Ala His Trp Ala Ser Gly 1205 1210 1215 ccc aaa gtg gac aac cgc gcg gtc agg agc atc aat gag gcc cgc tac 3753 Pro Lys Val Asp Asn Arg Ala Val Arg Ser Ile Asn Glu Ala Arg Tyr 1220 1225 1230 gcc ggc aag gag tag gggcggctgc agctgggccg ggacccaggg ccctcggtgg 3808 Ala Gly Lys Glu * 1235 gagccatgcc gtctgccgga cccggagccg aggcatgtgc atagtttctt tattttgtgt 3868 aaaaaaacca ccaaaaacaa aaaccaaatg tttattttct acgtttcttt aaccttgtat 3928 aaattattca gtaactgtca ggctgaaaac aatggagtat tctcggatag ttgctatttt 3988 tgtaaagttt ccgtgcgtgg cactcgctgt atgaaaggag agagcaaagg gtgtctgcgt 4048 cgtcaccaaa tcgtagcgtt tgttaccaga ggttgtgcac tgtttacaga atcttccttt 4108 tattcctcac tcgggtttct ctgtggctcc aggccaaagt gccggtgaga cccatggctg 4168 tgttggtgtg gcccatggct gttggtggga cccgtggctg atggtgtggc ctgtggctgt 4228 cggtgggact cgtggctgtc aatgggacct gtggctgtcg gtgggaccta cggtggtcgg 4288 tgggaccctg gttattgatg tggccctggc tgccggcacg gcccgtggct gttgacgcac 4348 ctgtggttgt tagtggggcc tgaggtcatc ggcgtgccca aggccggcag gtcaacctcg 4408 cgcttgctgg ccagtccacc ctgcctgccg tctgtgcttc ctcctgccca gaacgcccgc 4468 tccagcgatc tctccactgt gctttcagaa gtgcccttcc tgctgcgcag ttctcccatc 4528 ctgggacggc ggcagtattg aagctcgtga caagtgcctt cacacagacc cctcgcaact 4588 gtccacgcgt gccgtggcac caggcgctgc ccacctgccg gccccggccg cccctcctcg 4648 tgaaagtgca tttttgtaaa tgtgtacata ttaaaggaag cactctgtat atttgattga 4708 ataatgccac caaaaaaaaa aaaaaaaaaa aattcctgcc c 4749 377 16 DNA Artificial Sequence PCR Primer 377 cccagggctt ctccgg 16 378 26 DNA Artificial Sequence PCR Primer 378 aatagtcacc ctccaggtta tagcag 26 379 26 DNA Artificial Sequence PCR Probe 379 tggatgtcga cctttgtgag ccaagc 26 380 4974 DNA Homo sapiens CDS (405)...(4121) 380 ctcatgcata tgcaggtgcg cgggtgacga atgggcgagc gagctgtcag tctcgttccg 60 aacttgttgg ctgcggtgcc gggagcgcgg gcgcgcagag cccgaggccg ggacccgctg 120 ccttcaccgc cgccgccgtc gccgccgggt gggagccggg ccgggcagcc ggagcgcggc 180 cgccagcgag ccggagctgc cgccgcccct gcacgcccgc cgcccaggcc cgcgcgccgg 240 acgctgcgct cgaccccgcc cgcgccgccg ccgccgccgc ctctgccgct gccgctgcct 300 ctgcgggcgc tcggagggcg ggcgggcgct gggaggccgg cgcggcggct gggagccggg 360 cgcgggcggc ggcggcgggg ccgggcgggc gggtcgcggg ggca atg cgg gcg cag 416 Met Arg Ala Gln 1 ggc cgg ggg cgc ctt ccc cgg cgg ctg ctg ctg ctg ctg gcg ctc tgg 464 Gly Arg Gly Arg Leu Pro Arg Arg Leu Leu Leu Leu Leu Ala Leu Trp 5 10 15 20 gtg cag gcg gcg cgg ccc atg ggc tat ttc gag ctg cag ctg agc gcg 512 Val Gln Ala Ala Arg Pro Met Gly Tyr Phe Glu Leu Gln Leu Ser Ala 25 30 35 ctg cgg aac gtg aac ggg gag ctg ctg agc ggc gcc tgc tgt gac ggc 560 Leu Arg Asn Val Asn Gly Glu Leu Leu Ser Gly Ala Cys Cys Asp Gly 40 45 50 gac ggc cgg aca acg cgc gcg ggg ggc tgc ggc cac gac gag tgc gac 608 Asp Gly Arg Thr Thr Arg Ala Gly Gly Cys Gly His Asp Glu Cys Asp 55 60 65 acg tac gtg cgc gtg tgc ctt aag gag tac cag gcc aag gtg acg ccc 656 Thr Tyr Val Arg Val Cys Leu Lys Glu Tyr Gln Ala Lys Val Thr Pro 70 75 80 acg ggg ccc tgc agc tac ggc cac ggc gcc acg ccc gtg ctg ggc ggc 704 Thr Gly Pro Cys Ser Tyr Gly His Gly Ala Thr Pro Val Leu Gly Gly 85 90 95 100 aac tcc ttc tac ctg ccg ccg gcg ggc gct gcg ggg gac cga gcg cgg 752 Asn Ser Phe Tyr Leu Pro Pro Ala Gly Ala Ala Gly Asp Arg Ala Arg 105 110 115 gcg cgg gcc cgg gcc ggc ggc gac cag gac ccg ggc ctc gtc gtc atc 800 Ala Arg Ala Arg Ala Gly Gly Asp Gln Asp Pro Gly Leu Val Val Ile 120 125 130 ccc ttc cag ttc gcc tgg ccg cgc tcc ttt acc ctc atc gtg gag gcc 848 Pro Phe Gln Phe Ala Trp Pro Arg Ser Phe Thr Leu Ile Val Glu Ala 135 140 145 tgg gac tgg gac aac gat acc acc ccg aat gag gag ctg ctg atc gag 896 Trp Asp Trp Asp Asn Asp Thr Thr Pro Asn Glu Glu Leu Leu Ile Glu 150 155 160 cga gtg tcg cat gcc ggc atg atc aac ccg gag gac cgc tgg aag agc 944 Arg Val Ser His Ala Gly Met Ile Asn Pro Glu Asp Arg Trp Lys Ser 165 170 175 180 ctg cac ttc agc ggc cac gtg gcg cac ctg gag ctg cag atc cgc gtg 992 Leu His Phe Ser Gly His Val Ala His Leu Glu Leu Gln Ile Arg Val 185 190 195 cgc tgc gac gag aac tac tac agc gcc act tgc aac aag ttc tgc cgg 1040 Arg Cys Asp Glu Asn Tyr Tyr Ser Ala Thr Cys Asn Lys Phe Cys Arg 200 205 210 ccc cgc aac gac ttt ttc ggc cac tac acc tgc gac cag tac ggc aac 1088 Pro Arg Asn Asp Phe Phe Gly His Tyr Thr Cys Asp Gln Tyr Gly Asn 215 220 225 aag gcc tgc atg gac ggc tgg atg ggc aag gag tgc aag gaa gct gtg 1136 Lys Ala Cys Met Asp Gly Trp Met Gly Lys Glu Cys Lys Glu Ala Val 230 235 240 tgt aaa caa ggg tgt aat ttg ctc cac ggg gga tgc acc gtg cct ggg 1184 Cys Lys Gln Gly Cys Asn Leu Leu His Gly Gly Cys Thr Val Pro Gly 245 250 255 260 gag tgc agg tgc agc tac ggc tgg caa ggg agg ttc tgc gat gag tgt 1232 Glu Cys Arg Cys Ser Tyr Gly Trp Gln Gly Arg Phe Cys Asp Glu Cys 265 270 275 gtc ccc tac ccc ggc tgc gtg cat ggc agt tgt gtg gag ccc tgg cag 1280 Val Pro Tyr Pro Gly Cys Val His Gly Ser Cys Val Glu Pro Trp Gln 280 285 290 tgc aac tgt gag acc aac tgg ggc ggc ctg ctc tgt gac aaa gac ctg 1328 Cys Asn Cys Glu Thr Asn Trp Gly Gly Leu Leu Cys Asp Lys Asp Leu 295 300 305 aac tac tgt ggc agc cac cac ccc tgc acc aac gga ggc acg tgc atc 1376 Asn Tyr Cys Gly Ser His His Pro Cys Thr Asn Gly Gly Thr Cys Ile 310 315 320 aac gcc gag cct gac cag tac cgc tgc acc tgc cct gac ggc tac tcg 1424 Asn Ala Glu Pro Asp Gln Tyr Arg Cys Thr Cys Pro Asp Gly Tyr Ser 325 330 335 340 ggc agg aac tgt gag aag gct gag cac gcc tgc acc tcc aac ccg tgt 1472 Gly Arg Asn Cys Glu Lys Ala Glu His Ala Cys Thr Ser Asn Pro Cys 345 350 355 gcc aac ggg ggc tct tgc cat gag gtg ccg tcc ggc ttc gaa tgc cac 1520 Ala Asn Gly Gly Ser Cys His Glu Val Pro Ser Gly Phe Glu Cys His 360 365 370 tgc cca tcg ggc tgg agc ggg ccc acc tgt gcc ctt gac atc gat gag 1568 Cys Pro Ser Gly Trp Ser Gly Pro Thr Cys Ala Leu Asp Ile Asp Glu 375 380 385 tgt gct tcg aac ccg tgt gcg gcc ggt ggc acc tgt gtg gac cag gtg 1616 Cys Ala Ser Asn Pro Cys Ala Ala Gly Gly Thr Cys Val Asp Gln Val 390 395 400 gac ggc ttt gag tgc atc tgc ccc gag cag tgg gtg ggg gcc acc tgc 1664 Asp Gly Phe Glu Cys Ile Cys Pro Glu Gln Trp Val Gly Ala Thr Cys 405 410 415 420 cag ctg gac gcc aat gag tgt gaa ggg aag cca tgc ctt aac gct ttt 1712 Gln Leu Asp Ala Asn Glu Cys Glu Gly Lys Pro Cys Leu Asn Ala Phe 425 430 435 tct tgc aaa aac ctg att ggc ggc tat tac tgt gat tgc atc ccg ggc 1760 Ser Cys Lys Asn Leu Ile Gly Gly Tyr Tyr Cys Asp Cys Ile Pro Gly 440 445 450 tgg aag ggc atc aac tgc cat atc aac gtc aac gac tgt cgc ggg cag 1808 Trp Lys Gly Ile Asn Cys His Ile Asn Val Asn Asp Cys Arg Gly Gln 455 460 465 tgt cag cat ggg ggc acc tgc aag gac ctg gtg aac ggg tac cag tgt 1856 Cys Gln His Gly Gly Thr Cys Lys Asp Leu Val Asn Gly Tyr Gln Cys 470 475 480 gtg tgc cca cgg ggc ttc gga ggc cgg cat tgc gag ctg gaa cga gac 1904 Val Cys Pro Arg Gly Phe Gly Gly Arg His Cys Glu Leu Glu Arg Asp 485 490 495 500 aag tgt gcc agc agc ccc tgc cac agc ggc ggc ctc tgc gag gac ctg 1952 Lys Cys Ala Ser Ser Pro Cys His Ser Gly Gly Leu Cys Glu Asp Leu 505 510 515 gcc gac ggc ttc cac tgc cac tgc ccc cag ggc ttc tcc ggg cct ctc 2000 Ala Asp Gly Phe His Cys His Cys Pro Gln Gly Phe Ser Gly Pro Leu 520 525 530 tgt gag gtg gat gtc gac ctt tgt gag cca agc ccc tgc cgg aac ggc 2048 Cys Glu Val Asp Val Asp Leu Cys Glu Pro Ser Pro Cys Arg Asn Gly 535 540 545 gct cgc tgc tat aac ctg gag ggt gac tat tac tgc gcc tgc cct gat 2096 Ala Arg Cys Tyr Asn Leu Glu Gly Asp Tyr Tyr Cys Ala Cys Pro Asp 550 555 560 gac ttt ggt ggc aag aac tgc tcc gtg ccc cgc gag ccg tgc cct ggc 2144 Asp Phe Gly Gly Lys Asn Cys Ser Val Pro Arg Glu Pro Cys Pro Gly 565 570 575 580 ggg gcc tgc aga gtg atc gat ggc tgc ggg tca gac gcg ggg cct ggg 2192 Gly Ala Cys Arg Val Ile Asp Gly Cys Gly Ser Asp Ala Gly Pro Gly 585 590 595 atg cct ggc aca gca gcc tcc ggc gtg tgt ggc ccc cat gga cgc tgc 2240 Met Pro Gly Thr Ala Ala Ser Gly Val Cys Gly Pro His Gly Arg Cys 600 605 610 gtc agc cag cca ggg ggc aac ttt tcc tgc atc tgt gac agt ggc ttt 2288 Val Ser Gln Pro Gly Gly Asn Phe Ser Cys Ile Cys Asp Ser Gly Phe 615 620 625 act ggc acc tac tgc cat gag aac att gac gac tgc ctg ggc cag ccc 2336 Thr Gly Thr Tyr Cys His Glu Asn Ile Asp Asp Cys Leu Gly Gln Pro 630 635 640 tgc cgc aat ggg ggc aca tgc atc gat gag gtg gac gcc ttc cgc tgc 2384 Cys Arg Asn Gly Gly Thr Cys Ile Asp Glu Val Asp Ala Phe Arg Cys 645 650 655 660 ttc tgc ccc agc ggc tgg gag ggc gag ctc tgc gac acc aat ccc aac 2432 Phe Cys Pro Ser Gly Trp Glu Gly Glu Leu Cys Asp Thr Asn Pro Asn 665 670 675 gac tgc ctt ccc gat ccc tgc cac agc cgc ggc cgc tgc tac gac ctg 2480 Asp Cys Leu Pro Asp Pro Cys His Ser Arg Gly Arg Cys Tyr Asp Leu 680 685 690 gtc aat gac ttc tac tgt gcg tgc gac gac ggc tgg aag ggc aag acc 2528 Val Asn Asp Phe Tyr Cys Ala Cys Asp Asp Gly Trp Lys Gly Lys Thr 695 700 705 tgc cac tca cgc gag ttc cag tgc gat gcc tac acc tgc agc aac ggt 2576 Cys His Ser Arg Glu Phe Gln Cys Asp Ala Tyr Thr Cys Ser Asn Gly 710 715 720 ggc acc tgc tac gac agc ggc gac acc ttc cgc tgc gcc tgc ccc ccc 2624 Gly Thr Cys Tyr Asp Ser Gly Asp Thr Phe Arg Cys Ala Cys Pro Pro 725 730 735 740 ggc tgg aag ggc agc acc tgc gcc gtc gcc aag aac agc agc tgc ctg 2672 Gly Trp Lys Gly Ser Thr Cys Ala Val Ala Lys Asn Ser Ser Cys Leu 745 750 755 ccc aac ccc tgt gtg aat ggt ggc acc tgc gtg ggc agc ggg gcc tcc 2720 Pro Asn Pro Cys Val Asn Gly Gly Thr Cys Val Gly Ser Gly Ala Ser 760 765 770 ttc tcc tgc atc tgc cgg gac ggc tgg gag ggt cgt act tgc act cac 2768 Phe Ser Cys Ile Cys Arg Asp Gly Trp Glu Gly Arg Thr Cys Thr His 775 780 785 aat acc aac gac tgc aac cct ctg cct tgc tac aat ggt ggc atc tgt 2816 Asn Thr Asn Asp Cys Asn Pro Leu Pro Cys Tyr Asn Gly Gly Ile Cys 790 795 800 gtt gac ggc gtc aac tgg ttc cgc tgc gag tgt gca cct ggc ttc gcg 2864 Val Asp Gly Val Asn Trp Phe Arg Cys Glu Cys Ala Pro Gly Phe Ala 805 810 815 820 ggg cct gac tgc cgc atc aac atc gac gag tgc cag tcc tcg ccc tgt 2912 Gly Pro Asp Cys Arg Ile Asn Ile Asp Glu Cys Gln Ser Ser Pro Cys 825 830 835 gcc tac ggg gcc acg tgt gtg gat gag atc aac ggg tat cgc tgt agc 2960 Ala Tyr Gly Ala Thr Cys Val Asp Glu Ile Asn Gly Tyr Arg Cys Ser 840 845 850 tgc cca ccc ggc cga gcc ggc ccc cgg tgc cag gaa gtg atc ggg ttc 3008 Cys Pro Pro Gly Arg Ala Gly Pro Arg Cys Gln Glu Val Ile Gly Phe 855 860 865 ggg aga tcc tgc tgg tcc cgg ggc act ccg ttc cca cac gga agc tcc 3056 Gly Arg Ser Cys Trp Ser Arg Gly Thr Pro Phe Pro His Gly Ser Ser 870 875 880 tgg gtg gaa gac tgc aac agc tgc cgc tgc ctg gat ggc cgc cgt gac 3104 Trp Val Glu Asp Cys Asn Ser Cys Arg Cys Leu Asp Gly Arg Arg Asp 885 890 895 900 tgc agc aag gtg tgg tgc gga tgg aag cct tgt ctg ctg gcc ggc cag 3152 Cys Ser Lys Val Trp Cys Gly Trp Lys Pro Cys Leu Leu Ala Gly Gln 905 910 915 ccc gag gcc ctg agc gcc cag tgc cca ctg ggg caa agg tgc ctg gag 3200 Pro Glu Ala Leu Ser Ala Gln Cys Pro Leu Gly Gln Arg Cys Leu Glu 920 925 930 aag gcc cca ggc cag tgt ctg cga cca ccc tgt gag gcc tgg ggg gag 3248 Lys Ala Pro Gly Gln Cys Leu Arg Pro Pro Cys Glu Ala Trp Gly Glu 935 940 945 tgc ggc gca gaa gag cca ccg agc acc ccc tgc ctg cca cgc tcc ggc 3296 Cys Gly Ala Glu Glu Pro Pro Ser Thr Pro Cys Leu Pro Arg Ser Gly 950 955 960 cac ctg gac aat aac tgt gcc cgc ctc acc ttg cat ttc aac cgt gac 3344 His Leu Asp Asn Asn Cys Ala Arg Leu Thr Leu His Phe Asn Arg Asp 965 970 975 980 cac gtg ccc cag ggc acc acg gtg ggc gcc att tgc tcc ggg atc cgc 3392 His Val Pro Gln Gly Thr Thr Val Gly Ala Ile Cys Ser Gly Ile Arg 985 990 995 tcc ctg cca gcc aca agg gct gtg gca cgg gac cgc ctg ctg gtg ttg 3440 Ser Leu Pro Ala Thr Arg Ala Val Ala Arg Asp Arg Leu Leu Val Leu 1000 1005 1010 ctt tgc gac cgg gcg tcc tcg ggg gcc agt gcc gtg gag gtg gcc gtg 3488 Leu Cys Asp Arg Ala Ser Ser Gly Ala Ser Ala Val Glu Val Ala Val 1015 1020 1025 tcc ttc agc cct gcc agg gac ctg cct gac agc agc ctg atc cag ggc 3536 Ser Phe Ser Pro Ala Arg Asp Leu Pro Asp Ser Ser Leu Ile Gln Gly 1030 1035 1040 gcg gcc cac gcc atc gtg gcc gcc atc acc cag cgg ggg aac agc tca 3584 Ala Ala His Ala Ile Val Ala Ala Ile Thr Gln Arg Gly Asn Ser Ser 1045 1050 1055 1060 ctg ctc ctg gct gtc acc gag gtc aag gtg gag acg gtt gtt acg ggc 3632 Leu Leu Leu Ala Val Thr Glu Val Lys Val Glu Thr Val Val Thr Gly 1065 1070 1075 ggc tct tcc aca ggt ctg ctg gtg cct gtg ctg tgt ggt gcc ttc agc 3680 Gly Ser Ser Thr Gly Leu Leu Val Pro Val Leu Cys Gly Ala Phe Ser 1080 1085 1090 gtg ctg tgg ctg gcg tgc gtg gtc ctg tgc gtg tgg tgg aca cgc aag 3728 Val Leu Trp Leu Ala Cys Val Val Leu Cys Val Trp Trp Thr Arg Lys 1095 1100 1105 cgc agg aaa gag cgg gag agg agc cgg ctg ccg cgg gag gag agc gcc 3776 Arg Arg Lys Glu Arg Glu Arg Ser Arg Leu Pro Arg Glu Glu Ser Ala 1110 1115 1120 aac aac cag tgg gcc ccg ctc aac ccc atc cgc aac ccc atc gag cgg 3824 Asn Asn Gln Trp Ala Pro Leu Asn Pro Ile Arg Asn Pro Ile Glu Arg 1125 1130 1135 1140 ccg ggg ggc cac aag gac gtg ctc tac cag tgc aag aac ttc acg ccg 3872 Pro Gly Gly His Lys Asp Val Leu Tyr Gln Cys Lys Asn Phe Thr Pro 1145 1150 1155 ccg ccg cgc agg gcg gac gag gcg ctg ccc ggg ccg gcc ggc cac gcg 3920 Pro Pro Arg Arg Ala Asp Glu Ala Leu Pro Gly Pro Ala Gly His Ala 1160 1165 1170 gcc gtc agg gag gat gag gag gac gag gat ctg ggc cgc ggt gag gag 3968 Ala Val Arg Glu Asp Glu Glu Asp Glu Asp Leu Gly Arg Gly Glu Glu 1175 1180 1185 gac tcc ctg gag gcg gag aag ttc ctc tca cac aaa ttc acc aaa gat 4016 Asp Ser Leu Glu Ala Glu Lys Phe Leu Ser His Lys Phe Thr Lys Asp 1190 1195 1200 cct ggc cgc tcg ccg ggg agg ccg gcc cac tgg gcc tca ggc ccc aaa 4064 Pro Gly Arg Ser Pro Gly Arg Pro Ala His Trp Ala Ser Gly Pro Lys 1205 1210 1215 1220 gtg gac aac cgc gcg gtc agg agc atc aat gag gcc cgc tac gcc ggc 4112 Val Asp Asn Arg Ala Val Arg Ser Ile Asn Glu Ala Arg Tyr Ala Gly 1225 1230 1235 aag gag tag gggcggctgc cagctgggcc gggacccagg gccctcggtg 4161 Lys Glu * ggagccatgc cgtctgccgg acccggaggc cgaggccatg tgcatagttt ctttattttg 4221 tgtaaaaaaa ccaccaaaaa caaaaaccaa atgtttattt tctacgtttc tttaaccttg 4281 tataaattat tcagtaactg tcaggctgaa aacaatggag tattctcgga tagttgctat 4341 ttttgtaaag tttccgtgcg tggcactcgc tgtatgaaag gagagagcaa agggtgtctg 4401 cgtcgtcacc aaatcgtagc gtttgttacc agaggttgtg cactgtttac agaatcttcc 4461 ttttattcct cactcgggtt tctctgtggc tccaggccaa agtgccggtg agacccatgg 4521 ctgtgttggt gtggcccatg gctgttggtg ggacccgtgg ctgatggtgt ggcctgtggc 4581 tgtcggtggg actcgtggct gtcaatggga cctgtggctg tcggtgggac ctacggtggt 4641 cggtgggacc ctggttattg atgtggccct ggctgccggc acggcccgtg gctgttgacg 4701 cacctgtggt tgttagtggg gcctgaggtc atcggcgtgg cccaaggccg gcaggtcaac 4761 ctcgcgcttg ctggccagtc caccctgcct gccgtctgtg cttcctcctg cccagaacgc 4821 ccgctccagc gatctctcca ctgtgctttc agaagtgccc ttcctgctgc gaagttctcc 4881 catcctggga cggcggcagt attgaagctc gtgacaagtg ccttcacaca gaaccctcgg 4941 aactgtccac gcgttccgtg ggaacaaggg gtt 4974 381 28000 DNA Homo sapiens 381 aggtgacccc tagctctgga aaggaccgtg ctcactggag gagaggaagg tgccattggt 60 tttgaccctg tggaggagct gcgaggtcac ccagggagag ggcaaggagg tgaccgcaga 120 ggatggggtg tggaagcctg gtgaccaggg cagcagtggg aggcctctct cggggtagcc 180 ttcagggaca ggcactgccg acttttgttc cccatttccc gcctctcgcc ccccaagccc 240 agacctgagt ttggggggcg agaggcggga aacggggaat gtggcctgag catttcctga 300 gggcatggcc tggctacctc gacgccagcg ccgagctgag cagtctgcac cctggagcat 360 ttgttgactg gctgcttgac cagcgcgcct cgcagagggg aaggcagggg cgtcggaggg 420 gcgcagcgcc ccctgcagcc ggcgtggagg cggtaggagc ggcgcggaga aggggagatt 480 ctcggaggag gtggggggcg cgcagtaggg gctgggcccg gctctggccc cagggccgcg 540 ccaccccgcg tgggggccga gccctgatca gagtaggagg cggcatctcc tctgggactg 600 cgaggagcgc ggcggtggcg cactgatggg aggggaccac acggcaacct cggggcgccc 660 cacccccggt ttctgacacc cggcaggagc ccaggcggag gaggggaggc agctttgcgg 720 cgccggcgca cgcctcgccg actcacgcgg aggtgtgagc ggggcccccg cggcccgcgc 780 tgaccccgag gccccgtgcc cccgccgccc gggcgccctg gggggcgcgc gccgggccgg 840 ggcgctggca ggcgacgccc tccaccgcct ttaaagcctg gggcgccccc ggaccccccc 900 ccggccccac cccgcggcgc ggccccgccc cctcatgcat atgcaggtgc gcgggtgacg 960 aatgggcgag cgagctgtca gtctcgttcc gaacttgttg gctgcggtgc cgggagcgcg 1020 ggcgcgcaga gccgaggccg ggacccgctg ccttcaccgc cgccgccgtc gccgccgggt 1080 gggagccggg ccgggcagcc ggagcgcggc cgccagcgag ccggagctgc cgccgcccct 1140 gcacgcccgc cgcccaggcc cgcgcgccgc ggcgctgcgc tcgaccccgc ccgcgccgcc 1200 gccgccgccg cctctgccgc tgccgctgcc tctgcgggcg ctcggagggc gggcgggcgc 1260 tgggaggccg gcgcggcggc tgggagccgg gcgcgggcgg cggcggcggg gccgggcggg 1320 cgggtcgcgg gggcaatgcg ggcgcagggc cgggggcgcc ttccccggcg gctgctgctg 1380 ctgctggcgc tctgggtgca ggtgagcggg gcggcggggg cggcgggggt cgcggacggg 1440 gcacaccggg ccgcccctag gggccgggcg ggcactgcct ggggccgccg tggttcggaa 1500 gccctcgagg ctgcgcgcgg cggctggggc tccgggcggg cgcggctggg tgggggcggg 1560 gcggcggggc ctgttccccc acccctggcg cccggcccgc cgaccccggc ccgcgcctcc 1620 ctccgctctc ccgctgcctt atttttaggc ggcgcggccc atgggctatt tcgagctgca 1680 gctgagcgcg ctgcggaacg tgaacgggga gctgctgagc ggcgcctgct gtgacggcga 1740 cggccggaca acgcgcgcgg ggggctgcgg ccacgacgag tgcgacacgt acgtgcgcgt 1800 gtgccttaag gagtaccagg ccaaggtgac gcccacgggg ccctgcagct acggccacgg 1860 cgccacgccc gtgctgggcg gcaactcctt ctacctgccg ccggcgggcg ctgcggggga 1920 ccgagcgcgg gcgcgggccc gggccggcgg cgaccaggac ccgggcctcg tcgtcatccc 1980 cttccagttc gcctggccgg tacgtgcgct ccatccctcg tgctccagcc cttccctctc 2040 tctccgcgcc ccggccccgc gcgcttcgcg acccccaaca cctgcggccg ggtctgcgtg 2100 cgagccgcgc gcgcccaggc ggggcggggc cggcaggggg cgcgtgctct ggggacttgg 2160 tccgcgcctg gccacgtggg cgcgccgggg ccccggggcc accgggagcg gggtcgcggc 2220 gggggcgggg cggcggcgtc ccgcgtgcgc ggcggtgtgc ggcgtgtgcc tgcgtcgccc 2280 tgcgcgtgtc tgtctgggtg gggaggcgag gcgaggcgcc ccggtcccgg gcaggccgcg 2340 gtggcatgtg cgcagcgcgt gctggggctg gtctagggca ggccctgact gagccgcccc 2400 gggcccgtgg ccagcctgcg cctgccctgc agtttcctgg atgcctgggg ggcacgggcg 2460 ggcgccgtgg gacctaggcc cgggagagcc taacgcctaa cgcttatgtc ggcagaagcc 2520 cccgatggtg acccaagatc gttcagagac agagatagtg gatcctggtg cagtgacctt 2580 ctgtggcact gccctgtttg tgggtttttt tggttttgtt attctggagg ggcagaagct 2640 gagtcggggc tgtctggtct cccctggcag gtggccagtc aggcaggagc cctggcctgg 2700 gcgtgctggg aggaggggtg gtaggggtcc agtgtcactg ggaaacaggt actcatccca 2760 gtgggctggc aggtgggtag tggtaggtgg gcaggcccag gcctcgggcg ccttacctca 2820 ttgcctggag cacggccttg ccctggtgcc cagaggtcct tccctgcttg gtcattgtgc 2880 tgggggcctg gaactgggtg agtgcgggaa tgagagcacc atgcagacct gtgatcaggg 2940 agtagatgga tctgggagcc aggaagtggc tccagtcagc aggaggcacc ggagtgtgcc 3000 cacctggtat cctgggccct gaagtgattg tgagttgagg gcaatccctg ccgagctcac 3060 gccagttggg cctgccgtgt gtggctccca gtcctgtgct gtacctttgc agccctggct 3120 ggcagccttg cctgctgccc ccatcctcac cgcttcctga gctcccaccc gtggaagctg 3180 gccacagtct cctctggcca tgtcctcaac ccgtgagcac cccgccgagt atcccttgac 3240 caggggggcc ccagagaggg gaaagtgtcc cccagatgga aaaggcaggg gcgggcatgg 3300 gagggcccag gcagttgtga gaagcccagc ccctcgcccc cacggcggtg cagcaggcag 3360 gtctgagcag ggcccgcagc ctgtcatctg cacctgggcc tgagccagcg tggccccaca 3420 tcgctacctg aggatgtgtt ttctgctcga gttggcagca gtgggtgtgg gggcagggag 3480 gtcttggagg aatgtggcgg gctatcgcgt gtccgccctg gctcttcgcc ccgcgggcca 3540 gccggtcagg tgtgggatgg gaccgggtag gcccttgcct tccttggagt ccgggcactg 3600 ggtttcgggg ccagctcacc tccctgcctc ttgcttccag ccggttcctc gaatgcccca 3660 ggagggggca ggcggcctgt ctctgggttg ggggccaggg cagagtcata gctgcgtgtt 3720 tgggggcagc cctggtctcc tgccatgtgg cctggctgcc gggcgggagc tgtgccgtga 3780 tgccagcacc ctggtatttg cactcgggcg gcggcagtcc ctggccatgc tgccctggct 3840 tgctgaggtc cagctctgtg cggtgagctg aggtgtactt ggctgtgatg ggaaggcaag 3900 gaccgagttc aggctccctg ggacctgagg aggggtttca gcctggaggc tagggtggca 3960 tcctgcccag gcccgtgggg cttttgggct ccttggagta aagggaatga gagggccttg 4020 tggaagagga gtgggggagt ctgggctctg cattcgctcc ctccaccccc tgccccctga 4080 gtgactctcc caccttgtgg tctctgctgt tgacccaggc ctggctgggt ggccctctgc 4140 cccctggcct ggcttcttgt ggccggggtc tgtgtgctat tagtcatgga tctgtgctgg 4200 tctcgggctc agcttccctc agtgggtggg cccagggtct tgaatgtgga gaggtggtgg 4260 accacatgcc agcaggctgc ctggctgccc ctcctctcct ggctccaccc ccagacgtcc 4320 ccaggaggcc ggtgtcagcc tgggttggtt ctggtgcctg gcttgtagct ggcagggtga 4380 ggccacattc tcccagctgc gtgtgtgcac gcaccccggg tgctctgtag gcatggcagg 4440 tggtgatgga ggtttgggga ggagtagtgt catgctgggg gcagcaggga gctttgctct 4500 ggggcctggt aggtggcagg cccaggggac acctgctggc tgagggagga gcagggtggt 4560 ggcagttggc cgtgacctgg gcagccaggg ccccaccctc agaggtgcag ctggaagtcg 4620 tgcctgcctg gctggcccat ctctggagcc aggagcccag gagcctgcct gccagcgagg 4680 gtctttcttg ttctgtcttg gcatgtgtgt gctgggctcc agggcagctg tgcggggtgg 4740 tgtggctgga gcatggtccc cgtgacagat ctgggcttat gaggagaacg ggatgggtga 4800 aggccctgta gatacaggag gtgggcctgg ggctgaccct gcgtctatca gctcaggagg 4860 cctgaggtcc tgggccatca gaagggctga gcttttctca cctgtgaaag gggcacactg 4920 ccgctttttc attgcaggtc tcacgaagtc agatggggct gctggactcc cagctcgggc 4980 tctgcttgtg cccccagccc ggctcccaga cctgtccagt tcctcccctt cccagccttc 5040 cctaccctct cctttgcccc ctagggagga aggtttttac agagcccacc ccctgcatcc 5100 agccgcccta gggctcaagg tgggccaggc tgaggtctgt gcctggagct acctaagctg 5160 ctcgtggcag gtgtgaggtt cagcaccact ctgcttcctg ttttttctga gcttgggctg 5220 gggatgacag ggccctggcc tccccaccct accttcaggg gatcctgtct gcacactggg 5280 gaccaccccc ctccttccca caccttccca gtagggacca ggagagctgg ctggtctggt 5340 atggaatgtg ggcatctggg ttcctgtgtt gggtgggcat cggtctgttc ctcctgccat 5400 ggccctgggg cccagagccc tggggagaac tcagggcatg tccgccttgt acattggggg 5460 tctggttcaa agctttggta tgggggcagg gtggggcatt cagtgcccag gcaacacggg 5520 gaccattgga gccagggagg actgcccttg gccagggagg attggagagt gggctggggg 5580 tttgtcgctg gtccctgagg gtgggctgaa gggtcaaagc cgcagcacga taggaaggct 5640 gggaggtgga ggggcgggtt ggggagcagg cggcaggcct gggtgggagg ggactgctgc 5700 tctcaggggc cctcctgggc tgctccatgg tgtctttatg aggggagcaa gctaggccag 5760 tgaaggggtg cttgtggagc caggcttcgg cctgagctgc tgctggtggt ggagtggggg 5820 caggaagaca aggatctgca atcccaggcc ccagccacag tcgctatccc cagaccccag 5880 gcctgagcgg ggtccctgtc cccagaccct aggcctgatt ggagtccctg tccctagacc 5940 ccaggcctga gtggggcccc tatcctcagg ccccaggcct gagctgggtc cctgtcccca 6000 ggtcccagga ctgagcaggg tccctgtctg cagacctgag gcctaagcaa ggtccctgtc 6060 cccagacccc agatctgagt gaggtcactg tccccagacc acaggcctga gcggagtccc 6120 tgtcctcaag accacaggcc tgagcggagg ccctgtcccc agaccacagg cctgagcgga 6180 gtccctgtcc ccagaccaca ggcctgagcg ggattcctat ccccacatcc caggcctgag 6240 cagggtgtgg ctggcatcag ttgtaccctg ggctttgtgg caggtgctag ccggccctgg 6300 ctgccaccgt cttcacggtg ggggacctgg gacctagagg gggtgtgctg gggagtgggg 6360 gtacacccag gcaaggccct ggctggtctc tggtgtggag catgggtgtg tgtgttcctg 6420 cgtgggatgg gctttggtct gctcctcctg ctgcggccct ggggcccaga gccctgggga 6480 tggtgtttgc ccccacccct tcttccctgc ctcgggtgac aatggtggca gaggcctggg 6540 cctctcagaa gctcaggttt caggaaatgt atctgtgctt ggagctcctg gcgcctgcac 6600 caagcgctgt gctccgtagg gggcgggagg ctgatgcggg aggccgagga gaagaaacca 6660 agtcggggcg ttggtggggc agcaggtcta ggaggctgtg ttgtgttggc ctggaccgtg 6720 cagggccctg gacctggggg ggccgttagc ggggcagcag ggaggctgtg ttggccttga 6780 ccgtgcaggg ccctagactt gggttgcctg agttttggga tgctgtagat tggggtacag 6840 tgggcagtgg ggtgccgtgg acttagggtg cttggcattt ggagtaccct gggccatgag 6900 gtgtgctggg ccatgcagtg ccctgggctg ggggtgccct ggacctggag tgccctgagc 6960 tttggggtgc actgggccat ggggtgcaca aggctgtggg gtgtactgga tctagggtgc 7020 cctgggcagg agggtactct gtactttggg tgccttggac ctgaggtgtc ctgggcttta 7080 aggtgccctg gaccttgggg tgtgctgggc catgcagtgc tttggggctc tggggtaccc 7140 tgggctttgg ggtgccctgg aactggggtg ccctgggtct tggagtatgc tgggccatgc 7200 agtgccctgg gctgtgggat actctgggct ttggggtgcc ctggacctgg ggtaccctgg 7260 gctttgaggt gccctggcct ggggtggaac atctattgtc ttgtctgcct gtcctctggc 7320 ttgtgccact gctgttgccc ctgcctgggg acaggaggag gggtttagac ttagccttga 7380 gggttcgggc tggggaggag gcaatcagat ggtgggagat gaagttgggc tgcgggtctg 7440 cttgtgcggt gggggtgggt caggccgggc ttgtagggag aggcttagct gggcctgcag 7500 gggtgaagcc cttccccctt ggcctccaga gactgggcag gggcatagcc ctgctaggct 7560 ggccttgagg gagggcctgg gttcctctcc ctgcttgccg gggaacctgg gcaggtgatg 7620 ggtctctcac ctgtccccag acccccagcc cacacatcgc ctattgcccc tgccagcgcc 7680 aggcccacat ccccacatgt cccagccccg ttcctagaag ggcaacatgc ccgccaaccc 7740 ccgcccaatc caggccctat agtccctcct gtgttctagg ggtttggtgt tgacaaaacc 7800 ctgtcccaga tcgtggcccg ccaggcagga aggacagggg tgagaggttg ctattcgcag 7860 aggaggcaac tgagtcctgg aaggacaggg gtgagaggtt gctattcgca gaggaggcaa 7920 ctgagtcctg gaaggacagg gatgagaggt tgctattcgc agaggaggca actgagtcct 7980 ggaaggacgg gggtgagagg ttgttattca cagaagaggc aaataagtcc tggaggctgg 8040 cccctaggga agaaggggag ctgggagagc tggcaggtgg ggtgaggcag gtaccgcccc 8100 gtcagccagc tcaggttcac tctggatgac ttcctgccat ccaggtgtag ggaccccagc 8160 tggcgggcgg tgaggccctc tcggcgggcg ggcaggcaca cgtccctgcg ggagcaggta 8220 accggagccc tgggctcagg cgaaggtggc agtaatctta cctgagtggc tggcatgagg 8280 tttcctggga gtcgagagga actccctgct ggccctgaag cccaggtgtg gctgtgccgg 8340 gagaccgggt ggcctggctt ttctctgcct gccccgtggc cagagctgct ctcagaccca 8400 tgctggcccc atcctctgac ctcactattg ctgcttcctg gtcctgctgg ttcctgtcca 8460 gcggctacag tgactgttaa agcctggtgg gtcccagtcc tcactcagac ccccaacaac 8520 agacctcact cagaccccca acaacagacc tcactcagac ccccaacaac agacctcact 8580 cagaccccca acagacctca ctcagacccc caacagacct cactcggacc cccaacaccc 8640 gaacagacct cactcagacc cgcaacagtc acccacttcg cttagcctca ggaaggaagt 8700 ccgtggtggg gtctggatct gtggtatgac cccactgtcc ccgtgggcta tgcgttctca 8760 gcccctgggc cttcttgtgg gctctgccat gcagctcctt cacttcctca tgccctgcag 8820 cctcaatctc aatgccacct gttcaaagcc tggcctggcc tttttttttt ttttttgaga 8880 tggagttttg ccctcgttgc ccaggctgga gtgcaatggt gcgatctcgg ctcgctgcaa 8940 cctcggcctc ctgggttcag gtgattctcc tgcctcagcc tccagagtag ctgggactac 9000 agacacctgc caccatggct ggctaatttt tatattttta gtagagatga ggattaaccg 9060 tgttgaccag actagtctcg aactcctgac ctcaggtgat ctgcctgcct cagcctctta 9120 aagtgttggg attacaggcg tgagccactg tgacccgttg gcctggcctt attggaacaa 9180 cagcccctgc cccctgttgc tttccccgag ccccgctggc tataggttgc cgtccttggt 9240 ggcagaggca tgcctgctgt acacttgatg tgaacgaagg aaggaaggaa cgaaggaagg 9300 agccaaatgc cagacgcctg ggaagcggct gggtgctcca ggtgttaccg ggggtgggga 9360 agggcttggc caggtgcagc tgcgagggtg gtgctccagg cagatgggtt gataggctgg 9420 ggtgggtggg tgggggtggg caggagcctt gggaacccca agggtgctct gagctgagag 9480 ggcgtggaca gagtcctggt gggggtgtgg atggagccct ggggggtgtg gatggagctg 9540 acgggggtgg tttgtggaca gagcccttgg ggggtgtgga cacagtcctg ggggtggtgt 9600 ggacagagtc ctggggggtg tggatggagc cctggggggg tatggatgga gcatgttggg 9660 gggtgtggat ggagctctgg gggggtatgg atggagccct gggggggtgt ggatggagca 9720 tgttgggggg ggtggacaga gctctggggg gggtgtggac ggagccctgt tggggggtgt 9780 ggatggagca tgttggggtg tgtggatgga gcatgttggg gggtgtggat ggaactcggg 9840 gggtgtggat ggagctctgg ggggtatgga tggagccctg gggggtgtgg atggagcatg 9900 ttggggggtg tggacagagc tctggggggg ggtgtggacg gagcatgttg gggtgtgtgg 9960 atggaactct gggggggtgt ggatggagcc ctgggggggt gtggatggag ctctgggggg 10020 gtgtggatgg agcatgttgc ggggtgtgga tggagccctg gggaggtgat ggagcctgtt 10080 ggggggtgtg gatggaaccc cgttggggga tgtggattga gttctttggg ggtgtggatg 10140 gagctctggg gggtgtaaac agagctcggc ggggggtgtg gacggagcct tgggaggcat 10200 gtggatggaa ctctggggat tgtctggcgc ctgtaggcag aggtttgcgg gccctggtga 10260 cctcagggag ccctggagat gggcggggac tgggccccgt ggcctggcgg ggccatggcg 10320 gatgtgggaa aacgggttta aggggagctt aagaggtggg attgagggtc tgttgtcagc 10380 tcgacgtggc tagggagggt tctaggagcg ggttggggat ggccccccac ttccatcctg 10440 tgctcctacc tgggtgagcc tcctcgggcc gtccccgggt gttctgcagg caggggctcg 10500 ggggcggggc cggggttgcc cagctgtgag tgaggcccag ggtcagcagt catgttgggc 10560 cctagttgtc tgtatttgag ggacagtcgg aggtgtgggg cgggggactg ggtgggggtc 10620 ctggaggctg ggctgggtgt ggctggtagc acgttggtta ggggaggggc tggacgtggg 10680 agtgcagtct tctgagacat cttgggaggc caggcctgtc cttagctgga tgaggccgag 10740 gcactgggac gtgcgtgggg tgggcggcgg gtgaggacca gggaagggct ggcaggcgtg 10800 gggttgggcc ttgctgggga agtgtggttt tccccagctt agccaggcct tggggctggt 10860 tggatggggt gtgctgaggg atggagtgag cctggcctgc ctggacactg cccaacgcag 10920 catccccccg gggtgggaag ccagcaggcc ctgaggtgac tcagccccag ccccctcctc 10980 tgggccccac ctggaaggag ccagggctgg gctcaggggt caagagcaca ccaggggtag 11040 actggggggt tcctgggcag tgagggctga gaggctgtgg aatgtgggta cccagtgctg 11100 ggtagtacag ggcatgtccc gggggtccca cctgtctgag catgtctgtg agtgacggtc 11160 tccgtgggct gcactaggcg gagcaggggg ccagccctgt ggtctctttg cttggctgac 11220 agcatcgcct gtcgccatgg ctggggtaca agggccaggt ggcccggggg cagagggggc 11280 atagtggcca tggtctgagg ctgtgctggg cagtcccagg acctcttggc ctcagtttcc 11340 ccaactgtac cgcaagggcc cctcctgcca cctgttctgt gtgagggtgg aggtaggtgt 11400 gggtttgcct gtgtgctgta tgcctgcagg acctgagctc cggcctgttg gggcctctgg 11460 ctgggcgccc tgtacttggc caccccgtgc acttggtgga ggccgccagc gtggtgatgg 11520 ggccccacgt tctcccccgt ggtcaccccc agtgaggcac caaggggcgt tccacaggaa 11580 acgctcgggt cccggctgcc catggggccc ctgtctgtgg ccactccagc caggctgccc 11640 tttgcccacc tctccccccg gtcgctcttc ctgtgctccg tgctgacttg agccagctca 11700 gggcaggctg ggcctctggc accccaacgg tagggagccc aggcccctga gcccgcgtgg 11760 cctggagggg cagtctccct cccttgagct gggtcatttt tgggtctgca gaggatgtgg 11820 cctgaggatg aggagggtgg tgggtccctg gctggggagg aagggccaga gcctggcaga 11880 cccaggggca gcgtctgagc cctgggcctt gtcccaccct gaacgaggca ggcaggtgtg 11940 gcctcaggta cctgacccgc ctccccatgt ctgcagcgct cctttaccct catcgtggag 12000 gcctgggact gggacaacga taccaccccg aatggtgagt gagccctggg ccaggtggca 12060 gctcctctca gcttcagcgt gcctgtggca gggcccagct cctctgtctg cttgggacaa 12120 agccttgctt taccctgagg atcatgtgtg ctgtttccct ttttgctttg gctgccagga 12180 agctctgcca cgtttgggac ttgcagagct gtgcatgcac tctcttcccc agtcctggct 12240 ttgcctatgt tgttctcctc ttgggtgtgc tcttttgggg cccatggcag tgacttagtg 12300 gaggggacac ccttgagtgt gtctctggct ttgtggcccc ctctgcttgt ctgtactgga 12360 gcatggagcc ttggtggccc tctccctgag gcaggggctc tgcagggccc tgcaggggta 12420 acgggatgac ttccatgggt gaatgcagaa gcacccacag gccaagggag cagctcgtgt 12480 gaaggtctgg gcaggagcgg gctggctgtg cagggggagc agccggggct gggctcagat 12540 catggaggct ggcaagccac tgagaggaca cgggctccgc ctggcaagct gtggctgcct 12600 tatggagggt gggctgtggg gccaggacac agaccgagga ggagctgcca cgtgaatctg 12660 ggcgtgtcag ggtgacttgg accaggggca gtctgggggt gagaggggct ctcagaagtg 12720 gaggcatggg gttggccaat gggttggagg agggagagcg gggccagggc atcctggctg 12780 ccagcagagt ggaggggctg ttttcagggc agggacggcg gtgggggtgc ccaggtgggg 12840 agcagcagtt gtggggaccc cagcggctca gggcaggggt gtttcctgag ggggtggcag 12900 agagacaggt gggctgagtc ccaagcaagg tcgtcagggc tcttgacaac gtgagcctgg 12960 agaggctggg gcggccggga cgccccttgg ggagtgggcc agcacagtgt cctcccaggc 13020 cttggcccga ggcgggagag gtggggtctg gaggacccgt tcacctttta ttgtgcaaaa 13080 cgtcgagcct gtgcctaagc gcagggaccg gcatcacgga ctttgcatac cagcgccagc 13140 agctgtggtg cccctggccc ctggtctcct ggtggcttac ttaaagtgag gcttagacag 13200 cgggtcacgg gacctatgcc tgtcttgggg gcctgagggg aggcttgtct taaggtgggg 13260 acggtagtgg tgtttggcac ttctgggagc aagtcacagc gcaggagagg ggagggcaac 13320 tgagcaccat gtccgtgctg tcgagggctg gacacggcgc aggtgggtgc aggtgttgga 13380 gcagggctgc aggtgggtgg gcacaggtgt gggacgtgag actcacgccc tggcagcagc 13440 cgtgccttct ctgtggagcc tgtggtctca gcagccctcc ctgcagggcc cctggcccct 13500 agccgggccc cccgaccctc tgcgtttagg gtgggagcgg ggcgcaggct tggtggcggg 13560 agggagaggc ctctcggggc cctgagcttt ctgtagcagc ctggccgggg gccctgccct 13620 ccgtgtgctg ctgcctgctg tgccccggcc ttgcagcagc cgcaggcttc tgccccgtcc 13680 ccgttgttcc tggaggaccc ctggccgggc tggtttctct ggcctgtgct gactctgccg 13740 cctccccaag aggagctgct gatcgagcga gtgtcgcatg ccggcatgat caacccggag 13800 gaccgctgga agagcctgca cttcagcggc cacgtggcgc acctggagct gcagatccgc 13860 gtgcgctgcg acgagaacta ctacagcgcc acttgcaaca agttctgccg gccccgcaac 13920 gactttttcg gccactacac ctgcgaccag tacggcaaca aggcctgcat ggacggctgg 13980 atgggcaagg agtgcaagga aggtgagggg gccgctgggc cgcgtggagg gcagggaggg 14040 cctcgggcag ggccccgggc acaggccttg cggccaggct ggctgcagct gtgcctctcg 14100 ctcctctctg ttcgcagctg tgtgtaaaca agggtgtaat ttgctccacg ggggatgcac 14160 cgtgcctggg gagtgcaggt gagtgtgccg ccggcccgtc tttgccctcc caacctttgc 14220 cctcacgtcc tcactggcac acacagcctt gctgtcagga gtcgcccgga gctggctgga 14280 ggttgggcac acagctgtga gagccgggcc ctgagctcgg gaggctcctt agtgcagtag 14340 gtgcgtgtct gagcatggga tgtgtctgat ggcggcagcc atgtgaggac agtgaggaga 14400 gactggggag gctggctgga cagtcacgtc accgaggggc agagacccgg aggctgcaag 14460 ccacccagag atggggcatg ggcagaggac acggtaaccc tgcccatggg gagggggtgg 14520 gcggcgagcg gccggcaagt gacaccagca ggcgaggggc ggcagagcag accagtggtg 14580 ggagctgagg cctgcaggac cagggacaga ggaaggggct gctggcaggt ttgtagctgg 14640 gcaaggtggg tggaagggct gtggtagctg ttgagtgggg aagcaccaga cgggaggctg 14700 tgagggggag gccgctgtgg ggcatgtggg ggtggtgggg gaggggccag cgggatgggg 14760 agggggtcag tggaaggggg agaggcgcac gggtcctgca gacatcctgg ggtggagccc 14820 aggggtttgt ggatggattt gatcaagcag gaagggtgtg gagtcaggga gaaccccaag 14880 ctgctgagta gcagagccat ggtggcagga ggaatgccac agaggagcag gcggggccgg 14940 ggttagctgg atgtggagag gcgatgcctg ccctgtccct ggagacaccc agaaagctcg 15000 tgggagaggc ctggcctgcg ccacgcgggg cctgtggggg gtggcattca ggcggtgacg 15060 ggaaagtggg gaaggcagag aggagggagg ccaaggagca agtcccggct gccacaggtc 15120 agggcggatg gatgaggagt cagcaagggc ctccacaagg gagtgtccgg ggtcttacag 15180 ccaagtccag atggtggagg cctctggacc cagaccagag tgtgggggat ccagccaggg 15240 gggctggcag ctttgcccta gagtggagca gagaagtcag cagggcaacc agaggggctg 15300 gggcccaggg tctggggtgg gcacgggctt cgagccgtgg cgctcactgt gcgtgagcaa 15360 gctggggagc ccgagagagg ggcgcgagcg ggtggagaga cagcaggtgg aggtgagcac 15420 cgccctccag ccagccttgg attgcagggg tcccaggacc tccctctgtg gagtgggttt 15480 gcctccatgg gacgaggaca ctggggcaca gagagcctac tgatttcccc agggtcacac 15540 agcgtggcgt tttggagagg agtcggggag tttgggaacc agctgagttg ggagccaagg 15600 tggggaggtg ggtgaccctt ccacaggccc cacggttgag tggcctggag ggtacagtga 15660 ggagctttcc cggccagtcc cagagcgggg aggcaagcag ggctggggcc gcccacccgg 15720 tcacttgcac acacagggat tcccggcagg ttgagcgagt cccaagtcag ctcagaaagt 15780 gcaacaaggt ggacctggtc tgggcagatg tagatgtaga tctacgggag tcggccccac 15840 tcaccctcgc ctggcccagt gtgcatcaca caacctggat ggcagtgcca ccctccctgg 15900 atggctgctg gctggcagct tgaatgtcac accaaggctg gaggaaggca gcagagaagt 15960 tggccatccc tgccctttac ccgcaggaag atgagccgga gtctgggggg cctggtgggt 16020 gggggcagta ggtgagctcc gcctgcccct cttgctggcc ctgtcgggga ggcccagctg 16080 ttgctgacag cctcggctca ggttccagtg caggacgccc ccccaccgga tgctgcggag 16140 atggccatgc cttcctgccg ccgcctctcc agggccctgg ggctgctggc tggggaaacc 16200 aggaggtggg ggcctggtgt gggctgccct gcccagggtc gagagcacgc ccttgggacc 16260 cacgaggtct gggctctgag cccggctgtg gccgctctct ggccgatgac ccaaggtgtg 16320 tcacagcccc gccctgagcc tgggtctctg tgtctgtgga ggagggattc taggcgggat 16380 gtgaggccac ccacgcggac cactgtgcat gctgggctgg atactggaga cacgttcttc 16440 ccggcctcag tttccccatt tgtggcagct gaactgggct gataggcctt cggtgctggc 16500 tgtgtggctt gagggcggct caggaagggc cgtggttctt tccttttaca aaaataaagt 16560 gtggcgggtg ccggtgtgga agtgacgtgg cctggatgac attcccgtcc tgcaggaccg 16620 gagagttcta ggaagggccc cccgggagtc ccggcagggc ctggatggca gcctgctgag 16680 ccttggggtc gttgcaggct ctctcccctg acggaggcac cctcaagtca ggccatgttc 16740 taccctggcc acctgccctc tcctggggga ctcccaagac aggacgttgg ccgatagcct 16800 ggggcagggc gagtcctggt ggttgtgtcc tggggggtgc agctgggggt gcagctggag 16860 ctcctgcaga atcaggaact accctgggca gggctggccc aggccagcct gtgggcctca 16920 gtagccccat ctgtgagatg ggtaccttgt gggactttac tgggagcgag cgaaatgact 16980 gcctttgagg tgggggcgag ggcacgtgct gtgcccaggg ccacatggcc gaggcagagc 17040 caggagtgct cccctgctgc ccgctggcct acccagcccc tggtgcctcc cggccctggc 17100 agcaccttgt gagtccgagc cggcattctc atccccgggg tcccggcagg gccttccttt 17160 cctggtgcct gctctcgggg cccagctcac gggtgaatcc caaaatagct cagggaggag 17220 tgacgggaca gctggggctg accgtcggca gccagcggcc gggaatgccc gtgacagtgg 17280 ggctggccgg cagggctgca acccctgcct ggctggggct gctccagttc aaaggcctga 17340 ggccgcccgc cggccctggg tgtggcgtgg gtgactgtgc ctggctcccc tgccaccctt 17400 tcaggcacca cagctcactg ggtcttgcgc ccctcctcct tcccccaggt gcagctacgg 17460 ctggcaaggg aggttctgcg atgagtgtgt cccctacccc ggctgcgtgc atggcagttg 17520 tgtggagccc tggcagtgca actgtgagac caactggggc ggcctgctct gtgacaaagg 17580 tagtggtagg gggcggcagg cctaatgctc tgccatcgaa gtgtgggttg tgggggagcg 17640 gggggccggc ttttcccctg agcatcccac ccctgccccc agacctgaac tactgtggca 17700 gccaccaccc ctgcaccaac ggaggcacgt gcatcaacgc cgagcctgac cagtaccgct 17760 gcacctgccc tgacggctac tcgggcagga actgtgagaa gggtacgtgg ggggctggcc 17820 acccaaattc tggccaggca gggactggtt ccctggggag ccggtcaggc cccatccctc 17880 tggcgtcctg tgtggtgggc ccctgacccc cagcttggga acctgtgggc ttggggagga 17940 gtgcttgtgg aaagctgggg gcctggctgc cagctctgcc ccctccccgc ggttctacag 18000 ctgagcacgc ctgcacctcc aacccgtgtg ccaacggggg ctcttgccat gaggtgccgt 18060 ccggcttcga atgccactgc ccatcgggct ggagcgggcc cacctgtgcc cttggtgagt 18120 gtctgcacgt gagtagggga ctcctgccta gtatcagtgg gggtctggga gtggggcaac 18180 tcgctgggga tggggtgcag tggtcaagtc cacacgtgtg gctgcggctg gcttggcgag 18240 gacaaatggc aggaagaccc aggcttgcag cgccacctgc ccatggggac cttattccca 18300 cggctcacac tgccagggcc ccacctttct ccaccctctg cagacatcga tgagtgtgct 18360 tcgaacccgt gtgcggccgg tggcacctgt gtggaccagg tggacggctt tgagtgcatc 18420 tgccccgagc agtgggtggg ggccacctgc cagctgggta agggctccga gcgagtgcat 18480 gggaacgtgg gccgcgcatg cgggctgcgg gggctgctgg ggctgcgggg gctgctgggg 18540 ctgctggggc tgctgggctg cgggtgccag gtgcccgtgc tgcagggggc aggcagggcc 18600 cgagccccac ggctcccacc ttgtctcttt cacagacgcc aatgagtgtg aagggaagcc 18660 atgccttaac gctttttctt gcaaaaacct gattggcggc tattactgtg attgcatccc 18720 gggctggaag ggcatcaact gccatatcag tcagtatggg gggtgggcgc cggcgggtgg 18780 gccgaggcac atgggacccc gcctctgacc ctgctcctct gcccccagac gtcaacgact 18840 gtcgcgggca gtgtcagcat gggggcacct gcaaggtgag gcggggccag gagggtgtgt 18900 ggcgtgggtg ctgcggggcc gtcagggtgc ctgcgggacg ctcacctggc tggcccgccc 18960 aggacctggt gaacgggtac cagtgtgtgt gcccacgggg cttcggaggc cggcattgcg 19020 agctggaacg agacgagtgt gccagcagcc cctgccacag cggcggcctc tgcgaggacc 19080 tggccgacgg cttccactgc cactgccccc agggcttctc cgggcctctc tgtgaggtga 19140 ggtctgcctg gtcaccctgc cccacctgct gctctgggag ctgtagggca ggcctcgtcc 19200 cctgaccatg gggcctgagt gacccagggg tgctgcaggg gaagttgtcc ccaaggcgtc 19260 ccaggctcag ctctccactg ggtgccaggt gggcaggcgg ggctgtcaca ggtcaccagg 19320 cttggccccc tgtggccatt gcttgttgtg atgggtttcc tggtggcctg ggctaggagc 19380 ccccgggctg ctggctgccc aggcctatct gtccatctgt gcactccctc gggactggag 19440 ggcagggggc tctggtgggc agagcacatg gggtagggtg ggtgcctgat ggtggagagg 19500 tatacacctg tcataggtga gtcctgggtc ggagtgggca tctctctcag ggctgatgct 19560 ctcgcctccc tctgaccatc tgttggtact ggaccccccc cacccacctc cctaccaccc 19620 tcggccgccc acgatcctgc cctggccttg gtgcagagga tgggcctcct gtccagaggg 19680 cttcttgggg cccagggcag gggtctgacc tcaggacctg caagcatggc agtggctggc 19740 cctggaaaag acccacagtc ttggctctga gggtggccag gcagtgtgtg aggggctcag 19800 gagctgtcct tcctgccagc agcaggggcc aaggccacac tcctcccgag ggacagtgag 19860 gaagctgggc tgcagtggag gtgggggtgg gggcccacag gtatctgcgt tcagctaagg 19920 cctgggcagt ctcaggtggg caggggtctt gggctctggc tggcactgtt aggcccaggg 19980 cggaggggcc tgggggtccc cagggatcta ccttcgtatg gacagaggcc tggcctgtgt 20040 tcccggcctg ggcctgggcc taggctctca caggcacccc ccaccctgca ggtggatgtc 20100 gacctttgtg agccaagccc ctgccggaac ggcgctcgct gctataacct ggagggtgac 20160 tattactgcg cctgccctga tgactttggt ggcaagaact gctccgtgcc ccgcgagccg 20220 tgccctggcg gggcctgcag aggtgctggg tgcggcatgg ggtggtgggg gaggtggtgg 20280 ggcaggggcg ggcctgactc ctgactgtac tgcctgccat agtgatcgat ggctgcgggt 20340 cagacgcggg gcctgggatg cctggcacag cagcctccgg cgtgtgtggc ccccatggac 20400 gctgcgtcag ccagccaggg ggcaactttt cctgcatctg tgacagtggc tttactggca 20460 cctactgcca tgagagtgag tggccacgaa cggcgggctg gtggtggggc tgggctggcc 20520 tgaggccctg gctcaccccg ctcgcctctg cagacattga cgactgcctg ggccagccct 20580 gccgcaatgg gggcacatgc atcgatgagg tggacgcctt ccgctgcttc tgccccagcg 20640 gctgggaggg cgagctctgc gacaccagtg agtgttccag cacccgccca cacggcctgt 20700 gcctccaccc ctgtgggccc cttatcaccc tgagatggac cgctgtctgg gtgcggcagg 20760 ccccgtaccc agaaaggcct ggccaggggg tgctgccacc atggggtgga gtcccaggct 20820 gcccccatgc ccgaggccag ctcccccggc ccgacgctcc tcccccgccc ctctctgtcc 20880 tcacctggcc cagctccagt gcttcctccc ccgggaagcc ctccctgagc gccggtgacc 20940 ccccgcccgc tgaccggcgt cctcgccccc agatcccaac gactgccttc ccgatccctg 21000 ccacagccgc ggccgctgct acgacctggt caatgacttc tactgtgcgt gcgacgacgg 21060 ctggaagggc aagacctgcc actcacgtga gtgtccgcag gccctggccg cctggggctg 21120 cccccaggac cctggccctg gcggtctggg gcctgcctgc tgagcggccc atgtgccaac 21180 aggcgagttc cagtgcgatg cctacacctg cagcaacggt ggcacctgct acgacagcgg 21240 cgacaccttc cgctgcgcct gcccccccgg ctggaagggc agcacctgcg ccgtcggtga 21300 ggagcccccg ctgcctctgc gaccgccggg catatgccct cccaggcacc gctccctcgg 21360 gcgcgatggg ccgaggggtc ttttttgagg gccacacctg ccacctgccc cctgccccct 21420 gcccccgggt ctgtctgccc tgtctgggtt gggggcgcgg tatggagacc cagggccagc 21480 ccagggccag gtgagacgct ccctcctcct cctctcctta cagccaagaa cagcagctgc 21540 ctgcccaacc cctgtgtgaa tggtggcacc tgcgtgggca gcggggcctc cttctcctgc 21600 atctgccggg acggctggga gggtcgtact tgcactcaca gtgagtgtgg gaggggtgtg 21660 ggcgggggcc gctttcctcc acccagatga catccctgcc cccgactcgc cccccagtcc 21720 cttctgccag cccctccccc tgctgcccct gcccccagca aaaggcaccc tccttgatga 21780 ccctccccag ccccacagcc tgatcacgcc aagccagcct ggacagtgcc tggcacgctt 21840 ggggggtggg tactgatccc ctgcgttctc ttctcccaaa ccagatacca acgactgcaa 21900 ccctctgcct tggtgagtgg caccctgggg gccacagcag gggtgggtgg gacttggcat 21960 accacggggg gccacctgat gcccaccctc tgctctgcag ctacaatggt ggcatctgtg 22020 ttgacggcgt caactggttc cgctgcgagt gtgcacctgg cttcgcgggg cctgactgcc 22080 gcatcagtga gtggccagac agccccagcc ctgggagccc ctcagcccag ccgcggtgtc 22140 aggagtctgg ggacatcaac gtccacgtcc cttgaagggc agtgtggcca caactacttc 22200 ctgcctctct tctgagcctc agtttcccca catgtctgtg ccctgtgggg ttcctgctgt 22260 ataccctgcc aagtgattaa gtggggagcc ccagcctggg ggaccagtcc ggggcccagg 22320 gagctgtggg ggttggagcg tgcagcctga cgtgggctcc tctgtggccg cagggctgtt 22380 gtccctgggt gttggcccag ctgtctgtcc agcacccctt ggctggtccg acgcagcagc 22440 tggggctaat ccaggatggg acaggcccac tgcagaagca gacggaggag ggtgctgttg 22500 ggccagggtc aggctgggct caggaaggcc tcaggcaggc agcagcttgg gctcgggggc 22560 aggggctgct cctcattgtc ctggggcttg cgcctgtgtg ccactggctc cccgctgccc 22620 taggccatgc cggtcctgcg gtgggcgttg gcctcactgc actgagcagc ggtggctctc 22680 cctgcagaca tcgacgagtg ccagtcctcg ccctgtgcct acggggccac gtgtgtggat 22740 gagatcaacg ggtatcgctg tagctgccca cccggccgag ccggcccccg gtgccaggaa 22800 ggtaggcccc gtgtgattgc cctgggttgg ggcgggttgg ggggcatggg tgacacccag 22860 ccccgagggc cagatgccca ctgctgaccc tcgagcccct tctccccaca gtgatcgggt 22920 tcgggagatc ctgctggtcc cggggcactc cgttcccaca cggaagctcc tgggtggaag 22980 actgcaacag ctgccgctgc ctggatggcc gccgtgactg cagcaaggtg agggcagccc 23040 gtgagccgcc ctgccctacc cgaggctggt gcacgctgac cctggccact ctgtgagatc 23100 aggaggcggg tgctggggtc cggatggact gagagccgtc tgccctcagg gacacccagg 23160 gaggcgagag ctcagccagg ccccatgctt cgatgtgcag ttgggaaaac aggcctggtc 23220 tgggtcctgc cttgctccgc ctgccctttc tgatgtcgag cttggcctgc ctccctggga 23280 gccctgggta gggggtgggc tgggccctgg ggctcacaga cttgggcggt gtccctcctt 23340 ggcatggggc ccgtgcctgc ctgtgggttc tcatctgtgt gcctgcatct gaccctcctg 23400 tgcgcctgcg cctgaccctc ctgtgcgtgc ctgcccaggt gtggtgcgga tggaagcctt 23460 gtctgctggc cggccagccc gaggccctga gcgcccagtg cccactgggg caaaggtgcc 23520 tggagaaggc cccaggccag tgtctgcgac caccctgtga ggcctggggg gagtgcggcg 23580 cagaagagcc accgagcacc ccctgcctgc cacgctccgg ccacctggac aataactgtg 23640 cccgcctcac cttgcatttc aaccgtgacc acgtgcccca ggtgaggggc ctggtggcat 23700 ctgagcttgc agaggccaca cgccggcatc tgctcgtggc atggcgaaag cctagccccg 23760 cagggcaggg aggccctggt tggctgagca gagtcactct tggtcacaga gagtggccct 23820 gtggggtcag atgagagggg cattgggcct ggtgctgggt ggaggtggca gaggaggctg 23880 ggagagcagc cagctggggg tgcctgtttg tccagctgcc ctgagggcct ggactgacgg 23940 cgccatggct gcctggcccc agctcttggg ctgcagctcc gtgggcagtt ttgccctggc 24000 ctaggaccca cctttgcctg ctgtgtgctt ggagctgggc ccctgtctcc caggaggggc 24060 tcagaactgg aggagaccca ctgtaccccg ccctgcctct ccttccccca ctggcctgca 24120 ggtggagctg ggtccgccct gaggatgggc gggtgggcac cgtcactcct gcctcctggt 24180 atagggcaca gccgggtggg aagctgcccc cccaggccct tggcatcctt gctgtgctct 24240 cctgggcggg ctgtagggtg tgtcccacgt gtacccacag cgccagtcca gggatgtagg 24300 tgtcaggttc acggccctgc cctgcccacg cactgcctgt ctctgcccag ggcaccacgg 24360 tgggcgccat ttgctccggg atccgctccc tgccagccac aagggctgtg gcacgggacc 24420 gcctgctggt gttgctttgc gaccgggcgt cctcgggggc cagtgctgtg gaggtggccg 24480 tggtgagtgc ccagtgggga gcagcacctg ggtgggccct gggtcccgta ctatgcaggt 24540 cctggctatg ctggacagag gctctggcga ggctagtcct ggtgcggaag gactgcgggc 24600 aggcctgtct ccctgcggcc cctcgctgtc catgccgcag acccgtggaa ctgctccctg 24660 ggcctggcca gcatgaggga gatgcagggc tgtggtgtgg agcccgcttc ccctgcagct 24720 gcatcctcgc ccggtcccct gctctgtttt tgtctctgtg tccctacgtc acaggcagca 24780 ggagagtccg tgggcttagt ctgccctggg aggcctgctt tgggactggc acctgccctg 24840 gacctggggg gtgtcagatg tgaatggata ccaagggggt cgggtgagac tggggtggag 24900 acatgcccgg agaggggagg gaatgttctg gaacatggtg ggtgggtgtg cagagcagtg 24960 ggtgtggcca tggcacagtg tggctggtgg aggccatggc caggcacagg aaggacgtgc 25020 agtgttttgg tgccctgagg ccgcagaggg ggtgggggac atggatgggt gctgctgggt 25080 gatggaaggg cagtaggggc aggggaagat gtaagaagtg tgccagcaca ggtcagggcg 25140 ccatcaggga tgtggtggag gcaggggcac agccccgggt tgctgtggcc tcgtgaaggc 25200 actaggtttg tggtgcccct ggggtgtggc ccataggtgg gggtgggggc tgggaactga 25260 caagaaggga tggccatcac ggagcaggtg tcagcgaatg gggccacaca cctccccaac 25320 tcactgcctg gtggcgaggt ccccaccgca ggaccccggg ctctcctgtg tgcccggacg 25380 gggacaccct ccacccctcc acttcccccc acccctcact gcctgctggt gaggtcccca 25440 ccgcaggacc ctgggctgtc ccgtgcgccc ggatggggac atcctccacc cctccccttc 25500 cccccactgc tcgctgcctg gtggtgaggt ccccacacct caggaccctg ggctctcctg 25560 tgtgcccgga tggggacagc ctccacccct ccactcctcc ccccgctact ccccactcac 25620 tgcctggtgg tgaagtcgcc actgcaggac cccgggctct cgtctcccgt gcgcccacct 25680 tgctccagtg tggccagggc ctcagtgttg ggggcaggct gctgggagcc tggagccctc 25740 gagccatccc cacaatgccg ttctttgccg cagtccttca gccctgccag ggacctgcct 25800 gacagcagcc tgatccaggg cgcggcccac gccatcgtgg ccgccatcac ccagcggggg 25860 aacagctcac tgctcctggc tgtcaccgag gtcaaggtgg agacggttgt tacgggcggc 25920 tcttccacag gtaagcgcgg gaggtgggcc cctgggaagg caccaggcag gcaactcagg 25980 cattgggcac agagccggcc gatcctgccg atcctgccag ccaccaggaa cacagaagtc 26040 cctggcacct gctgccccag ccgcccagcc ccacaacctg accttcccag cccccgtcct 26100 gggaccctcc ccacgagcca gcaaccggag ggtggggccc ggccgcctgg cccgcagggc 26160 cctcccaggc ctgggtgtgt ggctagtgcc ccgcaggtgc ccaggcctca ttgcccaccg 26220 gctcttctcc ccggtcccca ggtctgctgg tgcctgtgct gtgtggtgcc ttcagcgtgc 26280 tgtggctggc gtgcgtggtc ctgtgcgtgt ggtggacacg caagcgcagg aaagagcggg 26340 agaggagccg gctgccgcgg gaggagagcg ccaacaacca gtgggccccg ctcaacccca 26400 tccgcaaccc cattgagcgg ccggggggcc acaaggacgt gctctaccag tgcaagaact 26460 tcacgccgcc gccgcgcagg gcggacgagg cgctgcccgg gccggccggc cacgcggccg 26520 tcagggagga tgaggaggac gaggatctgg gccgcggtga ggaggactcc ctggaggcgg 26580 agaagttcct ctcacacaaa ttcaccaaag atcctggccg ctcgccgggg aggccggccc 26640 actgggcctc aggccccaaa gtggacaacc gcgcggtcag gagcatcaat gaggcccgct 26700 acgccggcaa ggagtagggg cggctgccag ctgggccggg acccagggcc ctcggtggga 26760 gccatgccgt ctgccggacc cggaggccga ggccatgtgc atagtttctt tattttgtgt 26820 aaaaaaacca ccaaaaacaa aaaccaaatg tttattttct acgtttcttt aaccttgtat 26880 aaattattca gtaactgtca ggctgaaaac aatggagtat tctcggatag ttgctatttt 26940 tgtaaagttt ccgtgcgtgg cactcgctgt atgaaaggag agagcaaagg gtgtctgcgt 27000 cgtcaccaaa tcgtagcgtt tgttaccaga ggttgtgcac tgtttacaga atcttccttt 27060 tattcctcac tcgggtttct ctgtggctcc aggccaaagt gccggtgaga cccatggctg 27120 tgttggtgtg gcccatggct gttggtggga cccgtggctg atggtgtggc ctgtggctgt 27180 cggtgggact cgtggctgtc aatgggacct gtggctgtcg gtgggaccta cggtggtcgg 27240 tgggaccctg gttattgatg tggccctggc tgccggcacg gcccgtggct gttgacgcac 27300 ctgtggttgt tagtggggcc tgaggtcatc ggcgtggccc aaggccggca ggtcaacctc 27360 gcgcttgctg gccagtccac cctgcctgcc gtctgtgctt cctcctgccc agaacgcccg 27420 ctccagcgat ctctccactg tgctttcaga agtgcccttc ctgctgcgca gttctcccat 27480 cctgggacgg cggcagtatt gaagctcgtg acaagtgcct tcacacagac ccctcgcaac 27540 tgtccacgcg tgccgtggca ccaggcgctg cccacctgcc ggccccggcc gcccctcctc 27600 gtgaaagtgc atttttgtaa atgtgtacat attaaaggaa gcactctgta tatttgattg 27660 aataatgcca ccattccggc ctcccttgtt ctttcggtgc tgtccctttt gtattgagag 27720 tgaggttggg ggagagccac gccggcagag aggcttgggg cagtggggca cgtgctgggt 27780 attggcccac gtggctgtgg tggctgtaga gggcgagacg gttctgttga gtcggggcct 27840 gccagggcct cgaatgcgtt ggcatgccaa ggtggtggat gcaggtttgg ccaaaacctt 27900 cctgggaatg gggagggggg tgtctaggtg cctggcaccc gaccctgact aaaacagctg 27960 aaaacagttt tataaaatag tataaaattg cttacccacg 28000 382 419 DNA Homo sapiens 3′UTR (1)...(419) 382 tgcggccgcc ccttctcgtg aaagtgcatt tttgtaaatg tgtacatatt aaaggaagca 60 ctctgtatat ttgattgaat aatgccacca ttccggcctc ccttgttctt tcggtgctgt 120 cccttttgta ttgagagtga ggttggggga gagccacgcc ggcacatagg cttggggcag 180 tggggcacgt gctgggtatt ggcccacgtg gctgtggtgg ctgtataggg cgagaccgat 240 ctgttgagtc ggggcctgcc acggcctcga atgcgttggc atgccaaggt ggtggatgca 300 ggtttggcct aaaccttcct gagaatgggg acgggggtgg atctggaatt ggcatgatta 360 caaactactc tgcaattctt cctctcccca attaaggtgt ctctcttgaa ctgattgaa 419 383 20 DNA Artificial Sequence Antisense Oligonucleotide 383 tacaaaaatg cactttcacg 20 384 20 DNA Artificial Sequence Antisense Oligonucleotide 384 tggcattatt caatcaaata 20 385 20 DNA Artificial Sequence Antisense Oligonucleotide 385 gcgcacctgc atatgcatga 20 386 20 DNA Artificial Sequence Antisense Oligonucleotide 386 gaaatagccc atgggccgcg 20 387 20 DNA Artificial Sequence Antisense Oligonucleotide 387 cagctgcagc tcgaaatagc 20 388 20 DNA Artificial Sequence Antisense Oligonucleotide 388 gcagcgcgct cagctgcagc 20 389 20 DNA Artificial Sequence Antisense Oligonucleotide 389 gcagctcccc gttcacgttc 20 390 20 DNA Artificial Sequence Antisense Oligonucleotide 390 gctcagcagc tccccgttca 20 391 20 DNA Artificial Sequence Antisense Oligonucleotide 391 tggtactcct taaggcacac 20 392 20 DNA Artificial Sequence Antisense Oligonucleotide 392 caccttggcc tggtactcct 20 393 20 DNA Artificial Sequence Antisense Oligonucleotide 393 gccgtagctg cagggccccg 20 394 20 DNA Artificial Sequence Antisense Oligonucleotide 394 ggcaggtaga aggagttgcc 20 395 20 DNA Artificial Sequence Antisense Oligonucleotide 395 gacgaggccc gggtcctggt 20 396 20 DNA Artificial Sequence Antisense Oligonucleotide 396 ttgtcccagt cccaggcctc 20 397 20 DNA Artificial Sequence Antisense Oligonucleotide 397 aggctcttcc agcggtcctc 20 398 20 DNA Artificial Sequence Antisense Oligonucleotide 398 gctgaagtgc aggctcttcc 20 399 20 DNA Artificial Sequence Antisense Oligonucleotide 399 ccacgtggcc gctgaagtgc 20 400 20 DNA Artificial Sequence Antisense Oligonucleotide 400 ggccggcaga acttgttgca 20 401 20 DNA Artificial Sequence Antisense Oligonucleotide 401 ttgccgtact ggtcgcaggt 20 402 20 DNA Artificial Sequence Antisense Oligonucleotide 402 gcaggccttg ttgccgtact 20 403 20 DNA Artificial Sequence Antisense Oligonucleotide 403 catccagccg tccatgcagg 20 404 20 DNA Artificial Sequence Antisense Oligonucleotide 404 cccccgtgga gcaaattaca 20 405 20 DNA Artificial Sequence Antisense Oligonucleotide 405 gtagctgcac ctgcactccc 20 406 20 DNA Artificial Sequence Antisense Oligonucleotide 406 cagttgcact gccagggctc 20 407 20 DNA Artificial Sequence Antisense Oligonucleotide 407 gttggtctca cagttgcact 20 408 20 DNA Artificial Sequence Antisense Oligonucleotide 408 ccgccccagt tggtctcaca 20 409 20 DNA Artificial Sequence Antisense Oligonucleotide 409 gcaggccgcc ccagttggtc 20 410 20 DNA Artificial Sequence Antisense Oligonucleotide 410 acagagcagg ccgccccagt 20 411 20 DNA Artificial Sequence Antisense Oligonucleotide 411 ttgtcacaga gcaggccgcc 20 412 20 DNA Artificial Sequence Antisense Oligonucleotide 412 ttcaggtctt tgtcacagag 20 413 20 DNA Artificial Sequence Antisense Oligonucleotide 413 gccacagtag ttcaggtctt 20 414 20 DNA Artificial Sequence Antisense Oligonucleotide 414 ggtggtggct gccacagtag 20 415 20 DNA Artificial Sequence Antisense Oligonucleotide 415 gaggtgcagg cgtgctcagc 20 416 20 DNA Artificial Sequence Antisense Oligonucleotide 416 cccttcacac tcattggcgt 20 417 20 DNA Artificial Sequence Antisense Oligonucleotide 417 aggtttttgc aagaaaaagc 20 418 20 DNA Artificial Sequence Antisense Oligonucleotide 418 cacagtaata gccgccaatc 20 419 20 DNA Artificial Sequence Antisense Oligonucleotide 419 gatgcccttc cagcccggga 20 420 20 DNA Artificial Sequence Antisense Oligonucleotide 420 gcaggtgccc ccatgctgac 20 421 20 DNA Artificial Sequence Antisense Oligonucleotide 421 ccaggtcctt gcaggtgccc 20 422 20 DNA Artificial Sequence Antisense Oligonucleotide 422 gggcacacac actggtaccc 20 423 20 DNA Artificial Sequence Antisense Oligonucleotide 423 gggctgctgg cacacttgtc 20 424 20 DNA Artificial Sequence Antisense Oligonucleotide 424 gagcagttct tgccaccaaa 20 425 20 DNA Artificial Sequence Antisense Oligonucleotide 425 ccgcagccat cgatcactct 20 426 20 DNA Artificial Sequence Antisense Oligonucleotide 426 gtgcccccat tgcggcaggg 20 427 20 DNA Artificial Sequence Antisense Oligonucleotide 427 agaagtcatt gaccaggtcg 20 428 20 DNA Artificial Sequence Antisense Oligonucleotide 428 cacagtagaa gtcattgacc 20 429 20 DNA Artificial Sequence Antisense Oligonucleotide 429 cgtgagtggc aggtcttgcc 20 430 20 DNA Artificial Sequence Antisense Oligonucleotide 430 ctggaactcg cgtgagtggc 20 431 20 DNA Artificial Sequence Antisense Oligonucleotide 431 ccgttgctgc aggtgtaggc 20 432 20 DNA Artificial Sequence Antisense Oligonucleotide 432 caggtgccac cgttgctgca 20 433 20 DNA Artificial Sequence Antisense Oligonucleotide 433 cgtagcaggt gccaccgttg 20 434 20 DNA Artificial Sequence Antisense Oligonucleotide 434 ttgggcaggc agctgctgtt 20 435 20 DNA Artificial Sequence Antisense Oligonucleotide 435 agggttgcag tcgttggtat 20 436 20 DNA Artificial Sequence Antisense Oligonucleotide 436 gcagcggaac cagttgacgc 20 437 20 DNA Artificial Sequence Antisense Oligonucleotide 437 ccgtaggcac agggcgagga 20 438 20 DNA Artificial Sequence Antisense Oligonucleotide 438 ttgatctcat ccacacacgt 20 439 20 DNA Artificial Sequence Antisense Oligonucleotide 439 ggtgggcagc tacagcgata 20 440 20 DNA Artificial Sequence Antisense Oligonucleotide 440 gcagctgttg cagtcttcca 20 441 20 DNA Artificial Sequence Antisense Oligonucleotide 441 ccaggcagcg gcagctgttg 20 442 20 DNA Artificial Sequence Antisense Oligonucleotide 442 ctgctgtcag gcaggtccct 20 443 20 DNA Artificial Sequence Antisense Oligonucleotide 443 ctggatcagg ctgctgtcag 20 444 20 DNA Artificial Sequence Antisense Oligonucleotide 444 tccaccttga cctcggtgac 20 445 20 DNA Artificial Sequence Antisense Oligonucleotide 445 gcgcggttgt ccactttggg 20 446 20 DNA Artificial Sequence Antisense Oligonucleotide 446 ccctactcct tgccggcgta 20 447 20 DNA Artificial Sequence Antisense Oligonucleotide 447 gacggcatgg ctcccaccga 20 448 20 DNA Artificial Sequence Antisense Oligonucleotide 448 gaataattta tacaaggtta 20 449 20 DNA Artificial Sequence Antisense Oligonucleotide 449 aatactccat tgttttcagc 20 450 20 DNA Artificial Sequence Antisense Oligonucleotide 450 tcatacagcg agtgccacgc 20 451 20 DNA Artificial Sequence Antisense Oligonucleotide 451 caccctttgc tctctccttt 20 452 20 DNA Artificial Sequence Antisense Oligonucleotide 452 caccggcact ttggcctgga 20 453 20 DNA Artificial Sequence Antisense Oligonucleotide 453 gggtcccacc aacagccatg 20 454 20 DNA Artificial Sequence Antisense Oligonucleotide 454 gaagggcact tctgaaagca 20 455 20 DNA Artificial Sequence Antisense Oligonucleotide 455 acagttccga gggttctgtg 20 456 20 DNA Artificial Sequence Antisense Oligonucleotide 456 ctggctggat cccccacact 20 457 20 DNA Artificial Sequence Antisense Oligonucleotide 457 gggagcactc ctggctctgc 20 458 20 DNA Artificial Sequence Antisense Oligonucleotide 458 ccatactgac tgatatggca 20 459 20 DNA Artificial Sequence Antisense Oligonucleotide 459 cgacatccac ctgcagggtg 20 460 20 DNA Artificial Sequence Antisense Oligonucleotide 460 tggcaggccc cgactcaaca 20 461 20 DNA Artificial Sequence Antisense Oligonucleotide 461 nnnnnnnnnn nnnnnnnnnn 20 462 2574 DNA Homo sapiens CDS (254)...(1492) 462 cctgtttaga cacatggaca acaatcccag cgctacaagg cacacagtcc gcttcttcgt 60 cctcagggtt gccagcgctt cctggaagtc ctgaagctct cgcagtgcag tgagttcatg 120 caccttcttg ccaagcctca gtctttggga tctggggagg ccgcctggtt ttcctccctc 180 cttctgcacg tctgctgggg tctcttcctc tccaggcctt gccgtccccc tggcctctct 240 tcccagctca cac atg aag atg cac ttg caa agg gct ctg gtg gtc ctg 289 Met Lys Met His Leu Gln Arg Ala Leu Val Val Leu 1 5 10 gcc ctg ctg aac ttt gcc acg gtc agc ctc tct ctg tcc act tgc acc 337 Ala Leu Leu Asn Phe Ala Thr Val Ser Leu Ser Leu Ser Thr Cys Thr 15 20 25 acc ttg gac ttc ggc cac atc aag aag aag agg gtg gaa gcc att agg 385 Thr Leu Asp Phe Gly His Ile Lys Lys Lys Arg Val Glu Ala Ile Arg 30 35 40 gga cag atc ttg agc aag ctc agg ctc acc agc ccc cct gag cca acg 433 Gly Gln Ile Leu Ser Lys Leu Arg Leu Thr Ser Pro Pro Glu Pro Thr 45 50 55 60 gtg atg acc cac gtc ccc tat cag gtc ctg gcc ctt tac aac agc acc 481 Val Met Thr His Val Pro Tyr Gln Val Leu Ala Leu Tyr Asn Ser Thr 65 70 75 cgg gag ctg ctg gag gag atg cat ggg gag agg gag gaa ggc tgc acc 529 Arg Glu Leu Leu Glu Glu Met His Gly Glu Arg Glu Glu Gly Cys Thr 80 85 90 cag gaa aac acc gag tcg gaa tac tat gcc aaa gaa atc cat aaa ttc 577 Gln Glu Asn Thr Glu Ser Glu Tyr Tyr Ala Lys Glu Ile His Lys Phe 95 100 105 gac atg atc cag ggg ctg gcg gag cac aac gaa ctg gct gtc tgc cct 625 Asp Met Ile Gln Gly Leu Ala Glu His Asn Glu Leu Ala Val Cys Pro 110 115 120 aaa gga att acc tcc aag gtt ttc cgc ttc aat gtg tcc tca gtg gag 673 Lys Gly Ile Thr Ser Lys Val Phe Arg Phe Asn Val Ser Ser Val Glu 125 130 135 140 aaa aat aga acc aac cta ttc cga gca gaa ttc cgg gtc ttg cgg gtg 721 Lys Asn Arg Thr Asn Leu Phe Arg Ala Glu Phe Arg Val Leu Arg Val 145 150 155 ccc aac ccc agc tct aag cgg aat gag cag agg atc gag ctc ttc cag 769 Pro Asn Pro Ser Ser Lys Arg Asn Glu Gln Arg Ile Glu Leu Phe Gln 160 165 170 atc ctt cgg cca gat gag cac att gcc aaa cag cgc tat atc ggt ggc 817 Ile Leu Arg Pro Asp Glu His Ile Ala Lys Gln Arg Tyr Ile Gly Gly 175 180 185 aag aat ctg ccc aca cgg ggc act gcc gag tgg ctg tcc ttt gat gtc 865 Lys Asn Leu Pro Thr Arg Gly Thr Ala Glu Trp Leu Ser Phe Asp Val 190 195 200 act gac act gtg cgt gag tgg ctg ttg aga aga gag tcc aac tta ggt 913 Thr Asp Thr Val Arg Glu Trp Leu Leu Arg Arg Glu Ser Asn Leu Gly 205 210 215 220 cta gaa atc agc att cac tgt cca tgt cac acc ttt cag ccc aat gga 961 Leu Glu Ile Ser Ile His Cys Pro Cys His Thr Phe Gln Pro Asn Gly 225 230 235 gat atc ctg gaa aac att cac gag gtg atg gaa atc aaa ttc aaa ggc 1009 Asp Ile Leu Glu Asn Ile His Glu Val Met Glu Ile Lys Phe Lys Gly 240 245 250 gtg gac aat gag gat gac cat ggc cgt gga gat ctg ggg cgc ctc aag 1057 Val Asp Asn Glu Asp Asp His Gly Arg Gly Asp Leu Gly Arg Leu Lys 255 260 265 aag cag aag gat cac cac aac cct cat cta atc ctc atg atg att ccc 1105 Lys Gln Lys Asp His His Asn Pro His Leu Ile Leu Met Met Ile Pro 270 275 280 cca cac cgg ctc gac aac ccg ggc cag ggg ggt cag agg aag aag cgg 1153 Pro His Arg Leu Asp Asn Pro Gly Gln Gly Gly Gln Arg Lys Lys Arg 285 290 295 300 gct ttg gac acc aat tac tgc ttc cgc aac ttg gag gag aac tgc tgt 1201 Ala Leu Asp Thr Asn Tyr Cys Phe Arg Asn Leu Glu Glu Asn Cys Cys 305 310 315 gtg cgc ccc ctc tac att gac ttc cga cag gat ctg ggc tgg aag tgg 1249 Val Arg Pro Leu Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp Lys Trp 320 325 330 gtc cat gaa cct aag ggc tac tat gcc aac ttc tgc tca ggc cct tgc 1297 Val His Glu Pro Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly Pro Cys 335 340 345 cca tac ctc cgc agt gca gac aca acc cac agc acg gtg ctg gga ctg 1345 Pro Tyr Leu Arg Ser Ala Asp Thr Thr His Ser Thr Val Leu Gly Leu 350 355 360 tac aac act ctg aac cct gaa gca tct gcc tcg cct tgc tgc gtg ccc 1393 Tyr Asn Thr Leu Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys Val Pro 365 370 375 380 cag gac ctg gag ccc ctg acc atc ctg tac tat gtt ggg agg acc ccc 1441 Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg Thr Pro 385 390 395 aaa gtg gag cag ctc tcc aac atg gtg gtg aag tct tgt aaa tgt agc 1489 Lys Val Glu Gln Leu Ser Asn Met Val Val Lys Ser Cys Lys Cys Ser 400 405 410 tga gaccccacgt gcgacagaga gaggggagag agaaccacca ctgcctgact 1542 gcccgctcct cgggaaacac acaagcaaca aacctcactg agaggcctgg agcccacaac 1602 cttcggctcc gggcaaatgg ctgagatgga ggtttccttt tggaacattt ctttcttgct 1662 ggctctgaga atcacggtgg taaagaaagt gtgggtttgg ttagaggaag gctgaactct 1722 tcagaacaca cagactttct gtgacgcaga cagaggggat ggggatagag gaaagggatg 1782 gtaagttgag atgttgtgtg gcaatgggat ttgggctacc ctaaagggag aaggaagggc 1842 agagaatggc tgggtcaggg ccagactgga agacacttca gatctgaggt tggatttgct 1902 cattgctgta ccacatctgc tctagggaat ctggattatg ttatacaagg caagcatttt 1962 tttttttaaa gacaggttac gaagacaaag tcccagaatt gtatctcata ctgtctggga 2022 ttaagggcaa atctattact tttgcaaact gtcctctaca tcaattaaca tcgtgggtca 2082 ctacagggag aaaatccagg tcatgcagtt cctggcccat caactgtatt gggccttttg 2142 gatatgctga acgcagaaga aagggtggaa atcaaccctc tcctgtctgc cctctgggtc 2202 cctcctctca cctctccctc gatcatattt ccccttggac acttggttag acgccttcca 2262 ggtcaggatg cacatttctg gattgtggtt ccatgcagcc ttggggcatt atgggtcttc 2322 ccccacttcc cctccaagac cctgtgttca tttggtgttc ctggaagcag gtgctacaac 2382 atgtgaggca ttcggggaag ctgcacatgt gccacacagt gacttggccc cagacgcata 2442 gactgaggta taaagacaag tatgaatatt actctcaaaa tctttgtata aataaatatt 2502 tttggggcat cctggatgat ttcatcttct ggaatattgt ttctagaaca gtaaaagcct 2562 tattctaagg tg 2574 463 22 DNA Artificial Sequence PCR Primer 463 accaattact gcttccgcaa ct 22 464 24 DNA Artificial Sequence PCR Primer 464 gatcctgtcg gaagtcaatg taga 24 465 23 DNA Artificial Sequence PCR Probe 465 aggagaactg ctgtgtgcgc ccc 23 466 29000 DNA Homo sapiens 466 ttatctctaa gatcctttgt taacttgctt ctcagtgaga atactttgtt agattttaat 60 ctgaagaaac actcattgcc aaaaatccaa gacagatgaa atataggctc caatgaatcc 120 cttgttccct tcttcttcgg caccagatga ggaagaaggg attaatcttt ggatttttcc 180 atttcttgta agctcacagc atacgaccat caccttatag tcagtttcca gaccttcacc 240 cccacttctt ccccaacttg ctgaaaacag aaggcaaatg gtcctcactc tgggcagaga 300 ggtaccctgc agtagtagct tccagaactt gcttagcacc tgaatcacgt gtgaggtttg 360 taaagaaaca gagatgccag ggcctcagct ctggagactg atttggtaga ggtggagtcc 420 aaaaaagtat aactttaata attttccttc ctatcttgca actgtctgct caaaggcctt 480 cccttatcac cctatttgaa actgcaacat cccccaacct aggcacaccc catcctcctt 540 ccctgcttga ttttctgcca caccacattt gtttgtttgc ttgtctgttt gagacacggt 600 cttgctctgt cgtccaggct ggagtgcagt ggtgcaatct tggccccctg taaactctgc 660 ctccctggct caagtgatta tcctgcctca gcctcccaag tagatgcctg cgccaacatg 720 ccgggctaat ttttccattt ttttgtagag actgggtttc gccgtgttgc tggggctggt 780 ctcgaattcc tgagctcaag taatcctcct gcatgggcct ccccaaatgc tgggattaca 840 ggcgtgagcc actgcacctg gctcagcact ttttaccgta ctacatcatt tacatattta 900 tttagtttat cgcctcctcc actgccccac ccctgcctct aaaataaaat ttccctgagg 960 gcaggagttt tgtttcgttc actgatattc ttcacagagc ctagaatagt gcctggtata 1020 tagtaaacat taaacttttt ctgaaatttc agaggcagta tagcatagta attaagtcca 1080 gaatctggca acgtcctggg tccaaatccc aacagctgac acctaataac tatgtgacct 1140 tgggcaagtt acttttaaag tttctacccc taggtttccc attggttttg caaatgaaag 1200 taatgcctac ccaagctaga tagcctgtgt aaaatatcgc ctccatcact cacaagcagt 1260 gtggtctgta aaaaaaaaaa caaaaaactc tatgcctcag tttcctcatc cgtaaagtga 1320 cccaccgctg tgctgggata cagagaacag ccccttcagt tagtggcctg gaagccagac 1380 ctctcagaaa gggtccagga aggctggagt gagatggggt gggagcggca ctcactctca 1440 ggaaagttca gttcagaggc aagccctgtg ttgcggggtg cggggagcca cgtgccctac 1500 cctcccttgg ctgctcgtgg gaaaaggcct agaggttcgg gccgagaaga ggagcgaaag 1560 cacagagccg acttcccctc acccatctgg gaaatgggct cgggccaact gctgacttcg 1620 cgctcgctgg cgcagctccc tgcggagacc tcggcgggga gggaggctga acatctggat 1680 gacatttctg cgagagcggc tccggagcgg cggtcgggga gggagaggtg cgctcgtgcg 1740 cacgtcgggc cgggagggag gcgattcctc ggggcctggg tcttgttttt ctcgctctct 1800 accgcagccc cttctcccgc ccctcagccc ccaccccgca gcccccagcc cccgagcctc 1860 cccggctccc gaccagccga gctccttcac tggcggcctc gcctcgccag agggcaccct 1920 cgatcttccg gaaaacgcca ccatttttca ctgcccctgg agcgtctcca ggcttctgcc 1980 cgcctcccga ctccgatctt gtcaatgaag aatcgggcca ggatcgccgc ggagcggacg 2040 ccgaccctcc gacccggctc gcaggctggg agtcccctct gcgaggctgg catggccgcc 2100 cctaccgggt cccgcgccct ctgcggaccc tgccccgggt tgggcctggc ccgcgggcgg 2160 ccccgggacc gggggaccag gagggagagt agacgcgggc cgcggacggc gcggactgac 2220 agctggcgag agggcgccgg ggctggggga aagggaggga gggggctcat cggagtaact 2280 ttccagaaaa acagccaacg tgtggcagga gtgattccaa gaggggaaaa aaagttcagc 2340 taccacgtcg aacgagagga ctcgcaaagt atttttcaaa agggctcggc ttttcctgtg 2400 cctgtttaaa acattaacat cgtgcagcaa aagaggctgc gtgcgctggt ccctccctcc 2460 cccaccccag gccagagacg tcatgggagg gaggtataaa atttcagcag agagaaatag 2520 agaaagcagt gtgtgtgcat gtgtgtgtgt gtgagagaga gagggagagg agcgagaggg 2580 agagggagag ggagagagag aaagggaggg aagcagagag tcaagtccaa gggaatgagc 2640 gagagaggca gagacagggg aagaggcgtg cgagagaagg aataacagct ttccggagca 2700 ggcgtgccgt gaactggctt ctattttatt ttattttttt ctccttttta ttttttaaag 2760 agaagcaggg gacagaagca atggccgagg cagaagacaa gccgaggtgc tggtgaccct 2820 gggcgtctga gtggatgatt ggggctgctg cgctcagagg cctgcctccc tgccttccaa 2880 tgcatataac cccacacccc agccaatgaa gacgagaggc agcgtgaaca aagtcattta 2940 gaaagccccc gaggaagtgt aaacaaaaga gaaagcatga atggagtgcc tgagagacaa 3000 gtgtgtcctg tactgccccc acctttagct gggccagcaa ctgcccggcc ctgcttctcc 3060 ccacctactc actggtgatc tttttttttt tacttttttt tcccttttct tttccattct 3120 cttttcttat tttctttcaa ggcaaggcaa ggattttgat tttgggaccc agccatggtc 3180 cttctgcttc ttctttaaaa tacccacttt ctccccatcg ccaagcggcg tttggcaata 3240 tcagatatcc actctattta tttttaccta aggaaaaact ccagctccct tcccactccc 3300 agctgccttg ccacccctcc cagccctctg cttgccctcc acctggcctg ctgggagtca 3360 gagcccagca aaacctgttt agacacatgg acaagaatcc cagcgctaca aggcacacag 3420 tccgcttctt cgtcctcagg gttgccagcg cttcctggaa gtcctgaagc tctcgcagtg 3480 cagtgagttc atgcaccttc ttgccaagcc tcagtctttg ggatctgggg aggccgcctg 3540 gttttcctcc ctccttctgc acgtctgctg gggtctcttc ctctccaggc cttgccgtcc 3600 ccctggcctc tcttcccagc tcacacatga agatgcactt gcaaagggct ctggtggtcc 3660 tggccctgct gaactttgcc acggtcagcc tctctctgtc cacttgcacc accttggact 3720 tcggccacat caagaagaag agggtggaag ccattagggg acagatcttg agcaagctca 3780 ggctcaccag cccccctgag ccaacggtga tgacccacgt cccctatcag gtcctggccc 3840 tttacaacag cacccgggag ctgctggagg agatgcatgg ggagagggag gaaggctgca 3900 cccaggaaaa caccgagtcg gaatactatg ccaaagaaat ccataaattc gacatgatcc 3960 aggggctggc ggagcacagt aagtccaaat tctcgctggg gtgtctgctc tggagggtct 4020 gaactggagc tgggagctct gcagaggggg gcctagtgct ggccacacag cagggtgccc 4080 caggattcac cagcaccaag gctcaggatg tgcgatgctc ctccgttggg gctggggagg 4140 tgggtgggga aggagataga gccattctgt taagagccgg cgcttctggg aggccaggag 4200 ccctggagct gagtggcttg ctgaattcac atcacatcct tgactgattt taatttggaa 4260 ttacattgtg ctgtccaggg aaacatatgt attcttgcac atgcgatcgt atcagtaact 4320 gtaagcatct gggtgccata aaggggaagg ccggctctgt caggagccct tacggttctc 4380 agtgtggaga cctcatcttc tccctgcttt tcacaactca ttgtgacacg tctccgtttc 4440 agtttttcca gttcttggga agaagaatac ctgccccaaa ttaatgtctg tcaagctttt 4500 tgaagcccag gcaggagaca gcttcttgct gcctgggccc tttggtctac cccacccacg 4560 tgacccacga gacccacgtg agctgtgtgt gtggaaggaa gagggtatgc acgaatgttc 4620 ccagggccgt gtactttagg gtgacatgca gtcttgtgca gtagacagat tcatgtgctc 4680 aaaatgggcg ccctccaggc cggtgggcac ggggagagcg ggttttggct gtggatgcgt 4740 agaggaggct ggcgcccttt gtgtctgcgt gtcacgggag agcgggtgga ggggtggcag 4800 tgggtgcatg gtgggggggg gggatatgtc tgggagcctg ccgtcccagg aggctctgtc 4860 tgcatggagg agccgggcgg cttctgggcg agatgtctgt gtgtgttggt acacgtgtgg 4920 aagtcatatg tgtttactga aggggatttt aaaaacctca atacaagaga gagaaatttg 4980 gcagatgttg agaaactgac agcccaggaa agaggaatgt gagccactcg tgggccgtag 5040 actccgggag cagctctgtt tgcttttcct accagcaggt gtcctcgccg ccctgactac 5100 ctcagcccag gcccacctgg gaggtgggca gctcctggag tggggtggag ggcatgggat 5160 ggagctggca ggcaggggag ggtggtcagc agagcacaca gcaaggggtg aaaggaacct 5220 ggctggagag aaggaacagg agtgggtacc gatgggtgga ccagctctgg ctggaggtgc 5280 aaaggccccg ttcacggctc cacgccaggc agaggagcct gtggttactg gcgaggggtt 5340 cccgctccag cttcctgtgg ctgcctggag cgcctttctt caggatgtgg ctgccatgtg 5400 gggcggaggc tggaggccga tgcagagcta ctactccctg cccagggtct ctgggtgggg 5460 ctggctcaga gacccacagt tcccagaggc acctagcagc tcgatggcca aggctccaac 5520 tccctgggaa cccaccaacg cgggagatag tgaccacaag catcagagga aggtcgaaat 5580 ctgaggccgg caggagaggt gtgaggagag tccagggcaa gagggcagga ctcagacctt 5640 catggtctgg gtcagcagga ggagtccaag ggaggaagca ttctgagtca ccaggacccc 5700 cccatcccgg aatcctgagc tgagaatgaa tgagccacgt ggaggcaagg ccatgcaggt 5760 gcaagtggac actgattttg tgcagactca aagcacaaat agcagatgtc cttgggaaaa 5820 gcccgggcag ggccccatag atgctgggca gcttccaggc tgcagtacca agaccttaca 5880 actgcaacag atgggtggat gtggggttat ggagcaatgg tctggcctgg ggcaacccag 5940 cacagtgagc aggatgctgt tcaggatgct ggggaggagc caacgtgcga tgctatgagg 6000 ctcacaggta caaaccggaa gcaggcagac tctgcagctg ttggaggtga cttggaggct 6060 gagcagacgg acctgggccc gccctgcagc tggtcgggtg ctgagcccac cccagagagg 6120 cagacacaca aggcacacta actataaaga aggcagtggg caggtgctga gcaggagcag 6180 agagccatca tcaggggctt gcaaggcggc ggggcggggt gggggaagga agcctgtctt 6240 taactcatga gggcagacag gggtgacacc aggtctgtgg tggggcacag cagggtctca 6300 atgccagagc ctctgctggg aggtcatgag atcacgttct gttccatatt tcctcacttc 6360 tggccacttc cctgacccag tgaacatgca ttcaaaggaa agtgacagta ggagccaggg 6420 caaggagata gaggtccctg gagaggaaaa tgaaagagga aatacttttt agtagtgcag 6480 gagaaagggc accaaggtga gagcagagag gaaggccttt tcctaaataa ccttttctcc 6540 ctgttttaca gataaggaaa ctgagacctg gattgcttaa gtaatttgtc caaaaagagc 6600 agggacccta acctagacat tctgtgtgca ggacgcatgt agttaagcac tcatttatat 6660 gtaaaataca cgttgtaagt gttaccttta acctccttta acctttaggg ttcagtagaa 6720 ctttgattta taacataaat gaatcatgtg ttggaccaag caggagaggt cagagttatt 6780 atcttagtaa cccaggtggc agattgcaca atgataactg gatttgttct tccttagctc 6840 tgcatttttt tttttttttt tttgcccggg agattcatac tgccacaaat gttctcccta 6900 atttaatgaa ggagttttct ttatttaatg aagagtctca agcaggttaa gcaaccgcag 6960 ctacgtaaaa gtgacctctc tgagcctcag tttccccagc tgtaaagtta gagatgattt 7020 ccaaactcct tttcagctga aagaatttta taattccatc tgggatgaat cagcagagcc 7080 tctattgggg agtatgggca agactctgta atcctttttc taattctcca ggattttact 7140 gtcgggaggg agtagagagt ttctctgacc ccatgtgatg ggaaaggaca cagctttttt 7200 acttccgttg tcatccctct tacaaaggta tcaccaatgt aggtgtcatt ttatcttctg 7260 gcttgtaatt atctgtctct gttcggagac ttgttgtttt cagccaaggg cagcgctaag 7320 acaaccagca aacccagagt ttctcagcaa agagaaaact ctatatttta gtctttgttc 7380 tctagctgct aagtgtagat tttgtttatt ctgagaatta ttctgaaaat catttgctcc 7440 aagggccaat gccctctgca cagtagaggt cagcacttct ccaagtgtgg tccagaggaa 7500 gctggaggta aatgtagatt ccctggtccc acccaccctt atagaatcag aatcttgagg 7560 gggtggagtc ttggggaacc tgtattttcg acaagctcct tatggattct taagcacatt 7620 gaagcttaag agtcagtgaa ctagggcgaa acttttctta gagggatggc aaacacaagt 7680 gcctacagag acccggcagg aaatgcaaat gatctggaag aaaagccacg gcgtcatgat 7740 aaactgcacc aggacacttg gtcttggggt caagaagaaa gtagggtgtg tgagacaggg 7800 agagggaggg gacctggagc ccacgtgccc agccaaagca gcagccagcc tcagttcttg 7860 ctgggttttg cattgaggac tgtgggtcca gcttgattag ttcttcccgt gtcccagaaa 7920 agcagaaaat ctggatcttt ctgtgaagtg ttccaatttt taacatgggc ttaaaatgtt 7980 tatgggcttc taactcaaaa tttttaaagg tgttccatca gcgaaacaac atgtctaatt 8040 catttaacgg ttaatcaata gaaagctcac accattaaag cagtggtttc tcaaacttcc 8100 agaacatcta gaagccatgg tgccctttgc aacacattat aatctgtggt tctcaaccct 8160 ggctgcacgt tagaatcatc tggagatctt gaaaaaaata tgccgtggac cccactcact 8220 ccagtgtagt cagaactgct ggggaatggg tccaggaatc atttgttttt aaagctttcc 8280 aggtgattct aatgtgcagc cagggtagag aagtacagcc acactgataa atatagtccc 8340 ttcactagaa ccagcagaaa tgatatatac aagcaaaggc acacctagcc acccaggtgt 8400 ctgaacacat tttaaaaggc agttaactaa acatggtcag ctatttcctg gtttttccat 8460 gcatactgta catgaatatt ctttgcttat gttttgcccc gttaaacaaa atagagaaaa 8520 tggcattcac caatatatat tttttctgtg caatggaaaa agttgctcaa gatttaattt 8580 gtaaaggtgg gaccccctag tccagctctc aataatacta gtgttctgtg aggcatggct 8640 taagaaccac aaactcgttt gcagtgggtc attgtctgag gcataggttg acactctagg 8700 cccatttagt ggaatcttgc catattttgt tgatgaaacc atcttcacca gatgatctcc 8760 cagatccctc ccagcttgaa gagtctctgc ttcaataaat gaggtatgtt cagaagacct 8820 gggttcaaac cccacctcca ccaccttcta gttatgtgac cttgggaaag acatttaact 8880 ttttgaggct cagttttctc atttgtcaag tgataaattt tacatgtttt cattcttctc 8940 aggggttgtt agaaggtcac atgaagtaat aaaaactcga caaaacaagg tggtgctatt 9000 acattttgct tatttatgta tacgatgatt cattccacag attacttaaa acatcattat 9060 tcagtgaatt tgattgtcaa gaagattgta tgtacatttt ctttgatctc ccaggcaatt 9120 ctttttttta attaatttta attttaattt ttttgacaga gtctcactct gtcacccagc 9180 ctggagtgca ctggtgcaat ctcggctcac tgtagcttct gccttctggg ttcaagtgat 9240 tctcatgcct cagcctcccg agtagctggg gttacaggtg cccaccacca cacccagcta 9300 atttttgtat ttggagtaga gatggggttt tgccatgttg gccaggctgg tctcgaactc 9360 ctgacctcca gtgatccacc tgcctcggcc tcccaaagtg ctgggattac aggcatgagc 9420 cactgttctc ggcctttaaa atttttaatt ttaaataata gggataggtc ctccctatgt 9480 tgtccaggct gatcttgaac tcctgggctc aagcaatcct cccgcctcag cctcccgagt 9540 agctgaaata acagacatgt gctaccatgc ccagctaatt ttcgtatttt ttatagagat 9600 ggggtttcac catgttggcc aggctggtct caaacacctg agctcaagca atccacccac 9660 ctcagcctcc caaggtgctg gctgggatta caggcgtgag ccaccatgcc tggctgccaa 9720 ttcttcttct tcttcttctt tttttttttt tttttgagat ggagtctcac tctgttgccc 9780 aggctggagt gcagtgacac aatctcagct cactgcaacc tcgacctccc aggttcaagt 9840 gactctcctg cctcagcctc ctgaatagct aggattacaa gcatgcacca tcatgcctgg 9900 ctaatttttg tatttttagt agagacgggg tttcaccttg ttgcccaggt gccaattctt 9960 ttttaatcac tagcaattgt gtcctaagct ttgcttgcta gtgtcaagtt gcttgtgtca 10020 gctaacttct gagtgactct ggccaagacc ctctagacag ccatttcttc ctctgaagag 10080 ggttgcgcca catgactcct gatgtccctt ctaatcatgg gaaatctata tatcccagta 10140 atagaaaaat gacctttccc acctctttct tgaaacctta aaattctccc caggatgtgt 10200 tcatcctggg gagcagatta tgattgatag gctggaagaa accaaagagg acggccacta 10260 gggtgtcctg agaactctct tagctcataa ctttccccat ctcctggctt cccactgcct 10320 tgacccactc tgactgtctc accagcaagt gccattttcc atctcccttc ttttttttct 10380 gagatggagt ctcactctgt tgcccaggtt ggagtgcaat ggcaccacct cagctcattg 10440 caacctctgc ctcctgggtt caagcgattc tcctgcctca acctcctcag tagctgggat 10500 tacaggcacg caccaccagg cctggctaat tttcatattt ttagtagaga cagggtttca 10560 ccatgttggt caggctggtc tcaaactcct gatgtcgtga tctgcccacc tcggcttccc 10620 gaagtgctgg gattacaggc gtgagccacc gtgcccggcc ccatctccct tctttttaca 10680 gcaaggtgca tgttgcactg acttaccctt tattcctctt gtagtcactg gagctgtgtt 10740 atttatttac tttattaatt tatttattta cttgaaacag agtctccctc tgttgcccag 10800 gctggagtgc agtggcacaa tcctggctca ctgcaatctg gacctcccga gctcaagtga 10860 tcctcccagc aggtgctatt gtaactgaag ccatatcaat aacagctcct tcaaaaccca 10920 gctctgttgt ccttgatagg gttgccaatg caagtagctt atccacattc agagtattac 10980 aaacttgtaa acttacacat tacttaacta tcactgattt ctctccttgg ttctatctga 11040 aatggtttag ggaatcgttg gcagtatctg ttctttcaaa gccaattatt aatcagggct 11100 tcattagaca gcattcacac atttgttttc ctaacatctg ttccattaat tttctaagaa 11160 ccagcgtcag gcccaccaga tggcaatttc cagaaacact cactcatcct ttcctgaaga 11220 tcagtagcgc atttgcttgt ttccaggcct ctgatccttc ctgccttgtc tgtgacttcc 11280 tcaacaaccc ctcggggtga ttataagctc attccagcca tgtccattat gtgtggaatc 11340 tgggtctatg agcttgaatt tcaacttcgg gctattgtta ccatttgtgc agaaagtttt 11400 tctctgggtg ttaatactgc tcagaccttg aggctgtcaa gtgtacagga gcagagaaaa 11460 gacaggctct ttctctttct ctggctcaga ggggtgggaa agagcattcg ctgcccacat 11520 cttgtggaca gggatgaaga ggccagcagg tgacagcgtc tggcatagca cgtgctgtca 11580 aggaaagaga aaggagccaa tggtgacaca ccagcttggt cagaggaagc atctgtgttt 11640 ctgccaggct catgatgtgg gctctttgct atataagccc tgctttattg ggtctaaaac 11700 acaaggttga gatgtcactg cactgctcaa acactttcag tgactcccta ctgttaatgg 11760 gttaaaattt aaccttttag tctgacaggt ggaccccaat ctatcatctt gccctttctc 11820 acctggctcc cacctgctgt ttcgggcccc tcttactcat ttgcatttcc tcccctccct 11880 gcctttgctt ccagcagtca ctccatgtaa catttctttc ctccccatcc tcaaatcctc 11940 tcaattttca ccccttccgt gaagtgctcc ttgccatttc cctcctttga tttcctgcag 12000 caactcctgg acttctctga aaaccactgg tttcctgtcg ctcccctcac ctgtgctcct 12060 gcattgtgac atcttccggg gcactctgtc ctattatttc tctctagtcc tgttatttgg 12120 gcccatgtat taataccccc ccttagatat taacccataa gcctgaggct gcactttttt 12180 gaattttgaa atcagacctt ggccttgacc ttgagcagca ggatataaat aactcttaca 12240 tgcttagcgt tccaataatg gaacaccagg cataaatggg ttttaatccc cttgaaggca 12300 ggggttgtgt ctactcatgt tttgcttccc aaggttagca ctatgcttgg catatagtag 12360 ctgctcaata catctttgat aaatgaatga atgcccagat gaacaaacac acgaataaat 12420 caactagctg taagatatgt aaactactag gtgctgatat ctttctagaa tcagtatttt 12480 ctcaaaaagt aggaaaaacg ggttggaaaa cttaccagaa ctgagatgtc aaggcagtgg 12540 gaggaggggg caattagatt tgactggcca gtctagtgcc atgttgtgga gctctgaggc 12600 cacactgctc cttgctcagg actgtgtgtg attctagggc caccaagaat cttcctcgta 12660 tctccacctt gcggtctgag gcctcaagcc tctagggagg tggcaggcgg gacggtggcc 12720 acttggtgcc tgtccgttgg cagcacactg ttcctgcatg tctcgctcat gctgtgccct 12780 ctgctctgct ttatctccta gacgaactgg ctgtctgccc taaaggaatt acctccaagg 12840 ttttccgctt caatgtgtcc tcagtggaga aaaatagaac caacctattc cgagcagaat 12900 tccgggtctt gcgggtgccc aaccccagct ctaagcggaa tgagcagagg atcgagctct 12960 tccaggtaac tcctctctca gagcagaaac cacaccgacg ggaaagctgg ttcctttgcc 13020 atatcagggc accactgggt gcagcgtttg gcagacctgg gtttgaatcc tggcttctct 13080 gagccttcgt ttccgtatct gtgtctgtca ttaaaacact taagagttag ctaaggtgct 13140 cgagggccat ggcattcagg aaccactggt ttcctatcgc tccctcacct gtgctctgca 13200 ttgtgacatc ttctggggca ctctgtcctg gtctcgggta ctcactcctt tctctgccct 13260 gtagatcctt cggccagatg agcacattgc caaacagcgc tatatcggtg gcaagaatct 13320 gcccacacgg ggcactgccg agtggctgtc ctttgatgtc actgacactg tgcgtgagtg 13380 gctgttgaga agaggtaggt ggacccttca gataagcatt tcagaatgaa cctcaggtcc 13440 cttagtcctc catgaaatgg agggaagagg acagaattaa gggagtcaga gatctgggtt 13500 caaaccctag ctttgccact gagtatcctc cattcattca ctcaactaat gtttattaaa 13560 tgctcactgt aagacaggcc ctggggatgc agccacaggg ataggaacta tgagaaatag 13620 aaagagggca atgtgacaat gagtgggtgg agtccaacag ggaaggtctc tatgatgaag 13680 aaattcatgc attgacatct gaatgataag gatttagccc atgaagatca gaataaggga 13740 tgtgctaagc aaaggcaaca gggaggccca ggccctcaag tggaaataag cttgatttgt 13800 tctagcagca gcagcaaaca gatcggtgtg gctggagcat ggtgagctgg ggaggggaag 13860 aggaggggag gtggtcaggg aggttgctgg ggccatataa tttattatta ctattattat 13920 tattattatt attattatta ttattattat tattatttct tgagactgag tctcgctctg 13980 ttgcctaagc tggagtgcag tggtgcgatc tctgctcact gcacctccac catctgggtt 14040 caagcgattc tcacgtctca gtctcctgaa tagctgggac tacaggtgca cgctgccaca 14100 cctggctaat ttttttgtat ttttagtaaa gatggggttt caccatgttg gccaggctgg 14160 tctcgaactc ctgacctcaa gtgatccgcc cactttggct tccaaaagtg ctgggattat 14220 agatgtgagc cagcatgccc agccaattta atttagaaca tcatcaggtc atggcgaggt 14280 ttcaggactt attccaggtg tgatgagaag tgtgggagtg ctataaccag agctggggat 14340 actcaagata cccaggaatt ccttcctgtc cctctactgg gtgtgaagtc aagagcctag 14400 gagaacccac gtggatctgc caacggcagc tctgttggga attctgactc agacagctac 14460 agggaggagg ggctgggtga ggtgatttga ttgacatctt taaaagatcc ctctagtttc 14520 caggaggtca agggaagagg caggaaaatg agttaggagc cacggcggca gcccagatga 14580 gagcaatatc taggccgaga ctagggcggt agcagtggat atgacgatca gatggatttg 14640 ttctgtattt tgaaggtagc cagtagcaca ggctgattag gtatgggatg tgaggacaca 14700 agagcattcc agataacttc taaatttttt cgacatccag gtggtatcac ttattgaaat 14760 agggggccta ggagaagaac aggttctgtt ctgcccagtt aagtttaaaa ggccgggtcg 14820 tcatgcaagt agagctatcc tggaggcata tcaaacttca catgtcccaa atatcttacc 14880 cacacactgc cttcacctgg aaaatcaggc aatggttcct cctctatgta tgcctcacag 14940 agctgtttta aggatcaaat gtatttgaga gaacttcatg gtttttacca tgttttacaa 15000 gagtaagctt ttcttatttt agataaggaa acaggccgag agaagttaag tgacttgacc 15060 gaggtcgtcc agtctggatt agaactttgg tgtctcatga caccatcctc tgtgtttctt 15120 tcccttttct tggctggtac tgcctggtct gatgctcagt gggttggggt cacagatggc 15180 agtcccatct gttccttctc ttcctcttgg gcaaggtttt ctcctgtcat cagctgctat 15240 aaagccacag accatccaca tattgatgcc cagagtccct gaggcaggtg gatccttcta 15300 agtccttggt gttttaggca actaagagtt aaagctcaaa ggcagagctt acaaactatt 15360 tggcctgcac attgttttcg atttgactag tcatcaacag ttttgggtgt tttaagtcag 15420 gagatttcac ataaaacctg gacttcttgc tgtttttgaa aaatcgaaag atttcctgat 15480 aaccatccgt cagagatgag taccggccac cccttgagat ggggtatgca tcctcagtcc 15540 ccgcagcccc caccattccc tattgttccc caagagtgag gctggcagtt cctgtttagc 15600 atcatgtgct ggctcgattt tctcacttac gtgacctgcc tgggctcggt agccatcgag 15660 tttgcattgc ttgatgccac ggagcccagg caagtcacat aaatgagaaa attccccatc 15720 caaggggaat tatccagtgg ctgagttggc agatggtggg ctgaagatcc tgccccagtc 15780 ccaagggtac ccaggaattt catcctgtcc ctcctactga gcatgaaggc aagagcctag 15840 gagaacccac gtggatctgc cgacagcagc tctgttggga attctgactc agacggctac 15900 agaaaggagg ggctggggaa attaatctct taacttccct gtctgatttt gatcagctcc 15960 acctggattt ctttgaagcc ctgggcactt gaaggagttc ttattttcac agctgcagaa 16020 ctcaatgaga agtttgcatt gagaatgatt tccatcctcc tgagacatca aaaagataat 16080 ttcgtaataa aacctatggg tcccccaccc accaccccca cagctgccaa ttctgaggtt 16140 agttcttcat tggaaccttc agttcacact taggcagata ctgcccacct ttcccacagg 16200 ggaatcatca cacaggtttg tacttacaga gagcccatga gtctcttcag agttcatggc 16260 ttcaaaccag gcaacaaagg actccaaatt ggagcagttg gcggtgtaga ttgatgagaa 16320 aactgagtca cacatgtggt cttggattca ttcagcaaac atctgagagc ccttgtgcac 16380 caggtaccca ggctgcattc tgggtcgcag agtgggttgg agtccacaag ggccgctggg 16440 gacccaggtc tcataccctt gtgctattgc tcatatagtc tgcagcacct agctaggcag 16500 ggccaggcct cccctagtag gctggggagg gagcctctca gcatcatggc tcaggaaagg 16560 tgggacactg ggaaacaacc atcttgcatg ttggtgaatg tgtgggcatc ttccttggtg 16620 gtctctgttg ccccctcttt acccctcctt gtctctaaca agagtttggg atctggcatc 16680 aagctgtcag tgcttgaatc ctggcactac tatccactgg ttggatatct tgggcaagct 16740 gtttaatctc cctaagcctc agtgttctta tctgtacaat gggggataat agttcttgct 16800 ctatgggatt attatagaga tagaataagt tagtgattgt tgtcatcatc tctaagtcct 16860 ctatctggat acagcctgtt ggccaagcca ggccaccctc ttgtgcttac atcctggacc 16920 ctcactctcc ccaacacagc tgtctgcacc ttgactttct aactcacaga atcatggaac 16980 tcactcactc caggtctctt ccagcctgcc ttgaaccagc ttgaccagga ggtacactgt 17040 gttgttaggt agcccatttc agctactttg gctcctcctt ccagctgcct taacccaggg 17100 agagggcaat cctcatacct ccctctccat tcacttctcc tccagctggg tctcagctgc 17160 cttgttttat tggtctgcct tccctcactg agcgaacctg ctggaacaga gatcttcaag 17220 ctcagcaggc gcagtgtgcc tcagaggttg ccctgactta gggtagagca gatctggtta 17280 ggctctggag tttatggaag aaaggagctg ggttttaacc agtaggactg ggatgtccaa 17340 gccaacctaa tgttgatggg aatctccagt cttgtaggct tgtatccttc tgtctatgag 17400 aaggttgctg ggccaggttg gactttttgg ggtttgccct gatggcacaa tttcaggaag 17460 actccaggtt gtctccaagg ccagatgctc acacacatgg tgtgtggcct cagggagcag 17520 caaatcaatc aactcatcga gaggctgacc ctgaatccag agaggtccat cccccatgac 17580 ctctcctaca cctggccaca actggctgct atcccaggat caacagagct tcccaaatta 17640 agtcttaccc accagaattg acatgatacc agatcctacc tggttttctg tgtaaaacta 17700 cttgtctcag tgcagacttt tcattttctt tctttttcct tcacttcact caacctcatt 17760 tactgagttc ctgcttcctt gattttggtt gccaaaacat gtgatcccac aactactagg 17820 cgaatgggct ggagttgccc ttcacgcacc agaatgtcag gcaccaaacc ctggcacctc 17880 caggcttcat catgctcact gtctccgtgc tcaagtcatc tggaccctca gccatagttc 17940 tctatcatct cctctgtgct gttttctaag ttcacaactg tcttcccaag ctgttcatct 18000 tggtgagcaa tccacattcc aacttcccat catggtgaac aaggattccc aaagaagaaa 18060 tgtccaagta atttttacct cgttgtgtcc ttgttcctta ggaaaaatat ggcccagtgt 18120 aaccgtgatc ttcatcttat ctcttctaga atctgccact ttgtctaggc ccacagtcat 18180 ggccctggta gaaatgcttg catcttccac tgagacggat tctgcttcct gtttgcaagt 18240 gaccttgcct ctagcattgg ttcctgactt gaatcttttt gccagcatta catcctgtgg 18300 ctttttgaat ttgtggcctt ttgaatcaca gtctctgtgc tcggagactc tttagttact 18360 ccctgtccgt agtctcttcc agtccctctg cctcttgccc tgatccttct gcagtagatt 18420 ggctcaacga tcccctctcc caaaaaccat gtagatggca tgagtttttg ctttccttac 18480 tgtatctgtg tacttttgcc tccaagtagg taggtgacaa ttttctctta ataccatcct 18540 ttcaaaggga atgattattc cacttctgtt tcatgatggc cactagtgta tgcccccatt 18600 tggtgattca taatacaaca ggaatacctg gaatgtggca acgtgcgctt gaaggtccac 18660 tctgagctct ggaggcactt tctgtctcct gtgaccctca atagaactca gttcctatga 18720 gtccctatag gagcagaggc cctggctcac ccttgcatgg gtggtgggca cacttcccca 18780 tcacacagag gtgcttttct cactaattct gtcttatttt gcagagtcca acttaggtct 18840 agaaatcagc attcactgtc catgtcacac ctttcagccc aatggagata tcctggaaaa 18900 cattcacgag gtgatggaaa tcaaattcaa aggtaacaaa atgaatgtgt atggtaggat 18960 gggtgagtgg gggggaagtt aatgggacag gatagtgcag gagaccctta ccagacctca 19020 agaaaagaaa ccaagctcct tcagagagat agccgactat tttgtacttg agtaattctg 19080 ctttgcccca aaagcaatga gtgtaacttt cagtttatag cttagagaat gcattagcct 19140 ctggaagaca acacgtactg gtaagtggtg aaactgtgta ggcaagccat ctagcctctg 19200 gtcctagtga aatgggatga gagttcctct ttcacagtgt tgtcaggcaa ttaaatgaga 19260 taatgaataa ggaacacagt gccagaaatg ctcaacagat aggacttgtc ttcctcctcc 19320 ctaaaagaaa ttaagtttgg ctgtcctgaa catgagtgcc cagacaactg agctttccag 19380 atgtgcaggg cctacctgac cttgcccagg ggtcctctgg gtttggatga ttgcttcgag 19440 cctcagggtg tttgtccccg gggtgtttgg gtagagatgg cgaagtcgtt gagagtcatt 19500 tctggttttc cattatgttt gcaaggaact cagccttgat gatctctgga gttcagggaa 19560 gttctctttt cctttcatat tcccattttg ggtaactgcg gaacgcctga ggtcagaggc 19620 ttgtctggga aaaggtgcag gcctcttttg gctcagcgct ggacagtgat cttaccccac 19680 atgggctcta ttttacagcc ttttcttaaa gccaaagatt tgacactgta accacagaac 19740 cttagagccc agaggacctt tggagtcctt acctacaggc cagcttagga tgaaaccttc 19800 ccatttcagt gaatacttat cttgttcata aagattttca gaaaaaggga tttgtgatcc 19860 aggtctctca tttatcttac agatctggtg ccccttcctg agacccgagc cactcctgta 19920 gctatgtaaa ttaattcctc atgttcctgt cctcagtgag gatggacaac agttggcagc 19980 tgtccttcgc aaaatcgatc tccatttagt tgagactctt tctaagtcag tctccagtct 20040 tttccttttt tttcagatga aacgggttga tgaatttaga ttttctttcc agagcttatt 20100 tgctatttat catatgcttc attatctcat ctgaatttta tagtgaaaac acttcaaaga 20160 ctctaagtgc aatgtgaatg ttaacaatta tacagtcttg tttctttggc tcccattcag 20220 gctatcttaa gttgtgacac cttaaatttt tggtaggact tctgcgttat cttggtccat 20280 tcacatttta agaggaaact cacaccccaa gattctaagt ctagaatcta aagtgacaat 20340 ccagggctgg gtgcagtggc tcacacctgt aatcttagca ctctgggagg ccgaggtggg 20400 cggatcactt gaggtcagga gttcgagacc agcctggcca acatggtgaa accctgtctc 20460 tactaaaaat acaaaaatag ctgggcatgg tggcatgcac ctgtaatccc agctacttgg 20520 gaggctgagg caggagaatc tcttgaaccc cggaggcaga ggttgcagtg agccaagatg 20580 gggccactgc actccagcct ggccaacaga gcgagactct gtctcaaaac aaacaaacaa 20640 acaaataaac aagccgacaa cccggagata tgtgttaggt acccacttag taacagggat 20700 gcttcatagg tccatgaaga ttcctaggaa tctcagcaag ggctttctgc cccttggaag 20760 atttctatac aagggtatgg ggatctgaac acggggcatc tttcagtggg catccttaca 20820 ataataatga gttcttttga tactggcttc tccatctgct cttccccttt ctgcacctgg 20880 acatcagaat taagctgcac ttgtccccca cacctccctc gcagactgca ctgcccctcc 20940 tcctgggcag tgatggggcg tgtggaggag gcagcctcca agggctctgc tctcttcaga 21000 caggagattg tcactttcct tcccttcttc aggcgtggac aatgaggatg accatggccg 21060 tggagatctg gggcgcctca agaagcagaa ggatcaccac aaccctcatc taatcctcat 21120 gatgattccc ccacaccggc tcgacaaccc gggccagggg ggtcagagga agaagcgggc 21180 tttggacacc aattactgct tccggtgaga ctgggcccac atgggaacca acatctactg 21240 cctgcctact gcccaatggc taggtcaggc cccagagcca agccacactc aacagagggt 21300 ccctgatgct attcacaaac atctccagga agaagactga aaatctctca cagagatttt 21360 ctctgtgaaa tctctttctg ttttcctggg agtcccactg tttttccata ggctaactct 21420 ggaaggagct ggctgaagta aatgaggaaa actctgtgag gaggagtgtt gctaaaatag 21480 tttggattgg agaggcttgg tcaaagcctc tccatgattt ccatgtttta agcacttgta 21540 gagtgtatgt gtgagattaa tgtaggagtt tccattaaag aagtgctcag ttagttccct 21600 atgaagggtc caaggatgct actggatgga ggcaaataga atggtctcca tttgaacgga 21660 aagttggagc tagagaaatt aacaaatgaa ttcagaaatt actgggtagc cacaatagag 21720 agatagaaaa gacccagctt ctcttactca ggagcagttt cactgctcat ttataaaggg 21780 aggataaagt atgcatgcca actactaaaa gggagaagat gatcacgccc atgagagggt 21840 ccgaaggatt aagtgcttta actgggagca atgagttcac ctatggacac aggaaaggct 21900 tcagaagggt gtggaatttg agcagaggct tcaaggatga ggtttgggga tgaagggatc 21960 caggagggga agcactgcag gtaaaggaag gagcatgagt gagtgagtcc atctggcctc 22020 agaggatgcc gaaatgaagc tggggagaac gaattgggaa atatttagat ctggaaacca 22080 tgtcttatga ggatggttgg gcttgggaaa ctagggatgt tcagttgggg gaacagctca 22140 acagcaaggt ataggagagg caaggtagtt gccacaaagg ctggcatgta gatttattta 22200 ttccatcagt taggaacaaa tcagttagga acgaatcagt tatcagttag gaacgaatca 22260 gttaggaacg aatgatcttg gccagtgact ttaatcatag tgatttcttg ttcacaagag 22320 gcctgtagca gcagggttag ggtgggctgg ctgcttaatg atgccaccga agactcaggc 22380 tttctctctt tccagtctgc catgcttagt atgttggctt ttcatccttt tccttatggt 22440 cacaagtgat tgctagggct tcaggcacct tgtccacatt taagacaaga aggaatgagg 22500 gaaggggaag agccagaagc tttcttcttc catctgtcac ttttataaat aatcgaatat 22560 ctttgccaga acttgccctt accccctgca tacttctcct tgtctgatgg gtcattactg 22620 ggtcacatga ccaccgctac tctcaaggga ggacaggaaa aggagcatct ggtgttttcg 22680 actctgtaat gggatgtcac aagggagaag ggagttagga atggttattg aatagataac 22740 caatggtgtc tgccatggtt cacccttgga acccacaaga agccagattt tggctaatag 22800 ctgcctttgg aagtagcaag ttctaagtct cagcagatat taaagcagag gctagctgtc 22860 cacttggcaa gcggtattat tgccaaatga tctctgtagg caacagaatt gaaggggcct 22920 gataatcaca tttgggtgat ctgttgaacc acggttctaa tagaaggata tgccttattt 22980 ggctaaatgg cctttggatt gagtctcagc agtcacctac tatagtagtc aagctgcata 23040 aacttagaat tgatttctgt ctgggtgcac attaggaggg taaaaataaa accaacctca 23100 acaaagctga gttggctaat aacattcagt gcttggtttt atgtggagcg cttcatagca 23160 ctgctttgta ttgtgataga aaagggtgca gggccacctt tgcctcttta ctcttcctca 23220 tgcagcattt atctctgttt cttacatcct tgggatcctg gtctttaaca catgaatgtg 23280 cctttctggt ttcttctgcc ccatgccctt gaacctggga ttccattgat cagagccacc 23340 tatgatggca tgaaaggact ccaagggaga atatgagagc attcatgaag tttcttttat 23400 tggtggtttt aagttgattt tctataaatg ttttttgttg tagcaacttg gaggagaact 23460 gctgtgtgcg ccccctctac attgacttcc gacaggatct gggctggaag tgggtccatg 23520 aacctaaggg ctactatgcc aacttctgct caggcccttg cccatacctc cgcagtgcag 23580 acacaaccca cagcacggta tggagcaggc tcatgccatc tgaggcactg gggctgaccg 23640 accagaccac ttgttaaaaa gaatgagtga aggattgaat gttgagtgag caaatgatgg 23700 tctggggtga gtaaaattcc tctggtgaag gttctgatct tggcaccctg actcagttct 23760 actcagtcac attctgccct tttaaattcc taccatagtt tcaaccagct ttttaatttg 23820 ctttgtccaa agctctctgt accgtagaaa ttaattaact gccacgtgtt accctatgtc 23880 agagatatgt gcatgtggct ggcaaggaac actgaagtag aaaggcttct atcagaactc 23940 tgatcattcc agcctctcga atgtagaaaa cttactctga aagacaacaa caaggatgga 24000 caagaagcta atttgaaatg ctaggaacag aaagtgagat agccgagagt ccacaacccc 24060 tgaaactagt ctgtctttcc cttgagggga atcaaaaata gggcagtaat ttgtgaagca 24120 tgtttccttc tagctcattg tttctgcatc ctgtctgggg ccctgcacgc tgcacttact 24180 aaatggctca aggcaatgtt ttgtgagaac atttctcacc gaagtgatca gttccagcta 24240 ggaagagcaa tgtaagtgtt ttcttaaaag ccaagatagg ccgggcacgg tggctcacgc 24300 ctgtaatccc agcactctgg gaggccaagg cgggtggatc acaaggtcag gagttcgaga 24360 ccagcctggc caacatggtg aaaccctgtc tctaccaaaa atgtaaaaaa ttagccgggt 24420 gtggtggcac gcgcttgtaa tcccagctac ttgggaggct gaggcaggag aatcgcttga 24480 acccaggagg cggaagttgc agtgagccaa gattgcacca ctgcacttca gcctgggtga 24540 aagagtgaga ctctgactca aaaaaaaaaa aaaaaaaaaa aaaaaaaagc caagataatt 24600 cgttatcagt gtagtaactg tcatatgctt caactcatca ccccaaacaa gtgcagttgt 24660 tctgcttctg tcattgtgga tgaacagcaa ctacacaact actcactcac ccaaaccagg 24720 ttccaacagt tttttttttt ttcttttttt tgagacagac tcactctgtg gctcaggctg 24780 gagtgcggtg gcactatttc tgcttactgc aacctctgct tcctggattc aggtgatcct 24840 cccacctcag cctcccaagt agctgggatt acaggcgcct gccaccacag ccagctaatt 24900 tttttgtatt tttagtagag atggggtttc accatgctgg ccaggctggt ctcaaactcc 24960 tgacctgaag tgatctgcct gcctctgcct cccaagtcct gggactacag ctgtgagcca 25020 ctgcacccgg cccccaacag ttcctcttaa agagcacccg tggccattct agcacttgct 25080 cagcttctgg gactgcccct ggaactgggc gacttcctgg gttccaggcc tgagacttgg 25140 ccttccaacc tctcactgac atgtcccttc ccaggtgctg ggactgtaca acactctgaa 25200 ccctgaagca tctgcctcgc cttgctgcgt gccccaggac ctggagcccc tgaccatcct 25260 gtactatgtt gggaggaccc ccaaagtgga gcagctctcc aacatggtgg tgaagtcttg 25320 taaatgtagc tgagacccca cgtgcgacag agagagggga gagagaacca ccactgcctg 25380 actgcccgct cctcgggaaa cacacaagca acaaacctca ctgagaggcc tggagcccac 25440 aaccttcggc tccgggcaaa tggctgagat ggaggtttcc ttttggaaca tttctttctt 25500 gctggctctg agaatcacgg tggtaaagaa agtgtgggtt tggttagagg aaggctgaac 25560 tcttcagaac acacagactt tctgtgacgc agacagaggg gatggggata gaggaaaggg 25620 atggtaagtt gagatgttgt gtggcaatgg gatttgggct accctaaagg gagaaggaag 25680 ggcagagaat ggctgggtca gggccagact ggaagacact tcagatctga ggttggattt 25740 gctcattgct gtaccacatc tgctctaggg aatctggatt atgttataca aggcaagcat 25800 tttttttttt tttttaaaga caggttacga agacaaagtc ccagaattgt atctcatact 25860 gtctgggatt aagggcaaat ctattacttt tgcaaactgt cctctacatc aattaacatc 25920 gtgggtcact acagggagaa aatccaggtc atgcagttcc tggcccatca actgtattgg 25980 gccttttgga tatgctgaac gcagaagaaa gggtggaaat caaccctctc ctgtctgccc 26040 tctgggtccc tcctctcacc tctccctcga tcatatttcc ccttggacac ttggttagac 26100 gccttccagg tcaggatgca catttctgga ttgtggttcc atgcagcctt ggggcattat 26160 gggttcttcc cccacttccc ctccaagacc ctgtgttcat ttggtgttcc tggaagcagg 26220 tgctacaaca tgtgaggcat tcggggaagc tgcacatgtg ccacacagtg acttggcccc 26280 agacgcatag actgaggtat aaagacaagt atgaatatta ctctcaaaat ctttgtataa 26340 ataaatattt ttggggcatc ctggatgatt tcatcttctg gaatattgtt tctagaacag 26400 taaaagcctt attctaaggt gtatgtctga ctcgataaat atccttcaat tacccttaat 26460 tccatgtccg catctactaa tcagaggtaa ccagaatctg gggcagagaa tctgtcaatc 26520 accaaacaca ttgcttagcg caactcccct tacacagggg gcacaccgtg ctgacttccg 26580 cctgctaaga agactgcact attgcttgtg cgtctttcct tcttgcagag tatattattc 26640 tcagagacac agaggcagtg gctcagattg gcagaaagca catacgaatt tgacctccag 26700 atacctgtgg gcaggatccc ctggtgtgaa tccttgcata tggaaacatg gtttatttac 26760 taactataaa ttaccaacat cactgttttc gaaaatctcc ccccacccgt atcagttgag 26820 aatgagagaa aatgtgtatg gcaaatggcc taaaaatatg aggctaattc tgttctcagg 26880 ctaagcctaa aagagctaac caggaacccc ttttcagatt gtggccctct tgtcagggat 26940 ctgggaacca tagctctctt ttgagtgagg ccgtggatcc cactgtggta tggacatcca 27000 cgtggggcag ccgtccacag tgagcgggca cagagcgaca ggccatctag cagctcctga 27060 gaaacacatt cttctagtga gatcactttg cctctagtaa aagaaaagtc tatctgaagc 27120 taaagtatgc aggctgaagg atgtgtctga tgtgttcatg cctgtgtgtg tgtgtacgta 27180 tgtgtgtccc ttgttccttg agttctccaa gactgaagtg agtttggtca gtactttttt 27240 ccccgctttg tccacgccca gccaattcta agggtttccc tctcagtctt catcccatgt 27300 ggcacccact gacttccacc atcgttcgga gggctatgtc cctgtcctaa aatcctggct 27360 ggcgggatta tactccatct tgctccaggg agcccggggg cacagagagg ggatgcagta 27420 agctcagcac atcagccacg ggctgctgct gtcccagcat cagtctattc acctgagggc 27480 cattctcaaa ttcactgggc atgataaccc ccaagggttt atttaaaatg tacagtttca 27540 ggctgcagct ctagaggtac ctttaggact gcagtagggt ccaggttgcc tcaaaactat 27600 taacacattt tgagaagtgg tgcattacac ccgacatcac tcgtccttac ttgaggcttc 27660 aatatagaaa agggaaataa tttttttggc cccagatgaa accccctttt atccaacttc 27720 acagcacatt gctaaaacat tggcctgtgg ttcatcctaa tgaaccaagg cagctagata 27780 catttcctgg attattccaa agaaaacaga acgtggtgca attccaaatg gtctttttct 27840 tcagagctct acttgtaggt taggcagcag acacaaatac ggacaggggt ctgaagtcag 27900 cccccctatt ctacacatca ctgacaggtg ctacagaaac ttgaatcact gtcttcaaaa 27960 atcgacgctt gttttggggg agggtaaaga gtgacattgg aaatatcacc tctgttggag 28020 gagggctcat agcatctgtc tggtttattg ccaagtgaag tccagtccca ataaaaatga 28080 cttgaaagca cttggacaca tgaagggaga gatctggtgt cttagcacct gatcagcata 28140 tggtaagtgc agtaagaaat tagctggaag acttcattct gattggttac ctagggcaat 28200 ttcaagcatt atagtctaaa acttctttta ctgggctcat acttttttcc cttgtcacaa 28260 gattcacgtg gtgagtcctc ccaaacccct tatttcccaa ttctacacct catcagggga 28320 ctatggagga attctaattt gtcccctaat caactcacaa ccaattgagc aaatagttaa 28380 ggtggtcctg aaactactct ccagtcccgg ggacatttgg aatgcattct tacttctctt 28440 ctgaaaccca tagacctcat ccttcacaag caaacaaaat gtgtccatgt gcccaaacct 28500 ttgttttcat tcagtaagaa ggcaataaag tcccttttct gcccttttag gtgtcaattt 28560 tttctttttt tttttttttt tttttttttt caggtggagt cttgctctgt tgcccaggct 28620 ggagtgcagt agcatgatct cggctcactg caacctctgc ctcccaggtt caagcaattc 28680 tcctgcctca gcctcccgag tagctgagat tacaggcgcc tgccactgcg cccagctaat 28740 ctttgtattt ttagtagaga cgaggtttca ccatctttgc caggctagtc ttgaactcct 28800 gacctcgtga ttcacccgcc tcgacctccc aaagtgctgg gattacaggc gtgagccact 28860 gcgctcagcc aggtgtcaat tttctttttg gatttcaaca ctgagtccat agtaccctgc 28920 tgaagaagcc ccagagcctg ggttctcccc tgataactct ctagggcagc taagttaatc 28980 cttcagtgga ctctgctgtc 29000 467 20 DNA Artificial Sequence Antisense Oligonucleotide 467 ttgttgtcca tgtgtctaaa 20 468 20 DNA Artificial Sequence Antisense Oligonucleotide 468 ttcaggactt ccaggaagcg 20 469 20 DNA Artificial Sequence Antisense Oligonucleotide 469 aggtgcatga actcactgca 20 470 20 DNA Artificial Sequence Antisense Oligonucleotide 470 cggcaaggcc tggagaggaa 20 471 20 DNA Artificial Sequence Antisense Oligonucleotide 471 aagtgcatct tcatgtgtga 20 472 20 DNA Artificial Sequence Antisense Oligonucleotide 472 tttgcaagtg catcttcatg 20 473 20 DNA Artificial Sequence Antisense Oligonucleotide 473 agccctttgc aagtgcatct 20 474 20 DNA Artificial Sequence Antisense Oligonucleotide 474 ccagagccc tttgcaagtg 20 475 20 DNA Artificial Sequence Antisense Oligonucleotide 475 aagttcagca gggccaggac 20 476 20 DNA Artificial Sequence Antisense Oligonucleotide 476 aagtggacag agagaggctg 20 477 20 DNA Artificial Sequence Antisense Oligonucleotide 477 tgcaagtgga cagagagagg 20 478 20 DNA Artificial Sequence Antisense Oligonucleotide 478 gtggtgcaag tggacagaga 20 479 20 DNA Artificial Sequence Antisense Oligonucleotide 479 ttgatgtggc cgaagtccaa 20 480 20 DNA Artificial Sequence Antisense Oligonucleotide 480 tcttcttgat gtggccgaag 20 481 20 DNA Artificial Sequence Antisense Oligonucleotide 481 cctcttcttc ttgatgtggc 20 482 20 DNA Artificial Sequence Antisense Oligonucleotide 482 tccaccctct tcttcttgat 20 483 20 DNA Artificial Sequence Antisense Oligonucleotide 483 tggcttccac cctcttcttc 20 484 20 DNA Artificial Sequence Antisense Oligonucleotide 484 cctaatggct tccaccctct 20 485 20 DNA Artificial Sequence Antisense Oligonucleotide 485 tgtcccctaa tggcttccac 20 486 20 DNA Artificial Sequence Antisense Oligonucleotide 486 agatctgtcc cctaatggct 20 487 20 DNA Artificial Sequence Antisense Oligonucleotide 487 ctcaagatct gtcccctaat 20 488 20 DNA Artificial Sequence Antisense Oligonucleotide 488 ttgctcaaga tctgtcccct 20 489 20 DNA Artificial Sequence Antisense Oligonucleotide 489 ggacgtgggt catcaccgtt 20 490 20 DNA Artificial Sequence Antisense Oligonucleotide 490 atcatgtcga atttatggat 20 491 20 DNA Artificial Sequence Antisense Oligonucleotide 491 ccctggatca tgtcgaattt 20 492 20 DNA Artificial Sequence Antisense Oligonucleotide 492 tccactgagg acacattgaa 20 493 20 DNA Artificial Sequence Antisense Oligonucleotide 493 ttctccactg aggacacatt 20 494 20 DNA Artificial Sequence Antisense Oligonucleotide 494 atttttctcc actgaggaca 20 495 20 DNA Artificial Sequence Antisense Oligonucleotide 495 tgggcacccg caagacccgg 20 496 20 DNA Artificial Sequence Antisense Oligonucleotide 496 gtgggcagat tcttgccacc 20 497 20 DNA Artificial Sequence Antisense Oligonucleotide 497 cgcacagtgt cagtgacatc 20 498 20 DNA Artificial Sequence Antisense Oligonucleotide 498 aaggtgtgac atggacagtg 20 499 20 DNA Artificial Sequence Antisense Oligonucleotide 499 gctgaaaggt gtgacatgga 20 500 20 DNA Artificial Sequence Antisense Oligonucleotide 500 attgggctga aaggtgtgac 20 501 20 DNA Artificial Sequence Antisense Oligonucleotide 501 tctccattgg gctgaaaggt 20 502 20 DNA Artificial Sequence Antisense Oligonucleotide 502 aatttgattt ccatcacctc 20 503 20 DNA Artificial Sequence Antisense Oligonucleotide 503 tctccacggc catggtcatc 20 504 20 DNA Artificial Sequence Antisense Oligonucleotide 504 ttgcggaagc agtaattggt 20 505 20 DNA Artificial Sequence Antisense Oligonucleotide 505 tgagcagaag ttggcatagt 20 506 20 DNA Artificial Sequence Antisense Oligonucleotide 506 gggcctgagc agaagttggc 20 507 20 DNA Artificial Sequence Antisense Oligonucleotide 507 ggcaagggcc tgagcagaag 20 508 20 DNA Artificial Sequence Antisense Oligonucleotide 508 gcactgcgga ggtatgggca 20 509 20 DNA Artificial Sequence Antisense Oligonucleotide 509 tcagggttca gagtgttgta 20 510 20 DNA Artificial Sequence Antisense Oligonucleotide 510 gacttcacca ccatgttgga 20 511 20 DNA Artificial Sequence Antisense Oligonucleotide 511 gggtctcagc tacatttaca 20 512 20 DNA Artificial Sequence Antisense Oligonucleotide 512 agtgaggttt gttgcttgtg 20 513 20 DNA Artificial Sequence Antisense Oligonucleotide 513 gaaacctcca tctcagccat 20 514 20 DNA Artificial Sequence Antisense Oligonucleotide 514 agagttcagc cttcctctaa 20 515 20 DNA Artificial Sequence Antisense Oligonucleotide 515 ttagggtagc ccaaatccca 20 516 20 DNA Artificial Sequence Antisense Oligonucleotide 516 agccattctc tgcccttcct 20 517 20 DNA Artificial Sequence Antisense Oligonucleotide 517 tcagatctga agtgtcttcc 20 518 20 DNA Artificial Sequence Antisense Oligonucleotide 518 tccagattcc ctagagcaga 20 519 20 DNA Artificial Sequence Antisense Oligonucleotide 519 gtataacata atccagattc 20 520 20 DNA Artificial Sequence Antisense Oligonucleotide 520 aaaatgcttg ccttgtataa 20 521 20 DNA Artificial Sequence Antisense Oligonucleotide 521 ctgggacttt gtcttcgtaa 20 522 20 DNA Artificial Sequence Antisense Oligonucleotide 522 ttgcaaaagt aatagatttg 20 523 20 DNA Artificial Sequence Antisense Oligonucleotide 523 ttaattgatg tagaggacag 20 524 20 DNA Artificial Sequence Antisense Oligonucleotide 524 ctggattttc tccctgtagt 20 525 20 DNA Artificial Sequence Antisense Oligonucleotide 525 aactgcatga cctggatttt 20 526 20 DNA Artificial Sequence Antisense Oligonucleotide 526 atacagttga tgggccagga 20 527 20 DNA Artificial Sequence Antisense Oligonucleotide 527 atccaaaagg cccaatacag 20 528 20 DNA Artificial Sequence Antisense Oligonucleotide 528 ccaccctttc ttctgcgttc 20 529 20 DNA Artificial Sequence Antisense Oligonucleotide 529 gtctaaccaa gtgtccaagg 20 530 20 DNA Artificial Sequence Antisense Oligonucleotide 530 tgcatggaac cacaatccag 20 531 20 DNA Artificial Sequence Antisense Oligonucleotide 531 atgccccaag gctgcatgga 20 532 20 DNA Artificial Sequence Antisense Oligonucleotide 532 aatgaacaca gggtcttgga 20 533 20 DNA Artificial Sequence Antisense Oligonucleotide 533 cacctgcttc caggaacacc 20 534 20 DNA Artificial Sequence Antisense Oligonucleotide 534 tgtagcacct gcttccagga 20 535 20 DNA Artificial Sequence Antisense Oligonucleotide 535 agtcactgtg tggcacatgt 20 536 20 DNA Artificial Sequence Antisense Oligonucleotide 536 agtaatattc atacttgtct 20 537 20 DNA Artificial Sequence Antisense Oligonucleotide 537 atatttattt atacaaagat 20 538 20 DNA Artificial Sequence Antisense Oligonucleotide 538 ctgttctaga aacaatattc 20 539 20 DNA Artificial Sequence Antisense Oligonucleotide 539 ctgctggaag caaaggcagg 20 540 20 DNA Artificial Sequence Antisense Oligonucleotide 540 gaggagttac ctggaagagc 20 541 20 DNA Artificial Sequence Antisense Oligonucleotide 541 gtccacctac ctcttctcaa 20 542 20 DNA Artificial Sequence Antisense Oligonucleotide 542 atgccatcta catggttttt 20 543 20 DNA Artificial Sequence Antisense Oligonucleotide 543 ttgtccacgc ctgaagaagg 20 544 20 DNA Artificial Sequence Antisense Oligonucleotide 544 ccagtctcac cggaagcagt 20 545 14121 DNA Homo sapiens CDS (129)...(13820) 545 attcccaccg ggacctgcgg ggctgagtgc ccttctcggt tgctgccgct gaggagcccg 60 cccagccagc cagggccgcg aggccgaggc caggccgcag cccaggagcc gccccaccgc 120 agctggcg atg gac ccg ccg agg ccc gcg ctg ctg gcg ctg ctg gcg ctg 170 Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu 1 5 10 cct gcg ctg ctg ctg ctg ctg ctg gcg ggc gcc agg gcc gaa gag gaa 218 Pro Ala Leu Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu 15 20 25 30 atg ctg gaa aat gtc agc ctg gtc tgt cca aaa gat gcg acc cga ttc 266 Met Leu Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe 35 40 45 aag cac ctc cgg aag tac aca tac aac tat gag gct gag agt tcc agt 314 Lys His Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser 50 55 60 gga gtc cct ggg act gct gat tca aga agt gcc acc agg atc aac tgc 362 Gly Val Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys 65 70 75 aag gtt gag ctg gag gtt ccc cag ctc tgc agc ttc atc ctg aag acc 410 Lys Val Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr 80 85 90 agc cag tgc acc ctg aaa gag gtg tat ggc ttc aac cct gag ggc aaa 458 Ser Gln Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys 95 100 105 110 gcc ttg ctg aag aaa acc aag aac tct gag gag ttt gct gca gcc atg 506 Ala Leu Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met 115 120 125 tcc agg tat gag ctc aag ctg gcc att cca gaa ggg aag cag gtt ttc 554 Ser Arg Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe 130 135 140 ctt tac ccg gag aaa gat gaa cct act tac atc ctg aac atc aag agg 602 Leu Tyr Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg 145 150 155 ggc atc att tct gcc ctc ctg gtt ccc cca gag aca gaa gaa gcc aag 650 Gly Ile Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys 160 165 170 caa gtg ttg ttt ctg gat acc gtg tat gga aac tgc tcc act cac ttt 698 Gln Val Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe 175 180 185 190 acc gtc aag acg agg aag ggc aat gtg gca aca gaa ata tcc act gaa 746 Thr Val Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu 195 200 205 aga gac ctg ggg cag tgt gat cgc ttc aag ccc atc cgc aca ggc atc 794 Arg Asp Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile 210 215 220 agc cca ctt gct ctc atc aaa ggc atg acc cgc ccc ttg tca act ctg 842 Ser Pro Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu 225 230 235 atc agc agc agc cag tcc tgt cag tac aca ctg gac gct aag agg aag 890 Ile Ser Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys 240 245 250 cat gtg gca gaa gcc atc tgc aag gag caa cac ctc ttc ctg cct ttc 938 His Val Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe 255 260 265 270 tcc tac aac aat aag tat ggg atg gta gca caa gtg aca cag act ttg 986 Ser Tyr Asn Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu 275 280 285 aaa ctt gaa gac aca cca aag atc aac agc cgc ttc ttt ggt gaa ggt 1034 Lys Leu Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly 290 295 300 act aag aag atg ggc ctc gca ttt gag agc acc aaa tcc aca tca cct 1082 Thr Lys Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro 305 310 315 cca aag cag gcc gaa gct gtt ttg aag act ctc cag gaa ctg aaa aaa 1130 Pro Lys Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys 320 325 330 cta acc atc tct gag caa aat atc cag aga gct aat ctc ttc aat aag 1178 Leu Thr Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys 335 340 345 350 ctg gtt act gag ctg aga ggc ctc agt gat gaa gca gtc aca tct ctc 1226 Leu Val Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu 355 360 365 ttg cca cag ctg att gag gtg tcc agc ccc atc act tta caa gcc ttg 1274 Leu Pro Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu 370 375 380 gtt cag tgt gga cag cct cag tgc tcc act cac atc ctc cag tgg ctg 1322 Val Gln Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu Gln Trp Leu 385 390 395 aaa cgt gtg cat gcc aac ccc ctt ctg ata gat gtg gtc acc tac ctg 1370 Lys Arg Val His Ala Asn Pro Leu Leu Ile Asp Val Val Thr Tyr Leu 400 405 410 gtg gcc ctg atc ccc gag ccc tca gca cag cag ctg cga gag atc ttc 1418 Val Ala Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg Glu Ile Phe 415 420 425 430 aac atg gcg agg gat cag cgc agc cga gcc acc ttg tat gcg ctg agc 1466 Asn Met Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr Ala Leu Ser 435 440 445 cac gcg gtc aac aac tat cat aag aca aac cct aca ggg acc cag gag 1514 His Ala Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly Thr Gln Glu 450 455 460 ctg ctg gac att gct aat tac ctg atg gaa cag att caa gat gac tgc 1562 Leu Leu Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln Asp Asp Cys 465 470 475 act ggg gat gaa gat tac acc tat ttg att ctg cgg gtc att gga aat 1610 Thr Gly Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val Ile Gly Asn 480 485 490 atg ggc caa acc atg gag cag tta act cca gaa ctc aag tct tca atc 1658 Met Gly Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser Ser Ile 495 500 505 510 ctc aaa tgt gtc caa agt aca aag cca tca ctg atg atc cag aaa gct 1706 Leu Lys Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile Gln Lys Ala 515 520 525 gcc atc cag gct ctg cgg aaa atg gag cct aaa gac aag gac cag gag 1754 Ala Ile Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys Asp Gln Glu 530 535 540 gtt ctt ctt cag act ttc ctt gat gat gct tct ccg gga gat aag cga 1802 Val Leu Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly Asp Lys Arg 545 550 555 ctg gct gcc tat ctt atg ttg atg agg agt cct tca cag gca gat att 1850 Leu Ala Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln Ala Asp Ile 560 565 570 aac aaa att gtc caa att cta cca tgg gaa cag aat gag caa gtg aag 1898 Asn Lys Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu Gln Val Lys 575 580 585 590 aac ttt gtg gct tcc cat att gcc aat atc ttg aac tca gaa gaa ttg 1946 Asn Phe Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser Glu Glu Leu 595 600 605 gat atc caa gat ctg aaa aag tta gtg aaa gaa gct ctg aaa gaa tct 1994 Asp Ile Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu Lys Glu Ser 610 615 620 caa ctt cca act gtc atg gac ttc aga aaa ttc tct cgg aac tat caa 2042 Gln Leu Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg Asn Tyr Gln 625 630 635 ctc tac aaa tct gtt tct ctt cca tca ctt gac cca gcc tca gcc aaa 2090 Leu Tyr Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys 640 645 650 ata gaa ggg aat ctt ata ttt gat cca aat aac tac ctt cct aaa gaa 2138 Ile Glu Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu 655 660 665 670 agc atg ctg aaa act acc ctc act gcc ttt gga ttt gct tca gct gac 2186 Ser Met Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp 675 680 685 ctc atc gag att ggc ttg gaa gga aaa ggc ttt gag cca aca ttg gaa 2234 Leu Ile Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu 690 695 700 gct ctt ttt ggg aag caa gga ttt ttc cca gac agt gtc aac aaa gct 2282 Ala Leu Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala 705 710 715 ttg tac tgg gtt aat ggt caa gtt cct gat ggt gtc tct aag gtc tta 2330 Leu Tyr Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu 720 725 730 gtg gac cac ttt ggc tat acc aaa gat gat aaa cat gag cag gat atg 2378 Val Asp His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met 735 740 745 750 gta aat gga ata atg ctc agt gtt gag aag ctg att aaa gat ttg aaa 2426 Val Asn Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys 755 760 765 tcc aaa gaa gtc ccg gaa gcc aga gcc tac ctc cgc atc ttg gga gag 2474 Ser Lys Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Glu 770 775 780 gag ctt ggt ttt gcc agt ctc cat gac ctc cag ctc ctg gga aag ctg 2522 Glu Leu Gly Phe Ala Ser Leu His Asp Leu Gln Leu Leu Gly Lys Leu 785 790 795 ctt ctg atg ggt gcc cgc act ctg cag ggg atc ccc cag atg att gga 2570 Leu Leu Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Met Ile Gly 800 805 810 gag gtc atc agg aag ggc tca aag aat gac ttt ttt ctt cac tac atc 2618 Glu Val Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile 815 820 825 830 ttc atg gag aat gcc ttt gaa ctc ccc act gga gct gga tta cag ttg 2666 Phe Met Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly Leu Gln Leu 835 840 845 caa ata tct tca tct gga gtc att gct ccc gga gcc aag gct gga gta 2714 Gln Ile Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val 850 855 860 aaa ctg gaa gta gcc aac atg cag gct gaa ctg gtg gca aaa ccc tcc 2762 Lys Leu Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala Lys Pro Ser 865 870 875 gtg tct gtg gag ttt gtg aca aat atg ggc atc atc att ccg gac ttc 2810 Val Ser Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe 880 885 890 gct agg agt ggg gtc cag atg aac acc aac ttc ttc cac gag tcg ggt 2858 Ala Arg Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly 895 900 905 910 ctg gag gct cat gtt gcc cta aaa gct ggg aag ctg aag ttt atc att 2906 Leu Glu Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile 915 920 925 cct tcc cca aag aga cca gtc aag ctg ctc agt gga ggc aac aca tta 2954 Pro Ser Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly Asn Thr Leu 930 935 940 cat ttg gtc tct acc acc aaa acg gag gtg atc cca cct ctc att gag 3002 His Leu Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu 945 950 955 aac agg cag tcc tgg tca gtt tgc aag caa gtc ttt cct ggc ctg aat 3050 Asn Arg Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn 960 965 970 tac tgc acc tca ggc gct tac tcc aac gcc agc tcc aca gac tcc gcc 3098 Tyr Cys Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala 975 980 985 990 tcc tac tat ccg ctg acc ggg gac acc aga tta gag ctg gaa ctg agg 3146 Ser Tyr Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg 995 1000 1005 cct aca gga gag att gag cag tat tct gtc agc gca acc tat gag ctc 3194 Pro Thr Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu 1010 1015 1020 cag aga gag gac aga gcc ttg gtg gat acc ctg aag ttt gta act caa 3242 Gln Arg Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln 1025 1030 1035 gca gaa ggt gcg aag cag act gag gct acc atg aca ttc aaa tat aat 3290 Ala Glu Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr Asn 1040 1045 1050 cgg cag agt atg acc ttg tcc agt gaa gtc caa att ccg gat ttt gat 3338 Arg Gln Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp Phe Asp 1055 1060 1065 1070 gtt gac ctc gga aca atc ctc aga gtt aat gat gaa tct act gag ggc 3386 Val Asp Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser Thr Glu Gly 1075 1080 1085 aaa acg tct tac aga ctc acc ctg gac att cag aac aag aaa att act 3434 Lys Thr Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn Lys Lys Ile Thr 1090 1095 1100 gag gtc gcc ctc atg ggc cac cta agt tgt gac aca aag gaa gaa aga 3482 Glu Val Ala Leu Met Gly His Leu Ser Cys Asp Thr Lys Glu Glu Arg 1105 1110 1115 aaa atc aag ggt gtt att tcc ata ccc cgt ttg caa gca gaa gcc aga 3530 Lys Ile Lys Gly Val Ile Ser Ile Pro Arg Leu Gln Ala Glu Ala Arg 1120 1125 1130 agt gag atc ctc gcc cac tgg tcg cct gcc aaa ctg ctt ctc caa atg 3578 Ser Glu Ile Leu Ala His Trp Ser Pro Ala Lys Leu Leu Leu Gln Met 1135 1140 1145 1150 gac tca tct gct aca gct tat ggc tcc aca gtt tcc aag agg gtg gca 3626 Asp Ser Ser Ala Thr Ala Tyr Gly Ser Thr Val Ser Lys Arg Val Ala 1155 1160 1165 tgg cat tat gat gaa gag aag att gaa ttt gaa tgg aac aca ggc acc 3674 Trp His Tyr Asp Glu Glu Lys Ile Glu Phe Glu Trp Asn Thr Gly Thr 1170 1175 1180 aat gta gat acc aaa aaa atg act tcc aat ttc cct gtg gat ctc tcc 3722 Asn Val Asp Thr Lys Lys Met Thr Ser Asn Phe Pro Val Asp Leu Ser 1185 1190 1195 gat tat cct aag agc ttg cat atg tat gct aat aga ctc ctg gat cac 3770 Asp Tyr Pro Lys Ser Leu His Met Tyr Ala Asn Arg Leu Leu Asp His 1200 1205 1210 aga gtc cct gaa aca gac atg act ttc cgg cac gtg ggt tcc aaa tta 3818 Arg Val Pro Glu Thr Asp Met Thr Phe Arg His Val Gly Ser Lys Leu 1215 1220 1225 1230 ata gtt gca atg agc tca tgg ctt cag aag gca tct ggg agt ctt cct 3866 Ile Val Ala Met Ser Ser Trp Leu Gln Lys Ala Ser Gly Ser Leu Pro 1235 1240 1245 tat acc cag act ttg caa gac cac ctc aat agc ctg aag gag ttc aac 3914 Tyr Thr Gln Thr Leu Gln Asp His Leu Asn Ser Leu Lys Glu Phe Asn 1250 1255 1260 ctc cag aac atg gga ttg cca gac ttc cac atc cca gaa aac ctc ttc 3962 Leu Gln Asn Met Gly Leu Pro Asp Phe His Ile Pro Glu Asn Leu Phe 1265 1270 1275 tta aaa agc gat ggc cgg gtc aaa tat acc ttg aac aag aac agt ttg 4010 Leu Lys Ser Asp Gly Arg Val Lys Tyr Thr Leu Asn Lys Asn Ser Leu 1280 1285 1290 aaa att gag att cct ttg cct ttt ggt ggc aaa tcc tcc aga gat cta 4058 Lys Ile Glu Ile Pro Leu Pro Phe Gly Gly Lys Ser Ser Arg Asp Leu 1295 1300 1305 1310 aag atg tta gag act gtt agg aca cca gcc ctc cac ttc aag tct gtg 4106 Lys Met Leu Glu Thr Val Arg Thr Pro Ala Leu His Phe Lys Ser Val 1315 1320 1325 gga ttc cat ctg cca tct cga gag ttc caa gtc cct act ttt acc att 4154 Gly Phe His Leu Pro Ser Arg Glu Phe Gln Val Pro Thr Phe Thr Ile 1330 1335 1340 ccc aag ttg tat caa ctg caa gtg cct ctc ctg ggt gtt cta gac ctc 4202 Pro Lys Leu Tyr Gln Leu Gln Val Pro Leu Leu Gly Val Leu Asp Leu 1345 1350 1355 tcc acg aat gtc tac agc aac ttg tac aac tgg tcc gcc tcc tac agt 4250 Ser Thr Asn Val Tyr Ser Asn Leu Tyr Asn Trp Ser Ala Ser Tyr Ser 1360 1365 1370 ggt ggc aac acc agc aca gac cat ttc agc ctt cgg gct cgt tac cac 4298 Gly Gly Asn Thr Ser Thr Asp His Phe Ser Leu Arg Ala Arg Tyr His 1375 1380 1385 1390 atg aag gct gac tct gtg gtt gac ctg ctt tcc tac aat gtg caa gga 4346 Met Lys Ala Asp Ser Val Val Asp Leu Leu Ser Tyr Asn Val Gln Gly 1395 1400 1405 tct gga gaa aca aca tat gac cac aag aat acg ttc aca cta tca tgt 4394 Ser Gly Glu Thr Thr Tyr Asp His Lys Asn Thr Phe Thr Leu Ser Cys 1410 1415 1420 gat ggg tct cta cgc cac aaa ttt cta gat tcg aat atc aaa ttc agt 4442 Asp Gly Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser 1425 1430 1435 cat gta gaa aaa ctt gga aac aac cca gtc tca aaa ggt tta cta ata 4490 His Val Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile 1440 1445 1450 ttc gat gca tct agt tcc tgg gga cca cag atg tct gct tca gtt cat 4538 Phe Asp Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His 1455 1460 1465 1470 ttg gac tcc aaa aag aaa cag cat ttg ttt gtc aaa gaa gtc aag att 4586 Leu Asp Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile 1475 1480 1485 gat ggg cag ttc aga gtc tct tcg ttc tat gct aaa ggc aca tat ggc 4634 Asp Gly Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly 1490 1495 1500 ctg tct tgt cag agg gat cct aac act ggc cgg ctc aat gga gag tcc 4682 Leu Ser Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser 1505 1510 1515 aac ctg agg ttt aac tcc tcc tac ctc caa ggc acc aac cag ata aca 4730 Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr 1520 1525 1530 gga aga tat gaa gat gga acc ctc tcc ctc acc tcc acc tct gat ctg 4778 Gly Arg Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser Asp Leu 1535 1540 1545 1550 caa agt ggc atc att aaa aat act gct tcc cta aag tat gag aac tac 4826 Gln Ser Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr Glu Asn Tyr 1555 1560 1565 gag ctg act tta aaa tct gac acc aat ggg aag tat aag aac ttt gcc 4874 Glu Leu Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr Lys Asn Phe Ala 1570 1575 1580 act tct aac aag atg gat atg acc ttc tct aag caa aat gca ctg ctg 4922 Thr Ser Asn Lys Met Asp Met Thr Phe Ser Lys Gln Asn Ala Leu Leu 1585 1590 1595 cgt tct gaa tat cag gct gat tac gag tca ttg agg ttc ttc agc ctg 4970 Arg Ser Glu Tyr Gln Ala Asp Tyr Glu Ser Leu Arg Phe Phe Ser Leu 1600 1605 1610 ctt tct gga tca cta aat tcc cat ggt ctt gag tta aat gct gac atc 5018 Leu Ser Gly Ser Leu Asn Ser His Gly Leu Glu Leu Asn Ala Asp Ile 1615 1620 1625 1630 tta ggc act gac aaa att aat agt ggt gct cac aag gcg aca cta agg 5066 Leu Gly Thr Asp Lys Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg 1635 1640 1645 att ggc caa gat gga ata tct acc agt gca acg acc aac ttg aag tgt 5114 Ile Gly Gln Asp Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys 1650 1655 1660 agt ctc ctg gtg ctg gag aat gag ctg aat gca gag ctt ggc ctc tct 5162 Ser Leu Leu Val Leu Glu Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser 1665 1670 1675 ggg gca tct atg aaa tta aca aca aat ggc cgc ttc agg gaa cac aat 5210 Gly Ala Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn 1680 1685 1690 gca aaa ttc agt ctg gat ggg aaa gcc gcc ctc aca gag cta tca ctg 5258 Ala Lys Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu 1695 1700 1705 1710 gga agt gct tat cag gcc atg att ctg ggt gtc gac agc aaa aac att 5306 Gly Ser Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile 1715 1720 1725 ttc aac ttc aag gtc agt caa gaa gga ctt aag ctc tca aat gac atg 5354 Phe Asn Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met 1730 1735 1740 atg ggc tca tat gct gaa atg aaa ttt gac cac aca aac agt ctg aac 5402 Met Gly Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn Ser Leu Asn 1745 1750 1755 att gca ggc tta tca ctg gac ttc tct tca aaa ctt gac aac att tac 5450 Ile Ala Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu Asp Asn Ile Tyr 1760 1765 1770 agc tct gac aag ttt tat aag caa act gtt aat tta cag cta cag ccc 5498 Ser Ser Asp Lys Phe Tyr Lys Gln Thr Val Asn Leu Gln Leu Gln Pro 1775 1780 1785 1790 tat tct ctg gta act act tta aac agt gac ctg aaa tac aat gct ctg 5546 Tyr Ser Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr Asn Ala Leu 1795 1800 1805 gat ctc acc aac aat ggg aaa cta cgg cta gaa ccc ctg aag ctg cat 5594 Asp Leu Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro Leu Lys Leu His 1810 1815 1820 gtg gct ggt aac cta aaa gga gcc tac caa aat aat gaa ata aaa cac 5642 Val Ala Gly Asn Leu Lys Gly Ala Tyr Gln Asn Asn Glu Ile Lys His 1825 1830 1835 atc tat gcc atc tct tct gct gcc tta tca gca agc tat aaa gca gac 5690 Ile Tyr Ala Ile Ser Ser Ala Ala Leu Ser Ala Ser Tyr Lys Ala Asp 1840 1845 1850 act gtt gct aag gtt cag ggt gtg gag ttt agc cat cgg ctc aac aca 5738 Thr Val Ala Lys Val Gln Gly Val Glu Phe Ser His Arg Leu Asn Thr 1855 1860 1865 1870 gac atc gct ggg ctg gct tca gcc att gac atg agc aca aac tat aat 5786 Asp Ile Ala Gly Leu Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn 1875 1880 1885 tca gac tca ctg cat ttc agc aat gtc ttc cgt tct gta atg gcc ccg 5834 Ser Asp Ser Leu His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro 1890 1895 1900 ttt acc atg acc atc gat gca cat aca aat ggc aat ggg aaa ctc gct 5882 Phe Thr Met Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala 1905 1910 1915 ctc tgg gga gaa cat act ggg cag ctg tat agc aaa ttc ctg ttg aaa 5930 Leu Trp Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys 1920 1925 1930 gca gaa cct ctg gca ttt act ttc tct cat gat tac aaa ggc tcc aca 5978 Ala Glu Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr 1935 1940 1945 1950 agt cat cat ctc gtg tct agg aaa agc atc agt gca gct ctt gaa cac 6026 Ser His His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His 1955 1960 1965 aaa gtc agt gcc ctg ctt act cca gct gag cag aca ggc acc tgg aaa 6074 Lys Val Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys 1970 1975 1980 ctc aag acc caa ttt aac aac aat gaa tac agc cag gac ttg gat gct 6122 Leu Lys Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala 1985 1990 1995 tac aac act aaa gat aaa att ggc gtg gag ctt act gga cga act ctg 6170 Tyr Asn Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr Leu 2000 2005 2010 gct gac cta act cta cta gac tcc cca att aaa gtg cca ctt tta ctc 6218 Ala Asp Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu Leu Leu 2015 2020 2025 2030 agt gag ccc atc aat atc att gat gct tta gag atg aga gat gcc gtt 6266 Ser Glu Pro Ile Asn Ile Ile Asp Ala Leu Glu Met Arg Asp Ala Val 2035 2040 2045 gag aag ccc caa gaa ttt aca att gtt gct ttt gta aag tat gat aaa 6314 Glu Lys Pro Gln Glu Phe Thr Ile Val Ala Phe Val Lys Tyr Asp Lys 2050 2055 2060 aac caa gat gtt cac tcc att aac ctc cca ttt ttt gag acc ttg caa 6362 Asn Gln Asp Val His Ser Ile Asn Leu Pro Phe Phe Glu Thr Leu Gln 2065 2070 2075 gaa tat ttt gag agg aat cga caa acc att ata gtt gta gtg gaa aac 6410 Glu Tyr Phe Glu Arg Asn Arg Gln Thr Ile Ile Val Val Val Glu Asn 2080 2085 2090 gta cag aga aac ctg aag cac atc aat att gat caa ttt gta aga aaa 6458 Val Gln Arg Asn Leu Lys His Ile Asn Ile Asp Gln Phe Val Arg Lys 2095 2100 2105 2110 tac aga gca gcc ctg gga aaa ctc cca cag caa gct aat gat tat ctg 6506 Tyr Arg Ala Ala Leu Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu 2115 2120 2125 aat tca ttc aat tgg gag aga caa gtt tca cat gcc aag gag aaa ctg 6554 Asn Ser Phe Asn Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu 2130 2135 2140 act gct ctc aca aaa aag tat aga att aca gaa aat gat ata caa att 6602 Thr Ala Leu Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile 2145 2150 2155 gca tta gat gat gcc aaa atc aac ttt aat gaa aaa cta tct caa ctg 6650 Ala Leu Asp Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu 2160 2165 2170 cag aca tat atg ata caa ttt gat cag tat att aaa gat agt tat gat 6698 Gln Thr Tyr Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp 2175 2180 2185 2190 tta cat gat ttg aaa ata gct att gct aat att att gat gaa atc att 6746 Leu His Asp Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile Ile 2195 2200 2205 gaa aaa tta aaa agt ctt gat gag cac tat cat atc cgt gta aat tta 6794 Glu Lys Leu Lys Ser Leu Asp Glu His Tyr His Ile Arg Val Asn Leu 2210 2215 2220 gta aaa aca atc cat gat cta cat ttg ttt att gaa aat att gat ttt 6842 Val Lys Thr Ile His Asp Leu His Leu Phe Ile Glu Asn Ile Asp Phe 2225 2230 2235 aac aaa agt gga agt agt act gca tcc tgg att caa aat gtg gat act 6890 Asn Lys Ser Gly Ser Ser Thr Ala Ser Trp Ile Gln Asn Val Asp Thr 2240 2245 2250 aag tac caa atc aga atc cag ata caa gaa aaa ctg cag cag ctt aag 6938 Lys Tyr Gln Ile Arg Ile Gln Ile Gln Glu Lys Leu Gln Gln Leu Lys 2255 2260 2265 2270 aga cac ata cag aat ata gac atc cag cac cta gct gga aag tta aaa 6986 Arg His Ile Gln Asn Ile Asp Ile Gln His Leu Ala Gly Lys Leu Lys 2275 2280 2285 caa cac att gag gct att gat gtt aga gtg ctt tta gat caa ttg gga 7034 Gln His Ile Glu Ala Ile Asp Val Arg Val Leu Leu Asp Gln Leu Gly 2290 2295 2300 act aca att tca ttt gaa aga ata aat gat gtt ctt gag cat gtc aaa 7082 Thr Thr Ile Ser Phe Glu Arg Ile Asn Asp Val Leu Glu His Val Lys 2305 2310 2315 cac ttt gtt ata aat ctt att ggg gat ttt gaa gta gct gag aaa atc 7130 His Phe Val Ile Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile 2320 2325 2330 aat gcc ttc aga gcc aaa gtc cat gag tta atc gag agg tat gaa gta 7178 Asn Ala Phe Arg Ala Lys Val His Glu Leu Ile Glu Arg Tyr Glu Val 2335 2340 2345 2350 gac caa caa atc cag gtt tta atg gat aaa tta gta gag ttg acc cac 7226 Asp Gln Gln Ile Gln Val Leu Met Asp Lys Leu Val Glu Leu Thr His 2355 2360 2365 caa tac aag ttg aag gag act att cag aag cta agc aat gtc cta caa 7274 Gln Tyr Lys Leu Lys Glu Thr Ile Gln Lys Leu Ser Asn Val Leu Gln 2370 2375 2380 caa gtt aag ata aaa gat tac ttt gag aaa ttg gtt gga ttt att gat 7322 Gln Val Lys Ile Lys Asp Tyr Phe Glu Lys Leu Val Gly Phe Ile Asp 2385 2390 2395 gat gct gtg aag aag ctt aat gaa tta tct ttt aaa aca ttc att gaa 7370 Asp Ala Val Lys Lys Leu Asn Glu Leu Ser Phe Lys Thr Phe Ile Glu 2400 2405 2410 gat gtt aac aaa ttc ctt gac atg ttg ata aag aaa tta aag tca ttt 7418 Asp Val Asn Lys Phe Leu Asp Met Leu Ile Lys Lys Leu Lys Ser Phe 2415 2420 2425 2430 gat tac cac cag ttt gta gat gaa acc aat gac aaa atc cgt gag gtg 7466 Asp Tyr His Gln Phe Val Asp Glu Thr Asn Asp Lys Ile Arg Glu Val 2435 2440 2445 act cag aga ctc aat ggt gaa att cag gct ctg gaa cta cca caa aaa 7514 Thr Gln Arg Leu Asn Gly Glu Ile Gln Ala Leu Glu Leu Pro Gln Lys 2450 2455 2460 gct gaa gca tta aaa ctg ttt tta gag gaa acc aag gcc aca gtt gca 7562 Ala Glu Ala Leu Lys Leu Phe Leu Glu Glu Thr Lys Ala Thr Val Ala 2465 2470 2475 gtg tat ctg gaa agc cta cag gac acc aaa ata acc tta atc atc aat 7610 Val Tyr Leu Glu Ser Leu Gln Asp Thr Lys Ile Thr Leu Ile Ile Asn 2480 2485 2490 tgg tta cag gag gct tta agt tca gca tct ttg gct cac atg aag gcc 7658 Trp Leu Gln Glu Ala Leu Ser Ser Ala Ser Leu Ala His Met Lys Ala 2495 2500 2505 2510 aaa ttc cga gag act cta gaa gat aca cga gac cga atg tat caa atg 7706 Lys Phe Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr Gln Met 2515 2520 2525 gac att cag cag gaa ctt caa cga tac ctg tct ctg gta ggc cag gtt 7754 Asp Ile Gln Gln Glu Leu Gln Arg Tyr Leu Ser Leu Val Gly Gln Val 2530 2535 2540 tat agc aca ctt gtc acc tac att tct gat tgg tgg act ctt gct gct 7802 Tyr Ser Thr Leu Val Thr Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala 2545 2550 2555 aag aac ctt act gac ttt gca gag caa tat tct atc caa gat tgg gct 7850 Lys Asn Leu Thr Asp Phe Ala Glu Gln Tyr Ser Ile Gln Asp Trp Ala 2560 2565 2570 aaa cgt atg aaa gca ttg gta gag caa ggg ttc act gtt cct gaa atc 7898 Lys Arg Met Lys Ala Leu Val Glu Gln Gly Phe Thr Val Pro Glu Ile 2575 2580 2585 2590 aag acc atc ctt ggg acc atg cct gcc ttt gaa gtc agt ctt cag gct 7946 Lys Thr Ile Leu Gly Thr Met Pro Ala Phe Glu Val Ser Leu Gln Ala 2595 2600 2605 ctt cag aaa gct acc ttc cag aca cct gat ttt ata gtc ccc cta aca 7994 Leu Gln Lys Ala Thr Phe Gln Thr Pro Asp Phe Ile Val Pro Leu Thr 2610 2615 2620 gat ttg agg att cca tca gtt cag ata aac ttc aaa gac tta aaa aat 8042 Asp Leu Arg Ile Pro Ser Val Gln Ile Asn Phe Lys Asp Leu Lys Asn 2625 2630 2635 ata aaa atc cca tcc agg ttt tcc aca cca gaa ttt acc atc ctt aac 8090 Ile Lys Ile Pro Ser Arg Phe Ser Thr Pro Glu Phe Thr Ile Leu Asn 2640 2645 2650 acc ttc cac att cct tcc ttt aca att gac ttt gtc gaa atg aaa gta 8138 Thr Phe His Ile Pro Ser Phe Thr Ile Asp Phe Val Glu Met Lys Val 2655 2660 2665 2670 aag atc atc aga acc att gac cag atg cag aac agt gag ctg cag tgg 8186 Lys Ile Ile Arg Thr Ile Asp Gln Met Gln Asn Ser Glu Leu Gln Trp 2675 2680 2685 ccc gtt cca gat ata tat ctc agg gat ctg aag gtg gag gac att cct 8234 Pro Val Pro Asp Ile Tyr Leu Arg Asp Leu Lys Val Glu Asp Ile Pro 2690 2695 2700 cta gcg aga atc acc ctg cca gac ttc cgt tta cca gaa atc gca att 8282 Leu Ala Arg Ile Thr Leu Pro Asp Phe Arg Leu Pro Glu Ile Ala Ile 2705 2710 2715 cca gaa ttc ata atc cca act ctc aac ctt aat gat ttt caa gtt cct 8330 Pro Glu Phe Ile Ile Pro Thr Leu Asn Leu Asn Asp Phe Gln Val Pro 2720 2725 2730 gac ctt cac ata cca gaa ttc cag ctt ccc cac atc tca cac aca att 8378 Asp Leu His Ile Pro Glu Phe Gln Leu Pro His Ile Ser His Thr Ile 2735 2740 2745 2750 gaa gta cct act ttt ggc aag cta tac agt att ctg aaa atc caa tct 8426 Glu Val Pro Thr Phe Gly Lys Leu Tyr Ser Ile Leu Lys Ile Gln Ser 2755 2760 2765 cct ctt ttc aca tta gat gca aat gct gac ata ggg aat gga acc acc 8474 Pro Leu Phe Thr Leu Asp Ala Asn Ala Asp Ile Gly Asn Gly Thr Thr 2770 2775 2780 tca gca aac gaa gca ggt atc gca gct tcc atc act gcc aaa gga gag 8522 Ser Ala Asn Glu Ala Gly Ile Ala Ala Ser Ile Thr Ala Lys Gly Glu 2785 2790 2795 tcc aaa tta gaa gtt ctc aat ttt gat ttt caa gca aat gca caa ctc 8570 Ser Lys Leu Glu Val Leu Asn Phe Asp Phe Gln Ala Asn Ala Gln Leu 2800 2805 2810 tca aac cct aag att aat ccg ctg gct ctg aag gag tca gtg aag ttc 8618 Ser Asn Pro Lys Ile Asn Pro Leu Ala Leu Lys Glu Ser Val Lys Phe 2815 2820 2825 2830 tcc agc aag tac ctg aga acg gag cat ggg agt gaa atg ctg ttt ttt 8666 Ser Ser Lys Tyr Leu Arg Thr Glu His Gly Ser Glu Met Leu Phe Phe 2835 2840 2845 gga aat gct att gag gga aaa tca aac aca gtg gca agt tta cac aca 8714 Gly Asn Ala Ile Glu Gly Lys Ser Asn Thr Val Ala Ser Leu His Thr 2850 2855 2860 gaa aaa aat aca ctg gag ctt agt aat gga gtg att gtc aag ata aac 8762 Glu Lys Asn Thr Leu Glu Leu Ser Asn Gly Val Ile Val Lys Ile Asn 2865 2870 2875 aat cag ctt acc ctg gat agc aac act aaa tac ttc cac aaa ttg aac 8810 Asn Gln Leu Thr Leu Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn 2880 2885 2890 atc ccc aaa ctg gac ttc tct agt cag gct gac ctg cgc aac gag atc 8858 Ile Pro Lys Leu Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile 2895 2900 2905 2910 aag aca ctg ttg aaa gct ggc cac ata gca tgg act tct tct gga aaa 8906 Lys Thr Leu Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly Lys 2915 2920 2925 ggg tca tgg aaa tgg gcc tgc ccc aga ttc tca gat gag gga aca cat 8954 Gly Ser Trp Lys Trp Ala Cys Pro Arg Phe Ser Asp Glu Gly Thr His 2930 2935 2940 gaa tca caa att agt ttc acc ata gaa gga ccc ctc act tcc ttt gga 9002 Glu Ser Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr Ser Phe Gly 2945 2950 2955 ctg tcc aat aag atc aat agc aaa cac cta aga gta aac caa aac ttg 9050 Leu Ser Asn Lys Ile Asn Ser Lys His Leu Arg Val Asn Gln Asn Leu 2960 2965 2970 gtt tat gaa tct ggc tcc ctc aac ttt tct aaa ctt gaa att caa tca 9098 Val Tyr Glu Ser Gly Ser Leu Asn Phe Ser Lys Leu Glu Ile Gln Ser 2975 2980 2985 2990 caa gtc gat tcc cag cat gtg ggc cac agt gtt cta act gct aaa ggc 9146 Gln Val Asp Ser Gln His Val Gly His Ser Val Leu Thr Ala Lys Gly 2995 3000 3005 atg gca ctg ttt gga gaa ggg aag gca gag ttt act ggg agg cat gat 9194 Met Ala Leu Phe Gly Glu Gly Lys Ala Glu Phe Thr Gly Arg His Asp 3010 3015 3020 gct cat tta aat gga aag gtt att gga act ttg aaa aat tct ctt ttc 9242 Ala His Leu Asn Gly Lys Val Ile Gly Thr Leu Lys Asn Ser Leu Phe 3025 3030 3035 ttt tca gcc cag cca ttt gag atc acg gca tcc aca aac aat gaa ggg 9290 Phe Ser Ala Gln Pro Phe Glu Ile Thr Ala Ser Thr Asn Asn Glu Gly 3040 3045 3050 aat ttg aaa gtt cgt ttt cca tta agg tta aca ggg aag ata gac ttc 9338 Asn Leu Lys Val Arg Phe Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe 3055 3060 3065 3070 ctg aat aac tat gca ctg ttt ctg agt ccc agt gcc cag caa gca agt 9386 Leu Asn Asn Tyr Ala Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser 3075 3080 3085 tgg caa gta agt gct agg ttc aat cag tat aag tac aac caa aat ttc 9434 Trp Gln Val Ser Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe 3090 3095 3100 tct gct gga aac aac gag aac att atg gag gcc cat gta gga ata aat 9482 Ser Ala Gly Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn 3105 3110 3115 gga gaa gca aat ctg gat ttc tta aac att cct tta aca att cct gaa 9530 Gly Glu Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu 3120 3125 3130 atg cgt cta cct tac aca ata atc aca act cct cca ctg aaa gat ttc 9578 Met Arg Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe 3135 3140 3145 3150 tct cta tgg gaa aaa aca ggc ttg aag gaa ttc ttg aaa acg aca aag 9626 Ser Leu Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr Lys 3155 3160 3165 caa tca ttt gat tta agt gta aaa gct cag tat aag aaa aac aaa cac 9674 Gln Ser Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn Lys His 3170 3175 3180 agg cat tcc atc aca aat cct ttg gct gtg ctt tgt gag ttt atc agt 9722 Arg His Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu Phe Ile Ser 3185 3190 3195 cag agc atc aaa tcc ttt gac agg cat ttt gaa aaa aac aga aac aat 9770 Gln Ser Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn Asn 3200 3205 3210 gca tta gat ttt gtc acc aaa tcc tat aat gaa aca aaa att aag ttt 9818 Ala Leu Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile Lys Phe 3215 3220 3225 3230 gat aag tac aaa gct gaa aaa tct cac gac gag ctc ccc agg acc ttt 9866 Asp Lys Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro Arg Thr Phe 3235 3240 3245 caa att cct gga tac act gtt cca gtt gtc aat gtt gaa gtg tct cca 9914 Gln Ile Pro Gly Tyr Thr Val Pro Val Val Asn Val Glu Val Ser Pro 3250 3255 3260 ttc acc ata gag atg tcg gca ttc ggc tat gtg ttc cca aaa gca gtc 9962 Phe Thr Ile Glu Met Ser Ala Phe Gly Tyr Val Phe Pro Lys Ala Val 3265 3270 3275 agc atg cct agt ttc tcc atc cta ggt tct gac gtc cgt gtg cct tca 10010 Ser Met Pro Ser Phe Ser Ile Leu Gly Ser Asp Val Arg Val Pro Ser 3280 3285 3290 tac aca tta atc ctg cca tca tta gag ctg cca gtc ctt cat gtc cct 10058 Tyr Thr Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His Val Pro 3295 3300 3305 3310 aga aat ctc aag ctt tct ctt cca cat ttc aag gaa ttg tgt acc ata 10106 Arg Asn Leu Lys Leu Ser Leu Pro His Phe Lys Glu Leu Cys Thr Ile 3315 3320 3325 agc cat att ttt att cct gcc atg ggc aat att acc tat gat ttc tcc 10154 Ser His Ile Phe Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser 3330 3335 3340 ttt aaa tca agt gtc atc aca ctg aat acc aat gct gaa ctt ttt aac 10202 Phe Lys Ser Ser Val Ile Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn 3345 3350 3355 cag tca gat att gtt gct cat ctc ctt tct tca tct tca tct gtc att 10250 Gln Ser Asp Ile Val Ala His Leu Leu Ser Ser Ser Ser Ser Val Ile 3360 3365 3370 gat gca ctg cag tac aaa tta gag ggc acc aca aga ttg aca aga aaa 10298 Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys 3375 3380 3385 3390 agg gga ttg aag tta gcc aca gct ctg tct ctg agc aac aaa ttt gtg 10346 Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val 3395 3400 3405 gag ggt agt cat aac agt act gtg agc tta acc acg aaa aat atg gaa 10394 Glu Gly Ser His Asn Ser Thr Val Ser Leu Thr Thr Lys Asn Met Glu 3410 3415 3420 gtg tca gtg gca aaa acc aca aaa gcc gaa att cca att ttg aga atg 10442 Val Ser Val Ala Lys Thr Thr Lys Ala Glu Ile Pro Ile Leu Arg Met 3425 3430 3435 aat ttc aag caa gaa ctt aat gga aat acc aag tca aaa cct act gtc 10490 Asn Phe Lys Gln Glu Leu Asn Gly Asn Thr Lys Ser Lys Pro Thr Val 3440 3445 3450 tct tcc tcc atg gaa ttt aag tat gat ttc aat tct tca atg ctg tac 10538 Ser Ser Ser Met Glu Phe Lys Tyr Asp Phe Asn Ser Ser Met Leu Tyr 3455 3460 3465 3470 tct acc gct aaa gga gca gtt gac cac aag ctt agc ttg gaa agc ctc 10586 Ser Thr Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu Glu Ser Leu 3475 3480 3485 acc tct tac ttt tcc att gag tca tct acc aaa gga gat gtc aag ggt 10634 Thr Ser Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly Asp Val Lys Gly 3490 3495 3500 tcg gtt ctt tct cgg gaa tat tca gga act att gct agt gag gcc aac 10682 Ser Val Leu Ser Arg Glu Tyr Ser Gly Thr Ile Ala Ser Glu Ala Asn 3505 3510 3515 act tac ttg aat tcc aag agc aca cgg tct tca gtg aag ctg cag ggc 10730 Thr Tyr Leu Asn Ser Lys Ser Thr Arg Ser Ser Val Lys Leu Gln Gly 3520 3525 3530 act tcc aaa att gat gat atc tgg aac ctt gaa gta aaa gaa aat ttt 10778 Thr Ser Lys Ile Asp Asp Ile Trp Asn Leu Glu Val Lys Glu Asn Phe 3535 3540 3545 3550 gct gga gaa gcc aca ctc caa cgc ata tat tcc ctc tgg gag cac agt 10826 Ala Gly Glu Ala Thr Leu Gln Arg Ile Tyr Ser Leu Trp Glu His Ser 3555 3560 3565 acg aaa aac cac tta cag cta gag ggc ctc ttt ttc acc aac gga gaa 10874 Thr Lys Asn His Leu Gln Leu Glu Gly Leu Phe Phe Thr Asn Gly Glu 3570 3575 3580 cat aca agc aaa gcc acc ctg gaa ctc tct cca tgg caa atg tca gct 10922 His Thr Ser Lys Ala Thr Leu Glu Leu Ser Pro Trp Gln Met Ser Ala 3585 3590 3595 ctt gtt cag gtc cat gca agt cag ccc agt tcc ttc cat gat ttc cct 10970 Leu Val Gln Val His Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro 3600 3605 3610 gac ctt ggc cag gaa gtg gcc ctg aat gct aac act aag aac cag aag 11018 Asp Leu Gly Gln Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys 3615 3620 3625 3630 atc aga tgg aaa aat gaa gtc cgg att cat tct ggg tct ttc cag agc 11066 Ile Arg Trp Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser 3635 3640 3645 cag gtc gag ctt tcc aat gac caa gaa aag gca cac ctt gac att gca 11114 Gln Val Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala 3650 3655 3660 gga tcc tta gaa gga cac cta agg ttc ctc aaa aat atc atc cta cca 11162 Gly Ser Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro 3665 3670 3675 gtc tat gac aag agc tta tgg gat ttc cta aag ctg gat gta acc acc 11210 Val Tyr Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr Thr 3680 3685 3690 agc att ggt agg aga cag cat ctt cgt gtt tca act gcc ttt gtg tac 11258 Ser Ile Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe Val Tyr 3695 3700 3705 3710 acc aaa aac ccc aat ggc tat tca ttc tcc atc cct gta aaa gtt ttg 11306 Thr Lys Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val Lys Val Leu 3715 3720 3725 gct gat aaa ttc att act cct ggg ctg aaa cta aat gat cta aat tca 11354 Ala Asp Lys Phe Ile Thr Pro Gly Leu Lys Leu Asn Asp Leu Asn Ser 3730 3735 3740 gtt ctt gtc atg cct acg ttc cat gtc cca ttt aca gat ctt cag gtt 11402 Val Leu Val Met Pro Thr Phe His Val Pro Phe Thr Asp Leu Gln Val 3745 3750 3755 cca tcg tgc aaa ctt gac ttc aga gaa ata caa atc tat aag aag ctg 11450 Pro Ser Cys Lys Leu Asp Phe Arg Glu Ile Gln Ile Tyr Lys Lys Leu 3760 3765 3770 aga act tca tca ttt gcc ctc aac cta cca aca ctc ccc gag gta aaa 11498 Arg Thr Ser Ser Phe Ala Leu Asn Leu Pro Thr Leu Pro Glu Val Lys 3775 3780 3785 3790 ttc cct gaa gtt gat gtg tta aca aaa tat tct caa cca gaa gac tcc 11546 Phe Pro Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu Asp Ser 3795 3800 3805 ttg att ccc ttt ttt gag ata acc gtg cct gaa tct cag tta act gtg 11594 Leu Ile Pro Phe Phe Glu Ile Thr Val Pro Glu Ser Gln Leu Thr Val 3810 3815 3820 tcc cag ttc acg ctt cca aaa agt gtt tca gat ggc att gct gct ttg 11642 Ser Gln Phe Thr Leu Pro Lys Ser Val Ser Asp Gly Ile Ala Ala Leu 3825 3830 3835 gat cta aat gca gta gcc aac aag atc gca gac ttt gag ttg ccc acc 11690 Asp Leu Asn Ala Val Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr 3840 3845 3850 atc atc gtg cct gag cag acc att gag att ccc tcc att aag ttc tct 11738 Ile Ile Val Pro Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser 3855 3860 3865 3870 gta cct gct gga att gtc att cct tcc ttt caa gca ctg act gca cgc 11786 Val Pro Ala Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg 3875 3880 3885 ttt gag gta gac tct ccc gtg tat aat gcc act tgg agt gcc agt ttg 11834 Phe Glu Val Asp Ser Pro Val Tyr Asn Ala Thr Trp Ser Ala Ser Leu 3890 3895 3900 aaa aac aaa gca gat tat gtt gaa aca gtc ctg gat tcc aca tgc agc 11882 Lys Asn Lys Ala Asp Tyr Val Glu Thr Val Leu Asp Ser Thr Cys Ser 3905 3910 3915 tca acc gta cag ttc cta gaa tat gaa cta aat gtt ttg gga aca cac 11930 Ser Thr Val Gln Phe Leu Glu Tyr Glu Leu Asn Val Leu Gly Thr His 3920 3925 3930 aaa atc gaa gat ggt acg tta gcc tct aag act aaa gga aca ctt gca 11978 Lys Ile Glu Asp Gly Thr Leu Ala Ser Lys Thr Lys Gly Thr Leu Ala 3935 3940 3945 3950 cac cgt gac ttc agt gca gaa tat gaa gaa gat ggc aaa ttt gaa gga 12026 His Arg Asp Phe Ser Ala Glu Tyr Glu Glu Asp Gly Lys Phe Glu Gly 3955 3960 3965 ctt cag gaa tgg gaa gga aaa gcg cac ctc aat atc aaa agc cca gcg 12074 Leu Gln Glu Trp Glu Gly Lys Ala His Leu Asn Ile Lys Ser Pro Ala 3970 3975 3980 ttc acc gat ctc cat ctg cgc tac cag aaa gac aag aaa ggc atc tcc 12122 Phe Thr Asp Leu His Leu Arg Tyr Gln Lys Asp Lys Lys Gly Ile Ser 3985 3990 3995 acc tca gca gcc tcc cca gcc gta ggc acc gtg ggc atg gat atg gat 12170 Thr Ser Ala Ala Ser Pro Ala Val Gly Thr Val Gly Met Asp Met Asp 4000 4005 4010 gaa gat gac gac ttt tct aaa tgg aac ttc tac tac agc cct cag tcc 12218 Glu Asp Asp Asp Phe Ser Lys Trp Asn Phe Tyr Tyr Ser Pro Gln Ser 4015 4020 4025 4030 tct cca gat aaa aaa ctc acc ata ttc aaa act gag ttg agg gtc cgg 12266 Ser Pro Asp Lys Lys Leu Thr Ile Phe Lys Thr Glu Leu Arg Val Arg 4035 4040 4045 gaa tct gat gag gaa act cag atc aaa gtt aat tgg gaa gaa gag gca 12314 Glu Ser Asp Glu Glu Thr Gln Ile Lys Val Asn Trp Glu Glu Glu Ala 4050 4055 4060 gct tct ggc ttg cta acc tct ctg aaa gac aac gtg ccc aag gcc aca 12362 Ala Ser Gly Leu Leu Thr Ser Leu Lys Asp Asn Val Pro Lys Ala Thr 4065 4070 4075 ggg gtc ctt tat gat tat gtc aac aag tac cac tgg gaa cac aca ggg 12410 Gly Val Leu Tyr Asp Tyr Val Asn Lys Tyr His Trp Glu His Thr Gly 4080 4085 4090 ctc acc ctg aga gaa gtg tct tca aag ctg aga aga aat ctg cag aac 12458 Leu Thr Leu Arg Glu Val Ser Ser Lys Leu Arg Arg Asn Leu Gln Asn 4095 4100 4105 4110 aat gct gag tgg gtt tat caa ggg gcc att agg caa att gat gat atc 12506 Asn Ala Glu Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile 4115 4120 4125 gac gtg agg ttc cag aaa gca gcc agt ggc acc act ggg acc tac caa 12554 Asp Val Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln 4130 4135 4140 gag tgg aag gac aag gcc cag aat ctg tac cag gaa ctg ttg act cag 12602 Glu Trp Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln 4145 4150 4155 gaa ggc caa gcc agt ttc cag gga ctc aag gat aac gtg ttt gat ggc 12650 Glu Gly Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp Gly 4160 4165 4170 ttg gta cga gtt act caa aaa ttc cat atg aaa gtc aag cat ctg att 12698 Leu Val Arg Val Thr Gln Lys Phe His Met Lys Val Lys His Leu Ile 4175 4180 4185 4190 gac tca ctc att gat ttt ctg aac ttc ccc aga ttc cag ttt ccg ggg 12746 Asp Ser Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly 4195 4200 4205 aaa cct ggg ata tac act agg gag gaa ctt tgc act atg ttc ata agg 12794 Lys Pro Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr Met Phe Ile Arg 4210 4215 4220 gag gta ggg acg gta ctg tcc cag gta tat tcg aaa gtc cat aat ggt 12842 Glu Val Gly Thr Val Leu Ser Gln Val Tyr Ser Lys Val His Asn Gly 4225 4230 4235 tca gaa ata ctg ttt tcc tat ttc caa gac cta gtg att aca ctt cct 12890 Ser Glu Ile Leu Phe Ser Tyr Phe Gln Asp Leu Val Ile Thr Leu Pro 4240 4245 4250 ttc gag tta agg aaa cat aaa cta ata gat gta atc tcg atg tat agg 12938 Phe Glu Leu Arg Lys His Lys Leu Ile Asp Val Ile Ser Met Tyr Arg 4255 4260 4265 4270 gaa ctg ttg aaa gat tta tca aaa gaa gcc caa gag gta ttt aaa gcc 12986 Glu Leu Leu Lys Asp Leu Ser Lys Glu Ala Gln Glu Val Phe Lys Ala 4275 4280 4285 att cag tct ctc aag acc aca gag gtg cta cgt aat ctt cag gac ctt 13034 Ile Gln Ser Leu Lys Thr Thr Glu Val Leu Arg Asn Leu Gln Asp Leu 4290 4295 4300 tta caa ttc att ttc caa cta ata gaa gat aac att aaa cag ctg aaa 13082 Leu Gln Phe Ile Phe Gln Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys 4305 4310 4315 gag atg aaa ttt act tat ctt att aat tat atc caa gat gag atc aac 13130 Glu Met Lys Phe Thr Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn 4320 4325 4330 aca atc ttc aat gat tat atc cca tat gtt ttt aaa ttg ttg aaa gaa 13178 Thr Ile Phe Asn Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu 4335 4340 4345 4350 aac cta tgc ctt aat ctt cat aag ttc aat gaa ttt att caa aac gag 13226 Asn Leu Cys Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn Glu 4355 4360 4365 ctt cag gaa gct tct caa gag tta cag cag atc cat caa tac att atg 13274 Leu Gln Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr Ile Met 4370 4375 4380 gcc ctt cgt gaa gaa tat ttt gat cca agt ata gtt ggc tgg aca gtg 13322 Ala Leu Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly Trp Thr Val 4385 4390 4395 aaa tat tat gaa ctt gaa gaa aag ata gtc agt ctg atc aag aac ctg 13370 Lys Tyr Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu Ile Lys Asn Leu 4400 4405 4410 tta gtt gct ctt aag gac ttc cat tct gaa tat att gtc agt gcc tct 13418 Leu Val Ala Leu Lys Asp Phe His Ser Glu Tyr Ile Val Ser Ala Ser 4415 4420 4425 4430 aac ttt act tcc caa ctc tca agt caa gtt gag caa ttt ctg cac aga 13466 Asn Phe Thr Ser Gln Leu Ser Ser Gln Val Glu Gln Phe Leu His Arg 4435 4440 4445 aat att cag gaa tat ctt agc atc ctt acc gat cca gat gga aaa ggg 13514 Asn Ile Gln Glu Tyr Leu Ser Ile Leu Thr Asp Pro Asp Gly Lys Gly 4450 4455 4460 aaa gag aag att gca gag ctt tct gcc act gct cag gaa ata att aaa 13562 Lys Glu Lys Ile Ala Glu Leu Ser Ala Thr Ala Gln Glu Ile Ile Lys 4465 4470 4475 agc cag gcc att gcg acg aag aaa ata att tct gat tac cac cag cag 13610 Ser Gln Ala Ile Ala Thr Lys Lys Ile Ile Ser Asp Tyr His Gln Gln 4480 4485 4490 ttt aga tat aaa ctg caa gat ttt tca gac caa ctc tct gat tac tat 13658 Phe Arg Tyr Lys Leu Gln Asp Phe Ser Asp Gln Leu Ser Asp Tyr Tyr 4495 4500 4505 4510 gaa aaa ttt att gct gaa tcc aaa aga ttg att gac ctg tcc att caa 13706 Glu Lys Phe Ile Ala Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln 4515 4520 4525 aac tac cac aca ttt ctg ata tac atc acg gag tta ctg aaa aag ctg 13754 Asn Tyr His Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu 4530 4535 4540 caa tca acc aca gtc atg aac ccc tac atg aag ctt gct cca gga gaa 13802 Gln Ser Thr Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu 4545 4550 4555 ctt act atc atc ctc taa ttttttaaaa gaaatcttca tttattcttc 13850 Leu Thr Ile Ile Leu * 4560 ttttccaatt gaactttcac atagcacaga aaaaattcaa actgcctata ttgataaaac 13910 catacagtga gccagccttg cagtaggcag tagactataa gcagaagcac atatgaactg 13970 gacctgcacc aaagctggca ccagggctcg gaaggtctct gaactcagaa ggatggcatt 14030 ttttgcaagt taaagaaaat caggatctga gttattttgc taaacttggg ggaggaggaa 14090 caaataaatg gagtctttat tgtgtatcat a 14121 546 21 DNA Artificial Sequence PCR Primer 546 tgctaaaggc acatatggcc t 21 547 23 DNA Artificial Sequence PCR Primer 547 ctcaggttgg actctccatt gag 23 548 28 DNA Artificial Sequence PCR Probe 548 cttgtcagag ggatcctaac actggccg 28 549 20 DNA Artificial Sequence Antisense Oligonucleotide 549 ccgcaggtcc cggtgggaat 20 550 20 DNA Artificial Sequence Antisense Oligonucleotide 550 accgagaagg gcactcagcc 20 551 20 DNA Artificial Sequence Antisense Oligonucleotide 551 gcctcggcct cgcggccctg 20 552 20 DNA Artificial Sequence Antisense Oligonucleotide 552 tccatcgcca gctgcggtgg 20 553 20 DNA Artificial Sequence Antisense Oligonucleotide 553 cagcgccagc agcgccagca 20 554 20 DNA Artificial Sequence Antisense Oligonucleotide 554 gcccgccagc agcagcagca 20 555 20 DNA Artificial Sequence Antisense Oligonucleotide 555 cttgaatcag cagtcccagg 20 556 20 DNA Artificial Sequence Antisense Oligonucleotide 556 cttcagcaag gctttgccct 20 557 20 DNA Artificial Sequence Antisense Oligonucleotide 557 tttctgttgc cacattgccc 20 558 20 DNA Artificial Sequence Antisense Oligonucleotide 558 ggaagaggtg ttgctccttg 20 559 20 DNA Artificial Sequence Antisense Oligonucleotide 559 tgtgctacca tcccatactt 20 560 20 DNA Artificial Sequence Antisense Oligonucleotide 560 tcaaatgcga ggcccatctt 20 561 20 DNA Artificial Sequence Antisense Oligonucleotide 561 ggacacctca atcagctgtg 20 562 20 DNA Artificial Sequence Antisense Oligonucleotide 562 tcagggccac caggtaggtg 20 563 20 DNA Artificial Sequence Antisense Oligonucleotide 563 gtaatcttca tccccagtgc 20 564 20 DNA Artificial Sequence Antisense Oligonucleotide 564 tgctccatgg tttggcccat 20 565 20 DNA Artificial Sequence Antisense Oligonucleotide 565 gcagccagtc gcttatctcc 20 566 20 DNA Artificial Sequence Antisense Oligonucleotide 566 gtatagccaa agtggtccac 20 567 20 DNA Artificial Sequence Antisense Oligonucleotide 567 cccaggagct ggaggtcatg 20 568 20 DNA Artificial Sequence Antisense Oligonucleotide 568 ttgagccctt cctgatgacc 20 569 20 DNA Artificial Sequence Antisense Oligonucleotide 569 atctggaccc cactcctagc 20 570 20 DNA Artificial Sequence Antisense Oligonucleotide 570 cagacccgac tcgtggaaga 20 571 20 DNA Artificial Sequence Antisense Oligonucleotide 571 gccctcagta gattcatcat 20 572 20 DNA Artificial Sequence Antisense Oligonucleotide 572 gccatgccac cctcttggaa 20 573 20 DNA Artificial Sequence Antisense Oligonucleotide 573 aacccacgtg ccggaaagtc 20 574 20 DNA Artificial Sequence Antisense Oligonucleotide 574 actcccagat gccttctgaa 20 575 20 DNA Artificial Sequence Antisense Oligonucleotide 575 atgtggtaac gagcccgaag 20 576 20 DNA Artificial Sequence Antisense Oligonucleotide 576 ggcgtagaga cccatcacat 20 577 20 DNA Artificial Sequence Antisense Oligonucleotide 577 gtgttaggat ccctctgaca 20 578 20 DNA Artificial Sequence Antisense Oligonucleotide 578 cccagtgata gctctgtgag 20 579 20 DNA Artificial Sequence Antisense Oligonucleotide 579 atttcagcat atgagcccat 20 580 20 DNA Artificial Sequence Antisense Oligonucleotide 580 ccctgaacct tagcaacagt 20 581 20 DNA Artificial Sequence Antisense Oligonucleotide 581 gctgaagcca gcccagcgat 20 582 20 DNA Artificial Sequence Antisense Oligonucleotide 582 acagctgccc agtatgttct 20 583 20 DNA Artificial Sequence Antisense Oligonucleotide 583 cccaataaga tttataacaa 20 584 20 DNA Artificial Sequence Antisense Oligonucleotide 584 tggcctacca gagacaggta 20 585 20 DNA Artificial Sequence Antisense Oligonucleotide 585 tcatacgttt agcccaatct 20 586 20 DNA Artificial Sequence Antisense Oligonucleotide 586 gcatggtccc aaggatggtc 20 587 20 DNA Artificial Sequence Antisense Oligonucleotide 587 agtgatggaa gctgcgatac 20 588 20 DNA Artificial Sequence Antisense Oligonucleotide 588 atgagcatca tgcctcccag 20 589 20 DNA Artificial Sequence Antisense Oligonucleotide 589 gaacacatag ccgaatgccg 20 590 20 DNA Artificial Sequence Antisense Oligonucleotide 590 gtggtgccct ctaatttgta 20 591 20 DNA Artificial Sequence Antisense Oligonucleotide 591 cccgagaaag aaccgaaccc 20 592 20 DNA Artificial Sequence Antisense Oligonucleotide 592 tgccctgcag cttcactgaa 20 593 20 DNA Artificial Sequence Antisense Oligonucleotide 593 gaaatcccat aagctcttgt 20 594 20 DNA Artificial Sequence Antisense Oligonucleotide 594 agaagctgcc tcttcttccc 20 595 20 DNA Artificial Sequence Antisense Oligonucleotide 595 tcagggtgag ccctgtgtgt 20 596 20 DNA Artificial Sequence Antisense Oligonucleotide 596 ctaatggccc cttgataaac 20 597 20 DNA Artificial Sequence Antisense Oligonucleotide 597 acgttatcct tgagtccctg 20 598 20 DNA Artificial Sequence Antisense Oligonucleotide 598 tatatcccag gtttccccgg 20 599 20 DNA Artificial Sequence Antisense Oligonucleotide 599 acctgggaca gtaccgtccc 20 600 20 DNA Artificial Sequence Antisense Oligonucleotide 600 ctgcctactg caaggctggc 20 601 20 DNA Artificial Sequence Antisense Oligonucleotide 601 agagaccttc cgagccctgg 20 602 20 DNA Artificial Sequence Antisense Oligonucleotide 602 atgatacaca ataaagactc 20 603 2354 DNA Mus musculus allele (0)...(0) 603 gaattccaac ttcctcacct ctcacataca attgaaatac ctgcttttgg caaactgcat 60 agcatcctta agatccaatc tcctctcttt atattagatg ctaatgccaa catacagaat 120 gtaacaactt cagggaacaa agcagagatt gtggcttctg tcactgctaa aggagagtcc 180 caatttgaag ctctcaattt tgattttcaa gcacaagctc aattcctgga gttaaatcct 240 catcctccag tcctgaagga atccatgaac ttctccagta agcatgtgag aatggagcat 300 gagggtgaga tagtatttga tggaaaggcc attgagggga aatcagacac agtcgcaagt 360 ttacacacag agaaaaatga agtagagttt aataatggta tgactgtcaa agtaaacaat 420 cagctcaccc ttgacagtca cacaaagtac ttccacaagt tgagtgttcc taggctggac 480 ttctccagta aggcttctct taataatgaa atcaagacac tattagaagc tggacatgtg 540 gcattgacat cttcagggac agggtcatgg aactgggcct gtcccaactt ctcggatgaa 600 ggcatacatt cgtcccaaat tagctttact gtggatggtc ccattgcttt tgttggacta 660 tccaataaca taaatggcaa acacttacgg gtcatccaaa aactgactta tgaatctggc 720 ttcctcaact attctaagtt tgaagttgag tcaaaagttg aatctcagca cgtgggctcc 780 agcattctaa cagccaatgg tcgggcactg ctcaaggacg caaaggcaga aatgactggt 840 gagcacaatg ccaacttaaa tggaaaagtt attggaactt tgaaaaattc tctcttcttt 900 tcagcacaac catttgagat tactgcatcc acaaataatg aaggaaattt gaaagtgggt 960 tttccactaa agctgactgg gaaaatagac ttcctgaata actatgcatt gtttctgagt 1020 ccccgtgccc aacaagcaag ctggcaagcg agtaccagat tcaatcagta caaatacaat 1080 caaaactttt ctgctataaa caatgaacac aacatagaag ccagtatagg aatgaatgga 1140 gatgccaacc tggatttctt aaacatacct ttaacaattc ctgaaattaa cttgccttac 1200 acggagttca aaactccctt actgaaggat ttctccatat gggaagaaac aggcttgaaa 1260 gaatttttga agacaacaaa gcaatcattt gatttgagtg taaaggctca atataaaaag 1320 aacagtgaca agcattccat tgttgtccct ctgggtatgt tttatgaatt tattctcaac 1380 aatgtcaatt cgtgggacag aaaatttgag aaagtcagaa acaatgcttt acattttctt 1440 accacctcct ataatgaagc aaaaattaag gttgataagt acaaaactga aaattccctt 1500 aatcagccct ctgggacctt tcaaaatcat ggctacacta tcccagttgt caacattgaa 1560 gtatctccat ttgctgtaga gacactggct tccaggcatg tgatccccac agcaataagc 1620 accccaagtg tcacaatccc tggtcctaac atcatggtgc cttcatacaa gttagtgctg 1680 ccacccctgg agttgccagt tttccatggt cctgggaatc tattcaagtt tttcctccca 1740 gatttcaagg gattcaacac tattgacaat atttatattc cagccatggg caactttacc 1800 tatgactttt cttttaaatc aagtgtcatc acactgaata ccaatgctgg actttataac 1860 caatcagata tcgttgccca tttcctttct tcctcttcat ttgtcactga cgccctgcag 1920 tacaaattag agggaacatc acgtctgatg cgaaaaaggg gattgaaact agccacagct 1980 gtctctctaa ctaacaaatt tgtaaagggc agtcatgaca gcaccattag tttaaccaag 2040 aaaaacatgg aagcatcagt gagaacaact gccaacctcc atgctcccat attctcaatg 2100 aacttcaagc aggaacttaa tggaaatacc aagtcaaaac ccactgtttc atcatccatt 2160 gaactaaact atgacttcaa ttcctcaaag ctgcactcta ctgcaacagg aggcattgat 2220 cacaagttca gcttagaaag tctcacttcc tacttttcca ttgagtcatt caccaaagga 2280 aatatcaaga gttccttcct ttctcaggaa tattcaggaa gtgttgccaa tgaagccaat 2340 gtatatctga attc 2354 604 19 DNA Artificial Sequence PCR Primer 604 cgtgggctcc agcattcta 19 605 21 DNA Artificial Sequence PCR Primer 605 agtcatttct gcctttgcgt c 21 606 22 DNA Artificial Sequence PCR Probe 606 ccaatggtcg ggcactgctc aa 22 607 20 DNA Artificial Sequence Antisense Oligonucleotide 607 attgtatgtg agaggtgagg 20 608 20 DNA Artificial Sequence Antisense Oligonucleotide 608 gaggagattg gatcttaagg 20 609 20 DNA Artificial Sequence Antisense Oligonucleotide 609 cttcaaattg ggactctcct 20 610 20 DNA Artificial Sequence Antisense Oligonucleotide 610 tccaggaatt gagcttgtgc 20 611 20 DNA Artificial Sequence Antisense Oligonucleotide 611 ttcaggactg gaggatgagg 20 612 20 DNA Artificial Sequence Antisense Oligonucleotide 612 tctcaccctc atgctccatt 20 613 20 DNA Artificial Sequence Antisense Oligonucleotide 613 tgactgtcaa gggtgagctg 20 614 20 DNA Artificial Sequence Antisense Oligonucleotide 614 gtccagccta ggaacactca 20 615 20 DNA Artificial Sequence Antisense Oligonucleotide 615 atgtcaatgc cacatgtcca 20 616 20 DNA Artificial Sequence Antisense Oligonucleotide 616 ttcatccgag aagttgggac 20 617 20 DNA Artificial Sequence Antisense Oligonucleotide 617 atttgggacg aatgtatgcc 20 618 20 DNA Artificial Sequence Antisense Oligonucleotide 618 agttgaggaa gccagattca 20 619 20 DNA Artificial Sequence Antisense Oligonucleotide 619 ttcccagtca gctttagtgg 20 620 20 DNA Artificial Sequence Antisense Oligonucleotide 620 agcttgcttg ttgggcacgg 20 621 20 DNA Artificial Sequence Antisense Oligonucleotide 621 cctatactgg cttctatgtt 20 622 20 DNA Artificial Sequence Antisense Oligonucleotide 622 tgaactccgt gtaaggcaag 20 623 20 DNA Artificial Sequence Antisense Oligonucleotide 623 gagaaatcct tcagtaaggg 20 624 20 DNA Artificial Sequence Antisense Oligonucleotide 624 caatggaatg cttgtcactg 20 625 20 DNA Artificial Sequence Antisense Oligonucleotide 625 gcttcattat aggaggtggt 20 626 20 DNA Artificial Sequence Antisense Oligonucleotide 626 acaactggga tagtgtagcc 20 627 20 DNA Artificial Sequence Antisense Oligonucleotide 627 gttaggacca gggattgtga 20 628 20 DNA Artificial Sequence Antisense Oligonucleotide 628 accatggaaa actggcaact 20 629 20 DNA Artificial Sequence Antisense Oligonucleotide 629 tgggaggaaa aacttgaata 20 630 20 DNA Artificial Sequence Antisense Oligonucleotide 630 tgggcaacga tatctgattg 20 631 20 DNA Artificial Sequence Antisense Oligonucleotide 631 ctgcagggcg tcagtgacaa 20 632 20 DNA Artificial Sequence Antisense Oligonucleotide 632 gcatcagacg tgatgttccc 20 633 20 DNA Artificial Sequence Antisense Oligonucleotide 633 cttggttaaa ctaatggtgc 20 634 20 DNA Artificial Sequence Antisense Oligonucleotide 634 atgggagcat ggaggttggc 20 635 20 DNA Artificial Sequence Antisense Oligonucleotide 635 aatggatgat gaaacagtgg 20 636 20 DNA Artificial Sequence Antisense Oligonucleotide 636 atcaatgcct cctgttgcag 20 637 20 DNA Artificial Sequence Antisense Oligonucleotide 637 ggaagtgaga ctttctaagc 20 638 20 DNA Artificial Sequence Antisense Oligonucleotide 638 aggaaggaac tcttgatatt 20 639 20 DNA Artificial Sequence Antisense Oligonucleotide 639 attggcttca ttggcaacac 20 640 20 DNA Artificial Sequence Antisense Oligonucleotide 640 aggtgaggaa gttggaattc 20 641 20 DNA Artificial Sequence Antisense Oligonucleotide 641 ttgttccctg aagttgttac 20 642 20 DNA Artificial Sequence Antisense Oligonucleotide 642 gttcatggat tccttcagga 20 643 20 DNA Artificial Sequence Antisense Oligonucleotide 643 atgctccatt ctcacatgct 20 644 20 DNA Artificial Sequence Antisense Oligonucleotide 644 tgcgactgtg tctgatttcc 20 645 20 DNA Artificial Sequence Antisense Oligonucleotide 645 gtccctgaag atgtcaatgc 20 646 20 DNA Artificial Sequence Antisense Oligonucleotide 646 aggcccagtt ccatgaccct 20 647 20 DNA Artificial Sequence Antisense Oligonucleotide 647 ggagcccacg tgctgagatt 20 648 20 DNA Artificial Sequence Antisense Oligonucleotide 648 cgtccttgag cagtgcccga 20 649 20 DNA Artificial Sequence Antisense Oligonucleotide 649 cccatatgga gaaatccttc 20 650 20 DNA Artificial Sequence Antisense Oligonucleotide 650 catgcctgga agccagtgtc 20 651 20 DNA Artificial Sequence Antisense Oligonucleotide 651 gtgttgaatc ccttgaaatc 20 652 20 DNA Artificial Sequence Antisense Oligonucleotide 652 ggtaaagttg cccatggctg 20 653 20 DNA Artificial Sequence Antisense Oligonucleotide 653 gttataaagt ccagcattgg 20 654 20 DNA Artificial Sequence Antisense Oligonucleotide 654 catcagacgt gatgttccct 20 655 20 DNA Artificial Sequence Antisense Oligonucleotide 655 tggctagttt caatcccctt 20 656 20 DNA Artificial Sequence Antisense Oligonucleotide 656 ctgtcatgac tgccctttac 20 657 20 DNA Artificial Sequence Antisense Oligonucleotide 657 gcttgaagtt cattgagaat 20 658 20 DNA Artificial Sequence Antisense Oligonucleotide 658 ttcctgagaa aggaaggaac 20 659 20 DNA Artificial Sequence Antisense Oligonucleotide 659 tcagatatac attggcttca 20 660 20 DNA Artificial Sequence Antisense Oligonucleotide 660 tcgatctcct tttatgcccg 20 661 1105 DNA Homo sapiens CDS (141)...(728) 661 gggcgggtag tcgaccgtgt ccgcgcgcct gggagacgct gcctcggccc ggacgcgccc 60 gcgcccccgc ggctggaggg tggtcgccac tgggacactg tgaaccagga gtgagtcgga 120 gctgccgcgc tgcccaggcc atg gac tgt gag gtc aac aac ggt tcc agc ctc 173 Met Asp Cys Glu Val Asn Asn Gly Ser Ser Leu 1 5 10 agg gat gag tgc atc aca aac cta ctg gtg ttt ggc ttc ctc caa agc 221 Arg Asp Glu Cys Ile Thr Asn Leu Leu Val Phe Gly Phe Leu Gln Ser 15 20 25 tgt tct gac aac agc ttc cgc aga gag ctg gac gca ctg ggc cac gag 269 Cys Ser Asp Asn Ser Phe Arg Arg Glu Leu Asp Ala Leu Gly His Glu 30 35 40 ctg cca gtg ctg gct ccc cag tgg gag ggc tac gat gag ctg cag act 317 Leu Pro Val Leu Ala Pro Gln Trp Glu Gly Tyr Asp Glu Leu Gln Thr 45 50 55 gat ggc aac cgc agc agc cac tcc cgc ttg gga aga ata gag gca gat 365 Asp Gly Asn Arg Ser Ser His Ser Arg Leu Gly Arg Ile Glu Ala Asp 60 65 70 75 tct gaa agt caa gaa gac atc atc cgg aat att gcc agg cac ctc gcc 413 Ser Glu Ser Gln Glu Asp Ile Ile Arg Asn Ile Ala Arg His Leu Ala 80 85 90 cag gtc ggg gac agc atg gac cgt agc atc cct ccg ggc ctg gtg aac 461 Gln Val Gly Asp Ser Met Asp Arg Ser Ile Pro Pro Gly Leu Val Asn 95 100 105 ggc ctg gcc ctg cag ctc agg aac acc agc cgg tcg gag gag gac cgg 509 Gly Leu Ala Leu Gln Leu Arg Asn Thr Ser Arg Ser Glu Glu Asp Arg 110 115 120 aac agg gac ctg gcc act gcc ctg gag cag ctg ctg cag gcc tac cct 557 Asn Arg Asp Leu Ala Thr Ala Leu Glu Gln Leu Leu Gln Ala Tyr Pro 125 130 135 aga gac atg gag aag gag aag acc atg ctg gtg ctg gcc ctg ctg ctg 605 Arg Asp Met Glu Lys Glu Lys Thr Met Leu Val Leu Ala Leu Leu Leu 140 145 150 155 gcc aag aag gtg gcc agt cac acg ccg tcc ttg ctc cgt gat gtc ttt 653 Ala Lys Lys Val Ala Ser His Thr Pro Ser Leu Leu Arg Asp Val Phe 160 165 170 cac aca aca gtg aat ttt att aac cag aac cta cgc acc tac gtg agg 701 His Thr Thr Val Asn Phe Ile Asn Gln Asn Leu Arg Thr Tyr Val Arg 175 180 185 agc tta gcc aga aat ggg atg gac tga acggacagtt ccagaagtgt 748 Ser Leu Ala Arg Asn Gly Met Asp * 190 195 gactggctaa agcttgatgt ggtcacagct gtatagctgc ttccagtgta gacggagccc 808 tggcatgtca acagcgttcc tagagaagac aggctggaag atagctgtga cttctatttt 868 aaagacaatg ttaaacttat aacccacttt aaaatatcta cattaatata cttgaatgaa 928 aatgtccatt tacacgtatt tgaatggcct tcatatcatc cacacatgaa tctgcacatc 988 tgtaaatcta cacacggtgc ctttatttcc actgtgcagg ttcccactta aaaattaaat 1048 tggaaagcag gtttcaagga agtagaaaca aaatacaatt tttttggtaa aaaaaaa 1105 662 24 DNA Artificial Sequence PCR Primer 662 agaagacatc atccggaata ttgc 24 663 20 DNA Artificial Sequence PCR Primer 663 ggagggatgc tacggtccat 20 664 20 DNA Artificial Sequence PCR Probe 664 aggcacctcg cccaggtcgg 20 665 18000 DNA Homo sapiens CDS (14031)...(14243) Antisense Oligonucleotide 665 cctgggtatc caagtcgccc tggcagagaa acactgcatg agacacggcg ttagggtctg 60 gtgggagact caccacagtg ccaaggtggc tgcagtttgc ttgtgacatg ggcgtgtatc 120 tgagtgtgaa ggaagctggt ttttgtgagc tgcctcccga gctcagaggt gacagtgggc 180 actttcccca cagagacccc tgaagttgtt ccttggagaa caaagtggtg aggggcgggg 240 attccagacc ttgaggcaga agctagggtc tggtccactg ttctgtggac tgggcagtgg 300 ccctgggagg tgccgtggcc tctgtggcct gtttcctggg gtggggtctg tcttgcgctt 360 tgtctcttgt gggtgcagac tccccttcct ctgctgtgga gccggcagat ggccccggag 420 ccagatcctg gtgcctccct gtccacatgc agctcagtca tttgctcttg gtcccttcct 480 atgaaatgca cggccacaca cagccagggt ttctcctggg ctccccagag ggagagtagg 540 gtgcagcctg caacagtgca gggtccccag gcctgtgtga gcccccaggt ggggaggtgg 600 gtgatgcgca tgtcagtgct acctcctgcc acctcctctc tgcctgggca caggctttct 660 cctctgtttg ctttttattt cctatgtatt caggaaccat gtgaaattgc caatgcttgg 720 ttttgtccta caaaatggcc atttcatttg gttcaacctg atattgtgtc tacacacaca 780 cacgcacaca cacacacaca caggcaaata ctttttaaaa caggattatt ctattcacag 840 tgttctgtag aaatttgtgt tcagtctttt tttttttttt tgagacggag tctcgctctg 900 tcgcccaggt cggactgcgg actgcagtgg cgcaatctcg gctcactgca agctccgctt 960 cccgggttca cgccattctc ctgcctcagc ctcccgagta gctgggacta caggcgcccg 1020 ccaccgcgcc cggctaattt tttgtatttt tagtagagac ggggtttcac cttgttagcc 1080 aggatggtct cgatctcctg acctcatgat ccacccgcct cggcctccca aagtgctggg 1140 attacaggcg tgagccaccg cgcccggcct cagtcttttt aagacagctt actgtactga 1200 tgccgcacag atcttttttt tttttcgaga cagggtttca ctctcgccca ggctggagtg 1260 cagtggtgca atctccgctc actgcagcct ccacctcctg ggtgtaagtg atcctcctgc 1320 ttcagccccc caagtagctg ggcccacagg gcttgcatca ccacacctgg ctaattttgt 1380 atttttgtag agatggggtt tcaccatgtt ggccagactg gtcattcttt ttgagatgga 1440 gtctcgctct gtcgcccagg ctggagtgca gtggcgtgat ctcggcttac tgcaacctct 1500 ccctcccaag ttcatgccat tctcctgcct cagcctcccg agtagctggg actacaggcg 1560 cccgccacca cgcccggcta attttttgta tttttagtag agacagggtt tcaccgcatt 1620 agccagggtg gtctcgatct cctgacctca tgatccaccc gcctcggcct cccaaagtgc 1680 tgggattaca ggcatgagct actgcgtcca gccggaagat ttaatttttt aattgtcaaa 1740 tccattctct ctctctataa acattttaca ttttatgata ataaaataat ttgtgagccc 1800 acggccccgt ttccctgatg cctgaggtct tcctggggcg gcatgggagg gctgaattca 1860 ggtgcggggt cggccccagg gcactgagcg cctgggtgag tatctggaat gaggaaaaca 1920 aagcttggct cccgccaagg agaaagaaac tcaggatgcg gggctcaggc caggacctcg 1980 gctcagccgc catttctgga gcacaggcca gcttcgtcgt cctcccgagg ggtcctgacc 2040 agggcttccc aggagcggcc gcccactctg tgtgtccctt tccaggtcgc cactgggaca 2100 ctgtgaacca ggagtgagtc ggagctgccg cgctgcccag gccatggact gtgaggtcag 2160 aggccagatc ccctgcgggt gccttgtggg gggcggggtc gaggggtaag ggcctgcgtg 2220 tcccccacca cgcatccctg agggctgagg ctgagcccgc ctggccctta ccacagctcg 2280 gcacagacga accccgccca gccccttcac tgaagcaggc gggagccggg aagtcctacc 2340 tttccctgtc ctgcgccttc ctcgcactcc gcttgtggtg cagcccctcc acaccgcgcc 2400 tggggctaac tgcaagggcg agggggcttt gggtttaaga ccatttaaca gccataggct 2460 gtgggtccca gcactttggg aggccaaggc aggaggattc cttgaggcca ggaggtcgag 2520 gctacagtga gctgtgattg tgccactgca ctgcagccct gtccaaacaa acacgaaaga 2580 gatttaagaa gaagaaaggg ggcattagat aagcacttca tataattctc tcaactgtaa 2640 aagcaagaca atacttacct tgtctaacca atgccattgc tatgaggagc aaataaatca 2700 ataaaggtca aataaaagta ctgtaaactg taaggtgttt caaaaatttt ttaacccact 2760 ggatttaaat ttcccttcat agctgggcga ggtggcttag gcacataatc ccagtgactt 2820 gggaggcaga agcgagagga ttgcttgaag ccaggagttt gattgagaca aacctgggca 2880 acatagtaag accccgtctt tataaagata aaagcggtgg agttctggga ggggagcccg 2940 gagcccccgc cttcagcagg acgctccctg gatgcttcct tgtctctcct tccctttaaa 3000 tggtctgggg agagaaaaat cacagcacac gggtgctctc tcccacccgc tgcatcacat 3060 cctcctcccc tccctcctgc cgaattctgc agcctctggg cgcctcacgc tgtcctggca 3120 gcctctggga aggcatctgc gaagtctaat gccttggcac ttagtgactg tgtcgcagtt 3180 cctgagcatg gagagcaccc ggcacccagg aggttctcaa gctgccccta ctgggggtcc 3240 tttccaaagg tggggacggt gtggatttca gcgtggtggc tggagggctg aggcagtggc 3300 tcgagtttga tgttagttac ataaacagag gagattgcag gagctccccc ggccctgatc 3360 caggcttgtt gtcagtgtcc aaaagaccac tctgggtgcc actgtccctt cccacctgcc 3420 gctgctgttc cggcttcgcg ctctggcggc ctccgcaggt agaacaccac cgtcacccgc 3480 gcagcgccct gactcgccgg aggaggcgcc tgccctcccg cccgcctctc cccggccccc 3540 tcagtgaggg agggtggacg tcgccactcc cctttcttgc cttcggagtg aggaagcgga 3600 ggcagcagta cggcagcccg cccagggcca cagagctggg gtcacagcga aacactccga 3660 aactttcttt tcaattatag ggttcagcct tttttcccat cataacttta attctgtgta 3720 gatacttcta ttttttattt ttattttttt ttttgagatt gagtctctgt gtcgcccagg 3780 ctggagtgca gtggcacgat ctccgctcac tgcaggctcc gcctcccggg ttcaggccat 3840 tctcctgcct cagcctcccg agtagctggg actacaggcg cccgccacca cgcccggctc 3900 attttttgta tcttagtaaa gacggggttt caccgtgtta gccaggatgg tctcgatctc 3960 ctgacctcgt gatccgcccg tctgggcctc ccaaagtgct gggattacag gcgtgagcca 4020 ccgtgcccgg ccttattatt attatttttt tgagacgcag ttttgctctg tcgcccaggc 4080 tggagtgcag tgatgtgatc tccgctcact gccagctccg cctcccaagt tcatgccatt 4140 ctcctgcctc agcctctcga gtagctggga ctacaggcgc ccaccaccac gcccggctaa 4200 ttttttatat tttagtaaag acggggtttc accgtgttag ccaggatggt ctcgatctcc 4260 tgacctcgcg atctgcccgc ctcggcctcc catagtgctg ggattgcagg cgtgagccac 4320 cgcacctggc taatttttgt atttttagta gagatggggt ttcaccatgt tgcccaggat 4380 gttctcgacc tcttgacctc atgatccgcc cgcctcggct tcccaaagtg ctgggattac 4440 aggcgtgagc caccgcgccc ggccagcacc atcttttcct ttccactgga actgatctta 4500 ttatttttgc ctccattaga tcatttttgt aacatgtctt gcaggattta ctgtcttgat 4560 cgtttctctt aacatatttt tttcctgtga tctaaaaaga taaaaaacta tcaattcttt 4620 tatcaaaagt ggatctagag gctgggcatg gtggctcacg ccagtaatcc cagcactttg 4680 ggaggccaag gtgggcagat cacctgaggt caagagctcc agaccagcct ggccaacatg 4740 gtgaagcccc atctttacta aaaatacaaa aattagccag gcgtggtggc acgtgcctgt 4800 aaccccagct acttgggagg ctgaggcagg agaatccatt gaacctggga ggcagaggtt 4860 gcagtgagct gagatggcac cattgtactc cagcctgggc aacagaatga gactctgtct 4920 ccaaaaacaa agtggatcta gaagatcaaa aaagggcatg attccatatt ggcacagcac 4980 aagccctatt cttggaatta aatggcatcc atcttccgag cccactcctg tcctgcaggg 5040 ccggcccagc ctgtccctga ggcactggtc cagacaggag cctgtccaca cagctgtcca 5100 ctcagtgggc ccagtgcttg gcttcacggt cacttgcggc acctagacct cctctggcag 5160 gtgccattct ttcctctccc tccctgccgc ctcgagtctt tattttctgt gggatcttga 5220 gtttgataac ctgacctgct gtggtggcag caccgctctg tgtccagatt ctggatgcca 5280 atttaccaag cgcaggtcaa aaagaagtcc ttgggcagcg gctgcctgcg ttagcttctt 5340 ggggctgctg taggcggttc caagcaggag agtggcttta aacaacagat gcggatcccc 5400 tcccggttct agaggcccaa aggctggaat cccatgttgc ccggctgctt ccttctgggg 5460 cgctctcctg gctcctgtgg ctgcctctgt cttcacatgg cgtcctctct gtgtgtctct 5520 gcttaaatct ccctctcctt tctcttacaa agacaccagt cattggattt agggcccacc 5580 ctaatccaat atgacctcat cttaacttga ttacatctgt aaaaacctta ttttcaaata 5640 aggtcacatt gacaggtact tggggttagg acttgcgctt ttctttttgg gtgacacagc 5700 ttagcccagc actaactgtg tcaccaggac tgtcgcttga ggcaggaatg aagcacatcc 5760 tgtttgtaag ctgtcttgtg ccatgcggct gctccgtaca agaattgtta ggaattgatg 5820 cagtggaatt ttgcatacag tttttcctct cttcagaaac aactttggag aagtaaaggc 5880 tgaatagcaa tacacaagca ccttatttta ttttatttta gattcagggg cacgtgtaca 5940 tgtttgtcac atgggaatat tgtgcactgg tggggactgg gcttccggta tcgcatggag 6000 agggactctt tctgcgctcc cccgcccccg cctccctact gtaaagtgcc cggtgcctgc 6060 tctctccatc ttcgtgtcca tgggcaccca ttgtttagct cccacttata agtgagaaca 6120 gtcagtattt gattttctgt ttctgagtta gttcacttag ggtaatggcc tctagctcca 6180 tccgtgttgc tgcagaggac atgattttat tcttttttat ggctgcagca atacacaagc 6240 tccttatttt tatttattta tttatttatt tttgttgttt gtttgtttgt tttgagacgg 6300 agtctggctc tcgtccccca ggctggagtg caatggcgcg atctcggctc attgcaacct 6360 ccacctcccg ggttcaagcg attctcctgc ctcagcctcc caagtagctg ggactacaga 6420 cgcccgccac caggcccggc taatttttgt atttttagta gagacaaggt ttcatcatgt 6480 tggccaggct ggtctcaaac tcctgacttc gtgatccgcc cgcctcggcc tcccaaagtg 6540 ctgggattac aggcgtgagc caccgcgccc ggccaagctc cttattttaa gcattttttt 6600 tttctttttt gagacagggt ttcactttgt cacccaggtt ggagtgcagt ggtgtgatca 6660 tggctcattg cagcctcaaa cttctgggct caagtgacct tcccgcctca gtctcatgag 6720 tagctgggac tgcaggtgca tgccaccttg gctaattttt attttttgta gagatgggga 6780 tcttgttgcc aggctggtct caaattcctg ggctcaaacg atcctcctgc ctctgcctcc 6840 cagagtgccg ggattacagg catcacctag caaagcatta aaacaatttg ctgctgggtg 6900 cagtaggtca cacctgtaat cccagcactt tgagaggcca aggagttggg gggagttggg 6960 gggcgggcgg atcacgaggt caggagttcg agaccagcct gaccaacatg gtgaaacctc 7020 gtctctacta aaaatacaaa aattagccgg gcgtggtgat gcacacctgt aatcccagct 7080 actcaggaag ctgaggcggg agaatcattt gaacccagga agcggaggtt gtagtgagcc 7140 gagatcacac cactgcactc cagcctgggt gacagagcga gactccatct caaaacaaaa 7200 acaaaaacaa aaaaacaatt tgccctgtaa gaactgtcct ctaaaagttt ttggtttttc 7260 taatgaaaaa tattatggac ttagagaata gaaataaatt tctgcctaca cttccatctt 7320 ccctcccacc cttctctggc agcccaggag gtctttttgt gtgaatctgc gcagatctca 7380 gcgtccctgc ccttctttgt gttttgttct ctcttccacc ttaggtcttt ctctggtctg 7440 ggcacaccca gctgcagggc tcacctttgc ctgtaagaat acagccccca aacacagtca 7500 gtaccccaag aacagtccct gccatctctg gcggcacaga tgctggccaa gctgcagctg 7560 ccagtgctgc ccagggagct ggagagctgc cggccaagag cccagcccct ctgggtagag 7620 caggagccag tgccaccact ccctgtggga ttcggattaa ggacacaccc acccaaagta 7680 aaccaagctt ggccaaaggc aggtgcccag ctgtggtcac cactccgcag tagttactga 7740 aaatcttcca tctgcccaat accctcctga gcccgtgaag gagatgagcg gaaagaggct 7800 ccgcctgttg gaagcacagc caggaaaggt gggctcagat tgctgaagcc tgcaggggaa 7860 cttgaagaaa gcgtgccagc acaggatggc ggatgatgcc cgcatgacac tcgctcgcct 7920 ccccggaaca gcctgtggcc ttctcaccta gtgggaagct ccccagccgc gtgtttcagg 7980 aggtccagca gattcctctg cagaggaatc cctttctgca gagtcggggc tcgctccctg 8040 ccatctacgg gcagtgctgc ttaaagctgt ggctgcagac cttgcctctg cctgttgaga 8100 cctcctgcag ggccctccag cccacagggt ccctcagctc tctgggacct gtgaggctct 8160 ttgggccagc tgcaactgga gctctttgca ggaggggcct ctggcctggc tgaagtcccg 8220 gcttcctgac tcccctttcc cctcaggtca acaacggttc cagcctcagg gatgagtgca 8280 tcacaaacct actggtgttt ggcttcctcc aaagctgttc tgacaacagc ttccgcagag 8340 agctggacgc actgggccac gagctgccag tgctggctcc ccagtgggag ggctacgatg 8400 agctgcagac tgatggcaac cgcagcagcc actcccgctt gggaagaata gaggcaggta 8460 ggcggccggc cccacctcct tccccaaagc tgggcttctc tgtcgccagt aacattcagg 8520 gagcctcagg gctggaaggg acccccggga tcactctgcc tctgcagttt cagctgccac 8580 gtacgctggt atcacttaat cacttgactg gtctctactt gattccctcc agtgctgctg 8640 aactcactgc ctaccatttt tgggtgactc tgttagaaag ttcttccttt ctgttgagac 8700 agaatctcat gtactggtct tgagtccctt gtctggacca acatagaatg gtgtttttat 8760 ccaattttcc aaatgtgatt ctgatacaaa gattgcagac cacttgtctg gattatataa 8820 cccaaggggt tctcacactt ggccttgtat catttcaagg acctggagct ttaaatgctg 8880 gtgcctgcat ctcacctcca gagattctga ttggttggtc tgggcattgc tgggtctggg 8940 caaagccccc aggtggcact accggtgcgg cccctgcctc cccaagcagg cctggctgac 9000 tgtcccattg attgaggccc actggtttca cagtgacttt tgcactgtct atacctgaca 9060 tatttccttt catacattat gctccgtgat tacctataca agaacacaga agtatttgga 9120 acctcatttc caggtgagga aacccaggtc cagcaaaggg taaatgacta gctccagatc 9180 acacagcttg tggccatgtt accactggga catggggcca ggccccttct tgaggtgggc 9240 ctcagccgcc ctcccactgt agggcactga ctccaggtca ccatggtttc cagactgttc 9300 acctttcctg ttgctgatcc ctgcactctc ctccagcctc cagctccact cccctttgcc 9360 aaggggctgc ttctatggac aggggctgtc ccgagtggag gctgggggcg agtggaggct 9420 cacccacttc cagatccagc cctgcgacgc tggctttcag tagtgtgcac attggaatta 9480 cacgagaaac cttttccaaa tgcaggcctt gggccctact ccagctgcct gcatcaggct 9540 gttttagggc gggagactgc ccagaggatt ctgacgcagg tagaatccct gccctgaaag 9600 cctgcaggga tccccggacc ctggtccagg ccttccaagc tcaagggttg cactgccctc 9660 tggtggctgt gggggagacc aacagctgac ccagccttct gcctcccgcc tgtcttagat 9720 caggtgcttg aggacgtggc tggagttccc cactagaccg gggtgggggt gggggtgggg 9780 ggtgggggga ggtgtctgag aatgtctctg ccttctaatc cagccagcat atcttctggc 9840 tcgccctgaa ctgaggagaa accccagatc cctttgggaa ggtccaggaa gggcaggagt 9900 ggacaggcac agctctgctg tcagcactgc tgtgggggtg actgtagccc cagtctgccc 9960 tggtgttttt ctctcgctct tctccatgcc ggcctttgcc tctagactga gaaaccgggg 10020 ttgactcaag tggcacctgc aaaagtgatc atggcagttc acttagcctg caggtgacag 10080 ggactgtgaa tctagtccct ggcgagcctg gaaagagggg caaggtagag gctctggctg 10140 ccggggtttc tttggtgagt ccgttcactc ggctggacac agacggatca ggaaagattc 10200 ctgttgctac tcggctggtg gccagaggga gagaggacgt gtccgtaact gaagcaaggt 10260 ggataagctt cgggaacgag cgaggcacag attcggtgct gggggagtga tgaggtgctg 10320 gaggagctgg gtgctctgct ctgcagggaa tcaggaaaac tttggggctg cagctccaat 10380 tgagctgggc cttgggggtt gggtatgttt ggttccttgg aaactgggaa gagggaatgg 10440 ccatctttta agcaaaagcc cagcggctat aaatgctaca gtgaggctgg gtgcagtggt 10500 tcacgcctgt aatcccagca ctttgggagg ccaaggcagg tggatcatga ggtcaggagt 10560 tcaagaccac cctagccaag atggtgaaac cccgtctcta ctaaaaaaaa tatataaaaa 10620 ttagccaggc ggggtggcgg gtgcctgtaa tcccagctac ttgggaggct gaggtagaga 10680 attgtttgaa cccgggaagc ggaggttgca gtgagctgag attgtaccac tgcactccag 10740 cttggggaac agagtgagac tatgtcttga aaaaaaaaag aaaaaaaaaa gctacagtga 10800 gtagttgagt ttgcctagga agcgtggaag ttaagtcaga cgtactttca ggctgggtca 10860 tgacttgtca cttaagcaga gatgagcact tgagaggttt tgaagagaag tgatgtggca 10920 gccttactgc atgttccatg gacagactcc agggaggccg tgaaaccccc agagcacagc 10980 ttctaagaac gtgcccactc cttagcacgt cacttctccc aaccctgccc tgctctgagg 11040 tctgtgctgt gaaggtggcc gagtagactg gacggcaggg agtggggctg tcatcatcag 11100 atgagagcta aggggacccc caccagggtg gcggcaatgg cagagggtag gcaaaacgct 11160 tgtatttgca acataaggtg agatttgaca gctgaccgag ggtgggagca gcagccaaaa 11220 ccaaaaaagc cagagggaag ttgcaagcac agaaaaaata gaagatttaa tgggagaaat 11280 aacaatagct ggcatctatt gaacacttac tgggagctag gtacagggcc cattcattca 11340 ttcatgcaat taaaactttt tttaagaaac ggggtcttgc tctgttgccc aggctggagt 11400 gtagtggtat gatcacagct cactgcagcc ttgaattcct ggcctcaagg agtcctccca 11460 cctcagcctc ctgtgtagct gggattatag gtacgtgcgg tacacctggc tccctttaaa 11520 agttttttgt agaggcaggg cacagtggct cacacctgta atcccagcac tttgggaggc 11580 caaggcagga ggatcacaag gtcaggagtt cgagaccagc ctgaccaaca tggtgaaacc 11640 cgtctctact taaaatacaa aaattagccg ggtgtggtgg cgggcgcctg taatcccagc 11700 tactcaggag gctgaagcat gagacttgct tgaacccagg aggcgaaggt tgcagtgagc 11760 cgagatcgcg ccactgcact ccagcctggg tgacagagca agactccgtc tcaaaaaaaa 11820 aaaaaaagtt tcttgtagag gcagggcctt gctttgttgc tggtgcaatc acggctcact 11880 gcatcctcta actcctggcc ttaagcaatc ttctgtcctc agcctcccaa agcactggga 11940 ttacaggcat gcatgaccac acctggtccc tgccattgtt tattgagcac ctactgagtg 12000 ccatgtatta agtgctgggt atttgtcagt ggacaaaaca gattaaaaaa atcacagccc 12060 ttagggagct taccttctgg caggggcgtc agacaataac acagcaagtg ctgaggaaga 12120 aacggaggcg gcagggagcg tggcagttga gcgtggcctt catggagctg cgacagtggt 12180 actcgggcag gggcagcacg gaggctgtgc gccagaggag gaggactgag gggcaagggg 12240 gagagctctg gttggaaagg caggggagat tctccagggc cttgccggtg ccagtgacaa 12300 ctggggtttt cctgagacgg gactgcgagg aatgggggct ctcaggcttg agagggcaaa 12360 agtgggtctg ggatgccgtc tgcccacaga gccccttccc caacggctgc ccaggccaag 12420 gccaaccctg ttgggttgtg tggtgtgagc catgaagccg ctgccaggct tgtacctcag 12480 gcgtggtcgt gatgccccag cttcaccggc cctgcctgtg gggacgtggt gcctgtgtgc 12540 gggagcctgg gcctcagccg aggccctgag ctccggcact gcccagaacc cagctcagcg 12600 ctggtactca gcccgcccgc tgtggccctg gtggagtgga gcacgtgccc agtgggggct 12660 ggccttgtcc catcgcggac ctgtcctttc ccggggcagg gtggtgtggg agagggtatc 12720 agggacattt tctgagtctg ctctgtctct gccgcccctg cctgaacaca gattctgaaa 12780 gtcaagaaga catcatccgg aatattgcca ggcacctcgc ccaggtcggg gacagcatgg 12840 accgtagcat ccctccgggc ctggtgaacg gcctggccct gcagctcagg aacaccagcc 12900 ggtcggagga ggtgagtgag ggcctgagga ccgcgtgggc gggcaagtga gccaaggggg 12960 cctgtcccct gcctctcacc aggcagccca ctgtcccgtg aggccactca actcgtgact 13020 gtcaggtcca gaactctgac gaagtaactg gacgtagggt atggttcatt gccttgcaga 13080 agatttcagc tggttgacat cgaggaaacc tgaaccttaa atcagagtaa agagtttagg 13140 ggtaaaagcc tctaaaagat gaacgaagca tgtttggcca acagaagaaa cagacgcttc 13200 ctttggttgt agggagttta ataatggtgc cagtgagaac cgtaagccct gggagtggtg 13260 cctgctgctc tgctgagctc cttggttgga atccacacaa ctttctgagc tctaccatct 13320 gcttggcact gttggggata caagattggt ccggggcact gtgtccccag aacacttagc 13380 ggaaagaact acatcctccc aactgccaaa tgcaggcctg tagcggtagg agctgagagg 13440 agagaaagtt ccactttttc gactctacca gctgaaaatg caggcgtcct cacctcctag 13500 aaatccaatc atgcttctgt tcagtggggc cagcctgtga tgtcccagca gctgcctaga 13560 acgcaggagt ggctggcgca ctcccatgta actctgcatg tgcgccgacc gcctgacggt 13620 ccttgccagc cttgtagtct gtctagtgtc ccccaggaac ccccttcctc ctgtccattc 13680 agctaggtct gcaccaataa aatgggccta aggcgtcgca ggtggtcact agttctggac 13740 tcgaagtgcc ttgggcgcag ggatgaccca ggcttcttgt atcccatcac cgtctaacag 13800 tgggcacatg ggctcaccac acatgcgttt gcttaccgag ccccctgcag ggagtgattg 13860 cagtcttccc tttccattgc ctctcagaac tcaactgttt ctcattcttt ccgcccagca 13920 gccctggata cttaataagt actttgaagt gcttcttcat actggggact gtctttcctt 13980 tgagagggaa gagtattagt aaaccaggtt ctgtgtgccc ctctgtgcag gac cgg 14036 Asp Arg 1 aac agg gac ctg gcc act gcc ctg gag cag ctg ctg cag gcc tac cct 14084 Asn Arg Asp Leu Ala Thr Ala Leu Glu Gln Leu Leu Gln Ala Tyr Pro 5 10 15 aga gac atg gag aag gag aag acc atg ctg gtg ctg gcc ctg ctg ctg 14132 Arg Asp Met Glu Lys Glu Lys Thr Met Leu Val Leu Ala Leu Leu Leu 20 25 30 gcc aag aag gtg gcc agt cac acg ccg tcc ttg ctc cgt gat gtc ttt 14180 Ala Lys Lys Val Ala Ser His Thr Pro Ser Leu Leu Arg Asp Val Phe 35 40 45 50 cac aca aca gtg aat ttt att aac cag aac cta cgc acc tac gtg agg 14228 His Thr Thr Val Asn Phe Ile Asn Gln Asn Leu Arg Thr Tyr Val Arg 55 60 65 agc tta gcc aga aat gtaagaaccc ttgaggtcag ctccttccct gcctgccgcc 14283 Ser Leu Ala Arg Asn 70 catgcccttt tctctggaag gttgagaagc ccagcggggc ccctgcctct gatgccagca 14343 caagggttac aggctgtcct gctcgggttt ggttttgctg ttgtgagcta gaaagctgtg 14403 tgtaaaggtg acgaagagca cccagagtcc tttggagctt tagcagctta ctattggaga 14463 catgctccat tcagaggggt ggcaaaggct cacgtcacac tcctggtggg gtcctcaagg 14523 cacaagcagg tacagagtgg aaggaagggg ctggagggct cacaatgagc ttttcagacc 14583 tctcaccttg ccataaaaaa taagtgtaat gtggccagtg cggtggctca tgcctgtgat 14643 cccactgctc tgggaggcca aggcaggtgg atcacctgag gtcaggagtt ccagaccacc 14703 ctggccaaca gggtgaaagc ccgtctctac taaaatacaa aaattagccg ggcatggtgg 14763 cgcacacctg tagtcccagc tactcaggag gctgaggcag gagaactgct tgaaccctgg 14823 aggcagaggt tgcagtgaac tgagatcgca ccactgcact ttagcctggg cgacagagca 14883 agactccatc tcaaaaaaaa ggtgtaatgt gaaccaaaac gagtagtcaa aaaagggggg 14943 gaactgtctg aaatcttttc cagagcacat ctgtcccata accaggtatt acaagtcaca 15003 gtctaaaggc tgggcatggt ggctcaagcc tgtaatccca gcgatttggg aagcagaagc 15063 agtgggattg cttgaggcca ggagtttgag acaaaactga gcaacatggc gagaccctgt 15123 ctctaaaaaa tttataaaaa taattagctg agggccaggc gcggtggctc acgcctgtaa 15183 tcccagcact ttgggaggcc aaggcaggcg gatcatgaag tcaggagttc aagaccagcc 15243 tggccaagat ggtgaaaccc cgtttctact aaaaatacaa aaaaaattag ctgggtgtgg 15303 tggcgggcgc ctgtaatccc agctactcag gaggctaagg caggagaatc gcttgaaccc 15363 tggtggcaga ggttgcagtg agccgcaatc acgccactgc actccagcct ggatgatggg 15423 gtaagactgt ctcaaaaaaa aaaaaaatta gctgagcatg gtggcgtacg cctgtagttc 15483 acgccgtcat ggaggttgag gcagctcctc aggaggctgg ggcagaagga tctctttgct 15543 tgagcccagg agttcaaggc tgcagtgagc tgattgtgcc actgcactcc agcctgaaca 15603 aaaacaagac ctgtctctaa aaacaaacat acagtgttca caatgctgcc caagaagggc 15663 cagtttttgc agctgccccc atgtagcaaa atctggtgct tctgtttcat agacccaaat 15723 ggaaattaag tggatgtgtc ttatttgtaa atttaaaaat attagcgaat gtttgggaat 15783 tttttttttt tttttttttg agacagaatt ttgctcttgt tgcccaggct ggagtgcaat 15843 ggcacgatct cagctcacca caacctctgc ctcccaggtt caagcgattc tcctgcctca 15903 gccccccaag aagctgggat tacaggcaca caccaccatg accggctaat tttgtatttt 15963 tagtagagat gaggtttctc ccatgttagg ctggtctcga actcccaacc tcaggtgatc 16023 cgcccacctc ggcctcccaa agtgctggga ttacaggcgt gagccactgc gcccggccta 16083 atgtttggga ttttatgaca tgtcagaagc attacttcag gctttggttt ttaagtaaaa 16143 tagcatctaa tcctctactg agaactcata agaaaacatt ccttatatgc tgtggtcttc 16203 agttatacaa gcattttaaa aacaggagaa tgaatataaa tcttaaatca ggcattaaac 16263 ccagctgaat tgttggaagg aggtaagcct gagaccattc ctggacagct tttaccaaca 16323 cccatgtaaa gggggaaagg gtgggcaaga cgtgtgcagc agtctgtatg gacagcttac 16383 cagagactga gggctgaggc agaatcgtga ttcctctgac ccagcagggg cctcctgaca 16443 ccgtcagtgc cttggagatg tgaataccca cctcaccgcc tgaacggcct gtttttgcag 16503 ttgcccccat gtagcaaaaa gtaggatgca cggataggac ttcaggggtc tggagaacat 16563 gtttttgcat aaaccccagc tttgctctac tgtggcacag agctctggag cctggtttgt 16623 gaatgagcct agctgattct ggctttttct cctttcttgc tctaggggat ggactgaacg 16683 gacagttcca gaagtgtgac tggctaaagc tcgatgtggt cacagctgta tagctgcttc 16743 cagtgtagac ggagccctgg catgtcaaca gcgttcctag agaagacagg ctggaagata 16803 gctgtgactt ctattttaaa gacaatgtta aacttataac ccactttaaa atatctacat 16863 taatatactt gaatgaaaat gtccatttac acgtatttga atggccttca tatcatccac 16923 acatgaatct gcacatctgt aaatctacac acggtgcctt tatttccact gtgcaggttc 16983 ccacttaaaa attaaattgg aaagcaggtt tcaaggaagt agaaacaaaa tacaattttt 17043 ttggtaaaaa aaaattactg tttattaaag tacaaccata gaggatggtc ttacagcagg 17103 cagtatcctg tttgaggaaa gcaagaatca gagaaggaac atacccctta caaatgaaaa 17163 attccactca aaatagggac tatctatctt aatactaagg aaccaacaat cttcctgttt 17223 aaaaaaccac atggcacaga gattctgaac taaagtgctg cactcaaatg atgggaagtc 17283 cggccccagt acacaggggc ttgacttttt caacttcgtt tcctttgttg gagtcaaaaa 17343 gaaccacttg tggttctaaa aggtgtgaag gtgatttaag ggcccaggtc agccactgtt 17403 tgtttacaaa atcaggtaac taactgcata cactttttct ctttccatga catcaagact 17463 ttgctaaaga catgaagcca cgggtgccag aagctactgc gatgccccgg gagttagccc 17523 cctggtaata gctgtaaact tccaatttct agccatacgc tcagctcatc catgcctcag 17583 aagtgcatct ggagagaaca ggtttctaag cataaaagat gaaagagcag ttggactttt 17643 taaaaattca gcaaagtggt tccctctctt agggacagtc aaaaccaagt cacttaggta 17703 gtaccaaaat aaataaggaa aagcttagct ttagaaacag tgcaacactg gtctgctgtt 17763 ccagtggtaa gctatgtccc aggaatcagt ttaaaagcac gacagtggat gctgggtcca 17823 tatcacacac attgctgtga acaggaaact cctgtgacca caacatgagg ccactggaga 17883 cgcatatgag taagggcact gacggactca tgatttcttc ttaccagatg ctttcctgtt 17943 ctttaagagt ttaaaatcat cagaaaggaa aaacaaactc tatattgttc agcatgc 18000 666 20 DNA Artificial Sequence Antisense Oligonucleotide 666 ctttcagaat ctgcctctat 20 667 20 DNA Artificial Sequence Antisense Oligonucleotide 667 agtccatccc atttctggct 20 668 20 DNA Artificial Sequence Antisense Oligonucleotide 668 actgtggtga gtctcccacc 20 669 20 DNA Artificial Sequence Antisense Oligonucleotide 669 agtgtcccag tggcgacctg 20 670 20 DNA Artificial Sequence Antisense Oligonucleotide 670 cacagtccat ggcctgggca 20 671 20 DNA Artificial Sequence Antisense Oligonucleotide 671 ctccgcttcc tcactccgaa 20 672 20 DNA Artificial Sequence Antisense Oligonucleotide 672 tactcgggag gctgaggcag 20 673 20 DNA Artificial Sequence Antisense Oligonucleotide 673 ccgtctttac taagatacaa 20 674 20 DNA Artificial Sequence Antisense Oligonucleotide 674 tcaagacagt aaatcctgca 20 675 20 DNA Artificial Sequence Antisense Oligonucleotide 675 ctttttagat cacaggaaaa 20 676 20 DNA Artificial Sequence Antisense Oligonucleotide 676 gccatttaat tccaagaata 20 677 20 DNA Artificial Sequence Antisense Oligonucleotide 677 ggcccactga gtggacagct 20 678 20 DNA Artificial Sequence Antisense Oligonucleotide 678 gcatctgttg tttaaagcca 20 679 20 DNA Artificial Sequence Antisense Oligonucleotide 679 acggagcagc cgcatggcac 20 680 20 DNA Artificial Sequence Antisense Oligonucleotide 680 ggtttcacca tgttggtcag 20 681 20 DNA Artificial Sequence Antisense Oligonucleotide 681 tctcggctca ctacaacctc 20 682 20 DNA Artificial Sequence Antisense Oligonucleotide 682 agggacgctg agatctgcgc 20 683 20 DNA Artificial Sequence Antisense Oligonucleotide 683 ggtctcaaca ggcagaggca 20 684 20 DNA Artificial Sequence Antisense Oligonucleotide 684 atccctgagg ctggaaccgt 20 685 20 DNA Artificial Sequence Antisense Oligonucleotide 685 caaacaccag taggtttgtg 20 686 20 DNA Artificial Sequence Antisense Oligonucleotide 686 gaagccaaac accagtaggt 20 687 20 DNA Artificial Sequence Antisense Oligonucleotide 687 tgcggaagct gttgtcagaa 20 688 20 DNA Artificial Sequence Antisense Oligonucleotide 688 gggagccagc actggcagct 20 689 20 DNA Artificial Sequence Antisense Oligonucleotide 689 cgggagtggc tgctgcggtt 20 690 20 DNA Artificial Sequence Antisense Oligonucleotide 690 gctggacctg ggtttcctca 20 691 20 DNA Artificial Sequence Antisense Oligonucleotide 691 aagcagcccc ttggcaaagg 20 692 20 DNA Artificial Sequence Antisense Oligonucleotide 692 agggctggat ctggaagtgg 20 693 20 DNA Artificial Sequence Antisense Oligonucleotide 693 agaaggcaga gacattctca 20 694 20 DNA Artificial Sequence Antisense Oligonucleotide 694 gcccttcctg gaccttccca 20 695 20 DNA Artificial Sequence Antisense Oligonucleotide 695 ctcagtctag aggcaaaggc 20 696 20 DNA Artificial Sequence Antisense Oligonucleotide 696 ctgatccgtc tgtgtccagc 20 697 20 DNA Artificial Sequence Antisense Oligonucleotide 697 aagtagctgg gattacaggc 20 698 20 DNA Artificial Sequence Antisense Oligonucleotide 698 ggccctgtac ctagctccca 20 699 20 DNA Artificial Sequence Antisense Oligonucleotide 699 atcataccac tacactccag 20 700 20 DNA Artificial Sequence Antisense Oligonucleotide 700 ttgtatttta agtagagacg 20 701 20 DNA Artificial Sequence Antisense Oligonucleotide 701 acaaggccag cccccactgg 20 702 20 DNA Artificial Sequence Antisense Oligonucleotide 702 ggcagagaca gagcagactc 20 703 20 DNA Artificial Sequence Antisense Oligonucleotide 703 tgcctggcaa tattccggat 20 704 20 DNA Artificial Sequence Antisense Oligonucleotide 704 cccgacctgg gcgaggtgcc 20 705 20 DNA Artificial Sequence Antisense Oligonucleotide 705 gatgctacgg tccatgctgt 20 706 20 DNA Artificial Sequence Antisense Oligonucleotide 706 acctcctccg accggctggt 20 707 20 DNA Artificial Sequence Antisense Oligonucleotide 707 ccagggcagt ggccaggtcc 20 708 20 DNA Artificial Sequence Antisense Oligonucleotide 708 ctagggtagg cctgcagcag 20 709 20 DNA Artificial Sequence Antisense Oligonucleotide 709 tgtctctagg gtaggcctgc 20 710 20 DNA Artificial Sequence Antisense Oligonucleotide 710 cggagcaagg acggcgtgtg 20 711 20 DNA Artificial Sequence Antisense Oligonucleotide 711 aaattcactg ttgtgtgaaa 20 712 20 DNA Artificial Sequence Antisense Oligonucleotide 712 tgcgtaggtt ctggttaata 20 713 20 DNA Artificial Sequence Antisense Oligonucleotide 713 agagcagtgg gatcacaggc 20 714 20 DNA Artificial Sequence Antisense Oligonucleotide 714 tgttggccag ggtggtctgg 20 715 20 DNA Artificial Sequence Antisense Oligonucleotide 715 agctgtccat acagactgct 20 716 20 DNA Artificial Sequence Antisense Oligonucleotide 716 cttctggaac tgtccgttca 20 717 20 DNA Artificial Sequence Antisense Oligonucleotide 717 gttgacatgc cagggctccg 20 718 20 DNA Artificial Sequence Antisense Oligonucleotide 718 atagaagtca cagctatctt 20 719 20 DNA Artificial Sequence Antisense Oligonucleotide 719 tgtagattta cagatgtgca 20 720 20 DNA Artificial Sequence Antisense Oligonucleotide 720 ttaagataga tagtccctat 20 721 20 DNA Artificial Sequence Antisense Oligonucleotide 721 tccttagtat taagatagat 20 722 20 DNA Artificial Sequence Antisense Oligonucleotide 722 tagttcagaa tctctgtgcc 20 723 20 DNA Artificial Sequence Antisense Oligonucleotide 723 ccggacttcc catcatttga 20 724 20 DNA Artificial Sequence Antisense Oligonucleotide 724 aaaagtcaag cccctgtgta 20 725 20 DNA Artificial Sequence Antisense Oligonucleotide 725 aagttgaaaa agtcaagccc 20 726 20 DNA Artificial Sequence Antisense Oligonucleotide 726 gtaaacaaac agtggctgac 20 727 20 DNA Artificial Sequence Antisense Oligonucleotide 727 gtatgcagtt agttacctga 20 728 20 DNA Artificial Sequence Antisense Oligonucleotide 728 tgatgtcatg gaaagagaaa 20 729 20 DNA Artificial Sequence Antisense Oligonucleotide 729 tttagcaaag tcttgatgtc 20 730 20 DNA Artificial Sequence Antisense Oligonucleotide 730 tgtctttagc aaagtcttga 20 731 20 DNA Artificial Sequence Antisense Oligonucleotide 731 aacctgttct ctccagatgc 20 732 20 DNA Artificial Sequence Antisense Oligonucleotide 732 tagaaacctg ttctctccag 20 733 20 DNA Artificial Sequence Antisense Oligonucleotide 733 tgcttagaaa cctgttctct 20 734 20 DNA Artificial Sequence Antisense Oligonucleotide 734 aatttttaaa aagtccaact 20 735 20 DNA Artificial Sequence Antisense Oligonucleotide 735 tgttgcactg tttctaaagc 20 736 20 DNA Artificial Sequence Antisense Oligonucleotide 736 agcttaccac tggaacagca 20 737 20 DNA Artificial Sequence Antisense Oligonucleotide 737 gggacatagc ttaccactgg 20 738 20 DNA Artificial Sequence Antisense Oligonucleotide 738 tttaaactga ttcctgggac 20 739 20 DNA Artificial Sequence Antisense Oligonucleotide 739 gacccagcat ccactgtcgt 20 740 20 DNA Artificial Sequence Antisense Oligonucleotide 740 gaagaaatca tgagtccgtc 20 741 20 DNA Artificial Sequence Antisense Oligonucleotide 741 gattttaaac tcttaaagaa 20 742 20 DNA Artificial Sequence Antisense Oligonucleotide 742 tagagtttgt ttttcctttc 20 743 20 DNA Artificial Sequence Antisense Oligonucleotide 743 aatatagagt ttgtttttcc 20 744 791 DNA Mus musculus CDS (19)...(606) 744 agctacacag cttgtgcc atg gac tct gag gtc agc aac ggt tcc ggc ctg 51 Met Asp Ser Glu Val Ser Asn Gly Ser Gly Leu 1 5 10 ggg gcc aag cac atc aca gac ctg ctg gtg ttc ggc ttt ctc caa agc 99 Gly Ala Lys His Ile Thr Asp Leu Leu Val Phe Gly Phe Leu Gln Ser 15 20 25 tct ggc tgt act cgc caa gag ctg gag gtg ctg ggt cgg gaa ctg cct 147 Ser Gly Cys Thr Arg Gln Glu Leu Glu Val Leu Gly Arg Glu Leu Pro 30 35 40 gtg caa gct tac tgg gag gca gac ctc gaa gac gag ctg cag aca gac 195 Val Gln Ala Tyr Trp Glu Ala Asp Leu Glu Asp Glu Leu Gln Thr Asp 45 50 55 ggc agc cag gcc agc cgc tcc ttc aac caa gga aga ata gag cca gat 243 Gly Ser Gln Ala Ser Arg Ser Phe Asn Gln Gly Arg Ile Glu Pro Asp 60 65 70 75 tct gaa agt cag gaa gaa atc atc cac aac att gcc aga cat ctc gcc 291 Ser Glu Ser Gln Glu Glu Ile Ile His Asn Ile Ala Arg His Leu Ala 80 85 90 caa ata ggc gat gag atg gac cac aac atc cag ccc aca ctg gtg aga 339 Gln Ile Gly Asp Glu Met Asp His Asn Ile Gln Pro Thr Leu Val Arg 95 100 105 cag cta gcc gca cag ttc atg aat ggc agc ctg tcg gag gaa gac aaa 387 Gln Leu Ala Ala Gln Phe Met Asn Gly Ser Leu Ser Glu Glu Asp Lys 110 115 120 agg aac tgc ctg gcc aaa gcc ctt gat gag gtg aag aca gcc ttc ccc 435 Arg Asn Cys Leu Ala Lys Ala Leu Asp Glu Val Lys Thr Ala Phe Pro 125 130 135 aga gac atg gag aac gac aag gcc atg ctg ata atg aca atg ctg ttg 483 Arg Asp Met Glu Asn Asp Lys Ala Met Leu Ile Met Thr Met Leu Leu 140 145 150 155 gcc aaa aaa gtg gcc agt cac gca cca tct ttg ctc cgt gat gtc ttc 531 Ala Lys Lys Val Ala Ser His Ala Pro Ser Leu Leu Arg Asp Val Phe 160 165 170 cac acg act gtc aac ttt att aac cag aac cta ttc tcc tat gtg agg 579 His Thr Thr Val Asn Phe Ile Asn Gln Asn Leu Phe Ser Tyr Val Arg 175 180 185 aac ttg gtt aga aac gag atg gac tga ggagcccgca caagcccgat 626 Asn Leu Val Arg Asn Glu Met Asp * 190 195 ggtgacactg cctccagagg aaccgcgacc atggaaagac cttggcctga agacaggtcc 686 cagagaacag ctgtctccct atttccaggt ggtgggaacc ccaagctggt gattcactgg 746 acatctctgc gttcagcttg agtgtatctg aagagtttac gccgg 791 745 30310 DNA Mus musculus CDS (19791)...(19802) 745 gctcgctttg ggtcatgatg tttcattata ggaatagtaa gccaaactaa gatgatgtct 60 cttcacaaca ttagaaaagt gactaagact ggcctctata gactcatacg tttgaataga 120 actatttggg aaggactagg agatatagcc ttgttggaga aggcgtgtca ctgagggtgg 180 gctttgaggt ttcaaaagcc cagagtcttt ccttctctat ttcctaactg cagataggga 240 tgcaagctct cagtgattcg ccaccaccat gtctgcctgc ctcttgccac gttccctgcc 300 atgatggtca tggactctaa ctctatgaaa ccataagccc caaattaaaa gaaaaaaatt 360 gagagagagt ttttttctgt atagacctga ctgttccaga atcactcggt acgacacgac 420 gcgaagctgg ccttgaactc agggatcctc ctgcctctgc cttccaagtg ctgggattaa 480 agggatgtgc caccactact caactaaatg gtttctttta taattcatcg tggtcaaact 540 gttttgtcat ggtaacagaa aaacaactaa gacccagcca tgtctgaggc acacacattt 600 atagatgtac agttaagctt tttctaattc tgtaatggag acagactcac acaatagtac 660 cgcctggaat gttggggatg ggttctaatg cattatctta attcagctca caaagtcaca 720 tgggaatcta catgttcaca tgctgagggt ccctgtcccc agttggtttt tgattgatca 780 ataaagagcc aatggctagt ggttgggcag ggagaaagag gcaggacttt taggatttcc 840 aggcaagaaa ctcaggggag aagatgaaag gactctacca tgagaggggt gtaggacgga 900 ccacaccatt gacagggaag cagaaagatc agacttaaag gcctgccaac atgtaagaat 960 ccagaaaggt gactccaggg gccattgatt gggtctgggg tcacagagat aaaataaaga 1020 tttgtcaagt attaactcaa gaataccaga ggggagtgtg tgctagccta ggggagtttt 1080 ggaaataccc aacgtttgaa ctagtcaaga catctcaaaa tataaaggtt gcatgtatgt 1140 gtctttcatt cgcaaatcca gagagctctg gcgggtggct agaagtgtga tcactttctg 1200 ggaactcaga gtggattaac aattcaccat tacaagtgca gtttttggta gggaaggtca 1260 tgtttgtaat ggtgccgagt caccaaagaa agagaaacag ctcttagagt tctatgccag 1320 agggcagagg agcatgcaac ccatccttca gggtttgaca agcagaaggc aggctggtgg 1380 cacagaaaaa aatcatagtt ctggactagt ctgggctaca tagtaacctc tgtcttaacc 1440 ttctcccctt gccctaaagc atctatgatc tgtattggtg ggagcgagag ctgggtggtg 1500 ctgaggttag aaggctccct agctatgggt atttgttaaa atgtgaactc ctccaagaga 1560 tgttataaag tggaaatgtc tagtctcttt ggaaagttag ttatgacaaa tgacattttg 1620 ctggggcaca caagtgaaag gatgtcttcc taaagcagac acaggaaaga atgttttccg 1680 gaagcagaca caggtaaaag gatgttttga tatagcaaac atgtaaaagg acccttgaca 1740 aaggagtata aatatgaccc cacagaccac aggagatgag cactgagcct tggtttggtt 1800 tgttctgcct cgctgttctt cgctaactac atacatgcat tggtttacct tatatagtgt 1860 tgttaatcgc aacttgtgga aacaccacca ttgagagaaa gagcagtcca ccaaagaact 1920 gcttgtgagg ttcctacagc agcttgctgc ttctgcggcc tcgcctcagg ctgcttggtg 1980 agcctagcag tttcttcgac tggactgtcc ttgccagttt gtgtgtggtg tctgtctgct 2040 tagaagtctg atctgcagct gctgagttct atttggcgtt tgctacgaga ctgaactgcc 2100 cccaaagaac tatggcaccg tccacttccc ccatagccta attttctctt ctcccacctc 2160 tgctgggtgg tgggctagag gagacgttga acctttatta aaagtaggtt gcaaaaaagt 2220 tgagcctaca aggttatata ttcagaacaa tttctggaat acgattgggt ctacgtggtc 2280 ctagaaatat tcaggggcaa agaacacgca gcttgtgtgc gccaggttct gctggctggg 2340 tggagagagc gtgccaggta gcacagtgtg ccaggcagca cagagccttt gccctctccc 2400 accctagccc atccctattc cttgtgtcac aggaagtatg gagctaggac cagggaggtg 2460 attgttctgt gatctctaat gtttaggtga gaaatgcccc ttcacaccag acctttgtgt 2520 tcacaccagg cccctgggtt cacaccagtt acacttattt taatgaagct ctttctgtct 2580 aaaatttcta gctcctccct ttaacacttc ctaatttaga gattatttag gctgcacatt 2640 aaaactggaa gtttcactga tagttcagtg gtaaggttgg actcatttaa agtgaaaatt 2700 ggattcccag caaccacacg gtggcccaca gccatctgta atgggatccg atgccctctt 2760 ctgatgtggc tgaagacagc tacaatgtac tcatatacat aaatgaataa ttaaagtgaa 2820 aattggtatg ttccatcttt atgaagttgt gaaatcagtt tccctttttc atttgcattg 2880 attgccaagc acctcggaga gaatcccagt taaaaatatt acgtgttcag gtcatgatca 2940 tgcacgcctt taatcccaga ggcaaaagca ggaggagctc tgtgagttct aggccagcct 3000 ggtttgcata gctagttcca ggccagtcag ggctacatag tgagagcctg tctaaaaaaa 3060 aaaacaaaac aaaaacaaaa cttttttctc attattttcc actttgaaat ctagataatt 3120 cagcttgcat gttttaaatt taaaaactct gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 3180 tgcctgcata tatgtgcacc acatgtgtgc ctggtcctca tagaggccag aaggggggtc 3240 agtcccttgg aattagaata acagatgatt gtcagccacc atatgggtgc taagtactga 3300 acccagatgg atgctctgta agagtgagaa gtgcttttaa ccagtgagcc atctctccaa 3360 ccctgccccc gctgttcatc accaagctct tccactatgt gatttcaagt gtaacttttt 3420 ttttggcggg gggtgggggg gtgggggagt ggggggtggg gtggggttgg tttttcgaca 3480 gacagggttt ctctgtatag ccctggctgt cctggaactc actttgtaga ccaggctggc 3540 ctcgaacaga ggcctcccaa gtgccgggat taaaggcgtg cgacaccacg cccggcttca 3600 agtgtaactt ttattgatcg taaaattaga gccatcttcc tttaagaaga attggaaaat 3660 ataaagagga aaaagaaacc ctggagatgg ctcggtttgt aaagtacttc atatgcgtaa 3720 gaactggact ttggatccct agcacccatg taaaaactag agtgctgtgt gtatctacaa 3780 ttccattgtt attggtgcac ggtggaagct tcctggagct cacctggcag tcagcctagg 3840 gaaatcacgc gtggagctgg gaagctggtc cactcccctc accccacacc atctcaaaag 3900 aaaaaaaaaa aggtggaaag gtggagagtg atgaaggaaa acactgacct ctggcttaaa 3960 tacacacata cacacacaaa cacacaccaa ccatgtgatt tttttttttt tttttgtctt 4020 ctcagatcca gtttctctgc tcaggaacag caatttccat ggttctattt acttcctcat 4080 acttccagaa ttcactttct tgtttctctt tcacttttgt cactgccacg tgtcctttgg 4140 gggtactggc tggcacttaa gtatatagca ttgggacttc tctggacagg ggaactagct 4200 agcagtttga gattatctgc tagcctcctg gttctttcca cattcatcct tgctgattca 4260 ttccatgacc gagaaccccg caacccccat ccctgccttc cccacaagag tttaaaaatt 4320 ctgcaagcag ctgcgcagga gaaacaatag ggacctccca gcatctctga tagggccgat 4380 tctgacaggg tcactagtct tgagtgtgcc aaccctgcta tgtaatacat caagacaatg 4440 cggagaggtc gggatcaagt atgacacccc atcctcacga gggcaggtcg cccaggcttt 4500 ggggactctg gggagcgcag gttccgggtg taccttcctt cctgtccccc gtagcgagcg 4560 ggtaggaccc ttgggtttcc gcaaagtgtg gccagtcgga gggcggagca tccggagggc 4620 ggggctatca caggggcggg gctcccgggc gagcacgagg aaaggtaggt ggagtagagc 4680 gccgggccga gtgtggctcc gcaaaccttt gccttagccc gttcgccgcc cggtaccggc 4740 gcagcggcgt ctgcgtggtg agtatgccca ccctactggg cgcccccacg gttcccctct 4800 gggaggacgg ggtcggcacg gagctcagtt tcgtatgcta tcgatccttc gtgatggcgg 4860 ggctcttgcg ccttgatgga ggcggggtgg gggcgccggc cacagggtgc caccgcggag 4920 ctgaggggaa ggcactcact cgaaggcctg gggcgtgcgc cactcgcggt ccccctcagc 4980 gctcggtcct ggtccgcttc gggcaggcct cctggtggac ccggggtccc cgcggtcgcg 5040 cgccactcgg caggtgcgcg cagagctgga aaggcgggcc tgaggtctcg ctgcgctccg 5100 ctatggccac ccacaaaaat caacaaggaa cggctacagc ccacaaatgg gccctgcaaa 5160 agccctggaa ccccaaccca gggaacacag accttggaag actgcagcga ggggcacctt 5220 tcctacaccc gtgggcacta ctgtgtgcac agctcacact cacgcctgaa ctgtgaggaa 5280 gtggctgacc cctccgcatc tccagtaccc aaaatggttt gaaaatgtgc acagactggt 5340 tgctgatgtt tttaaaaagt ttgttgaatg gttggctgaa taaccctata ggattctaga 5400 agaaacccac agccttcagc caccaagtgg cctgggccca caaggattca cacattcgtt 5460 cattcattct ttcgtacatt catttacata ctcaacaaat aagtgtggac cagggacgga 5520 tcagggtaga actttgtggg tggtgagagg ctggaatgaa gagctctgta aaggaccagg 5580 tggtgttgag tatgggactt ctaggctggg cttgaccttc atctgataag ccacatagtt 5640 ctgagtcaag agcatcctga ggacccaggc agggctcccc tactttccca ggctactgcc 5700 tggtgccatg gccaggattg cccttactgg aagactacct tgaagccggg tctaggataa 5760 gctagctgtg gaatggagct gggagaaacc acaagaagga tgtggacttt ccacattcca 5820 gctctaccca accaggagac tttgcagccc tgccccatcc cctgggactt ggtcccaggc 5880 actaccctgg cagtcagctc tgagtgtttc catggggggg ggggggggag cctgatccag 5940 tgctggggct gagttcagag gctttaatac ttgagtgggc tgagctctaa gaaggactcg 6000 gctgggtggt ggtggggaag cagggtggcg attgtgtgtg tcctggcctc tactgcctct 6060 cttgcccaga gagggaatgg cagggaggtt ggcttattac agctgggtta gcaggcattt 6120 cacccactga cgaaaggtgc tatctcctgg ctactgcggg gtggagttgg gtacaggctt 6180 tggtgatggc aagtgaagag aagccggctg gatgtggcat gctctataaa gagatttaag 6240 tagccccaag gtggccaggt tactggagct ctgaaggatg agttgagggt gtacctgaaa 6300 agtgggctgt tagggcagtt actggcgagg ctgggggagg ggaagtgatg ctcacagctt 6360 gaggttacct ggttcctctt atttgcaaga aagaatagcc tacggggggg gggggggggg 6420 cacagtgctg ggtgcctggc ctccggaagg aaggcctgat gacacagcct tttagacctt 6480 ccgaagggca ctgcatgctt ttccagctgc ccttttgctc tctagtggga agctgagggt 6540 tggggaccca catctaggct gtgttcaaga ccaaagagcc attcctcatc agggagacag 6600 tgaatctgat ggttccaagg atgagagttg gaaactgccc gtccataaga agcccccact 6660 gtgggtctgt ggtcactgga cattttgtct gtggttgtat ctctggccac catttgctgg 6720 gccgtggctg tggagggcag ctggtgtttc tgtttctttc tgggcacgct gcctggctgg 6780 ccagtctcag aggccacatg tatttttcct catagtctga aggagacaga taaactgaag 6840 cttcaggttg gagggcagtg atgggcaagt gctatacaga gccttctggg tctgataagc 6900 ccacagagag ctttgttttc cttctcaaat ttcttttttt aaaaggcaga atgtcgccca 6960 gacttgtctc caactcctgc tcaacaatac ctccttgctg ggccgtggtg ggacaccttt 7020 aatccaagaa ctcaggagac agaggccagt ggatctctga gttccagcca gggctgtaca 7080 gagaaaccct acaacaaaca aacaaacaaa acaaaacaaa agagtacttc ctgcctcgtc 7140 ctcctaagta ctgggactac agagtgtatc gtttatttta attaactcat gtcgtattac 7200 aataattaga gactagatta ttacttcctt cttcagaaag gtacattggg cagagagggg 7260 ctaatttact tacccagggt ctcaaaatca ggtggaaaac tcccagttta actgtaccac 7320 ctgattctca ggctgcgctc tgcttcccaa gggaggtcca tctgtggagc ccaatagtcc 7380 tcgggggtaa ggaacagaga ggatgcccac ggtgttgttt gcttttttaa cactagggaa 7440 aaccccggcc tagtgtttgt tccatgtgca ttctgccact gagtcagaca tgcacagccc 7500 cttcctgtgg actcttcccc ctagcaggta gagggagaca gggcagctag gtgtatgaat 7560 ggggaagctg gaactttagt gccagggacc tttatggtgg ggtttccccc acgaaccatc 7620 ctggcagatg tccacagcag atgtgtctcc agttcactgt gtcttactct ctgactcttc 7680 tccctcgact ttcgctggtc caaacaggga tatttccgac aaaagggtgg tagcatctac 7740 cctgagctaa acaagatgaa aggcaaccat ttctagaggt gctgccatct tgaaaattga 7800 gttcttagtt ggctttatgg gcatttatcc tcacagacat gttagccttc caaaaacatt 7860 caaacaaaac caagtgaaat caagggaaca gaaaacagag gacaagtgtt ttgtgctctc 7920 ttctcttctc ccacccctct ccctctccct ctccccctcc ccacctcccc ctctctgtct 7980 ctgttggtgt caagtgactt cctcagtcat tctctacatt tccctgtgtg tgacaggact 8040 cttcactcac cgatttagta gactggctgg ccagtgggct ctagggatac tccagtctct 8100 gcctccccag cactcggatt ctaggctcag agcactacac tagccttccc atggtcctcg 8160 tgatcccagc tcagacccct atgcttatat aggcctggag tttacagact gagccatatc 8220 ctagccctgg tttgccttaa gttacccttc ttccccagta atgcaaacag acattaggaa 8280 gtacttagga gccaggtgtt tccctactgg cccctggatc ggcctaagaa gggcagtgtg 8340 ctttctggca ctatgcctgg aagggtgagg atagctaaac cctggcccag gactgggctg 8400 tgtggaagaa ggcagccaaa tgtagagaga gtttgcctat ctgtgtgtcg tgagacacag 8460 gacagatgct tttttgcagt ttcctgcata gtttctctag tctggaggga tctcctggcc 8520 catagtgggt ctactgtcac catgatggcc acagccaggg aaggcctgta ctgccttagg 8580 ctactgttcc ctccttcagt gacaaacctt ctttgttttt gatttttttg ttttgttttg 8640 ttttgttttt ttggttttcg agacagagtt tctctgtata gccctggctg tcctggaact 8700 cactttgtag accaggctgg ccgcgcctag ttttgttttt gcttgttttg ttttgtttta 8760 tgaggcaggg tctcacatat acctgaggct ggtttttgtc tcactatata cctgaggcta 8820 gccttgaaca cttgattctc ctgcttccag cttcccaagt gccaggatta caggcttcaa 8880 atctttcttc agaggcagta aaagaacagc tgaagcctgg gtactcgaga ttccagcttg 8940 tgtgatccag agcccttggc tgtaggcttt tacctgagcc agcagtttag ttttcataac 9000 tggtgtatgc atacatgttt ctcctgtagt ggtgctgttc ccaataagta cgttacctca 9060 gcccacctta tgtgtcctca gaacagacag ctagccttcc aaggacaagt gtgactgatg 9120 ggggaaaagg gaccctggaa ctcaccagag ccaccctcct ctagctgagg acatagaaaa 9180 cctttacctg gatttctgtg ggaacttccc aacaggcttt tcctaaccag tcttggaaag 9240 gtgtattgag actgggtgac accatctgga agaggccttg gaacccatag gagcctacca 9300 tgcctcctca gtctggcgtg ttgctatctt atagcataga cctatcttcc cttgagttct 9360 agacaaggca agtttctggc caggacatgg tcttgttttt ctttgagcat cttctagaaa 9420 ccagggagac cataccacaa agcccttact ggactgacta ctgcatgcgc acctccagga 9480 gcccatctca tcaggcaagg tgactgctgt cctgtctctc tgatggaggc cattgcccct 9540 ttaacaaacg aataaaggtc gctctcccct ctagggtgtg gaagacagga aatggctgtt 9600 acccaatgca ggcccactgc cagctctgcc ctcagagcac ggtgcagaca gtccagtcgt 9660 cctccattgg attctctgct gggctaggca cccccagtcc ctctgtggct aagctaagaa 9720 aaagagagag aaaaaaaaaa aaaaaagagt aaagcattgg gggtggggca ggaagagagc 9780 acaggcgtgc aaacatcgaa gagcggcctc tgtgacatct gtctgcgccc ctgttggctc 9840 acccttagga catctgactc cctttctgct agccatcttg tcccacccaa tgcttagata 9900 tttcagaagc ctcggtcctg ggtagggagg gaaagcaggt ctctgtatct tataggcctc 9960 agacaaccag gacagccatc ttctgcaggc ctagtgaggc cccagggatg ggcagcttca 10020 gtggcatggt gcacacgccc ttttccacac caccctttgg caagattact ttctgtgcta 10080 atggttaaag gcagaaacct ttgcccacta agcagttgct gcgcccctga gctacgctcg 10140 cgttcttaaa accattgtat tgctggtgtg gtgggtcaag tctgtgatgc cagcacttgg 10200 caggccaagg caggaatgag aaggagaaca agtttcaaag caagcctggg cttcatagta 10260 agaacttgtc tccaaagccc aaagaaaggg ctggagatac aggacagctg gcagaaacca 10320 ggcacagagg ttggcatctg tagacccaac acccggacag tggaggcagg aggatcagaa 10380 gggaagaccg ttcttgcctg aacgtcaagt tctaggccag gctgagggcc atgccaggct 10440 ctctactgtc tatgtatgtg ggtgtttgct tacaccactt tcaaacctgg tgcccaagga 10500 ggccagaaga tggggtcgaa tcccctggaa ctagagttac agacaaatat gagctgctgt 10560 gtaggttctg ggaaatgaac ccaggtcctc tggaagagca gcctgtgctt ttaacaactg 10620 ggccattttt ccggcccata ttcattttta ttacgtgtag ttgtttattt cattatggga 10680 catcccacag catgcacctg gctatcagac ttgcggaagt cagttctttc tttgcccagt 10740 gtgggtccta aggcttcatt cagttcatgt tggcaggctt gtgccccctg ctttagatgc 10800 cacgtcatct ccagccactc acatattctt gctacccgtt ccttgtcaga tactttgtag 10860 acgtttcctc cccaggctgg atttgaactc actgtgcaga tccgtctgtc ctgttttagc 10920 ttcctggatg ttgagattac agataggaag caccatgtct gactcggttt tatcgtctca 10980 ggagtgtctt ttgaatcata aaagttttca actttgaaga ctacgttagg taattttttt 11040 ttcttttgtt acttgtgcct ctgggctatg tctaagacgt tgcctaatac aagataattg 11100 agacttcctc tcgtgttctc tttttaaatt ttttatttta taaattatgt gtatcggtgt 11160 tttgactgcg tgtctgtgta ctatgtctgt gtctggtgcc ccaagaggcc cagaaaagga 11220 cattgggtct cctgagcctg gagtttcagt tctgagccag tggatcctgg gaatcaaacc 11280 caggtcctct ggaagagtag ccagtactct actgctgaac cagctactct ccagccccca 11340 cccttcttac acttaggtct atctgttttg gtttggtttg gtttttaaga atttgttatt 11400 caggggcaag agagatggct cagcagttaa gagcactgac tgctcttcca gaggtcctga 11460 gttcaattcc cagcaaccac atggtggctg aaatgggatc tgataccctc ttctagtgtg 11520 tctgaagaca gtgacagtat actaatacat caaataaata aataaataaa tctttttaaa 11580 aaataaaaag agaatttgtt attcaaagcc aggtgcatct ctttgggagg ctagcctagt 11640 ctacatagta agtttgagaa cagtcagggc tacatagtga gacctatctc aaaagaaaat 11700 ctgttattca gactggagag atggtgactc agtggttaag agcactggct gctcttcccg 11760 aggacttgtg tgactcctgg catccacatg ggagcacgcc accctctgta actccagttc 11820 caggtcatct ggcaccctct tctggcctcc acgggcacca ggcacagaga tacatgcagg 11880 caaaacacca tatacatcaa ataaaaataa aatagtttgt tatctttttt tttgaaaggg 11940 aagacaaagt tttactttta aaaaagatta caagcacccc aaataacatg taacgagttg 12000 agtcctcgca tctcgtgatt tgggatagga tacactaaca gcagccggaa taagcatacc 12060 atattgactg tcctaaatta tccaggctag agtactgtaa ggctggctgc tacttcatag 12120 gagttgctaa tagctattac tacttttcca taaataacgc ccctgacctt taagaaagta 12180 gaagggaaca gcttactccc tttctttcaa agaatttttt ctacttgact aataaaaaag 12240 tcagcactga tatccattac ttgcagaaga cacaggaaac aggtgacaaa cactccttaa 12300 agacacacaa gataagaaga tggaacttca ggtacatagc aagtcggtac aaaaagctag 12360 atttgatact cttaaaacgt gaagggtcct acaacggcat agagaaataa tttaatgcct 12420 tccagaacag aactcgagct ctgtggaggt ttcctattct ataggggcag atctcatgcc 12480 aacccacaga gcaggcgctt ccacctccta tccctttatg cggtagcttt catggatttc 12540 tggctggatg tcacacacag aggccaagag gtcattcagg actccatccc tgttctgctc 12600 gaagtggttc tggaggacgt tcatcttccc ctgggtctcc tcttccacct cactgctgca 12660 gctgccatga gaccccagtg ctgcagcttc cttggcctct gcagtactgt tcaatttcag 12720 cctggcggct tctttggcct gcttcggcct ccggttcttt cacttgcagg ccttggacac 12780 cttcttggct gcctgcagta gctgctggat gccccgcaac tgactctcgc cattgctgag 12840 gggactttgg gccgagagaa tggcctaaat caaccaacgg ctcaaacata gtcagaagcc 12900 cctccgtttg atgtcattta atgagccttt ctgtgtagct tcaggtcact ccctgaggcc 12960 tggaacaccc tgaatctttt tcagcttttc tgctgaattt ggctgtcacc aggacagact 13020 gctgagggag tgtgttagta ctccagagga gcccagttgt cactatgact ggagcagcgc 13080 agtcttgttt gtggcactgt tgggctatgt ctgctcactg acagttggga tcagttcctc 13140 ttaggtgact cataactgtt gcggtaaatc tcctcccaaa tatgccccgg caatgaaaac 13200 acaacacagt tcatatgaat acatgctgtg cgcctagatt gggcagatct accgctacac 13260 taccatcttc cacatctatg agacccctta gaacttgcgg tttctccagg ccttgtgctt 13320 ctgctccact tttccccttc tttctccttg tctgtgtcct ctccctcttc cattttctct 13380 ttgttctctc cccccacctt ccgctccacc ttccctttta tctgcccaaa cttcagctcc 13440 cctttatttt acaaattaag gtgggaagca ggtttacagg aaatcacctg agtgctgact 13500 atgttcttgt tcacaaccac tctcaggaga acggaattaa catcaaatat aattagcccc 13560 agggctatct gcaacacata acaactatgt cagtgtgatc tggctctatc tgcaagagtt 13620 gaccctctgg tgatgccctg actgagcgtg tcctgcgctt gctaatgctg tggtgctgcc 13680 cctggatggt atgtccacgg ccaacatatg tccaaaagga aagcccctgt cagctgttgt 13740 ttttttcaaa tttatgtcta tgtgtgtgag tattttccct ttttgtatat ctgtgtacca 13800 catgggtgcc cagtgcctgt ggaggcagat gccccagtac tggtgttaca ggcagttaat 13860 atgagctggg aattgaaccc aggtcctttg gaagagcagc cagtgctctt aacttctgag 13920 tcctctctgc agccttctta gcatccattt ttaatctttt gtatgacatc tggcagaggt 13980 aggaattcat gccttttggg gggatagttg gctatcccag tgtccttggt taaaactgtc 14040 tgttctttcc ctggcggtgg cccgggtcag tgtctgatga actcgatgct cactgctctc 14100 tgatttcttc aaccaggccc gcaccttcat gacgtcatga cgagagctat gggaaggttt 14160 gaaatcagga agtacaagtc tgtcatccac tttgttcctt ttcaagaatg gcgatttttg 14220 aaaatgtcct ccgcgttcat gtatggattt aggaattgtt tgtcactttc tggagtattt 14280 tttataggaa ttgtgtggag tgctgtagtc tgatagtgtg ttgtctcttc cagcccctga 14340 caggtgcttg ccttccgttg tttatctcaa caagttttgc agttttcgtt tagtgtctaa 14400 tgctcgtata acattcgctc ctaaatgctt tgtgcattaa ttttgttcac ggcactgggg 14460 ttgctctcaa gctctcggta gacgtgtgtt ctactgtgga gatgcaggcc gggtcttagg 14520 attttctgtc tcttggtagc acaataatca tttcatttta ttttgggtta tgagtagtgt 14580 atagaaaaac aggacagcag gggcttgctc tctgctactt tgttttcttc atgaattcct 14640 tgggtgctgt gtgtaaggtc atgtcagatc actgtgttca ggggcttcca gaagattcca 14700 ctgtgcagct aagcttgaaa attgctgagg aagctgggca ccacagcacc tacctgtctt 14760 cctgaggcct gcaaggtagc gccaagagta gacctcgctg gcggcgtgcc tggcaccccc 14820 cgcctgccat ggaacttgtc ttggtctatg attggtacat gatagacaaa gaggctcttt 14880 tttgtcacat caaggattca gctttgtgac cttaacgttt gttcatcttt atgaataggt 14940 gacatagctg ctttctgttg gggggctggg agagcacacc cggttgctgg actgttttct 15000 ctgcgtcctt ggtcgcaagc tcggttgaac tgttttgtgt ccaaggagaa gaacagcatc 15060 cgttactgga cctgtgagtt tgggtctctt tgtcctgcct ccctctccct gcctgcctat 15120 gtgtgctcgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtagaggg 15180 aacctcaatt gagaaaatgc ctccatcaga tttgcttgta ggtaagcccg cagggtattt 15240 tcttgattgg tgatggtgtg ggaggtctgg cttactgtgg acagtgccgc tcctgggcag 15300 gtggccctga gttctgtaag aaagagcctg agcaagacat ggaacaagtc agtaagcggc 15360 ccccctccct ggccatgact ccagctcctg cctccaggtt cctgccttga cttccctcag 15420 ggggaggggg acggggacgg gacctgagag ttgttgtgct gagatatgta cttttctccc 15480 caaattgttt ttggtcaagt gttttattac gatagaaagt aaactaaaac acactctccc 15540 cacacacaca ctgactccac cccacacacc gtgaacacag ggccttgagg attccagaca 15600 gccttgtttt gtatttattt tgggacaagg tcttagaaag ttgaacttgt gatcctcctg 15660 cctcagcctt ttgagtagct gggattataa tctgtgtcac cgagtttgtt cttgacctaa 15720 gtagttgaga agagcctttg ctcttgtgta aatgggaaaa ggtgctttag tcacagaggt 15780 ttaggctctg gcttctcact gatgcagcac caactggagg agacattcat acaaattaaa 15840 catttttagg atttttaaaa agtgtgtttc aatgttacat ttggggtaag aatgaaaata 15900 caggaattat gtcggtgcat tgggtgtttt agattgtgtg tgtgtgtgtg tgtgtgtgtg 15960 tgtgtgtgtg tgtgtgcgtg cacagagttt tgaactgaag gttttgctca tgctaagcat 16020 gtgtgctatc acccagttcc tctgaaaaag catctctaat agaaactgcc cattctcggg 16080 cactccgggt agcagagcag cttccgctac tgcgtgttga ctttattgtg ctcttggctt 16140 tttagacatt gtgggaaggg gtggacaaag ctcactgttt atgaaacagt ctgggtttgt 16200 gtcattaatg gataaccatg cctattctcg tgcatgtgac cctgtgttaa ttggatgtcc 16260 taccacctaa tgcttcttac aacacttgat gtttactgtt tccaaaattg gacctagatt 16320 tagaaaaaac aaaacaaaac aaaacaaaac aaaacaaaac ttgatttgct tatttctatt 16380 ttgcatgctg gggatggaat gctcaggcct tactcttgca ggcaggcatt ctaccatcaa 16440 gctgtgttcc cagccctttc aggagcctga cacctaaagc tgagcttggg caatcctgga 16500 aaatctcagg tgtggccatt tgtattgtaa aaagggaaaa ttagggagag atggagggat 16560 ggatactgga aactgaactc atgtcctctg gtaggataga cagaacactt aaccactgag 16620 ccttctgcaa ccccctttag agagagagag ggagagagag agagagagag agagagagag 16680 agagagagag agagagcgtg catgtgtgtg ttacacacag aggccagaac agctgtcctg 16740 gaactcactt tgtagaccag gctggcctcg aactcagaaa tccgcctgca tctgcctccc 16800 gagttctggg attaaaggcg tgcgccacca cggcccagct ttcaagacaa attcttaacc 16860 gccagtccat ctcgccattc tccaaccagt cccttaaaaa tatttttttt tcaggtgttg 16920 agggtctagc cccgggatac aggcatacta ggcacggctg aagcactgag ctccacacca 16980 caattgggta ttattaccgt cttaccctct aggttattga tatgctgcag aatacagata 17040 ttaatgcagg cacttgtcca caggcctttg tccagtgcag tgtggttatt atcttacagc 17100 tattggcagt cttgcctgcg tctctaagtt cttctgtttc tcatcatctg tgcatatggt 17160 tctttgtcat ttgagttttg tttatttact tatttgtttg tttattttta tggagacaag 17220 gtattgtata gcccagcctg gcttccagct cacagtgttg aagaaggcgg ccgggaactt 17280 ctgcttcctg cgtgctgcag ttacgggtgt gtgccatcgt ctccggcagc ccggggctct 17340 gcatgcatgt gaggcaggca ctctaccaac agggctgcat ctcaagcacc tgggcagttt 17400 tagcacagtt ccttggtttc ccattaagta atgagttaaa tatttaacat atgtccattt 17460 gaaaagatgg aaaacaactt ctcctggtca ctcggcattc atcagccaga agtctgggag 17520 gctttttctt ctctggatct ccacttggcg gcgttctctg cctgctctgt agcctttgat 17580 aagtggatgg ctgggtgccc tctccgtaat atttatcaca tttttctcgg ttacttgtat 17640 agataaacct cagcagggca ggggcacaag gacacccagc tctgtgtaac agtactttgt 17700 accttcctcc ctattggtgt gtcccgagtc tgcacttcgg gtgggcgggg ttttgtgaag 17760 ttcagagttt tcagctactt cagggctttt ggcttctaca gtacaagaga aacttccagg 17820 ttcctgggag agtgagttgg agtctgagta gtgtgaccca cgtgagctgc tgtccattcc 17880 tcttactcag gacacagctc tctgctcaga aatagctctc tcgtcccaag actccacctg 17940 gtggcttctg gaagaagtgg cctctgtgat ggtggagatt gacagctctg actgtgattg 18000 acagctctga ccaccatgag gtgcatgcaa agtgctttca cacctgtcta ataattctgg 18060 atgtaatgag aaataccaag caaggtgttt ttttttttaa ttagaatttt tattcatcac 18120 tgtgtgtata tgagggaggt gaactcatgc gtatggaggg aagagggacc tggaaccggc 18180 tcctctttga cctttcacat tgttccaggg atggaatgca ggccatctgg cttgctgact 18240 ggcacattca ccagctctct tgcttgcatc tgatcttagc ttttttgagg gacctctaca 18300 ctattttcca tagtagccat attaatttgc attctcagta acagtatata caatgaatgg 18360 atatactttt ttaaccatgc aacaaaacct ttattaacat tttaaacaga tgttccgcta 18420 ttactgaaac tttgtggggg ttggggcggg ggcaggtttc aagacagggt ttttctctga 18480 atagtcctgg ctgccctgaa acttggtttg tagaccaggc tagccgaaaa ctcagggatc 18540 cacctccttc tgcctccagg tgctggaatt aaagttctat accaccaagc ctggctgtac 18600 tgaaacttat aatttctaaa ttcaaatgca caaatggttt tagtgtagag taataccatt 18660 agtgcctacg ggaaatttag gctgaagaac ggagaccatg tgtgggcttg agtcttttct 18720 ggatcaaaaa gagtatggtc atctttcagc tgcttgcctg taacgatgag cgtctgctgg 18780 gtggggtggg aggtgccctc ctaatcctgg gtcttaccct tcacattctc tgtggtatca 18840 gtgggctcta cctcagggtc tgggtcttca caaagattca catctttttt gggggagggg 18900 gtgcgttgag acagcgtttc tctgtgtagt cctggctgtc ctggaactca ctttgtagac 18960 caggctggcc ttgaactcag aaatctgcct gcctttgtct cctgagtgct gggattaaag 19020 gcgtgtgcca tcatgcccgg caagactcac atcttaacct gttaatgaag ggattaaagt 19080 gcaaagttca aagcacatca gggcacctag ttataagagc ctctgcactg gacaaagctg 19140 ctcgtctgga catcctcaat gaagttcttc aatgactttg gtccagtcag ctatggtaga 19200 tcagaagact tgcatggcgg gcacgtttta ccagccaagc tgccttgccg gctcctccag 19260 atgacatctt cttcccatta agttggaata catactgtgt gctttgcctc atcgtgtgga 19320 aagaggaagt ggttggtggt ttgggggcac tgtggtcctg tagtgtagat gccctgcagt 19380 cttgcaggag tgtgtgacta gctgggaaac ccactaacca gtgtgaggat tagcagcagc 19440 agttcttgtg ggaagcgccg gttggcctga tcagacttac tgaacatggg aagaaagctg 19500 agctctggag aactggcctg gggatgccca ggtcagtgcc agcggaggct tcaaggagga 19560 agactgcaga cctgactcac tgggtctgtg tggagagcaa acaaatgagc caaagccagc 19620 ggtgtggctg ggtgtgcctc agctgcaggt gtgacagtgt cctgtatccc gcggggcccc 19680 gcagaggcat tgctttaggg aacagccacc catggcttgt atatgtcctt tttcaggtga 19740 ttccctggac tctgtgagct ggcagtgctt ggagctacac agcttgtgcc atg gac 19796 Met Asp 1 tct gag gttagattct ggtatctttt cattttgttc atcctgggtg tccccgttaa 19852 Ser Glu gcaacctgac ccctcagttg tcaggtctgg caaggtgtac ctcagataat ccaacagagt 19912 tcatctccac tggcacctga tagggactta gtacagaatg gggaaggggg acgtccttcc 19972 agaaggacgg aacggcgtga ctgtcagctt ggtagacata gcaagggcgg cacaaaggcg 20032 ggacagaaaa gatctggaag gttccctttt gccccagtca gggggctgag ctgggctcgg 20092 gcaatagtgc tttctagcct cccagtatct cctgctgtcc tgcagggcct cttgagagtg 20152 ggcccctcct ggacaacggt agacttgctg ctgtcccctt cttctacctt ggagcaggaa 20212 agctgaggca cagaagaaag tgaaatgctg acattttctc ttacatcttg gcatttgaca 20272 tccttgcccc acatcagaac ttgtatctta ttgtagatgt ttctgacttt atgacaactg 20332 ttatgcacac agttgaggga cattaagtga agcaggtttt gctactacgt ttttttgtac 20392 tacagggact catggaacag gcgttgctga gtgctcctcc ttttttttgt tttttgtttt 20452 tttcgagaca ggatttctct gtatagccct ggctgtcctg gaactcactg tgtagaccag 20512 gctggcttcg aactcagaaa tccgcctgcc tctgcctctg cctcccgagt gctgggatta 20572 aaggcgtgcg ccaccacgcc tggcgctaag tgctccttca tagtgctcct acccagggct 20632 gcttttgtac acaccataga actggcagag aggccggtga gcaagaccct ccctgctgcc 20692 tctgatagtg cacatgtccc cctgaaaggc acaggcagag tcggacctgg gtccctgctt 20752 cctagagttt atcaggcatc ctgtgtctgc tcatgaggga gtgaggggaa agaggaaccg 20812 cttgctgcta ggagcacagc ccgtacagtc aggctcagcc ctgaacggaa acatggatgg 20872 aactgaagta gtgacatttg cctgccaccc cagtgtccct gagaccttcc ctcgaagcag 20932 cttccccagt gggtgtcttc aggaggggat ctgtagaagg tggctcgatg gccccttggt 20992 gtcttctgtt tggcaagcac accacagcct gtttctctgc ccctgggcct ctcactaggg 21052 catttagatc ctccgagtta ttgattgtca caggccattg tgactcgggt ccaactgtgc 21112 tctgacccag gctcccgtga gccttcctga ctccccttcc accttaggtc agcaacggtt 21172 ccggcctggg ggccaagcac atcacagacc tgctggtgtt cggctttctc caaagctctg 21232 gctgtactcg ccaagagctg gaggtgctgg gtcgggaact gcctgtgcaa gcttactggg 21292 aggcagacct cgaagacgag ctgcagacag acggcagcca ggccagccgc tccttcaacc 21352 aaggaagaat agagccaggt aggtcctggc cttgtccacc tcatcccaaa tgtagccttt 21412 actgaccccc aaaagctaca agggcttttg gagctcagtc tctaacctta cattgtcagg 21472 ctggtgtgtg tgtgcatgtc atgtgactcc tgccttgtga tctgcatgtg actgccccca 21532 gtaatgtcca gttcatatga catcgcctgt atcaggacaa ctaattagaa agttcttcct 21592 tctgatgagt cctgagttct cttcaggtct ggacctgagg atcctctctg gaccaatatt 21652 taaaacatgg tttttaaaac atatgtccca aacagttata gtacagccaa agtatggaaa 21712 ttgattgtct agtttaggct tcattgctgt gaaaagacac catgaccaag gcaactgttt 21772 tttgaggggg agggggcttc gagacagggt gtctctgtgt agccctggct atcctggaac 21832 tcactctgta gaccaggctg gcctcgaact cagagatccg cctgcctctg cctcccatgt 21892 gctggctagg ttttttattt ttttattttt ttttatttct tagttctttc ctgcaactat 21952 caagtcattc agaaaagagg agtcaagaga ggggatgagg tacatttgaa ataaaaaact 22012 ataatgatga ttggtcctgc ttctgcctcc ctagtgctgg gattaaaggt gtgcgccacc 22072 acgcccagcc caaggcaatt cttataaagg acaaatttgg ttgaggctgg cttacaagtt 22132 cagaaggtca gtccattaac atcatggcag gaagcatggc agcgtccagg taggatggtg 22192 ctggaggaag agctgagagc tctgcatctt gatccagctg tcatcttccg ggctgctagg 22252 aggagggtct gaaagcccac tcccacactt cttccaacaa ggacacactt cctatcagtg 22312 ccactatctg ggccaagcat gttcaagcca ccatgctggt caagatgtta taacccagaa 22372 gtgccatcag cttcagcttg tggagttttg gaaagtagca aggcagagtc cttcgtcctg 22432 ccattcagat ctgggaggtc tgggacattg ctagtctggt catggctgcc aggtaagcat 22492 ccttcaatag ccacacagca cctcatttgt gtaggctagc tgaactctca atccagtgaa 22552 aactcctgcc gttagagtca ttttgcctcc taaatgaaac tttaacatat gtgacttgct 22612 attacctaaa gagatgaccg agtattgaag tatcctgacc ctcatttcca gataaggaaa 22672 ctgaggcaca gcagagaaat ggctgacctc agatcaaact gcccatgcag caggagcaag 22732 gctcaaccaa gctgctcctt catcagtgca gtcacctcct gctaagcctg tgtcactcgg 22792 ctgctcctag ccttcacctg tcccctgtcc cctgtcccca tgctgtgttt acagcaactg 22852 aggagacctc cctaaaggct gaggtgcagc gagtgctcag agcgctgtgg gcagcatgca 22912 ggtgggcatc actgagttct tcagagtgta caggcctggc tcgggctctg ctcctccagc 22972 aggttctgga gctgcatgat tttttttaaa atgcttgtct gtctgtctgt ctgtctgtct 23032 gtctgagtat ggggtatgca catgccctag catatgtatg gagtcagagc tggctgtttt 23092 ccttccacca tgtgtgtcct gggatcaaac tcaggtcagg atacttcagg actctaagca 23152 ctgctgcctc cgatcttgga cacagaggct tcactgccct ctagtggttg caagggagac 23212 cagcagctag tttggcttcc ctacccccct ctggctagtt tatttctttt gagacagggc 23272 cttaccctgc ctagcctgaa atttgttgtg ttgaccaggc taatcatgaa ctcccagaac 23332 tctgcctgct tctgccaaat gtggttcatt tttcaaatgc cctgaagtgg tatcttgagt 23392 aggctgggat gtgacaggta ttctctacaa gctgggtttt accatagcct tgtctccgaa 23452 gcccaccagt gagccagcca gccaggccaa aactgaagag aagcgccagg cagtccagga 23512 aaggctcagg aagttcaggg cagcgggagg aggctctggc tgtgcgcagg tgtctgtcac 23572 tctgtgccat acccgcttct ttctgcatca gtccatgcca gacttcaaag cctggcttaa 23632 gtcacgagac tggggatgac gaggctttgc agacgatcga tcggctgcag attgggagca 23692 gggcaaagta gtggcttcag caagccagtg agcagctgag tctgcctaga acactcggct 23752 agtagtggat ttaaatcaca gggaaccgga agccatgcag ttactgtcac ctaagcagaa 23812 gcagtgagca ccagagaggc cttgaggaga gcagtgtggt gaccatgtga caggcatgga 23872 ctgagggagg gcctggagta ccgctgaatg ctgaagcagt tgcccactgc attaaagcag 23932 cagtgacaca ggcaggacac aggacaggag cacccccaac cccccagccc ccgcagcagc 23992 aagcatataa tctgggacag gcctgcttct ccagccaggt tctgctaccc aggccttccc 24052 tgcacccggg gaggggcggc actcatggtc ctcactaggg caggtgcgga ggtaggaagt 24112 ggcctgaagc tgttgacaga accattgctg agtcttgtat ttgttgccta aacagattct 24172 gaaagtcagg aagaaatcat ccacaacatt gccagacatc tcgcccaaat aggcgatgag 24232 atggaccaca acatccagcc cacactggtg agacagctag ccgcacagtt catgaatggc 24292 agcctgtcgg aggaagtaag tatgactctg gtctgggagc ccctcttatg ggacatttcg 24352 gaagtgtggg acatttttcc ttgtcgaacc agtctttccc aggaagtaaa ccctgtcctt 24412 gactgcccgt cagcatggtc tctccaaaga atttagtcag agtacagagc ttaggagtca 24472 ggcctccagg aagatccctg aagtacctga tctgtacaga tactcagtct tctcttgtgg 24532 cgaactccat gtcgttcccc cagggtgagc atctgctcgg ctgtgtggtt agaatcagca 24592 catggaaacc gatacaagtc cacctcttgc tgggtatacg gtgaaggacc caaagctcgt 24652 tcctcagcac cgggtccttc ctaaagcaga ggtggagggg tggtggggag aggggagaga 24712 gagaaaccaa accccggggc tgtgaagtac ctgcccaagg aggaagattc tgttcttagg 24772 acttccagca gctgaaatcg tggctgccct caccatctag attcattgtg cctacataca 24832 gcctgtcttt gctggcactc tctctacctg ccactctcca gtggctgtca aagacacaca 24892 catttgtcaa cagccttggg ctcctcctat ggggtagatt ctttaatgtg agccacagaa 24952 cctgaagctc actttccacc ccaccttgtt tttttgtttt ttgttttttt gttttttttt 25012 tgaggcaggg tttctctgta tagccctggc tgtcctggaa ctcactttgt agaccaggct 25072 ggccttgaac tcagaaatcc acctgcctct gcctcccgag tgctgggatt aaaggcctgc 25132 actcccctcc ccatttttta aagagttaac gttacctgtt tctgcgtgca cctcatgtgt 25192 gagtacatga gcatgcttgc aggtacatgc attgccatca gatcccctgg agctgaagtt 25252 tcaggccatt gtgagctgtt gcctataggt gctgggaact gaacgggctc ctctggcaga 25312 gcagtacatg ctcttcaggt ccaggggtcc agtatcttcc tttcctgcct gaagggaaga 25372 taacatgtag cccctaaagc taagctcaca gtaacatgag cctaagatgt gctcgtgtcc 25432 agccaattct gtaagcatct gagtgcaggg aagagctcag acgcccatat gtcagtagtg 25492 tgtacaggct actcactaac catgcactgg tgagtctcca cgtccctctc tggtctgtgg 25552 agagtgaatc ctctatcatt tcctccaccc aacgttctta gctatttaac caccactccc 25612 ctctgaaagg ctgcttcctc ctttggcctg atttggtctc tctgaaggaa gagcatcagt 25672 aaactgtctt ctttaatgta caggacaaaa ggaactgcct ggccaaagcc cttgatgagg 25732 tgaagacagc cttccccaga gacatggaga acgacaaggc catgctgata atgacaatgc 25792 tgttggccaa aaaagtggcc agtcacgcac catctttgct ccgtgatgtc ttccacacga 25852 ctgtcaactt tattaaccag aacctattct cctatgtgag gaacttggtt agaaacgtaa 25912 gagccagcag tgacaccagc ccctgcctgc ttgcctaccc tattctaatg cagcagagcc 25972 tctgctgaag cccctctggc ccgctctccc ttttgaccac ccgcagactg agagaggcaa 26032 ggctgtttca caccactgat gggaatcgag caagctgggg ggacgtggag tgtttaggaa 26092 gatgactaag ggctcagccc cctaagtgtg tgtggtgtgc acatggaagc cagaggtcat 26152 tattgggtgc ctttttatct cgctctacct atctttgtga ggtagggttg gttctccgtg 26212 aagtcagaac ttgccggtta ggctaaacta gcaaaccctg ggcttccact gcctgccttc 26272 ccttccctca ctggggtacc agttgtttaa tgtgtattga tgctctacct gaatgtgtgc 26332 ctgtggacca tgtgtgcctg atgcctggat agccaggagg gtgctgcatc atctgggatt 26392 gagttgcaag tggttgtgag ctgccatatg ggtgccagga atctgaactc ggttcttcag 26452 gcctctgtag ctcttactga gccatctgca cagccccagg tattatgagt aatcagaaag 26512 tgactacact tatttgtgtg cgcatgttgc tgtgggagca tgtgtgctac agcatagtcg 26572 gtcaggacga ctctgaggtc ccagggattg cactcagctc atcaggcttg gcactgtaag 26632 ccatggccca tgacttagat tctttcgaag ggcgcttccc gaggatggag agagaaactg 26692 ataggagtaa taaatgagtt aagtgagaat cgctgtcaag ctctccagta agcctgagga 26752 cgggcccatt gctagggtag ccctgagttt ctattgcgca tgctcaggaa gtggttacac 26812 ggagctaagc ccaaggtcag tctactgaga ctgctggaaa atgaccacgt gttcttagag 26872 tcttgtgctc tggttacaca aacccaagtg ggagctggat ggagatacct aacctgcact 26932 aggattttac aatgtttggg attttagaac ctgtcagaaa cattatccga gattcttttg 26992 gggggagggg gtttttgttt attctgggtg aaggcagagt ccacattccc agatggcaat 27052 ggaatgcaag gcaatcctcc tgcctcagca tctgcaggca tgcaccccca cacctgggtg 27112 ggtggagcag aggacaggtc tctgtgtgcc aggcaggcac tgttgactga gcagcagccc 27172 agtgcttgtt ttctaacgca ccgtatcctc caatgagact tactctgctg cctctttctt 27232 aggagatgga ctgaggagcc cgcacaagcc cgatggtgac actgcctcca gaggaaccgc 27292 gaccatggaa agaccttggc ctgaagacag gtcccagaga acagctgtct ccctatttcc 27352 aggtggtggg aaccccaagc tggtgattca ctggacatct ctgcgttcag cttgagtgta 27412 tctgaagagt ttacgccggc tcctgcatcc acaccatgta cctttgtcct atcagctgta 27472 tgggttccca cttgggaatg aaacttaaca gcaggctgta aggcagaaaa gcatctttgt 27532 aatgccaagt gactgttcct gagagccagc tctgggctgt cttcaccatg taggtgggct 27592 tctgtctaag gagaacagca ttaggagagg tgcatcggcc catgagcgtg aagtccaccc 27652 agcctagtgg acactgaagt gctcacaagg cctccacctg cctttgtaaa agccgaatgg 27712 ctgatctcaa accatgggaa gcccgaccgc cccacccctc ctcaccccag cgtttagctg 27772 tttcaggggt cagctattat ctcaagattt ctatccaagt ggaaacaaac tgaatcatgc 27832 acacgactta tctgtgtggt gtcagttaca ctcaggctct tgctacggaa tgcaaagaac 27892 aactcacata ccagtgtcaa acagaatgca cagaagagac ctaaaacagc agcaggtcac 27952 tcggttcaca aaaggtgact cccagtcagg tctgacactg tcttggttgt agagcacagc 28012 tgccatcctc tttccctggg taacatcaca gaagattcca tatcaaaagc aaatgttccc 28072 tccgcttctg tatttcagag acaaggcctc actgtatcct caagcgttgt tacgtcttgt 28132 gctgaacttt gcttaaagct gggatcgtca gcacgagccg ccacagcctg caagtattct 28192 agttctgaac tcatcccagc catggtggct gtgatggctt gggtgtatca tacctgtaaa 28252 ttagtggatt tttctttagg aacatgacct ttgggtgagt ataattgaga aattatttta 28312 attcagaaag tacttttcat tctgttctaa aaatatgtga attgtcttaa gtggtagaaa 28372 tttgtttctt caaaataaaa ggctcttctc tagatgtttg ggagagctgt atctccaaat 28432 gacctagtac atcagaaggt cagaccatcc cagcagaaac acacagctgt ttgggtcaca 28492 gttctgaggg ctgtctttat tccagcgact tcactagctc tgctgactgg ggactgaggt 28552 gtggttttgt atcccaggac catgttttca acactgaaag gcaaaccaag agtgcatgca 28612 cttttagaat atgaaacgtg acctgaaata atcccccaag taaatagtgg acaaaaagat 28672 gagtcaccag ttatcataaa atctcgtttt attgtcacct ccagggtgct tccccccatg 28732 atgttgcttc taaatgaaag cacagtttgt agacttgaat tgtcacttgc cgataaagaa 28792 tagattgggc acaaagtaga caacagtatg ggaaaggggc cggaacaatt ggaacaattc 28852 gcagtaatag agtgagcaga tcagacagca gcagtcagct gttggcgcac actgcaaatg 28912 aacgctgcct gggttaaatg cttatgctag tttagttttt ttttttttaa gataggatct 28972 caagtgtcca gggctagcct ttagctctga gcctagtatg gccttgaaca ttgtcttcct 29032 gccttcaccc gagtactggg attacaggta cgtattccat gcccaggatg gaacccagga 29092 tttcatgcac cccgggcaga cattgatagc tacatctacc tgactctgct atgttaagga 29152 taaccattcc agtacctggg ggacaagata ccagaaccac taacaaactg agtttaatca 29212 aggagttagg agaaagaggc acttttagtc tcaaggaaga aaatcatggg ttgtcagagc 29272 aggggaaata caggtccagg agaaaaaggc tggccaacag atggcccatg gatgtaggac 29332 cacacagact gttttaggcc tcactaaggg aggtgtgtag ctcaccttcc tgggggaagg 29392 catccacaaa cctgtcatct cacaatgaca aaacgtggca ctggcaagaa aactccatgg 29452 atcaaggtgc cttccatcaa gcattgggac ccacatatcg gaagtagaga acaaaccaac 29512 ttcacaagtt gtcctctgac tcccacatgc acactgtggc atgcagccac acacacataa 29572 ataaatgaac agcttttcgt atcaaaatgt ttgccgaaag ctatccagta accagcttat 29632 tattccgtgc cgcaaagggc agcaccagag tgacgtgctg acggaggccc ctgagctgac 29692 tgctaatttg ggcctcggcc tcaaaggtgt ccctgagacg gttctgacct gagacactga 29752 caacatcgga ggggatgggg gcgtgtgtaa acatgagcat gggaaggacc ctcgctgcac 29812 acagggacat ggcaagccaa gttgggtttt cgaggagggc tgtgtgaaga tgactaggag 29872 agcttccagc tctcgaatag ctttttacag ggtagataac taagaccaca gactcgggtc 29932 tgatgggcac agcactgttc tgtggcagag ttttcactag gaagcactct cgtcagatga 29992 gtgggatgga aggctacctc gttaatcctg agcctgaggg ccaggaatcc aaacagtatc 30052 tctaggtgtc cactcatcct tccgtgtgcc taccctagac cgatggccat tgcagggagg 30112 aaggaccgga gggatcaaaa ctgcaacaac aaaaacccga caaaaatgtc aagtggctgg 30172 ccgccttcat atcgctgctt ggtgatgaga gctgtgtcag atggcctgac cttgtttaca 30232 gcaagaagac aacacattca ccaacaacac tacagaccac agggtcaccc agtgcctaaa 30292 ggggcagtgg tgcaatac 30310 746 20 DNA Artificial Sequence PCR Primer 746 tcgaagacga gctgcagaca 20 747 23 DNA Artificial Sequence PCR Primer 747 tggctctatt cttccttggt tga 23 748 19 DNA Artificial Sequence PCR Probe 748 cagccaggcc agccgctcc 19 749 20 DNA Artificial Sequence Antisense Oligonucleotide 749 cgttgctgac ctcagagtcc 20 750 20 DNA Artificial Sequence Antisense Oligonucleotide 750 ctttcagaat ctggctctat 20 751 20 DNA Artificial Sequence Antisense Oligonucleotide 751 ggcccggcgc tctactccac 20 752 20 DNA Artificial Sequence Antisense Oligonucleotide 752 gctaaggcaa aggtttgcgg 20 753 20 DNA Artificial Sequence Antisense Oligonucleotide 753 cgggtccacc aggaggcctg 20 754 20 DNA Artificial Sequence Antisense Oligonucleotide 754 gccatggcac caggcagtag 20 755 20 DNA Artificial Sequence Antisense Oligonucleotide 755 gccaggcagc gtgcccagaa 20 756 20 DNA Artificial Sequence Antisense Oligonucleotide 756 cttccccatt catacaccta 20 757 20 DNA Artificial Sequence Antisense Oligonucleotide 757 cacttgacac caacagagac 20 758 20 DNA Artificial Sequence Antisense Oligonucleotide 758 gaagcctgta atcctggcac 20 759 20 DNA Artificial Sequence Antisense Oligonucleotide 759 gaccatgtcc tggccagaaa 20 760 20 DNA Artificial Sequence Antisense Oligonucleotide 760 gtcagtccag taagggcttt 20 761 20 DNA Artificial Sequence Antisense Oligonucleotide 761 ttagcttagc cacagaggga 20 762 20 DNA Artificial Sequence Antisense Oligonucleotide 762 cgcctgtgct ctcttcctgc 20 763 20 DNA Artificial Sequence Antisense Oligonucleotide 763 cccatcttct ggcctccttg 20 764 20 DNA Artificial Sequence Antisense Oligonucleotide 764 ctgaaactcc aggctcagga 20 765 20 DNA Artificial Sequence Antisense Oligonucleotide 765 ctcatggcag ctgcagcagt 20 766 20 DNA Artificial Sequence Antisense Oligonucleotide 766 cttgaaaagg aacaaagtgg 20 767 20 DNA Artificial Sequence Antisense Oligonucleotide 767 tctatacact actcataacc 20 768 20 DNA Artificial Sequence Antisense Oligonucleotide 768 ccatcacaga ggccacttct 20 769 20 DNA Artificial Sequence Antisense Oligonucleotide 769 tccatccctg gaacaatgtg 20 770 20 DNA Artificial Sequence Antisense Oligonucleotide 770 cagagctcag ctttcttccc 20 771 20 DNA Artificial Sequence Antisense Oligonucleotide 771 agctcacaga gtccagggaa 20 772 20 DNA Artificial Sequence Antisense Oligonucleotide 772 caagcactgc cagctcacag 20 773 20 DNA Artificial Sequence Antisense Oligonucleotide 773 tcagagtcca tggcacaagc 20 774 20 DNA Artificial Sequence Antisense Oligonucleotide 774 ttgccaaaca gaagacacca 20 775 20 DNA Artificial Sequence Antisense Oligonucleotide 775 gcagagaaac aggctgtggt 20 776 20 DNA Artificial Sequence Antisense Oligonucleotide 776 gtctgtgatg tgcttggccc 20 777 20 DNA Artificial Sequence Antisense Oligonucleotide 777 tggagaaagc cgaacaccag 20 778 20 DNA Artificial Sequence Antisense Oligonucleotide 778 acaggcagtt cccgacccag 20 779 20 DNA Artificial Sequence Antisense Oligonucleotide 779 ggtctgcctc ccagtaagct 20 780 20 DNA Artificial Sequence Antisense Oligonucleotide 780 cgtctgtctg cagctcgtct 20 781 20 DNA Artificial Sequence Antisense Oligonucleotide 781 cttttctgaa tgacttgata 20 782 20 DNA Artificial Sequence Antisense Oligonucleotide 782 cactgatagg aagtgtgtcc 20 783 20 DNA Artificial Sequence Antisense Oligonucleotide 783 ctcagttgct gtaaacacag 20 784 20 DNA Artificial Sequence Antisense Oligonucleotide 784 ccacagcgct ctgagcactc 20 785 20 DNA Artificial Sequence Antisense Oligonucleotide 785 gtcctgaagt atcctgacct 20 786 20 DNA Artificial Sequence Antisense Oligonucleotide 786 gaaataaact agccagaggg 20 787 20 DNA Artificial Sequence Antisense Oligonucleotide 787 tttcttcctg actttcagaa 20 788 20 DNA Artificial Sequence Antisense Oligonucleotide 788 ttgggcgaga tgtctggcaa 20 789 20 DNA Artificial Sequence Antisense Oligonucleotide 789 cgcctatttg ggcgagatgt 20 790 20 DNA Artificial Sequence Antisense Oligonucleotide 790 gaactgtgcg gctagctgtc 20 791 20 DNA Artificial Sequence Antisense Oligonucleotide 791 cgccacaaga gaagactgag 20 792 20 DNA Artificial Sequence Antisense Oligonucleotide 792 aatgtgtgtg tctttgacag 20 793 20 DNA Artificial Sequence Antisense Oligonucleotide 793 ctacatgtta tcttcccttc 20 794 20 DNA Artificial Sequence Antisense Oligonucleotide 794 agggctttgg ccaggcagtt 20 795 20 DNA Artificial Sequence Antisense Oligonucleotide 795 acagcattgt cattatcagc 20 796 20 DNA Artificial Sequence Antisense Oligonucleotide 796 gagcaaagat ggtgcgtgac 20 797 20 DNA Artificial Sequence Antisense Oligonucleotide 797 tgtggaagac atcacggagc 20 798 20 DNA Artificial Sequence Antisense Oligonucleotide 798 gacagtcgtg tggaagacat 20 799 20 DNA Artificial Sequence Antisense Oligonucleotide 799 aggttctggt taataaagtt 20 800 20 DNA Artificial Sequence Antisense Oligonucleotide 800 gtcattttcc agcagtctca 20 801 20 DNA Artificial Sequence Antisense Oligonucleotide 801 gcgggctcct cagtccatct 20 802 20 DNA Artificial Sequence Antisense Oligonucleotide 802 gttctctggg acctgtcttc 20 803 20 DNA Artificial Sequence Antisense Oligonucleotide 803 tcattcccaa gtgggaaccc 20 804 20 DNA Artificial Sequence Antisense Oligonucleotide 804 cagaagccca cctacatggt 20 805 20 DNA Artificial Sequence Antisense Oligonucleotide 805 atgcacctct cctaatgctg 20 806 20 DNA Artificial Sequence Antisense Oligonucleotide 806 gccgatgcac ctctcctaat 20 807 20 DNA Artificial Sequence Antisense Oligonucleotide 807 gagcacttca gtgtccacta 20 808 20 DNA Artificial Sequence Antisense Oligonucleotide 808 agatcagcca ttcggctttt 20 809 20 DNA Artificial Sequence Antisense Oligonucleotide 809 cccatggttt gagatcagcc 20 810 20 DNA Artificial Sequence Antisense Oligonucleotide 810 gatagaaatc ttgagataat 20 811 20 DNA Artificial Sequence Antisense Oligonucleotide 811 caccacacag ataagtcgtg 20 812 20 DNA Artificial Sequence Antisense Oligonucleotide 812 gtaactgaca ccacacagat 20 813 20 DNA Artificial Sequence Antisense Oligonucleotide 813 agcctgagtg taactgacac 20 814 20 DNA Artificial Sequence Antisense Oligonucleotide 814 gtagcaagag cctgagtgta 20 815 20 DNA Artificial Sequence Antisense Oligonucleotide 815 ttgcattccg tagcaagagc 20 816 20 DNA Artificial Sequence Antisense Oligonucleotide 816 agtgacctgc tgctgtttta 20 817 20 DNA Artificial Sequence Antisense Oligonucleotide 817 cttttgatat ggaatcttct 20 818 20 DNA Artificial Sequence Antisense Oligonucleotide 818 aatacagaag cggagggaac 20 819 20 DNA Artificial Sequence Antisense Oligonucleotide 819 gaggccttgt ctctgaaata 20 820 20 DNA Artificial Sequence Antisense Oligonucleotide 820 cgtaacaacg cttgaggata 20 821 20 DNA Artificial Sequence Antisense Oligonucleotide 821 gctgacgatc ccagctttaa 20 822 20 DNA Artificial Sequence Antisense Oligonucleotide 822 cttgcaggct gtggcggctc 20 823 20 DNA Artificial Sequence Antisense Oligonucleotide 823 atacttgcag gctgtggcgg 20 824 20 DNA Artificial Sequence Antisense Oligonucleotide 824 ctgggatgag ttcagaacta 20 825 20 DNA Artificial Sequence Antisense Oligonucleotide 825 cacatatttt tagaacagaa 20 826 20 DNA Artificial Sequence Antisense Oligonucleotide 826 gagcctttta ttttgaagaa 20 827 20 DNA Artificial Sequence Antisense Oligonucleotide 827 ctacgctttc cacgcacagt 20 828 3160 DNA Homo sapiens CDS (1035)...(2246) 828 cctcccctcg cccggcgcgg tcccgtccgc ctctcgctcg cctcccgcct cccctcggtc 60 ttccgaggcg cccgggctcc cggcgcggcg gcggaggggg cgggcaggcc ggcgggcggt 120 gatgtggcag gactctttat gcgctgcggc aggatacgcg ctcggcgctg ggacgcgact 180 gcgctcagtt ctctcctctc ggaagctgca gccatgatgg aagtttgaga gttgagccgc 240 tgtgaggcga ggccgggctc aggcgaggga gatgagagac ggcggcggcc gcggcccgga 300 gcccctctca gcgcctgtga gcagccgcgg gggcagcgcc ctcggggagc cggccggcct 360 gcggcggcgg cagcggcggc gtttctcgcc tcctcttcgt cttttctaac cgtgcagcct 420 cttcctcggc ttctcctgaa agggaaggtg gaagccgtgg gctcgggcgg gagccggctg 480 aggcgcggcg gcggcggcgg cggcacctcc cgctcctgga gcggggggga gaagcggcgg 540 cggcggcggc cgcggcggct gcagctccag ggagggggtc tgagtcgcct gtcaccattt 600 ccagggctgg gaacgccgga gagttggtct ctccccttct actgcctcca acacggcggc 660 ggcggcggcg gcacatccag ggacccgggc cggttttaaa cctcccgtcc gccgccgccg 720 caccccccgt ggcccgggct ccggaggccg ccggcggagg cagccgttcg gaggattatt 780 cgtcttctcc ccattccgct gccgccgctg ccaggcctct ggctgctgag gagaagcagg 840 cccagtcgct gcaaccatcc agcagccgcc gcagcagcca ttacccggct gcggtccaga 900 gccaagcggc ggcagagcga ggggcatcag ctaccgccaa gtccagagcc atttccatcc 960 tgcagaagaa gccccgccac cagcagcttc tgccatctct ctcctccttt ttcttcagcc 1020 acaggctccc agac atg aca gcc atc atc aaa gag atc gtt agc aga aac 1070 Met Thr Ala Ile Ile Lys Glu Ile Val Ser Arg Asn 1 5 10 aa agg aga tat caa gag gat gga ttc gac tta gac ttg acc tat att 1118 Lys Arg Arg Tyr Gln Glu Asp Gly Phe Asp Leu Asp Leu Thr Tyr Ile 15 20 25 at cca aac att att gct atg gga ttt cct gca gaa aga ctt gaa ggc 1166 Tyr Pro Asn Ile Ile Ala Met Gly Phe Pro Ala Glu Arg Leu Glu Gly 30 35 40 ta tac agg aac aat att gat gat gta gta agg ttt ttg gat tca aag 1214 Val Tyr Arg Asn Asn Ile Asp Asp Val Val Arg Phe Leu Asp Ser Lys 45 50 55 60 at aaa aac cat tac aag ata tac aat ctt tgt gct gaa aga cat tat 1262 His Lys Asn His Tyr Lys Ile Tyr Asn Leu Cys Ala Glu Arg His Tyr 65 70 75 ac acc gcc aaa ttt aat tgc aga gtt gca caa tat cct ttt gaa gac 1310 Asp Thr Ala Lys Phe Asn Cys Arg Val Ala Gln Tyr Pro Phe Glu Asp 80 85 90 at aac cca cca cag cta gaa ctt atc aaa ccc ttt tgt gaa gat ctt 1358 His Asn Pro Pro Gln Leu Glu Leu Ile Lys Pro Phe Cys Glu Asp Leu 95 100 105 ac caa tgg cta agt gaa gat gac aat cat gtt gca gca att cac tgt 1406 Asp Gln Trp Leu Ser Glu Asp Asp Asn His Val Ala Ala Ile His Cys 110 115 120 aa gct gga aag gga cga act ggt gta atg ata tgt gca tat tta tta 1454 Lys Ala Gly Lys Gly Arg Thr Gly Val Met Ile Cys Ala Tyr Leu Leu 125 130 135 140 at cgg ggc aaa ttt tta aag gca caa gag gcc cta gat ttc tat ggg 1502 His Arg Gly Lys Phe Leu Lys Ala Gln Glu Ala Leu Asp Phe Tyr Gly 145 150 155 aa gta agg acc aga gac aaa aag gga gta act att ccc agt cag agg 1550 Glu Val Arg Thr Arg Asp Lys Lys Gly Val Thr Ile Pro Ser Gln Arg 160 165 170 gc tat gtg tat tat tat agc tac ctg tta aag aat cat ctg gat tat 1598 Arg Tyr Val Tyr Tyr Tyr Ser Tyr Leu Leu Lys Asn His Leu Asp Tyr 175 180 185 ga cca gtg gca ctg ttg ttt cac aag atg atg ttt gaa act att cca 1646 Arg Pro Val Ala Leu Leu Phe His Lys Met Met Phe Glu Thr Ile Pro 190 195 200 tg ttc agt ggc gga act tgc aat cct cag ttt gtg gtc tgc cag cta 1694 Met Phe Ser Gly Gly Thr Cys Asn Pro Gln Phe Val Val Cys Gln Leu 205 210 215 220 ag gtg aag ata tat tcc tcc aat tca gga ccc aca cga cgg gaa gac 1742 Lys Val Lys Ile Tyr Ser Ser Asn Ser Gly Pro Thr Arg Arg Glu Asp 225 230 235 ag ttc atg tac ttt gag ttc cct cag ccg tta cct gtg tgt ggt gat 1790 Lys Phe Met Tyr Phe Glu Phe Pro Gln Pro Leu Pro Val Cys Gly Asp 240 245 250 tc aaa gta gag ttc ttc cac aaa cag aac aag atg cta aaa aag gac 1838 Ile Lys Val Glu Phe Phe His Lys Gln Asn Lys Met Leu Lys Lys Asp 255 260 265 aa atg ttt cac ttt tgg gta aat aca ttc ttc ata cca gga cca gag 1886 Lys Met Phe His Phe Trp Val Asn Thr Phe Phe Ile Pro Gly Pro Glu 270 275 280 aa acc tca gaa aaa gta gaa aat gga agt cta tgt gat caa gaa atc 1934 Glu Thr Ser Glu Lys Val Glu Asn Gly Ser Leu Cys Asp Gln Glu Ile 285 290 295 300 at agc att tgc agt ata gag cgt gca gat aat gac aag gaa tat cta 1982 Asp Ser Ile Cys Ser Ile Glu Arg Ala Asp Asn Asp Lys Glu Tyr Leu 305 310 315 ta ctt act tta aca aaa aat gat ctt gac aaa gca aat aaa gac aaa 2030 Val Leu Thr Leu Thr Lys Asn Asp Leu Asp Lys Ala Asn Lys Asp Lys 320 325 330 cc aac cga tac ttt tct cca aat ttt aag gtg aag ctg tac ttc aca 2078 Ala Asn Arg Tyr Phe Ser Pro Asn Phe Lys Val Lys Leu Tyr Phe Thr 335 340 345 aa aca gta gag gag ccg tca aat cca gag gct agc agt tca act tct 2126 Lys Thr Val Glu Glu Pro Ser Asn Pro Glu Ala Ser Ser Ser Thr Ser 350 355 360 ta aca cca gat gtt agt gac aat gaa cct gat cat tat aga tat tct 2174 Val Thr Pro Asp Val Ser Asp Asn Glu Pro Asp His Tyr Arg Tyr Ser 365 370 375 380 ac acc act gac tct gat cca gag aat gaa cct ttt gat gaa gat cag 2222 Asp Thr Thr Asp Ser Asp Pro Glu Asn Glu Pro Phe Asp Glu Asp Gln 385 390 395 at aca caa att aca aaa gtc tga attttttttt atcaagaggg ataaaacacc 2276 His Thr Gln Ile Thr Lys Val * 400 atgaaaataa acttgaataa actgaaaatg gacctttttt tttttaatgg caataggaca 2336 ttgtgtcaga ttaccagtta taggaacaat tctcttttcc tgaccaatct tgttttaccc 2396 tatacatcca cagggttttg acacttgttg tccagttgaa aaaaggttgt gtagctgtgt 2456 catgtatata cctttttgtg tcaaaaggac atttaaaatt caattaggat taataaagat 2516 ggcactttcc cgttttattc cagttttata aaaagtggag acagactgat gtgtatacgt 2576 aggaattttt tccttttgtg ttctgtcacc aactgaagtg gctaaagagc tttgtgatat 2636 actggttcac atcctacccc tttgcacttg tggcaacaga taagtttgca gttggctaag 2696 agaggtttcc gaaaggtttt gctaccattc taatgcatgt attcgggtta gggcaatgga 2756 ggggaatgct cagaaaggaa ataattttat gctggactct ggaccatata ccatctccag 2816 ctatttacac acacctttct ttagcatgct acagttatta atctggacat tcgaggaatt 2876 ggccgctgtc actgcttgtt gtttgcgcat ttttttttaa agcatattgg tgctagaaaa 2936 ggcagctaaa ggaagtgaat ctgtattggg gtacaggaat gaaccttctg caacatctta 2996 agatccacaa atgaagggat ataaaaataa tgtcataggt aagaaacaca gcaacaatga 3056 cttaaccata taaatgtgga ggctatcaac aaagaatggg cttgaaacat tataaaaatt 3116 gacaatgatt tattaaatat gttttctcaa ttgtaaaaaa aaaa 3160 829 26 DNA Artificial Sequence PCR Primer 829 aatggctaag tgaagatgac aatcat 26 830 25 DNA Artificial Sequence PCR Primer 830 tgcacatatc attacaccag ttcgt 25 831 30 DNA Artificial Sequence PCR Probe 831 ttgcagcaat tcactgtaaa gctggaaagg 30 832 18 DNA Artificial Sequence Antisense Oligonucleotide 832 cgagaggcgg acgggacc 18 833 18 DNA Artificial Sequence Antisense Oligonucleotide 833 cgggcgcctc ggaagacc 18 834 18 DNA Artificial Sequence Antisense Oligonucleotide 834 tggctgcagc ttccgaga 18 835 18 DNA Artificial Sequence Antisense Oligonucleotide 835 cccgcggctg ctcacagg 18 836 18 DNA Artificial Sequence Antisense Oligonucleotide 836 caggagaagc cgaggaag 18 837 18 DNA Artificial Sequence Antisense Oligonucleotide 837 gggaggtgcc gccgccgc 18 838 18 DNA Artificial Sequence Antisense Oligonucleotide 838 ccgggtccct ggatgtgc 18 839 18 DNA Artificial Sequence Antisense Oligonucleotide 839 cctccgaacg gctgcctc 18 840 18 DNA Artificial Sequence Antisense Oligonucleotide 840 tctcctcagc agccagag 18 841 18 DNA Artificial Sequence Antisense Oligonucleotide 841 cgcttggctc tggaccgc 18 842 18 DNA Artificial Sequence Antisense Oligonucleotide 842 tcttctgcag gatggaaa 18 843 18 DNA Artificial Sequence Antisense Oligonucleotide 843 ggataaatat aggtcaag 18 844 18 DNA Artificial Sequence Antisense Oligonucleotide 844 tcaatattgt tcctgtat 18 845 18 DNA Artificial Sequence Antisense Oligonucleotide 845 ttaaatttgg cggtgtca 18 846 18 DNA Artificial Sequence Antisense Oligonucleotide 846 caagatcttc acaaaagg 18 847 18 DNA Artificial Sequence Antisense Oligonucleotide 847 attacaccag ttcgtccc 18 848 18 DNA Artificial Sequence Antisense Oligonucleotide 848 tgtctctggt ccttactt 18 849 18 DNA Artificial Sequence Antisense Oligonucleotide 849 acatagcgcc tctgactg 18 850 18 DNA Artificial Sequence Antisense Oligonucleotide 850 gaatatatct tcaccttt 18 851 18 DNA Artificial Sequence Antisense Oligonucleotide 851 ggaagaactc tactttga 18 852 18 DNA Artificial Sequence Antisense Oligonucleotide 852 tgaagaatgt atttaccc 18 853 18 DNA Artificial Sequence Antisense Oligonucleotide 853 ggttggcttt gtctttat 18 854 18 DNA Artificial Sequence Antisense Oligonucleotide 854 tgctagcctc tggatttg 18 855 18 DNA Artificial Sequence Antisense Oligonucleotide 855 tctggatcag agtcagtg 18 856 18 DNA Artificial Sequence Antisense Oligonucleotide 856 tattttcatg gtgtttta 18 857 18 DNA Artificial Sequence Antisense Oligonucleotide 857 tgttcctata actggtaa 18 858 18 DNA Artificial Sequence Antisense Oligonucleotide 858 gtgtcaaaac cctgtgga 18 859 18 DNA Artificial Sequence Antisense Oligonucleotide 859 actggaataa aacgggaa 18 860 18 DNA Artificial Sequence Antisense Oligonucleotide 860 acttcagttg gtgacaga 18 861 18 DNA Artificial Sequence Antisense Oligonucleotide 861 tagcaaaacc tttcggaa 18 862 18 DNA Artificial Sequence Antisense Oligonucleotide 862 aattatttcc tttctgag 18 863 18 DNA Artificial Sequence Antisense Oligonucleotide 863 gctg gagatggt 18 864 18 DNA Artificial Sequence Antisense Oligonucleotide 864 cagattaata actgtagc 18 865 18 DNA Artificial Sequence Antisense Oligonucleotide 865 ccccaataca gattcact 18 866 18 DNA Artificial Sequence Antisense Oligonucleotide 866 attgttgctg tgtttctt 18 867 18 DNA Artificial Sequence Antisense Oligonucleotide 867 tgtttcaagc ccattctt 18 868 20 DNA Artificial Sequence Antisense Oligonucleotide 868 ctgctagcct ctggatttga 20 869 20 DNA Artificial Sequence Antisense Oligonucleotide 869 acatagcgcc tctgactggg 20 870 20 DNA Artificial Sequence Antisense Oligonucleotide 870 cttctggcat ccggtttaga 20 871 2160 DNA Mus musculus CDS (949)...(2160) 871 ggcgccctgc tctcccggcg gggcggcgga gggggcgggc tggccggcgc acggtgatgt 60 ggcgggactc tttgtgcact gcggcaggat acgcgcttgg gcgtcgggac gcggctgcgc 120 tcagctctct cctctcggaa gctgcagcca tgatggaagt ttgagagttg agccgctgtg 180 aggccaggcc cggcgcaggc gagggagatg agagacggcg gcggccacgg cccagagccc 240 ctctcagcgc ctgtgagcag ccgcgggggc agcgccctcg gggagccggc cgggcggcgg 300 cggcggcagc ggcggcgggc ctcgcctcct cgtcgtctgt tctaaccggg cagcttctga 360 gcagcttcgg agagagacgg tggaagaagc cgtgggctcg agcgggagcc ggcgcaggct 420 cggcggctgc acctcccgct cctggagcgg gggggagaag cggcggcggc ggccgcggct 480 ccggggaggg ggtcggagtc gcctgtcacc attgccaggg ctgggaacgc cggagagttg 540 ctctctcccc ttctcctgcc tccaacacgg cggcggcggc ggcggcacgt ccagggaccc 600 gggccggtgt taagcctccc gtccgccgcc gccgcacccc ccctggcccg ggctccggag 660 gccgccggag gaggcagccg ctgcgaggat tatccgtctt ctccccattc cgctgcctcg 720 gctgccaggc ctctggctgc tgaggagaag caggcccagt ctctgcaacc atccagcagc 780 cgccgcagca gccattaccc ggctgcggtc cagggccaag cggcagcaga gcgaggggca 840 tcagcgaccg ccaagtccag agccatttcc atcctgcaga agaagcctcg ccaccagcag 900 cttctgccat ctctctcctc ctttttcttc agccacaggc tcccagac atg aca gcc 957 Met Thr Ala 1 atc atc aaa gag atc gtt agc aga aac aaa agg aga tat caa gag gat 1005 Ile Ile Lys Glu Ile Val Ser Arg Asn Lys Arg Arg Tyr Gln Glu Asp 5 10 15 gga ttc gac tta gac ttg acc tat att tat cca aat att att gct atg 1053 Gly Phe Asp Leu Asp Leu Thr Tyr Ile Tyr Pro Asn Ile Ile Ala Met 20 25 30 35 gga ttt cct gca gaa aga ctt gaa ggt gta tac agg aac aat att gat 1101 Gly Phe Pro Ala Glu Arg Leu Glu Gly Val Tyr Arg Asn Asn Ile Asp 40 45 50 gat gta gta agg ttt ttg gat tca aag cat aaa aac cat tac aag ata 1149 Asp Val Val Arg Phe Leu Asp Ser Lys His Lys Asn His Tyr Lys Ile 55 60 65 tac aat cta tgt gct gag aga cat tat gac acc gcc aaa ttt aac tgc 1197 Tyr Asn Leu Cys Ala Glu Arg His Tyr Asp Thr Ala Lys Phe Asn Cys 70 75 80 aga gtt gca cag tat cct ttt gaa gac cat aac cca cca cag cta gaa 1245 Arg Val Ala Gln Tyr Pro Phe Glu Asp His Asn Pro Pro Gln Leu Glu 85 90 95 ctt atc aaa ccc ttc tgt gaa gat ctt gac caa tgg cta agt gaa gat 1293 Leu Ile Lys Pro Phe Cys Glu Asp Leu Asp Gln Trp Leu Ser Glu Asp 100 105 110 115 gac aat cat gtt gca gca att cac tgt aaa gct gga aag gga cgg act 1341 Asp Asn His Val Ala Ala Ile His Cys Lys Ala Gly Lys Gly Arg Thr 120 125 130 ggt gta atg att tgt gca tat tta ttg cat cgg ggc aaa ttt tta aag 1389 Gly Val Met Ile Cys Ala Tyr Leu Leu His Arg Gly Lys Phe Leu Lys 135 140 145 gca caa gag gcc cta gat ttt tat ggg gaa gta agg acc aga gac aaa 1437 Ala Gln Glu Ala Leu Asp Phe Tyr Gly Glu Val Arg Thr Arg Asp Lys 150 155 160 aag gga gtc aca att ccc agt cag agg cgc tat gta tat tat tat agc 1485 Lys Gly Val Thr Ile Pro Ser Gln Arg Arg Tyr Val Tyr Tyr Tyr Ser 165 170 175 tac ctg cta aaa aat cac ctg gat tac aga ccc gtg gca ctg ctg ttt 1533 Tyr Leu Leu Lys Asn His Leu Asp Tyr Arg Pro Val Ala Leu Leu Phe 180 185 190 195 cac aag atg atg ttt gaa act att cca atg ttc agt ggc gga act tgc 1581 His Lys Met Met Phe Glu Thr Ile Pro Met Phe Ser Gly Gly Thr Cys 200 205 210 aat cct cag ttt gtg gtc tgc cag cta aag gtg aag ata tat tcc tcc 1629 Asn Pro Gln Phe Val Val Cys Gln Leu Lys Val Lys Ile Tyr Ser Ser 215 220 225 aat tca gga ccc acg cgg cgg gag gac aag ttc atg tac ttt gag ttc 1677 Asn Ser Gly Pro Thr Arg Arg Glu Asp Lys Phe Met Tyr Phe Glu Phe 230 235 240 cct cag cca ttg cct gtg tgt ggt gat atc aaa gta gag ttc ttc cac 1725 Pro Gln Pro Leu Pro Val Cys Gly Asp Ile Lys Val Glu Phe Phe His 245 250 255 aaa cag aac aag atg ctc aaa aag gac aaa atg ttt cac ttt tgg gta 1773 Lys Gln Asn Lys Met Leu Lys Lys Asp Lys Met Phe His Phe Trp Val 260 265 270 275 aat acg ttc ttc ata cca gga cca gag gaa acc tca gaa aaa gtg gaa 1821 Asn Thr Phe Phe Ile Pro Gly Pro Glu Glu Thr Ser Glu Lys Val Glu 280 285 290 aat gga agt ctt tgt gat cag gaa atc gat agc att tgc agt ata gag 1869 Asn Gly Ser Leu Cys Asp Gln Glu Ile Asp Ser Ile Cys Ser Ile Glu 295 300 305 cgt gca gat aat gac aag gag tat ctt gta ctc acc cta aca aaa aac 1917 Arg Ala Asp Asn Asp Lys Glu Tyr Leu Val Leu Thr Leu Thr Lys Asn 310 315 320 gat ctt gac aaa gca aac aaa gac aag gcc aac cga tac ttc tct cca 1965 Asp Leu Asp Lys Ala Asn Lys Asp Lys Ala Asn Arg Tyr Phe Ser Pro 325 330 335 aat ttt aag gtg aaa cta tac ttt aca aaa aca gta gag gag cca tca 2013 Asn Phe Lys Val Lys Leu Tyr Phe Thr Lys Thr Val Glu Glu Pro Ser 340 345 350 355 aat cca gag gct agc agt tca act tct gtg act cca gat gtt agt gac 2061 Asn Pro Glu Ala Ser Ser Ser Thr Ser Val Thr Pro Asp Val Ser Asp 360 365 370 aat gaa cct gat cat tat aga tat tct gac acc act gac tct gat cca 2109 Asn Glu Pro Asp His Tyr Arg Tyr Ser Asp Thr Thr Asp Ser Asp Pro 375 380 385 gag aat gaa cct ttt gat gaa gat cag cat tca caa att aca aaa gtc 2157 Glu Asn Glu Pro Phe Asp Glu Asp Gln His Ser Gln Ile Thr Lys Val 390 395 400 872 24 DNA Artificial Sequence PCR Primer 872 atgacaatca tgttgcagca attc 24 873 25 DNA Artificial Sequence PCR Primer 873 cgatgcaata aatatgcaca aatca 25 874 28 DNA Artificial Sequence PCR Probe 874 ctgtaaagct ggaaagggac ggactggt 28 875 1212 DNA Rattus norvegicus CDS (1)...(1212) 875 atg aca gcc atc atc aaa gag atc gtt agc aga aac aaa agg aga tat 48 Met Thr Ala Ile Ile Lys Glu Ile Val Ser Arg Asn Lys Arg Arg Tyr 1 5 10 15 caa gag gat gga ttc gac tta gac ttg acc tat att tat cca aat att 96 Gln Glu Asp Gly Phe Asp Leu Asp Leu Thr Tyr Ile Tyr Pro Asn Ile 20 25 30 att gct atg gga ttt cct gca gaa aga ctt gaa ggt gta tac agg aac 144 Ile Ala Met Gly Phe Pro Ala Glu Arg Leu Glu Gly Val Tyr Arg Asn 35 40 45 aat att gat gat gta gta agg ttt ttg gat tca aag cat aaa aac cat 192 Asn Ile Asp Asp Val Val Arg Phe Leu Asp Ser Lys His Lys Asn His 50 55 60 tac aag ata tac aat cta tgt gct gag aga cat tat gac acc gcc aaa 240 Tyr Lys Ile Tyr Asn Leu Cys Ala Glu Arg His Tyr Asp Thr Ala Lys 65 70 75 80 ttt aac tgc aga gtt gca cag tat cct ttt gaa gac cat aac cca cca 288 Phe Asn Cys Arg Val Ala Gln Tyr Pro Phe Glu Asp His Asn Pro Pro 85 90 95 cag cta gaa ctt atc aaa ccc ttt tgt gaa gat ctt gac caa tgg cta 336 Gln Leu Glu Leu Ile Lys Pro Phe Cys Glu Asp Leu Asp Gln Trp Leu 100 105 110 agt gaa gac gac aat cat gtt gca gca att cac tgt aaa gct ggg aaa 384 Ser Glu Asp Asp Asn His Val Ala Ala Ile His Cys Lys Ala Gly Lys 115 120 125 gga cgg act ggt gta atg att tgt gca tat tta ttg cat cgg ggc aag 432 Gly Arg Thr Gly Val Met Ile Cys Ala Tyr Leu Leu His Arg Gly Lys 130 135 140 ttt tta aag gca caa gag gcc ctg gat ttt tat ggg gaa gta agg acc 480 Phe Leu Lys Ala Gln Glu Ala Leu Asp Phe Tyr Gly Glu Val Arg Thr 145 150 155 160 aga gat aaa aag gga gta act att ccc agt cag agg cgc tat gta tat 528 Arg Asp Lys Lys Gly Val Thr Ile Pro Ser Gln Arg Arg Tyr Val Tyr 165 170 175 tat tat agc tac ctg tta aag aat cac ctg gat tac aga cca gtg gca 576 Tyr Tyr Ser Tyr Leu Leu Lys Asn His Leu Asp Tyr Arg Pro Val Ala 180 185 190 ctg ttg ttt cac aag atg atg ttt gaa act att cca atg ttc agt ggc 624 Leu Leu Phe His Lys Met Met Phe Glu Thr Ile Pro Met Phe Ser Gly 195 200 205 gga act tgc aat ccc cag ttt gtg gtc tgc cag cta aag gtg aag atc 672 Gly Thr Cys Asn Pro Gln Phe Val Val Cys Gln Leu Lys Val Lys Ile 210 215 220 tac tcc tcc aac tca gga ccc acg cgg cgg gag gac aag ctc atg tac 720 Tyr Ser Ser Asn Ser Gly Pro Thr Arg Arg Glu Asp Lys Leu Met Tyr 225 230 235 240 ttt gag ttc cct cag cca ttg cct gtg tgt ggt gac atc aaa gta gag 768 Phe Glu Phe Pro Gln Pro Leu Pro Val Cys Gly Asp Ile Lys Val Glu 245 250 255 ttc ttc cac aaa cag aac aag atg ctc aaa aag gac aaa atg ttt cac 816 Phe Phe His Lys Gln Asn Lys Met Leu Lys Lys Asp Lys Met Phe His 260 265 270 ttt tgg gta aat acg ttc ttc ata cca gga cca gag gaa acc tca gaa 864 Phe Trp Val Asn Thr Phe Phe Ile Pro Gly Pro Glu Glu Thr Ser Glu 275 280 285 aaa gtg gaa aat gga agt ctt tgt gat cag gaa atc gat agc att tgt 912 Lys Val Glu Asn Gly Ser Leu Cys Asp Gln Glu Ile Asp Ser Ile Cys 290 295 300 agt ata gag cgt gcg gat aat gac aag gag tat ctt gtg ctc acc ctg 960 Ser Ile Glu Arg Ala Asp Asn Asp Lys Glu Tyr Leu Val Leu Thr Leu 305 310 315 320 aca aaa aat gat ctt gac aaa gca aac aaa gac aag gcc aac cga tac 1008 Thr Lys Asn Asp Leu Asp Lys Ala Asn Lys Asp Lys Ala Asn Arg Tyr 325 330 335 ttc tct cca aat ttt aag gtg aag tta tac ttc aca aaa aca gta gag 1056 Phe Ser Pro Asn Phe Lys Val Lys Leu Tyr Phe Thr Lys Thr Val Glu 340 345 350 gag cca tca aat cca gag gct agc agt tca act tct gtg act cca gac 1104 Glu Pro Ser Asn Pro Glu Ala Ser Ser Ser Thr Ser Val Thr Pro Asp 355 360 365 gtt agt gac aat gaa cct gat cat tat aga tat tct gac acc act gac 1152 Val Ser Asp Asn Glu Pro Asp His Tyr Arg Tyr Ser Asp Thr Thr Asp 370 375 380 tct gat cca gag aat gaa cct ttt gat gaa gat cag cat tca caa att 1200 Ser Asp Pro Glu Asn Glu Pro Phe Asp Glu Asp Gln His Ser Gln Ile 385 390 395 400 aca aaa gtc tga 1212 Thr Lys Val * 876 21 DNA Artificial Sequence Oligomeric Compound 876 cgagaggcgg acgggaccgt t 21 877 21 DNA Artificial Sequence Oligomeric Compound 877 cgggcgcctc ggaagaccgt t 21 878 21 DNA Artificial Sequence Oligomeric Compound 878 tggctgcagc ttccgagagt t 21 879 21 DNA Artificial Sequence Oligomeric Compound 879 cccgcggctg ctcacaggct t 21 880 21 DNA Artificial Sequence Oligomeric Compound 880 caggagaagc cgaggaagat t 21 881 21 DNA Artificial Sequence Oligomeric Compound 881 gggaggtgcc gccgccgcct t 21 882 21 DNA Artificial Sequence Oligomeric Compound 882 ccgggtccct ggatgtgcct t 21 883 21 DNA Artificial Sequence Oligomeric Compound 883 cctccgaacg gctgcctcct t 21 884 21 DNA Artificial Sequence Oligomeric Compound 884 tctcctcagc agccagaggt t 21 885 21 DNA Artificial Sequence Oligomeric Compound 885 cgcttggctc tggaccgcat t 21 886 21 DNA Artificial Sequence Oligomeric Compound 886 tcttctgcag gatggaaatt t 21 887 21 DNA Artificial Sequence Oligomeric Compound 887 ggataaatat aggtcaagtt t 21 888 21 DNA Artificial Sequence Oligomeric Compound 888 tcaatattgt tcctgtatat t 21 889 21 DNA Artificial Sequence Oligomeric Compound 889 ttaaatttgg cggtgtcatt t 21 890 21 DNA Artificial Sequence Oligomeric Compound 890 caagatcttc acaaaagggt t 21 891 21 DNA Artificial Sequence Oligomeric Compound 891 attacaccag ttcgtccctt t 21 892 21 DNA Artificial Sequence Oligomeric Compound 892 tgtctctggt ccttacttct t 21 893 21 DNA Artificial Sequence Oligomeric Compound 893 acatagcgcc tctgactggt t 21 894 21 DNA Artificial Sequence Oligomeric Compound 894 gaatatatct tcacctttat t 21 895 21 DNA Artificial Sequence Oligomeric Compound 895 ggaagaactc tactttgatt t 21 896 21 DNA Artificial Sequence Oligomeric Compound 896 tgaagaatgt atttacccat t 21 897 21 DNA Artificial Sequence Oligomeric Compound 897 ggttggcttt gtctttattt t 21 898 21 DNA Artificial Sequence Oligomeric Compound 898 tgctagcctc tggatttgat t 21 899 21 DNA Artificial Sequence Oligomeric Compound 899 tctggatcag agtcagtggt t 21 900 21 DNA Artificial Sequence Oligomeric Compound 900 tattttcatg gtgttttact t 21 901 21 DNA Artificial Sequence Oligomeric Compound 901 tgttcctata actggtaatt t 21 902 21 DNA Artificial Sequence Oligomeric Compound 902 gtgtcaaaac cctgtggatt t 21 903 21 DNA Artificial Sequence Oligomeric Compound 903 actggaataa aacgggaaat t 21 904 21 DNA Artificial Sequence Oligomeric Compound 904 acttcagttg gtgacagaat t 21 905 21 DNA Artificial Sequence Oligomeric Compound 905 tagcaaaacc tttcggaaat t 21 906 21 DNA Artificial Sequence Oligomeric Compound 906 aattatttcc tttctgagct t 21 907 21 DNA Artificial Sequence Oligomeric Compound 907 taaatagctg gagatggtct t 21 908 21 DNA Artificial Sequence Oligomeric Compound 908 cagattaata actgtagcat t 21 909 21 DNA Artificial Sequence Oligomeric Compound 909 ccccaataca gattcacttt t 21 910 21 DNA Artificial Sequence Oligomeric Compound 910 attgttgctg tgtttcttat t 21 911 21 DNA Artificial Sequence Oligomeric Compound 911 tgtttcaagc ccattctttt t 21 912 21 DNA Artificial Sequence Oligomeric Compound 912 cggtcccgtc cgcctctcgt t 21 913 21 DNA Artificial Sequence Oligomeric Compound 913 cggtcttccg aggcgcccgt t 21 914 21 DNA Artificial Sequence Oligomeric Compound 914 ctctcggaag ctgcagccat t 21 915 21 DNA Artificial Sequence Oligomeric Compound 915 gcctgtgagc agccgcgggt t 21 916 21 DNA Artificial Sequence Oligomeric Compound 916 tcttcctcgg cttctcctgt t 21 917 21 DNA Artificial Sequence Oligomeric Compound 917 ggcggcggcg gcacctccct t 21 918 21 DNA Artificial Sequence Oligomeric Compound 918 ggcacatcca gggacccggt t 21 919 21 DNA Artificial Sequence Oligomeric Compound 919 ggaggcagcc gttcggaggt t 21 920 21 DNA Artificial Sequence Oligomeric Compound 920 cctctggctg ctgaggagat t 21 921 21 DNA Artificial Sequence Oligomeric Compound 921 tgcggtccag agccaagcgt t 21 922 21 DNA Artificial Sequence Oligomeric Compound 922 atttccatcc tgcagaagat t 21 923 21 DNA Artificial Sequence Oligomeric Compound 923 acttgaccta tatttatcct t 21 924 21 DNA Artificial Sequence Oligomeric Compound 924 tatacaggaa caatattgat t 21 925 21 DNA Artificial Sequence Oligomeric Compound 925 atgacaccgc caaatttaat t 21 926 21 DNA Artificial Sequence Oligomeric Compound 926 cccttttgtg aagatcttgt t 21 927 21 DNA Artificial Sequence Oligomeric Compound 927 agggacgaac tggtgtaatt t 21 928 21 DNA Artificial Sequence Oligomeric Compound 928 gaagtaagga ccagagacat t 21 929 21 DNA Artificial Sequence Oligomeric Compound 929 ccagtcagag gcgctatgtt t 21 930 21 DNA Artificial Sequence Oligomeric Compound 930 taaaggtgaa gatatattct t 21 931 21 DNA Artificial Sequence Oligomeric Compound 931 atcaaagtag agttcttcct t 21 932 21 DNA Artificial Sequence Oligomeric Compound 932 tgggtaaata cattcttcat t 21 933 21 DNA Artificial Sequence Oligomeric Compound 933 aataaagaca aagccaacct t 21 934 21 DNA Artificial Sequence Oligomeric Compound 934 tcaaatccag aggctagcat t 21 935 21 DNA Artificial Sequence Oligomeric Compound 935 ccactgactc tgatccagat t 21 936 21 DNA Artificial Sequence Oligomeric Compound 936 gtaaaacacc atgaaaatat t 21 937 21 DNA Artificial Sequence Oligomeric Compound 937 attaccagtt ataggaacat t 21 938 21 DNA Artificial Sequence Oligomeric Compound 938 atccacaggg ttttgacact t 21 939 21 DNA Artificial Sequence Oligomeric Compound 939 tttcccgttt tattccagtt t 21 940 21 DNA Artificial Sequence Oligomeric Compound 940 ttctgtcacc aactgaagtt t 21 941 21 DNA Artificial Sequence Oligomeric Compound 941 tttccgaaag gttttgctat t 21 942 21 DNA Artificial Sequence Oligomeric Compound 942 gctcagaaag gaaataattt t 21 943 21 DNA Artificial Sequence Oligomeric Compound 943 gaccatctcc agctatttat t 21 944 21 DNA Artificial Sequence Oligomeric Compound 944 tgctacagtt attaatctgt t 21 945 21 DNA Artificial Sequence Oligomeric Compound 945 aagtgaatct gtattggggt t 21 946 21 DNA Artificial Sequence Oligomeric Compound 946 taagaaacac agcaacaatt t 21 947 21 DNA Artificial Sequence Oligomeric Compound 947 aaagaatggg cttgaaacat t 21 

What is claimed is:
 1. A method comprising: (a) identifying a target; (b) generating a plurality of virtual compounds targeted to said target; (c) robotically synthesizing a plurality of real compounds corresponding to at least some of said virtual compounds; (d) identifying a modulator of said target from said plurality of real compounds; (e) contacting said modulator with said target in an assay of a biochemical or biological parameter indicative of a biological process to determine one of: an effect of modulation of said target on said parameter or a lack of an effect of modulation of said target on said parameter, thereby effecting gene function analysis.
 2. The method of claim 1 wherein said plurality of real compounds corresponds to a subset of virtual compounds selected from said plurality of virtual compounds.
 3. The method of claim 1 wherein said target is a gene.
 4. The method of claim 3 wherein the best possible representation of the nucleotide sequence of said gene is obtained using computerized searches of available databases.
 5. The method of claim 4 wherein said sequence represents a transcript isoform of said gene.
 6. The method of claim 5 wherein the formation of said transcript isoform is directed by alternative splicing.
 7. The method of claim 1 wherein said target is a polypeptide-encoding nucleic acid.
 8. The method of claim 1 wherein said target is a non-polypeptide-encoding nucleic acid.
 9. The method of claim 8 wherein said non-polypeptide-encoding nucleic acid is one of a structural RNA or an enzymatic RNA.
 10. The method of claim 1 wherein said plurality of virtual compounds is targeted to functional regions of said target.
 11. The method of claim 10 wherein said functional regions are selected from the group consisting of: the transcription start site, the 5′ cap, the 5′ untranslated region, the start codon, the coding region, the stop codon, the 3′ untranslated region, 5′ splice sites, 3′ splice sites, exons, introns, exon: intron junctions, intron: exon junctions, exon: exon junctions, mRNA destablization signals, mRNA destabilization signals, poly-A signals and 5′ sequences of pre-mRNA.
 12. The method of claim 2 wherein said subset of virtual compounds is selected by evaluation of thermodynamic properties of said plurality of virtual compounds in silico.
 13. The method of claim 1 wherein the accessibility of said target to said plurality of virtual compounds is evaluated in silico.
 14. The method of claim 1 wherein said virtual compounds are 8 to 30 nucleobases in length and specifically hybridize with said target.
 15. The method of claim 14 wherein said virtual compounds are antisense compounds.
 16. The method of claim 15 wherein said antisense compounds are antisense oligonucleotides.
 17. The method of claim 16 wherein said antisense oligonucleotides comprise at least one modified internucleoside linkage.
 18. The method of claim 17 wherein said modified internucleoside linkage is a phosphorothioate linkage.
 19. The method of claim 16 wherein said antisense oligonucleotides comprise at least one modified sugar moiety.
 20. The method of claim 19 wherein said modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
 21. The method of claim 16 wherein said antisense oligonucleotides comprise at least one modified nucleobase.
 22. The method of claim 21 wherein said modified nucleobase is a 5-methylcytosine.
 23. The method of claim 14 wherein said virtual compounds are double-stranded oligomeric compounds.
 24. The method of claim 23 wherein said double-stranded oligomeric compounds are double-stranded RNA oligomeric compounds.
 25. The method of claim 24 wherein said double-stranded RNA oligomeric compounds are siRNAs.
 26. The method of claim 23 wherein said double-stranded oligomeric compounds comprise at least one two-nucleobase overhang of deoxythymidine.
 27. The method of claim 23 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified internucleoside linkage.
 28. The method of claim 27 wherein said modified internucleoside linkage is a phosphorothioate linkage.
 29. The method of claim 23 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified sugar moiety.
 30. The method of claim 29 wherein said modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
 31. The method of claim 23 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified nucleobase.
 32. The method of claim 31 wherein said modified nucleobase is a 5-methylcytosine.
 33. The method of claim 1 wherein said target is expressed in a sample capable of exhibiting said parameter wherein said sample is selected from the group consisting of: a cell culture, a cell-free extract, a tissue and an animal.
 34. The method of claim 1 wherein said modulator is identified by a computer-controlled real-time polymerase chain reaction or a computer-controlled enzyme-linked immunosorbent assay.
 35. The method of claim 1 wherein said parameter is the expression of at least one gene related to said biological process.
 36. The method of claim 1 wherein said parameter is determined by an assay selected from the group consisting of: a caspase activity assay, a cell cycle assay, a matrix metalloproteinase activity assay and a tube formation assay.
 37. The method of claim 1 wherein the value of said parameter is increased as a result of modulation of said target.
 38. The method of claim 1 wherein the value of said parameter is decreased as a result of modulation of said target.
 39. The method of claim 1 wherein said biological process is selected from the group consisting of apoptosis, inflammation and angiogenesis.
 40. A method comprising: (a) identifying a target; (b) generating a plurality of virtual compounds targeted to said target; (c) robotically synthesizing a plurality of real compounds corresponding to at least some of said virtual compounds; (d) identifying a modulator of said target from said real compounds; (e) contacting said modulator with said target in an assay of a biochemical or biological parameter indicative of a disease or disorder to determine one of: an effect of modulation of said target on said parameter or a lack of an effect of modulation of said target on said parameter, thereby effecting target validation.
 41. The method of claim 40 wherein said plurality of real compounds corresponds to a subset of virtual compounds selected from said plurality of virtual compounds.
 42. The method of claim 40 wherein said target is a gene.
 43. The method of claim 42 wherein the best possible representation of the nucleotide sequence of said gene is obtained using computerized searches of available databases.
 44. The method of claim 43 wherein said sequence represents a transcript isoform of said gene.
 45. The method of claim 44 wherein the formation of said transcript isoform is directed by alternative splicing.
 46. The method of claim 40 wherein said target is a polypeptide-encoding nucleic acid.
 47. The method of claim 40 wherein said target is a non-polypeptide-encoding nucleic acid.
 48. The method of claim 47 wherein said non-polypeptide-encoding nucleic acid is one of a structural RNA or an enzymatic RNA.
 49. The method of claim 40 wherein said plurality of virtual compounds is targeted to functional regions of said target.
 50. The method of claim 49 wherein said functional regions are selected from the group consisting of: the transcription start site, the 5′ cap, the 5′ untranslated region, the start codon, the coding region, the stop codon, the 3′ untranslated region, 5′ splice sites, 3′ splice sites, specific exons, specific introns, exon: intron junctions, intron: exon junctions, exon: exon junctions, mRNA destablization signals, mRNA destabilization signals, poly-A signals and 5′ sequences of known pre-mRNA.
 51. The method of claim 41 wherein said subset is selected by evaluation of thermodynamic properties of said plurality of virtual compounds in silico.
 52. The method of claim 40 wherein the accessibility of said target to said plurality of virtual compounds is evaluated in silico.
 53. The method of claim 40 wherein said virtual compounds are 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding said target and specifically hybridize with said target.
 54. The method of claim 53 wherein said virtual compounds are antisense compounds.
 55. The method of claim 54 wherein said antisense compounds are antisense oligonucleotides.
 56. The method of claim 55 wherein said antisense oligonucleotides comprise at least one modified internucleoside linkage.
 57. The method of claim 56 wherein said modified internucleoside linkage is a phosphorothioate linkage.
 58. The method of claim 55 wherein said antisense oligonucleotides comprise at least one modified sugar moiety.
 59. The method of claim 58 wherein said modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
 60. The method of claim 55 wherein said antisense oligonucleotides comprise at least one modified nucleobase.
 61. The method of claim 60 wherein said modified nucleobase is a 5-methylcytosine.
 62. The method of claim 53 wherein said virtual compounds are double-stranded oligomeric compounds.
 63. The method of claim 62 wherein said double-stranded oligomeric compounds are double-stranded RNA oligomeric compounds.
 64. The method of claim 63 wherein said double-stranded RNA oligomeric compounds are siRNAs.
 65. The method of claim 62 wherein said double-stranded oligomeric compounds comprise at least one two-nucleobase overhang of deoxythymidine.
 66. The method of claim 62 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified internucleoside linkage.
 67. The method of claim 66 wherein said modified internucleoside linkage is a phosphorothioate linkage.
 68. The method of claim 62 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified sugar moiety.
 69. The method of claim 68 wherein said modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
 70. The method of claim 62 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified nucleobase.
 71. The method of claim 70 wherein said modified nucleobase is a 5-methylcytosine.
 72. The method of claim 40 wherein said target is expressed in a sample capable of exhibiting said parameter wherein said sample is selected from the group consisting of: a cell culture, a cell-free extract, a tissue and an animal.
 73. The method of claim 40 wherein said modulator is identified by a computer-controlled real-time polymerase chain reaction or a computer-controlled enzyme-linked immunosorbent assay.
 74. The method of claim 40 wherein said parameter is the expression of at least one gene related to said disease or disorder.
 75. The method of claim 40 wherein said parameter is the level of a biochemical component selected from the group consisting of cholesterol, triglyceride, lipoprotein, glucose, insulin and PEPCK.
 76. The method of claim 40 wherein said parameter is measured in a rodent.
 77. The method of claim 76 wherein said parameter measured in a rodent is selected from the group consisting of survival rate, spleen weight, liver weight and fat pad weight.
 78. The method of claim 40 wherein the valuse of said parameter is decreased as a result of modulation of said target.
 79. The method of claim 40 wherein the value of said parameter is increased as a result of modulation of said target.
 80. A method comprising: (a) identifying a target; (b) generating a plurality of virtual compounds designed to modulate said target; (c) robotically synthesizing a plurality of real compounds corresponding to at least some of said virtual compounds; (d) identifying at least one modulator of said target by contacting said target with said real compounds and measuring the extent of modulation of said target using an automated means; (e) performing an automated assay of at least one biological or biochemical parameter indicative of one of: (i) a biological process, thereby effecting gene function analysis or (ii) a disease or disorder, thereby effecting target validation.
 81. A method comprising: (a) identifying a target; (b) generating a plurality of virtual double-stranded oligomeric compounds designed to modulate said target; (c) robotically synthesizing a plurality of real double-stranded oligomeric compounds corresponding to at least some of said virtual double-stranded oligomeric compounds; (d) identifying at least one modulator of said target by contacting said target with said real double-stranded oligomeric compounds and measuring the extent of modulation of said target using an automated means; (e) performing an automated assay of at least one biological or biochemical parameter indicative of one of: (i) a biological process, thereby effecting gene function analysis or (ii) a disease or disorder, thereby effecting target validation.
 82. The method of claim 81 wherein said double-stranded oligomeric compounds are double-stranded RNA oligomeric compounds.
 83. The method of claim 82 wherein said double-stranded RNA oligomeric compounds are siRNAs.
 84. The method of claim 81 wherein said double-stranded oligomeric compounds are 15 to 30 nucleobases in length.
 85. The method of claim 81 wherein said double-stranded oligomeric compounds are 20 to 25 nucleobases in length.
 86. The method of claim 81 wherein said double-stranded oligomeric compounds comprise at least one two-nucleobase overhang of deoxythymidine.
 87. The method of claim 81 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified internucleoside linkage.
 88. The method of claim 87 wherein said modified internucleoside linkage is a phosphorothioate linkage.
 89. The method of claim 81 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified sugar moiety.
 90. The method of claim 89 wherein said modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
 91. The method of claim 81 wherein both strands of said double-stranded oligomeric compounds comprise at least one modified nucleobase.
 92. The method of claim 91 wherein said modified nucleobase is a 5-methylcytosine. 